Clustering O 0 2.523417424526997e-05
of O 0 3.009620641591937e-08
missense O 0 0.00022607951541431248
mutations O 0 0.0002910266339313239
in O 0 5.651251058225171e-07
the O 0 0.0004955957410857081
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
telangiectasia I-Disease 1 0.9999996423721313
gene O 0 0.023783881217241287
in O 0 1.9546195062503102e-07
a O 0 2.747319740592502e-07
sporadic B-Disease 0 0.001856897259131074
T I-Disease 1 0.9990636706352234
- I-Disease 1 0.9866113662719727
cell I-Disease 1 0.922929048538208
leukaemia I-Disease 1 0.9949476718902588
. O 0 2.3002665727744898e-07

Ataxia B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999921321868896
telangiectasia I-Disease 1 0.9999988079071045
( O 0 0.009737171232700348
A B-Disease 1 0.9999951124191284
- I-Disease 1 0.9999990463256836
T I-Disease 1 0.9999998807907104
) O 0 5.622984531328257e-07
is O 0 1.3273389498635879e-08
a O 0 6.202087377005228e-08
recessive B-Disease 0 0.0038553266786038876
multi I-Disease 1 0.8476142883300781
- I-Disease 1 0.9999926090240479
system I-Disease 1 0.9648445844650269
disorder I-Disease 1 0.7635709643363953
caused O 0 7.764942893118132e-07
by O 0 8.256550998453349e-09
mutations O 0 4.71014459435537e-07
in O 0 6.7399059666684025e-09
the O 0 4.8586663581318135e-09
ATM O 0 6.233428575797006e-05
gene O 0 8.460415301669855e-07
at O 0 2.0035805903262371e-07
11q22 O 0 1.866569732555945e-06
- O 0 0.0006482894532382488
q23 O 0 2.1625753561238525e-06
( O 0 1.5979880751970654e-09
ref O 0 0.00010629083408275619
. O 0 1.4384122781763153e-09
3 O 0 1.020726969613861e-08
) O 0 2.042875646424136e-09
. O 0 1.2208723809692401e-08

The O 0 8.54019344842527e-06
risk O 0 9.341185432276689e-06
of O 0 6.320867385056772e-08
cancer B-Disease 0 0.03177526220679283
, O 0 5.926783330778562e-08
especially O 0 5.635262212422276e-08
lymphoid B-Disease 0 0.00013721981667913496
neoplasias I-Disease 0 0.009822330437600613
, O 0 9.050080507222447e-08
is O 0 1.7169313082376902e-08
substantially O 0 3.4483116451156093e-06
elevated O 0 0.007510801311582327
in O 0 3.3479832381999586e-06
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 1 0.5770689845085144
and O 0 9.323483936896082e-06
has O 0 4.029971478303196e-06
long O 0 7.795224519213662e-06
been O 0 9.112989687309891e-07
associated O 0 2.004987322834495e-07
with O 0 4.008781615993939e-06
chromosomal O 1 0.999998927116394
instability O 1 0.9999756813049316
. O 0 2.2483943666884443e-06

By O 0 8.906747694936712e-08
analysing O 0 2.6619949494488537e-05
tumour B-Disease 1 0.9999756813049316
DNA O 0 0.0007674701046198606
from O 0 6.779177219584653e-09
patients O 0 3.747519983221537e-08
with O 0 4.451832680274492e-09
sporadic B-Disease 0 0.0006319621461443603
T I-Disease 1 0.9995821118354797
- I-Disease 1 0.9521666169166565
cell I-Disease 1 0.9675166010856628
prolymphocytic I-Disease 1 0.768998384475708
leukaemia I-Disease 1 0.9927505254745483
( O 0 8.377175930718295e-08
T B-Disease 0 0.447277307510376
- I-Disease 0 0.3678070604801178
PLL I-Disease 0 0.007078093476593494
) O 0 1.5910000428220883e-08
, O 0 7.31613658544461e-10
a O 0 4.9979078653450415e-09
rare O 0 2.2755499173854332e-07
clonal B-Disease 0 0.000742460077162832
malignancy I-Disease 0 0.34647515416145325
with O 0 7.021333914281058e-08
similarities O 0 3.462065251369495e-06
to O 0 3.8652768097335866e-08
a O 0 1.4012547921993246e-07
mature B-Disease 0 2.6890969820669852e-05
T I-Disease 1 0.5835347175598145
- I-Disease 0 0.3615105152130127
cell I-Disease 0 0.10435759276151657
leukaemia I-Disease 1 0.571745753288269
seen O 0 8.815430192044005e-06
in O 0 2.6034084044113115e-07
A B-Disease 1 0.9999918937683105
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
, O 0 1.0513782626730972e-06
we O 0 3.5413329158018314e-08
demonstrate O 0 1.2453542364010417e-10
a O 0 3.7556215082279465e-11
high O 0 9.258576683102149e-10
frequency O 0 5.8322231488716625e-09
of O 0 3.9739680990358295e-10
ATM O 0 4.758253271575086e-05
mutations O 0 3.5739558370551094e-06
in O 0 4.6944487053224293e-07
T B-Disease 1 0.5118507742881775
- I-Disease 0 0.1972474306821823
PLL I-Disease 0 0.013890989124774933
. O 0 2.311117981435018e-07

In O 0 4.4976243884775613e-07
marked O 0 2.6841237854569044e-07
contrast O 0 1.6826159310312505e-07
to O 0 5.084773047059343e-09
the O 0 1.1377387920674664e-09
ATM O 0 3.952794577344321e-05
mutation O 0 3.454456646068138e-06
pattern O 0 0.00280859787017107
in O 0 1.0172218935622368e-05
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
, O 0 1.3324865903996397e-06
the O 0 2.4767028428129834e-09
most O 0 3.899863487699662e-10
frequent O 0 2.431483014930791e-09
nucleotide O 0 3.4535560189397074e-08
changes O 0 1.0411171480484427e-08
in O 0 4.7093426935873595e-09
this O 0 4.0967975678540824e-08
leukaemia B-Disease 0 0.10611768811941147
were O 0 2.0149107626821205e-07
missense O 0 7.149901648517698e-05
mutations O 0 5.371219594962895e-05
. O 0 2.6131712616006553e-07

These O 0 2.961133986900677e-07
clustered O 0 7.812265039319755e-07
in O 0 1.058537613118915e-08
the O 0 3.731313036325901e-09
region O 0 8.824293296072483e-09
corresponding O 0 8.244338545182472e-09
to O 0 6.912330707820047e-09
the O 0 1.9571677611907035e-09
kinase O 0 2.0794150259462185e-06
domain O 0 4.3424279283499345e-06
, O 0 5.024194749125854e-08
which O 0 1.1427654378337593e-08
is O 0 3.1571215086678706e-10
highly O 0 1.6019788273702318e-10
conserved O 0 1.4595215702684072e-08
in O 0 1.4255594926737558e-08
ATM O 0 9.298405348090455e-05
- O 0 0.00016856995353009552
related O 0 8.78394530445803e-08
proteins O 0 4.451851864928358e-08
in O 0 2.4665403941526165e-08
mouse O 0 7.05847269273363e-05
, O 0 1.4173229700986667e-08
yeast O 0 5.94876553350332e-07
and O 0 4.979821710549004e-08
Drosophila O 0 9.052790517216636e-08
. O 0 1.1102565089515792e-08

The O 0 7.280298177647637e-07
resulting O 0 1.249321996965591e-07
amino O 0 9.949052071078768e-08
- O 0 4.0409795474261045e-05
acid O 0 2.8375853844408994e-07
substitutions O 0 1.0059492794312064e-08
are O 0 6.306290489810351e-10
predicted O 0 7.369263812506688e-07
to O 0 1.660289683513838e-08
interfere O 0 1.3853390612439398e-07
with O 0 9.791776278689213e-09
ATP O 0 8.948140020947903e-06
binding O 0 1.2620299116861133e-07
or O 0 1.1111377595796057e-08
substrate O 0 8.026662726479117e-06
recognition O 0 6.02835484642128e-07
. O 0 2.84929740246298e-07

Two O 0 1.6889340770376293e-07
of O 0 1.937848548294596e-09
seventeen O 0 1.2778954783243535e-07
mutated O 0 2.7189891625312157e-05
T B-Disease 1 0.5405245423316956
- I-Disease 0 0.007564500905573368
PLL I-Disease 0 0.0002154609392164275
samples O 0 1.0518635917833308e-06
had O 0 3.0480552482003986e-07
a O 0 4.788241358966161e-09
previously O 0 4.3676213863363955e-06
reported O 0 1.1628237189142965e-05
A B-Disease 1 0.9999322891235352
- I-Disease 1 0.9999830722808838
T I-Disease 1 0.9999964237213135
allele O 0 4.887353134108707e-05
. O 0 2.8574172006301524e-07

In O 0 1.353209171384151e-07
contrast O 0 6.744518259438337e-07
, O 0 1.8322641182066945e-08
no O 0 7.1702008774821024e-09
mutations O 0 1.3923471442467417e-07
were O 0 2.829078482591285e-08
detected O 0 1.3970718555356143e-06
in O 0 4.948979448471391e-09
the O 0 4.765254857375112e-09
p53 O 0 3.352674937673328e-08
gene O 0 9.880877627210793e-08
, O 0 4.774853401556811e-09
suggesting O 0 5.193952645754507e-08
that O 0 3.9445886557132326e-08
this O 0 2.613854519495362e-07
tumour B-Disease 1 0.9999997615814209
suppressor O 0 0.008109559305012226
is O 0 1.1566968396437005e-06
not O 0 1.2355904743799329e-07
frequently O 0 1.3605068183153435e-08
altered O 0 3.21134643854748e-06
in O 0 3.3077864003416835e-08
this O 0 8.329678280460939e-07
leukaemia B-Disease 1 0.9123275279998779
. O 0 4.6443210521829315e-07

Occasional O 0 4.9220303480979055e-05
missense O 0 0.00014941209519747645
mutations O 0 8.952186180977151e-05
in O 0 2.827681200301413e-08
ATM O 0 0.00020409084390848875
were O 0 1.7557458704686724e-06
also O 0 1.0949528359560645e-06
found O 0 2.704576900214306e-07
in O 0 3.2075220701699436e-07
tumour B-Disease 1 0.9999998807907104
DNA O 0 0.017031818628311157
from O 0 1.8068462281917164e-08
patients O 0 5.317042450769804e-07
with O 0 6.412805930722243e-08
B B-Disease 0 0.07852492481470108
- I-Disease 0 0.009587232954800129
cell I-Disease 0 0.018673855811357498
non I-Disease 0 5.053279164712876e-05
- I-Disease 1 0.9991260170936584
Hodgkins I-Disease 1 0.9999791383743286
lymphomas I-Disease 1 0.9965253472328186
( O 0 3.525118685843154e-08
B B-Disease 0 0.0004760328447446227
- I-Disease 0 0.002088620327413082
NHL I-Disease 0 1.643691211938858e-05
) O 0 2.4366642037421116e-09
and O 0 3.262439651763316e-09
a O 0 2.4671710008306036e-08
B B-Disease 0 0.005098932422697544
- I-Disease 0 0.0007279018755070865
NHL I-Disease 0 2.7020889774576062e-06
cell O 0 4.831190744880587e-05
line O 0 4.140680539421737e-05
. O 0 2.4382785568377585e-08

The O 0 1.978731631879782e-07
evidence O 0 3.291492589596601e-08
of O 0 2.5356092225869986e-10
a O 0 5.160612381871488e-09
significant O 0 1.713112873780176e-09
proportion O 0 9.53586294372144e-08
of O 0 2.5546459170300295e-08
loss O 0 0.0011938459938392043
- O 0 0.003760390682145953
of O 0 3.947147320104705e-08
- O 0 0.037698499858379364
function O 0 1.3553236613006447e-06
mutations O 0 2.1216012555669295e-06
and O 0 8.541667284589494e-08
a O 0 3.953031679770902e-08
complete O 0 1.622637500986457e-05
absence O 0 1.244813461198646e-07
of O 0 3.769257961305783e-10
the O 0 5.241220346619002e-09
normal O 0 8.844496690585402e-09
copy O 0 2.8909619231853867e-07
of O 0 4.801399278164808e-10
ATM O 0 3.383626972208731e-05
in O 0 2.1035237551814134e-08
the O 0 5.985273610065178e-09
majority O 0 8.809763585304609e-09
of O 0 1.5003415398950892e-08
mutated O 0 0.10299290716648102
tumours B-Disease 1 0.9999984502792358
establishes O 0 6.35353273992223e-07
somatic O 0 9.936383804642901e-08
inactivation O 0 1.5829529729671776e-05
of O 0 5.827561766480471e-10
this O 0 2.043136770879528e-09
gene O 0 1.496555341873318e-07
in O 0 2.064026460857349e-08
the O 0 1.0449568321746483e-08
pathogenesis O 0 3.4835895803553285e-06
of O 0 8.099233284042384e-09
sporadic B-Disease 0 0.006970350164920092
T I-Disease 1 0.9992815852165222
- I-Disease 1 0.53882896900177
PLL I-Disease 0 0.005224674008786678
and O 0 1.013077508105198e-06
suggests O 0 4.5642011059499055e-08
that O 0 2.3612860555743964e-09
ATM O 0 2.197846242779633e-06
acts O 0 3.61360179113035e-07
as O 0 1.719736708594155e-08
a O 0 2.482408945070347e-06
tumour B-Disease 1 0.9999983310699463
suppressor O 0 0.034515030682086945
. O 0 8.38991013552004e-07

As O 0 5.187042262377872e-08
constitutional O 0 6.444724220955322e-08
DNA O 0 7.786881178617477e-05
was O 0 1.446695591766911e-06
not O 0 8.537282880638486e-09
available O 0 6.683116282601986e-10
, O 0 5.099299871247354e-10
a O 0 6.272273367358139e-09
putative O 0 0.00012638453335966915
hereditary O 1 0.9691852927207947
predisposition O 0 0.046303294599056244
to O 0 3.894890141964424e-06
T B-Disease 1 0.9829131960868835
- I-Disease 0 0.4359612464904785
PLL I-Disease 0 0.0014192989328876138
will O 0 3.293979489171761e-08
require O 0 2.1534872496342672e-10
further O 0 2.0435138303742661e-10
investigation O 0 2.522162478868495e-09
. O 0 5.167763550417703e-09
. O 0 1.8297878767725706e-08

Myotonic B-Disease 1 0.9999606609344482
dystrophy I-Disease 1 0.9999868869781494
protein O 0 0.0005702127236872911
kinase O 0 0.000186233373824507
is O 0 4.354701133024719e-08
involved O 0 3.1453186721819293e-09
in O 0 3.1985494808317583e-10
the O 0 3.4077685118205636e-10
modulation O 0 6.925685802627868e-09
of O 0 1.8483876929042964e-10
the O 0 8.59946691633695e-09
Ca2 O 0 1.6596331988694146e-06
+ O 0 2.299008428963134e-06
homeostasis O 0 2.215239692304749e-05
in O 0 1.0410521156245522e-07
skeletal O 0 0.07284753769636154
muscle O 0 0.0003600421769078821
cells O 0 1.097606491384795e-05
. O 0 1.2738169630210905e-07

Myotonic B-Disease 1 0.9999880790710449
dystrophy I-Disease 1 0.9999971389770508
( O 0 0.0017414444591850042
DM B-Disease 1 0.9999990463256836
) O 0 4.0832037484506145e-06
, O 0 8.392428973991173e-09
the O 0 3.4101435009148418e-09
most O 0 1.6747355502388928e-08
prevalent O 0 0.003510927315801382
muscular B-Disease 1 0.993557870388031
disorder I-Disease 1 0.9281761050224304
in O 0 4.533030733000487e-06
adults O 0 0.0006237582419998944
, O 0 1.6234019994953997e-07
is O 0 2.563554630796716e-07
caused O 0 8.499428076902404e-07
by O 0 1.695346263375086e-08
( O 0 2.253894182402405e-09
CTG O 0 1.7114208503699047e-06
) O 0 6.794072526794537e-10
n O 0 1.0004195019064355e-06
- O 0 0.00036129922955296934
repeat O 0 4.765711764775915e-06
expansion O 0 1.837822161121494e-08
in O 0 2.677519039817611e-10
a O 0 1.408971411764881e-10
gene O 0 2.6368487393568785e-09
encoding O 0 7.012186942212395e-10
a O 0 1.6207621911235037e-08
protein O 0 9.678068408902618e-07
kinase O 0 5.70535303268116e-05
( O 0 2.516522457085557e-08
DM B-Disease 1 0.9999926090240479
protein O 0 4.316621198086068e-05
kinase O 0 0.0004794269916601479
; O 0 1.3437876589250664e-07
DMPK O 0 0.00020109293109271675
) O 0 2.235113205628636e-09
and O 0 1.915626324233699e-09
involves O 0 4.631962036150128e-10
changes O 0 4.879655346456957e-09
in O 0 6.290508558493002e-09
cytoarchitecture O 0 3.4820408473024145e-05
and O 0 1.9738895673526713e-07
ion O 0 4.4419302867027e-06
homeostasis O 0 0.00044020533096045256
. O 0 2.1861221455310442e-07

To O 0 5.927563506702427e-08
obtain O 0 8.752015112634126e-09
clues O 0 1.5778744000272127e-07
to O 0 3.1189968385803013e-09
the O 0 7.022091241815076e-10
normal O 0 1.2299667062620756e-08
biological O 0 2.1772041947087928e-08
role O 0 2.1467627675519907e-09
of O 0 2.8463578716220184e-10
DMPK O 0 8.095998055068776e-06
in O 0 3.927080438614894e-09
cellular O 0 2.2229987735045142e-06
ion O 0 2.477952648405335e-06
homeostasis O 0 0.0002422769321128726
, O 0 2.2145039579868353e-08
we O 0 6.46635811563101e-08
have O 0 3.122312186576437e-09
compared O 0 2.3633768275743705e-09
the O 0 7.423660353111927e-09
resting O 0 2.2521264781971695e-06
[ O 0 1.0234679770348976e-08
Ca2 O 0 1.5201770509065682e-08
+ O 0 1.599920125272547e-07
] O 0 6.738159754604567e-07
i O 0 5.8073333093489055e-06
, O 0 5.003874051223711e-11
the O 0 3.281157637258225e-11
amplitude O 0 3.3772802332521223e-09
and O 0 2.0608990070059008e-08
shape O 0 1.6917469736199564e-07
of O 0 2.6190488666699707e-10
depolarization O 0 4.334415493190136e-08
- O 0 2.8327929612714797e-05
induced O 0 2.747702410488273e-06
Ca2 O 0 2.1141183026429644e-08
+ O 0 3.3400944232653274e-08
transients O 0 3.9944779928191565e-06
, O 0 2.4730681946749655e-09
and O 0 1.6612550224337497e-09
the O 0 1.9338376733291085e-10
content O 0 6.520615603022861e-09
of O 0 3.5333611037025037e-10
ATP O 0 2.9030925361439586e-06
- O 0 6.468617812060984e-06
driven O 0 4.372499802229868e-07
ion O 0 4.719055723967358e-08
pumps O 0 6.528556895091242e-08
in O 0 2.7334925434274737e-09
cultured O 0 5.97543248659349e-07
skeletal O 0 0.0002553441154304892
muscle O 0 1.5414054814755218e-06
cells O 0 2.9746653140705348e-08
of O 0 2.1022983354157532e-10
wild O 0 1.1404352335375734e-05
- O 0 0.18507356941699982
type O 0 0.025823106989264488
and O 0 5.1002184591197874e-06
DMPK O 0 6.999594916123897e-05
[ O 0 2.514970844913478e-07
- O 0 0.0001410696713719517
/ O 0 9.594619768904522e-05
- O 0 0.002531843027099967
] O 0 4.961659669788787e-06
knockout O 0 0.0003281569224782288
mice O 0 0.00011603810708038509
. O 0 4.874095083096108e-08

In O 0 1.886585323518375e-07
vitro O 0 1.8373322745901532e-05
- O 0 0.000516977219376713
differentiated O 0 1.8403765352559276e-05
DMPK O 0 0.00022711543715558946
[ O 0 4.888894977739255e-07
- O 0 0.00013363735342863947
/ O 0 0.0001706947950879112
- O 0 0.00046966408262960613
] O 0 2.0665127919983206e-07
myotubes O 0 2.6796936936079874e-07
exhibit O 0 2.695147394149444e-08
a O 0 3.952057348044491e-09
higher O 0 1.8555034841938323e-08
resting O 0 1.2284589274713653e-06
[ O 0 1.6304328553928826e-08
Ca2 O 0 9.144751800249651e-08
+ O 0 6.705307100673963e-07
] O 0 2.6145698939217255e-06
i O 0 5.651683295582188e-06
than O 0 7.364297505141337e-10
do O 0 8.890912539527562e-08
wild O 0 3.869865849992493e-07
- O 0 0.0021348849404603243
type O 0 0.00019702357531059533
myotubes O 0 3.7637735658790916e-05
because O 0 4.5681463944902134e-08
of O 0 6.110666139758081e-11
an O 0 1.0200413846916945e-09
altered O 0 5.586137831414817e-06
open O 0 3.740885574643471e-07
probability O 0 4.237901141124212e-09
of O 0 2.662439990697152e-10
voltage O 0 5.0168549933005124e-05
- O 0 8.607128984294832e-05
dependent O 0 3.552536895767844e-07
l O 0 1.457077178201871e-05
- O 0 1.0459903023729566e-05
type O 0 1.7779234440240543e-06
Ca2 O 0 6.259440255007576e-08
+ O 0 5.622486298761942e-08
and O 0 2.3684952665803394e-08
Na O 0 5.96444897382753e-06
+ O 0 7.758341524777279e-08
channels O 0 2.1387783988302544e-07
. O 0 5.237775368982511e-08

The O 0 2.0786171717190882e-07
mutant O 0 1.5025402717583347e-06
myotubes O 0 5.101424449094338e-06
exhibit O 0 1.3379744245867187e-07
smaller O 0 1.0310270859292814e-08
and O 0 1.5418265775224427e-08
slower O 0 4.57590346059078e-07
Ca2 O 0 2.941866910077806e-07
+ O 0 3.220969517769845e-07
responses O 0 1.0693333329925281e-08
upon O 0 6.038982647282864e-10
triggering O 0 1.2652277447955385e-08
by O 0 1.189616405383731e-09
acetylcholine O 0 5.217816124059027e-06
or O 0 3.401379728984466e-07
high O 0 3.492058340270887e-06
external O 0 3.767231874007848e-06
K O 0 8.691019502293784e-06
+ O 0 1.8741291114565684e-06
. O 0 1.532205828880251e-07

In O 0 9.711559556535576e-08
addition O 0 4.982308343670638e-09
, O 0 3.511360757713078e-09
we O 0 5.303487871088919e-09
observed O 0 5.839801420215451e-10
that O 0 3.225487377189751e-10
these O 0 1.6752130238550933e-10
Ca2 O 0 8.005992668813633e-08
+ O 0 1.7435519339414896e-06
transients O 0 0.0004079381178598851
partially O 0 9.034316462930292e-05
result O 0 8.553193708848994e-08
from O 0 1.7125141582585712e-10
an O 0 1.1502804264651445e-10
influx O 0 1.7170605215444112e-10
of O 0 2.2080812872582456e-11
extracellular O 0 1.291536300129792e-08
Ca2 O 0 4.931860075885197e-08
+ O 0 1.4700208161855244e-08
through O 0 5.422837179303031e-10
the O 0 1.9495265402014184e-09
l O 0 1.0168522521780687e-06
- O 0 2.6230866296828026e-06
type O 0 3.2349640832762816e-07
Ca2 O 0 6.376836836352595e-08
+ O 0 2.9322080763449776e-08
channel O 0 6.212666221472318e-07
. O 0 4.2823824486504236e-08

Neither O 0 6.8267750066297594e-06
the O 0 8.050456301589293e-09
content O 0 3.461826025841219e-08
nor O 0 2.67761368633046e-08
the O 0 1.0137838485357875e-10
activity O 0 1.2763766710222058e-09
of O 0 1.2322524944874402e-10
Na O 0 1.1689346138155088e-05
+ O 0 1.705188026335236e-07
/ O 0 8.36985861951689e-07
K O 0 1.3999057557612105e-07
+ O 0 2.062350112908007e-08
ATPase O 0 1.8854589143302292e-06
and O 0 4.594588176587422e-08
sarcoplasmic O 0 3.244928734602581e-07
reticulum O 0 3.909792098966136e-07
Ca2 O 0 1.9891129454663314e-07
+ O 0 3.9033506027408293e-07
- O 0 3.853562520816922e-05
ATPase O 0 8.519378752680495e-06
are O 0 6.3770047020739185e-09
affected O 0 1.3572306833964376e-08
by O 0 5.903279642893722e-09
DMPK O 0 0.000813809281680733
absence O 0 2.9098148957018566e-07
. O 0 3.477291343756406e-08

In O 0 4.592109235090902e-07
conclusion O 0 1.0824155793898171e-07
, O 0 5.379715339870472e-09
our O 0 1.346572853222483e-09
data O 0 1.8785577537983045e-08
suggest O 0 5.253744106425984e-08
that O 0 1.2087080669687111e-08
DMPK O 0 1.3004126230953261e-05
is O 0 4.8488715265193605e-09
involved O 0 5.178001916128494e-10
in O 0 5.45940959106872e-10
modulating O 0 2.9423438263620483e-07
the O 0 9.1350553788061e-09
initial O 0 2.1990187448750476e-08
events O 0 1.12866516133181e-09
of O 0 3.3692168499577235e-10
excitation O 0 3.141564661746088e-07
- O 0 0.016111237928271294
contraction O 0 1.732919736241456e-05
coupling O 0 7.479100531782024e-06
in O 0 1.4785797475269646e-07
skeletal O 0 0.05982614681124687
muscle O 0 2.5862496841000393e-05
. O 0 7.984866989829698e-09
. O 0 2.9411591384587155e-08

Constitutional O 0 0.0001046762554324232
RB1 O 0 0.005288749001920223
- O 0 0.0032767443917691708
gene O 0 2.378614772169385e-05
mutations O 0 5.757627513958141e-05
in O 0 1.3236710572073207e-07
patients O 0 9.118353432313597e-07
with O 0 5.297344074506327e-08
isolated O 0 0.00033187036751769483
unilateral B-Disease 0 0.0019273234065622091
retinoblastoma I-Disease 1 0.8645474314689636
. O 0 9.307838809036184e-06

In O 0 6.962521865716553e-07
most O 0 4.254919971913296e-08
patients O 0 1.8366364429311943e-07
with O 0 8.085126346202287e-09
isolated O 0 3.0505632821586914e-05
unilateral B-Disease 0 0.00043399998685345054
retinoblastoma I-Disease 1 0.9251351356506348
, O 0 8.804970093478914e-06
tumor B-Disease 0 0.001915655448101461
development O 0 2.9880567353757215e-08
is O 0 1.5712403600431912e-09
initiated O 0 9.407593815069504e-09
by O 0 4.5496900691333053e-10
somatic O 0 5.887001108817458e-08
inactivation O 0 6.537194622069364e-06
of O 0 2.823151712405547e-10
both O 0 1.0862951427270673e-08
alleles O 0 2.755604189275118e-09
of O 0 5.96367621952254e-10
the O 0 6.913625583138128e-08
RB1 O 0 0.00011282823834335431
gene O 0 5.642478413392382e-07
. O 0 8.519961625097494e-08

However O 0 2.249493081762921e-05
, O 0 1.7098420457273278e-09
some O 0 1.7715107158977617e-11
of O 0 2.3382307201558206e-10
these O 0 4.691226607178578e-08
patients O 0 1.2312104900047416e-06
can O 0 2.901427080814756e-07
transmit O 0 0.0003421348810661584
retinoblastoma B-Disease 0 0.2999562919139862
predisposition O 0 0.012421573512256145
to O 0 5.722966989196721e-07
their O 0 8.083261491265148e-07
offspring O 0 1.2868189514847472e-05
. O 0 1.4423008565245254e-07

To O 0 1.1351777118306927e-07
determine O 0 8.97636009966618e-09
the O 0 5.259965241144471e-10
frequency O 0 1.7820164543991268e-07
and O 0 5.715942208439628e-08
nature O 0 2.4754054805953274e-08
of O 0 2.2303212054985977e-10
constitutional O 0 1.8116833189196768e-07
RB1 O 0 0.00025678621022962034
- O 0 0.00016090749704744667
gene O 0 2.865578835553606e-06
mutations O 0 1.216283976646082e-06
in O 0 1.0316313137082034e-07
patients O 0 7.522741043430869e-07
with O 0 4.2510670539286366e-08
isolated O 0 0.0011506451992318034
unilateral B-Disease 0 0.00044285861076787114
retinoblastoma I-Disease 0 0.02545812726020813
, O 0 6.155723752954145e-08
we O 0 7.76642306021813e-09
analyzed O 0 2.380782015976024e-09
DNA O 0 4.709089296284219e-07
from O 0 4.187759028440041e-10
peripheral O 0 0.004077148158103228
blood O 0 8.559312846045941e-05
and O 0 7.705573921157338e-07
from O 0 8.149334718154932e-08
tumor B-Disease 0 0.018882475793361664
tissue O 0 0.0009437631233595312
. O 0 2.7450988682176103e-07

The O 0 7.26099500525379e-08
analysis O 0 7.056118533910194e-08
of O 0 1.6575754102632345e-07
tumors B-Disease 1 0.9999997615814209
from O 0 4.561912092526654e-08
54 O 0 8.43754776269634e-07
( O 0 2.0922947818746707e-09
71 O 0 8.603126389061799e-07
% O 0 1.1902859808898825e-09
) O 0 3.834593476081949e-10
of O 0 5.677234238277151e-10
76 O 0 7.245731922012055e-06
informative O 0 6.952933472348377e-05
patients O 0 4.274722232366912e-05
showed O 0 2.2744334273738787e-05
loss O 0 2.1391731479525333e-06
of O 0 4.135216169487421e-09
constitutional O 0 2.5676456516521284e-06
heterozygosity O 0 0.03637494519352913
( O 0 1.7868762824946316e-06
LOH O 1 0.9999141693115234
) O 0 9.651397903098768e-08
at O 0 7.78008057977786e-08
intragenic O 0 4.2333918827353045e-05
loci O 0 1.1742826018235064e-06
. O 0 6.796502560746376e-08

Three O 0 4.2500050767557696e-07
of O 0 5.180997852960445e-09
13 O 0 1.88852411042717e-07
uninformative O 0 0.0011791031574830413
patients O 0 4.727474879473448e-05
had O 0 1.1458514563855715e-06
constitutional O 0 6.533776542028136e-08
deletions O 0 3.3633401471888646e-05
. O 0 9.241326779374504e-07

For O 0 3.580166918482064e-08
39 O 0 6.342774838685727e-08
randomly O 0 1.8100013221555855e-07
selected O 0 1.1693672604451422e-05
tumors B-Disease 1 0.9999996423721313
, O 0 2.837006434219802e-07
SSCP O 0 0.0005376103799790144
, O 0 2.0025542113444317e-08
hetero O 0 4.503582658799132e-06
- O 0 7.58136820877553e-06
duplex O 0 0.00018141929467674345
analysis O 0 2.2396848819994375e-08
, O 0 1.02626233899894e-10
sequencing O 0 4.0213837593228163e-08
, O 0 3.4525464709389553e-09
and O 0 4.335364511831585e-09
Southern O 0 7.378150090886493e-09
blot O 0 1.571368738950696e-05
analysis O 0 2.0761705687988297e-09
were O 0 1.1521210652176705e-09
used O 0 8.57429327538739e-09
to O 0 3.826427175113167e-09
identify O 0 1.2840243357459258e-07
mutations O 0 1.0278705531163723e-06
. O 0 6.998697443805213e-08

Mutations O 0 0.00013433891581371427
were O 0 1.5032810551929288e-07
detected O 0 6.96169820457726e-07
in O 0 9.806280232282916e-09
21 O 0 2.063883499658914e-07
( O 0 2.5540647374810987e-09
91 O 0 6.6024654188368e-07
% O 0 4.6938106734728535e-09
) O 0 9.16227715919149e-09
of O 0 1.1212893014089786e-07
23 O 1 0.7104019522666931
tumors B-Disease 1 0.9999998807907104
with O 0 0.001373880309984088
LOH O 1 0.999994158744812
. O 0 8.591684490966145e-06

In O 0 1.790081256558551e-07
6 O 0 1.329191405829988e-07
( O 0 6.133872298974552e-10
38 O 0 3.126467262859478e-08
% O 0 1.1399826638225363e-09
) O 0 8.854805777502861e-10
of O 0 1.0369514136243652e-08
16 O 0 0.1261373907327652
tumors B-Disease 1 1.0
without O 0 3.1428215152118355e-05
LOH O 1 0.9999949932098389
, O 0 6.085307546754848e-08
one O 0 3.5096998640682386e-09
mutation O 0 8.040761656502582e-08
was O 0 1.4285379847933655e-06
detected O 0 2.5291451493103523e-06
, O 0 9.018646274228104e-09
and O 0 1.5206177650384234e-08
in O 0 7.919858546756586e-09
9 O 0 6.703497206217435e-07
( O 0 1.207649646950415e-09
56 O 0 1.8052570283089153e-07
% O 0 1.3746698224181841e-09
) O 0 3.00048252910301e-09
of O 0 9.13763464893691e-09
the O 0 0.08756302297115326
tumors B-Disease 1 1.0
without O 0 3.573338472051546e-05
LOH O 1 0.9999856948852539
, O 0 4.165696054769796e-08
both O 0 1.0718040677204499e-08
mutations O 0 3.102782386577019e-07
were O 0 4.2200447580853506e-08
found O 0 3.3528226595080923e-07
. O 0 7.496772980175592e-08

Thus O 0 7.182876743172528e-06
, O 0 3.06703551444798e-09
a O 0 3.4594793696385295e-10
total O 0 9.744671736200416e-10
of O 0 1.9373042059456225e-10
45 O 0 1.2333872589920247e-08
mutations O 0 9.279876849177526e-07
were O 0 1.3524646647056215e-07
identified O 0 4.823834387934767e-06
in O 0 2.4567598302382976e-05
tumors B-Disease 1 1.0
of O 0 1.2320228393036814e-07
36 O 0 1.575140777276829e-05
patients O 0 9.668819075159263e-06
. O 0 1.4467022424469178e-07

Thirty O 0 7.229939001263119e-06
- O 0 0.0001424560323357582
nine O 0 7.75341604253299e-08
of O 0 1.6304778360787253e-10
the O 0 8.967462328257625e-09
mutations O 0 6.415082225430524e-07
- O 0 3.878913776134141e-05
including O 0 8.73310579407871e-09
34 O 0 1.9104204440623107e-08
small O 0 1.7067181445895585e-08
mutations O 0 3.3171136237797327e-06
, O 0 5.940576475182979e-09
2 O 0 1.676339778100555e-08
large O 0 1.0993164067940597e-07
structural O 0 0.004268439020961523
alterations O 0 0.0022177069913595915
, O 0 1.580347230856205e-07
and O 0 2.378301218186607e-07
hypermethylation O 0 0.0005460685351863503
in O 0 2.13786597669241e-06
3 O 0 0.01805298402905464
tumors O 1 1.0
- O 1 0.5335655212402344
were O 0 4.955625627189875e-06
not O 0 5.326015184436983e-08
detected O 0 9.099288433844777e-08
in O 0 5.251374890491434e-10
the O 0 8.985503452407784e-10
corresponding O 0 2.354460271192238e-08
peripheral O 0 0.0033516224939376116
blood O 0 1.275516115128994e-05
DNA O 0 3.979743996751495e-05
. O 0 1.3777501806089276e-07

In O 0 4.0547803337176447e-07
6 O 0 5.19983075264463e-07
( O 0 1.7075866276528018e-09
17 O 0 4.548341436816372e-08
% O 0 2.9858435168783615e-10
) O 0 1.7202073099298332e-10
of O 0 2.117792885503178e-10
the O 0 2.0081313323316863e-07
36 O 0 6.695768206554931e-06
patients O 0 5.290684725878236e-07
, O 0 5.223991794700567e-10
a O 0 4.065115355444959e-09
mutation O 0 7.279409146576654e-07
was O 0 1.415641918356414e-06
detected O 0 1.0840704334214024e-07
in O 0 7.815202929251086e-10
constitutional O 0 1.2127932436101219e-08
DNA O 0 0.001028229482471943
, O 0 1.1373948893833585e-07
and O 0 3.856682795344568e-08
1 O 0 8.920310712312585e-09
of O 0 5.4233155744043415e-09
these O 0 8.595534950472938e-08
mutations O 0 6.274837005548761e-07
is O 0 3.6926582680507636e-08
known O 0 5.651482979374123e-07
to O 0 2.0156987545760785e-07
be O 0 2.5105393319790892e-08
associated O 0 9.09317865449566e-09
with O 0 1.6410655945264807e-08
reduced O 0 4.794769665750209e-06
expressivity O 0 0.02444199100136757
. O 0 2.544767028211936e-07

The O 0 2.3794036962954124e-07
presence O 0 7.529987300358698e-09
of O 0 1.19552992505767e-10
a O 0 2.015105193819977e-09
constitutional O 0 4.899167649341507e-08
mutation O 0 2.1768195438198745e-05
was O 0 0.0004988833679817617
not O 0 1.982571689040924e-07
associated O 0 6.198206392582506e-09
with O 0 2.0898935915170114e-09
an O 0 1.4333518372211529e-08
early O 0 3.5568459679780062e-06
age O 0 2.3261053172518587e-07
at O 0 4.078849258348782e-08
treatment O 0 2.860239192159497e-07
. O 0 1.596136733894582e-08

In O 0 3.1477364359489e-07
1 O 0 2.3340874122368405e-07
patient O 0 4.377905042929342e-06
, O 0 1.209509936650477e-09
somatic O 0 2.0112516097015032e-07
mosaicism O 0 0.0006539477035403252
was O 0 1.71545434568543e-05
demonstrated O 0 1.7754475223341615e-08
by O 0 5.61635737916788e-11
molecular O 0 6.996639712042452e-09
analysis O 0 1.453392628469885e-09
of O 0 1.0248265430723436e-10
DNA O 0 8.114371303236112e-05
and O 0 2.5935051439773815e-08
RNA O 0 3.9271603782253806e-06
from O 0 1.1423732182436197e-08
peripheral O 0 0.032740477472543716
blood O 0 7.31759428163059e-05
. O 0 2.8367574600451917e-07

In O 0 1.8539153643359896e-06
2 O 0 4.006274139101151e-06
patients O 0 5.195696530790883e-07
without O 0 1.554392836666807e-09
a O 0 8.019529929015334e-09
detectable O 0 1.0746580301201902e-05
mutation O 0 8.227475518651772e-06
in O 0 5.52319932012324e-07
peripheral O 1 0.9602859616279602
blood O 0 0.03771279379725456
, O 0 9.144682167061546e-08
mosaicism O 0 4.107965651201084e-05
was O 0 5.68450514037977e-06
suggested O 0 2.753444618974754e-07
because O 0 2.723190206666004e-08
1 O 0 4.697446875923106e-09
of O 0 2.5460393793252933e-09
the O 0 9.239811333827674e-07
patients O 0 7.4692638918349985e-06
showed O 0 0.0013263910077512264
multifocal O 1 0.999988317489624
tumors B-Disease 1 1.0
and O 0 5.876803697901778e-05
the O 0 6.895044180055265e-08
other O 0 1.4477823384595467e-08
later O 0 3.9703018046566285e-06
developed O 0 8.776215508987661e-06
bilateral B-Disease 0 2.456395804983913e-06
retinoblastoma I-Disease 0 0.036506183445453644
. O 0 1.1141511322421138e-06

In O 0 8.628895216133969e-07
conclusion O 0 4.3800329763143964e-07
, O 0 1.7957558995362888e-08
our O 0 3.6754967958074758e-09
results O 0 3.7106746564319337e-09
emphasize O 0 2.1813484352151136e-08
that O 0 1.8719799044220053e-08
the O 0 1.4712318030518645e-09
manifestation O 0 3.23493623000104e-07
and O 0 3.321980912573963e-08
transmissibility O 0 5.038417043579102e-07
of O 0 6.298380705871409e-10
retinoblastoma B-Disease 0 6.559751454915386e-06
depend O 0 3.3297961721245883e-08
on O 0 3.219556958811154e-07
the O 0 1.8990853334344138e-08
nature O 0 2.0727497940242756e-07
of O 0 1.0957337259753785e-09
the O 0 1.939394955741136e-08
first O 0 2.988513472246268e-07
mutation O 0 1.6203394181957265e-07
, O 0 5.742019082433103e-10
its O 0 6.66057986542512e-10
time O 0 2.4090907047025212e-08
in O 0 3.3015006284387027e-09
development O 0 1.5155853461124025e-08
, O 0 7.206987895358452e-09
and O 0 2.457538172961904e-08
the O 0 2.3785624581051934e-09
number O 0 9.778175069641293e-08
and O 0 2.8750889669026947e-07
types O 0 1.1873732574940732e-07
of O 0 1.7528787310538974e-09
cells O 0 1.4302706858870806e-06
that O 0 2.4665167686066525e-08
are O 0 3.99290422947729e-09
affected O 0 3.2464942734122815e-08
. O 0 3.2306302077955706e-09
. O 0 1.6056789675644723e-08

Hereditary B-Disease 1 0.9999659061431885
deficiency I-Disease 1 0.9998672008514404
of I-Disease 0 1.3923272490501404e-07
the I-Disease 0 2.995024317442585e-07
fifth I-Disease 0 1.0015335647040047e-05
component I-Disease 0 1.2385079628529638e-07
of I-Disease 0 5.80484160739303e-10
complement I-Disease 0 1.7415365505257796e-07
in O 0 9.233683329057385e-08
man O 0 0.00015664726379327476
. O 0 5.3101711472436364e-08

I O 0 0.03636045753955841
. O 0 1.4977288174122805e-06

Clinical O 0 0.006157848984003067
, O 0 3.6788938473364396e-07
immunochemical O 0 0.0005280418554320931
, O 0 2.495358728538122e-07
and O 0 1.645532847760478e-07
family O 0 6.230519744576668e-08
studies O 0 1.4121332014838117e-07
. O 0 5.043954942607343e-08

The O 0 1.0031767487816978e-06
first O 0 3.883471038079733e-07
recognized O 0 4.7600607899767056e-08
human O 0 2.4893785166568705e-07
kindred O 0 4.888654075330123e-05
with O 0 0.00023048538423608989
hereditary B-Disease 1 0.9999921321868896
deficiency I-Disease 1 0.995212197303772
of I-Disease 0 7.369391141764936e-08
the I-Disease 0 9.323458129983919e-07
fifth I-Disease 0 0.00011059198004659265
component I-Disease 0 6.507187322313257e-07
of I-Disease 0 1.264532922817807e-08
complement I-Disease 0 4.100701517018024e-06
( O 0 3.7393515839312386e-08
C5 O 0 0.0026583056896924973
) O 0 5.191147067762358e-09
is O 0 1.0346616008405363e-08
described O 0 2.062086423393339e-06
. O 0 8.017131847282144e-08

The O 0 8.94909476301109e-07
proband O 0 3.930804450646974e-05
, O 0 4.755603022488231e-09
a O 0 1.0998062460743085e-09
20 O 0 9.739251183304987e-09
- O 0 9.368878818349913e-05
year O 0 3.3533854093548143e-07
- O 0 0.016935493797063828
old O 0 0.006076321471482515
black O 0 1.5080069715622813e-05
female O 0 4.78961464978056e-06
with O 0 8.328253898071125e-06
systemic B-Disease 1 0.999998927116394
lupus I-Disease 1 0.999927282333374
erythematosus I-Disease 1 0.9999945163726807
since O 0 0.013014658354222775
age O 0 6.279691297095269e-05
11 O 0 1.6681178749422543e-06
, O 0 6.238225580545986e-08
lacked O 0 2.3218741262098774e-05
serum O 0 5.417295324150473e-05
hemolytic O 0 4.8687183152651414e-05
complement O 0 1.0461337751621613e-07
activity O 0 2.721669432048657e-07
, O 0 3.6938467840030853e-09
even O 0 2.677501242942526e-08
during O 0 6.933499463457338e-08
remission O 0 4.72668580187019e-06
. O 0 2.3310368746365384e-08

C5 O 0 0.30423977971076965
was O 0 9.093747939914465e-05
undetectable O 0 4.568981967167929e-05
in O 0 1.837135243931698e-08
her O 0 7.73148485677666e-07
serum O 0 1.1962322332692565e-06
by O 0 4.824532440217411e-10
both O 0 1.5698333299951628e-08
immunodiffusion O 0 0.0010447680251672864
and O 0 5.655641416524304e-06
hemolytic O 0 0.016085781157016754
assays O 0 5.654472261085175e-05
. O 0 5.128303541823698e-07

Other O 0 2.1064666455572478e-08
complement O 0 1.592126253058268e-08
components O 0 7.091036025030917e-08
were O 0 9.918676546760707e-09
normal O 0 4.256145658132482e-08
during O 0 6.183943668247593e-08
remission O 0 1.0052166317109368e-06
of O 0 1.1768636731801507e-08
lupus O 0 0.4810076355934143
, O 0 1.2312369790379307e-07
but O 0 8.923903465074545e-07
C1 O 0 0.009738029912114143
, O 0 2.343599625476145e-08
C4 O 0 0.000661382160615176
, O 0 4.27905519018168e-07
C2 O 0 0.06257502734661102
, O 0 2.338558502401611e-08
and O 0 2.1079139855828544e-07
C3 O 0 0.0009675711626186967
levels O 0 1.2708650274362299e-06
fell O 0 0.0003627494443207979
during O 0 8.303789513774973e-07
exacerbations O 0 0.017555132508277893
. O 0 3.4709509577623976e-07

A O 0 9.43070335779339e-06
younger O 0 3.684023795358371e-06
half O 0 7.021654937489075e-07
- O 0 0.018471119925379753
sister O 0 0.005125435069203377
, O 0 3.1594322535966057e-07
who O 0 6.642736479989253e-06
had O 0 0.0002529512858018279
no O 0 3.1893650884740055e-06
underlying O 0 0.02204975299537182
disease O 1 0.9494483470916748
, O 0 9.686714719236988e-08
was O 0 5.756177779403515e-05
also O 0 1.488788711867528e-06
found O 0 5.825633593303792e-07
to O 0 6.187695333892407e-08
lack O 0 3.0940921647015784e-07
immunochemically O 0 0.00043952016858384013
detectable O 0 7.715214451309294e-05
C5 O 0 0.0014829434221610427
. O 0 1.2717509889625944e-07

By O 0 1.589899511600379e-06
hemolytic O 0 0.0060827177949249744
assay O 0 3.0205266739358194e-05
, O 0 8.857634981040974e-08
she O 0 4.4306449353825883e-07
exhibited O 0 4.032505529494301e-08
1 O 0 2.138459720413266e-08
- O 0 0.00037528687971644104
2 O 0 3.516523747748579e-07
% O 0 2.7537691571488665e-10
of O 0 8.866901657356152e-11
the O 0 1.2738698096370626e-08
normal O 0 1.6263971929220133e-06
serum O 0 1.9501188944559544e-05
C5 O 0 2.6688987418310717e-05
level O 0 3.758035234113777e-07
and O 0 2.0748968765360587e-08
normal O 0 4.785885465707906e-09
concentrations O 0 2.7155449444649093e-08
of O 0 7.128140439016661e-11
other O 0 3.781334134700387e-10
complement O 0 1.4697992156698092e-08
components O 0 4.941850875184173e-07
. O 0 9.252652688473972e-08

C5 O 0 0.01967475935816765
levels O 0 7.75111675466178e-06
of O 0 7.02080560355256e-10
other O 0 1.933189608394059e-09
family O 0 1.0455408983034431e-08
members O 0 1.621017070574382e-10
were O 0 1.6514180245508214e-08
either O 0 1.990110476413065e-08
normal O 0 6.47173763468345e-08
or O 0 1.1512955921944013e-08
approximately O 0 1.0602247968449774e-08
half O 0 9.09136645077524e-07
- O 0 0.014364359900355339
normal O 0 1.140222138928948e-05
, O 0 2.5969999484232176e-08
consistent O 0 1.5344299697517272e-07
with O 0 4.400993347530857e-08
autosomal O 0 0.0006217053160071373
codominant O 0 0.00014731090050190687
inheritance O 0 7.69152904922521e-07
of O 0 3.549906146815829e-09
the O 0 9.972649195333361e-08
gene O 0 5.4287451348500326e-05
determining O 0 0.0032218960113823414
C5 B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999988079071045
. O 0 3.4930574202007847e-06

Normal O 0 0.0006085301283746958
hemolytic O 0 0.14925812184810638
titers O 0 0.0015117948642000556
were O 0 3.4355591651547e-06
restored O 0 5.9131139096280094e-06
to O 0 1.4478873211487553e-08
both O 0 1.094696386871874e-07
homozygous O 0 0.006025160662829876
C5 B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999984502792358
deficient I-Disease 1 0.9999998807907104
( O 0 2.864506677724421e-05
C5D B-Disease 1 0.9999995231628418
) O 0 1.1651776503640576e-06
sera O 0 6.010260221955832e-06
by O 0 2.860278958127793e-10
addition O 0 2.0356634433671417e-10
of O 0 4.1018990981633863e-10
highly O 0 2.301379140590143e-07
purified O 0 6.297993422776926e-06
human O 0 4.753342750518641e-07
C5 O 0 0.0005180826992727816
. O 0 1.338076600632121e-07

In O 0 1.6820287385144184e-07
specific O 0 3.3438997348866906e-08
C5 O 0 9.409509948454797e-05
titrations O 0 8.678353333380073e-05
, O 0 1.7332553170490428e-07
however O 0 1.122969450761957e-07
, O 0 1.1573348501769942e-08
it O 0 1.4949833371247223e-07
was O 0 7.396212367893895e-06
noted O 0 1.685185253563759e-07
that O 0 4.272160225582411e-08
when O 0 1.9721653643500758e-08
limited O 0 6.183160095041274e-10
amounts O 0 8.944119750387003e-11
of O 0 9.109647480798344e-10
C5 O 0 3.927657235180959e-05
were O 0 1.4822116867208024e-08
assayed O 0 2.088819286427679e-07
in O 0 2.542904331548357e-09
the O 0 1.4484832222549926e-09
presence O 0 2.2249644349159325e-09
of O 0 1.8264038892379375e-10
low O 0 4.6138205789247877e-07
dilutions O 0 3.3269095638388535e-06
of O 0 3.7034835198568317e-09
either O 0 5.836827767780051e-06
C5D B-Disease 1 0.9999986886978149
serum O 0 0.0009468506323173642
, O 0 1.4925459757009207e-09
curving O 0 4.104220465706021e-07
rather O 0 5.809094871800369e-10
than O 0 3.333438733377214e-11
linear O 0 3.513345347982977e-08
dose O 0 2.2396555721115874e-07
- O 0 3.784930959227495e-05
response O 0 1.2194060872161572e-08
plots O 0 1.25403391848522e-06
were O 0 1.8294011283614964e-07
consistently O 0 3.601618630000303e-07
obtained O 0 2.476221006020296e-09
, O 0 8.559905562144365e-11
suggesting O 0 3.7155944987432576e-10
some O 0 1.4607114129372434e-11
inhibitory O 0 2.7975804783864078e-08
effect O 0 1.7836929089298792e-07
. O 0 4.247687002134626e-08

Further O 0 4.147055108205677e-07
studies O 0 4.332101255499765e-08
suggested O 0 1.4936151160327427e-07
that O 0 1.574198904563673e-08
low O 0 8.740514658711618e-07
dilutions O 0 0.0002171131782233715
of O 0 5.528416409106285e-07
C5D B-Disease 1 0.9999979734420776
serum O 0 0.0025887840893119574
contain O 0 1.0849351639308225e-07
a O 0 1.4723694263807374e-08
factor O 0 4.068910541832338e-08
( O 0 5.627233123917108e-10
or O 0 1.1109894337835158e-08
factors O 0 4.690293486930841e-09
) O 0 2.1557887419643151e-10
interfering O 0 1.673712723970766e-09
at O 0 2.0664203681519666e-09
some O 0 9.743236079051698e-11
step O 0 2.255271347451071e-08
in O 0 5.7271578590700756e-09
the O 0 4.197423209006956e-08
hemolytic O 0 0.0005334090674296021
assay O 0 1.0334880471418728e-06
of O 0 1.1774654140594976e-08
C5 O 0 0.009250849485397339
, O 0 3.544378568420825e-09
rather O 0 2.304817725562458e-10
than O 0 1.4534003167643306e-10
a O 0 3.949111260226346e-09
true O 0 4.2880139972112374e-07
C5 O 0 7.317084964597598e-05
inhibitor O 0 1.1706709983627661e-06
or O 0 4.800699215934401e-08
inactivator O 0 0.00038644802407361567
. O 0 4.332754315328202e-07

Of O 0 6.271725538908868e-08
clinical O 0 9.387462341692299e-06
interest O 0 1.0331909550131968e-07
are O 0 1.2392162851426747e-08
( O 0 2.203279114709744e-09
a O 0 2.964226908375167e-08
) O 0 4.0460554906474044e-09
the O 0 4.8715089739914674e-09
documentation O 0 9.196313612847007e-07
of O 0 2.1516918025099585e-07
membranous O 1 0.999962329864502
glomerulonephritis B-Disease 1 0.9999998807907104
, O 0 0.18425479531288147
vasculitis B-Disease 1 0.9999994039535522
, O 0 0.0006217443733476102
and O 1 0.768805742263794
arthritis B-Disease 1 1.0
in O 0 8.990514857032395e-07
an O 0 2.2962488799294078e-07
individual O 0 4.905853643322189e-07
lacking O 0 8.106242603389546e-06
C5 O 0 0.0029872835148125887
( O 0 5.835951277788354e-09
and O 0 7.735789786522673e-09
its O 0 1.853110859206808e-10
biologic O 0 7.717995913480991e-07
functions O 0 1.52572798839401e-08
) O 0 7.948641744803808e-09
, O 0 1.4271591908254777e-08
and O 0 2.4669645881658653e-07
( O 0 6.5577205887734635e-09
b O 0 1.308600894844858e-05
) O 0 4.5350567745572334e-10
a O 0 7.382429334512608e-09
remarkable O 0 7.209176260403183e-07
propensity O 0 0.00011627647472778335
to O 0 0.00033243559300899506
bacterial B-Disease 1 0.9999996423721313
infections I-Disease 1 0.9999998807907104
in O 0 1.6812409739941359e-06
the O 0 5.710895720767439e-07
proband O 0 0.002270027995109558
, O 0 1.4994261832157463e-08
even O 0 6.789840245602363e-09
during O 0 4.719828083921129e-09
periods O 0 9.400580758267552e-09
of O 0 1.1669937238778516e-10
low O 0 4.985139412383433e-07
- O 0 4.651777544495417e-06
dose O 0 1.4309369689158302e-08
or O 0 1.440173952316215e-10
alternate O 0 3.0090678837524365e-09
- O 0 5.548864919546759e-06
day O 0 2.575910151847438e-08
corticosteroid O 0 6.460640179284383e-06
therapy O 0 2.1889979961997597e-06
. O 0 1.198570043214886e-08

Other O 0 6.880212310989009e-08
observations O 0 2.8122187245571695e-07
indicate O 0 7.396194519060373e-07
that O 0 7.728817053020975e-08
the O 0 1.1726672966005935e-07
C5D B-Disease 1 0.9999982118606567
state O 0 9.057540495405192e-08
is O 0 1.5074322234909232e-08
compatible O 0 1.803498435037909e-07
with O 0 6.475291414176354e-09
normal O 0 2.706579209643678e-07
coagulation O 0 2.410102126759739e-07
function O 0 5.234060722614231e-07
and O 0 1.4034654327588214e-07
the O 0 4.522111574090104e-09
capacity O 0 5.130873947933878e-09
to O 0 8.067791434918092e-10
mount O 0 1.8911445920366532e-07
a O 0 2.7158876036992297e-07
neutrophilic O 0 0.008398701436817646
leukocytosis O 0 0.004717840347439051
during O 0 8.259266905952245e-06
pyogenic B-Disease 1 0.5862327814102173
infection I-Disease 0 0.4672764241695404
. O 0 1.4005275161821373e-08
. O 0 2.9117543931533874e-08

Susceptibility O 1 0.596484899520874
to O 0 0.0008994163363240659
ankylosing B-Disease 1 0.9999991655349731
spondylitis I-Disease 1 1.0
in O 0 0.01206512376666069
twins O 0 0.4391343295574188
: O 0 3.486981370315334e-08
the O 0 8.557721753454928e-10
role O 0 4.245732654339918e-09
of O 0 4.394304087274037e-10
genes O 0 1.8585041061669472e-07
, O 0 3.8956446957172375e-08
HLA O 0 0.0005507671739906073
, O 0 3.0498053860128493e-08
and O 0 1.22175514150058e-08
the O 0 9.907804354725158e-09
environment O 0 1.8925243239209522e-06
. O 0 1.7862079815245124e-08

OBJECTIVE O 0 4.776431978825713e-06
To O 0 1.6046135087322e-08
determine O 0 6.256358542344742e-09
the O 0 4.5932696535189166e-10
relative O 0 7.177097138821864e-09
effects O 0 1.945523706581298e-07
of O 0 1.172091534940023e-09
genetic O 0 2.7395455617806874e-05
and O 0 2.9211426522124384e-07
environmental O 0 1.1061558780056657e-08
factors O 0 2.1015336137963914e-09
in O 0 5.380098144769363e-08
susceptibility O 0 0.02308783307671547
to O 0 0.0008523188880644739
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0025456156581640244
AS B-Disease 1 0.9999375343322754
) O 0 3.400766388494958e-07
. O 0 8.904471826554072e-08

METHODS O 0 0.00016541616059839725
Twins O 0 0.0011983190197497606
with O 0 2.515124606361496e-07
AS B-Disease 1 0.9962484240531921
were O 0 1.0774307668270922e-07
identified O 0 9.242228315997636e-08
from O 0 5.446294526478823e-10
the O 0 3.5910886708734324e-08
Royal O 0 1.4815277609159239e-05
National O 0 1.946941665664781e-07
Hospital O 0 4.5570635847980157e-05
for O 0 1.7653059103395208e-06
Rheumatic B-Disease 1 0.9999890327453613
Diseases I-Disease 1 0.5214188694953918
database O 0 1.7831800505518913e-05
. O 0 5.761321517638862e-07

Clinical O 0 0.0003655434411484748
and O 0 1.563118843250777e-07
radiographic O 0 1.6818323274492286e-05
examinations O 0 6.895596015965566e-06
were O 0 5.505635058966618e-08
performed O 0 1.0797838285725447e-06
to O 0 7.577764193911207e-09
establish O 0 5.195537937652261e-07
diagnoses O 1 0.8997299671173096
, O 0 2.294483238074463e-06
and O 0 0.0008201961754821241
disease O 1 0.8151758909225464
severity O 0 0.0029262658208608627
was O 0 5.449891887110425e-06
assessed O 0 1.1865147975242962e-08
using O 0 9.72946612165515e-09
a O 0 4.1307249176725236e-08
combination O 0 1.2758317780026118e-06
of O 0 2.2383555009497513e-09
validated O 0 2.543328719184501e-06
scoring O 0 3.148315954604186e-07
systems O 0 1.626012999622617e-05
. O 0 1.8142198143777932e-07

HLA O 0 0.0011621093144640326
typing O 0 5.94897719565779e-05
for O 0 2.460680725846487e-08
HLA O 0 0.0001290035725105554
- O 0 0.00011740689660655335
B27 O 0 9.993334515456809e-07
, O 0 2.8779838512349443e-09
HLA O 0 1.8371338228462264e-06
- O 0 9.180731467495207e-06
B60 O 0 2.761267694495473e-07
, O 0 5.262855706789082e-10
and O 0 2.8682678454572397e-09
HLA O 0 2.7068190320278518e-05
- O 0 0.00024269495042972267
DR1 O 0 0.20243218541145325
was O 0 1.7068309716705699e-06
performed O 0 2.236487617324201e-08
by O 0 8.384549304851774e-11
polymerase O 0 2.4954371724561497e-07
chain O 0 3.2826949336595135e-06
reaction O 0 3.979780505147801e-09
with O 0 6.235055249881327e-10
sequence O 0 9.348266161168794e-08
- O 0 6.458841653511627e-06
specific O 0 1.6114001244460496e-09
primers O 0 7.696306965954136e-06
, O 0 6.009043040933193e-09
and O 0 1.4197905962021196e-08
zygosity O 0 1.5591080000376678e-06
was O 0 1.215156686384944e-07
assessed O 0 1.920415160228117e-09
using O 0 1.47052556798144e-08
microsatellite O 0 0.00013123686949256808
markers O 0 0.0005215301644057035
. O 0 1.86231517318447e-07

Genetic O 0 0.005030112806707621
and O 0 2.64896186763508e-07
environmental O 0 2.361331130629196e-09
variance O 0 1.2407648242174218e-09
components O 0 9.767268238647375e-07
were O 0 2.1592441612483526e-07
assessed O 0 1.1058757110049555e-07
with O 0 1.098670310284433e-08
the O 0 3.057166964026692e-08
program O 0 1.4243043722217408e-07
Mx O 0 1.2367364433885086e-05
, O 0 1.6280291004200365e-10
using O 0 2.2345622574526658e-10
data O 0 4.7961506766114326e-08
from O 0 3.3992772485724743e-10
this O 0 6.256525519887646e-09
and O 0 2.3632336976220358e-08
previous O 0 1.7674297581038445e-08
studies O 0 3.596275943706928e-09
of O 0 8.844913690353451e-10
twins O 0 0.00602092407643795
with O 0 6.48040838768793e-07
AS B-Disease 1 0.9999082088470459
. O 0 1.1443095218055532e-06

RESULTS O 0 4.7091481974348426e-05
Six O 0 6.703088928361467e-08
of O 0 1.5681625997743254e-09
8 O 0 4.159718400842394e-07
monozygotic O 0 0.00030171548132784665
( O 0 3.421338590214873e-07
MZ O 1 0.9999110698699951
) O 0 1.003814190880803e-06
twin O 0 0.17399147152900696
pairs O 0 0.001632230938412249
were O 0 0.0002934819203801453
disease O 0 0.17121076583862305
concordant O 0 5.49448341189418e-05
, O 0 2.6561411914372e-07
compared O 0 1.6728128571230627e-07
with O 0 4.285961452410447e-08
4 O 0 1.093566993404238e-06
of O 0 1.155656192963761e-08
15 O 0 2.0784882792668213e-07
B27 O 0 1.2907034943054896e-06
- O 0 7.231540803331882e-05
positive O 0 2.327771220222985e-08
dizygotic O 0 3.1562342428514967e-07
( O 0 1.8893799857977456e-09
DZ O 0 0.0005806758999824524
) O 0 5.9831961607415e-09
twin O 0 2.0671664969995618e-05
pairs O 0 2.45328180881188e-07
( O 0 7.564893156342123e-10
27 O 0 1.8663688194919814e-07
% O 0 6.789707129861711e-10
) O 0 1.637010083044288e-09
and O 0 6.620953030278542e-08
4 O 0 6.632745908063953e-08
of O 0 5.225269550379608e-09
32 O 0 1.4369712516781874e-05
DZ O 1 0.9930633902549744
twin O 0 0.07541204988956451
pairs O 0 1.774284896782774e-06
overall O 0 2.0569973457895685e-06
( O 0 2.871151982830611e-09
12 O 0 1.4282212745797551e-08
. O 0 7.090312781343755e-10
5 O 0 9.184515370463942e-09
% O 0 9.945400059052645e-10
) O 0 5.450838447274009e-09
. O 0 4.849003332196844e-08

Nonsignificant O 0 0.0004452616849448532
increases O 0 1.7333672985841986e-06
in O 0 4.8403978603062114e-09
similarity O 0 5.123541768625728e-08
with O 0 5.996368734884072e-09
regard O 0 5.0307633614465885e-08
to O 0 1.9493755587518535e-07
age O 0 5.214965767663671e-06
at O 0 8.718197932466865e-06
disease O 0 0.13685645163059235
onset O 0 0.005309932865202427
and O 0 8.237415386247449e-06
all O 0 8.229100068035677e-09
of O 0 6.4188609982807066e-09
the O 0 1.256352334166877e-05
disease O 0 0.19036252796649933
severity O 0 1.2938168765685987e-05
scores O 0 8.066151053753856e-07
assessed O 0 1.6010557146728388e-07
were O 0 4.3559640516832587e-07
noted O 0 2.8159913654235424e-06
in O 0 1.5625359083060175e-05
disease O 1 0.9660038948059082
- O 1 0.9104664325714111
concordant O 0 0.3197474777698517
MZ O 1 0.9999265670776367
twins O 0 0.020590342581272125
compared O 0 3.859571791053895e-07
with O 0 1.4434870365676034e-07
concordant O 0 0.023546814918518066
DZ O 1 0.999001681804657
twins O 1 0.7646135091781616
. O 0 8.403298465964326e-07

HLA O 0 0.053859643638134
- O 0 0.007544859312474728
B27 O 0 1.767600406310521e-05
and O 0 6.06441616923803e-08
B60 O 0 1.228433887945357e-07
were O 0 1.2209095956450255e-08
associated O 0 1.517523351424188e-08
with O 0 9.41993292258303e-08
the O 0 2.4084849428618327e-05
disease O 1 0.5154411792755127
in O 0 3.6559958971338347e-07
probands O 0 0.024143535643815994
, O 0 3.020328449565568e-07
and O 0 6.813168340613629e-08
the O 0 5.396755042852419e-09
rate O 0 4.628541319107171e-06
of O 0 3.9397615836378463e-08
disease O 0 0.0006856703548692167
concordance O 0 2.091690703309723e-06
was O 0 2.046060672000749e-06
significantly O 0 8.960404329627636e-08
increased O 0 3.1692941604433145e-08
among O 0 9.707500581157547e-09
DZ O 1 0.939624547958374
twin O 0 0.37165236473083496
pairs O 0 2.9239481591503136e-06
in O 0 2.731211345974316e-08
which O 0 2.1226220781045413e-07
the O 0 2.4645893859087664e-07
co O 0 0.02869957871735096
- O 0 0.41603294014930725
twin O 0 0.011914549395442009
was O 0 1.280649371437903e-06
positive O 0 5.067111730205909e-10
for O 0 3.8892094406106636e-11
both O 0 1.562966867041382e-09
B27 O 0 5.733269858865242e-07
and O 0 9.478380746941184e-08
DR1 O 0 0.03322949633002281
. O 0 8.053424238596563e-08

Additive O 0 5.039732513978379e-06
genetic O 0 5.00431633554399e-05
effects O 0 7.024192200333346e-06
were O 0 4.71223806641774e-08
estimated O 0 1.3883038718631724e-08
to O 0 1.4086664279489014e-08
contribute O 0 1.2247713954138817e-09
97 O 0 6.415729814079896e-08
% O 0 2.5425492267139305e-10
of O 0 1.8160833947789e-10
the O 0 5.3671502797669746e-09
population O 0 4.8717780920526366e-09
variance O 0 6.748385317223438e-08
. O 0 6.074743197359567e-08

CONCLUSION O 0 6.499708888441091e-06
Susceptibility O 0 0.0011570575879886746
to O 0 2.3639336177438963e-06
AS B-Disease 1 0.9914982914924622
is O 0 2.5349104149086088e-08
largely O 0 9.73876801424467e-09
genetically O 0 3.3246402608710923e-07
determined O 0 2.5693461793707684e-05
, O 0 5.303166972225881e-08
and O 0 5.739561714790398e-08
the O 0 1.1797628651777359e-08
environmental O 0 1.8456528039223485e-07
trigger O 0 3.147891220578458e-06
for O 0 3.446087504244133e-08
the O 0 1.1673927474475931e-05
disease O 0 0.226713627576828
is O 0 8.299500109387736e-08
probably O 0 6.574918529622664e-07
ubiquitous O 0 7.709860255999956e-06
. O 0 2.123547346855048e-07

HLA O 0 0.057425256818532944
- O 0 0.0021363948471844196
B27 O 0 2.9025331969023682e-06
accounts O 0 1.2371404345401515e-08
for O 0 4.245131468572083e-10
a O 0 4.3074308564428065e-09
minority O 0 8.096827031067733e-08
of O 0 1.092167800642585e-09
the O 0 4.1179184506745514e-08
overall O 0 8.156157491612248e-06
genetic O 0 1.874107329058461e-05
susceptibility O 0 0.00011570828792173415
to O 0 1.1030145969925798e-06
AS B-Disease 1 0.9994304776191711
. O 0 5.998155643283098e-07

Cell O 0 0.008449852466583252
cycle O 0 0.0019899681210517883
- O 0 0.000356041215127334
dependent O 0 3.735499092272221e-07
colocalization O 0 1.0352960998716298e-05
of O 0 9.480889850976837e-09
BARD1 O 0 0.0004967759596183896
and O 0 3.9288735820264264e-07
BRCA1 O 0 2.0628674519684864e-06
proteins O 0 1.2303585705808473e-08
in O 0 4.329692993021439e-10
discrete O 0 3.058523248000711e-07
nuclear O 0 2.6389232516521588e-05
domains O 0 1.3052409485680982e-05
. O 0 5.514856979971228e-07

Germ O 1 0.8680885434150696
- O 1 0.6833498477935791
line O 0 0.001341481227427721
mutations O 0 1.3164038819013513e-06
of O 0 9.016010715789946e-10
the O 0 3.236935697259469e-08
BRCA1 O 0 4.1288833017461e-05
gene O 0 2.285938990098657e-06
predispose O 0 9.8161171990796e-06
women O 0 2.9015211566729704e-07
to O 0 5.2968158748001315e-09
early O 0 1.1842910225823289e-06
- O 1 0.9831651449203491
onset O 1 0.9966841340065002
breast B-Disease 1 0.9999912977218628
and I-Disease 1 0.9999898672103882
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
by O 0 1.2872071408764896e-07
compromising O 0 1.8192029529018328e-05
the O 0 7.554879033477846e-08
genes O 0 3.485752131382469e-07
presumptive O 0 4.355920282250736e-06
function O 0 4.635997186142049e-08
as O 0 1.0830449426180166e-08
a O 0 2.8162094167782925e-07
tumor B-Disease 0 0.005522965453565121
suppressor O 0 0.0005825498374179006
. O 0 5.63312312351627e-07

Although O 0 3.492447149255895e-07
the O 0 1.249986003593051e-09
biochemical O 0 1.7182867395604262e-07
properties O 0 4.6798808739367814e-07
of O 0 8.10519829030909e-09
BRCA1 O 0 0.00010013540304498747
polypeptides O 0 1.1345622624503449e-05
are O 0 2.1338887279398477e-07
not O 0 6.94728669259348e-07
understood O 0 2.9475228302544565e-07
, O 0 1.6718558759620805e-09
their O 0 1.3914578378404485e-09
expression O 0 2.3216569999817693e-08
pattern O 0 1.417575367668178e-05
and O 0 3.9124735451423476e-08
subcellular O 0 5.162218712939648e-06
localization O 0 1.0971062692988198e-05
suggest O 0 1.7643671412770345e-07
a O 0 3.0711799769989057e-09
role O 0 6.109463157599748e-08
in O 0 4.9634735432846355e-08
cell O 0 0.0007829615497030318
- O 0 0.08667871356010437
cycle O 0 8.436432108283043e-05
regulation O 0 6.919455586285039e-07
. O 0 2.4879632576357835e-08

When O 0 0.0001044582822942175
resting O 0 9.7057736638817e-06
cells O 0 9.151563062914647e-07
are O 0 4.217805660289287e-09
induced O 0 2.596480590000283e-05
to O 0 1.9043195464973905e-08
proliferate O 0 1.4929308235878125e-05
, O 0 1.826777618063602e-09
the O 0 5.812331727028663e-10
steady O 0 1.7116121853177901e-07
- O 0 1.562385591569182e-06
state O 0 1.9422778940736407e-09
levels O 0 1.064850985166288e-09
of O 0 1.602390616028959e-11
BRCA1 O 0 7.083506403660067e-08
increase O 0 1.4296540618019549e-09
in O 0 1.8993089323515733e-09
late O 0 4.3952052664053554e-08
G1 O 0 3.5117936931783333e-05
and O 0 1.4113854085451294e-08
reach O 0 1.0869515287836862e-09
a O 0 2.471256255187626e-10
maximum O 0 1.559827822461557e-09
during O 0 1.1200918414999705e-08
S O 0 4.265916686563287e-06
phase O 0 6.375243515321927e-07
. O 0 5.8029659300018466e-08

Moreover O 0 1.9401817553443834e-05
, O 0 1.703686791643122e-08
in O 0 4.400831699058472e-09
S O 0 6.659520295215771e-06
phase O 0 1.146627596426697e-06
cells O 0 5.273630449664779e-06
, O 0 3.563079831181426e-09
BRCA1 O 0 1.2350183169473894e-06
polypeptides O 0 6.022390266480215e-07
are O 0 9.644604226366482e-09
hyperphosphorylated O 0 2.284315269207582e-05
and O 0 1.8524366396377445e-07
accumulate O 0 1.628957022603572e-07
into O 0 1.3835819157037577e-09
discrete O 0 1.9433443867455935e-06
subnuclear O 0 0.002443488920107484
foci O 0 0.000106686660728883
termed O 0 1.641427843424026e-05
" O 0 7.602761229463795e-07
BRCA1 O 0 5.526188942894805e-06
nuclear O 0 7.424770046782214e-06
dots O 0 0.00046098825987428427
. O 0 1.019280375658127e-06

" O 0 1.5714465916971676e-05
BRCA1 O 0 0.000188099016668275
associates O 0 4.524202086031437e-05
in O 0 1.1429769131154899e-08
vivo O 0 9.95481968857348e-06
with O 0 1.0378457204751612e-08
a O 0 6.103022087700083e-08
structurally O 0 7.720321445958689e-05
related O 0 9.977155741580646e-07
protein O 0 6.726290303049609e-05
termed O 0 0.0008860717061907053
BARD1 O 0 0.21157163381576538
. O 0 7.722244390606647e-07

Here O 0 1.4965067975936108e-06
we O 0 8.65266258642805e-08
show O 0 9.584381288618715e-09
that O 0 1.0058566202175712e-09
the O 0 3.301543205491697e-10
steady O 0 3.5792626817965356e-07
- O 0 5.87657905271044e-06
state O 0 5.333046892985749e-09
levels O 0 7.869894957934775e-09
of O 0 2.910841012671028e-10
BARD1 O 0 8.01283385953866e-05
, O 0 1.4735513920172139e-09
unlike O 0 2.6602178238022134e-09
those O 0 1.05687014695377e-10
of O 0 4.332080250080139e-10
BRCA1 O 0 4.751329470309429e-05
, O 0 1.7186874146091213e-08
remain O 0 2.4500719231212997e-09
relatively O 0 2.998913617435761e-10
constant O 0 3.654177183065599e-09
during O 0 1.5578306644670192e-08
cell O 0 3.169615592923947e-05
cycle O 0 6.296823266893625e-05
progression O 0 0.00038402745849452913
. O 0 6.540684438505195e-08

However O 0 1.2599469300766941e-05
, O 0 2.3277667793308865e-08
immunostaining O 0 2.065225453407038e-05
revealed O 0 9.118856723944191e-06
that O 0 5.5662006559487054e-08
BARD1 O 0 0.0001997464569285512
resides O 0 5.658321242663078e-07
within O 0 2.084725947426591e-09
BRCA1 O 0 1.7448360267735552e-06
nuclear O 0 4.581247878832073e-07
dots O 0 8.863430593919475e-06
during O 0 3.8121589795991895e-07
S O 0 1.2344822607701644e-05
phase O 0 1.384533447890135e-07
of O 0 6.183489831279587e-10
the O 0 1.4680733961824899e-08
cell O 0 0.0003586447855923325
cycle O 0 4.2445088183740154e-05
, O 0 3.9989860312061865e-09
but O 0 3.780383561746703e-09
not O 0 7.595747364419481e-10
during O 0 2.5673532744185934e-10
the O 0 8.561117925687256e-10
G1 O 0 1.1284038919257e-05
phase O 0 5.278025696497934e-07
. O 0 2.3976898688715664e-08

Nevertheless O 0 0.0003485042543616146
, O 0 4.804812192560348e-08
BARD1 O 0 8.641183740110137e-06
polypeptides O 0 6.043978260095173e-07
are O 0 2.1868848065764723e-08
found O 0 1.8757578601480418e-08
exclusively O 0 3.0828946062655405e-09
in O 0 2.7574129646268375e-09
the O 0 1.0283986995318628e-09
nuclear O 0 2.849494862289248e-08
fractions O 0 9.559419922311463e-10
of O 0 1.1118871795501306e-10
both O 0 6.406556618543391e-09
G1 O 0 2.7611262339632958e-05
- O 0 0.0001245888415724039
and O 0 7.39164647711732e-07
S O 0 3.858975105686113e-06
- O 0 1.2936141047248384e-06
phase O 0 1.1929849108582857e-07
cells O 0 2.660960660705314e-07
. O 0 9.501056830174548e-09

Therefore O 0 3.5866734833689407e-05
, O 0 4.734653202831396e-08
progression O 0 3.697989814099856e-05
to O 0 4.2089677521062185e-08
S O 0 1.8426593669573776e-05
phase O 0 9.372338922730705e-07
is O 0 1.912801295134159e-08
accompanied O 0 2.3230786183603414e-08
by O 0 8.878109358789743e-10
the O 0 4.166272327132958e-10
aggregation O 0 1.4369431866612103e-08
of O 0 4.866176350759588e-10
nuclear O 0 2.1920188828516984e-06
BARD1 O 0 1.7321181076113135e-06
polypeptides O 0 3.223166089583174e-08
into O 0 1.1388466170103584e-08
BRCA1 O 0 4.332343451096676e-06
nuclear O 0 1.296784944315732e-06
dots O 0 8.626586350146681e-05
. O 0 2.149669455775438e-07

This O 0 2.7089757281828497e-07
cell O 0 3.950854079448618e-05
cycle O 0 9.938729635905474e-05
- O 0 0.00013757498527411371
dependent O 0 2.9529473977163434e-07
colocalization O 0 6.05044169788016e-06
of O 0 5.799466684663912e-09
BARD1 O 0 0.0021745481062680483
and O 0 8.045177537496784e-07
BRCA1 O 0 3.1084741749509703e-06
indicates O 0 8.095792480844466e-08
a O 0 2.3322097586486734e-09
role O 0 2.8196941670444176e-08
for O 0 7.935978096895724e-09
BARD1 O 0 9.803731518331915e-05
in O 0 5.040838857439667e-08
BRCA1 O 0 5.987816257402301e-05
- O 0 0.014619632624089718
mediated O 0 0.0008206160855479538
tumor B-Disease 0 0.0019003936322405934
suppression O 0 2.1195191948208958e-05
. O 0 2.788466133551992e-07

Ethnic O 0 6.07096626481507e-06
differences O 0 1.3662501260114368e-05
in O 0 6.974271826720724e-08
the O 0 5.479099485228289e-08
HFE O 0 0.0054554627276957035
codon O 0 3.450749136391096e-05
282 O 0 8.671480827615596e-06
( O 0 4.041244494601415e-08
Cys O 0 0.3243826925754547
/ O 0 0.0002399550867266953
Tyr O 0 3.870806540362537e-05
) O 0 2.1109018977227834e-09
polymorphism O 0 9.834227512328653e-07
. O 0 4.808387643606693e-08

Recent O 0 1.661704800426378e-06
studies O 0 1.8336911011829216e-07
have O 0 6.31658920724476e-08
shown O 0 1.099137762139435e-06
that O 0 0.001510600559413433
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0038987246807664633
HH B-Disease 1 0.9999799728393555
) O 0 3.5200400816393085e-07
is O 0 1.24483122476704e-07
likely O 0 4.069769090619957e-07
to O 0 4.6863885216907875e-08
be O 0 1.9007600826626003e-07
caused O 0 1.1389579412934836e-07
by O 0 4.7605852593335385e-09
homozygosity O 0 3.361056951689534e-05
for O 0 2.340364346764545e-09
a O 0 2.606935467497351e-08
Cys282Tyr O 0 0.00010732970986282453
mutation O 0 2.885425374188344e-07
in O 0 2.6964879218382976e-09
the O 0 7.300166249279982e-09
HFE O 0 0.0001801124744815752
gene O 0 4.6211658855099813e-07
located O 0 1.0107613661602954e-06
4 O 0 2.0698098524007946e-06
. O 0 2.720870213579474e-07

5 O 0 1.8456032648828113e-06
Mb O 0 0.00023802166106179357
telomeric O 0 0.0012072449317201972
to O 0 1.5307496141758747e-06
HLA O 0 0.003297952003777027
- O 0 0.0026646219193935394
A O 0 1.3764345112576848e-06
. O 0 1.1091562868159599e-07

Population O 0 2.0772161235527165e-07
studies O 0 8.398609807613866e-09
of O 0 1.6604843888767817e-10
this O 0 5.493901444886262e-10
polymorphism O 0 9.219197067977802e-07
are O 0 1.4590086916399514e-09
facilitated O 0 2.488538370926108e-07
by O 0 1.7553922759816487e-08
the O 0 2.9474263030238035e-08
fact O 0 1.0282348483769965e-07
that O 0 8.218249547553569e-08
the O 0 1.2979496588627626e-08
Cys282Tyr O 0 3.154917067149654e-05
mutation O 0 1.5660208418921684e-07
creates O 0 9.195277428375448e-09
a O 0 5.885404164018837e-09
Rsal O 0 1.9372382666915655e-05
restriction O 0 1.001679947876255e-07
site O 0 8.789791650087864e-07
. O 0 4.020785837610674e-08

We O 0 1.9112980226054788e-05
have O 0 4.966548505791479e-09
studied O 0 4.100782380334067e-09
the O 0 1.793194814858623e-09
codon O 0 1.364060835840064e-06
282 O 0 4.661942796246876e-07
( O 0 9.924901789304386e-09
Cys O 0 0.07685603946447372
/ O 0 9.986953955376521e-05
Tyr O 0 9.25981566979317e-06
) O 0 3.526742509141201e-10
polymorphism O 0 2.6860126567385123e-08
in O 0 3.8790246015274477e-10
different O 0 9.131458089672861e-11
ethnic O 0 7.909653376714232e-09
groups O 0 4.514564366786544e-08
. O 0 1.461705068095398e-07

In O 0 1.7143256059171108e-07
agreement O 0 2.8342634905698105e-08
with O 0 1.953665673681826e-09
previous O 0 3.5677874876682836e-08
observations O 0 9.702247183440704e-08
the O 0 3.098634682174861e-09
Tyr O 0 1.3876891671316116e-06
allele O 0 3.397219572320864e-08
appeared O 0 1.3043894568909309e-06
to O 0 6.111243511242037e-09
be O 0 1.1252438092412831e-08
rare O 0 2.3175775965000867e-08
or O 0 1.3890274885852705e-07
absent O 0 2.623992259032093e-07
in O 0 1.0498557401206199e-07
Asiatic O 0 8.660965977469459e-05
( O 0 8.910104321024903e-10
Indian O 0 1.8074776164667128e-07
, O 0 3.804355497294409e-09
Chinese O 0 2.8739464141835924e-09
) O 0 1.0238286884955983e-09
populations O 0 2.3946643779027e-08
. O 0 3.2310694564330333e-08

The O 0 2.97394464610079e-08
highest O 0 6.358106929837959e-09
allele O 0 7.821082448344896e-09
frequency O 0 1.6512674960722507e-07
( O 0 3.278450566579494e-10
7 O 0 8.469826617840681e-09
. O 0 5.139274561472007e-10
5 O 0 4.362513461586559e-09
% O 0 9.927074717808182e-10
) O 0 2.3883091060383776e-09
was O 0 1.5227531093842117e-06
found O 0 9.248859811350485e-08
in O 0 1.735089512067134e-07
Swedes O 0 0.039435628801584244
. O 0 4.180652695140452e-07

Saamis O 0 0.000597681850194931
( O 0 4.0324518835177514e-08
2 O 0 5.581253859077151e-08
% O 0 1.6005382574846294e-09
) O 0 7.566985371632029e-10
and O 0 2.6690932131145928e-08
Mordvinians O 0 1.490439990448067e-05
( O 0 2.496612361291284e-10
1 O 0 7.563237147678592e-09
. O 0 4.788862195681531e-09
8 O 0 3.4872609688818557e-08
% O 0 4.794554198106482e-10
) O 0 1.9693680020083093e-09
had O 0 4.920660217067052e-07
significantly O 0 2.948123345447584e-08
lower O 0 6.712169486888797e-09
frequencies O 0 6.168321409205646e-09
of O 0 6.883330017082301e-10
the O 0 2.68317581486599e-08
Tyr O 0 1.6137950296979398e-05
allele O 0 2.3291752881959837e-07
. O 0 3.712679585987644e-08

Comparisons O 0 2.102177631968516e-06
with O 0 4.833672129223032e-09
allele O 0 1.7239470295749015e-08
frequencies O 0 2.759487394143889e-08
based O 0 1.3409017007859347e-08
on O 0 9.568640280122054e-08
prevalence O 0 6.854107050457969e-05
estimates O 0 4.3310524233675096e-07
of O 0 1.0160341901155334e-08
HH B-Disease 1 0.9998527765274048
showed O 0 0.0004109503352083266
some O 0 7.317852990240681e-10
disagreements O 0 1.127514565268939e-06
with O 0 1.5267819009068262e-08
the O 0 1.8486222330693636e-08
RFLP O 0 1.5388879546662793e-05
data O 0 2.1433234564938175e-07
, O 0 1.2833780704823994e-09
particularly O 0 1.379847458515826e-09
in O 0 6.64157928653708e-09
Finns O 0 0.00019919851911254227
. O 0 7.705781257527633e-08

The O 0 7.484827619919088e-07
newly O 0 5.722601486013446e-07
described O 0 3.1616796150046866e-06
HFE O 0 0.0008627055212855339
marker O 0 2.0335664885351434e-05
provides O 0 5.025744709286073e-09
a O 0 1.9020280905834852e-09
new O 0 4.742124914969281e-09
approach O 0 1.0501761238401741e-07
to O 0 1.0498868441288778e-09
the O 0 2.3641058555234906e-10
screening O 0 1.5482717330428386e-08
of O 0 6.86054990595153e-10
HH B-Disease 1 0.6531625986099243
as O 0 1.2303907226396404e-07
well O 0 4.567658606902114e-08
as O 0 2.6883484327555607e-09
studies O 0 6.393174323271467e-10
of O 0 5.39796436715978e-11
the O 0 4.036127876361206e-09
relationship O 0 5.120298851579719e-08
between O 0 1.9296908959631764e-08
the O 0 8.867405654200411e-08
HFE O 0 0.00492562260478735
Tyr O 0 6.673379630228737e-06
allele O 0 9.138980772149807e-08
and O 0 6.096960447621314e-08
different O 0 3.443052420948334e-08
disorders O 0 0.002889953088015318
including O 0 9.735630328577827e-07
cancer B-Disease 0 0.21442633867263794

Autosomal B-Disease 1 0.9996070265769958
dominant I-Disease 1 0.9989182949066162
neurohypophyseal I-Disease 1 0.9998615980148315
diabetes I-Disease 1 0.9999932050704956
insipidus I-Disease 1 0.9997496008872986
associated O 0 3.093779014307074e-05
with O 0 4.6288935351412874e-08
a O 0 4.90649902928908e-08
missense O 0 4.793148036696948e-05
mutation O 0 1.1112352922282298e-06
encoding O 0 5.773301268163777e-07
Gly23 O 0 0.032270386815071106
- O 0 0.31712737679481506
- O 0 0.46882179379463196
> O 0 2.1991208996041678e-05
Val O 0 0.0002473978966008872
in O 0 6.196601276542424e-08
neurophysin O 0 0.0001419397012796253
II O 0 0.0003249738656450063
. O 0 3.306759026600048e-07

Autosomal B-Disease 1 0.9994122982025146
dominant I-Disease 1 0.9981759786605835
neurohypophyseal I-Disease 1 0.9996688365936279
diabetes I-Disease 1 0.9999841451644897
insipidus I-Disease 1 0.9996589422225952
( O 0 2.8247379304957576e-05
ADNDI B-Disease 1 0.7749559283256531
) O 0 4.6085170879450743e-07
is O 0 1.057381155078474e-06
an O 0 0.009398515336215496
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.6200183033943176
by O 0 3.4127147955587134e-05
progressive O 1 0.7686715126037598
degeneration O 1 0.9999709129333496
of O 0 1.0069804545764782e-07
the O 0 3.5265586006971716e-07
magnocellular O 0 0.00020207760098855942
neurons O 0 4.882227131020045e-06
of O 0 7.969561011123005e-09
the O 0 7.081074926418296e-08
hypothalamus O 0 4.989443596059573e-07
leading O 0 4.3658411641445127e-07
to O 0 7.823723002786664e-09
decreased O 0 2.4047116653491685e-07
ability O 0 3.094619671628607e-08
to O 0 7.87609255592514e-10
produce O 0 1.041923103350939e-09
the O 0 6.109146077903915e-09
hormone O 0 2.942831223151643e-08
arginine O 0 8.85364883629336e-08
vasopressin O 0 4.1547931317609255e-08
( O 0 3.111415125545136e-09
AVP O 0 3.08584594677086e-06
) O 0 3.7032998889685587e-09
. O 0 1.115952663610642e-08

Affected O 0 3.964440475101583e-05
individuals O 0 1.3276503452175348e-08
are O 0 1.208592781409834e-08
not O 0 1.074721609484186e-07
symptomatic O 0 1.0956257028738037e-05
at O 0 1.1287033885309938e-06
birth O 0 7.94723819126375e-05
, O 0 1.841110162104087e-07
but O 0 7.920373263914371e-07
usually O 0 3.3519861517561367e-06
develop O 0 0.0003141943598166108
diabetes B-Disease 1 0.9821484088897705
insipidus I-Disease 0 0.3010358512401581
at O 0 3.2128168641065713e-06
1 O 0 1.8998771338374354e-06
- O 1 0.6886323690414429
6 O 0 3.477358404779807e-05
yr O 0 0.0036402023397386074
of O 0 8.173225651830762e-09
age O 0 1.188895453196892e-06
. O 0 3.245893864800564e-08

The O 0 2.542790014103957e-07
genetic O 0 3.884896159433993e-06
locus O 0 2.421089220661088e-06
of O 0 6.237250005369788e-08
the O 0 2.80560980172595e-05
disease O 0 0.41624754667282104
is O 0 3.1248696075181215e-08
the O 0 8.970390297236008e-08
AVP O 0 0.00040481978794559836
- O 0 0.015322490595281124
neurophysin O 0 0.001620046910829842
II O 0 0.0005903614801354706
( O 0 1.0294741725758172e-09
NPII O 0 4.276051186025143e-06
) O 0 4.250057250576589e-10
gene O 0 3.443820872917058e-08
, O 0 1.643546454488387e-08
and O 0 9.041677628829348e-08
mutations O 0 8.021137887226359e-07
that O 0 7.335593181778677e-07
cause O 0 8.412110901190317e-07
ADNDI B-Disease 0 0.0038086571730673313
have O 0 4.485212230065372e-06
been O 0 1.0395623348813388e-06
found O 0 1.844403527684335e-07
in O 0 6.662171259108618e-09
both O 0 3.9468370793827035e-09
the O 0 1.1626397622421791e-09
signal O 0 5.0678512053536906e-08
peptide O 0 5.856994000907889e-09
of O 0 2.1410286044076798e-10
the O 0 2.0669457256872192e-08
prepro O 0 3.50695445376914e-05
- O 0 0.00033677584724500775
AVP O 0 9.715820851852186e-06
- O 0 1.2122796761104837e-05
NPII O 0 2.949810777863604e-06
precursor O 0 2.3280509964251905e-08
and O 0 9.487963303911329e-09
within O 0 2.990193426199994e-09
NPII O 0 7.665390148758888e-05
itself O 0 8.173616379281157e-07
. O 0 6.071569202958926e-08

An O 0 2.9150561431379174e-07
affected O 0 1.5026333244350099e-07
girl O 0 0.0003097502631135285
who O 0 6.042145628271101e-07
presented O 0 9.569603776071745e-09
at O 0 2.6019280952027657e-08
9 O 0 2.7805793934021494e-07
months O 0 1.4546302828932767e-08
of O 0 2.8316899935987294e-09
age O 0 3.782968269661069e-05
and O 0 1.7657857824815437e-06
her O 0 2.3215432065626374e-06
similarly O 0 1.209987999573059e-06
affected O 0 9.453065104025882e-07
younger O 0 9.719397894514259e-06
brother O 0 2.2825646738056093e-05
and O 0 9.656273505243007e-07
father O 0 2.281613433297025e-06
were O 0 1.1323577808752816e-07
all O 0 1.4998228214935239e-09
found O 0 7.577521898838313e-08
to O 0 6.634173210784411e-09
have O 0 5.692091242792685e-09
a O 0 3.620101551859989e-09
novel O 0 2.598794253572123e-06
missense O 0 1.6215855794143863e-05
mutation O 0 1.7880133782455232e-06
( O 0 2.2922366227362545e-09
G1758 O 0 5.283399104882847e-07
- O 0 0.0017023165710270405
- O 0 0.019456537440419197
> O 0 1.4229618727767956e-06
T O 0 1.952983257069718e-05
) O 0 1.3453777154837088e-11
encoding O 0 9.386774690867128e-11
the O 0 4.999507474678921e-10
amino O 0 2.8370530369414837e-09
acid O 0 2.72620304109239e-09
substitution O 0 1.691282447424669e-09
Gly23 O 0 4.8252650231006555e-06
- O 0 0.00013085636601317674
- O 0 0.0016373286489397287
> O 0 9.8625821465248e-07
Val O 0 1.755754419718869e-05
within O 0 1.9949599305846277e-08
NPII O 0 3.868732528644614e-05
. O 0 4.829896482760887e-08

The O 0 4.632699983631028e-07
mutation O 0 3.7890808926022146e-06
was O 0 4.858525244344492e-07
confirmed O 0 1.264986337901064e-08
by O 0 4.714085233281651e-10
restriction O 0 3.788282398886622e-08
endonuclease O 0 5.0501763325883076e-05
analysis O 0 6.633554789914342e-07
. O 0 1.2901186607905402e-07

A O 0 1.6291744486807147e-06
T1 O 0 0.0008932255441322923
- O 0 1.0055118764284998e-05
weighted O 0 4.197207204015285e-08
magnetic O 0 3.500575829207264e-08
resonance O 0 5.672466585338043e-08
imaging O 0 8.936542144510895e-06
of O 0 8.406094487156679e-09
the O 0 6.612635843339376e-07
fathers O 0 3.301338801975362e-05
pituitary O 0 1.2302432878641412e-05
gland O 0 1.250117520612548e-06
demonstrates O 0 2.854042975286575e-07
an O 0 1.1196518379108511e-08
attenuated O 0 0.008044827729463577
posterior O 0 0.1120108813047409
pituitary O 0 0.004091078415513039
bright O 0 8.769512351136655e-05
spot O 0 0.00020437533385120332
. O 0 2.441227309191163e-07

This O 0 5.336295885172149e-07
mutation O 0 2.5183380785165355e-05
may O 0 1.972727659449447e-06
be O 0 2.7049567030701382e-09
valuable O 0 1.116192693828566e-09
for O 0 1.0494844993047536e-09
developing O 0 2.9690534475435015e-08
models O 0 1.5554842320852913e-06
of O 0 3.994360753267756e-08
dominantly B-Disease 1 0.9440822601318359
inherited I-Disease 1 0.9999085664749146
neurodegeneration I-Disease 1 0.9999998807907104
, O 0 4.844353611588303e-07
as O 0 1.0912375003613306e-08
the O 0 5.1528621369811844e-09
early O 0 2.9461486406034965e-07
age O 0 8.042648858008761e-08
of O 0 1.462636345372914e-09
onset O 0 0.00033354194601997733
of O 0 2.6360589799878653e-07
symptoms O 0 0.0005686135264113545
suggests O 0 1.1116109988051903e-07
that O 0 2.0003131595558443e-08
this O 0 5.324194418676598e-09
mutation O 0 2.5904407721100142e-06
may O 0 2.3136658455769066e-06
be O 0 2.736770099431851e-08
particularly O 0 9.197189676513062e-09
deleterious O 0 3.5486056049194303e-07
to O 0 4.066218650677911e-08
the O 0 1.654233194869903e-08
magnocellular O 0 5.100706766825169e-05
neuron O 0 0.00023675666307099164
. O 0 3.17688986228859e-08
. O 0 2.2872983507227218e-08

Frequent O 0 5.80395499127917e-05
inactivation O 0 0.00021349737653508782
of O 0 1.4001161119381322e-08
PTEN O 0 0.0007747026393190026
/ O 0 0.0012338784290477633
MMAC1 O 0 0.0025283077266067266
in O 0 4.1367989069840405e-06
primary O 1 0.5314140915870667
prostate B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999961853027344
. O 0 6.775405836378923e-06

Sporadic B-Disease 1 0.999016523361206
prostate I-Disease 1 0.9999889135360718
carcinoma I-Disease 1 1.0
is O 0 0.0001249894849024713
the O 0 3.2268479799313354e-07
most O 0 5.478410258774602e-08
common O 0 1.5266806485669804e-06
male B-Disease 0 0.0016224231803789735
cancer I-Disease 0 0.0017189213540405035
in O 0 5.0328363698781686e-08
the O 0 6.339732863125391e-07
Western O 0 0.0054637896828353405
world O 0 0.0009603651706129313
, O 0 4.2188133875242784e-08
yet O 0 1.7613787761661115e-08
many O 0 7.836156029616959e-11
of O 0 6.012958186918382e-11
the O 0 4.1428185326708444e-09
major O 0 7.303605720210271e-09
genetic O 0 3.7405288821901195e-07
events O 0 1.2538716731569366e-08
involved O 0 2.0738839978662327e-08
in O 0 4.018156118945626e-08
the O 0 2.3443291752300865e-07
progression O 0 0.002164253033697605
of O 0 1.2555299910843587e-08
this O 0 1.5383185427708668e-06
often O 0 0.0001546400599181652
fatal O 1 0.5973755121231079
cancer B-Disease 0 0.13675324618816376
remain O 0 2.0974425751774106e-07
to O 0 1.4554434102365121e-08
be O 0 3.65132244439792e-08
elucidated O 0 0.0002797910419758409
. O 0 1.4753780419596296e-07

Numerous O 0 1.5660658618799062e-06
cytogenetic O 0 0.00046794721856713295
and O 0 2.7935764137509977e-06
allelotype O 0 4.8909903853200376e-05
studies O 0 5.750354148403858e-07
have O 0 4.6581030233028287e-07
reported O 0 1.1066116485380917e-06
frequent O 0 2.52090012509143e-06
loss O 0 1.806738873710856e-05
of O 0 3.486022359666663e-09
heterozygosity O 0 0.000138865812914446
on O 0 1.2149590475019068e-05
chromosomal O 1 0.7521944642066956
arm O 1 0.5450875163078308
10q O 0 5.313516339811031e-06
in O 0 1.8986712291280128e-07
sporadic B-Disease 1 0.9153069853782654
prostate I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999977350234985
. O 0 7.846957487345207e-06

Deletion O 0 0.0002576509432401508
mapping O 0 0.00010796695278258994
studies O 0 1.7610113900445867e-06
have O 0 2.630614517329377e-07
unambiguously O 0 1.520240130048478e-05
identified O 0 1.09893642274983e-06
a O 0 2.9782700750047297e-08
region O 0 3.740329361789918e-07
of O 0 1.4116438684652621e-08
chromosome O 0 0.014354749582707882
10q23 O 0 6.649809620284941e-06
to O 0 4.3782954151083686e-08
be O 0 7.2831292108332946e-09
the O 0 1.6085627274620151e-09
minimal O 0 3.542333502082329e-07
area O 0 1.7485672287875786e-06
of O 0 3.1758780494328676e-08
loss O 0 0.00029902075766585767
. O 0 3.4041639196402684e-07

A O 0 8.600944170211733e-07
new O 0 1.665591895516627e-07
tumor B-Disease 0 4.861433990299702e-05
suppressor O 0 1.8045606339001097e-05
gene O 0 3.316721404189593e-06
, O 0 3.4005775972900665e-08
PTEN O 0 0.00024161535839084536
/ O 0 0.004187036771327257
MMAC1 O 0 0.039466265588998795
, O 0 1.7233740834399214e-07
was O 0 1.5332742577811587e-06
isolated O 0 2.746004838627414e-06
recently O 0 6.721179488522466e-06
at O 0 1.5717034784756834e-07
this O 0 5.041490336310517e-09
region O 0 1.0699739760866578e-08
of O 0 9.618109642062223e-10
chromosome O 0 5.895720096305013e-05
10q23 O 0 8.251270742221095e-07
and O 0 9.950133517122595e-08
found O 0 2.1143319983707443e-08
to O 0 2.2746584615873644e-09
be O 0 1.3646227481345363e-09
inactivated O 0 5.0682864127793437e-08
by O 0 4.5591153075008606e-10
mutation O 0 1.304773462607045e-07
in O 0 3.787466766880243e-07
three O 0 0.005781284999102354
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999983310699463
cell O 0 0.16766822338104248
lines O 0 0.06940421462059021
. O 0 2.677813654372585e-06

We O 0 9.089101513382047e-05
screened O 0 0.00011598346463870257
80 O 0 1.1372183507774025e-05
prostate B-Disease 1 0.9979812502861023
tumors I-Disease 1 0.9999995231628418
by O 0 4.579278112259999e-08
microsatellite O 0 0.00021481070143636316
analysis O 0 2.863284180421033e-06
and O 0 4.936998720950214e-07
found O 0 2.5642711420914566e-07
chromosome O 0 3.256508716731332e-05
10q23 O 0 7.060688744786603e-07
to O 0 2.6903657968091466e-08
be O 0 1.0299735286878331e-08
deleted O 0 4.2640235164981277e-07
in O 0 8.245255145311603e-08
23 O 0 1.3672727163793752e-06
cases O 0 1.467684853651008e-07
. O 0 5.59039449399279e-07

We O 0 2.361451151955407e-05
then O 0 2.8539332674881734e-08
proceeded O 0 3.3812508348773918e-09
with O 0 3.02359734472013e-11
sequence O 0 6.96945479106148e-09
analysis O 0 2.0736536932020044e-09
of O 0 1.514254555079475e-10
the O 0 1.1942069555459511e-08
entire O 0 4.912065492135298e-07
PTEN O 0 0.00029006568365730345
/ O 0 1.3694644621864427e-05
MMAC1 O 0 1.9536091713234782e-05
coding O 0 5.4429743613582104e-05
region O 0 1.1262540056122816e-06
and O 0 2.2302516811123496e-07
tested O 0 1.3002075149870507e-07
for O 0 4.779240544983132e-11
homozygous O 0 8.480932400800612e-09
deletion O 0 5.286231186119039e-08
with O 0 2.7569446725550506e-09
new O 0 4.273610443306097e-08
intragenic O 0 5.189294461160898e-05
markers O 0 0.00019453230197541416
in O 0 1.1398702426390628e-08
these O 0 4.607785264454378e-09
23 O 0 5.679665804336764e-08
cases O 0 7.630616138953883e-09
with O 0 2.949176121092023e-07
10q23 O 0 0.00020531930204015225
loss O 0 6.8464846663118806e-06
of O 0 9.437122194810854e-09
heterozygosity O 0 0.0004827282391488552
. O 0 6.670717880297161e-07

The O 0 7.9035636701974e-08
identification O 0 1.7384758521643562e-08
of O 0 4.401089770400546e-10
the O 0 9.805251721672903e-09
second O 0 6.410274977497465e-07
mutational O 0 9.301609679823741e-06
event O 0 2.5593186592232087e-07
in O 0 3.083988620034006e-09
10 O 0 4.0677061718952245e-09
( O 0 7.522935052683977e-10
43 O 0 3.6938774883310543e-07
% O 0 3.765116218801268e-08
) O 0 3.1676370326749748e-06
tumors B-Disease 1 0.9999997615814209
establishes O 0 0.0002737352333497256
PTEN O 0 0.01073385588824749
/ O 0 0.0022400079760700464
MMAC1 O 0 0.00020427830168046057
as O 0 1.7229607962576665e-08
a O 0 6.780535244388375e-09
main O 0 5.228203576734813e-07
inactivation O 0 5.119536945130676e-05
target O 0 7.540870683442336e-07
of O 0 8.966602460525053e-10
10q O 0 7.882509635237511e-06
loss O 0 5.555017651204253e-06
in O 0 3.9337774637715484e-07
sporadic B-Disease 1 0.9984638690948486
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 7.312808634196699e-07
. O 0 6.729914048264618e-08

Risk O 0 0.00013579840015154332
reversals O 0 1.7140604313681251e-06
in O 0 2.9829305692175012e-09
predictive O 0 8.261088737526734e-07
testing O 0 5.973819042992545e-06
for O 0 5.6603139455546625e-06
Huntington B-Disease 1 0.9999991655349731
disease I-Disease 1 0.9999983310699463
. O 0 4.692050879384624e-06

The O 0 3.1233323483093045e-08
first O 0 2.8453168710029786e-09
predictive O 0 1.9396028960727563e-07
testing O 0 1.8046647483060951e-06
for O 0 7.653867442058981e-07
Huntington B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999997615814209
( O 0 4.4446910152373675e-08
HD B-Disease 0 0.19998683035373688
) O 0 6.04207528454026e-08
was O 0 7.174471079451905e-07
based O 0 3.318432861831866e-09
on O 0 1.558805529100482e-08
analysis O 0 2.624295225572837e-09
of O 0 4.8889572945576276e-11
linked O 0 2.744345124483516e-07
polymorphic O 0 2.03767825723844e-07
DNA O 0 4.486223406274803e-05
markers O 0 5.786409383290447e-05
to O 0 9.503630771234839e-09
estimate O 0 3.982573844041326e-07
the O 0 1.2641084623510324e-08
likelihood O 0 6.759476889328653e-08
of O 0 1.1500440599832018e-09
inheriting O 0 3.6453212715059635e-07
the O 0 7.743835794826737e-09
mutation O 0 5.64020865567727e-08
for O 0 4.175510603943167e-09
HD B-Disease 0 0.006094442214816809
. O 0 3.130925847472099e-07

Limits O 0 6.079873173803207e-07
to O 0 8.022635000770606e-09
accuracy O 0 1.4141453164029372e-07
included O 0 2.54485349460154e-10
recombination O 0 4.596742098073037e-09
between O 0 3.5940199705208897e-09
the O 0 4.5112908964028975e-09
DNA O 0 0.0007012722780928016
markers O 0 0.011532420292496681
and O 0 5.914553184993565e-07
the O 0 2.296105883203836e-08
mutation O 0 1.8968573840538738e-06
, O 0 2.0640106512814782e-08
pedigree O 0 9.084546036319807e-06
structure O 0 5.8337559494248126e-06
, O 0 4.601953040861417e-09
and O 0 5.812264558535674e-10
whether O 0 1.8851242788997524e-10
DNA O 0 7.352149964390264e-07
samples O 0 8.786605221189348e-09
were O 0 1.2050611619685014e-09
available O 0 7.451745331898962e-10
from O 0 4.2349174167455317e-10
family O 0 1.4642114187779498e-08
members O 0 9.76059455481959e-10
. O 0 3.521382296867159e-08

With O 0 4.8943295638537165e-08
direct O 0 3.081308719288245e-08
tests O 0 1.4403696013687295e-07
for O 0 4.648244289473524e-11
the O 0 8.034790610622622e-10
HD B-Disease 0 0.002696900861337781
mutation O 0 4.407564574648859e-06
, O 0 1.498822754797402e-08
we O 0 3.2595735888207855e-08
have O 0 4.757716887127117e-09
assessed O 0 2.820865319108634e-09
the O 0 1.9751009716628687e-09
accuracy O 0 1.8771035684039816e-05
of O 0 1.8873484997072865e-09
results O 0 1.13245391730743e-07
obtained O 0 2.736956661308909e-09
by O 0 5.185751272840378e-10
linkage O 0 1.1804594350905973e-06
approaches O 0 4.082117399661911e-08
when O 0 2.1338962596928468e-08
requested O 0 7.322125683550951e-10
to O 0 3.238578116793178e-08
do O 0 2.8534270057889444e-08
so O 0 8.163204001654378e-10
by O 0 5.993230217660184e-11
the O 0 1.8958490333176314e-09
test O 0 9.162732794720796e-07
individuals O 0 3.8693523385369133e-10
. O 0 1.1141619182808427e-08

For O 0 1.0817922202477348e-07
six O 0 1.0182109377865345e-08
such O 0 1.2155461082130614e-09
individuals O 0 1.946802941077408e-09
, O 0 6.488569237461661e-09
there O 0 2.5311759799251377e-08
was O 0 4.830311013392929e-07
significant O 0 4.857376167954897e-10
disparity O 0 1.6625212140297663e-07
between O 0 2.7648347611375357e-08
the O 0 5.979011774570608e-08
tests O 0 2.1616785943479044e-06
. O 0 1.9791329464169394e-08

Three O 0 3.775101049541263e-06
went O 0 3.903819560946431e-07
from O 0 2.1243064252107757e-10
a O 0 4.247952212210748e-09
decreased O 0 5.8398682085680775e-06
risk O 0 6.862204600110999e-07
to O 0 1.1491850138156678e-08
an O 0 5.841452654919976e-09
increased O 0 2.3668480935157277e-06
risk O 0 2.200828203058336e-05
, O 0 2.849038338581522e-08
while O 0 1.6820600023947918e-08
in O 0 9.494969255285923e-09
another O 0 8.63816822516128e-08
three O 0 7.852970185240338e-08
the O 0 3.2024328788793355e-07
risk O 0 3.726788690983085e-06
was O 0 2.280082071592915e-06
decreased O 0 3.240492560507846e-06
. O 0 1.2805904248125444e-07

Knowledge O 0 4.435963774085394e-07
of O 0 1.0239302739023515e-09
the O 0 3.915457735814698e-09
potential O 0 3.753584110199881e-09
reasons O 0 4.4366657570016343e-10
for O 0 7.729838297221292e-11
these O 0 1.5242729300979363e-09
changes O 0 9.331659889255661e-09
in O 0 8.388560246430643e-08
results O 0 3.1831600608711597e-06
and O 0 2.823130955675879e-07
impact O 0 5.823000748250706e-08
of O 0 3.187534014514881e-09
these O 0 4.5852388552702905e-08
risk O 0 7.167155047227425e-08
reversals O 0 1.035759993328611e-07
on O 0 1.4631026488132193e-06
both O 0 7.732236895208189e-07
patients O 0 2.6613568024913548e-06
and O 0 7.969062920665237e-08
the O 0 8.117901018067641e-09
counseling O 0 6.438555999466189e-08
team O 0 2.022429690384797e-08
can O 0 3.832592021524306e-09
assist O 0 3.0900396130739693e-10
in O 0 8.293447595342229e-10
the O 0 1.1011033196339781e-09
development O 0 6.539593311316594e-10
of O 0 9.626602293089093e-11
strategies O 0 1.035370367219457e-08
for O 0 2.8977675814445547e-10
the O 0 1.1163848512296681e-08
prevention O 0 2.039829951172578e-06
and O 0 6.651787742839588e-08
, O 0 2.5527986391438162e-09
where O 0 1.8116118383204594e-08
necessary O 0 5.131891800402855e-09
, O 0 5.330613173093468e-10
management O 0 1.8124474143732527e-09
of O 0 3.0627066854860274e-11
a O 0 6.665757723567367e-08
risk O 0 1.528813555751185e-07
reversal O 0 1.9314139620973947e-08
in O 0 2.55079207756026e-10
any O 0 1.7315740508117017e-10
predictive O 0 1.0158446173136326e-07
testing O 0 2.0083649587832042e-07
program O 0 1.3087210426476759e-08
. O 0 1.5324118640691609e-09
. O 0 1.4200775666495247e-08

A O 0 3.0808323572273366e-06
novel O 0 1.8501814338378608e-06
common O 0 3.0948268658903544e-07
missense O 0 7.620959513587877e-05
mutation O 0 8.996811629913282e-06
G301C O 0 1.572715632391919e-06
in O 0 8.127893913467688e-09
the O 0 2.41906388254165e-08
N O 0 0.005894574802368879
- O 0 0.0871531143784523
acetylgalactosamine O 0 0.0008110706694424152
- O 0 0.0012852676445618272
6 O 0 1.128982262343925e-06
- O 0 0.00019175045599695295
sulfate O 0 2.8526219466584735e-06
sulfatase O 0 6.0588831729546655e-06
gene O 0 1.2559293338654243e-07
in O 0 8.271275930837874e-08
mucopolysaccharidosis B-Disease 0 0.0011162343434989452
IVA I-Disease 1 0.9848361611366272
. O 0 2.690715291464585e-06

Mucopolysaccharidosis B-Disease 1 0.8927144408226013
IVA I-Disease 1 0.9989354014396667
( O 0 0.0005095070227980614
MPS B-Disease 1 0.9999502897262573
IVA I-Disease 1 0.9999994039535522
) O 0 1.1197862477274612e-05
is O 0 1.0860816246349714e-06
an O 0 5.117768523632549e-06
autosomal B-Disease 1 0.9999796152114868
recessive I-Disease 1 0.9999929666519165
lysosomal I-Disease 1 0.9999994039535522
storage I-Disease 1 0.9999995231628418
disorder I-Disease 1 0.999997615814209
caused O 0 0.002978377975523472
by O 0 1.0105206627031293e-07
a O 0 9.220734682457987e-06
genetic B-Disease 1 0.9999990463256836
defect I-Disease 1 0.9999982118606567
in O 0 4.0962393654808693e-07
N O 0 0.019879883155226707
- O 0 0.4549696743488312
acetylgalactosamine O 0 0.08525136113166809
- O 0 0.12310443073511124
6 O 0 2.879691237467341e-05
- O 0 0.03721810132265091
sulfate O 0 0.00012174290895927697
sulfatase O 0 0.00025945145171135664
( O 0 1.1625205686982554e-08
GALNS O 0 2.003789268201217e-05
) O 0 5.914933876027817e-09
. O 0 1.1955356704618225e-08

In O 0 2.082851722207124e-07
previous O 0 4.4187666503603396e-07
studies O 0 1.0101217640112736e-07
, O 0 2.0115654919550252e-08
we O 0 1.2821301709209365e-07
have O 0 1.633109469878491e-08
found O 0 1.7819850484102062e-08
two O 0 4.342630699483152e-09
common O 0 6.464347990231545e-08
mutations O 0 1.566645437378611e-06
in O 0 6.76378419939283e-08
Caucasians O 0 4.0660521335667e-05
and O 0 4.617280353613751e-07
Japanese O 0 1.6774944015196525e-05
, O 0 1.6591089391226888e-08
respectively O 0 1.108111717940119e-07
. O 0 4.0396724187985456e-08

To O 0 1.4700943040679704e-07
characterize O 0 1.8429457213642308e-06
the O 0 7.07116543097186e-09
mutational O 0 1.1401255051168846e-06
spectrum O 0 2.4362199724237144e-07
in O 0 8.59593674018555e-10
various O 0 5.767492733399493e-11
ethnic O 0 1.313477415720854e-08
groups O 0 4.738059189435262e-08
, O 0 2.1969436048152602e-08
mutations O 0 1.0420016138823485e-07
in O 0 3.4060871900720713e-09
the O 0 1.2653074143997856e-08
GALNS O 0 1.931762926687952e-05
gene O 0 1.5818052645499847e-07
in O 0 8.380148130981979e-08
Colombian O 0 1.4335111700347625e-05
MPS B-Disease 1 0.9999176263809204
IVA I-Disease 1 0.9999997615814209
patients O 0 0.008043077774345875
were O 0 4.830394004784466e-07
investigated O 0 1.0443188330100384e-05
, O 0 1.1570615754408209e-07
and O 0 1.2611516808647139e-07
genetic O 0 8.94928234629333e-07
backgrounds O 0 1.7941900409823575e-07
were O 0 1.0307753761651384e-08
extensively O 0 1.5431923827691207e-07
analyzed O 0 5.797080007141631e-07
to O 0 2.4497914807852794e-09
identify O 0 3.6395977343062214e-09
racial O 0 9.154765834296086e-09
origin O 0 8.436532361599802e-09
, O 0 5.110711853717476e-10
based O 0 4.945145959389663e-10
on O 0 6.664637286490915e-09
mitochondrial O 0 5.898139079363318e-07
DNA O 0 9.972845873562619e-06
( O 0 3.4076189092679954e-10
mtDNA O 0 6.65332251514883e-08
) O 0 1.328351428853125e-09
lineages O 0 1.205311548346799e-07
. O 0 5.878238695800064e-08

Three O 0 3.3997198443103116e-06
novel O 0 3.5912373732571723e-06
missense O 0 0.00012573997082654387
mutations O 0 0.0004800640163011849
never O 0 0.00022128658019937575
identified O 0 8.178092230082257e-07
previously O 0 1.2601864227690385e-06
in O 0 5.550700521439467e-08
other O 0 1.1283429302011427e-08
populations O 0 6.442855919885915e-07
and O 0 1.20692470773065e-06
found O 0 4.201628769351373e-07
in O 0 3.658377067949914e-08
16 O 0 1.6281092030112632e-07
out O 0 4.3350851797185896e-08
of O 0 9.803245992756615e-10
19 O 0 7.004399549259688e-07
Colombian O 0 8.11014047030767e-07
MPS B-Disease 1 0.9919468760490417
IVA I-Disease 1 0.9999958276748657
unrelated O 0 4.365614131529583e-06
alleles O 0 1.0388978921582748e-07
account O 0 6.675045938209223e-08
for O 0 6.163099808276229e-09
84 O 0 4.044721663376549e-06
. O 0 1.1619724205047532e-07

2 O 0 8.43539169181895e-07
% O 0 2.2355182149880193e-09
of O 0 1.4762174815885487e-10
the O 0 4.2882977169256264e-09
alleles O 0 2.6039986167347706e-08
in O 0 1.1809155431308227e-08
this O 0 4.200769065931809e-09
study O 0 5.998339247526019e-08
. O 0 5.647959611110309e-08

The O 0 7.072826520015951e-07
G301C O 0 5.485877863975475e-06
and O 0 1.1827463453073506e-07
S162F O 0 5.842313157700119e-07
mutations O 0 5.520176955542411e-07
account O 0 1.7632242332865644e-08
for O 0 9.099788478295068e-09
68 O 0 1.835538751038257e-05
. O 0 1.3472858029217605e-07

4 O 0 2.6132088351005223e-06
% O 0 1.272769711846422e-08
and O 0 2.6965613741936068e-08
10 O 0 2.575590940523398e-08
. O 0 7.33615337367155e-08

5 O 0 4.4753153360943543e-07
% O 0 3.3308744651350253e-09
of O 0 6.651325046291845e-10
mutations O 0 8.382116902794223e-06
, O 0 8.311571519925565e-08
respectively O 0 2.9621114094879886e-07
, O 0 9.737114226027188e-09
whereas O 0 1.253621064734034e-07
the O 0 6.478863667780388e-08
remaining O 0 2.4996603542604134e-07
F69V O 0 0.0030334263574332
is O 0 2.77775313861639e-08
limited O 0 1.6475199871024415e-08
to O 0 2.3373487589850583e-09
a O 0 4.3367291979734546e-09
single O 0 9.351936682833184e-07
allele O 0 7.167564035626128e-07
. O 0 8.874901169519944e-08

The O 0 2.132924237230327e-07
skewed O 0 1.9078552213613875e-06
prevalence O 0 4.629847171599977e-05
of O 0 2.125332576596861e-09
G301C O 0 1.2341729416220915e-06
in O 0 1.2466887966411377e-08
only O 0 8.475789847750548e-09
Colombian O 0 1.4422843719330558e-07
patients O 0 1.9548488694454136e-07
and O 0 1.811220617931042e-09
haplotype O 0 2.921423742918705e-07
analysis O 0 3.698006123542541e-09
by O 0 2.4668672660155266e-10
restriction O 0 1.5385012375190854e-08
fragment O 0 4.052737949677976e-06
length O 0 6.637265414610738e-06
polymorphisms O 0 2.6352312488597818e-05
in O 0 5.34198818513687e-08
the O 0 2.564903844870514e-08
GALNS O 0 7.246092718560249e-05
gene O 0 3.68444148080016e-07
suggest O 0 1.4861768704577116e-07
that O 0 6.103531902112991e-09
G301C O 0 2.4567228251726192e-08
originated O 0 1.0211437029283843e-08
from O 0 7.363044202124414e-11
a O 0 2.117111375099512e-09
common O 0 5.350798915060295e-08
ancestor O 0 1.1033649798264378e-06
. O 0 2.4583076196904585e-07

Investigation O 0 2.859731239368557e-06
of O 0 2.445030178321872e-09
the O 0 5.727966101432003e-09
genetic O 0 8.055665148276603e-07
background O 0 1.921171275398592e-07
by O 0 2.561172385284749e-09
means O 0 4.24693968881229e-09
of O 0 1.1364174185013454e-10
mtDNA O 0 1.4498291989184509e-07
lineages O 0 1.2256909087682288e-07
indicate O 0 8.993344522423286e-07
that O 0 1.4040973894680064e-07
all O 0 3.051702179845961e-08
our O 0 3.0442700449384574e-07
patients O 0 2.9236693066536645e-08
are O 0 2.686394162676464e-10
probably O 0 1.959574369436723e-08
of O 0 1.0739475281296151e-10
native O 0 8.279988605863764e-08
American O 0 2.8202646262798226e-06
descent O 0 0.0004226875607855618

Low O 0 1.0658335668267682e-05
frequency O 0 1.5495486422878457e-06
of O 0 6.1366369763504736e-09
BRCA1 O 0 1.0995571756211575e-05
germline O 0 1.1701090443239082e-05
mutations O 0 6.9517204792646226e-06
in O 0 1.4045080654057074e-08
45 O 0 2.5718605911606573e-07
German O 1 0.9964547157287598
breast B-Disease 1 0.9999982118606567
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 1.0342105269955937e-05
. O 0 6.13399492976896e-07

In O 0 1.4239743961752538e-07
this O 0 1.3986554137090934e-09
study O 0 3.273522120039729e-09
we O 0 3.0941935680317556e-09
investigated O 0 1.123656723223121e-08
45 O 0 1.7814244301916915e-08
German O 1 0.8599319458007812
breast B-Disease 1 0.9999932050704956
/ I-Disease 1 0.9999988079071045
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 3.4674405924306484e-07
for O 0 9.894433716794993e-09
germline O 0 0.00017890866729430854
mutations O 0 5.359303941077087e-06
in O 0 9.679655299521528e-09
the O 0 5.1462837546978335e-08
BRCA1 O 0 0.00017884199041873217
gene O 0 6.690336249448592e-06
. O 0 4.2236041508658673e-07

We O 0 1.1353838090144563e-05
identified O 0 1.2555184980556078e-07
four O 0 1.975191343817073e-09
germline O 0 2.2139943212096114e-06
mutations O 0 7.569022272946313e-06
in O 0 2.414922164462041e-07
three O 0 5.9869824326597154e-05
breast B-Disease 1 0.9999722242355347
cancer I-Disease 1 0.9795802235603333
families O 0 1.9330509815063124e-07
and O 0 1.7472505078330869e-06
in O 0 1.380929916194873e-06
one O 0 0.036566056311130524
breast B-Disease 1 0.999998927116394
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.1878179975610692e-05
. O 0 3.097596135148706e-08
among O 0 4.152460320039353e-10
these O 0 2.7007498459852286e-09
were O 0 4.378596329956963e-08
one O 0 5.871862285289353e-08
frameshift O 0 0.00029981546686030924
mutation O 0 4.232541414239677e-06
, O 0 1.5083669424598156e-08
one O 0 7.165733251213169e-08
nonsense O 0 0.0011961692944169044
mutation O 0 2.500781192793511e-06
, O 0 1.7537189478389337e-08
one O 0 1.681703842848492e-08
novel O 0 1.776130375219509e-06
splice O 0 0.0021230438724160194
site O 0 4.368743611848913e-05
mutation O 0 1.285311645915499e-05
, O 0 2.2582671732607196e-08
and O 0 8.635907100540408e-09
one O 0 9.120344479640607e-09
missense O 0 3.3594486012589186e-05
mutation O 0 8.398296813538764e-06
. O 0 2.3492034983974008e-07

The O 0 6.787097390770214e-07
missense O 0 4.8891342885326594e-05
mutation O 0 0.0002627373323775828
was O 0 4.553783219307661e-05
also O 0 6.959029974495934e-07
found O 0 1.240550631109727e-07
in O 0 6.51447678023942e-08
2 O 0 7.056965841911733e-06
. O 0 7.813576985427062e-07

8 O 0 3.893549546774011e-06
% O 0 3.79425335594874e-09
of O 0 2.7444932437781233e-10
the O 0 1.78860819488591e-08
general O 0 1.5279267628898197e-08
population O 0 4.736267378291359e-09
, O 0 2.5402671077756622e-09
suggesting O 0 8.190863098889167e-08
that O 0 4.6378371365563e-08
it O 0 1.24429831771522e-07
is O 0 2.8539230356727785e-07
not O 0 1.4987595932325348e-05
disease O 0 0.0023513236083090305
associated O 0 2.2649756203918514e-07
. O 0 3.048305075026292e-07

The O 0 1.0137199524251628e-06
average O 0 1.122720459534321e-05
age O 0 2.341215122214635e-06
of O 0 9.251488108930062e-08
disease O 0 0.2122100293636322
onset O 0 0.00089787517208606
in O 0 2.717004008445656e-07
those O 0 6.716257416883309e-08
families O 0 1.3978801227665372e-08
harbouring O 0 0.00018983648624271154
causative O 0 6.395275704562664e-05
mutations O 0 2.0783387299161404e-05
was O 0 1.8628850284585496e-06
between O 0 8.563461761923463e-08
32 O 0 1.7667072143012774e-06
. O 0 2.428208176752378e-07

3 O 0 6.0415964071580674e-06
and O 0 4.1213922941096826e-07
37 O 0 4.689383672484837e-07
. O 0 8.426597730704088e-08

4 O 0 4.881996210315265e-05
years O 0 6.764350928278873e-07
, O 0 3.109439594695118e-09
whereas O 0 1.8392388057009157e-08
the O 0 1.506636060355504e-08
family O 0 1.0428506413973082e-07
harbouring O 0 4.606659786077216e-05
the O 0 1.1428854307382608e-08
missense O 0 7.482182354578981e-06
mutation O 0 7.136977728805505e-06
had O 0 1.030021576298168e-05
an O 0 8.751447566623938e-09
average O 0 5.9892668105021585e-06
age O 0 2.2965096491134318e-07
of O 0 9.678340351371162e-10
onset O 0 1.4851575542706996e-05
of O 0 1.015958606132017e-08
51 O 0 2.0513576600933447e-05
. O 0 1.7592292067547532e-07

2 O 0 1.0801219104905613e-05
years O 0 5.800354188068013e-07
. O 0 1.6861352492014703e-07

These O 0 1.659866057934778e-07
findings O 0 6.906351046609416e-08
show O 0 3.9979209986995556e-07
that O 0 6.8068551684064e-08
BRCA1 O 0 1.3958338058728259e-05
is O 0 8.927974448624809e-08
implicated O 0 8.224135399359511e-07
in O 0 1.6252293733032275e-08
a O 0 4.844119771973965e-09
small O 0 3.389244440654693e-09
fraction O 0 5.312521622613531e-08
of O 0 3.6592471133189974e-06
breast B-Disease 1 0.9999974966049194
/ I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.9859476196870673e-07
suggesting O 0 3.0902231173968175e-07
the O 0 2.4965518541364418e-09
involvement O 0 1.8133611945359007e-08
of O 0 7.572544258316327e-10
another O 0 1.6335214070295478e-07
susceptibility O 0 0.00011066361184930429
gene O 0 1.3851815310772508e-05
( O 0 7.679634705937133e-08
s O 0 0.00012706751294899732
) O 0 3.3975896940319217e-07

Paternal O 0 0.005147311836481094
transmission O 0 0.20509742200374603
of O 0 8.00242560217157e-05
congenital B-Disease 1 0.9999943971633911
myotonic I-Disease 1 0.9999980926513672
dystrophy I-Disease 1 0.9999983310699463
. O 0 0.001139703905209899

We O 0 0.0001397369196638465
report O 0 3.2058576238114256e-08
a O 0 9.737575190627012e-10
rare O 0 1.2930250647968933e-08
case O 0 2.3241740620960627e-07
of O 0 1.4495734035335772e-07
paternally O 1 0.9662497043609619
transmitted O 1 0.9999079704284668
congenital B-Disease 1 0.999998927116394
myotonic I-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.002213836181908846
DM B-Disease 1 0.9999978542327881
) O 0 1.9397062715142965e-05
. O 0 4.6906450279493583e-07

The O 0 5.64523986668064e-07
proband O 0 1.1771332538046408e-05
is O 0 7.219755460141641e-09
a O 0 9.114240917540428e-09
23 O 0 2.7702145644070697e-07
year O 0 3.87660996636896e-08
old O 0 0.340151846408844
, O 0 8.447510481346399e-05
mentally B-Disease 1 0.9999997615814209
retarded I-Disease 1 0.9999992847442627
male O 0 0.13555258512496948
who O 0 0.05601823702454567
suffers O 1 0.995746910572052
severe O 0 0.19888043403625488
muscular B-Disease 1 0.9990577101707458
weakness I-Disease 1 0.9003549814224243
. O 0 1.6745138964324724e-06

He O 0 8.840848022373393e-05
presented O 0 4.879174184679869e-07
with O 0 1.9287697796244174e-05
respiratory O 1 0.9998438358306885
and O 0 0.0003952634579036385
feeding O 0 0.0022095153108239174
difficulties O 0 1.1455934327386785e-05
at O 0 2.6981157930094923e-07
birth O 0 1.1228254152229056e-05
. O 0 9.591882843551502e-08

His O 0 4.282148074707948e-05
two O 0 2.1963439849059796e-06
sibs O 1 0.9058857560157776
suffer O 0 0.0019414989510551095
from O 0 7.837392246301533e-08
childhood O 0 0.04577590897679329
onset O 1 0.9967425465583801
DM B-Disease 1 0.9999971389770508
. O 0 8.400068327318877e-05

Their O 0 1.2920976359964698e-06
late O 0 5.807090133203019e-07
father O 0 1.512572453066241e-06
had O 0 1.5437223055414506e-07
the O 0 3.187495822842834e-10
adult O 0 1.092764634336163e-07
type O 0 9.323511221737135e-06
of O 0 1.3003734977701242e-07
DM B-Disease 1 0.9999998807907104
, O 0 5.055542260379298e-07
with O 0 6.64329249389084e-08
onset O 0 2.2898968381923623e-05
around O 0 6.394082419092229e-08
30 O 0 3.2085797130321225e-08
years O 0 2.4775877349725306e-08
. O 0 1.7967906273952394e-08

Only O 0 8.582885584473843e-07
six O 0 4.754813431873117e-09
other O 0 2.843899560289742e-10
cases O 0 2.7976054806089223e-09
of O 0 6.931025087197895e-09
paternal O 0 0.06899242848157883
transmission O 1 0.9818096160888672
of O 0 3.0121358577162027e-05
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 1.0
have O 0 0.04447536543011665
been O 0 1.1074836947955191e-05
reported O 0 2.9826755962858442e-06
recently O 0 1.5548999726888724e-05
. O 0 9.509562914900016e-08

We O 0 3.2380150969402166e-06
review O 0 2.298200385553173e-08
the O 0 6.004892694200237e-10
sex O 0 3.68179939869151e-08
related O 0 2.542391541737743e-08
effects O 0 2.991409701280645e-06
on O 0 2.5342735625599744e-06
transmission O 0 0.11332935094833374
of O 0 8.692793926456943e-06
congenital B-Disease 1 0.9999974966049194
DM I-Disease 1 0.9999992847442627
. O 0 0.00014451595779974014

Decreased O 0 0.0017949960893020034
fertility O 0 9.730377496453002e-05
of O 0 1.5859999979994654e-09
males O 0 1.1019694490244092e-08
with O 0 1.3620567784755622e-08
adult O 0 9.696910274215043e-05
onset O 1 0.9257092475891113
DM B-Disease 1 0.9999998807907104
and O 0 0.0007056785398162901
contraction O 0 8.608973075752147e-06
of O 0 2.5463502417721884e-09
the O 0 5.917543433042738e-08
repeat O 0 8.979016456578393e-06
upon O 0 1.7873250657274298e-09
male O 0 1.5184824064817803e-07
transmission O 0 2.2468606402981095e-05
contribute O 0 1.2170912055964322e-09
to O 0 5.048957252284936e-09
the O 0 4.286564436739582e-09
almost O 0 3.4698580009262514e-08
absent O 0 4.998444680381908e-08
occurrence O 0 1.4848608032025368e-07
of O 0 5.536064495714754e-09
paternal O 0 0.00011601996811805293
transmission O 0 0.040742915123701096
of O 0 6.757344181096414e-06
congenital B-Disease 1 0.9999959468841553
DM I-Disease 1 0.9999991655349731
. O 0 6.347853195620701e-05

Also O 0 4.804625496035442e-05
the O 0 1.604255572829061e-08
fathers O 0 4.990347335365186e-08
of O 0 2.234894630470663e-10
the O 0 2.7315028461316615e-08
reported O 0 3.8038313050492434e-06
congenitally O 0 0.0019745465833693743
affected O 0 3.0619426070188638e-06
children O 0 5.081266749584756e-07
showed O 0 1.054568201652728e-05
, O 0 6.235772342932933e-09
on O 0 1.576032246930481e-07
average O 0 2.136068360414356e-06
, O 0 7.631969722865506e-09
shorter O 0 4.791615424437623e-07
CTG O 0 6.706978183501633e-06
repeat O 0 2.0670837329817005e-05
lengths O 0 0.00022541657381225377
and O 0 3.1542032274956e-07
hence O 0 1.5819712473330583e-07
less O 0 3.475448195899844e-08
severe O 0 4.566228744806722e-05
clinical O 0 0.003144229995086789
symptoms O 0 0.0003422046429477632
than O 0 2.3848734542752936e-08
the O 0 5.204911417422409e-07
mothers O 0 5.2506861720758025e-06
of O 0 7.417092717787455e-09
children O 0 7.115529115253594e-06
with O 0 8.429421723121777e-05
congenital B-Disease 1 0.9999972581863403
DM I-Disease 1 0.9999994039535522
. O 0 6.254870095290244e-05

We O 0 2.5902978450176306e-05
conclude O 0 9.364914035359106e-07
that O 0 3.555498295781945e-08
paternal O 0 2.763460361165926e-05
transmission O 0 0.08088846504688263
of O 0 6.138119260867825e-06
congenital B-Disease 1 0.9999992847442627
DM I-Disease 1 1.0
is O 0 0.0013951149303466082
rare O 0 6.0019033298885915e-06
and O 0 5.125457960275526e-07
preferentially O 0 5.12191547841212e-07
occurs O 0 1.974111185631955e-08
with O 0 3.99103861070671e-09
onset O 0 6.694237526971847e-05
of O 0 2.5402232495252974e-07
DM B-Disease 1 0.9999998807907104
past O 0 0.000956777308601886
30 O 0 1.5586873303163884e-07
years O 0 2.107499597059359e-08
in O 0 3.91734733540261e-09
the O 0 2.3039410379510628e-08
father O 0 1.6645661844449933e-06
. O 0 4.14407530513472e-09
. O 0 1.0093586411130673e-08

The O 0 1.0435146577947307e-06
RB1 O 0 0.00014656706480309367
gene O 0 2.0115078314120183e-06
mutation O 0 2.5385477329109563e-06
in O 0 7.909020105500986e-09
a O 0 2.8760956638507196e-07
child O 0 0.0003371536440681666
with O 0 4.9004862376023084e-05
ectopic B-Disease 1 0.9999887943267822
intracranial I-Disease 1 0.999911904335022
retinoblastoma I-Disease 1 0.9991336464881897
. O 0 6.35285468888469e-05

The O 0 3.972430022258777e-06
RB1 O 0 0.00042360686347819865
gene O 0 4.079925929545425e-06
mutation O 0 1.2012602383038029e-05
was O 0 1.6989190498861717e-06
investigated O 0 5.079692186882312e-07
in O 0 8.464416723086288e-09
a O 0 8.275021627923707e-07
child O 0 0.003054851433262229
with O 0 1.5997133232303895e-05
ectopic B-Disease 1 0.9999817609786987
intracranial I-Disease 1 0.997112512588501
retinoblastoma I-Disease 0 0.0007632494089193642
using O 0 4.771018780047598e-07
DNA O 0 6.847541953902692e-05
obtained O 0 2.8905171589599377e-08
from O 0 9.946576895458747e-10
both O 0 3.4955785821466634e-08
the O 0 6.68756001687143e-08
pineal B-Disease 0 0.00016883407079149038
and I-Disease 0 4.973179238731973e-05
retinal I-Disease 1 0.9996355772018433
tumours I-Disease 1 0.9999998807907104
of O 0 1.5143794485084072e-07
the O 0 2.4469918571412563e-06
patient O 0 0.0002800448564812541
. O 0 2.3695170625614992e-07

A O 0 1.3393267863648362e-06
nonsense O 0 3.757741433219053e-05
mutation O 0 7.376428925454093e-07
in O 0 1.732324950154407e-09
exon O 0 5.013204827264417e-06
17 O 0 7.553321665909607e-07
( O 0 8.3824258645393e-10
codon O 0 3.116132631930668e-07
556 O 0 1.587611677678069e-07
) O 0 1.6645281819549496e-09
of O 0 1.9241391813196174e-10
the O 0 3.805772408327357e-08
RB1 O 0 8.288116077892482e-05
gene O 0 8.661048696012585e-07
was O 0 3.854634996969253e-06
found O 0 4.769967532070041e-08
to O 0 3.5642218065845555e-09
be O 0 4.695888122796532e-09
present O 0 8.115017546828085e-10
homozygously O 0 9.942838005372323e-06
in O 0 2.2891008200076612e-08
both O 0 2.6132330077643928e-08
the O 0 4.069585912702678e-08
retinal B-Disease 0 0.022608816623687744
and I-Disease 0 2.1281484805513173e-06
the I-Disease 0 9.459919851906307e-07
pineal I-Disease 0 0.34250083565711975
tumours I-Disease 1 0.9999967813491821
. O 0 2.082221271848539e-06

The O 0 1.2812793670491374e-07
same O 0 9.211269080822149e-09
mutation O 0 2.693698775146913e-07
was O 0 4.6617159910056216e-07
present O 0 1.035772800861423e-09
heterozygously O 0 3.248156644986011e-06
in O 0 3.672238735319411e-09
the O 0 4.019641064445523e-09
DNA O 0 7.149075827328488e-06
from O 0 3.9689460051839376e-10
the O 0 2.5072937059889e-09
constitutional O 0 1.970657592664793e-08
cells O 0 6.558648379950682e-08
of O 0 3.2359503965295744e-10
the O 0 1.7962291565254418e-07
patient O 0 1.5826451999600977e-05
, O 0 3.8801366564200634e-09
proving O 0 1.3110492318446632e-06
it O 0 3.1300114500254494e-08
to O 0 8.234025683506729e-10
be O 0 3.977888851647293e-10
of O 0 8.711088100854525e-11
germline O 0 2.6230013645545114e-06
origin O 0 1.3467462167682243e-07
. O 0 7.40693124612335e-08

The O 0 7.42653867291665e-08
initial O 0 3.818875526917509e-08
mutation O 0 6.26806638592825e-07
was O 0 7.125641445782094e-07
shown O 0 3.240932500148119e-08
to O 0 2.8510482863453035e-09
have O 0 2.4805666853922048e-08
occurred O 0 8.675484508557929e-08
in O 0 3.5278477916733664e-09
the O 0 2.991632541693434e-08
paternally O 0 5.833043815073324e-06
derived O 0 6.373140593041171e-08
RB1 O 0 1.552810317662079e-05
allele O 0 4.2997581317649747e-07
. O 0 9.904255193760036e-08

The O 0 3.3328367976537265e-07
mutation O 0 2.3406614673149306e-06
is O 0 2.971880697089091e-08
in O 0 2.2528883203420946e-09
an O 0 3.703787498920974e-09
area O 0 5.316231863616849e-07
of O 0 4.874760040074477e-10
the O 0 9.290032743081156e-09
gene O 0 1.1530805466009042e-07
that O 0 1.0896464175402798e-08
encodes O 0 6.746079250774528e-09
the O 0 3.2304883212930235e-09
protein O 0 5.0476987922820626e-08
- O 0 1.746787347656209e-05
binding O 0 5.495699184621117e-08
region O 0 1.4762050248862124e-08
known O 0 5.0782624327894155e-08
as O 0 1.749639544357251e-08
the O 0 2.966478085397739e-08
pocket O 0 0.023235732689499855
region O 0 9.406446679349756e-07
and O 0 2.1082598777866224e-07
has O 0 6.288532006237801e-08
been O 0 1.3950832489229015e-08
detected O 0 8.428060738197019e-08
in O 0 7.395165591006503e-10
other O 0 3.039436202723067e-10
cases O 0 2.691016298683735e-09
of O 0 4.7791810509068e-09
retinoblastoma B-Disease 0 0.011648398824036121
. O 0 1.789036900845531e-07
. O 0 5.713271988838642e-08

Low O 0 0.00041217601392418146
levels O 0 1.1347014350349127e-07
of O 0 2.5693960847839037e-10
beta O 0 1.1355887785668983e-08
hexosaminidase O 0 2.17013293877244e-05
A O 0 2.2989536319073522e-06
in O 0 4.4220675476935867e-07
healthy O 0 1.7680066548564355e-06
individuals O 0 1.2628498247124753e-09
with O 0 4.7571114691891125e-07
apparent O 0 0.05019598826766014
deficiency O 0 0.24299556016921997
of O 0 2.333357729256136e-09
this O 0 7.487926723115379e-08
enzyme O 0 9.73512123891851e-06
. O 0 1.9771792381106934e-07

Appreciable O 0 2.824021430569701e-05
beta O 0 1.7087430705942097e-06
hexosaminidase O 0 0.0001624695723876357
A O 0 1.7400933529643225e-06
( O 0 8.676026119758262e-09
hex O 0 1.7121135897468776e-05
A O 0 8.995737630357326e-07
) O 0 1.058957033173158e-09
activity O 0 2.2342533156916033e-08
has O 0 7.194657314357755e-08
been O 0 3.068177889531398e-08
detected O 0 2.633131828133628e-07
in O 0 1.7666748064470994e-08
cultured O 0 8.958658872870728e-05
skin O 1 0.9077063202857971
fibroblasts O 0 0.0015384575817734003
and O 0 0.027758240699768066
melanoma B-Disease 1 0.9999310970306396
tissue O 0 0.09954148530960083
from O 0 6.011212150269785e-08
healthy O 0 1.6485138303323765e-06
individuals O 0 8.537733298119576e-10
previously O 0 6.49557989618188e-07
reported O 0 2.726033244471182e-06
as O 0 6.648148428212153e-06
having O 0 0.08301109075546265
deficiency B-Disease 0 0.14984771609306335
of I-Disease 0 2.9202904539005203e-09
hex I-Disease 0 0.00037651995080523193
A I-Disease 0 5.408452921074058e-07
activity O 0 6.22811953121527e-08
indistinguishable O 0 2.4138234522297353e-08
from O 0 3.495014833099219e-10
that O 0 8.421644714928789e-09
of O 0 3.5069227521944413e-09
patients O 0 5.137122570886277e-06
with O 0 0.0002901688567362726
Tay B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Sachs I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9995879530906677
( O 0 2.0641367726170756e-08
TSD B-Disease 0 0.00014507333980873227
) O 0 2.870233828389246e-08
. O 0 2.6300190469896734e-08

Identification O 0 1.3391324500844348e-05
and O 0 2.2415167677536374e-07
quantitation O 0 7.221091891551623e-06
of O 0 5.3402127164758895e-09
hex O 0 4.289840580895543e-05
A O 0 9.82875235422398e-07
, O 0 1.7346989400479629e-09
amounting O 0 1.933945670273829e-09
to O 0 7.352918718339652e-09
3 O 0 3.138240742828202e-07
. O 0 1.4634218814535416e-07

5 O 0 1.5061094700286048e-06
% O 0 3.7632563731904156e-08
- O 0 0.0002265302318846807
6 O 0 2.5992057999246754e-06
. O 0 1.4800370706780086e-07

9 O 0 3.7349968806665856e-06
% O 0 1.415919936853527e-09
of O 0 1.1833607704847537e-10
total O 0 2.1461650234755325e-09
beta O 0 1.1430380197907652e-08
hexosaminidase O 0 3.0248676921473816e-05
activity O 0 1.8916871340479702e-06
, O 0 1.2594972176316332e-08
has O 0 1.1156058299377491e-08
been O 0 1.4545296078694037e-09
obtained O 0 6.157820919838741e-10
by O 0 1.7214850656088743e-09
cellulose O 0 0.0018090670928359032
acetate O 0 0.002162280725315213
gel O 0 0.023951681330800056
electrophoresis O 0 1.1739663932530675e-05
, O 0 3.950293869792176e-09
DEAE O 0 2.965832891277387e-06
- O 0 3.5511652640707325e-06
cellulose O 0 3.084549825871363e-05
ion O 0 2.82221577663222e-07
- O 0 8.945307854446582e-06
exchange O 0 6.191638846075875e-08
chromatography O 0 8.079223334789276e-07
, O 0 4.099570460880386e-09
radial O 0 1.9375502233742736e-06
immunodiffusion O 0 2.9491575332940556e-05
, O 0 3.551878791085983e-08
and O 0 6.733792190516397e-08
radioimmunoassay O 0 9.540845348965377e-05
. O 0 9.321345828539052e-08

Previous O 0 5.121586946188472e-05
family O 0 1.7932920570729038e-07
studies O 0 4.5029029394072495e-08
suggested O 0 2.014720479337484e-07
that O 0 2.244928332117979e-08
these O 0 2.260907905338172e-09
individuals O 0 1.5338008640952694e-09
may O 0 6.759179314030916e-07
be O 0 4.337100900642099e-09
compound O 0 8.58997921682203e-08
heterozygotes O 0 4.405360982673301e-07
for O 0 2.9838238546631146e-09
the O 0 2.7803876534449046e-08
common O 0 9.570209869025348e-08
mutant O 0 3.336648433105438e-06
TSD B-Disease 0 1.4407146409212146e-05
gene O 0 1.3309156656760024e-06
and O 0 7.141446189962153e-08
a O 0 2.4309043666903563e-08
rare O 0 4.657978820432618e-07
( O 0 3.5632021777587397e-09
allelic O 0 1.0292055776517373e-06
) O 0 5.48077982998052e-09
mutant O 0 7.371232300101838e-07
gene O 0 2.1999560431140708e-06
. O 0 2.2686852219067077e-07

Thus O 0 1.7422722521587275e-05
, O 0 8.775919546621935e-09
the O 0 3.57234630765646e-10
postulated O 0 1.9323414335303823e-07
rate O 0 2.3374153101940465e-07
mutant O 0 3.1825516089156736e-07
gene O 0 3.0794177519055665e-07
appears O 0 2.4407080445598694e-07
to O 0 3.5279534849053107e-10
code O 0 4.7793542456986415e-09
for O 0 1.738584276544941e-09
the O 0 5.092635202430529e-09
expression O 0 4.6396948505389446e-08
of O 0 3.236660384153822e-10
low O 0 3.34139514279741e-07
amounts O 0 2.83554207891612e-10
of O 0 4.19269036155967e-10
hex O 0 1.874034023785498e-05
A O 0 8.786003604654979e-07
. O 0 6.29765395387949e-08

Heterozygotes O 0 3.279908560216427e-05
for O 0 2.5683894122607853e-08
the O 0 6.611511338405762e-09
rare O 0 3.2748978640029236e-08
mutant O 0 4.296022234484553e-05
may O 0 4.7646485654695425e-06
be O 0 1.2754909350931598e-09
indistinguishable O 0 2.885537497832047e-08
from O 0 6.57739640530508e-10
heterozygotes O 0 1.8607458684982703e-07
for O 0 2.1923756143849005e-09
the O 0 3.253213876064365e-08
common O 0 2.832551331266586e-07
TSD B-Disease 0 0.00021273312449920923
mutant O 0 2.567122646723874e-05
. O 0 1.1055256265990465e-07

However O 0 6.186348855408141e-06
, O 0 4.677545017983675e-09
direct O 0 4.780329909692682e-09
visualization O 0 1.353933294012677e-05
and O 0 3.362755762736924e-07
quantitation O 0 2.9698787329834886e-05
of O 0 6.7632659472849355e-09
hex O 0 0.00014883620315231383
A O 0 3.3926585274457466e-07
by O 0 3.5783560559110583e-09
the O 0 3.0978073439769105e-09
methods O 0 6.347470389300724e-07
described O 0 1.7978545656660572e-05
may O 0 1.1532733878993895e-06
prevent O 0 8.454771460719712e-08
false O 0 2.490926931386639e-07
- O 0 0.0003130515688098967
positive O 0 5.544669079426967e-08
prenatal O 0 6.672793915640796e-06
diagnosis O 0 7.633397763129324e-05
of O 0 6.533409369069432e-10
TSD B-Disease 0 0.0004073987074662
in O 0 9.974187378247734e-07
fetuses O 0 2.679696808627341e-05
having O 0 8.033861149669974e-07
the O 0 2.1382721371310254e-08
incomplete O 0 6.653349373664241e-06
hex B-Disease 0 0.014839348383247852
A I-Disease 0 0.014809029176831245
deficiency I-Disease 0 0.05340049788355827
of O 0 1.56413582086401e-09
the O 0 2.993185432842438e-07
type O 0 0.015141411684453487
described O 0 7.358291622949764e-05
in O 0 1.4872416898015217e-07
the O 0 1.9629079872629518e-07
four O 0 1.1375677786418237e-06
healthy O 0 5.038064955442678e-06
individuals O 0 2.3572821916673092e-08

The O 0 5.027790166423074e-07
tumor B-Disease 0 2.6172738216700964e-05
suppressor O 0 1.1066000297432765e-05
gene O 0 6.175332146085566e-06
Smad4 O 0 0.0017187248449772596
/ O 0 0.00033527371124364436
Dpc4 O 0 0.00034492471604608
is O 0 1.62391842195575e-08
required O 0 5.624882781773977e-10
for O 0 3.3953051481461216e-10
gastrulation O 0 3.094339626841247e-05
and O 0 4.533255378191825e-06
later O 0 2.9178645490901545e-06
for O 0 1.9064673395519094e-08
anterior O 0 0.00017903649131767452
development O 0 4.447710111321612e-08
of O 0 6.507615557538315e-10
the O 0 3.8825593406954795e-08
mouse O 0 4.933392847306095e-05
embryo O 0 1.858945211097307e-06
. O 0 7.658103129415395e-08

Mutations O 0 0.00020313197455834597
in O 0 3.3751824446426326e-08
the O 0 4.143492304820029e-08
SMAD4 O 0 0.0017845951952040195
/ O 0 0.0002721800410654396
DPC4 O 0 0.0008225394994951785
tumor B-Disease 0 6.96284623700194e-05
suppressor O 0 3.4803485959855607e-06
gene O 0 1.2381730130073265e-06
, O 0 4.568457612208476e-09
a O 0 7.776987387408951e-10
key O 0 4.7201002217889254e-08
signal O 0 3.824014811470988e-07
transducer O 0 1.1124759566882858e-06
in O 0 2.380923902478571e-08
most O 0 1.3875308901845074e-08
TGFbeta O 0 0.00021382718114182353
- O 0 0.001979609252884984
related O 0 6.266272976063192e-07
pathways O 0 3.8708217289240565e-06
, O 0 2.4651609642489802e-09
are O 0 4.696546276883318e-11
involved O 0 1.810376987210205e-10
in O 0 1.060938337182904e-09
50 O 0 1.8374426424827561e-09
% O 0 5.710716899365309e-10
of O 0 7.151914616088106e-08
pancreatic B-Disease 1 0.9916752576828003
cancers I-Disease 1 0.996673583984375
. O 0 1.0536829222473898e-06

Homozygous O 0 4.2664632928790525e-05
Smad4 O 0 0.0004524167743511498
mutant O 0 0.0002925957378465682
mice O 0 0.08408400416374207
die O 0 0.001221344224177301
before O 0 4.8729983603834626e-08
day O 0 5.6576201501457035e-08
7 O 0 3.350802160184685e-07
. O 0 1.0695561059037573e-07

5 O 0 3.380311284217896e-07
of O 0 9.300404002487994e-09
embryogenesis O 0 4.053670272696763e-05
. O 0 5.107876859256066e-07

Mutant O 0 1.692485238891095e-05
embryos O 0 7.243634740916605e-07
have O 0 9.317506055595004e-08
reduced O 0 3.157142813847713e-08
size O 0 1.6801062656668364e-06
, O 0 7.92876164723566e-07
fail O 0 1.960069675988052e-05
to O 0 1.4817310933779027e-08
gastrulate O 0 0.00010184550046687946
or O 0 1.0941036521217029e-07
express O 0 5.310201700581274e-08
a O 0 2.1983175280126943e-09
mesodermal O 0 4.494623681239318e-06
marker O 0 0.003136924235150218
, O 0 5.6780631751962574e-08
and O 0 1.334033612465646e-07
show O 0 4.673036073654657e-06
abnormal O 0 5.425317340268521e-06
visceral O 0 2.8081340133212507e-06
endoderm O 0 0.00022789159265812486
development O 0 1.149518084275769e-06
. O 0 1.8087709463543433e-07

Growth B-Disease 1 0.9999878406524658
retardation I-Disease 1 0.9999908208847046
of O 0 1.6435973293482675e-07
the O 0 1.1182366961293155e-06
Smad4 O 1 0.5020999908447266
- O 1 0.9223897457122803
deficient O 0 0.026175573468208313
embryos O 0 4.595872553636582e-07
results O 0 5.097613353655106e-08
from O 0 2.1750561074451724e-10
reduced O 0 6.839038491079918e-08
cell O 0 5.699404937331565e-05
proliferation O 0 1.5295034927476081e-06
rather O 0 2.588111391865766e-10
than O 0 5.2632946612174436e-11
increased O 0 4.782299889427577e-09
apoptosis O 0 5.48174602954532e-06
. O 0 9.519126820123347e-08

Aggregation O 0 1.945840813277755e-05
of O 0 2.014030364705377e-08
mutant O 0 3.251196176279336e-05
Smad4 O 0 0.0005579055286943913
ES O 0 2.831367510225391e-06
cells O 0 4.941926476931258e-07
with O 0 1.3375809793103599e-08
wild O 0 1.3461029993777629e-05
- O 0 0.2135057896375656
type O 0 0.00036290011485107243
tetraploid O 0 5.267919186735526e-05
morulae O 0 0.00021004104928579181
rescues O 0 2.0311130356276408e-05
the O 0 4.058431812836716e-08
gastrulation B-Disease 0 0.00010080738866236061
defect I-Disease 0 0.00025204994017258286
. O 0 1.3169409385227482e-07

These O 0 9.312599900113128e-07
results O 0 1.12076754987811e-07
indicate O 0 2.450020133437647e-07
that O 0 5.188071483530621e-08
Smad4 O 0 8.610331133240834e-05
is O 0 1.9595894684698578e-08
initially O 0 6.482596859314071e-08
required O 0 8.545195662179594e-10
for O 0 1.2917049374561174e-10
the O 0 8.528521777684261e-10
differentiation O 0 1.0684917128855886e-07
of O 0 2.0838990533178503e-09
the O 0 2.239710461537925e-08
visceral O 0 2.655287289599073e-06
endoderm O 0 0.00014536950038746
and O 0 1.6894220777885494e-07
that O 0 7.847066996191643e-09
the O 0 1.5899799254981417e-09
gastrulation B-Disease 0 4.427567546372302e-06
defect I-Disease 0 1.9411441826377995e-05
in O 0 5.7346456472373575e-09
the O 0 1.1043555403489336e-08
epiblast O 0 9.548153320793062e-05
is O 0 7.97754893255842e-08
secondary O 0 9.966981906472938e-08
and O 0 6.414898479079056e-08
non O 0 4.2111356179930226e-08
- O 0 0.00010338250285713002
cell O 0 3.9583363104611635e-05
autonomous O 0 1.898630898722331e-06
. O 0 3.483558828065725e-07

Rescued O 0 0.0004494415770750493
embryos O 0 1.1370632819307502e-05
show O 0 0.0004230407066643238
severe O 0 0.0025490347761660814
anterior O 0 0.02400943823158741
truncations O 0 0.012084629386663437
, O 0 3.864370683004381e-06
indicating O 0 2.884750756493304e-06
a O 0 3.194377029558382e-07
second O 0 6.579273758688942e-06
important O 0 1.0021402374604804e-08
role O 0 3.04859533173385e-08
for O 0 1.4825170424614953e-08
Smad4 O 0 0.00023839618370402604
in O 0 4.068103720555882e-08
anterior O 0 1.7875796402222477e-05
patterning O 0 9.943659824784845e-05
during O 0 3.612051386880921e-07
embryogenesis O 0 6.29747728453367e-06
. O 0 9.25514171967734e-08

Prevalence O 0 0.0033616607543081045
of O 0 2.1075155842709137e-08
p16 O 0 1.2677202221311745e-06
and O 0 3.8714975403308927e-07
CDK4 O 0 2.865971327992156e-05
germline O 0 5.114548002893571e-06
mutations O 0 5.1061460908385925e-06
in O 0 2.6811909137336443e-08
48 O 0 1.6987933122436516e-05
melanoma B-Disease 1 0.9999852180480957
- O 1 0.9999784231185913
prone O 1 0.9986977577209473
families O 0 2.3281626226889784e-07
in O 0 1.9040949439386168e-07
France O 0 2.9652515877387486e-05
. O 0 3.2214148859566194e-07

The O 0 2.796671424221131e-06
French O 0 0.00016059573681559414
Familial B-Disease 1 0.8692991137504578
Melanoma I-Disease 1 0.9999452829360962
Study O 0 9.188755029754248e-06
Group O 0 5.7871984608937055e-06
. O 0 8.128982642574556e-08

Germline O 0 0.0016623740084469318
mutations O 0 0.0020809676498174667
in O 0 3.619108923658132e-08
the O 0 2.8615301239653945e-09
p16 O 0 1.2712320085483952e-07
and O 0 2.786360937534482e-07
CDK4 O 0 3.975563959102146e-05
genes O 0 6.495382081084244e-07
have O 0 9.558877991366899e-07
been O 0 8.466420808872499e-07
reported O 0 2.7759875820265734e-07
in O 0 1.985609010546341e-09
a O 0 2.3202919585685322e-09
subset O 0 1.180102572106989e-06
of O 0 5.792576303065289e-07
melanoma B-Disease 1 0.9999222755432129
pedigrees O 0 0.030675161629915237
, O 0 5.323344680618902e-07
but O 0 2.108694161506719e-07
their O 0 2.4706933388074503e-08
prevalence O 0 0.0005821391241624951
is O 0 1.2823612394186057e-07
not O 0 4.320911273225647e-08
well O 0 6.709341082711262e-09
known O 0 5.784897325611382e-07
. O 0 1.5914652351511904e-07

We O 0 2.067401055683149e-06
searched O 0 7.016514302904397e-08
for O 0 2.1139913430889834e-10
such O 0 3.116010227621757e-10
germline O 0 9.940931704477407e-07
mutations O 0 1.823758680075116e-06
in O 0 4.0136292511760985e-08
48 O 0 2.6471411729289684e-06
French O 0 0.07008872926235199
melanoma B-Disease 1 0.9999943971633911
- O 1 0.9997345805168152
prone O 1 0.8548673987388611
families O 0 1.3836010559487022e-08
selected O 0 4.6481956061938945e-09
according O 0 1.3824370537207642e-09
to O 0 2.897802442447528e-09
two O 0 1.208605993063827e-09
major O 0 1.0783576698258912e-08
criteria O 0 3.1338824868498705e-08
families O 0 7.79967090913658e-10
with O 0 1.1774361929894894e-08
at O 0 1.8356664099883346e-07
least O 0 3.106647383788186e-09
three O 0 5.8398703650652806e-09
affected O 0 5.676479286620406e-09
members O 0 4.749479282084579e-11
( O 0 2.2499198337744275e-10
n O 0 9.661003787186928e-06
= O 0 1.9382991013117135e-05
20 O 0 2.2228828555626023e-08
) O 0 2.2810975330855854e-09
or O 0 5.783341805454256e-08
families O 0 4.579415069372317e-09
with O 0 2.2482277373114812e-08
two O 0 9.753661345257569e-08
affected O 0 4.067646131034053e-08
members O 0 2.850177038826729e-10
, O 0 1.915688496723078e-09
one O 0 7.873554030979335e-10
of O 0 1.0359422347727687e-10
them O 0 1.512823644134187e-09
affected O 0 1.1859619952758749e-09
before O 0 2.7489479581532805e-09
the O 0 8.834764031462328e-10
age O 0 3.7754119830424315e-09
of O 0 1.0370883839205813e-11
50 O 0 1.2918608405243504e-09
( O 0 2.2491862539109064e-10
n O 0 1.4222417121345643e-05
= O 0 0.00019634002819657326
28 O 0 5.882870368623117e-07
) O 0 1.6714987172150586e-09
, O 0 1.3880966376333959e-09
and O 0 3.599803344300767e-09
one O 0 5.228138477697541e-10
additional O 0 2.8557545217466895e-10
minor O 0 2.003712324949447e-07
criterion O 0 4.571718454826623e-05
. O 0 2.5790671998038306e-07

Sixteen O 0 9.028095178109652e-07
different O 0 1.1788676701485201e-08
p16 O 0 1.9240168569467642e-07
germline O 0 2.040828121607774e-06
mutations O 0 1.2482966667448636e-05
were O 0 1.9218163060941151e-07
found O 0 1.1766643126520648e-07
in O 0 2.176498270500815e-08
21 O 0 2.4358091650356073e-06
families O 0 4.262181718672764e-08
, O 0 4.8906155569738985e-08
while O 0 2.490745565353336e-08
one O 0 1.405145777511052e-08
germline O 0 5.488436727318913e-06
mutation O 0 1.2758695220327354e-06
, O 0 7.427300108275858e-09
Arg24His O 0 2.9629223718075082e-05
, O 0 1.0229020297458646e-08
was O 0 3.091956557454978e-07
detected O 0 1.535833860089042e-07
in O 0 1.6602919039598873e-09
the O 0 1.0011123485753615e-08
CDK4 O 0 0.00010145950363948941
gene O 0 1.0622842410157318e-06
. O 0 8.544812857280704e-08

The O 0 1.5572959810583598e-08
frequency O 0 5.5695352330076275e-08
of O 0 1.0926214100148712e-10
p16 O 0 1.8910537136207495e-08
gene O 0 6.266082408501461e-08
mutation O 0 8.284948904702105e-08
in O 0 2.0963610847246628e-09
our O 0 8.033752330049992e-09
sample O 0 1.1931437171597281e-08
( O 0 1.5511253392830326e-10
44 O 0 4.023798627628139e-09
% O 0 4.88785012464632e-10
) O 0 7.675322044597976e-10
is O 0 2.4321833436147244e-09
among O 0 4.411797316361543e-10
the O 0 2.90955437520779e-09
highest O 0 3.0710944542988727e-07
rates O 0 1.249500837730011e-05
yet O 0 2.992820213876257e-07
reported O 0 5.378752803153475e-07
and O 0 4.094438210699991e-08
the O 0 5.032843475305526e-09
CDK4 O 0 0.00017126915918197483
mutation O 0 2.566627017586143e-07
is O 0 3.961944550212593e-09
the O 0 1.6249308565363663e-09
second O 0 4.467835594823555e-07
mutation O 0 1.3230285844656464e-07
detected O 0 3.757322133424168e-07
in O 0 1.9109331894640036e-09
this O 0 1.377097325061527e-09
gene O 0 1.3287325373312342e-07
worldwide O 0 1.572663137494601e-07
. O 0 2.2496352869438851e-07

In O 0 1.0538863648434926e-07
summary O 0 8.189563232008368e-06
, O 0 8.439706533636127e-08
our O 0 1.1481859907291891e-08
results O 0 1.2928129677902689e-08
show O 0 6.513047878797806e-08
frequent O 0 1.1394419630050834e-08
involvement O 0 1.7820463327211655e-08
of O 0 1.3497170048282214e-10
the O 0 6.6551737454290105e-09
p16 O 0 4.587801782918177e-08
gene O 0 1.1870856297946375e-07
in O 0 7.049890626831257e-08
familial B-Disease 1 0.5538846850395203
melanoma I-Disease 1 0.9999948740005493
and O 0 1.0349752301408444e-05
confirm O 0 1.7040765669662505e-05
the O 0 2.5917842094713706e-08
role O 0 3.892347066880575e-08
of O 0 1.110944447546558e-09
the O 0 1.313477415720854e-08
CDK4 O 0 1.291876378672896e-05
gene O 0 2.9447964067230714e-08
as O 0 3.832153261384974e-09
a O 0 4.0027509840001585e-07
melanoma B-Disease 1 0.9960989952087402
- O 0 0.026523787528276443
predisposing O 0 1.3735962966165971e-05
gene O 0 8.155739124049433e-07
. O 0 1.3250422092880854e-08
. O 0 3.2395728766232423e-08

Progression O 0 0.0010184117127209902
of O 0 8.481968016837982e-09
somatic O 0 2.1279111024341546e-06
CTG O 0 0.00021387002198025584
repeat O 0 0.00012033482198603451
length O 0 2.157187054763199e-06
heterogeneity O 0 5.342627446225379e-06
in O 0 5.333374986093986e-08
the O 0 1.1463877314099591e-07
blood O 0 4.3936561269219965e-06
cells O 0 1.9351550690771546e-06
of O 0 9.027097007674456e-07
myotonic B-Disease 1 0.9999992847442627
dystrophy I-Disease 1 0.9999995231628418
patients O 0 0.05598236992955208
. O 0 1.8823691050329217e-07

The O 0 9.78121548200761e-08
genetic O 0 7.270958803928806e-07
basis O 0 5.2844267628415764e-08
of O 0 4.621638254320715e-06
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 0 0.0009780444670468569
DM B-Disease 1 0.9999998807907104
) O 0 4.071569037478184e-06
is O 0 1.626978374247301e-08
the O 0 1.1149968726087423e-09
expansion O 0 1.1570703861707443e-07
of O 0 2.032870760615424e-09
an O 0 7.898771769987434e-08
unstable O 0 0.00022164767142385244
CTG O 0 4.5357021008385345e-05
repeat O 0 6.105547527113231e-06
in O 0 2.8193272161303184e-09
the O 0 4.8180064382563614e-09
34 O 0 7.498342391443202e-09
UTR O 0 4.565543349599466e-06
of O 0 1.1688812140420168e-09
the O 0 1.0390603932819431e-07
DM B-Disease 1 0.9999954700469971
protein O 0 1.383183757752704e-06
kinase O 0 1.4333771787278238e-06
gene O 0 2.5234155032194394e-07
on O 0 4.904955517304188e-07
chromosome O 0 0.0003773525240831077
19 O 0 2.528267259549466e-06
. O 0 1.735607355612956e-07

One O 0 5.115681460665655e-07
of O 0 7.659367029511088e-10
the O 0 5.143710346544594e-09
principal O 0 9.376227794177794e-09
features O 0 1.3893082950744429e-07
of O 0 7.655544642659606e-09
the O 0 2.01821603695862e-06
DM B-Disease 1 0.9999998807907104
mutation O 0 9.402262367075309e-05
is O 0 1.552962380912959e-08
an O 0 7.866064466455214e-10
extraordinarily O 0 9.176496860163752e-07
high O 0 4.3926073090005957e-07
level O 0 1.8540779578302136e-08
of O 0 1.3321362068996478e-10
somatic O 0 4.236117376876791e-07
mosaicism O 0 0.00012618774781003594
, O 0 6.46009539195802e-08
due O 0 1.6455539153525933e-08
to O 0 1.4359130773300421e-08
an O 0 3.9369649762477366e-09
extremely O 0 2.9402568202385737e-07
high O 0 1.9639153947537125e-07
degree O 0 1.188283516029287e-08
of O 0 1.0371526970587297e-09
somatic O 0 1.0535930414334871e-05
instability O 0 2.9095257559674792e-05
both O 0 7.248209499266522e-08
within O 0 1.555657114238329e-08
and O 0 1.5396439323467348e-07
between O 0 1.3627142081418242e-08
different O 0 1.2614831845780827e-08
tissues O 0 2.5270958303735824e-06
. O 0 6.291423204629609e-08

This O 0 1.6421353166151675e-06
instability O 0 6.048133855074411e-06
appears O 0 5.654879373651056e-07
to O 0 5.302254191263955e-09
be O 0 1.9733685796552436e-09
biased O 0 2.514831862754363e-07
towards O 0 2.092817474874664e-09
further O 0 7.579003535873596e-10
expansion O 0 1.0854959953121579e-07
and O 0 4.891063554168795e-08
continuous O 0 1.3351167638120387e-07
throughout O 0 7.96010013459636e-08
the O 0 9.405049894439799e-08
life O 0 1.8353530606418644e-07
of O 0 3.535370052265563e-10
an O 0 3.587308228247821e-09
individual O 0 6.008928465917052e-09
, O 0 2.2683763756248254e-09
features O 0 3.303819084976567e-06
that O 0 3.285150341980625e-06
could O 0 7.263561656145612e-06
be O 0 2.25579608326143e-08
associated O 0 9.228961594942575e-09
with O 0 2.077031169278598e-08
the O 0 2.672583434559783e-07
progressive O 0 2.7670042982208543e-05
nature O 0 2.41889460994571e-06
of O 0 1.0857938548269885e-08
the O 0 7.239156730065588e-06
disease O 0 0.03903445973992348
. O 0 5.8190369855992685e-08

Although O 0 3.643878585535276e-07
increasing O 0 1.1717367520702737e-08
measured O 0 1.0666794025837589e-07
allele O 0 6.120333040371406e-08
size O 0 5.277839250084071e-07
between O 0 2.2392976006813115e-06
patients O 0 6.5462904785817955e-06
clearly O 0 3.9332147139248264e-07
correlates O 0 4.507715232193732e-07
with O 0 1.666660764954031e-08
an O 0 2.343090166334605e-08
increased O 0 6.61917226807418e-07
severity O 0 0.004322885535657406
of O 0 5.287552653499006e-07
symptoms O 0 0.04718857258558273
and O 0 1.9273059592705977e-07
an O 0 9.709204107366531e-09
earlier O 0 2.3049222363624722e-05
age O 0 4.557302872854052e-07
of O 0 3.580731933183756e-09
onset O 0 0.0009017018601298332
, O 0 7.881943098198008e-09
this O 0 1.9601331668894773e-10
correlation O 0 1.2591350184720795e-07
is O 0 2.4510361740226472e-08
not O 0 1.0691784346761324e-08
precise O 0 9.637766851255947e-08
and O 0 1.8709627624957648e-08
measured O 0 5.000571334790038e-08
allele O 0 6.165298493954197e-09
length O 0 1.0678702892619185e-05
cannot O 0 9.450277502764948e-06
be O 0 7.020273695701462e-09
used O 0 4.850640777931403e-08
as O 0 1.232317270449812e-08
an O 0 3.3782401320792133e-09
accurate O 0 1.6459720427519642e-05
predictor O 0 7.222358362923842e-06
of O 0 1.8308832228086658e-09
age O 0 1.7869824375793542e-07
of O 0 2.896686002173965e-09
onset O 0 0.00012951505777891725
. O 0 3.040547369437263e-07

In O 0 1.916278336011601e-07
order O 0 2.060140502635477e-08
to O 0 4.843545009514116e-10
further O 0 2.25087282146319e-10
characterize O 0 5.701808163394162e-07
the O 0 1.4463692465938038e-08
dynamics O 0 4.885240286967019e-06
of O 0 3.6843678685727355e-07
DM B-Disease 1 0.9999984502792358
CTG O 0 0.05429024249315262
repeat O 0 0.00023038631479721516
somatic O 0 9.621375284041278e-06
instability O 0 6.30165304755792e-05
, O 0 4.3230958368667416e-08
we O 0 6.083520531774411e-08
have O 0 1.5818069076800612e-09
studied O 0 8.49675085845547e-09
repeat O 0 2.627522803777538e-07
length O 0 9.088689978398179e-08
changes O 0 1.473416499919722e-09
over O 0 1.1851983394706167e-08
time O 0 1.4728250619100436e-07
in O 0 2.1188684229400678e-07
111 O 0 0.040826912969350815
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999998807907104
patients O 0 0.0003199316852260381
with O 0 1.710641184260453e-09
varying O 0 2.644233632054238e-08
clinical O 0 7.842741615604609e-05
severity O 0 0.00034736518864519894
and O 0 2.7049173922932823e-07
CTG O 0 8.642748980491888e-06
repeat O 0 2.9745910978817847e-06
size O 0 1.497602575284418e-08
over O 0 8.66260378984407e-08
time O 0 1.6061783014720277e-08
intervals O 0 8.83440165466709e-08
of O 0 1.4399843817347602e-10
1 O 0 1.013230388480224e-07
- O 0 0.0006274358602240682
7 O 0 1.5989270423233393e-06
years O 0 5.278483428128311e-08
. O 0 2.6754644721904697e-08

We O 0 0.0003445918846409768
have O 0 1.3017607614074223e-07
found O 0 2.2964812274040014e-09
a O 0 2.0892945706840749e-10
direct O 0 8.312122545817147e-09
progression O 0 0.00022051403357181698
of O 0 1.4717481677806177e-09
the O 0 1.4904784961800033e-08
size O 0 1.210527642570014e-07
heterogeneity O 0 2.1537027805607067e-06
over O 0 2.2098420515703765e-07
time O 0 3.197912334940156e-08
related O 0 1.9424002406509544e-09
to O 0 1.8974153359607726e-09
initial O 0 6.084887704815856e-09
CTG O 0 1.142473138315836e-06
repeat O 0 2.0554834918584675e-06
size O 0 5.729663143938524e-08
and O 0 5.851357798292156e-08
the O 0 2.9482851715556535e-09
time O 0 6.874755342778371e-08
interval O 0 5.977740329399239e-06
and O 0 7.301798632397549e-08
always O 0 2.3266172988201106e-08
biased O 0 3.5886920102257136e-08
towards O 0 1.409253547191014e-10
further O 0 2.4233007267504547e-10
expansion O 0 8.864327583069098e-08
. O 0 6.308702182877823e-08

Attempts O 0 2.732813845796045e-05
to O 0 7.642049659750683e-09
mathematically O 0 9.322056371274812e-08
model O 0 4.356042779818381e-07
the O 0 1.4537510750756155e-08
dynamics O 0 2.8668513550655916e-05
have O 0 1.7142327124020085e-05
proved O 0 0.00041823051287792623
only O 0 1.0969558417173175e-07
partially O 0 3.8585483707720414e-05
successful O 0 3.844066327474138e-07
suggesting O 0 3.5264173448013025e-07
that O 0 2.63150443657878e-08
individual O 0 2.426686351864049e-10
specific O 0 5.047472440011802e-10
genetic O 0 4.950235961587168e-06
and O 0 1.645978386477509e-06
/ O 0 0.0004269925120752305
or O 0 4.770996042680054e-07
environmental O 0 2.9840248316759244e-07
factors O 0 4.5136516746424604e-08
also O 0 3.4989446362487797e-07
play O 0 2.0622975682726974e-07
a O 0 7.285935854639547e-09
role O 0 2.0219438567892212e-08
in O 0 1.1981448722053756e-08
somatic O 0 3.372425965153525e-07
mosaicism O 0 3.67800603271462e-05
. O 0 1.2742222388339997e-08
. O 0 3.3542868038693996e-08

Aspartylglucosaminuria B-Disease 1 0.9972079396247864
among O 0 8.298374609694292e-07
Palestinian O 0 1.1445472409832291e-05
Arabs O 0 3.3449221518822014e-05
. O 0 8.755490057410498e-07

Aspartylglucosaminuria B-Disease 1 0.9999721050262451
( O 0 0.0004568285949062556
AGU B-Disease 1 0.9999724626541138
) O 0 4.897392500424758e-07
is O 0 3.052726427199559e-08
a O 0 4.1927745542125194e-07
rare O 0 0.0003439161810092628
disorder B-Disease 1 0.7660664319992065
of I-Disease 0 1.0445766207567431e-07
glycoprotein I-Disease 0 0.4285016357898712
metabolism I-Disease 1 0.7580533027648926
caused O 0 2.627860703796614e-05
by O 0 1.5191501745448477e-07
the O 0 3.570558692445047e-05
deficiency B-Disease 0 0.1528841108083725
of I-Disease 0 3.026064065991818e-09
the I-Disease 0 5.392707862483803e-07
lysosomal I-Disease 0 0.3888837993144989
enzyme I-Disease 0 0.0001169613897218369
aspartylglucosaminidase I-Disease 0 0.0006777546368539333
( O 0 1.4705228146283389e-08
AGA O 0 8.746829735173378e-06
) O 0 6.869037783019394e-09
. O 0 1.6559788207359816e-08

AGU B-Disease 1 0.9999587535858154
is O 0 0.00020612844673451036
inherited O 0 0.009874530136585236
as O 0 4.3273777805552527e-07
an O 0 3.347244330598187e-07
autosomal O 1 0.9884203672409058
recessive O 1 0.999803364276886
trait O 1 0.9190089702606201
and O 0 0.0002947173488792032
occurs O 0 9.204669026985357e-08
with O 0 7.2106178805597665e-09
a O 0 6.926547513330661e-08
high O 0 1.9795670596067794e-06
frequency O 0 8.995319149107672e-06
in O 0 4.388478771488735e-07
Finland O 0 0.0019969407003372908
because O 0 5.0310507759832035e-08
of O 0 7.933623896727582e-11
a O 0 2.453870706631278e-08
founder O 0 3.5661932997754775e-06
effect O 0 2.0581049398060713e-07
. O 0 3.716377960927275e-08

While O 0 4.790555522049544e-06
very O 0 6.457471357634859e-08
few O 0 4.475605663856186e-08
patients O 0 5.117291834721982e-07
with O 0 1.5657014955650084e-06
AGU B-Disease 1 0.9999996423721313
have O 0 7.15919304639101e-05
been O 0 1.789736415958032e-06
reported O 0 8.181259545381181e-07
from O 0 2.1459849453009383e-09
non O 0 1.9759312408496044e-07
- O 0 0.06613781303167343
Finnish O 0 0.0027977030258625746
origin O 0 5.344679152585741e-07
, O 0 4.4848263769381447e-07
we O 0 1.7192147424793802e-05
diagnosed O 0 0.00023056560894474387
the O 0 1.7635463223086845e-07
disorder O 0 0.0006458745338022709
in O 0 2.5370969325422266e-08
8 O 0 2.1057881838260073e-07
patients O 0 1.931981508107583e-08
originating O 0 1.7569825594421218e-09
from O 0 1.977253027973802e-09
3 O 0 2.3687940142735897e-07
unrelated O 0 7.453556349901191e-07
families O 0 9.88783455113662e-08
, O 0 6.434440980029876e-09
all O 0 3.839013551498738e-10
Palestinian O 0 1.4176791296449665e-07
Arabs O 0 9.522940302986171e-08
from O 0 1.0475300488144157e-10
the O 0 5.406973202504162e-10
region O 0 4.483061921689568e-09
of O 0 4.429723532428653e-10
Jerusalem O 0 4.455244925338775e-05
. O 0 1.5002548536813265e-07

The O 0 2.282438344991533e-06
clinical O 0 0.00014159161946736276
diagnosis O 1 0.9236406683921814
of O 0 7.155378170864424e-06
AGU B-Disease 1 0.9999996423721313
is O 0 0.00014971301425248384
often O 0 2.3027536371955648e-05
difficult O 0 2.5485644073341973e-05
, O 0 3.4828653294738388e-09
in O 0 1.5066726755108562e-09
particular O 0 7.745135199854758e-09
early O 0 1.585750482036019e-07
in O 0 1.5036189182637827e-08
the O 0 6.826721943298253e-08
course O 0 1.209516358358087e-05
of O 0 6.509344618876867e-09
the O 0 5.632825559587218e-05
disease O 1 0.8867833018302917
, O 0 5.4521308356925147e-08
and O 0 6.414285991240831e-08
most O 0 1.2164088625254976e-09
of O 0 1.2092931100937676e-09
the O 0 4.379540143872873e-07
patients O 0 7.632408483004838e-07
are O 0 4.181856638751924e-08
diagnosed O 0 0.009896415285766125
after O 0 1.0186113996724089e-07
the O 0 3.542792015309715e-08
age O 0 1.9616167890035285e-07
of O 0 3.5296363054548863e-10
5 O 0 1.2103025426313252e-07
years O 0 5.067657582458196e-08
. O 0 4.728056168801231e-08

However O 0 4.2174353438895196e-05
, O 0 3.446745111546079e-08
since O 0 3.10053991370296e-08
these O 0 5.716746187545141e-09
patients O 0 2.094363971139046e-08
excrete O 0 4.483232896035361e-09
early O 0 3.9984291433370345e-09
large O 0 4.4969936108252284e-10
amounts O 0 1.850807701542223e-10
of O 0 7.47370831888361e-10
aspartylglucosamine O 0 8.963410800788552e-05
in O 0 5.9069769520192494e-08
urine O 0 1.4646143142726942e-07
, O 0 6.807131247565934e-11
biochemical O 0 2.5813289283860286e-09
screening O 0 2.9511051380382014e-08
is O 0 4.6129469133404655e-09
easy O 0 2.479087015672121e-07
by O 0 1.2233425383811891e-09
urine O 0 2.8794161721634737e-07
chromatography O 0 1.337113872068585e-06
. O 0 1.2850026820387939e-08
. O 0 2.4074644500160503e-08

Detection O 0 3.137060775770806e-05
of O 0 6.76896982909625e-09
heterozygous O 0 2.7026740667679405e-07
carriers O 0 2.461136716647161e-07
of O 0 2.6017991316962252e-08
the O 0 0.00038908072747290134
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999990463256836
telangiectasia I-Disease 1 0.9999996423721313
( O 0 8.64536900735402e-07
ATM O 0 4.475625610211864e-05
) O 0 4.1960263041929124e-10
gene O 0 3.205788745574978e-09
by O 0 1.2440302121774494e-09
G2 O 0 5.028340092394501e-05
phase O 0 1.7581385236553615e-06
chromosomal O 0 0.0017508366145193577
radiosensitivity O 0 0.00011071120388805866
of O 0 2.241975671779528e-08
peripheral O 0 0.4969816207885742
blood O 0 0.0006527266232296824
lymphocytes O 0 0.00031913176644593477
. O 0 2.2496074336686434e-07

In O 0 0.002630172297358513
ataxia B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999947547912598
telangiectasia I-Disease 1 0.9999992847442627
( O 0 0.015260720625519753
A B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
) O 0 8.805255674815271e-06
patients O 0 6.871615369163919e-06
, O 0 1.23219274783537e-08
mutations O 0 4.0986972749124106e-07
in O 0 5.803306279972276e-09
a O 0 5.017548332375554e-08
single O 0 2.0750114344991744e-05
gene O 0 2.4629873678350123e-06
, O 0 4.4503575935550543e-08
ATM O 0 0.0004664770676754415
, O 0 6.041222633257348e-08
result O 0 7.263779622235234e-08
in O 0 3.778685027100437e-07
an O 0 0.15929220616817474
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 0.08558488637208939
embraces O 0 1.5305951819755137e-05
a O 0 1.1783993869585174e-07
variety O 0 7.186030615002892e-08
of O 0 1.972846419562302e-08
clinical O 0 3.9401045796694234e-05
features O 0 0.0007565204286947846
and O 0 2.1051382645964622e-05
manifests O 0 1.2758276170643512e-05
extreme O 0 7.395817647193326e-06
radiosensitivity O 0 9.059214062290266e-05
and O 0 8.664321882179138e-08
a O 0 7.2568937525829824e-09
strong O 0 3.9147725061638994e-08
pre O 0 9.979657079384197e-06
- O 0 0.017828218638896942
disposition O 0 2.4093624233501032e-05
to O 0 1.8788055911045376e-07
malignancy B-Disease 0 0.0008654803386889398
. O 0 5.236846689626873e-08

Heterozygotes O 0 1.8897138943430036e-05
for O 0 1.0975666597801137e-08
the O 0 4.910381434797273e-09
ATM O 0 1.301606243941933e-05
gene O 0 3.686322088469751e-06
have O 0 1.2508342024375452e-06
no O 0 8.68854925784035e-08
clinical O 0 3.0749305324206944e-07
expression O 0 2.729126435951912e-07
of O 0 1.9866598677253933e-07
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
but O 0 0.019964059814810753
may O 0 2.526268690417055e-05
be O 0 4.218590675009182e-06
cancer B-Disease 0 0.009303615428507328
prone O 0 0.0005225591594353318
with O 0 1.0143843987009404e-08
a O 0 1.735369039579382e-07
moderate O 0 7.516525784012629e-06
increase O 0 4.610794235304638e-08
in O 0 1.891075562809874e-08
in O 0 7.891151909689142e-08
vitro O 0 0.00010766510968096554
radiosensitivity O 0 0.00010014801227953285
. O 0 1.0658151694542539e-07

We O 0 8.863919356372207e-05
performed O 0 4.992165827388817e-07
a O 0 7.692898762456934e-09
blind O 0 4.370762781036319e-06
chromosomal O 0 1.610682920727413e-05
analysis O 0 4.0203943285632704e-08
on O 0 1.0472437850239658e-07
G2 O 0 0.00045338316704146564
- O 0 0.0023372385185211897
phase O 0 1.8253160760650644e-06
lymphocytes O 0 1.4706791944263387e-06
from O 0 7.071498941968457e-10
7 O 0 8.016490227191753e-08
unrelated O 0 1.9948056433349848e-06
A B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 0.0818491131067276
, O 0 1.652776049354543e-08
13 O 0 2.2114521769367457e-08
obligate O 0 6.89413582222187e-07
A B-Disease 1 0.9999840259552002
- I-Disease 1 0.9999943971633911
T I-Disease 1 0.9999995231628418
heterozygotes O 0 2.4680033675394952e-05
( O 0 8.582246024957385e-09
parents O 0 6.878398739473823e-09
of O 0 6.783040795710349e-10
the O 0 4.5126702730158286e-07
patients O 0 3.129204969809507e-06
) O 0 2.2383725983843306e-09
, O 0 7.39329353294238e-09
and O 0 4.025243782734833e-08
14 O 0 1.3509005469813928e-08
normal O 0 7.962420056628616e-09
controls O 0 2.535157932470611e-07
following O 0 8.440008691934509e-09
X O 0 0.0007654826622456312
- O 0 1.3353092981560621e-05
irradiation O 0 6.521437967421662e-08
with O 0 3.074919652235053e-09
1 O 0 3.27532241328754e-08
Gy O 0 0.00019118341151624918
in O 0 8.146346708315377e-09
order O 0 2.1625643498168756e-09
to O 0 1.9285262276014237e-10
evaluate O 0 8.970948428554948e-10
this O 0 6.504199262513666e-11
cytogenetic O 0 6.474922997767862e-08
method O 0 2.182709302189778e-08
as O 0 6.033479271749798e-10
a O 0 5.895737786865141e-10
tool O 0 2.3064170306952292e-07
for O 0 8.424399372541913e-11
detection O 0 3.150796246131904e-08
of O 0 4.090008609569651e-10
ATM O 0 7.176357030402869e-05
carriers O 0 1.597847813172848e-06
. O 0 1.0627519486661186e-07

Both O 0 7.178293890319765e-05
A B-Disease 1 0.9990953207015991
- I-Disease 1 0.9999562501907349
T I-Disease 1 0.999997615814209
homozygotes O 0 0.0027309097349643707
and O 0 5.308120876179601e-07
heterozygotes O 0 2.9423915748338914e-07
showed O 0 2.5796748559514526e-07
significantly O 0 9.48615319629198e-09
increased O 0 5.515953915846694e-09
levels O 0 5.716092044139032e-09
of O 0 1.2260030768374008e-09
radiation O 0 0.009776312857866287
- O 1 0.7495280504226685
induced O 0 0.34423068165779114
chromatid O 0 0.015580310486257076
damage O 0 0.00010147799184778705
relative O 0 1.5747761494822043e-07
to O 0 1.6301250127526146e-08
that O 0 3.6339513620475827e-09
of O 0 2.7562965798644257e-10
normal O 0 2.703777397528029e-07
controls O 0 3.154339356115088e-05
. O 0 1.1717484227347086e-07

These O 0 4.6607070203208423e-07
results O 0 1.1482872253054666e-07
show O 0 1.2100082358301734e-07
that O 0 2.832716283762693e-09
the O 0 1.3747537552788458e-09
G2 O 0 3.681118323584087e-05
- O 0 3.338584065204486e-05
phase O 0 5.358244266062684e-07
chromosomal O 0 3.927166835637763e-05
radiosensitivity O 0 1.373775830870727e-05
assay O 0 2.450462034175871e-06
can O 0 1.8865745232687914e-07
be O 0 1.1808991562389792e-09
used O 0 1.882338196423916e-08
for O 0 7.062360141141255e-10
the O 0 3.2263380855823698e-09
detection O 0 7.90294393482327e-07
of O 0 2.5707761253102035e-08
A B-Disease 1 0.9999933242797852
- I-Disease 1 0.9999942779541016
T I-Disease 1 0.9999980926513672
heterozygotes O 0 0.0011873478069901466
. O 0 3.9058082279552764e-07

In O 0 4.011842520412756e-07
combination O 0 5.225591621638159e-07
with O 0 3.7150227338855757e-09
molecular O 0 1.0908401009146473e-06
genetic O 0 4.6108787500998005e-05
analyses O 0 3.363243740750477e-05
, O 0 1.3732764259088981e-08
this O 0 3.0327029776344716e-09
test O 0 6.115739779488649e-06
may O 0 7.054813266904603e-08
be O 0 7.065674156869761e-10
of O 0 7.790226103088216e-11
value O 0 1.798498061589271e-08
in O 0 1.1482297779252804e-08
studies O 0 7.1183925420825744e-09
of O 0 7.601225204822981e-10
familial B-Disease 0 0.0020238179713487625
and I-Disease 0 1.828011590987444e-05
sporadic I-Disease 0 0.0068709710612893105
cancers I-Disease 1 0.9518175721168518
aimed O 0 1.107309458348027e-06
at O 0 3.105897121713497e-07
determination O 0 6.261267344598309e-07
of O 0 2.2913655695067092e-10
the O 0 3.3632667761906987e-09
potential O 0 1.6473997721533351e-09
involvement O 0 3.400161041611227e-09
of O 0 5.288192106434053e-10
ATM O 0 0.0005991830839775503
mutations O 0 1.3700639101443812e-05
in O 0 6.103296072978992e-07
tumor B-Disease 0 0.09045557677745819
risk O 0 3.7802744827786228e-06
or O 0 5.9135604857374346e-08
development O 0 3.0032100539756357e-07
. O 0 8.12126472737873e-08
. O 0 1.167272500879335e-07

Ataxia B-Disease 1 0.9999982118606567
- I-Disease 1 0.9999775886535645
telangiectasia I-Disease 1 0.9999927282333374
: O 0 2.050236844297615e-06
identification O 0 5.203918931329099e-07
and O 0 4.8244181982681766e-08
detection O 0 4.5226184397506586e-07
of O 0 7.014220315681996e-10
founder O 0 5.094744665257167e-06
- O 0 0.0004140896489843726
effect O 0 2.620641055273154e-07
mutations O 0 1.5809050069037767e-07
in O 0 8.032461362716958e-10
the O 0 1.2394780757318813e-09
ATM O 0 6.441076948249247e-06
gene O 0 7.58949809664955e-08
in O 0 6.828516418977415e-09
ethnic O 0 1.1223848872532471e-07
populations O 0 7.841929800633807e-06
. O 0 2.327139441149484e-07

To O 0 4.477415771475535e-08
facilitate O 0 1.0733937294560292e-08
the O 0 6.982411315803461e-10
evaluation O 0 1.2179411923440853e-09
of O 0 5.629420540831376e-11
ATM O 0 2.0625016077246983e-06
heterozygotes O 0 1.716149569119807e-07
for O 0 2.5292490324346772e-09
susceptibility O 0 2.4981232854770496e-05
to O 0 2.869211073175393e-07
other O 0 5.673445002685185e-07
diseases O 1 0.7073006629943848
, O 0 7.747750885300775e-09
such O 0 1.7922861417218883e-08
as O 0 0.00092170579591766
breast B-Disease 1 0.9998831748962402
cancer I-Disease 1 0.9756356477737427
, O 0 4.496195913361589e-07
we O 0 8.144298249135318e-07
have O 0 2.4112051022484593e-08
attempted O 0 1.8063780089505599e-06
to O 0 3.5229124062396977e-09
define O 0 1.1229715823901643e-07
the O 0 7.318051942206694e-09
most O 0 5.592247998009725e-09
common O 0 8.263265272034914e-08
mutations O 0 1.7847763729150756e-06
and O 0 3.219786393060531e-08
their O 0 5.839447592137503e-09
frequencies O 0 1.3010895827392233e-06
in O 0 0.0002966848260257393
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.001777007128112018
A B-Disease 1 0.9999977350234985
- I-Disease 1 0.9999986886978149
T I-Disease 1 0.9999997615814209
) O 0 4.28552020537154e-08
homozygotes O 0 7.115313565009274e-07
from O 0 6.796068707792813e-10
10 O 0 9.141395418410525e-10
ethnic O 0 1.0338883527083453e-08
populations O 0 2.2965145944908727e-06
. O 0 2.482647687429562e-07

Both O 0 2.17247574596513e-07
genomic O 0 8.542221621610224e-06
mutations O 0 0.0004954292089678347
and O 0 5.448392812468228e-07
their O 0 1.1061495719388859e-08
effects O 0 3.9677397012383153e-07
on O 0 4.841757927920298e-08
cDNA O 0 5.389206876316166e-07
were O 0 1.3710118196286203e-07
characterized O 0 7.97484699432971e-06
. O 0 3.9718511857245176e-07

Protein O 0 8.246249308285769e-06
- O 0 2.701532321225386e-05
truncation O 0 1.4487068256130442e-05
testing O 0 6.525930302814231e-07
of O 0 4.622022556355354e-11
the O 0 3.4781635904757024e-10
entire O 0 2.3352455524872084e-09
ATM O 0 5.880004323444155e-07
cDNA O 0 4.025750754976798e-08
detected O 0 3.033051996226277e-07
92 O 0 6.541096553291936e-08
( O 0 3.687558869369667e-10
66 O 0 1.8030289083981188e-07
% O 0 5.414217407739841e-10
) O 0 2.2759331919086634e-10
truncating O 0 4.478291373288812e-07
mutations O 0 5.46470687368128e-07
in O 0 1.7426912135576345e-09
140 O 0 4.756736782240978e-09
mutant O 0 3.058140009670751e-06
alleles O 0 1.861661615976118e-07
screened O 0 4.027153772767633e-05
. O 0 1.500949053934164e-07

The O 0 6.5781301827883e-07
haplotyping O 0 4.97685578011442e-05
of O 0 2.5005418180512606e-08
patients O 0 1.5194137858998147e-06
with O 0 6.046490597100274e-08
identical O 0 0.002584557281807065
mutations O 0 0.002497357316315174
indicates O 0 9.193522419082001e-05
that O 0 8.699359455022204e-07
almost O 0 7.500834442453197e-08
all O 0 1.2361804913041397e-08
of O 0 1.4435352913011457e-09
these O 0 7.43973460615166e-09
represent O 0 1.162332186055437e-08
common O 0 1.3097344435664127e-06
ancestry O 0 0.0001267282059416175
and O 0 4.121873644180596e-06
that O 0 2.903270797105506e-07
very O 0 8.795144168516345e-08
few O 0 4.070424353130875e-08
spontaneously O 0 3.525243812418921e-07
recurring O 0 2.9225486741779605e-06
ATM O 0 0.0015128316590562463
mutations O 0 9.897098789224401e-05
exist O 0 6.493997261713957e-06
. O 0 2.7195835627935594e-07

Assays O 0 6.241579285415355e-06
requiring O 0 1.594481524591629e-08
minimal O 0 2.0692612068273775e-08
amounts O 0 3.6227104649455555e-10
of O 0 1.0542769435240018e-10
genomic O 0 8.492184520036972e-07
DNA O 0 0.0007018335163593292
were O 0 3.8246787426032824e-07
designed O 0 1.1783428817579988e-05
to O 0 2.4173005819250193e-09
allow O 0 2.317907865645452e-09
rapid O 0 2.1904790870053148e-08
screening O 0 2.8861538936553188e-08
for O 0 7.722091299733336e-10
common O 0 1.8014814529010437e-08
ethnic O 0 4.463989853320527e-07
mutations O 0 6.975779251661152e-05
. O 0 2.713231310735864e-07

These O 0 5.9484708714308e-08
rapid O 0 1.1792008791644548e-07
assays O 0 1.0304809450190078e-07
detected O 0 1.954388437752641e-07
mutations O 0 1.697743243767036e-07
in O 0 3.66594710143886e-09
76 O 0 6.734562703059055e-07
% O 0 6.029614030289565e-10
of O 0 3.527935277247707e-09
Costa O 0 6.9599595917679835e-06
Rican O 0 1.5741816241643392e-06
patients O 0 4.2378431430734054e-07
( O 0 3.396820880130491e-10
3 O 0 4.9983491123839485e-08
) O 0 3.99915389692751e-09
, O 0 1.5669308073285038e-09
50 O 0 9.629783637166156e-10
% O 0 2.4688065480837906e-10
of O 0 6.752074455107504e-10
Norwegian O 0 0.2168014794588089
patients O 0 2.776021972294984e-07
( O 0 6.968132321150122e-11
1 O 0 8.020248465356872e-09
) O 0 4.404770326260632e-09
, O 0 6.35999919396113e-09
25 O 0 2.4318400626555103e-09
% O 0 1.36957639673696e-10
of O 0 1.4976018203327612e-09
Polish O 0 0.1745324581861496
patients O 0 6.949930480004696e-07
( O 0 2.2156761148028892e-10
4 O 0 1.6623943110971595e-07
) O 0 1.4554156990698175e-08
, O 0 1.647444491936767e-08
and O 0 8.690604857974904e-08
14 O 0 4.3322007314827715e-08
% O 0 2.381139452278802e-10
of O 0 8.329513190297178e-10
Italian O 0 0.00035740461316891015
patients O 0 6.372131338139297e-07
( O 0 3.6349129262092106e-10
1 O 0 6.332729896030287e-08
) O 0 1.0288229823629536e-08
, O 0 7.136187640810476e-09
as O 0 1.1030419244661971e-08
well O 0 1.7011410946565775e-08
as O 0 1.026934981496197e-08
in O 0 1.2558055040301497e-08
patients O 0 2.0611899742561945e-08
of O 0 1.5683353227213814e-10
Amish O 0 0.05552547797560692
/ O 0 4.504072785493918e-05
Mennonite O 0 4.420069672050886e-05
and O 0 7.746614869574842e-07
Irish O 0 1.693739022812224e-06
English O 0 6.166242201288696e-07
backgrounds O 0 1.940962874869001e-07
. O 0 4.1565371589058486e-08

Additional O 0 5.0727059885957715e-08
mutations O 0 6.015495728206588e-06
were O 0 2.6421364651696422e-08
observed O 0 2.691063727411347e-08
in O 0 2.5261970293399827e-09
Japanese O 0 2.751871988948551e-06
, O 0 7.746387420404233e-10
Utah O 0 1.5707557921018633e-08
Mormon O 0 2.081687355826034e-08
, O 0 1.3994747583012668e-09
and O 0 3.671005943672867e-09
African O 0 1.0924114945964902e-09
American O 0 7.05622653640603e-08
patients O 0 2.4864814918146294e-07
. O 0 1.2486926159738232e-08

These O 0 3.955166150149125e-08
assays O 0 1.4941964820991416e-07
should O 0 1.6742364161714818e-09
facilitate O 0 4.597669467365506e-10
screening O 0 8.505656978741172e-08
for O 0 2.5525126901015938e-08
A B-Disease 1 0.9999587535858154
- I-Disease 1 0.9999947547912598
T I-Disease 1 0.9999997615814209
heterozygotes O 0 1.5124285710044205e-05
in O 0 1.1850921133316206e-08
the O 0 3.6607485931483552e-09
populations O 0 1.4959953276161286e-08
studied O 0 1.1419771794862754e-07
. O 0 3.539399884289196e-09
. O 0 1.007262451224733e-08

The O 0 1.1358917618053965e-05
von B-Disease 1 0.9713401198387146
Hippel I-Disease 1 0.9975157976150513
- I-Disease 1 0.992957592010498
Lindau I-Disease 1 0.9903128147125244
tumor I-Disease 0 0.0004952638992108405
suppressor O 0 5.251137281447882e-06
gene O 0 1.6875701476237737e-06
is O 0 2.0941962830534067e-08
required O 0 1.2162048035335715e-09
for O 0 7.903918630702833e-10
cell O 0 0.00022638558584731072
cycle O 0 6.619749910896644e-05
exit O 0 1.287418740503199e-06
upon O 0 6.614462755294426e-09
serum O 0 6.286568350333255e-06
withdrawal O 0 4.816354817194224e-07
. O 0 4.970559785988371e-08

The O 0 3.1312600867750007e-07
inactivation O 0 4.1447179683018476e-05
of O 0 4.656910412847992e-09
the O 0 3.5291526501168846e-07
von B-Disease 1 0.9996639490127563
Hippel I-Disease 1 0.9999179840087891
- I-Disease 1 0.9999195337295532
Lindau I-Disease 1 0.9997598528862
( I-Disease 0 5.524263428924314e-07
VHL I-Disease 0 0.0009009341592900455
) I-Disease 0 3.8430691517987725e-08
tumor I-Disease 0 3.2033152820076793e-05
suppressor O 0 2.121191573678516e-05
gene O 0 8.234304914367385e-06
predisposes O 0 0.00012297944340389222
affected O 0 1.3526275779440766e-06
individuals O 0 6.936129448575912e-09
to O 0 6.790956064151032e-08
the O 0 1.8561603383204783e-06
human O 0 0.21656434237957
VHL B-Disease 1 0.999994158744812
cancer I-Disease 1 0.9999986886978149
syndrome I-Disease 1 0.9999988079071045
and O 0 1.7981667042477056e-05
is O 0 1.9261942441062274e-07
associated O 0 1.1136248190268816e-07
with O 0 2.737016302489792e-07
sporadic B-Disease 1 0.6211438775062561
renal I-Disease 1 0.9999250173568726
cell I-Disease 1 0.9999754428863525
carcinomas I-Disease 1 1.0
( O 0 8.06438474683091e-05
RCC B-Disease 1 0.9947124719619751
) O 0 2.563698899393785e-06
and O 0 2.973841219500173e-05
brain B-Disease 0 0.3846088945865631
hemangioblastomas I-Disease 0 0.014883192256093025
. O 0 4.636960966308834e-07

VHL O 0 0.009275521151721478
- O 0 0.014175204560160637
negative O 0 7.733985512459185e-06
786 O 0 1.2683934073720593e-05
- O 0 0.036291882395744324
0 O 0 7.233111318782903e-06
RCC B-Disease 0 0.001215421943925321
cells O 0 6.586431027244544e-06
are O 0 1.9458273214922883e-08
tumorigenic O 0 8.094609074760228e-05
in O 0 7.112728326319484e-07
nude O 1 0.7042319178581238
mice O 0 0.30236050486564636
which O 0 3.4146955840697046e-07
is O 0 9.552224788933472e-09
suppressed O 0 3.649665458738127e-08
by O 0 2.3550417171946947e-10
the O 0 7.819004887998915e-10
reintroduction O 0 1.1180553656231496e-06
of O 0 1.099165025664206e-08
VHL B-Disease 0 0.0012405241141095757
. O 0 1.1014403611397938e-07

Remarkably O 0 0.0009951114188879728
, O 0 2.921736097505345e-07
this O 0 2.1445529796437768e-09
occurs O 0 5.0196713452521635e-09
without O 0 4.069861392341778e-10
affecting O 0 2.0349695262211753e-09
the O 0 2.3617916511398107e-08
growth O 0 2.71514659289096e-06
rate O 0 4.857306521444116e-06
and O 0 1.1179451320231237e-07
cell O 0 1.8764878404908814e-05
cycle O 0 2.684909304662142e-06
profile O 0 4.3564622131953e-08
of O 0 2.3965215922849836e-10
these O 0 8.555556263445396e-09
cells O 0 1.3164800805043342e-07
in O 0 2.5326041264150945e-09
culture O 0 1.346986238104364e-07
. O 0 9.495045105722966e-08

The O 0 2.5845702111837454e-07
786 O 0 2.5565188934706384e-06
- O 0 0.001448599505238235
0 O 0 2.6979919311997946e-06
cell O 0 0.0004491422150749713
line O 0 0.06830771267414093
, O 0 1.958531825607679e-08
like O 0 1.441514285716039e-07
many O 0 4.9507377752888715e-08
cancer B-Disease 0 0.00011277232260908931
cells O 0 1.445891484763706e-06
, O 0 2.694875078645964e-08
fails O 0 6.068663651603856e-07
to O 0 8.543859508769458e-10
exit O 0 2.733098654061905e-07
the O 0 2.266577148191118e-09
cell O 0 1.0041138011729345e-05
cycle O 0 2.4994078557938337e-06
upon O 0 1.9873669376835323e-09
serum O 0 1.8172549971495755e-06
withdrawal O 0 1.2866978238434967e-07
. O 0 3.875213039350456e-08

Here O 0 3.053360342164524e-05
, O 0 5.464310959268914e-08
it O 0 9.014467394763415e-09
is O 0 5.959844284753046e-10
shown O 0 2.447512414960329e-09
that O 0 6.28985696859985e-10
reintroduction O 0 1.59706331714915e-07
of O 0 1.5363774696908195e-09
the O 0 6.77088323186581e-08
wild O 0 8.474919013679028e-05
- O 0 0.16650670766830444
type O 0 0.00034176683402620256
VHL B-Disease 0 1.9887438611476682e-05
gene O 0 2.738702846727392e-07
restores O 0 7.80266236688476e-06
the O 0 3.246643132115423e-08
ability O 0 8.921914229631511e-08
of O 0 2.5956909954771845e-09
VHL O 0 0.0014580199494957924
- O 0 0.16783957183361053
negative O 0 1.4730072507518344e-05
RCC B-Disease 0 0.12823228538036346
cancer I-Disease 0 0.0014634826220571995
cells O 0 3.465480062914139e-07
to O 0 1.4218928257037078e-09
exit O 0 2.707663782075542e-07
the O 0 5.89679771678675e-09
cell O 0 7.069837010931224e-05
cycle O 0 1.2725442502414808e-05
and O 0 1.3037829482698271e-08
enter O 0 6.176550382264168e-09
G0 O 0 1.2301412652959698e-06
/ O 0 9.494934261056187e-07
quiescence O 0 5.729274334953516e-07
in O 0 1.7695480636348293e-08
low O 0 1.5381807315861806e-05
serum O 0 7.658252434339374e-05
. O 0 5.1525898214777044e-08

Both O 0 8.803517630440183e-06
VHL O 0 0.0010338559513911605
- O 0 0.05349140614271164
positive O 0 1.7908189420268172e-06
and O 0 6.024331469234312e-07
VHL O 0 0.0004020283231511712
- O 0 0.013382721692323685
negative O 0 5.631518888549181e-06
RCC B-Disease 0 0.0014027459546923637
cells O 0 7.674742619201425e-07
exit O 0 5.491842784977052e-07
the O 0 7.759330067358405e-09
cell O 0 3.5297365684527904e-05
cycle O 0 2.9285833988978993e-06
by O 0 2.4915141061399027e-09
contact O 0 2.5181461182910425e-07
inhibition O 0 3.687038940825005e-07
. O 0 4.524028796026869e-08

The O 0 3.3975314295275894e-07
cyclin O 0 9.641822543926537e-06
- O 0 1.1336688658047933e-05
dependent O 0 4.835472822151132e-08
kinase O 0 8.997102440844174e-07
inhibitor O 0 7.265316526172683e-07
, O 0 1.7562119536407295e-09
p27 O 0 5.918164447393792e-08
, O 0 3.7288780396771415e-10
accumulates O 0 4.952652510326061e-09
upon O 0 1.6185330853346613e-10
serum O 0 1.5407441367187857e-07
withdrawal O 0 2.0234529074514285e-07
, O 0 8.348619573439464e-09
only O 0 2.456234104997179e-09
in O 0 2.2119024389866127e-09
the O 0 3.6658072133377573e-09
presence O 0 1.7994004508636863e-08
of O 0 3.6705718464702386e-09
VHL B-Disease 0 0.006479650270193815
, O 0 2.5588642316165533e-08
as O 0 2.9384155109113408e-09
a O 0 2.4073358417808777e-08
result O 0 9.198491568440659e-08
of O 0 9.096395164887028e-11
the O 0 2.3756063782798265e-09
stabilization O 0 1.7057645962381685e-08
of O 0 3.3948197031286043e-10
the O 0 1.2686445671761248e-08
protein O 0 4.116897969197453e-07
. O 0 6.567273658220074e-08

We O 0 5.069870439911028e-06
propose O 0 5.410981529507808e-08
that O 0 1.023331748228884e-07
the O 0 1.730506227204387e-08
loss O 0 1.0882963579206262e-06
of O 0 2.9250175614947693e-09
wild O 0 0.00031029939418658614
- O 1 0.9358970522880554
type O 0 0.0565609335899353
VHL B-Disease 0 0.00018639648624230176
gene O 0 1.139301616603916e-06
results O 0 1.9732986800136132e-07
in O 0 4.036972978127551e-10
a O 0 3.762551159525174e-09
specific O 0 1.446176067787519e-08
cellular O 0 0.014002368785440922
defect O 0 0.002355784410610795
in O 0 3.914467185950343e-07
serum O 0 0.0005814888863824308
- O 0 0.0005675452412106097
dependent O 0 6.565394414792536e-07
growth O 0 5.405088359111687e-06
control O 0 1.0068620213132817e-05
, O 0 1.0799384497772735e-08
which O 0 4.4695998013821736e-08
may O 0 9.736672268445545e-08
initiate O 0 1.182729505444513e-07
tumor B-Disease 0 3.0506998882628977e-05
formation O 0 1.2584351338773558e-07
. O 0 9.57917691835064e-08

This O 0 1.0756326673799776e-06
is O 0 2.363265316773777e-08
corrected O 0 7.438654847646831e-06
by O 0 4.4669876131386843e-10
the O 0 4.070381531828815e-10
reintroduction O 0 9.454760174776311e-07
of O 0 6.087395032494669e-09
wild O 0 0.0005012715118937194
- O 1 0.9460076093673706
type O 0 0.32325947284698486
VHL B-Disease 0 0.11242608726024628
, O 0 2.2730253590452776e-07
implicating O 0 9.882213817036245e-06
VHL B-Disease 0 0.00022245748550631106
as O 0 1.8635795129284816e-08
the O 0 8.076248114718965e-09
first O 0 3.5324356417731906e-07
tumor B-Disease 0 6.87298552293214e-06
suppressor O 0 1.11669362468092e-06
involved O 0 2.2374388564116998e-08
in O 0 7.438472060528056e-09
the O 0 1.5394110874922262e-08
regulation O 0 1.3656679698215157e-07
of O 0 2.536547638598563e-10
cell O 0 0.00015273834287654608
cycle O 0 4.361624814919196e-05
exit O 0 2.882837361539714e-05
, O 0 6.112201589303368e-08
which O 0 5.4998938736616765e-08
is O 0 5.643143285993801e-09
consistent O 0 4.48145698328517e-08
with O 0 8.067668755273871e-10
its O 0 2.4306066048751518e-09
gatekeeper O 0 1.1390569852665067e-05
function O 0 2.386450717040134e-07
in O 0 4.049693913543706e-08
the O 0 1.7296996475124615e-06
kidney O 0 8.570461068302393e-05
. O 0 8.89665852099597e-09
. O 0 3.6097748790098194e-08

Piebaldism B-Disease 1 0.9999371767044067
with O 0 0.206809863448143
deafness B-Disease 1 0.9999998807907104
: O 0 7.105453505573678e-07
molecular O 0 1.641471499169711e-06
evidence O 0 4.0392652067566814e-07
for O 0 3.373507695414446e-09
an O 0 4.6291717126223375e-07
expanded O 1 0.830687403678894
syndrome O 1 0.9999812841415405
. O 0 6.167759352138091e-07

In O 0 1.3534710774365522e-07
a O 0 8.600864731533875e-08
South O 0 1.0987562291120412e-06
African O 0 8.239717352864773e-09
girl O 0 1.6036779015848879e-06
of O 0 5.539177450053501e-10
Xhosa O 0 0.001972296042367816
stock O 0 2.1214857497398043e-06
with O 0 7.814381319803942e-07
severe O 0 0.0003912689571734518
piebaldism B-Disease 0 0.15573714673519135
and O 0 0.00028276158263906837
profound O 0 0.002074624178931117
congenital O 1 0.9999986886978149
sensorineural B-Disease 1 0.9999982118606567
deafness I-Disease 1 1.0
we O 1 0.9925923943519592
identified O 0 2.145564758393448e-05
a O 0 5.711746098313597e-08
novel O 0 1.2864319387517753e-06
missense O 0 2.3093141408025986e-06
substitution O 0 7.145983715872717e-08
at O 0 5.2406534223337076e-08
a O 0 2.4558126643370315e-09
highly O 0 5.033918615282573e-09
conserved O 0 1.079032898587684e-07
residue O 0 1.8660891782928957e-06
in O 0 3.1385767318425906e-09
the O 0 1.0477103629114026e-09
intracellular O 0 1.9730917699689599e-07
kinase O 0 1.4179767049427028e-06
domain O 0 8.943841578457068e-08
of O 0 5.485525367276978e-10
the O 0 2.2439051505784846e-08
KIT O 0 0.00020689083612523973
proto O 0 0.00011014815390808508
- O 0 7.173229823820293e-05
oncogene O 0 3.864455266011646e-06
, O 0 2.227006801192033e-09
R796G O 0 1.5926812579891703e-07
. O 0 8.611152679804945e-09

Though O 0 7.738316526229028e-06
auditory B-Disease 0 0.00018498180725146085
anomalies I-Disease 0 0.04758923128247261
have O 0 1.3860359331374639e-06
been O 0 1.0309016573728513e-07
observed O 0 1.8496614018204127e-07
in O 0 5.563950367104553e-08
mice O 0 0.0026365320663899183
with O 0 3.444766960569723e-08
dominant O 0 4.088416608283296e-05
white O 0 1.986798997677397e-05
spotting O 0 0.0025922462809830904
( O 0 7.74125439306772e-08
W O 1 0.986177921295166
) O 0 8.27408097592297e-09
due O 0 1.8247066080334662e-08
to O 0 1.0886186174730028e-07
KIT O 0 0.23176772892475128
mutations O 0 0.0014245019992813468
, O 0 1.838502794271335e-05
deafness B-Disease 1 1.0
is O 0 4.823935159947723e-05
not O 0 8.180822419490141e-07
typical O 0 7.822061434126226e-07
in O 0 1.3912838880969502e-07
human O 0 1.6979925021587405e-06
piebaldism B-Disease 0 0.0005164906033314764
. O 0 4.1098607539424847e-07

Thus O 0 5.233169758867007e-06
, O 0 4.7892734222898525e-09
the O 0 6.45904218998794e-10
occurrence O 0 9.009896189127176e-07
of O 0 1.5730425673154969e-07
sensorineural B-Disease 1 0.9999867677688599
deafness I-Disease 1 1.0
in O 0 0.0010033260332420468
this O 0 7.946520668156154e-07
patient O 0 5.0367057156108785e-06
extends O 0 3.2465500510170386e-08
considerably O 0 1.4277963700237706e-08
the O 0 3.112024804519109e-10
phenotypic O 0 1.2049288500293187e-07
range O 0 2.621168277983088e-07
of O 0 1.3761179973315052e-09
piebaldism B-Disease 0 5.6013934226939455e-05
due O 0 7.479961539047508e-08
to O 0 7.1694215009188156e-09
KIT O 0 7.905108759587165e-06
gene O 0 1.6247973633198853e-07
mutation O 0 1.7408889618764078e-07
in O 0 1.3279973565261116e-08
humans O 0 2.386831738476758e-06
and O 0 3.424541148433491e-07
tightens O 0 0.000505862117279321
the O 0 5.315187223686735e-08
clinical O 0 1.0185283372265985e-06
similarity O 0 3.561879680091806e-07
between O 0 6.110046228968713e-07
piebaldism B-Disease 0 0.096820168197155
and O 0 1.7579205859874492e-06
the O 0 1.2977434682426292e-09
various O 0 2.3385696157340874e-10
forms O 0 3.9155500530796417e-07
of O 0 1.3714928172703367e-05
Waardenburg B-Disease 1 0.9999933242797852
syndrome I-Disease 1 0.9999487400054932
. O 0 4.4043186875342144e-08
. O 0 5.779063627642245e-08

Cycloheximide O 0 0.000753119180444628
facilitates O 0 1.7962103129320894e-06
the O 0 1.046077446886784e-08
identification O 0 1.4618228405538503e-08
of O 0 8.209609658749173e-10
aberrant O 0 4.689976049121469e-05
transcripts O 0 0.0002104762679664418
resulting O 0 3.0497928946715547e-06
from O 0 7.035004578881399e-09
a O 0 1.2419960171428102e-07
novel O 0 1.699329550319817e-05
splice O 0 0.016910705715417862
- O 0 0.08456950634717941
site O 0 1.493967829446774e-05
mutation O 0 3.8753356079723744e-07
in O 0 5.274615855199727e-09
COL17A1 O 0 6.302061956375837e-05
in O 0 1.3152222422263549e-08
a O 0 1.7782323880055628e-07
patient O 0 1.9950108253397048e-05
with O 0 3.535556345468649e-07
generalized O 0 0.16126810014247894
atrophic B-Disease 1 0.9998741149902344
benign I-Disease 1 0.9990837574005127
epidermolysis I-Disease 1 0.9978187084197998
bullosa I-Disease 1 0.9868777394294739
. O 0 8.282362614409067e-06

Patients O 0 0.0014409497380256653
with O 0 1.6115365042423946e-06
generalized O 0 0.02016160823404789
atrophic B-Disease 1 0.9997817873954773
benign I-Disease 1 0.9990484118461609
epidermolysis I-Disease 1 0.9972953200340271
bullosa I-Disease 1 0.9802605509757996
often O 0 0.0003314861678518355
show O 0 7.790773452143185e-06
decreased O 0 1.957786935236072e-06
expression O 0 1.5035621458991955e-07
of O 0 1.071297273114169e-08
type O 0 0.07478328794240952
XVII O 0 0.08992303907871246
collagen O 0 0.011878950521349907
, O 0 5.359112620340056e-08
a O 0 3.763076961149636e-08
transmembrane O 0 9.588701686880086e-06
hemidesmosomal O 0 4.1956132008635905e-06
protein O 0 1.0879912970551686e-08
encoded O 0 1.677100947006238e-08
by O 0 2.7715032047126442e-08
COL17A1 O 0 0.00044284595060162246
. O 0 1.3402961940300884e-07

This O 0 3.3580130320842727e-07
report O 0 9.494606878490686e-09
documents O 0 3.509693202730091e-09
a O 0 1.5655276186521405e-08
novel O 0 3.2620639558444964e-06
splice O 0 0.001393670216202736
- O 0 0.01399895828217268
site O 0 4.771364729094785e-06
mutation O 0 2.7958103032688086e-07
in O 0 6.862254320338934e-09
COL17A1 O 0 0.00011758727487176657
in O 0 2.7222244014524222e-08
a O 0 5.43258352081466e-07
patient O 0 0.00013246029266156256
with O 0 7.400363983833813e-07
generalized O 0 0.11776845902204514
atrophic B-Disease 1 0.9999195337295532
benign I-Disease 1 0.9986861348152161
epidermolysis I-Disease 1 0.992381751537323
bullosa I-Disease 1 0.9838737845420837
, O 0 6.735629085596884e-06
and O 0 2.5405205050788027e-08
applies O 0 4.12008427375099e-09
a O 0 1.2820372541355596e-09
new O 0 8.292471598281281e-09
methodology O 0 2.4261203179776203e-07
to O 0 4.427850530674959e-09
define O 0 1.1849654129036935e-06
and O 0 8.410572860384491e-08
characterize O 0 2.796673925331561e-06
the O 0 1.0257369176258635e-08
resulting O 0 8.727644384975974e-09
mRNA O 0 5.637992828155802e-08
splice O 0 1.5536517821601592e-05
variants O 0 3.0364319627551595e-06
. O 0 1.3309595203736535e-07

Mutational O 0 0.0005525247543118894
analysis O 0 1.5456123492185725e-06
of O 0 1.1272588196220568e-08
COL17A1 O 0 0.0002849520242307335
identified O 0 2.8479901175160194e-06
a O 0 1.0607895006842227e-07
maternally O 0 7.67790770623833e-05
inherited O 0 0.03572283312678337
G O 0 0.43153122067451477
- O 0 0.11311119049787521
to O 0 3.7381291804194916e-06
- O 0 0.1391676962375641
T O 0 0.0504940003156662
transversion O 0 8.966318091552239e-06
at O 0 2.2148164191548858e-08
the O 0 1.588779552363917e-09
- O 0 5.053766471974086e-06
1 O 0 4.7690917881482164e-09
position O 0 5.406192382650943e-09
of O 0 6.616625997102332e-11
exon O 0 2.11296287488949e-06
32 O 0 5.055426299804822e-07
. O 0 6.363204363424302e-08

This O 0 2.7183018502796585e-08
acceptor O 0 2.8369353088919524e-08
splice O 0 4.9923146434593946e-05
- O 0 0.007811733987182379
site O 0 3.839299552055309e-06
mutation O 0 1.1351727380315424e-06
led O 0 2.0545749634948152e-07
to O 0 5.630897081942976e-09
the O 0 1.510176983465783e-09
formation O 0 5.228599775364273e-09
of O 0 3.15811515827491e-10
aberrant O 0 2.017811766563682e-06
transcripts O 0 2.362987061133026e-06
present O 0 1.9153313601805166e-08
at O 0 4.382005158731772e-08
extremely O 0 9.500426045860877e-08
low O 0 4.756358521262882e-06
levels O 0 2.8080970082555723e-07
. O 0 3.342299592645759e-08

Based O 0 2.7499042971612653e-06
on O 0 2.2202287652817176e-07
our O 0 7.618051078850385e-09
recent O 0 1.0312153353453368e-09
finding O 0 2.2374635477717675e-09
that O 0 1.1137030853092256e-08
cycloheximide O 0 8.266658369393554e-06
stabilized O 0 3.454192847129889e-05
mutant O 0 4.987740567230503e-07
COL17A1 O 0 2.9807079044985585e-06
transcripts O 0 2.8986477218495565e-07
in O 0 1.9054011701769014e-09
keratinocytes O 0 4.891053890787589e-07
homozygous O 0 1.2482705358252133e-07
for O 0 9.277137391627832e-10
a O 0 6.164500376826254e-08
frameshift O 0 0.0367121584713459
mutation O 0 7.918711344245821e-05
, O 0 7.183248840192391e-08
the O 0 1.2192945320066428e-08
effects O 0 1.3214402088124189e-06
of O 0 2.454309422361689e-09
the O 0 3.761075006991632e-08
splice O 0 0.0032529502641409636
- O 0 0.003042274620383978
site O 0 8.066227792369318e-07
mutation O 0 6.330179047608908e-09
on O 0 1.0915721659898736e-09
splicing O 0 1.74564949162459e-08
of O 0 4.804477371500582e-10
COL17A1 O 0 2.211179435107624e-06
transcripts O 0 1.2841736918289826e-07
were O 0 4.7473105446727004e-09
determined O 0 4.080262794303735e-09
using O 0 2.0302901582169852e-09
reverse O 0 8.910942597140092e-06
transcriptase O 0 6.48590357741341e-05
polymerase O 0 7.692044164286926e-06
chain O 0 1.742277163430117e-05
reaction O 0 1.2325429565862578e-08
of O 0 1.499178697850212e-10
total O 0 1.1064296145946173e-09
RNA O 0 1.7439975863453583e-06
from O 0 6.204850522273375e-10
keratinocytes O 0 6.337647846521577e-07
incubated O 0 1.3209748317422054e-07
for O 0 1.0017460194688965e-09
2 O 0 1.1100981112122099e-07
. O 0 7.503095389438386e-08

5 O 0 4.3308846215950325e-06
h O 0 0.00012766127474606037
in O 0 5.799201119316422e-09
the O 0 5.637871502983671e-09
presence O 0 4.5623821165463596e-08
or O 0 4.702559408542584e-08
absence O 0 1.5643752959704216e-08
of O 0 2.5841306872109726e-10
10 O 0 1.2137928884214944e-08
microg O 0 1.5259749488905072e-05
cycloheximide O 0 8.487904779030941e-06
per O 0 1.0510896153448357e-08
ml O 0 1.9338249330758117e-06
. O 0 8.696126485574496e-08

Using O 0 3.6790939361708297e-07
this O 0 1.1765584062572998e-08
approach O 0 4.5775314561069536e-07
, O 0 3.175760987517151e-09
an O 0 1.5998453672949609e-09
abnormally O 0 9.815649718802888e-06
spliced O 0 0.00786296185106039
transcript O 0 0.18857891857624054
was O 0 0.0011497784871608019
identified O 0 2.6426514523336664e-06
that O 0 6.0014948566333715e-09
contains O 0 6.731037949236907e-10
an O 0 3.8585626360720937e-10
extra O 0 1.1557217405311349e-09
264 O 0 1.0802557071087904e-08
bases O 0 1.2340154675882786e-08
upstream O 0 2.28474195118622e-09
from O 0 2.3294199902323953e-11
exon O 0 6.716167888498603e-08
32 O 0 3.0215991841942014e-07
, O 0 3.3283213962675973e-09
resulting O 0 6.886839987174653e-09
in O 0 6.918846828796177e-09
a O 0 3.392655116840615e-07
premature O 0 1.796248761820607e-05
termination O 0 1.2593407063832274e-06
codon O 0 1.772522750798089e-06
27 O 0 7.496392981920508e-07
bp O 0 1.1058099289584788e-06
downstream O 0 1.1461013116331742e-07
from O 0 4.189181224134586e-10
the O 0 3.938497084021719e-09
cryptic O 0 5.481427251652349e-06
splice O 0 0.0005418985383585095
site O 0 1.2682894521276467e-05
. O 0 1.4463036279721564e-07

Three O 0 2.2402579702429648e-07
other O 0 3.8569142324362815e-10
splice O 0 4.00531916966429e-06
variants O 0 3.333343784106546e-06
, O 0 1.5855411206189274e-08
including O 0 7.164182580510214e-10
one O 0 1.7782425532075763e-09
derived O 0 5.387003065848717e-10
from O 0 2.830619350024932e-10
the O 0 3.9087105774271436e-10
skipping O 0 1.0362416702491828e-08
of O 0 1.279967104528268e-10
exon O 0 5.93058814502001e-07
32 O 0 5.05387902194343e-07
, O 0 4.039824919033208e-09
were O 0 7.1650472222017925e-09
also O 0 5.158410942840419e-08
identified O 0 9.597443977327202e-07
. O 0 7.957989822671152e-08

These O 0 8.993062010631547e-07
results O 0 1.0856306431605844e-07
indicate O 0 3.023798100798558e-08
the O 0 1.4441466911208067e-09
usefulness O 0 1.1216229722776916e-07
of O 0 8.957269925780054e-10
cycloheximide O 0 6.057135033188388e-05
treatment O 0 5.98911356064491e-07
in O 0 6.316354106417066e-10
evaluating O 0 8.302299292495263e-09
the O 0 1.4838324347010712e-08
abnormal O 0 2.0316707605161355e-07
processing O 0 1.6361587640290054e-08
of O 0 5.68998237415741e-10
mRNA O 0 3.0025285013834946e-07
due O 0 5.4746912780956336e-08
to O 0 7.761564724262371e-09
splice O 0 0.00011704272037604824
- O 0 0.005255669355392456
site O 0 1.6988127754302695e-05
mutations O 0 6.388015208358411e-06
, O 0 4.8224219284520586e-08
because O 0 1.1984469949766208e-07
( O 0 4.10145517548699e-09
i O 0 2.262746602355037e-05
) O 0 6.888202785937381e-10
aberrant O 0 1.4380650270595652e-07
splicing O 0 9.407701782038203e-07
often O 0 8.252177252643378e-08
generates O 0 1.8558707903792993e-09
a O 0 4.139037201866813e-08
premature O 0 1.8506243577576242e-06
termination O 0 3.7238538652673014e-07
codon O 0 1.4104953152127564e-06
, O 0 6.366868809948301e-09
( O 0 8.12531653071602e-10
ii O 0 4.1417097236262634e-06
) O 0 1.5525941643446117e-09
transcripts O 0 4.4285710032454517e-07
with O 0 8.115813443509978e-08
premature O 0 5.649732884194236e-06
termination O 0 6.076829208723211e-07
codons O 0 2.798536115733441e-06
can O 0 1.4131370562608936e-06
occur O 0 1.85803941121776e-08
at O 0 1.0747358913931748e-07
low O 0 6.797400419600308e-05
or O 0 1.9082337985310005e-06
undetectable O 0 0.0008265048381872475
levels O 0 1.0307757492000746e-07
due O 0 1.1269814415015844e-08
to O 0 7.083435615840017e-09
nonsense O 0 7.78824687586166e-06
- O 0 2.6911927761830157e-06
mediated O 0 1.2198520948913938e-07
mRNA O 0 1.6273292047230825e-08
decay O 0 1.5623646731910412e-06
, O 0 4.172166612192996e-09
and O 0 3.779720536556397e-09
( O 0 2.1054161192246568e-10
iii O 0 2.6657919534045504e-06
) O 0 2.7105859778941976e-09
the O 0 5.098651278956368e-09
levels O 0 5.26344035023385e-09
of O 0 6.092452931039105e-11
these O 0 7.39900307689112e-10
transcripts O 0 8.102355764094682e-07
can O 0 8.22232664177136e-08
be O 0 1.631330959206423e-09
increased O 0 1.1413011646865812e-09
by O 0 5.119211721194006e-09
cycloheximide O 0 8.261886978289112e-05
. O 0 1.2281914507639158e-07

A O 0 5.956792961114843e-07
deletion O 0 1.829665052355267e-05
mutation O 0 7.527443813160062e-06
in O 0 1.9570308040783857e-08
COL17A1 O 0 0.0019719451665878296
in O 0 1.053852116683629e-07
five O 0 1.622061773787209e-07
Austrian O 0 0.07166542857885361
families O 0 1.4049199137389223e-07
with O 0 2.412485400782316e-06
generalized O 0 0.32855862379074097
atrophic B-Disease 1 0.9999171495437622
benign I-Disease 1 0.999283492565155
epidermolysis I-Disease 1 0.9976007342338562
bullosa I-Disease 1 0.7881527543067932
represents O 0 1.5886794244579505e-06
propagation O 0 3.7787317523907404e-06
of O 0 1.823999173922175e-09
an O 0 5.248643741850856e-09
ancestral O 0 1.2880971553386189e-05
allele O 0 3.948446192225674e-06
. O 0 1.7344028435672953e-07

Patients O 0 0.0010712019866332412
with O 0 2.9449536214087857e-06
generalized O 0 0.07665689289569855
atrophic B-Disease 1 0.9998496770858765
benign I-Disease 1 0.9997691512107849
epidermolysis I-Disease 1 0.9989225268363953
bullosa I-Disease 1 0.9982866644859314
, O 0 3.1433703497896204e-06
a O 0 5.2077211876166984e-08
usually O 0 2.6561176369455097e-08
nonlethal O 0 1.6652536771744053e-07
form O 0 3.238547492401267e-07
of O 0 1.3419820277249528e-07
junctional B-Disease 1 0.9989124536514282
epidermolysis I-Disease 1 0.9951573014259338
bullosa I-Disease 1 0.8884139657020569
, O 0 1.4421772220885032e-06
have O 0 5.738314001746403e-08
generalized O 0 3.510188435029704e-06
blistering B-Disease 0 0.10006020218133926
, O 0 5.045960278948769e-06
nail B-Disease 1 0.9999767541885376
dystrophy I-Disease 1 0.9998766183853149
, O 0 1.8719570107350592e-06
patchy B-Disease 1 0.830094575881958
alopecia I-Disease 1 0.9999903440475464
, O 0 4.397026259539416e-06
and O 0 1.4902652765158564e-05
dental B-Disease 1 0.9984583854675293
abnormalities I-Disease 1 0.9973610043525696
. O 0 7.767164333927212e-07

Skin B-Disease 1 0.9998972415924072
fragility I-Disease 0 0.3100011646747589
in O 0 5.9376343841677226e-08
most O 0 5.35253130706792e-09
cases O 0 1.85064727986628e-08
is O 0 8.462193079594726e-08
due O 0 1.4733616637840896e-07
to O 0 3.005570547998104e-08
mutations O 0 3.3661635256976297e-07
in O 0 1.1763559015776082e-09
the O 0 1.0636858061019439e-09
gene O 0 8.672291329503423e-08
encoding O 0 1.0888455790336593e-06
type O 0 0.3466678857803345
XVII O 0 0.48186954855918884
collagen O 0 0.03399043530225754
( O 0 9.838432646347428e-08
COL17A1 O 0 0.00029713381081819534
) O 0 2.4090216044214685e-08
. O 0 4.6318255897404015e-08

Recently O 0 0.00025294211809523404
, O 0 1.9163294950885756e-07
we O 0 9.902517206228367e-08
reported O 0 1.6585330442353552e-08
five O 0 6.533213969817098e-09
Austrian O 0 0.000930064357817173
families O 0 6.746853387085139e-08
with O 0 9.786820100998739e-07
generalized O 0 0.3432752192020416
atrophic B-Disease 1 0.9999580383300781
benign I-Disease 1 0.9997555613517761
epidermolysis I-Disease 1 0.9991625547409058
bullosa I-Disease 1 0.9980652928352356
who O 0 0.0013122826348990202
share O 0 1.226275401222665e-07
the O 0 3.203400567031167e-08
same O 0 1.8714092675509164e-07
COL17A1 O 0 0.0017884031403809786
mutation O 0 1.180826893687481e-05
. O 0 2.4856376512616407e-07

Affected O 0 8.83111533767078e-06
individuals O 0 4.431297995211025e-09
in O 0 3.366289469397543e-09
three O 0 2.0605138928431188e-08
families O 0 4.73353978236446e-09
are O 0 3.8300834726001654e-10
homozygous O 0 2.3265549486950476e-08
for O 0 1.5217166415837369e-09
4003delTC O 0 2.2366937173501356e-06
, O 0 4.454983937307588e-09
whereas O 0 3.413659399598146e-08
those O 0 2.142026334084335e-09
in O 0 8.215518931820043e-09
two O 0 1.3406536325533125e-08
others O 0 1.127080384577539e-08
are O 0 5.443313577657705e-10
compound O 0 4.1338981304761546e-07
heterozygotes O 0 7.515350262110587e-06
. O 0 9.375067833161665e-08

To O 0 3.909191832462966e-07
determine O 0 1.499784190173159e-07
if O 0 1.247647496427362e-08
the O 0 8.660100969670737e-10
occurrence O 0 1.647676270977172e-07
of O 0 2.510978758252236e-09
4003delTC O 0 1.3295732969709206e-05
in O 0 4.763657557305123e-08
these O 0 2.9396489686916993e-09
unrelated O 0 7.837631699203484e-08
families O 0 7.306420357622301e-09
signifies O 0 4.4159943257682244e-08
propagation O 0 3.8777682220825227e-07
of O 0 3.387355396178293e-10
an O 0 1.87491289160846e-09
ancestral O 0 2.3937934656714788e-06
allele O 0 1.580421127300724e-07
or O 0 3.0259442951319215e-08
a O 0 2.4827867761700873e-08
mutational O 0 6.338199455058202e-05
hot O 0 0.0011672732653096318
spot O 0 5.293587310006842e-05
, O 0 4.862968250307631e-09
haplotypes O 0 2.1414601292235602e-07
were O 0 4.00239912323741e-08
determined O 0 7.165815674170517e-08
for O 0 3.955011318446111e-10
polymorphisms O 0 7.1408035182685126e-06
both O 0 9.850262472355098e-08
within O 0 8.109794435995354e-08
and O 0 2.8902527446916793e-06
flanking O 1 0.5065650939941406
COL17A1 O 0 0.22236081957817078
. O 0 9.665782272350043e-07

Five O 0 4.007410439044179e-07
intragenic O 0 6.853664217487676e-06
polymorphisms O 0 9.594345101504587e-06
were O 0 8.5426449913939e-08
chosen O 0 2.0038788406395724e-09
based O 0 1.5119812069031013e-09
on O 0 1.114479104558086e-07
their O 0 1.121821995297978e-07
informativeness O 0 0.00024519269936718047
. O 0 1.2716115804778383e-07

One O 0 9.980180948332418e-07
of O 0 1.4131409376005877e-09
these O 0 1.8868636431079722e-08
, O 0 1.0975749198394169e-08
not O 0 9.481577301073685e-09
previously O 0 1.600019317038459e-07
reported O 0 1.1075640031776857e-06
, O 0 2.853013469916732e-08
was O 0 2.0957879769412102e-06
2988 O 0 1.285171379095118e-06
A O 0 1.1333252132317284e-06
or O 0 7.573907510050049e-07
C O 0 0.001110119977965951
that O 0 1.6717930151344262e-08
introduces O 0 1.0668561145621425e-08
a O 0 1.6098732347202827e-09
new O 0 5.202079655930447e-09
restriction O 0 2.825675515794046e-08
site O 0 1.1917169473463218e-07
for O 0 2.9994182693116045e-09
Eco0109 O 0 4.320575499150436e-06
I O 0 5.3062984079588205e-05
. O 0 1.5420736687588033e-08

All O 0 1.0661668170541816e-07
the O 0 2.7207072150758904e-09
4003delTC O 0 1.506756035496437e-07
alleles O 0 9.937176415064641e-09
showed O 0 3.746401944226818e-07
the O 0 1.6539980496332873e-10
same O 0 6.931444307411994e-10
haplotype O 0 1.5265743513737107e-06
for O 0 1.545264582958339e-09
these O 0 1.3483925087598436e-09
five O 0 2.9746125562724046e-09
polymorphic O 0 7.181445198511938e-06
markers O 0 0.009340227581560612
. O 0 8.466541885354673e-07

Fourteen O 0 2.2812739643995883e-06
microsatellite O 0 4.244840602041222e-05
polymorphisms O 0 3.051881503779441e-05
were O 0 2.753234298324969e-07
selected O 0 3.74822572979383e-09
based O 0 1.3170446955257376e-08
on O 0 5.750891318712092e-07
their O 0 1.0262070304634108e-07
high O 0 1.4618390196119435e-06
heterozygosity O 0 1.0027148164226674e-05
and O 0 4.908389996671758e-07
their O 0 1.5985857082512211e-09
location O 0 1.1573274605325423e-07
within O 0 4.599759684253968e-09
10q23 O 0 7.719240215919854e-07
- O 0 6.710939487675205e-05
q25 O 0 1.5273839153451263e-06
near O 0 1.6188085965040955e-06
COL17A1 O 0 6.96320494171232e-05
. O 0 4.3892573131643076e-08

Three O 0 2.2208587324712425e-06
families O 0 3.187717823038838e-08
shared O 0 5.507483535893698e-08
microsatellite O 0 8.44226815388538e-05
polymorphisms O 0 0.0005500424304045737
covering O 0 0.0004759661096613854
at O 0 1.9677165710163536e-06
most O 0 1.5855501800388083e-08
19 O 0 8.388445849050186e-07
cM O 0 1.675320163485594e-05
, O 0 2.0369030551137257e-07
whereas O 0 3.878851941863104e-07
the O 0 8.59160138588777e-08
others O 0 2.1313016418389452e-07
shared O 0 6.315697476111382e-08
smaller O 0 7.259166778794679e-08
regions O 0 3.112491526735539e-07
consistent O 0 6.550362286361633e-06
with O 0 9.73279199456556e-08
cross O 0 6.973557901801541e-05
- O 0 0.007337368093430996
over O 0 8.615121487309807e-07
events O 0 8.438772880481338e-08
during O 0 1.9370807180507654e-08
passage O 0 2.9252296140924727e-09
of O 0 1.879982419739079e-10
this O 0 2.019684197662741e-09
mutation O 0 1.2168271723567159e-08
through O 0 1.4832601813452584e-09
several O 0 1.6600735230909436e-09
generations O 0 3.4571812079775555e-07
. O 0 4.239932849259276e-08

These O 0 2.69804854724498e-06
results O 0 3.275472977293248e-07
indicate O 0 1.5770666550452006e-07
that O 0 2.7884176745374134e-08
4003delTC O 0 9.161823072645348e-06
occurs O 0 2.7017611259338992e-08
on O 0 1.0597617894347877e-08
a O 0 4.4860559711423775e-09
single O 0 9.102393505600048e-07
ancestral O 0 7.046299742796691e-06
allele O 0 1.8603981288833893e-07
. O 0 8.396095374507695e-09
. O 0 1.2416555783545391e-08

The O 0 3.2154329687728023e-07
haptoglobin O 0 6.481783657363849e-06
- O 0 3.2006068067857996e-05
gene O 0 7.418362315547711e-07
deletion O 0 6.559826488228282e-06
responsible O 0 4.993642050976632e-07
for O 0 1.4146113613833222e-08
anhaptoglobinemia B-Disease 0 0.002015928039327264
. O 0 5.893596153327962e-07

We O 0 4.9447819037595764e-05
have O 0 1.9492150116207085e-08
found O 0 1.884672196084125e-09
an O 0 4.5186066693903015e-11
allelic O 0 1.9808764761819475e-07
deletion O 0 5.102407612866955e-06
of O 0 5.1174060544667554e-09
the O 0 9.254029720295875e-08
haptoglobin O 0 3.0316919946926646e-05
( O 0 2.3923347747256685e-09
Hp O 0 1.276635970270945e-07
) O 0 5.567383776217127e-10
gene O 0 2.0372112885524984e-08
from O 0 1.1725700410636364e-09
an O 0 6.03336758331352e-09
individual O 0 1.790376202848165e-08
with O 0 3.762525011552498e-07
anhaptoglobinemia B-Disease 0 0.01490230206400156
. O 0 4.675362390571536e-07

The O 0 2.8257034045964247e-07
Hp O 0 4.045969319577125e-07
gene O 0 2.689045288661873e-07
cluster O 0 4.4270592525208485e-07
consists O 0 1.2260154669263557e-08
of O 0 2.3141308869156774e-09
coding O 0 0.0023816986940801144
regions O 0 6.536232035614375e-07
of O 0 6.594206958254745e-09
the O 0 5.104823230794864e-08
alpha O 0 3.2197988275584066e-08
chain O 0 1.7719477909849957e-05
and O 0 5.6066475906391133e-08
beta O 0 2.49734255497458e-09
chain O 0 6.902425297994341e-07
of O 0 1.3430376255563203e-10
the O 0 3.0135938189346234e-09
haptoglobin O 0 3.483033879092545e-07
gene O 0 7.235626497958947e-08
( O 0 1.8121182332464514e-10
Hp O 0 4.490826555070271e-08
) O 0 2.215161831742307e-09
and O 0 5.922915491396452e-09
of O 0 2.386350006489124e-10
the O 0 6.33820107509564e-09
alpha O 0 1.0475869949289063e-08
chain O 0 4.471393913263455e-05
and O 0 2.747989924500871e-08
beta O 0 7.093680642888955e-10
chain O 0 4.4934870402357774e-07
of O 0 1.7406438790334988e-10
the O 0 2.5389932378772073e-09
haptoglobin O 0 4.785016471942072e-07
- O 0 5.6451335694873706e-06
related O 0 2.96691364809476e-08
gene O 0 2.805489600632427e-07
( O 0 6.724891199461069e-10
Hpr O 0 2.540729838074185e-06
) O 0 3.951311278171943e-09
, O 0 1.3153569344837024e-09
in O 0 2.7148598924497946e-09
tandem O 0 1.425818663847167e-05
from O 0 1.822893280767346e-09
the O 0 2.215399597105261e-08
5 O 0 8.397410056204535e-07
side O 0 6.9191082729958e-05
. O 0 2.3923433900563396e-07

Southern O 0 1.247693830919161e-06
blot O 0 0.0007298189448192716
and O 0 2.8568797105776866e-08
PCR O 0 9.135370078183769e-07
analyses O 0 1.3508623908364825e-07
have O 0 2.4907361506620873e-08
indicated O 0 2.182287346386147e-07
that O 0 2.9520904831770167e-08
the O 0 6.739211411144197e-09
individual O 0 5.512745815394737e-09
with O 0 1.9764961223245336e-08
anhaptoglobinemia B-Disease 0 8.903556590666994e-05
was O 0 8.983444104160299e-07
homozygous O 0 6.629492954601801e-09
for O 0 1.0834116936919713e-10
the O 0 5.058459762175005e-10
gene O 0 2.8466049073472277e-08
deletion O 0 1.3253476254249108e-06
and O 0 1.4090015554302227e-07
that O 0 8.810368434808424e-09
the O 0 7.436127269500048e-10
gene O 0 6.20792235395129e-08
deletion O 0 1.6835065252962522e-06
was O 0 8.083685315796174e-06
included O 0 1.436271901411601e-08
at O 0 3.826326633316057e-08
least O 0 5.576779038563018e-10
from O 0 2.5992916152794976e-10
the O 0 4.175024770347591e-09
promoter O 0 1.3304979802342132e-05
region O 0 2.0431611957860696e-08
of O 0 1.5133018449464686e-10
Hp O 0 8.374683346801248e-08
to O 0 1.2911193225662032e-09
Hpr O 0 6.993093393248273e-08
alpha O 0 1.9058774558544656e-09
but O 0 1.1585252757129183e-08
not O 0 1.032589125316008e-09
to O 0 5.027027127901817e-10
Hpr O 0 6.6690193989416e-07
beta O 0 9.78989067590419e-09
( O 0 1.4953954741159237e-09
Hpdel O 0 1.8938510038424283e-05
) O 0 9.925053667814154e-09
. O 0 2.236641094555125e-08

In O 0 2.414081734514184e-07
addition O 0 7.019309578026878e-09
, O 0 1.1675648892151003e-08
we O 0 5.5112558072778484e-08
found O 0 4.310554135855682e-09
seven O 0 2.385600383902897e-09
individuals O 0 4.9180909345025725e-11
with O 0 1.9155714792162826e-09
hypohaptoglobinemia B-Disease 0 2.531989593990147e-05
in O 0 8.724052946718075e-08
three O 0 1.0872054900801231e-07
families O 0 1.941012151007726e-08
, O 0 2.141570121239056e-08
and O 0 8.865765011023541e-08
the O 0 4.604183256873284e-09
genotypes O 0 8.284460051299902e-08
of O 0 1.7178115596649945e-09
six O 0 7.161087722806769e-08
of O 0 2.1336064026655777e-09
the O 0 5.459623153569737e-08
seven O 0 1.255247550346894e-08
individuals O 0 8.729799522155801e-11
were O 0 2.6189299617840334e-09
found O 0 5.436831429506128e-09
to O 0 3.922042690618355e-09
be O 0 3.1478649020755256e-08
Hp2 O 0 9.101981413550675e-05
/ O 0 2.7564645279198885e-05
Hpdel O 0 6.41972292214632e-05
. O 0 5.8519603385320806e-08

The O 0 1.6509950455656508e-06
phenotypes O 0 1.369365145365009e-05
and O 0 6.927524509592331e-07
genotypes O 0 4.154415819357382e-06
in O 0 6.458913048845716e-08
one O 0 2.9217684271998223e-08
of O 0 4.488118321432921e-09
these O 0 4.0163477876831166e-08
three O 0 4.545401210975797e-08
families O 0 9.65130286800786e-09
showed O 0 3.4753402360365726e-06
the O 0 2.61723371863809e-08
father O 0 1.1634854217845714e-06
to O 0 4.0656891187040856e-09
be O 0 5.951123593916918e-09
hypohaptoglobinemic B-Disease 0 2.890423502321937e-06
( O 0 3.8589970108304783e-10
Hp2 O 0 4.509672635322204e-06
) O 0 1.1967236090981714e-09
and O 0 1.299135998777956e-08
Hp2 O 0 1.593234992469661e-05
/ O 0 7.522363375755958e-06
Hpdel O 0 1.8605396689963527e-05
, O 0 2.516679753483686e-09
the O 0 2.4421775712824e-09
mother O 0 1.0410684581074747e-06
to O 0 1.6891612553138202e-09
be O 0 2.1167236852193128e-09
Hp2 O 0 1.7191551933137816e-06
- O 0 8.020075256354176e-06
1 O 0 4.315895196782549e-08
and O 0 7.994410822220743e-08
Hp1 O 0 1.3366725397645496e-05
/ O 0 1.7858353658084525e-06
Hp2 O 0 6.904677320562769e-06
, O 0 2.4781678931162787e-09
one O 0 5.07386188619563e-10
of O 0 1.7108067740245758e-10
the O 0 4.6569301304089095e-08
two O 0 1.590066318613026e-07
children O 0 6.07570456168105e-08
to O 0 6.211011260859323e-09
be O 0 1.2148746009188471e-08
hypohaptoglobinemic B-Disease 0 2.453986326145241e-06
( O 0 6.674645280924096e-10
Hp2 O 0 2.981589432238252e-06
) O 0 6.787220785398063e-10
and O 0 9.877821227632921e-09
Hp2 O 0 6.57304008200299e-06
/ O 0 5.5759137467248365e-06
Hpdel O 0 2.1443720470415428e-05
, O 0 1.1581562375795329e-08
and O 0 2.8863618162233706e-09
the O 0 1.0227454438904715e-09
other O 0 2.0555119828458146e-09
child O 0 1.6677727217029314e-06
to O 0 1.120155879164031e-08
be O 0 1.760512269299852e-08
Hp1 O 0 7.050010481179925e-06
and O 0 6.959574960774262e-08
Hp1 O 0 5.2177772886352614e-05
/ O 0 1.4354811355588026e-05
Hpdel O 0 1.6233294445555657e-05
, O 0 2.4143977928048344e-09
showing O 0 7.692535319847593e-08
an O 0 4.374943463059111e-10
anomalous O 0 5.001343765798083e-07
inheritance O 0 9.228557473761612e-07
of O 0 1.1135436572828894e-08
Hp O 0 7.30307647245354e-06
phenotypes O 0 3.2392072171205655e-06
in O 0 5.734911212584848e-08
the O 0 1.0763463365037751e-07
child O 0 8.311559213325381e-06
with O 0 1.590943128348954e-07
Hp1 O 0 0.00531967356801033
. O 0 1.5567857758469472e-07

The O 0 1.9238952972955303e-06
Hp2 O 0 0.0004437519528437406
/ O 0 0.0003627311089076102
Hpdel O 0 0.00016641618276480585
individuals O 0 3.2288145490610987e-08
had O 0 4.851278845308116e-06
an O 0 5.06585751125499e-09
extremely O 0 5.206435957916256e-07
low O 0 6.937785656191409e-06
level O 0 1.1830543655833026e-07
of O 0 2.9868116313558346e-10
Hp O 0 1.808050029694641e-07
( O 0 3.983423868536562e-10
mean O 0 1.8779273247560013e-08
+ O 0 3.1512829679058996e-08
/ O 0 1.3946064427727833e-06
- O 0 4.769019506056793e-05
SD O 0 0.0006004986353218555
= O 0 7.864974236326816e-07
0 O 0 1.7546483155328474e-09
. O 0 3.8252193079735264e-11
049 O 0 1.780442815402239e-08
+ O 0 1.343359201655403e-08
/ O 0 5.623976448987378e-07
- O 0 5.1559800340328366e-06
0 O 0 2.9004745272231958e-08
. O 0 1.483364125975939e-10
043 O 0 3.1467603633927865e-08
mg O 0 1.3927322584095236e-07
/ O 0 3.9940948681760347e-07
ml O 0 2.0334734074367589e-07
; O 0 1.9559476260866404e-09
n O 0 2.705786528167664e-06
= O 0 5.0583666961756535e-06
6 O 0 9.324510585884127e-08
) O 0 7.842425042703383e-10
, O 0 4.49519255152353e-10
compared O 0 2.4158901545945355e-09
with O 0 2.6671325148441838e-09
the O 0 1.9591819722108994e-08
level O 0 4.069795878081095e-08
( O 0 2.9944994400787905e-11
1 O 0 5.903592059652851e-10
. O 0 8.554588148967923e-10
64 O 0 3.542871551687199e-09
+ O 0 1.166872465319102e-08
/ O 0 7.582088414892496e-07
- O 0 5.586638962995494e-06
1 O 0 2.638686780187527e-08
. O 0 3.0894991009944306e-09
07 O 0 2.832339518477056e-08
mg O 0 2.232119200584748e-08
/ O 0 7.786345435079056e-08
ml O 0 1.7882637592947503e-08
) O 0 3.5788913499423813e-11
obtained O 0 4.3073300481921706e-10
from O 0 3.4703706575101023e-10
52 O 0 5.012392989556247e-07
healthy O 0 1.211919595789368e-07
volunteers O 0 2.458207193356543e-09
having O 0 3.6719111307093044e-08
phenotype O 0 5.807582965644542e-07
Hp2 O 0 8.421570782957133e-06
, O 0 1.3245714525211838e-09
whereas O 0 5.8334137520432705e-09
the O 0 2.0063035677253538e-09
serum O 0 1.2316027095948812e-06
Hp O 0 2.8354476100389547e-08
level O 0 1.4367266487624875e-08
of O 0 1.9272759776978177e-10
an O 0 5.0668238493756235e-09
individual O 0 5.572124539554579e-09
with O 0 4.484081728151068e-08
Hp1 O 0 0.008267097175121307
/ O 0 4.455134330783039e-05
Hpdel O 0 6.653767195530236e-05
was O 0 3.3539463402121328e-06
0 O 0 2.1287178242346272e-07
. O 0 2.3345430477661466e-08

50 O 0 1.6586491824455152e-07
mg O 0 1.4027618817635812e-06
/ O 0 5.689207227987936e-06
ml O 0 4.5876195144956e-06
, O 0 1.1801905230868215e-08
which O 0 1.5133437614167633e-08
was O 0 8.230296799638381e-08
approximately O 0 4.528012409465987e-10
half O 0 4.072008508160252e-08
the O 0 1.2929560533336826e-08
level O 0 2.0529153488269003e-08
of O 0 1.1545247396993474e-10
Hp O 0 1.836154837064896e-07
in O 0 1.130160853790585e-08
control O 0 5.462692570290528e-06
sera O 0 1.4831980479357298e-06
from O 0 5.911578171424736e-11
the O 0 9.901659492328463e-10
Hp1 O 0 6.128257609816501e-06
phenotype O 0 2.6164582322962815e-07
( O 0 2.3488723119302612e-11
1 O 0 2.55882259825313e-10
. O 0 5.621493825991308e-10
26 O 0 4.05524946955893e-09
+ O 0 3.441463647391174e-08
/ O 0 1.5950647593854228e-06
- O 0 1.0158268196391873e-05
0 O 0 2.4226840977803477e-08
. O 0 1.006274438775101e-10
33 O 0 1.5399008734817698e-09
mg O 0 3.3296121415560265e-08
/ O 0 3.526000114106864e-07
ml O 0 2.5599240416340763e-07
; O 0 2.5535387138120313e-09
n O 0 7.498154900531517e-06
= O 0 1.6739404600230046e-05
9 O 0 1.5203690395537706e-07
) O 0 3.7334613178785503e-10
, O 0 1.5137001374565529e-10
showing O 0 2.2259801113477806e-08
a O 0 4.2556642654290044e-09
gene O 0 9.908087577059632e-07
- O 0 0.0014133850345388055
dosage O 0 6.183753612276632e-06
effect O 0 2.8738830337715626e-07
. O 0 4.19494234904505e-08

The O 0 1.7232228799457516e-07
other O 0 1.4420465932474258e-09
allele O 0 4.5716504359916144e-08
( O 0 1.3644274599045048e-09
Hp2 O 0 1.0170220775762573e-05
) O 0 4.63938942818487e-10
of O 0 1.2710799079940216e-10
individuals O 0 6.870423119309521e-10
with O 0 2.3169942409140276e-08
Hp2 O 0 0.0064036729745566845
/ O 0 9.676736226538196e-05
Hpdel O 0 9.770934411790222e-05
was O 0 3.631394065450877e-06
found O 0 6.198646218535941e-08
to O 0 1.1940566757573379e-08
have O 0 4.744678605561603e-08
, O 0 1.9000845341565764e-09
in O 0 1.6707784045166818e-09
all O 0 4.659069130497073e-09
exons O 0 9.415346539753955e-06
, O 0 3.974738049805637e-08
no O 0 1.2798830439919584e-08
mutation O 0 1.6695878457539948e-08
, O 0 6.486520348625291e-11
by O 0 5.589960092033941e-11
DNA O 0 6.455192647081276e-07
sequencing O 0 7.185508934526297e-07
. O 0 1.0484909296337719e-07

On O 0 1.1139195521536749e-06
the O 0 2.526062248264793e-09
basis O 0 7.622785735961202e-10
of O 0 2.3916765790055194e-10
the O 0 8.864441625178188e-09
present O 0 7.096499388126176e-09
study O 0 6.213001668697871e-09
, O 0 9.943010859103651e-10
the O 0 8.336315526769056e-10
mechanism O 0 3.097040846000709e-08
of O 0 4.4544379296240777e-10
anhaptoglobinemia B-Disease 0 0.0004904986126348376
and O 0 3.7674584518754273e-07
the O 0 3.2172189357027037e-09
mechanism O 0 2.11975912378648e-08
of O 0 9.939706696604489e-11
anomalous O 0 2.9264711542964505e-07
inheritance O 0 1.1002084647770971e-06
of O 0 6.192344859101695e-09
Hp O 0 8.843773684930056e-06
phenotypes O 0 5.46374531040783e-06
were O 0 4.0648930621500767e-07
well O 0 2.967811383314256e-07
explained O 0 4.010165412182687e-06
. O 0 2.6194658886424804e-08

However O 0 2.349265560042113e-05
, O 0 1.1063077565154344e-08
the O 0 1.486437750664038e-09
mechanism O 0 2.607661464537614e-08
of O 0 1.5075235504369289e-09
hypohaptoglobinemia B-Disease 0 0.0006299702217802405
remains O 0 4.789331342180958e-06
unknown O 0 4.503574473346816e-06

ATM O 0 0.0022893056739121675
mutations O 0 0.0015613277209922671
and O 0 6.091513569117524e-06
phenotypes O 0 0.0005226563080213964
in O 0 0.00016316570690833032
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 0.9999998807907104
families O 0 0.0034587050322443247
in O 0 1.125514245359227e-06
the O 0 6.283327707024e-07
British O 0 0.00040340214036405087
Isles O 0 0.0001280254073208198
: O 0 5.475614961447661e-10
expression O 0 4.3931139281916387e-10
of O 0 2.0879194206901985e-11
mutant O 0 1.9807667683835462e-07
ATM O 0 9.946726095222402e-06
and O 0 1.036556369626851e-07
the O 0 1.0870164324217058e-08
risk O 0 1.0462414934409026e-07
of O 0 1.8562964498869405e-08
leukemia B-Disease 1 0.9992532134056091
, O 0 0.0017803683876991272
lymphoma B-Disease 1 1.0
, O 0 5.0867991376435384e-05
and O 0 0.0033617012668401003
breast B-Disease 1 0.999756395816803
cancer I-Disease 1 0.5406684279441833
. O 0 6.92381263434072e-07

We O 0 9.050328117155004e-06
report O 0 4.240747308870141e-09
the O 0 1.5161330524371408e-10
spectrum O 0 6.23127816012925e-09
of O 0 2.6931765151338993e-10
59 O 0 4.4882833094561647e-07
ATM O 0 5.798478741780855e-05
mutations O 0 8.62241540744435e-06
observed O 0 4.521968094195472e-06
in O 0 4.742624150821939e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
( O 0 0.014122724533081055
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
) O 0 1.264860543415125e-06
patients O 0 1.8389832234788628e-07
in O 0 2.2737607352496525e-09
the O 0 1.0318399290554225e-07
British O 0 0.0002283043577335775
Isles O 0 0.0004072482115589082
. O 0 5.7309311074504876e-08

Of O 0 3.401239112577059e-08
51 O 0 1.2489567779994104e-06
ATM O 0 4.979628647561185e-05
mutations O 0 8.648718903714325e-06
identified O 0 1.5068566199261113e-06
in O 0 1.820989936618389e-08
families O 0 8.274744445202487e-09
native O 0 4.429339384159903e-08
to O 0 3.991976882389281e-08
the O 0 2.9745686802584714e-08
British O 0 8.844559488352388e-05
Isles O 0 0.0002651827526278794
, O 0 9.655519050966177e-09
11 O 0 1.1202499372586772e-08
were O 0 8.306353826981194e-09
founder O 0 1.0056893415821833e-06
mutations O 0 2.563358975748997e-06
, O 0 2.372175345044525e-08
and O 0 5.7536901465482515e-08
2 O 0 3.12002157443203e-08
of O 0 1.0908727254843598e-09
these O 0 1.2983853991954675e-08
11 O 0 1.5675533759917926e-08
conferred O 0 3.54236484589876e-09
a O 0 2.089814898909026e-08
milder O 0 9.425461939827073e-06
clinical O 0 2.0310528270783834e-05
phenotype O 0 1.1906692634511273e-05
with O 0 3.235546586211058e-08
respect O 0 3.134055859277396e-08
to O 0 8.302951925998059e-08
both O 0 1.1883695378855919e-06
cerebellar B-Disease 1 0.7260966897010803
degeneration I-Disease 1 0.9999608993530273
and O 0 5.236504421191057e-06
cellular O 0 0.0004960297956131399
features O 0 0.0009912692476063967
. O 0 3.687918479045038e-06

We O 0 0.00013468984980136156
report O 0 2.4495037109772966e-07
, O 0 2.130592813287535e-09
in O 0 1.8305793547668259e-09
two O 0 1.7922029371675308e-07
A B-Disease 1 0.9999966621398926
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
families O 0 8.331886647283682e-07
, O 0 2.878719485011061e-09
an O 0 3.292217332084846e-10
ATM O 0 2.443460289214272e-05
mutation O 0 4.595964355758042e-07
( O 0 4.100170480914045e-10
7271T O 0 1.0924395610345528e-07
- O 0 0.0002344244421692565
- O 0 0.003188353730365634
> O 0 9.028715339809423e-07
G O 0 0.002161571057513356
) O 0 9.758305274942813e-10
that O 0 9.091638020208848e-08
may O 0 5.14457667577517e-07
be O 0 1.3168839352317718e-08
associated O 0 5.200432529051113e-09
with O 0 2.6908673067538302e-09
an O 0 1.1085933060428488e-08
increased O 0 8.857463740241656e-07
risk O 0 2.2356871340889484e-06
of O 0 2.020710638817036e-07
breast B-Disease 1 0.9993731379508972
cancer I-Disease 0 0.4785628616809845
in O 0 9.179352389310225e-08
both O 0 1.851675222042104e-07
homozygotes O 0 5.014486669097096e-05
and O 0 6.057237555978645e-07
heterozygotes O 0 4.6083238203209476e-07
( O 0 1.1696439372599343e-09
relative O 0 8.952324748179308e-08
risk O 0 7.761389042570954e-07
12 O 0 1.7397162821453094e-08
. O 0 3.5785541196986514e-09
7 O 0 4.1200087252946105e-07
; O 0 1.8142716839975037e-07
P O 1 0.5098927617073059
= O 0 0.00010392335389042273
. O 0 6.773542171600866e-09
0025 O 0 3.3061911608456285e-07
) O 0 2.298575996206864e-09
, O 0 2.3222046507953564e-09
although O 0 2.960175748967231e-08
there O 0 4.4024375256412895e-08
is O 0 6.479849989915465e-09
a O 0 3.273823523386454e-08
less O 0 5.711326025448216e-07
severe O 0 0.0036548145581036806
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
phenotype O 0 0.002552278805524111
in O 0 8.71373817545873e-09
terms O 0 2.4526340958175297e-09
of O 0 1.0452826798568182e-10
the O 0 4.943017106739944e-09
degree O 0 4.498816608133893e-08
of O 0 3.7960504073453194e-08
cerebellar B-Disease 1 0.974854588508606
degeneration I-Disease 1 0.9999284744262695
. O 0 3.2253728932118975e-06

This O 0 3.3633298812674184e-07
mutation O 0 1.3293654319568304e-06
( O 0 2.049483249777495e-09
7271T O 0 4.7462359020755684e-07
- O 0 0.000533386948518455
- O 0 0.012636450119316578
> O 0 5.942873485764721e-06
G O 0 0.0021516280248761177
) O 0 2.0388546406735486e-09
also O 0 2.940798715656001e-09
allows O 0 6.74535483025096e-10
expression O 0 3.6540515058192113e-09
of O 0 3.0679350726536825e-10
full O 0 3.93545072085999e-08
- O 0 9.77609888650477e-05
length O 0 1.5185272559392615e-06
ATM O 0 3.1919942102831556e-06
protein O 0 3.744604626376713e-08
at O 0 2.398461651509365e-09
a O 0 1.159955131946333e-09
level O 0 1.4236356982166853e-08
comparable O 0 6.41075175167316e-08
with O 0 5.5815839061779116e-08
that O 0 2.405255088433478e-07
in O 0 5.979810424605603e-08
unaffected O 0 1.4459782505582552e-05
individuals O 0 4.182971302668648e-09
. O 0 2.147836930532776e-08

In O 0 2.53476628131466e-07
addition O 0 4.0825536729016676e-08
, O 0 7.967706494582671e-09
we O 0 3.100569401226494e-08
have O 0 1.8145815960934897e-09
studied O 0 1.1379025721680591e-07
18 O 0 1.3175593949199538e-06
A B-Disease 1 0.9999819993972778
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 0.0016714398516342044
, O 0 9.165248116005387e-09
in O 0 5.45717426803094e-09
15 O 0 5.7430661115631665e-08
families O 0 6.991903944708611e-09
, O 0 2.518015840280441e-08
who O 0 1.655088817642536e-05
developed O 0 0.076957106590271
leukemia B-Disease 1 0.9998536109924316
, O 0 0.001543374382890761
lymphoma B-Disease 1 1.0
, O 0 1.4186476846589358e-06
preleukemic O 0 0.0016030243132263422
T O 0 0.4264419674873352
- O 0 0.007518326863646507
cell O 0 0.008213285356760025
proliferation O 0 0.0009656104957684875
, O 0 5.145170121068077e-07
or O 0 0.0009690342121757567
Hodgkin B-Disease 1 0.9999997615814209
lymphoma I-Disease 1 1.0
, O 0 1.7003987977659563e-06
mostly O 0 3.2559452023406266e-08
in O 0 6.862263148832426e-07
childhood O 0 0.0011707000667229295
. O 0 3.438216538143024e-07

A O 0 2.385320613029762e-06
wide O 0 8.104859716695501e-07
variety O 0 1.1516513964693331e-08
of O 0 1.5005725551020532e-09
ATM O 0 0.00010988640860887244
mutation O 0 2.8578990622918354e-06
types O 0 8.935357413974998e-07
, O 0 2.520849751164178e-09
including O 0 2.6969406707877397e-09
missense O 0 8.029462333070114e-05
mutations O 0 0.0006823913427069783
and O 0 2.8058022962795803e-06
in O 0 1.5220170723750925e-07
- O 0 0.11096557974815369
frame O 1 0.8950649499893188
deletions O 0 1.21372440844425e-05
, O 0 3.967126005477439e-08
were O 0 2.1952137885250522e-08
seen O 0 2.4209614934989077e-07
in O 0 1.017261652691559e-08
these O 0 1.9981662546797452e-08
patients O 0 1.2807822713511996e-07
. O 0 2.0638532660655073e-08

We O 0 4.540557347354479e-05
also O 0 2.9064555207014564e-08
show O 0 4.620196492055584e-08
that O 0 1.3824958067232274e-08
25 O 0 3.5340843584918957e-09
% O 0 1.274383792937428e-10
of O 0 3.635835243986918e-10
all O 0 1.6665039481722488e-07
A B-Disease 1 0.999994158744812
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 0 0.0002155145921278745
carried O 0 2.7703808314072376e-07
in O 0 6.667383090075418e-09
- O 0 0.001888696919195354
frame O 0 0.04528548941016197
deletions O 0 1.8433676132190158e-06
or O 0 5.97491904841263e-08
missense O 0 1.4806972103542648e-05
mutations O 0 3.198144258931279e-05
, O 0 3.215502886178001e-08
many O 0 7.157012205105673e-10
of O 0 3.231203304920882e-09
which O 0 2.7610209144768305e-05
were O 0 6.775857855245704e-06
also O 0 2.3356490146397846e-06
associated O 0 2.364121698406052e-08
with O 0 2.550097688569508e-09
expression O 0 2.630109463552799e-08
of O 0 2.7322660800521703e-10
mutant O 0 1.4395129710464971e-06
ATM O 0 8.219445589929819e-06
protein O 0 8.447564141533803e-07
. O 0 5.521409107700492e-08

The O 0 2.5562158612046915e-07
DMPK O 0 2.9348178941290826e-05
gene O 0 1.2636837709578685e-06
of O 0 8.691864650245407e-08
severely O 1 0.9526507258415222
affected O 0 0.15754134953022003
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 1.0
patients O 1 0.9451160430908203
is O 0 9.552115898259217e-07
hypermethylated O 0 0.0006873940583318472
proximal O 0 0.000203634612262249
to O 0 9.486444696449325e-07
the O 0 1.6327170726526674e-08
largely O 0 4.204570558385967e-08
expanded O 0 6.092352009545721e-07
CTG O 0 0.00013067270629107952
repeat O 0 4.09284039051272e-05
. O 0 1.0592165722300706e-07

Using O 0 2.0581343562753318e-07
methylation O 0 1.356422399112489e-05
- O 0 7.193164492491633e-05
sensitive O 0 3.37842743647343e-06
restriction O 0 8.773259878580575e-07
enzymes O 0 1.486905716774345e-06
, O 0 3.024951666930065e-08
we O 0 2.791046149752674e-08
characterized O 0 8.860537192845186e-09
the O 0 4.4959214129391967e-10
methylation O 0 1.79390599441831e-06
pattern O 0 6.731436587870121e-05
on O 0 1.8447427692080964e-06
the O 0 1.7326009071894077e-07
5 O 0 3.0388132472580764e-06
side O 0 2.3078848244040273e-05
of O 0 5.695215965495493e-10
the O 0 2.6500197591872166e-08
CTG O 0 9.454468454350717e-06
repeat O 0 2.6918985440715915e-06
in O 0 1.439427577132335e-09
the O 0 3.2668980853856056e-09
DMPK O 0 5.65987147638225e-06
gene O 0 2.81657666079127e-08
of O 0 6.234912586222663e-10
normal O 0 1.1025165491673761e-07
individuals O 0 4.021272481669058e-10
and O 0 1.5512956252905497e-08
of O 0 1.2827448436780742e-08
patients O 0 2.9309724141057814e-06
affected O 0 5.260954480945657e-07
with O 0 0.0009638924966566265
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 4.7385967150148645e-07
showing O 0 5.298546739140875e-07
expansions O 0 2.070380560326157e-06
of O 0 3.087732070028437e-09
the O 0 4.252031970963799e-08
repetitive O 0 0.0003283756668679416
sequence O 0 2.1922276573604904e-05
. O 0 1.7372799732129351e-07

The O 0 1.750720315385479e-07
gene O 0 1.3482637939432607e-07
segment O 0 3.134827579742705e-07
analyzed O 0 7.511471977750261e-08
corresponds O 0 1.8168128335105393e-08
to O 0 1.3063710113669913e-09
the O 0 5.751895626460168e-10
genomic O 0 1.6985366073640762e-06
SacI O 0 0.00024103253963403404
- O 0 0.0009628879488445818
HindIII O 0 1.594346213096287e-05
fragment O 0 8.27113240120525e-07
carrying O 0 7.738564455905816e-09
exons O 0 3.0302674076665426e-06
11 O 0 6.239093863769085e-07
- O 0 0.00015772206825204194
15 O 0 2.473666711466649e-07
. O 0 6.740306446317845e-08

There O 0 3.1106606002140325e-07
is O 0 4.782954032833686e-10
constitutive O 0 7.165716908730246e-09
methylation O 0 2.054870265055797e-06
in O 0 7.813642177723068e-09
intron O 0 0.002166162943467498
12 O 0 2.599894912691525e-07
at O 0 7.395592582781774e-09
restriction O 0 5.3015964951441674e-09
sites O 0 4.577799472826882e-09
of O 0 5.742446518297584e-10
SacII O 0 0.00044722098391503096
and O 0 1.3959861178136634e-07
HhaI O 0 4.025549969810527e-06
, O 0 2.526730769059071e-10
localized O 0 1.4342981025095014e-08
1 O 0 2.204230042934796e-08
, O 0 2.168049073603129e-09
159 O 0 3.5929865305206476e-08
- O 0 0.00012587242235895246
1 O 0 1.5464217995031504e-07
, O 0 5.942933700708863e-09
232 O 0 7.928292689030059e-09
bp O 0 3.350463657625369e-07
upstream O 0 1.0925141680218076e-08
of O 0 9.417692320434767e-11
the O 0 5.1074691143071504e-09
CTG O 0 2.490409542588168e-06
repeat O 0 4.544206149148522e-06
, O 0 6.299438193302365e-10
whereas O 0 1.47795375937676e-09
most O 0 8.722048083775746e-10
, O 0 6.002147223682641e-09
if O 0 4.296511590951013e-08
not O 0 1.625588730291838e-08
all O 0 5.374513056821684e-10
, O 0 6.41871056306087e-10
of O 0 2.5065404613000553e-11
the O 0 1.3944972954149648e-09
other O 0 1.1197084232028587e-10
sites O 0 5.078405251879303e-09
of O 0 2.9285388003508217e-10
SacII O 0 3.553510032361373e-05
, O 0 2.4168764767296125e-09
HhaI O 0 9.437022754354984e-07
, O 0 1.5420611454430855e-09
and O 0 8.541012341822807e-09
HpaII O 0 2.5894082682498265e-06
in O 0 3.0674216500159446e-09
this O 0 1.5978052214649097e-09
region O 0 9.714575810448878e-09
are O 0 6.180318479209745e-10
unmethylated O 0 3.3997198443103116e-06
, O 0 1.770418145419228e-09
in O 0 7.86103959704576e-10
normal O 0 2.3138762017538284e-08
individuals O 0 5.273466663346937e-10
and O 0 4.766345540474504e-09
most O 0 1.257148690703147e-10
of O 0 5.786325862899844e-10
the O 0 1.1424438071117038e-06
patients O 0 2.530776328057982e-06
. O 0 3.1508804454460915e-08

In O 0 1.2567213047987025e-07
a O 0 6.568874333368058e-09
number O 0 1.4714682805561097e-08
of O 0 1.0638000702556383e-08
young O 0 0.0001601148396730423
and O 0 2.060226870526094e-05
severely O 0 0.3651788830757141
affected O 0 2.8935319278389215e-06
patients O 0 4.273303602531087e-06
, O 0 2.7749624820216923e-08
however O 0 1.2156537820828817e-07
, O 0 1.539451566223704e-09
complete O 0 2.8482343594760096e-08
methylation O 0 1.3890131640437176e-06
of O 0 9.185509575182493e-10
these O 0 2.1654784632119117e-09
restriction O 0 7.484068476060202e-09
sites O 0 5.609396680483769e-08
was O 0 2.5914685011230176e-06
found O 0 1.3594795511551183e-08
in O 0 8.511735205551929e-10
the O 0 3.00584401813353e-09
mutated O 0 1.2118078984713065e-06
allele O 0 3.3265052934439154e-07
. O 0 8.682320640218677e-08

In O 0 1.5808869591182884e-07
most O 0 2.071969484873648e-09
of O 0 1.1105927288923567e-09
these O 0 7.248195288411807e-08
patients O 0 5.360984118851775e-07
, O 0 2.7523894274850136e-09
the O 0 1.3231279183401057e-08
onset O 0 4.3655032641254365e-05
of O 0 8.899615977497888e-08
the O 0 0.002988080494105816
disease O 1 0.999683141708374
was O 0 0.2329426258802414
congenital O 1 0.9999576807022095
. O 0 2.1968908185954206e-06

Preliminary O 0 9.945635611074977e-06
in O 0 7.906564292170515e-08
vivo O 0 7.451036708516767e-06
footprinting O 0 4.1083418182097375e-05
data O 0 1.42834565508565e-07
gave O 0 1.70985927638867e-08
evidence O 0 3.45678330404553e-09
for O 0 8.933838391289584e-11
protein O 0 5.4152767603454777e-08
- O 0 0.00048225937644019723
DNA O 0 0.0001607550511835143
contact O 0 2.9297746095835464e-07
in O 0 8.560616215902428e-09
normal O 0 1.1787634690563209e-07
genes O 0 1.0530283134357887e-07
at O 0 6.032471588923727e-08
an O 0 2.062035342476065e-08
Sp1 O 0 0.0002866965951398015
consensus O 0 3.023819639125236e-09
binding O 0 2.093181983298109e-08
site O 0 1.9387282179650356e-07
upstream O 0 1.2317274311612891e-08
of O 0 1.6515801226635318e-10
the O 0 2.9609705798350205e-09
CTG O 0 3.738389523277874e-06
repeat O 0 1.0766624654934276e-05
and O 0 1.017368411737607e-08
for O 0 2.433684330449548e-11
a O 0 3.5796443587088334e-10
significant O 0 4.067277348251963e-10
reduction O 0 4.4670088072962244e-08
of O 0 2.2418195078088843e-10
this O 0 2.6383883966474286e-09
interaction O 0 3.0195086431206164e-09
in O 0 8.78144490457089e-09
cells O 0 2.5879441523102287e-07
with O 0 3.5429794653651925e-09
a O 0 1.7649712447109778e-07
hypermethylated O 0 0.00034168263664469123
DMPK O 0 4.624609573511407e-05
gene O 0 6.549660724886053e-07
. O 0 7.832756665493434e-09
. O 0 2.2311956726639437e-08

The O 0 1.6729765775380656e-05
hemochromatosis B-Disease 1 0.9999521970748901
gene O 0 4.189639730611816e-05
product O 0 1.8828068277798593e-06
complexes O 0 8.936439712670108e-07
with O 0 2.641879426334981e-08
the O 0 3.849833163371841e-08
transferrin O 0 6.879864031361649e-06
receptor O 0 8.484965263733102e-08
and O 0 1.1429730051304432e-07
lowers O 0 2.3703446458966937e-06
its O 0 2.120909559089057e-10
affinity O 0 1.0460011745649922e-09
for O 0 1.0527397009685302e-10
ligand O 0 2.8171998067705317e-08
binding O 0 2.392580995547178e-07
. O 0 8.523765160362018e-08

We O 0 5.4085096053313464e-05
recently O 0 8.702993454789976e-07
reported O 0 2.9097281029066835e-08
the O 0 1.5840220801699445e-10
positional O 0 6.665134719696653e-07
cloning O 0 8.259750075012562e-07
of O 0 2.4982510504756306e-10
a O 0 1.2323878806341781e-08
candidate O 0 8.078669821998119e-08
gene O 0 6.6278785197937395e-06
for O 0 3.716997161973268e-05
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
called O 1 0.9397200345993042
HFE O 1 0.9948796033859253
. O 0 3.623893690019031e-06

The O 0 2.198977284706416e-07
gene O 0 1.0757137260952732e-06
product O 0 1.9168408016412286e-06
, O 0 1.136813132518455e-08
a O 0 8.00849342397214e-09
member O 0 2.966742407295442e-09
of O 0 8.010246355105721e-10
the O 0 3.699172168580844e-08
major O 0 8.650121685604972e-08
histocompatibility O 0 1.2936314988110098e-06
complex O 0 4.570190867525525e-06
class O 0 0.0031210780143737793
I O 0 0.2961367964744568
- O 0 0.0001552404573885724
like O 0 2.648464032972697e-06
family O 0 2.5551193516548665e-07
, O 0 7.305807070423498e-09
was O 0 4.932527986056812e-07
found O 0 1.603698684959909e-08
to O 0 1.8827284176126113e-09
have O 0 2.638357976536554e-09
a O 0 2.330324377908255e-09
mutation O 0 2.847224891411315e-07
, O 0 3.1147107115714334e-09
Cys O 0 0.00012135173165006563
- O 0 1.4551302228937857e-05
282 O 0 5.838637662236579e-07
- O 0 0.00017973849026020616
- O 0 0.0004745454352814704
> O 0 1.995557994405317e-07
Tyr O 0 4.918914555673837e-07
( O 0 7.292629694566344e-11
C282Y O 0 4.034219180937271e-09
) O 0 5.966551558378441e-11
, O 0 4.775932080369749e-11
in O 0 9.294365277412453e-11
85 O 0 1.859953080440846e-09
% O 0 1.5338029457634406e-10
of O 0 9.490728203331855e-10
patient O 0 1.938062450790312e-05
chromosomes O 0 8.388810783799272e-06
. O 0 1.8284592329109728e-07

This O 0 3.4464432019376545e-07
mutation O 0 1.7080425323001691e-06
eliminates O 0 2.701769290069933e-06
the O 0 8.871990075931535e-08
ability O 0 4.003705100785737e-07
of O 0 2.4949617927205736e-09
HFE O 0 0.008869853802025318
to O 0 4.616390825162853e-08
associate O 0 3.23553450698455e-08
with O 0 2.3061964782300493e-08
beta2 O 0 0.00140776252374053
- O 0 0.26739493012428284
microglobulin O 0 0.002412814646959305
( O 0 4.0530068190491875e-09
beta2m O 0 2.6944620913127437e-05
) O 0 5.86356652121367e-09
and O 0 1.0929476879084632e-08
prevents O 0 2.2729942372734513e-08
cell O 0 6.273005419643596e-05
- O 0 0.059939634054899216
surface O 0 0.0005184709443710744
expression O 0 5.9806193348777015e-06
. O 0 7.782573874237642e-08

A O 0 8.419097866863012e-06
second O 0 2.9255213576107053e-06
mutation O 0 4.66319306724472e-06
that O 0 4.3693194129446056e-07
has O 0 1.378900407189576e-07
no O 0 1.2019788719896951e-08
effect O 0 1.6198381302956477e-08
on O 0 3.756440776214731e-07
beta2m O 0 0.0007627310114912689
association O 0 5.3006488087703474e-08
, O 0 5.290636373445068e-09
H63D O 0 2.8688695238088258e-05
, O 0 1.4987570295943442e-08
was O 0 1.8828499150913558e-06
found O 0 6.101986116391345e-08
in O 0 1.1010470757355506e-08
eight O 0 8.563004172401634e-08
out O 0 4.957862742571706e-08
of O 0 6.959953169349831e-10
nine O 0 3.561682433428359e-07
patients O 0 1.637116930908178e-08
heterozygous O 0 1.8717720706717955e-09
for O 0 1.6544020320363728e-10
the O 0 5.224034094197805e-09
C282Y O 0 1.5009676417321316e-06
mutant O 0 2.9450434340105858e-06
. O 0 1.2470509602735547e-07

In O 0 2.0098690356462612e-07
this O 0 6.068834323968986e-09
report O 0 1.7839303367850334e-08
, O 0 1.6504441147091597e-09
we O 0 9.791403243752939e-09
demonstrate O 0 1.2580055885891284e-09
in O 0 6.757124304535012e-10
cultured O 0 3.771063745716674e-07
293 O 0 1.4519116575684166e-07
cells O 0 3.118653637557145e-07
overexpressing O 0 2.955036507046316e-06
wild O 0 8.267305929621216e-06
- O 0 0.012019014917314053
type O 0 0.0012231662403792143
or O 0 1.490069791998394e-07
mutant O 0 2.8590056899702176e-06
HFE O 0 4.753278335556388e-05
proteins O 0 6.96529838251081e-08
that O 0 4.444292756033974e-08
both O 0 3.2763518564848937e-09
the O 0 2.6029407962369078e-08
wild O 0 0.0001718131679808721
- O 1 0.810896098613739
type O 0 0.2116336226463318
and O 0 2.649223642947618e-05
H63D O 0 0.0005659948801621795
HFE O 0 0.00020628650963772088
proteins O 0 5.520429340322153e-07
form O 0 2.480122702763765e-07
stable O 0 5.387572628023918e-07
complexes O 0 3.365595375726116e-07
with O 0 1.6992830254025648e-08
the O 0 7.963836168300986e-08
transferrin O 0 3.135110455332324e-05
receptor O 0 5.43269777608657e-07
( O 0 8.861940514748312e-09
TfR O 0 0.0010291252983734012
) O 0 9.231002628951046e-09
. O 0 1.7776805805169715e-08

The O 0 4.5866121922699676e-07
C282Y O 0 1.7611894236324588e-06
mutation O 0 2.4756168386375066e-06
nearly O 0 2.249895061368079e-07
completely O 0 2.8563883461174555e-05
prevents O 0 3.277672817603161e-07
the O 0 2.703029089445863e-08
association O 0 2.228205886467549e-08
of O 0 1.803951987788821e-10
the O 0 4.528662778113812e-09
mutant O 0 2.333972361157066e-06
HFE O 0 3.129112519673072e-05
protein O 0 7.453770933807391e-08
with O 0 4.500256167716543e-09
the O 0 6.185972978300924e-08
TfR O 0 0.184971883893013
. O 0 1.7262048856991896e-07

Studies O 0 5.458164764604589e-07
on O 0 6.407011454712119e-08
cell O 0 1.3577955542132258e-05
- O 0 0.0001412659476045519
associated O 0 5.583915907436676e-08
transferrin O 0 6.15516114521597e-07
at O 0 2.8768367688059016e-09
37 O 0 2.264183285305421e-09
degrees O 0 2.7380179901115298e-08
C O 0 7.792934775352478e-05
suggest O 0 3.2803936278469337e-07
that O 0 1.7636919480423785e-08
the O 0 5.302931427308977e-09
overexpressed O 0 0.00012351041368674487
wild O 0 1.4456886674452107e-05
- O 0 0.004988414701074362
type O 0 4.3513467971934006e-05
HFE O 0 3.837280019070022e-05
protein O 0 5.9357095238965485e-08
decreases O 0 6.6945511356664156e-09
the O 0 1.9369385262368866e-10
affinity O 0 8.568648568463288e-10
of O 0 2.3784432756635e-10
the O 0 1.9419786667640437e-08
TfR O 0 0.002260599983856082
for O 0 1.1888956485961444e-08
transferrin O 0 1.6105188478832133e-05
. O 0 4.731223057774514e-08

The O 0 4.436082292613719e-07
overexpressed O 0 6.502617907244712e-05
H63D O 0 0.00010290096543030813
protein O 0 1.4688781675431528e-06
does O 0 4.823107246920699e-07
not O 0 5.918931833548413e-08
have O 0 1.752077416483644e-08
this O 0 9.530490840958805e-10
effect O 0 1.2985778141683113e-07
, O 0 4.178027701584597e-09
providing O 0 7.453465622475619e-10
the O 0 4.776757211999438e-09
first O 0 3.6690408933282015e-08
direct O 0 3.741311704885675e-09
evidence O 0 1.0919895743199959e-07
for O 0 1.4533981795850082e-09
a O 0 6.739291080748444e-08
functional O 0 3.7899267226748634e-06
consequence O 0 7.618548636401101e-08
of O 0 7.621215880604382e-10
the O 0 1.5089000271473196e-07
H63D O 0 0.00478721596300602
mutation O 0 4.2636434045562055e-06
. O 0 9.613018647769422e-08

Addition O 0 1.946923049445104e-07
of O 0 6.912989736207464e-09
soluble O 0 1.3931620742368978e-05
wild O 0 5.238718222244643e-05
- O 0 0.22834718227386475
type O 0 0.01696467027068138
HFE O 0 0.3123769462108612
/ O 0 0.0028545137029141188
beta2m O 0 8.41864020912908e-05
heterodimers O 0 2.479506110830698e-05
to O 0 9.332268291473156e-08
cultured O 0 1.9769199752772693e-06
cells O 0 3.638652970039402e-06
also O 0 1.1926685772323253e-07
decreased O 0 1.3472575233208772e-07
the O 0 2.951447086729786e-09
apparent O 0 2.5129011760327558e-08
affinity O 0 6.348376047071724e-09
of O 0 1.0056609989206322e-09
the O 0 3.4035302576285176e-08
TfR O 0 0.0032957459334284067
for O 0 4.322052715721725e-10
its O 0 4.92813845287543e-11
ligand O 0 8.8358087513285e-10
under O 0 3.2870361987846763e-09
steady O 0 2.715685809562274e-07
- O 0 1.1182451999047771e-05
state O 0 2.2107899511070173e-08
conditions O 0 3.0125149805826368e-06
, O 0 4.043291534916449e-10
both O 0 2.5630819688871043e-10
in O 0 8.809792895192459e-10
293 O 0 8.98252991987647e-08
cells O 0 2.5249852342312806e-07
and O 0 1.4965575445557988e-08
in O 0 2.315059255408869e-08
HeLa O 0 0.0003514624258968979
cells O 0 6.812991841798066e-07
. O 0 2.1508869352260263e-08

Furthermore O 0 6.1416371863742825e-06
, O 0 7.719193284572157e-09
at O 0 1.1923217968501376e-09
4 O 0 5.889154941485231e-09
degrees O 0 1.476473130423983e-07
C O 0 0.125680074095726
, O 0 1.6133051872202486e-07
the O 0 1.5422361343553348e-07
added O 0 5.632646661979379e-06
soluble O 0 7.837397788534872e-07
complex O 0 1.369720621369197e-07
of O 0 2.4330475412170927e-08
HFE O 0 0.07741014659404755
/ O 0 6.619130726903677e-05
beta2m O 0 2.4460027816530783e-06
inhibited O 0 3.09792724806357e-08
binding O 0 3.6522469493149856e-09
of O 0 1.3215703531521683e-10
transferrin O 0 1.0113167263625655e-06
to O 0 5.3745874417643336e-09
HeLa O 0 2.786937875498552e-05
cell O 0 1.1097250535385683e-05
TfR O 0 0.0006648463313467801
in O 0 2.526211462239303e-09
a O 0 2.3434164830860027e-08
concentration O 0 5.9558675275184214e-05
- O 0 0.0005507003515958786
dependent O 0 9.247656862498843e-07
manner O 0 8.523795713699656e-07
. O 0 2.6007771936065183e-08

Scatchard O 0 0.001848922111093998
plots O 0 1.5819494365132414e-05
of O 0 3.866616804515388e-09
these O 0 1.6454088092032748e-09
data O 0 1.061704466565061e-07
indicate O 0 3.222739337616076e-07
that O 0 8.859966982299738e-08
the O 0 4.9008313851572893e-08
added O 0 2.3361926650977693e-06
heterodimer O 0 4.930815862280724e-07
substantially O 0 4.4186572267790325e-07
reduced O 0 1.4001428461085652e-08
the O 0 6.221299031494709e-10
affinity O 0 4.0185752503418826e-09
of O 0 1.895154699838031e-09
TfR O 0 0.0006413081428036094
for O 0 8.389643646466993e-09
transferrin O 0 1.0816290341608692e-05
. O 0 8.618057734111062e-08

These O 0 1.3636381481774151e-06
results O 0 2.3760294709518348e-07
establish O 0 9.0280778408669e-09
a O 0 4.1810732653857485e-09
molecular O 0 1.2468420891309506e-06
link O 0 0.0021123476326465607
between O 0 3.2016466775530716e-06
HFE O 1 0.9541062712669373
and O 0 1.5898131096037105e-06
a O 0 9.651633270379989e-09
key O 0 6.837120736236102e-08
protein O 0 7.877933683175797e-08
involved O 0 2.0417081358914402e-08
in O 0 1.5431719191383308e-07
iron O 0 0.16469532251358032
transport O 0 1.897990159704932e-06
, O 0 7.133057700059453e-09
the O 0 6.270048924506e-09
TfR O 0 0.020623696967959404
, O 0 3.083766486611239e-08
and O 0 2.7804937019482168e-08
raise O 0 4.714860946108956e-09
the O 0 4.368381489872064e-10
possibility O 0 2.651540542686348e-09
that O 0 4.553948684815623e-08
alterations O 0 6.930511062819278e-07
in O 0 1.060711740663578e-09
this O 0 9.734064665423148e-10
regulatory O 0 4.3289958284731256e-08
mechanism O 0 1.8504056242818478e-06
may O 0 1.0324419008611585e-06
play O 0 1.0105457448617017e-07
a O 0 3.4899274581334794e-09
role O 0 5.42098099742816e-08
in O 0 9.938617040461395e-09
the O 0 1.3090755146549782e-08
pathogenesis O 0 5.4953743529040366e-05
of O 0 4.651888502849033e-06
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
. O 0 7.927248225314543e-05
. O 0 3.658007869944413e-07

Genomic O 0 9.144331852439791e-05
organization O 0 1.902189126212761e-07
of O 0 1.085300516123766e-09
the O 0 1.9358397551627604e-08
UBE3A O 0 0.00013120334187988192
/ O 0 2.28224689635681e-05
E6 O 0 1.8310211089556105e-05
- O 0 0.0009737715008668602
AP O 0 1.8251772416988388e-05
gene O 0 2.3198535359369998e-07
and O 0 1.3430645928735885e-08
related O 0 2.1643646874736078e-08
pseudogenes O 0 1.3103031960781664e-05
. O 0 5.914366738579702e-07

The O 0 3.249843700814381e-07
UBE3A O 0 2.4819359168759547e-05
gene O 0 5.318808007359621e-07
encodes O 0 1.9524809147242195e-07
the O 0 2.0125325406183947e-08
E6 O 0 3.606924292398617e-05
- O 0 0.010076787322759628
AP O 0 2.6245423214277253e-05
ubiquitin O 0 2.869194588583923e-07
- O 0 1.6199426681851037e-05
protein O 0 5.8594661567212825e-08
ligase O 0 4.098618333614468e-08
and O 0 1.2355137357644708e-07
has O 0 4.972873668407374e-08
recently O 0 2.815041284520703e-07
been O 0 6.177577915877919e-08
shown O 0 1.8335015283810208e-08
to O 0 1.4437280260182206e-09
be O 0 9.080403984285113e-09
mutated O 0 0.00012107051588827744
in O 0 0.4800434708595276
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.15399552881717682
who O 0 7.640181138413027e-06
lack O 0 1.3104312301948084e-07
15q11 O 0 4.391235052025877e-06
- O 0 0.00046601463691331446
q13 O 0 9.457266969548073e-07
deletions O 0 8.615853062110546e-07
or O 0 4.673850924064027e-07
chromosome O 0 0.0006633766461163759
15 O 0 1.5764455838507274e-06
paternal O 0 0.0002866960421670228
uniparental B-Disease 1 0.8709431886672974
disomy I-Disease 0 0.39230120182037354
. O 0 2.741682010309887e-06

Previous O 0 5.0029648264171556e-06
UBE3A O 0 9.694173968455289e-06
cDNA O 0 7.713765057815181e-07
analysis O 0 4.2622957607818535e-07
has O 0 5.359276400440649e-08
shown O 0 7.848923289088816e-09
a O 0 2.059204584625718e-09
coding O 0 4.011912824353203e-05
region O 0 1.1279065859071125e-07
of O 0 2.3390692160951687e-10
approximately O 0 5.577101003240159e-09
2 O 0 4.813030614059244e-07
. O 0 2.1417257300981873e-07

6 O 0 1.4714194549014792e-05
kb O 0 0.00025475051370449364
and O 0 5.031329806115536e-07
a O 0 1.4953113236515492e-07
3 O 0 1.023593813442858e-05
- O 1 0.9134788513183594
untranslated O 1 0.9826580882072449
region O 0 0.00015150770195759833
( O 0 6.3047060905319086e-09
UTR O 0 4.35644578828942e-05
) O 0 3.8287251147295365e-10
of O 0 7.424757336726984e-11
< O 0 8.49942978220497e-08
50 O 0 6.195700397171322e-09
bp O 0 3.352387807353807e-07
, O 0 5.113325318717443e-10
whereas O 0 1.074316968718847e-09
Northern O 0 2.7421298565144525e-09
analysis O 0 1.8319067374150677e-09
has O 0 2.9120972300233916e-09
indicated O 0 1.09574416207181e-09
mRNA O 0 4.651191376492392e-10
sizes O 0 4.9821848868703e-09
of O 0 8.80149508830641e-10
5 O 0 1.8847330807147955e-07
- O 0 0.0010314435930922627
8 O 0 2.1907230802753475e-06
kb O 0 0.0023833513259887695
. O 0 1.74486473270008e-07

We O 0 4.9584577936911955e-06
have O 0 2.3093469359025676e-09
analyzed O 0 2.12425455003995e-09
additional O 0 8.702651793646154e-11
cDNA O 0 7.67349987995658e-08
clones O 0 2.4192304408643395e-05
and O 0 5.44189724394073e-08
provide O 0 5.094828448015676e-10
evidence O 0 3.909241819144427e-09
for O 0 1.345963757115598e-10
an O 0 2.60710675270559e-10
additional O 0 3.2313327569255534e-09
0 O 0 4.472457931115059e-06
. O 0 9.159187897012089e-08

5 O 0 9.338845075035351e-07
kb O 0 1.7449694496463053e-05
of O 0 1.4341557275088235e-08
5 O 0 6.989092753428849e-07
- O 0 0.005313626490533352
UTR O 0 0.008799601346254349
and O 0 7.937567829685577e-07
> O 0 6.307956113005275e-08
2 O 0 3.832893469279952e-08
kb O 0 4.698696284322068e-05
of O 0 1.5685342802385094e-08
3 O 0 8.201670425478369e-06
- O 0 0.4662073850631714
UTR O 0 0.42206260561943054
. O 0 8.359520506928675e-07

We O 0 0.00012065102782798931
have O 0 4.157679001082215e-08
established O 0 3.1183187143568603e-09
the O 0 5.355694221442775e-10
genomic O 0 2.92420281766681e-07
organization O 0 6.2084528629213764e-09
of O 0 2.857721559390569e-10
UBE3A O 0 1.8687765987124294e-05
and O 0 1.4916444968093856e-08
the O 0 1.2491987999574405e-10
sequence O 0 1.2314713693228896e-08
of O 0 5.583132844932948e-10
intron O 0 0.0023266044445335865
- O 0 0.0018873304361477494
exon O 0 1.792557850421872e-05
borders O 0 1.994185595322051e-06
. O 0 1.423500606279049e-07

We O 0 0.00013706719619221985
have O 0 1.3796540088151232e-07
also O 0 3.0937936656982856e-08
mapped O 0 4.0148647713067476e-06
two O 0 6.7974332829123796e-09
highly O 0 6.9887970965965e-09
homologous O 0 2.280263267095961e-08
processed O 0 5.338972997037672e-08
pseudogenes O 0 4.0367928022533306e-07
, O 0 4.299036504562537e-08
UBE3AP1 O 0 8.600745786679909e-05
and O 0 4.760996716868249e-07
UBE3AP2 O 0 3.462745371507481e-05
, O 0 4.9176924754590345e-09
to O 0 7.307141558499097e-10
chromosomes O 0 6.222016679657827e-08
2 O 0 2.0484804963416536e-07
and O 0 5.364818775888125e-07
21 O 0 5.217225975684414e-07
, O 0 2.374248531111789e-08
respectively O 0 2.7705286242962757e-07
, O 0 2.4499236417341308e-08
and O 0 9.164378411696816e-08
determined O 0 3.5150986832377384e-07
their O 0 1.6895865817545541e-09
genomic O 0 1.2332646974755335e-06
organization O 0 1.0327594424097697e-07
. O 0 2.4936024800581436e-08

These O 0 4.460157470020931e-06
results O 0 1.480182504565164e-06
will O 0 3.072435461604073e-08
form O 0 5.486365139972804e-09
the O 0 2.275726052047844e-09
basis O 0 8.522623495821335e-09
for O 0 2.9580238258830605e-09
studies O 0 8.239307902613291e-09
of O 0 3.8283964887142474e-10
mutation O 0 6.277572310864343e-07
and O 0 4.249526597277509e-08
imprinting O 0 2.7736885385820642e-05
of O 0 5.087782994905865e-08
UBE3A O 0 0.002560907043516636
. O 0 3.525159684159007e-07

Mutation O 0 1.7642252714722417e-05
spectrum O 0 5.18598653798108e-06
and O 0 2.7547920922188496e-07
genotype O 0 7.138019100239035e-06
- O 0 0.0007043254445306957
phenotype O 0 0.00010563184332568198
analyses O 0 5.055550445831614e-06
in O 0 4.66680916133555e-07
Cowden B-Disease 1 0.9997974038124084
disease I-Disease 1 0.9978596568107605
and O 0 2.6509951567277312e-05
Bannayan B-Disease 1 0.9968230724334717
- I-Disease 1 0.9999819993972778
Zonana I-Disease 1 0.9999876022338867
syndrome I-Disease 1 0.9999945163726807
, O 0 1.0204684741665915e-07
two O 0 4.586900388403592e-07
hamartoma B-Disease 1 0.9721131920814514
syndromes I-Disease 1 0.8703653216362
with O 0 7.246770792335155e-07
germline O 0 0.005824823398143053
PTEN O 0 0.03396456316113472
mutation O 0 0.0004368519294075668
. O 0 6.833599854871863e-07

The O 0 1.4737392120878212e-05
tumour B-Disease 1 0.9999104738235474
suppressor O 0 0.001563117140904069
gene O 0 1.8684164388105273e-05
PTEN O 0 0.0004246531752869487
, O 0 5.045677298198825e-08
which O 0 5.956369619752877e-09
maps O 0 4.621166681317845e-06
to O 0 1.3124085285198817e-07
10q23 O 0 8.30745466373628e-06
. O 0 9.885835083878192e-08

3 O 0 3.2980080959532643e-06
and O 0 2.4655149033492307e-08
encodes O 0 6.4417351453016636e-09
a O 0 6.601405200257204e-09
403 O 0 2.468422977131013e-08
amino O 0 4.6389605046215365e-08
acid O 0 8.466390255534861e-08
dual O 0 1.7359099047098425e-06
specificity O 0 9.042330930242315e-06
phosphatase O 0 0.016020622104406357
( O 0 7.002620705520712e-09
protein O 0 7.919091160601965e-08
tyrosine O 0 2.544177732488606e-06
phosphatase O 0 0.005100940819829702
; O 0 4.5261952408282013e-08
PTPase O 0 1.6360285371774808e-05
) O 0 2.797781784025233e-09
, O 0 1.448295372519226e-09
was O 0 8.454513533706631e-08
shown O 0 4.181665147484637e-08
recently O 0 9.488670116297726e-07
to O 0 3.03139771062888e-08
play O 0 1.2284971262488398e-07
a O 0 2.7494930776583715e-09
broad O 0 9.741183930600528e-07
role O 0 1.966497933381106e-07
in O 0 1.9325146638493607e-07
human O 0 3.0411786156037124e-06
malignancy B-Disease 0 0.02650299109518528
. O 0 2.005537993454709e-07

Somatic O 0 0.000126302576973103
PTEN O 0 0.00020560825942084193
deletions O 0 7.488784467568621e-05
and O 0 2.8927952371304855e-06
mutations O 0 9.078743460122496e-06
were O 0 4.200122205588741e-08
observed O 0 9.565793845922599e-08
in O 0 1.8207050089813492e-08
sporadic B-Disease 0 0.025208275765180588
breast I-Disease 1 0.9999674558639526
, I-Disease 0 0.002187790349125862
brain I-Disease 1 0.9926940202713013
, I-Disease 0 0.00016926074749790132
prostate I-Disease 1 0.9998326301574707
and I-Disease 1 0.689214825630188
kidney I-Disease 1 0.7060197591781616
cancer I-Disease 0 0.08946371078491211
cell O 0 0.04791222885251045
lines O 1 0.6851760745048523
and O 0 9.770876204129308e-06
in O 0 4.014555443632162e-08
several O 0 3.186690733514297e-08
primary O 0 0.0002516734239179641
tumours B-Disease 1 0.9999995231628418
such O 0 2.2351319728386443e-07
as O 0 5.401345333666541e-05
endometrial B-Disease 1 0.997826874256134
carcinomas I-Disease 1 1.0
, O 1 0.9987891316413879
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9998499155044556
thyroid B-Disease 1 0.9999932050704956
tumours I-Disease 1 0.9999997615814209
. O 0 4.260584319126792e-05

In O 0 7.584245054204075e-08
addition O 0 6.558333431883057e-09
, O 0 3.972810969088414e-09
PTEN O 0 7.538364116044249e-06
was O 0 7.661813015147345e-07
identified O 0 6.440165378762686e-08
as O 0 2.242633190263632e-09
the O 0 2.2181636527562887e-09
susceptibility O 0 1.8201480997959152e-06
gene O 0 2.5928974878297595e-07
for O 0 4.4611763172497376e-08
two O 0 1.9417180737946182e-05
hamartoma B-Disease 1 0.9998472929000854
syndromes I-Disease 1 0.9999796152114868
Cowden B-Disease 1 0.99997878074646
disease I-Disease 1 0.9999407529830933
( O 0 3.9050629396797376e-08
CD B-Disease 0 0.00842652190476656
; O 0 1.065121637111588e-06
MIM O 0 0.1305559277534485
158350 O 0 9.090479579754174e-05
) O 0 2.0250698895551977e-08
and O 0 2.730928088112705e-07
Bannayan B-Disease 0 0.00611253222450614
- I-Disease 1 0.5426081418991089
Zonana I-Disease 0 0.2624809443950653
( I-Disease 0 2.6589852542002745e-09
BZS I-Disease 0 1.165391040558461e-06
) I-Disease 0 6.560169074631972e-10
or I-Disease 0 2.459107806274119e-09
Ruvalcaba I-Disease 0 4.959610669175163e-05
- I-Disease 0 0.009476889856159687
Riley I-Disease 0 0.00010122873936779797
- I-Disease 1 0.9886533617973328
Smith I-Disease 1 0.9271923899650574
syndrome I-Disease 1 0.9971471428871155
( O 0 3.846366780635435e-09
MIM O 0 0.0013418172020465136
153480 O 0 1.9936642274842598e-05
) O 0 1.253852488503071e-08
. O 0 3.366618273048516e-08

Constitutive O 0 4.490408173296601e-06
DNA O 0 0.00017697415023576468
from O 0 9.840343651035255e-09
37 O 0 9.531117939332034e-08
CD B-Disease 0 5.099417467135936e-05
families O 0 1.510869935827941e-07
and O 0 1.8846397153993166e-07
seven O 0 2.340749460927327e-08
BZS B-Disease 0 1.2818277355108876e-05
families O 0 2.7458415985393003e-08
was O 0 3.296362081073312e-07
screened O 0 7.472103789041284e-07
for O 0 4.15352374716349e-09
germline O 0 6.793110514990985e-05
PTEN O 0 0.000850020325742662
mutations O 0 5.918962779105641e-05
. O 0 2.3588793851558876e-07

PTEN O 0 0.00038406503153964877
mutations O 0 0.0002238199522253126
were O 0 4.3597873400358367e-07
identified O 0 3.260174423758144e-07
in O 0 1.870612109655667e-09
30 O 0 7.120728007237176e-09
of O 0 6.544909614270011e-10
37 O 0 5.972213443783403e-07
( O 0 3.3689038225759305e-09
81 O 0 1.8997489803496137e-07
% O 0 8.286459296513726e-10
) O 0 8.953922048249296e-10
CD B-Disease 0 4.6807803300907835e-05
families O 0 3.9566824483472374e-08
, O 0 2.2116872777644403e-09
including O 0 4.704026057567035e-10
missense O 0 1.2620033885468729e-05
and O 0 1.9844267171720276e-06
nonsense O 0 0.00011574482778087258
point O 0 2.37654217016825e-06
mutations O 0 2.643515699674026e-07
, O 0 1.0506600034432267e-09
deletions O 0 1.078499991535864e-07
, O 0 5.0551629549033805e-09
insertions O 0 1.4400183090401697e-06
, O 0 8.326975553529792e-09
a O 0 9.256603483720482e-09
deletion O 0 2.716599374252837e-05
/ O 0 7.57222151150927e-05
insertion O 0 4.3476907194417436e-06
and O 0 8.748846198614046e-07
splice O 0 0.006016972940415144
site O 0 7.47278390917927e-05
mutations O 0 3.724341877386905e-05
. O 0 1.4880276921758195e-07

These O 0 9.788659554033075e-07
mutations O 0 3.3279472972935764e-06
were O 0 2.376772201273525e-08
scattered O 0 2.5037966366880937e-08
over O 0 3.244619222186884e-07
the O 0 9.470790729437795e-08
entire O 0 5.147437605046434e-07
length O 0 7.854833711462561e-06
of O 0 3.167328399555913e-09
PTEN O 0 2.4149707314791158e-05
, O 0 9.13446296380016e-09
with O 0 1.522033055145755e-09
the O 0 2.1269224159681244e-09
exception O 0 2.5206381426556845e-09
of O 0 3.8141181879502994e-10
the O 0 4.5367656298367365e-08
first O 0 1.2631760910153389e-05
, O 0 8.336004952980147e-08
fourth O 0 1.1540255400177557e-05
and O 0 8.054131228618644e-08
last O 0 1.5813995446478657e-07
exons O 0 3.8927879359107465e-05
. O 0 2.988997778174962e-07

A O 0 5.91498655921896e-06
hot O 0 8.141755097312853e-05
spot O 0 5.219398644840112e-06
for O 0 2.2047712544548403e-09
PTEN O 0 8.386242370761465e-06
mutation O 0 1.1106865258625476e-06
in O 0 5.313491868719211e-09
CD B-Disease 0 0.00010791343811433762
was O 0 1.9803126633632928e-05
identified O 0 2.274241808208899e-07
in O 0 1.6543050262995962e-09
exon O 0 4.304712092562113e-06
5 O 0 9.620738410376362e-07
that O 0 3.536864312536636e-08
contains O 0 9.118378940797811e-09
the O 0 3.130972814346933e-08
PTPase O 0 2.782197952910792e-05
core O 0 2.3270933979802066e-06
motif O 0 1.4019116861163639e-05
, O 0 5.6488294042367215e-09
with O 0 5.500234157018724e-10
13 O 0 4.1650825011174675e-09
of O 0 1.7855079914586014e-10
30 O 0 1.1655290066414636e-08
( O 0 3.0584001997624455e-10
43 O 0 7.58741336426283e-08
% O 0 5.901047983591923e-10
) O 0 4.095496441980373e-10
CD B-Disease 0 1.4585285498469602e-05
mutations O 0 1.1265192370046861e-06
identified O 0 2.163869936566698e-07
in O 0 2.7896289722662004e-09
this O 0 4.1404963901925385e-09
exon O 0 2.1835559891769662e-05
. O 0 2.6489340143598383e-07

Seven O 0 2.3133981130740722e-07
of O 0 7.833141357771467e-10
30 O 0 1.2848923702790671e-08
( O 0 4.3894873846817006e-10
23 O 0 5.7711769585466755e-08
% O 0 6.908530969518267e-10
) O 0 9.787159971352821e-10
were O 0 1.6169488858963632e-08
within O 0 1.138641958497999e-09
the O 0 3.61427843209583e-09
core O 0 2.1428752461361e-06
motif O 0 1.1934146641578991e-05
, O 0 8.629617020972091e-09
the O 0 1.2850608355208237e-09
majority O 0 1.2628697199090766e-08
( O 0 7.016468517306862e-10
five O 0 2.212404481838348e-09
of O 0 5.63477320358885e-10
seven O 0 7.273484214920245e-08
) O 0 7.842798632751169e-10
of O 0 2.1319332410563163e-10
which O 0 1.2504115431966056e-07
were O 0 4.533790232130741e-08
missense O 0 7.02202942193253e-06
mutations O 0 3.438915655351593e-06
, O 0 1.038669594777275e-08
possibly O 0 8.641345417004231e-09
pointing O 0 1.815633481783152e-06
to O 0 2.003562826757843e-08
the O 0 2.2293356050084867e-09
functional O 0 7.650350397625516e-08
significance O 0 1.1833732216359749e-08
of O 0 8.335473422604878e-10
this O 0 2.0948712986523788e-08
region O 0 6.123609068708902e-07
. O 0 9.848609039408984e-08

Germline O 0 0.0014189346693456173
PTEN O 0 0.00029420023201964796
mutations O 0 0.0002925268199760467
were O 0 7.504268637603673e-07
identified O 0 1.0744721521405154e-06
in O 0 1.1064429372709128e-08
four O 0 5.648401213420584e-08
of O 0 6.231681837221004e-09
seven O 0 4.854194912695675e-07
( O 0 1.1243298736474117e-08
57 O 0 2.4592478098384163e-07
% O 0 1.1003264965836479e-09
) O 0 2.3569977081194793e-09
BZS B-Disease 0 7.468779585906304e-06
families O 0 9.871059525323744e-09
studied O 0 3.2609955269435886e-07
. O 0 8.477120161387575e-08

Interestingly O 0 0.00044302837341092527
, O 0 4.4996062342761434e-07
none O 0 2.8511694338817506e-08
of O 0 8.700792170079907e-11
these O 0 3.944045090520376e-09
mutations O 0 1.3953141433376004e-06
was O 0 1.9484700715111103e-06
observed O 0 1.177003312591296e-07
in O 0 1.1768883645402184e-08
the O 0 1.5543699660724997e-08
PTPase O 0 8.135693497024477e-05
core O 0 4.613645160134183e-06
motif O 0 3.985540024586953e-05
. O 0 1.471597954605386e-07

It O 0 5.029371095588431e-06
is O 0 2.116684427733162e-08
also O 0 2.861144032806351e-08
worthy O 0 7.53264561836886e-09
of O 0 9.208805384908203e-10
note O 0 4.5022002268524375e-06
that O 0 1.8807543256116332e-07
a O 0 7.749660113631762e-08
single O 0 1.6460600818390958e-05
nonsense O 0 0.00022463493223767728
point O 0 1.1624716762526077e-06
mutation O 0 1.4273366844008706e-07
, O 0 1.5522241270105042e-09
R233X O 0 8.435441856136094e-08
, O 0 1.8035779536518248e-09
was O 0 9.203528605894462e-08
observed O 0 9.352328689260503e-09
in O 0 6.373085947863899e-10
the O 0 4.52336834655398e-10
germline O 0 9.611258633412945e-08
DNA O 0 6.330402356979903e-06
from O 0 2.187650199880764e-10
two O 0 1.5164463018635388e-09
unrelated O 0 1.9042946064473654e-07
CD B-Disease 0 0.11794667690992355
families O 0 8.914682894101134e-07
and O 0 3.4954493344230286e-07
one O 0 5.984933437730433e-08
BZS B-Disease 0 9.571335976943374e-05
family O 0 4.86268334043416e-07
. O 0 8.286482255925876e-08

Genotype O 0 0.0012003525625914335
- O 0 0.016489673405885696
phenotype O 0 8.06177849881351e-05
studies O 0 1.5032152589355974e-07
were O 0 7.683590297347109e-08
not O 0 3.378190172043105e-08
performed O 0 9.8543739568413e-07
on O 0 2.702127517295594e-07
this O 0 6.321395407127284e-09
small O 0 9.184708105181016e-09
group O 0 3.5351857263776765e-07
of O 0 1.7781782712944505e-09
BZS B-Disease 0 9.978852904168889e-05
families O 0 5.98473945956357e-08
. O 0 8.353561753438044e-08

However O 0 2.064910404442344e-06
, O 0 6.345918457384414e-09
genotype O 0 7.52756363908702e-07
- O 0 0.00011551790521480143
phenotype O 0 4.231335424265126e-06
analysis O 0 2.2107055741571457e-08
inthe O 0 4.828118562727468e-06
group O 0 6.967729291318392e-07
of O 0 3.571932527535182e-09
CD B-Disease 0 0.04370022565126419
families O 0 4.010916825336608e-07
revealed O 0 1.1965542398684192e-05
two O 0 8.586420463529976e-09
possible O 0 1.4370966638921345e-08
associations O 0 1.1033044478026e-09
worthy O 0 9.544830703589469e-09
of O 0 4.559645716550875e-10
follow O 0 1.068563051376259e-07
- O 0 3.562131314538419e-05
up O 0 2.0946640688634943e-07
in O 0 1.6893125787120766e-09
independent O 0 9.359271579967299e-09
analyses O 0 1.7438134136682493e-07
. O 0 1.5899443539524327e-08

The O 0 8.986023090074013e-07
first O 0 1.5700092035331181e-06
was O 0 1.2230138963786885e-06
an O 0 2.5446171836307485e-09
association O 0 2.58649031081859e-08
noted O 0 2.600760637960775e-07
in O 0 1.4469569542541194e-08
the O 0 4.66486014261136e-08
group O 0 4.4641643626164296e-07
of O 0 1.2459678844223276e-09
CD B-Disease 0 0.005189978983253241
families O 0 2.330179569298707e-07
with O 0 1.1765799172280822e-05
breast B-Disease 1 0.999816358089447
disease I-Disease 1 0.9443690180778503
. O 0 4.0680617985344725e-07

A O 0 7.423556667163211e-07
correlation O 0 4.706077561422717e-06
was O 0 4.6612235564680304e-06
observed O 0 6.683747244551341e-08
between O 0 1.3185502467649712e-08
the O 0 2.4769876816321812e-08
presence O 0 2.9969785941830196e-07
/ O 0 0.0017637887503951788
absence O 0 7.05146376844823e-08
of O 0 2.4576998769454406e-10
a O 0 1.0072243838976647e-07
PTEN O 0 0.00015290503506548703
mutation O 0 4.240428097546101e-06
and O 0 6.737003843682032e-08
the O 0 6.043272104960806e-09
type O 0 4.766200436279178e-05
of O 0 1.2228304058226058e-07
breast O 0 0.48872435092926025
involvement O 0 8.418005563726183e-06
( O 0 2.0340975126487137e-08
unaffected O 0 1.8921069568023086e-05
versus O 0 7.77525274315849e-05
benign O 0 0.10546834766864777
versus O 0 0.0017332341521978378
malignant O 1 0.9991717338562012
) O 0 1.5889871463059535e-07
. O 0 7.713942551390573e-08

Specifically O 0 4.481812538870145e-06
and O 0 9.450887006323683e-08
more O 0 7.169550370056399e-11
directly O 0 4.801493425077297e-09
, O 0 5.1200714779042755e-09
an O 0 1.9934298656210103e-09
association O 0 1.5011035259249184e-07
was O 0 0.0003110674733761698
also O 0 5.787496206721698e-07
observed O 0 9.450382520981293e-08
between O 0 1.026374985002576e-08
the O 0 2.0548103218942515e-09
presence O 0 2.516185260148518e-09
of O 0 1.18602488941022e-10
a O 0 9.393826871928468e-08
PTEN O 0 0.0027527587953954935
mutation O 0 0.00013776085688732564
and O 0 0.000807124306447804
malignant B-Disease 1 0.9999532699584961
breast I-Disease 1 0.9999669790267944
disease I-Disease 1 0.9988366961479187
. O 0 2.1971632122586016e-06

Secondly O 0 0.07647807151079178
, O 0 3.6964783589610306e-07
there O 0 3.527876302200639e-08
appeared O 0 2.59116200140852e-06
to O 0 2.3521396386172455e-08
be O 0 5.863222440893878e-08
an O 0 1.3027488421357702e-08
interdependent O 0 0.01082316879183054
association O 0 4.0955674762699346e-07
between O 0 4.0861652905732626e-07
mutations O 0 8.05161653261166e-06
upstream O 0 3.063213398490916e-06
and O 0 1.7186653167300392e-07
within O 0 2.037109370078838e-09
the O 0 1.546037786681609e-08
PTPase O 0 9.176442290481646e-06
core O 0 1.695270839263685e-06
motif O 0 9.937472896126565e-06
, O 0 4.303899459046079e-09
the O 0 7.463352158509906e-10
core O 0 7.889885864642565e-07
motif O 0 2.779961278065457e-06
containing O 0 4.585623258890337e-08
the O 0 1.8527309464388964e-08
majority O 0 1.8323268236031254e-08
of O 0 7.246322986098619e-10
missense O 0 3.864776226691902e-05
mutations O 0 0.00026810195413418114
, O 0 9.509635390259064e-08
and O 0 8.744828505768965e-08
the O 0 7.705615701070201e-09
involvement O 0 1.6455578588647768e-07
of O 0 3.2831579677150557e-09
all O 0 1.1605865601893584e-08
major O 0 4.4875640980990283e-08
organ O 0 0.00023395239259116352
systems O 0 0.000122955534607172
( O 0 3.436443796189792e-09
central O 0 1.945762875266155e-07
nervous O 0 5.4732310672989115e-05
system O 0 5.098992915009148e-06
, O 0 3.1320695370595786e-07
thyroid O 0 0.027560757473111153
, O 0 2.017578935920028e-06
breast O 1 0.9869887828826904
, O 0 0.000794166058767587
skin O 1 0.999995231628418
and O 1 0.8412312865257263
gastrointestinal O 1 0.9999077320098877
tract O 1 0.9989975094795227
) O 0 3.4078993849107064e-07
. O 0 4.023870303626609e-07

However O 0 3.5582543205237016e-05
, O 0 6.327631751901208e-09
these O 0 1.7904121241141269e-10
observations O 0 2.136792076612437e-08
would O 0 2.935162690675952e-08
need O 0 1.9780641569155932e-09
to O 0 2.8503850391103924e-09
be O 0 9.109721865740994e-09
confirmed O 0 2.4513914453905272e-08
by O 0 1.7232745785911163e-10
studying O 0 6.738514191084732e-10
a O 0 3.462649722507649e-09
larger O 0 5.971442007535188e-09
number O 0 1.7742152635946695e-08
of O 0 2.4900033146479927e-09
CD B-Disease 0 0.0016739036655053496
families O 0 1.9691402997068508e-07
. O 0 3.366592693510029e-08

Molecular O 0 0.23381513357162476
defects O 1 0.9986237287521362
leading O 0 2.0167202819720842e-05
to O 0 5.5093536843742186e-08
human O 0 1.4497338440833119e-07
complement B-Disease 0 3.0803741992713185e-06
component I-Disease 0 0.42677393555641174
C6 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
in O 0 5.294687639434414e-07
an O 0 1.2492292000843008e-07
African O 0 1.3709987456422823e-07
- O 0 0.0012458325363695621
American O 0 1.4336737876874395e-06
family O 0 3.7143732356526016e-07
. O 0 6.128136220695524e-08

Complement B-Disease 0 0.0004312886740081012
component I-Disease 1 0.5596441626548767
C6 I-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9999992847442627
( O 0 1.2750070936817792e-06
C6D B-Disease 0 0.06263049691915512
) O 0 5.902027169213397e-07
was O 0 0.0013265268644317985
diagnosed O 0 0.01524409744888544
in O 0 1.0770502711920926e-08
a O 0 2.5351070576107304e-07
16 O 0 2.651190925462288e-06
- O 0 0.021748002618551254
year O 0 4.94922744564974e-07
- O 0 0.001013298286125064
old O 0 0.0053058797493577
African O 0 8.795860928501043e-09
- O 0 1.1831292567876517e-06
American O 0 5.657760482336016e-08
male O 0 5.7607511649848675e-08
with O 0 7.207045626955733e-08
meningococcal B-Disease 1 0.9999929666519165
meningitis I-Disease 1 0.9999922513961792
. O 0 1.2487412277550902e-06

The O 0 1.4864923286950216e-05
patients O 0 2.3695654817856848e-05
father O 0 7.203896529972553e-06
and O 0 5.257999760033272e-07
two O 0 2.903547624555358e-07
brothers O 0 0.007101924158632755
also O 0 1.9734896341105923e-05
had O 0 0.00018188105605076998
C6D B-Disease 0 0.0024581074248999357
, O 0 3.521590485888737e-08
but O 0 2.681937694148928e-08
gave O 0 4.6942787435000355e-08
no O 0 8.085156544268557e-09
history O 0 3.674159998467985e-08
of O 0 3.940437665050922e-08
meningitis B-Disease 1 0.9999986886978149
or O 0 7.66419589126599e-07
other O 0 1.0322317223199207e-07
neisserial B-Disease 1 0.549526035785675
infection I-Disease 0 0.22183017432689667
. O 0 2.652888042575796e-07

By O 0 6.839517840973031e-09
using O 0 2.948588706530586e-09
exon O 0 1.6327939533766767e-07
- O 0 1.4860104784020223e-05
specific O 0 1.125024873260827e-08
polymerase O 0 7.932172593427822e-06
chain O 0 1.5587464076816104e-05
reaction O 0 4.427151978347865e-08
( O 0 3.291162620211452e-10
PCR O 0 3.967523298342712e-06
) O 0 1.0047176424166082e-09
/ O 0 3.5548481491787243e-07
single O 0 3.419466167997598e-07
- O 0 3.5481698432704434e-05
strand O 0 1.2918270840600599e-05
conformation O 0 4.971934686182067e-08
polymorphism O 0 9.400405076576135e-08
as O 0 3.008268911752765e-10
a O 0 2.563125822696577e-10
screening O 0 3.58091831742513e-08
step O 0 4.547376253327684e-09
and O 0 1.3099733797705682e-10
nucleotide O 0 7.189848716393499e-10
sequencing O 0 6.484993431143948e-09
of O 0 1.447714587099469e-10
target O 0 6.489667043751979e-07
exons O 0 2.4528421818104107e-06
, O 0 1.0534984795640412e-07
we O 0 1.4682363769225049e-07
determined O 0 7.532030821266744e-08
that O 0 4.458247992999986e-09
the O 0 4.7155266358345216e-09
proband O 0 2.2781197912991047e-05
was O 0 4.062482616973284e-07
a O 0 1.3010248434142113e-09
compound O 0 3.411648208384577e-08
heterozygote O 0 8.046576738252043e-08
for O 0 7.2666689332479e-10
two O 0 2.0754391982791276e-08
C6 O 0 0.016040010377764702
gene O 0 1.1101717973360792e-05
mutations O 0 2.3991273337742314e-05
. O 0 3.3153887102344015e-07

The O 0 6.121022124716546e-07
first O 0 2.6608847747411346e-07
, O 0 2.562941192607582e-09
1195delC O 0 5.701503980048983e-08
located O 0 8.21022361208179e-09
in O 0 6.425104892571198e-10
exon O 0 3.3229871405637823e-06
7 O 0 1.0762272722786292e-05
, O 0 3.6869717945364755e-08
is O 0 8.17954148857325e-09
a O 0 2.705505153244303e-08
novel O 0 9.341720215161331e-06
mutation O 0 4.126979092688998e-06
, O 0 2.992802450307863e-08
while O 0 1.44032092919133e-08
the O 0 1.606404964604735e-08
second O 0 1.7923258610608173e-06
, O 0 1.4204887266444644e-09
1936delG O 0 3.671560833140575e-08
in O 0 4.813080489718402e-10
exon O 0 5.719824116567906e-07
12 O 0 3.7326998381104204e-07
, O 0 1.2951749006617774e-08
has O 0 9.589578553459432e-08
been O 0 1.1499101759682162e-07
described O 0 1.3102091998007381e-06
before O 0 1.865989815996727e-07
to O 0 6.424509990665683e-08
cause O 0 1.323971474676e-07
C6D B-Disease 0 5.954499283689074e-05
in O 0 1.1773710006934834e-08
an O 0 4.36040892282108e-09
unrelated O 0 2.6621688675732e-07
African O 0 2.0179606963210972e-07
- O 0 0.00019422110926825553
American O 0 5.082575285086932e-07
individual O 0 3.141075666235338e-08
. O 0 4.9669299784227405e-08

Both O 0 4.826617896469543e-06
mutations O 0 4.4696971599478275e-05
result O 0 6.190482508827699e-07
in O 0 3.715350516131366e-08
premature O 0 2.5745217499206774e-05
termination O 0 1.3910246707382612e-05
codons O 0 0.0001076417975127697
and O 0 1.0180507160839625e-05
C6 O 1 0.5608025789260864
null O 0 0.0005158018320798874
alleles O 0 6.350719104375457e-06
. O 0 7.409050795104122e-07

Allele O 0 3.599974434109754e-06
- O 0 7.595726401632419e-06
specific O 0 1.712672670350912e-08
PCR O 0 2.0539455363177694e-05
indicated O 0 8.728570151106396e-07
that O 0 1.8585533112513986e-08
the O 0 8.815377761095533e-09
probands O 0 0.00013296405086293817
two O 0 1.9451579191809287e-06
brothers O 0 0.019890062510967255
also O 0 6.776052487111883e-06
inherited O 0 2.8998112611589022e-05
the O 0 1.2923988101931627e-08
1195delC O 0 8.7775947577029e-07
mutation O 0 1.0433559793909808e-07
from O 0 3.020526606611895e-10
their O 0 9.433773762168585e-09
heterozygous O 0 9.232007869286463e-07
mother O 0 1.1213849575142376e-05
and O 0 2.2691910572802954e-08
the O 0 2.7510249633877493e-09
1936delG O 0 6.286360871854413e-07
mutation O 0 4.787057150679175e-08
from O 0 2.854540215313506e-10
their O 0 8.08677658170609e-09
homozygous O 0 5.460315151140094e-07
father O 0 8.08211325420416e-07
. O 0 3.9080489955267694e-09
. O 0 2.6005340103552044e-08

PAX6 O 0 0.01437021978199482
mutations O 0 0.0010963373351842165
reviewed O 0 4.657377576222643e-05
. O 0 2.239208015453187e-06

Mutations O 0 0.001839524949900806
in O 0 8.05889470711918e-08
PAX6 O 0 0.0002479346876498312
are O 0 7.516975841781459e-08
responsible O 0 1.71750514255109e-07
for O 0 1.7078905401035627e-08
human O 0 6.669739832432242e-06
aniridia B-Disease 1 0.9999997615814209
and O 0 0.00023616416729055345
have O 0 1.0322547723262687e-06
also O 0 5.678928687302687e-07
been O 0 3.7144795328458713e-07
found O 0 1.8815453017850814e-07
in O 0 2.7888225417882495e-07
patients O 0 3.126576984868734e-06
with O 0 3.0055591651034774e-06
Peters B-Disease 1 0.9999997615814209
anomaly I-Disease 1 0.9999990463256836
, O 0 1.7093794667744078e-05
with O 0 0.0021670081187039614
congenital B-Disease 1 0.9999997615814209
cataracts I-Disease 1 0.9999997615814209
, O 0 1.7012285752571188e-05
with O 0 6.250049864320317e-06
autosomal B-Disease 1 0.9968427419662476
dominant I-Disease 1 0.9957278966903687
keratitis I-Disease 1 0.9999680519104004
, O 0 6.687059794785455e-05
and O 0 5.9683748077077325e-06
with O 0 8.34271213534521e-06
isolated B-Disease 1 0.9775769114494324
foveal I-Disease 1 0.9999921321868896
hypoplasia I-Disease 1 0.9999971389770508
. O 0 9.883574239211157e-05

No O 0 3.5707703318621498e-06
locus O 0 4.3491274936968694e-07
other O 0 3.0277902407505053e-09
than O 0 6.65117605436194e-09
chromosome O 0 0.0002925522276200354
11p13 O 0 2.6972849809681065e-05
has O 0 1.4896165794198168e-06
been O 0 4.132447770643921e-07
implicated O 0 2.0178213162580505e-06
in O 0 3.3277503916906426e-06
aniridia B-Disease 1 0.9999992847442627
, O 0 2.3113900624593953e-06
and O 0 9.021296705213899e-07
PAX6 O 0 0.0001433105644537136
is O 0 3.1518487730863853e-07
clearly O 0 7.000219284236664e-07
the O 0 4.099906192323033e-09
major O 0 4.5549391813892726e-08
, O 0 2.4520414143580638e-08
if O 0 4.54194335475222e-08
not O 0 7.56750928587735e-09
only O 0 4.161443412087351e-10
, O 0 5.874298270036604e-10
gene O 0 6.429413446085164e-08
responsible O 0 2.7768615495915583e-07
. O 0 1.2398669468893786e-07

Twenty O 0 3.209852138752467e-06
- O 0 0.0001093683167709969
eight O 0 7.07792864318435e-08
percent O 0 1.0506646219710092e-08
of O 0 2.8238464344632064e-10
identified O 0 9.873300541585195e-07
PAX6 O 0 6.580267654499039e-05
mutations O 0 3.4375450468360214e-06
are O 0 4.397167430170157e-08
C O 0 0.000536854553502053
- O 0 0.04551411420106888
T O 0 0.00460722716525197
changes O 0 7.0837598009632075e-09
at O 0 1.971581564674807e-09
CpG O 0 3.1765189305588137e-06
dinucleotides O 0 2.29740840040904e-06
, O 0 1.4599550457461419e-09
20 O 0 3.22687820908385e-10
% O 0 2.3165046270090528e-11
are O 0 6.254013973361339e-11
splicing O 0 1.543426492389699e-06
errors O 0 0.024317946285009384
, O 0 4.3287560202998066e-08
and O 0 1.4731756259322992e-08
more O 0 5.2983260140360144e-11
than O 0 1.3854674074664786e-09
30 O 0 1.4452055552283127e-08
% O 0 2.4858640146341315e-10
are O 0 1.0144961537505992e-09
deletion O 0 2.792639008930564e-07
or O 0 1.2516088609970666e-08
insertion O 0 8.709536700735043e-07
events O 0 1.024682887873496e-06
. O 0 3.290068377737043e-07

There O 0 5.865303137397859e-06
is O 0 1.0230854385895327e-08
a O 0 7.484482367203782e-09
noticeably O 0 3.739291742022033e-06
elevated O 0 0.0002524106530472636
level O 0 1.4864957620375208e-07
of O 0 4.2180126058610767e-10
mutation O 0 5.385846293393115e-07
in O 0 5.28894128493107e-09
the O 0 8.916773097666919e-09
paired O 0 1.7574310504642199e-06
domain O 0 3.3294600143563e-07
compared O 0 4.7048558826645603e-08
with O 0 2.0887908291911117e-08
the O 0 4.032997935610183e-08
rest O 0 1.9214713375959036e-08
of O 0 4.910329781671052e-11
the O 0 2.3527353398833384e-09
gene O 0 4.40390749645303e-07
. O 0 8.326073697162428e-08

Increased O 0 6.630420102737844e-06
mutation O 0 5.396023880166467e-06
in O 0 8.482647473329052e-09
the O 0 1.2351151212897094e-08
homeodomain O 0 1.2279317161301151e-05
is O 0 2.2985947367715198e-08
accounted O 0 6.002596819598693e-08
for O 0 2.4217852723218414e-10
by O 0 2.194622261697532e-09
the O 0 1.7640687133280153e-08
hypermutable O 0 0.00010007010132540017
CpG O 0 3.0063847589190118e-05
dinucleotide O 0 5.122037691762671e-07
in O 0 1.4781172952282873e-09
codon O 0 2.1261695337670972e-07
240 O 0 2.697230172543641e-08
. O 0 3.443472706976536e-08

Very O 0 1.2811379974664305e-06
nearly O 0 1.5908847572632112e-08
all O 0 4.3440304686725995e-09
mutations O 0 1.1893184819200542e-06
appear O 0 1.932960230988101e-06
to O 0 1.8935353409688105e-06
cause O 0 0.00018620178161654621
loss O 0 5.203595355851576e-05
of O 0 4.333404746148517e-09
function O 0 3.086883282321651e-07
of O 0 1.3015312161357429e-09
the O 0 7.948110614108828e-09
mutant O 0 5.931668738412554e-07
allele O 0 1.7218766856785805e-08
, O 0 1.759638657006235e-09
and O 0 2.893454364993886e-10
more O 0 3.2603694050115095e-12
than O 0 3.9683083208341685e-11
80 O 0 7.560262971217924e-10
% O 0 2.8034641275098693e-10
of O 0 4.675687614863477e-10
exonic O 0 3.0480943678412586e-05
substitutions O 0 3.3514319852656627e-07
result O 0 7.581873262552108e-08
in O 0 8.377203819520673e-09
nonsense O 0 6.54811883578077e-05
codons O 0 4.943010026181582e-06
. O 0 7.069347418564575e-08

In O 0 1.858268490195769e-07
a O 0 7.948292690684866e-09
gene O 0 9.631040853719242e-08
with O 0 6.101855909435017e-09
such O 0 6.553906306550061e-09
extraordinarily O 0 4.3642567106871866e-06
high O 0 3.2085438306239666e-07
sequence O 0 2.645397216838319e-07
conservation O 0 4.011675436288442e-09
throughout O 0 1.082080092196236e-09
evolution O 0 9.691113689314079e-08
, O 0 1.1221895412916183e-08
there O 0 9.567340697458349e-09
are O 0 3.5544862608816175e-09
presumed O 0 1.6343112747563282e-06
undiscovered O 0 1.0715459211496636e-05
missense O 0 4.774680201080628e-05
mutations O 0 0.0003002622979693115
, O 0 2.0490972474362934e-08
these O 0 1.2825265294225119e-09
are O 0 1.1498905161388961e-09
hypothesized O 0 1.1786414688685909e-06
to O 0 1.0760322766145691e-07
exist O 0 2.0271613720979076e-07
in O 0 9.175883164402876e-09
as O 0 3.818041989234189e-07
- O 0 0.14071130752563477
yet O 0 1.8846175180442515e-06
unidentified O 0 9.680874200057588e-07
phenotypes O 0 5.547810246753215e-07
. O 0 3.1596414373780135e-09
. O 0 6.701475374626398e-09

Genetic O 0 0.001829582848586142
heterogeneity O 0 0.000423327466705814
and O 0 2.14013834920479e-06
penetrance O 0 2.7579790184972808e-05
analysis O 0 6.491257664720251e-08
of O 0 1.4482787191738566e-09
the O 0 1.0739879741095137e-07
BRCA1 O 0 0.0003208774433005601
and O 0 1.3638839391205693e-06
BRCA2 O 0 1.766767854860518e-05
genes O 0 4.914328656013822e-06
in O 0 2.77652834483888e-05
breast B-Disease 1 0.9999212026596069
cancer I-Disease 1 0.8412396311759949
families O 0 1.1267878790022223e-06
. O 0 9.795662663236726e-07

The O 0 0.0029493479523807764
Breast B-Disease 1 0.9999957084655762
Cancer I-Disease 1 0.999972939491272
Linkage O 0 0.1176372542977333
Consortium O 0 4.8220121243502945e-05
. O 0 3.632546849985374e-07

The O 0 3.04150979957285e-08
contribution O 0 1.0728302690665714e-09
of O 0 3.2437613706193247e-10
BRCA1 O 0 6.477936403825879e-05
and O 0 5.834869170939783e-06
BRCA2 O 0 0.011760495603084564
to O 0 0.02332223579287529
inherited B-Disease 1 1.0
breast I-Disease 1 0.9999998807907104
cancer I-Disease 1 1.0
was O 1 0.5610715746879578
assessed O 0 3.605069423429086e-06
by O 0 2.3558978767823646e-08
linkage O 0 0.005613122601062059
and O 0 1.936118678713683e-06
mutation O 0 1.7539339580707747e-07
analysis O 0 1.4699927497474619e-08
in O 0 4.461914837605718e-09
237 O 0 1.9079284641065897e-07
families O 0 4.29844604354912e-08
, O 0 5.596473506841448e-09
each O 0 3.106325752177952e-10
with O 0 1.8454411332413656e-08
at O 0 7.84005393938969e-08
least O 0 9.160036062993981e-10
four O 0 8.452897048982777e-09
cases O 0 7.150919145715307e-08
of O 0 1.2934057167512947e-06
breast B-Disease 1 0.9998745918273926
cancer I-Disease 1 0.5866992473602295
, O 0 3.697505412958435e-09
collected O 0 1.2881700151012865e-09
by O 0 2.9547040369948263e-08
the O 0 0.00016182266699615866
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999978542327881
Linkage O 0 0.010397425852715969
Consortium O 0 1.586538019182626e-05
. O 0 1.0382343162973484e-07

Families O 0 4.435047685547033e-06
were O 0 6.035637056811538e-08
included O 0 5.3662083665528826e-09
without O 0 1.1640087782538444e-09
regard O 0 2.610188065688135e-09
to O 0 1.5896099991863366e-09
the O 0 2.0348647211676507e-09
occurrence O 0 6.412527000065893e-06
of O 0 7.746193659841083e-07
ovarian B-Disease 1 0.9984059929847717
or I-Disease 0 2.4468097308272263e-06
other I-Disease 0 1.13995258743671e-06
cancers I-Disease 1 0.8561511039733887
. O 0 4.2756167317747895e-07

Overall O 0 0.1536809355020523
, O 0 4.925204120809212e-05
disease O 0 0.09003573656082153
was O 0 3.1006993594928645e-06
linked O 0 7.74282671045512e-06
to O 0 2.1296661145697726e-07
BRCA1 O 0 1.5868679838604294e-05
in O 0 1.7468517299334962e-08
an O 0 5.151505888534302e-09
estimated O 0 6.803402641253342e-08
52 O 0 3.8833712778796325e-07
% O 0 1.0225933433360979e-09
of O 0 1.009633598947346e-09
families O 0 3.9312869404284356e-08
, O 0 6.806722741004023e-09
to O 0 4.963963018411732e-09
BRCA2 O 0 9.277074752844783e-08
in O 0 9.832781699969928e-09
32 O 0 2.5675664261370912e-08
% O 0 1.960054618610485e-10
of O 0 4.4715481317680883e-10
families O 0 3.5526852570910705e-08
, O 0 1.352517031705247e-08
and O 0 1.9297312192634308e-08
to O 0 1.4421042138224038e-09
neither O 0 3.6249931945064873e-09
gene O 0 8.878418888969009e-09
in O 0 9.401835754374588e-09
16 O 0 3.0182317090066135e-08
% O 0 1.8836218695916784e-10
( O 0 1.1303795399708605e-10
95 O 0 4.4982762403833476e-08
% O 0 3.7588141488242854e-09
confidence O 0 8.908749805414118e-06
interval O 0 1.9482213247101754e-05
[ O 0 4.55268093446648e-07
CI O 0 0.002365380059927702
] O 0 1.517309868859229e-07
6 O 0 4.3307462505026706e-08
% O 0 6.051827372566265e-10
- O 0 0.0004287567862775177
28 O 0 1.351479909317277e-06
% O 0 5.946241277143827e-10
) O 0 2.9283375724276084e-10
, O 0 2.63541466427597e-10
suggesting O 0 1.4479204502038101e-08
other O 0 3.1585567494829547e-09
predisposition O 0 1.432314093108289e-05
genes O 0 1.079866251529893e-06
. O 0 1.9063841705246887e-07

The O 0 3.2376337344430794e-07
majority O 0 4.192326485963349e-08
( O 0 2.2209747374546396e-09
81 O 0 1.4267541814660945e-07
% O 0 4.2207490280610216e-10
) O 0 1.3098210016604384e-10
of O 0 5.974811201348018e-10
the O 0 6.496185233118013e-05
breast B-Disease 1 0.9999977350234985
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 8.84345467966341e-08
were O 0 6.782723716014516e-08
due O 0 2.984092617452916e-08
to O 0 4.492908445286048e-08
BRCA1 O 0 1.5143077689572237e-05
, O 0 1.1436092961503164e-08
with O 0 7.102701093941732e-09
most O 0 2.8210605407252842e-08
others O 0 1.4133605930055637e-07
( O 0 3.510336021861349e-09
14 O 0 8.892692449080641e-08
% O 0 1.0764603652901883e-09
) O 0 5.5437676671488134e-09
due O 0 4.400850883712337e-08
to O 0 1.948977796928375e-07
BRCA2 O 0 0.000182379997568205
. O 0 5.442633437269251e-07

Conversely O 0 0.00020680564921349287
, O 0 1.0212161782874318e-07
the O 0 4.384895557763002e-09
majority O 0 2.453916181366367e-09
of O 0 1.0289205043534366e-09
families O 0 1.0510534664831539e-08
with O 0 5.919349277405672e-08
male B-Disease 0 1.0970707080559805e-05
and I-Disease 0 3.433204028624459e-06
female I-Disease 0 6.839912384748459e-05
breast I-Disease 1 0.9206417798995972
cancer I-Disease 0 0.05470734089612961
were O 0 4.089826290964993e-07
due O 0 4.7353577770081756e-07
to O 0 2.3074908028775099e-07
BRCA2 O 0 3.1341416615759954e-05
( O 0 7.492937825759327e-09
76 O 0 1.6736423731344985e-06
% O 0 4.134411923928383e-09
) O 0 1.2518380110293492e-08
. O 0 4.9513801059219986e-08

The O 0 1.1516836906366734e-07
largest O 0 8.53205683881697e-09
proportion O 0 4.865661296094004e-08
( O 0 7.595544193605974e-10
67 O 0 3.7898152527304774e-07
% O 0 2.1363224522730206e-09
) O 0 7.841228222282837e-10
of O 0 5.86775850131005e-10
families O 0 1.7184971667916216e-08
due O 0 6.846542532912281e-08
to O 0 9.152757662889144e-09
other O 0 6.312729228241665e-10
genes O 0 1.4661935665571946e-07
was O 0 0.0011801084037870169
found O 0 1.0237861260975478e-06
in O 0 8.568510168061039e-08
families O 0 1.0688765428312763e-08
with O 0 6.64136692307693e-08
four O 0 2.168259669588224e-07
or O 0 5.799635260927971e-08
five O 0 3.683300997536776e-09
cases O 0 4.847779955241549e-09
of O 0 2.0907958031557428e-08
female O 0 0.09700339287519455
breast B-Disease 1 0.9975985884666443
cancer I-Disease 0 0.025621561333537102
only O 0 1.5872892333845812e-07
. O 0 1.1860196735824502e-07

These O 0 5.207428444009565e-07
estimates O 0 1.0405890407128027e-06
were O 0 1.3448634206270071e-07
not O 0 5.951262949110969e-08
substantially O 0 2.5705611506054993e-07
affected O 0 1.7733052359858448e-08
either O 0 8.21105405890421e-09
by O 0 2.577240643120149e-09
changing O 0 5.264758229373001e-08
the O 0 8.101303627938705e-09
assumed O 0 8.316010990938594e-08
penetrance O 0 1.2933846846863162e-06
model O 0 7.121369094420515e-07
for O 0 3.3560703105450784e-09
BRCA1 O 0 8.728196917218156e-06
or O 0 1.3659436248758539e-08
by O 0 1.6088941290348657e-09
including O 0 6.088602511056251e-09
or O 0 1.5668470609853102e-07
excluding O 0 2.1344228571251733e-06
BRCA1 O 0 0.00020255678100511432
mutation O 0 3.2523937534278957e-06
data O 0 2.013043058468611e-06
. O 0 2.704396422359423e-07

Among O 0 1.146991849054757e-06
those O 0 1.4072034559831081e-07
families O 0 5.604039188256138e-08
with O 0 2.077136059597251e-06
disease O 0 0.40652692317962646
due O 0 6.943570838302549e-07
to O 0 1.8625335940214427e-07
BRCA1 O 0 0.002225149655714631
that O 0 8.556963621231262e-06
were O 0 1.3782985206489684e-06
tested O 0 2.3403536033583805e-06
by O 0 1.3294261247409622e-09
one O 0 2.9591074035550946e-09
of O 0 8.619080449356886e-11
the O 0 8.335886425570038e-10
standard O 0 3.37792620541677e-08
screening O 0 4.006697196246023e-09
methods O 0 1.1732530502683858e-08
, O 0 4.745225878899362e-10
mutations O 0 9.310858750666284e-09
were O 0 7.044819838597505e-09
detected O 0 1.336575365940007e-07
in O 0 1.0531820970882677e-09
the O 0 1.2991004938456285e-09
coding O 0 4.1201087697118055e-06
sequence O 0 1.238634695255314e-06
or O 0 5.66239943822211e-09
splice O 0 5.246311502560275e-06
sites O 0 2.1737440647484618e-07
in O 0 1.0564412677993573e-09
an O 0 8.135024320843343e-10
estimated O 0 2.6579368039847395e-08
63 O 0 4.346561013335304e-07
% O 0 2.426445988579218e-10
( O 0 1.200353288988154e-10
95 O 0 8.275662821688456e-08
% O 0 5.910073319626008e-09
CI O 0 0.05913389101624489
51 O 0 2.0854845388385e-06
% O 0 7.111376820745363e-09
- O 0 0.0026717630680650473
77 O 0 1.4486270174529636e-06
% O 0 1.3978126434111005e-09
) O 0 2.2675024080598405e-09
. O 0 1.28284023404035e-08

The O 0 1.1277409583954068e-07
estimated O 0 9.316294402594849e-09
sensitivity O 0 5.712257689083344e-07
was O 0 1.0869147217817954e-06
identical O 0 8.137266149788047e-08
for O 0 1.1004665928515678e-10
direct O 0 9.046930982137269e-10
sequencing O 0 2.411937032320566e-07
and O 0 1.8307270366335615e-08
other O 0 2.314270997061385e-10
techniques O 0 1.91511776392872e-06
. O 0 7.251293254739721e-08

The O 0 4.800864417120465e-07
penetrance O 0 2.2965998141444288e-05
of O 0 2.5614619758584922e-08
BRCA2 O 0 0.00020228774519637227
was O 0 2.8450606350816088e-06
estimated O 0 2.345127869674002e-09
by O 0 6.778811401098039e-10
maximizing O 0 1.6576923655975406e-07
the O 0 1.6670618663283676e-07
LOD O 0 0.46525830030441284
score O 0 3.570157423382625e-05
in O 0 2.4415456323367835e-08
BRCA2 O 0 8.297406566271093e-06
- O 0 0.00901473592966795
mutation O 0 8.812455234874506e-06
families O 0 2.6407306563669408e-08
, O 0 9.527691968713725e-10
over O 0 6.88699763884415e-09
all O 0 2.665927034684046e-09
possible O 0 1.3693294498295927e-08
penetrance O 0 1.7721877156873234e-05
functions O 0 2.1538494365813676e-07
. O 0 1.1697007096245216e-07

The O 0 1.25495603242598e-07
estimated O 0 2.111933916637554e-08
cumulative O 0 3.464620874638058e-07
risk O 0 2.5080876184802037e-06
of O 0 1.5547219334166584e-07
breast B-Disease 1 0.9994853734970093
cancer I-Disease 1 0.5972189903259277
reached O 0 4.557626198220532e-06
28 O 0 1.7823649045567436e-07
% O 0 2.858397685212566e-10
( O 0 2.406819188394138e-10
95 O 0 1.0017984664045798e-07
% O 0 8.434440701421408e-09
CI O 0 0.03676272928714752
9 O 0 6.636187777075975e-07
% O 0 2.1344448430937746e-09
- O 0 7.436486339429393e-05
44 O 0 4.237725548250637e-08
% O 0 2.2939761201712372e-10
) O 0 5.584014153847683e-11
by O 0 1.819824846371887e-10
age O 0 1.7308460442677642e-08
50 O 0 6.644262362520692e-10
years O 0 5.831122251720444e-09
and O 0 8.918915384015236e-09
84 O 0 6.173134892151211e-09
% O 0 4.6534692765831664e-11
( O 0 2.2500688812154834e-11
95 O 0 1.5778812922917496e-08
% O 0 6.017986664552666e-10
CI O 0 0.003328857244923711
43 O 0 9.210974383222492e-08
% O 0 8.701078746398139e-10
- O 0 5.0306709454162046e-05
95 O 0 1.07317157471698e-06
% O 0 7.77959863196287e-10
) O 0 1.8436485671458058e-10
by O 0 5.067865571639629e-10
age O 0 3.3283292566466116e-08
70 O 0 7.022296077963119e-09
years O 0 1.9051842770068106e-08
. O 0 3.161976280807721e-08

The O 0 2.334109194634948e-05
corresponding O 0 0.2707684338092804
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999997615814209
risks O 0 0.036057472229003906
were O 0 1.187923089673859e-06
0 O 0 9.133052117249463e-06
. O 0 2.955559068595903e-07

4 O 0 8.213883120333776e-07
% O 0 1.5261667485333419e-09
( O 0 1.7607018620857673e-10
95 O 0 4.184337853985198e-08
% O 0 4.906047124109136e-09
CI O 0 0.09800659120082855
0 O 0 7.654349474250921e-07
% O 0 2.5239046408387367e-09
- O 0 0.00011752305726986378
1 O 0 2.2374823060999915e-07
% O 0 1.192135390404303e-09
) O 0 6.239121025375383e-11
by O 0 2.469183468800651e-10
age O 0 9.091738917277326e-09
50 O 0 7.890783026986981e-10
years O 0 5.3385225129432e-09
and O 0 1.9248753702072463e-08
27 O 0 3.00624165561203e-08
% O 0 6.533169838451869e-11
( O 0 3.8364717652727975e-11
95 O 0 1.615383027342432e-08
% O 0 1.4594789821131826e-09
CI O 0 0.001604248071089387
0 O 0 5.829712890204064e-08
% O 0 1.109021985357117e-09
- O 0 0.0001908309932332486
47 O 0 2.072047664114507e-06
% O 0 7.881156838251968e-10
) O 0 1.5229557892570966e-10
by O 0 1.0660703431142338e-09
age O 0 5.803984493013559e-08
70 O 0 5.530829572109042e-09
years O 0 9.445423110321371e-09
. O 0 2.8713399657931404e-08

The O 0 1.0964596413032268e-06
lifetime O 0 2.1411754005384864e-06
risk O 0 3.135137603749172e-06
of O 0 7.73032127199258e-08
breast B-Disease 1 0.9988190531730652
cancer I-Disease 0 0.19480298459529877
appears O 0 4.126729322706524e-07
similar O 0 2.4259993125497203e-08
to O 0 6.487816506250965e-08
the O 0 7.37702734454615e-08
risk O 0 4.212606086184678e-07
in O 0 8.226228587204787e-09
BRCA1 O 0 1.9916193195967935e-05
carriers O 0 1.3196267900639214e-06
, O 0 4.576500955977281e-08
but O 0 3.0716833521182707e-07
there O 0 2.8731367507361938e-08
was O 0 7.590691097902891e-07
some O 0 2.645582919402756e-10
suggestion O 0 1.762837520402627e-08
of O 0 1.2248968506156643e-10
a O 0 1.8655325106919918e-07
lower O 0 0.0005257381126284599
risk O 0 1.3613421288027894e-06
in O 0 1.1593519921859752e-08
BRCA2 O 0 1.222733999384218e-06
carriers O 0 1.7238813043718437e-08
< O 0 2.3239783430994976e-08
50 O 0 2.770872642443578e-09
years O 0 2.0597270555811065e-09
of O 0 1.8061218076681484e-09
age O 0 1.0770522749226075e-06
. O 0 4.0814637003450116e-08

Eye B-Disease 1 0.9741795063018799
movement I-Disease 0 0.0005783555097877979
abnormalities I-Disease 0 0.10944528132677078
correlate O 0 5.1422302931314334e-06
with O 0 1.9001403472884704e-07
genotype O 0 0.000689995416905731
in O 0 1.5955036360537633e-05
autosomal O 1 0.9996351003646851
dominant O 1 0.999790370464325
cerebellar B-Disease 1 0.9999628067016602
ataxia I-Disease 1 0.9999977350234985
type I-Disease 1 0.9999738931655884
I I-Disease 1 0.9995230436325073
. O 0 2.243012431790703e-06

We O 0 4.690539572038688e-05
compared O 0 3.063074132114707e-07
horizontal O 0 0.0003255158371757716
eye O 1 0.6267465949058533
movements O 0 0.000372084992704913
( O 0 4.274955855976259e-08
visually O 0 1.7840220607467927e-05
guided O 0 1.9377297576284036e-05
saccades O 0 0.003006085753440857
, O 0 7.417393277364681e-08
antisaccades O 0 2.7605152354226448e-05
, O 0 4.514736318128598e-08
and O 0 2.5911615963991608e-08
smooth O 0 1.9997121398773743e-06
pursuit O 0 5.964812771708239e-06
) O 0 1.1268369570771597e-09
in O 0 1.5376203643668873e-09
control O 0 7.195185389718972e-07
subjects O 0 1.2915639047150762e-07
( O 0 8.398028938927382e-10
n O 0 4.663920117309317e-05
= O 0 0.00017496173677500337
14 O 0 2.052802443586188e-07
) O 0 7.438627935840714e-09
and O 0 7.547014320152812e-07
patients O 0 3.025676562629087e-07
with O 0 1.1537885313828156e-08
three O 0 5.500313804418511e-08
forms O 0 5.082691814095597e-07
of O 0 3.3799761922637117e-07
autosomal O 1 0.8402662873268127
dominant O 1 0.9385636448860168
cerebellar B-Disease 1 0.9291417002677917
ataxias I-Disease 1 0.9304463267326355
type I-Disease 1 0.9924611449241638
I I-Disease 1 0.8556355237960815
spinocerebellar B-Disease 1 0.9747830629348755
ataxias I-Disease 0 0.0018209482077509165
1 I-Disease 0 8.618466722509766e-07
and I-Disease 0 3.4063103271364525e-07
2 I-Disease 0 4.6107197704259306e-07
( O 0 8.826615882639999e-09
SCA1 B-Disease 0 0.00017289567040279508
, O 0 3.536628057076996e-08
n O 0 3.089044912485406e-05
= O 0 1.5086831808730494e-05
11 O 0 5.695612870226796e-08
; O 0 1.8695920367406416e-09
SCA2 B-Disease 0 1.2233113920956384e-05
, O 0 3.585892249802214e-09
n O 0 2.7668136226566276e-06
= O 0 6.320376542134909e-06
10 O 0 3.180555818715902e-09
) O 0 9.108483967068537e-10
and O 0 4.128575596951123e-07
SCA3 B-Disease 1 0.9999940395355225
/ O 0 0.007960804738104343
Machado B-Disease 0 0.00012569465616252273
- I-Disease 0 0.3140120804309845
Joseph I-Disease 0 0.352180153131485
disease I-Disease 1 0.7332728505134583
( O 0 9.31203345544418e-08
MJD B-Disease 1 0.9999955892562866
) O 0 2.879006366640624e-08
( O 0 1.7731285328892454e-09
n O 0 4.587374860420823e-05
= O 0 5.851381865795702e-05
16 O 0 3.2801615645894344e-08
) O 0 4.03798372516917e-09
. O 0 2.2736013960411583e-08

In O 0 3.0038688692002324e-07
SCA1 B-Disease 0 2.526837124605663e-05
, O 0 1.4799452774383326e-09
saccade O 0 9.64034043704487e-08
amplitude O 0 2.65301896007486e-08
was O 0 4.384287706216128e-07
significantly O 0 4.548349963329201e-08
increased O 0 2.0416536017364706e-08
, O 0 2.9850761862348918e-09
resulting O 0 1.4621797994607277e-08
in O 0 1.0318871801473506e-07
hypermetria B-Disease 0 0.0019928717520087957
. O 0 3.598590296860493e-07

The O 0 2.798008154059062e-07
smooth O 0 4.47975298811798e-06
pursuit O 0 3.5246457628090866e-06
gain O 0 2.209712192779989e-06
was O 0 5.822989351145225e-06
decreased O 0 8.988629815576132e-06
. O 0 1.1792796783538506e-07

In O 0 5.09282244820497e-07
SCA2 B-Disease 0 4.257367254467681e-05
, O 0 5.4768505286517666e-09
saccade O 0 3.156580419272359e-07
velocity O 0 5.725958658331365e-07
was O 0 4.5979373908267007e-07
markedly O 0 9.308586186307366e-07
decreased O 0 1.0629445569065865e-05
. O 0 1.3613470173368114e-07

The O 0 4.1254071447838214e-07
percentage O 0 4.546016896256333e-07
of O 0 4.841635092844854e-09
errors O 0 0.00046704590204171836
in O 0 1.1867834359691187e-07
antisaccades O 0 0.016406409442424774
was O 0 2.3234269974636845e-05
greatly O 0 9.311642656939512e-08
increased O 0 3.4157629613673635e-08
and O 0 1.5584792834033578e-07
was O 0 8.161901519088133e-07
significantly O 0 3.104297263689659e-08
correlated O 0 1.496455297456123e-07
with O 0 2.1308953535026376e-07
age O 0 2.7381924155633897e-05
at O 0 1.3856915757060051e-05
disease O 0 0.0324259027838707
onset O 0 0.0001805431820685044
. O 0 3.167819784266612e-07

In O 0 2.8526741857604065e-07
addition O 0 2.1241261194404615e-08
, O 0 2.1388175674985632e-09
a O 0 1.0047099818777383e-09
correlation O 0 7.927778824523557e-07
between O 0 3.480729446891928e-07
smooth O 0 6.169917469378561e-05
pursuit O 0 0.000278470542980358
gain O 0 1.8298513168701902e-05
and O 0 1.1381836628743258e-07
the O 0 5.898864730013997e-10
number O 0 3.6640177558666664e-09
of O 0 7.117021638691767e-09
trinucleotide O 0 0.010162699967622757
repeats O 0 0.0004407994856592268
was O 0 1.350991351500852e-05
found O 0 2.3949505134623905e-07
. O 0 6.541819175254204e-08

In O 0 8.870093552104663e-06
SCA3 B-Disease 1 0.9998249411582947
, O 0 1.5891491784714162e-06
gaze B-Disease 0 0.000343991705449298
- I-Disease 0 0.024739382788538933
evoked I-Disease 0 6.393703370122239e-05
nystagmus I-Disease 0 0.004863041918724775
was O 0 1.4247502804209944e-05
often O 0 2.1138845340828993e-08
present O 0 5.871206854024535e-10
as O 0 2.32394148369508e-09
was O 0 5.604092052635679e-07
saccade O 0 7.859689503675327e-06
hypometria O 0 0.00010093810851685703
and O 0 1.4070840848035004e-07
smooth O 0 1.2227084198457305e-06
pursuit O 0 1.7823100506575429e-06
gain O 0 3.619171593527426e-07
was O 0 7.777171049383469e-07
markedly O 0 8.802878710412188e-07
decreased O 0 2.132309191438253e-06
. O 0 9.039521842169052e-08

Three O 0 4.5143059423935483e-07
major O 0 5.092142174589753e-08
criteria O 0 3.938769665978725e-08
, O 0 4.725617119838432e-10
saccade O 0 2.1429598007216555e-07
amplitude O 0 2.0480772633391098e-08
, O 0 8.691177222353019e-10
saccade O 0 1.7214669867371413e-07
velocity O 0 9.277177923650015e-07
, O 0 4.354067328904421e-09
and O 0 3.4119391756348705e-09
presence O 0 1.6347511122560832e-09
of O 0 1.4599996767117318e-09
gaze B-Disease 0 0.0004943211679346859
- I-Disease 0 0.0008533835061825812
evoked I-Disease 0 5.313521796779241e-06
nystagmus I-Disease 0 1.4785890925850254e-05
, O 0 5.674246073006373e-10
permitted O 0 1.7224398296544763e-10
the O 0 2.057267967092713e-10
correct O 0 2.565613783644949e-07
assignment O 0 5.043855999531388e-09
of O 0 3.131081852125739e-11
90 O 0 7.199949525471538e-10
% O 0 6.7206185061508e-11
of O 0 5.677750977706175e-11
the O 0 5.613846276730783e-09
SCA1 B-Disease 0 1.2837803296861239e-05
, O 0 3.800908199291797e-10
90 O 0 1.4376763668444426e-10
% O 0 2.6228866301103437e-11
of O 0 5.302976807675108e-11
the O 0 2.5779501200418053e-08
SCA2 B-Disease 0 0.0024413536302745342
, O 0 1.7537692187374887e-08
and O 0 1.6997692142695087e-08
93 O 0 2.3641353763537154e-08
% O 0 7.933139561933089e-11
of O 0 2.1657375892658592e-10
the O 0 5.299759209265176e-07
patients O 0 9.470824124946375e-07
with O 0 4.600657064202096e-07
SCA3 B-Disease 1 0.9999998807907104
to O 0 1.7430797925044317e-06
their O 0 7.147466618562248e-09
genetically O 0 1.3080052951863763e-07
confirmed O 0 5.530238013307098e-06
patient O 0 2.1954620024189353e-05
group O 0 1.669268385739997e-06
and O 0 1.1466472642496228e-06
, O 0 4.792785190943505e-08
therefore O 0 1.3991262903800816e-07
, O 0 2.784728891924715e-08
may O 0 5.971176619823382e-07
help O 0 2.9304136006658155e-08
orient O 0 0.00011681904288707301
diagnoses O 0 0.0020012748427689075
of O 0 6.65810651057086e-09
SCA1 B-Disease 0 0.015658363699913025
, O 0 6.660420126536337e-08
SCA2 B-Disease 0 0.00016635302745271474
, O 0 4.7544716608172166e-08
and O 0 2.5589699248484976e-07
SCA3 B-Disease 1 0.9999877214431763
at O 0 1.4896917832629697e-07
early O 0 1.8071190766022482e-07
clinical O 0 7.92414311945322e-07
stages O 0 2.153355580958305e-06
of O 0 1.3939528642481491e-08
the O 0 1.9978968339273706e-05
diseases O 1 0.769100546836853
. O 0 3.027098927077532e-08
. O 0 3.247293278718644e-08

Genetic O 0 5.621942182187922e-05
basis O 0 1.0641839764957695e-07
and O 0 4.7056907703790785e-08
molecular O 0 9.437451808480546e-06
mechanism O 0 0.001075770240277052
for O 0 0.00026576087111607194
idiopathic B-Disease 1 0.9999998807907104
ventricular I-Disease 1 0.9999923706054688
fibrillation I-Disease 1 0.9999994039535522
. O 0 0.0008754530572332442

Ventricular B-Disease 1 0.9974465370178223
fibrillation I-Disease 1 0.9981964230537415
causes O 0 3.4764729207381606e-05
more O 0 6.763997695280466e-10
than O 0 3.3745356509129465e-10
300 O 0 1.1510316033636059e-09
, O 0 2.405255550286256e-09
000 O 0 3.2815299366717454e-09
sudden O 0 4.4440727720029827e-07
deaths O 0 3.7187612633715617e-07
each O 0 3.18170267910034e-09
year O 0 1.605351229727603e-08
in O 0 1.590915132965165e-08
the O 0 1.6546472636491671e-07
USA O 0 0.00016011117259040475
alone O 0 4.4899618956151244e-07
. O 0 1.3533867360138174e-08

In O 0 4.0446991533826804e-08
approximately O 0 3.3206171146105135e-09
5 O 0 5.207959574704546e-08
- O 0 0.00018243512022309005
12 O 0 1.6711082650999742e-07
% O 0 4.327274094606537e-10
of O 0 1.6134227287523117e-10
these O 0 1.5138461151309457e-08
cases O 0 7.67923964417605e-08
, O 0 5.3802004629233124e-08
there O 0 3.290419314794235e-08
are O 0 5.406594283385857e-09
no O 0 1.5186576263204188e-07
demonstrable O 0 0.00035164118162356317
cardiac O 0 0.012308701872825623
or O 0 9.528506552669569e-07
non O 0 1.1864753105328418e-05
- O 1 0.9999464750289917
cardiac O 1 0.9848201870918274
causes O 0 3.3466935747128446e-06
to O 0 1.246209109240226e-07
account O 0 1.3159930745132442e-07
for O 0 8.805126405775354e-09
the O 0 1.1874049477000881e-07
episode O 0 0.000914512958843261
, O 0 1.1927073728656978e-07
which O 0 3.948434823541902e-08
is O 0 7.983512517739655e-09
therefore O 0 1.3058883752137262e-08
classified O 0 2.0469935861910926e-06
as O 0 0.006826411001384258
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999963045120239
fibrillation I-Disease 1 0.9999998807907104
( O 0 0.00057718635071069
IVF B-Disease 1 0.9999954700469971
) O 0 4.852806227972906e-07
. O 0 1.860887692828328e-07

A O 0 3.9262030782083457e-07
distinct O 0 2.8435605869958636e-08
group O 0 6.415816073968017e-07
of O 0 5.512202250201881e-08
IVF B-Disease 1 0.9999996423721313
patients O 0 0.00074857531581074
has O 0 1.7492411643615924e-06
been O 0 4.94124776651006e-07
found O 0 1.1988402093265904e-07
to O 0 1.582248287945731e-08
present O 0 3.93405263920954e-09
with O 0 4.642152884315465e-09
a O 0 2.2755889972359e-07
characteristic O 0 0.00010730463691288605
electrocardiographic O 0 0.0018746618879958987
pattern O 0 0.0007059779018163681
. O 0 6.938956289559428e-07

Because O 0 4.756471753353253e-06
of O 0 5.791780388619827e-10
the O 0 2.0846662174278663e-09
small O 0 2.8276743169186602e-09
size O 0 7.178729077850221e-08
of O 0 1.280116790347563e-09
most O 0 7.45750750041907e-09
pedigrees O 0 1.2118288395868149e-05
and O 0 3.4336812859692145e-07
the O 0 1.6484376530456757e-08
high O 0 2.804830955938087e-06
incidence O 0 0.010512317530810833
of O 0 1.8754573005708153e-08
sudden B-Disease 0 0.0001309349900111556
death I-Disease 0 7.40094474167563e-05
, O 0 2.1816187967260703e-08
however O 0 1.3532860165810234e-08
, O 0 7.638077670346632e-11
molecular O 0 1.9592080846564386e-08
genetic O 0 1.5228170013870113e-06
studies O 0 1.5447554346792458e-08
of O 0 1.0925266913375253e-08
IVF B-Disease 1 0.9999991655349731
have O 0 8.63061814015964e-06
not O 0 9.102326714582887e-08
yet O 0 3.630461620218739e-08
been O 0 7.891768660783782e-08
done O 0 2.434324812838895e-07
. O 0 2.465223403191885e-08

Because O 0 0.0014274202985689044
IVF B-Disease 1 0.9999498128890991
causes O 0 0.0005925193545408547
cardiac O 1 0.7874915599822998
rhythm O 1 0.8975023627281189
disturbance O 0 0.0013470645062625408
, O 0 6.08761823173154e-08
we O 0 3.2147053019571104e-08
investigated O 0 2.2716074354889315e-08
whether O 0 1.2000180404925231e-08
malfunction O 0 0.00010328790085623041
of O 0 1.47999543176347e-10
ion O 0 5.111312475492014e-07
channels O 0 5.249550304142758e-05
could O 0 0.0025882499758154154
cause O 0 3.5279617804917507e-06
the O 0 2.0454527316360327e-07
disorder O 0 6.975659198360518e-05
by O 0 6.710451083691282e-10
studying O 0 5.5048343661212584e-09
mutations O 0 7.47941157897003e-07
in O 0 9.201435169359229e-09
the O 0 6.268831498346117e-08
cardiac O 0 4.653733049053699e-05
sodium O 0 2.818829329953587e-07
channel O 0 1.4885464224789757e-05
gene O 0 6.952158400963526e-06
SCN5A O 0 0.0005407854914665222
. O 0 1.5596270941387047e-07

We O 0 0.00042740703793242574
have O 0 2.2942329280795093e-07
now O 0 4.83468642897833e-09
identified O 0 9.435574099825317e-09
a O 0 3.9309999699810305e-09
missense O 0 5.0833226850954816e-05
mutation O 0 1.3468169527186546e-05
, O 0 5.265337943427539e-09
a O 0 1.6549369874496733e-08
splice O 0 0.12139291316270828
- O 0 0.41128385066986084
donor O 0 5.2322334909149504e-08
mutation O 0 7.516566711274209e-07
, O 0 1.6012352332950286e-08
and O 0 1.7496262216809555e-08
a O 0 1.652716186129055e-08
frameshift O 0 0.00029743308550678194
mutation O 0 1.3958093632027158e-06
in O 0 6.593288581768775e-09
the O 0 1.0776338932316776e-08
coding O 0 0.00024330406449735165
region O 0 4.107603501779522e-07
of O 0 4.148203558429486e-09
SCN5A O 0 0.002464358927682042
in O 0 1.0329958399779571e-07
three O 0 6.961671488170396e-07
IVF B-Disease 1 0.99996018409729
families O 0 1.7283660724842775e-07
. O 0 4.19607850687953e-08

We O 0 8.574412277084775e-06
show O 0 2.1381088899374845e-08
that O 0 2.8421967557257233e-10
sodium O 0 8.972009246654977e-10
channels O 0 2.245476338202934e-08
with O 0 1.5309364886917365e-09
the O 0 5.739591468767458e-09
missense O 0 1.8710483345785178e-05
mutation O 0 3.960461526730796e-06
recover O 0 1.66854272265482e-06
from O 0 8.005267004840277e-10
inactivation O 0 1.8307189748156816e-05
more O 0 1.3100663887044561e-09
rapidly O 0 1.2426701800904993e-07
than O 0 5.520090162747238e-09
normal O 0 7.608077794429846e-07
and O 0 2.0184612026241666e-07
that O 0 9.351083463116083e-08
the O 0 2.8995508216667076e-08
frameshift O 0 0.0014109952608123422
mutation O 0 1.8427383565722266e-06
causes O 0 2.6208953229911458e-08
the O 0 9.293785185882086e-10
sodium O 0 4.217164217834579e-08
channel O 0 9.791173397388775e-06
to O 0 3.398464087922548e-08
be O 0 9.421474267412577e-09
non O 0 5.843637129743229e-09
- O 0 5.863883416168392e-05
functional O 0 4.221592917019734e-06
. O 0 8.70907328476278e-08

Our O 0 3.4819024676835397e-06
results O 0 1.737697630233015e-07
indicate O 0 9.406825540736463e-08
that O 0 1.1751387418712511e-08
mutations O 0 3.136912027912331e-07
in O 0 1.4447259388816747e-08
cardiac O 0 1.095349853130756e-05
ion O 0 1.0175351690122625e-06
- O 0 0.006113036535680294
channel O 0 5.7725479564396665e-05
genes O 0 2.498142066542641e-07
contribute O 0 3.1551727897038973e-09
to O 0 2.5386011071049097e-09
the O 0 6.208570546561987e-09
risk O 0 8.78830235251371e-08
of O 0 2.0371626607840199e-10
developing O 0 1.4816682778473478e-06
IVF B-Disease 1 0.999932050704956
. O 0 2.7710381544920892e-08
. O 0 3.5268133302679416e-08

Molecular O 0 6.758909876225516e-06
heterogeneity O 0 2.0247191059752367e-05
in O 0 1.2162011842065112e-07
mucopolysaccharidosis B-Disease 0 0.00021437183022499084
IVA I-Disease 1 0.9487830996513367
in O 0 3.7354991491156397e-06
Australia O 0 1.5264989997376688e-05
and O 0 1.7528019213841617e-07
Northern O 0 1.3537166978494497e-06
Ireland O 0 4.9738766392692924e-05
: O 0 1.4171498641246671e-08
nine O 0 2.0860674965206272e-08
novel O 0 1.262451519323804e-06
mutations O 0 6.800742085033562e-07
including O 0 1.1041196401606612e-08
T312S O 0 1.0189170097874012e-05
, O 0 4.70628958026964e-09
a O 0 4.31313651461096e-09
common O 0 2.7591189777353975e-08
allele O 0 1.5539489695015618e-08
that O 0 1.6098342214831973e-08
confers O 0 5.756511356480587e-08
a O 0 3.4186871289421106e-07
mild O 0 0.0017623426392674446
phenotype O 0 0.002808718243613839
. O 0 3.4291784345441556e-07

Mucopolysaccharidosis B-Disease 1 0.9747071862220764
IVA I-Disease 1 0.9996761083602905
( O 0 0.0041990866884589195
MPS B-Disease 1 0.9999643564224243
IVA I-Disease 1 0.9999992847442627
) O 0 9.248113201465458e-06
is O 0 1.3866441577192745e-06
an O 0 2.5867227577691665e-06
autosomal B-Disease 1 0.999953031539917
recessive I-Disease 1 0.9999895095825195
lysosomal I-Disease 1 0.9999986886978149
storage I-Disease 1 0.9999986886978149
disorder I-Disease 1 0.9999961853027344
caused O 0 0.003805309534072876
by O 0 9.275782986151171e-08
a O 0 1.2926256204082165e-05
genetic B-Disease 1 0.9999992847442627
defect I-Disease 1 0.9999977350234985
in O 0 1.1724575870175613e-06
N O 0 0.058664266020059586
- O 1 0.5838866233825684
acetylgalactosamine O 0 0.01249042246490717
- O 0 0.05779127776622772
6 O 0 1.56528167281067e-05
- O 0 0.03992790728807449
sulfate O 0 0.00010248223406961188
sulfatase O 0 0.00037383573362603784
( O 0 1.5539669107056397e-08
GALNS O 0 3.471553645795211e-05
) O 0 1.021660001043756e-08
. O 0 2.0539806300234886e-08

Previous O 0 9.5443356258329e-06
studies O 0 6.941108665614593e-08
of O 0 2.4074495730275203e-09
patients O 0 2.1872962463476142e-07
from O 0 7.210957941872209e-10
a O 0 3.45220314557082e-07
British O 0 0.05201509967446327
- O 0 0.3856249153614044
Irish O 0 1.1298803656245582e-05
population O 0 3.778350965433219e-09
showed O 0 5.268374820843746e-07
that O 0 2.102467755449311e-09
the O 0 1.1088908680179088e-09
I113F O 0 1.8011076008406235e-07
mutation O 0 6.828493326338503e-08
is O 0 4.089971472609477e-09
the O 0 2.2584210057630116e-09
most O 0 2.1551485041015894e-09
common O 0 3.4525811543062446e-08
single O 0 4.712032023235224e-06
mutation O 0 4.26870883529773e-06
among O 0 2.131709379682434e-06
MPS B-Disease 1 0.9999960660934448
IVA I-Disease 1 1.0
patients O 1 0.7633532285690308
and O 0 3.7042491385363974e-06
produces O 0 2.791400959267776e-07
a O 0 1.020179934130283e-05
severe O 0 0.004128618165850639
clinical O 0 0.00031317005050368607
phenotype O 0 0.0015357339289039373
. O 0 5.398017606239591e-07

We O 0 6.435538580262801e-06
studied O 0 1.7550115671838284e-07
mutations O 0 4.777069193551142e-07
in O 0 1.7793961859524643e-09
the O 0 2.725287995275494e-09
GALNS O 0 1.2667784176301211e-05
gene O 0 1.5413509402151249e-07
from O 0 7.206159557959779e-10
23 O 0 4.2052924698054994e-08
additional O 0 2.4078870453081436e-08
MPS B-Disease 1 0.9999890327453613
IVA I-Disease 1 0.9999998807907104
patients O 0 0.04094375669956207
( O 0 5.58142154716279e-09
15 O 0 1.6446001893655193e-08
from O 0 3.3063907167729667e-09
Australia O 0 1.5935655710563879e-06
, O 0 8.810464580122357e-10
8 O 0 6.8760641624976415e-09
from O 0 4.687116805790481e-10
Northern O 0 1.6751337170717306e-06
Ireland O 0 8.869129487720784e-06
) O 0 2.083891059712073e-09
, O 0 1.9730628242342618e-10
with O 0 3.221576894141265e-10
various O 0 1.6844671213434026e-09
clinical O 0 5.283253631205298e-05
phenotypes O 0 1.9189248632756062e-05
( O 0 3.9205861668278885e-08
severe O 0 1.7355427189613692e-05
, O 0 8.108105298276769e-09
16 O 0 1.648362335515685e-08
cases O 0 1.6527099688801172e-08
; O 0 9.391834865368764e-09
intermediate O 0 6.045742111382424e-07
, O 0 6.28619023501642e-09
4 O 0 8.947015572857708e-08
cases O 0 5.308774007062311e-07
; O 0 1.9512890503392555e-06
mild O 0 0.0006466517224907875
, O 0 5.7356437821454165e-08
3 O 0 3.6144530213277903e-07
cases O 0 4.3559640516832587e-07
) O 0 7.03192171158662e-08
. O 0 1.8598586848384002e-07

We O 0 8.826695557218045e-05
found O 0 3.819727822929053e-08
two O 0 2.188198067187841e-09
common O 0 4.6083233229410325e-08
mutations O 0 2.3931906980578788e-06
that O 0 2.5884972387757443e-07
together O 0 1.4635357814540839e-08
accounted O 0 5.062422019364021e-07
for O 0 3.1235509734273137e-09
32 O 0 9.773439302307452e-08
% O 0 2.774568075292194e-10
of O 0 2.781053165534786e-10
the O 0 2.5210047382984158e-08
44 O 0 2.0549993706708847e-08
unrelated O 0 2.211388938633263e-08
alleles O 0 1.2784118652575671e-08
in O 0 1.8342467100751492e-08
these O 0 6.322301970840272e-08
patients O 0 1.4719616956426762e-06
. O 0 4.0909096554742064e-08

One O 0 1.42053761464922e-06
is O 0 1.005331551340305e-08
the O 0 2.926256570390251e-09
T312S O 0 1.264035631720617e-06
mutation O 0 2.052670424745884e-06
, O 0 2.666689979946568e-09
a O 0 6.934145257986302e-09
novel O 0 3.257776597820339e-06
mutation O 0 7.226177558550262e-07
found O 0 6.280104969391687e-08
exclusively O 0 1.0761159074945681e-08
in O 0 3.335905063295286e-08
milder O 0 5.216438876232132e-05
patients O 0 1.3245920854387805e-05
. O 0 7.044231864483663e-08

The O 0 7.837913926778128e-07
other O 0 4.4011256861153925e-09
is O 0 3.308889162667583e-09
the O 0 3.2461275889517083e-09
previously O 0 1.7474870901423856e-06
described O 0 3.2908853881963296e-06
I113F O 0 4.3235431803623214e-06
that O 0 5.4318697095823154e-08
produces O 0 1.0540929906710517e-08
a O 0 2.7811628910967556e-07
severe O 0 8.703397907083854e-05
phenotype O 0 0.00024068713537417352
. O 0 1.5011379161933291e-07

The O 0 3.9079583302736864e-07
I113F O 0 1.5463849649677286e-06
and O 0 2.3220199096840588e-08
T312S O 0 3.865269704306229e-08
mutations O 0 3.8972199689624176e-08
accounted O 0 5.012488202282839e-08
for O 0 2.9729334549699615e-09
8 O 0 1.6877459074748913e-07
( O 0 2.54402032773271e-09
18 O 0 3.270952220191248e-08
% O 0 1.0518029780470783e-09
) O 0 6.5616867495066344e-09
and O 0 2.9845429594388406e-07
6 O 0 1.6103044799820054e-06
( O 0 3.6945726478165852e-09
14 O 0 1.0785966964022009e-07
% O 0 5.185602502955078e-10
) O 0 1.3801153275760925e-10
of O 0 7.97613711189804e-11
44 O 0 1.0595758048737025e-08
unrelated O 0 2.997109760372041e-08
alleles O 0 3.846192697665174e-08
, O 0 1.893472045821909e-08
respectively O 0 2.3221156197905657e-07
. O 0 1.2000917593013583e-07

The O 0 2.3788092562426755e-07
relatively O 0 2.797665743514699e-08
high O 0 3.477172327848166e-08
residual O 0 7.921324822746101e-07
GALNS O 0 8.602943125879392e-05
activity O 0 4.4428097112358955e-07
seen O 0 4.1024318875315657e-07
when O 0 9.008503276675128e-09
the O 0 1.8763464393334317e-10
T312S O 0 1.4258586311655108e-08
mutant O 0 6.706615707230412e-09
cDNA O 0 8.838004106337394e-09
is O 0 1.2835910112585225e-09
overexpressed O 0 3.515259834330209e-07
in O 0 2.841797019925707e-09
mutant O 0 1.1224582294744323e-06
cells O 0 1.0893060675698507e-07
provides O 0 8.331737522127014e-10
an O 0 1.933284365929211e-10
explanation O 0 1.6416625836512821e-09
for O 0 6.028831878168717e-10
the O 0 5.521777879380352e-08
mild O 0 2.0691168174380437e-05
phenotype O 0 2.950639827759005e-05
in O 0 2.393528006905399e-07
patients O 0 5.819547368446365e-07
with O 0 1.86389503831208e-09
this O 0 3.496258571544786e-08
mutation O 0 3.570876060621231e-06
. O 0 1.2440634122867777e-07

The O 0 4.198800596100227e-08
distribution O 0 3.233591172602246e-08
and O 0 3.310492546759747e-09
relative O 0 4.736138703442805e-10
frequencies O 0 1.6338315145247861e-09
of O 0 1.231982293958822e-10
the O 0 3.417651273096567e-09
I113F O 0 5.260663442641089e-07
and O 0 1.981444519572051e-08
T312S O 0 2.7262773372171978e-08
mutations O 0 5.470547392860681e-08
in O 0 1.9420742791709245e-09
Australia O 0 2.0496678132531088e-08
corresponded O 0 2.3967055007290128e-09
to O 0 1.660396486968807e-09
those O 0 1.8568542536900878e-10
observed O 0 1.0938862260445603e-08
in O 0 4.229737005090328e-09
Northern O 0 2.5700612695800373e-06
Ireland O 0 3.69834597222507e-05
and O 0 1.62212060672573e-07
are O 0 4.374334505730104e-10
unique O 0 7.794663581250916e-09
to O 0 2.9672078127873647e-08
these O 0 2.261835385652944e-09
two O 0 5.043471418275658e-09
populations O 0 6.649504058486855e-08
, O 0 2.6725863744303524e-09
suggesting O 0 2.5324894181721902e-08
that O 0 2.375000285326223e-08
both O 0 5.4135802507460085e-09
mutations O 0 1.8566547055343108e-07
were O 0 4.8087361648185833e-08
probably O 0 8.181729782563707e-08
introduced O 0 1.2868942178556608e-07
to O 0 7.245113664566816e-08
Australia O 0 4.479226589637619e-08
by O 0 1.651551811976404e-10
Irish O 0 1.0611092449153148e-07
migrants O 0 3.1175990677922982e-09
during O 0 4.0497307729481236e-09
the O 0 1.8016146352550777e-09
19th O 0 2.195879005739698e-06
century O 0 1.1390721738280263e-05
. O 0 9.277676582541972e-08

Haplotype O 0 0.00020959209359716624
analysis O 0 6.18971455423889e-07
using O 0 5.767017441371536e-08
6 O 0 2.1154336593554035e-07
RFLPs O 0 7.882982572482433e-06
provides O 0 1.5219748794592647e-09
additional O 0 9.231786168850675e-11
data O 0 4.2039772552016075e-07
that O 0 4.6222236704807074e-08
the O 0 7.270165802708561e-09
I113F O 0 1.309708181906899e-06
mutation O 0 1.350461786842061e-07
originated O 0 3.4343422328220186e-08
from O 0 1.8595017192701846e-10
a O 0 2.671011634092224e-09
common O 0 6.53515996873466e-08
ancestor O 0 3.118462473139516e-06
. O 0 5.323466325535264e-07

The O 0 1.0727780619390614e-07
other O 0 1.9685379992750995e-09
9 O 0 1.1215416861887206e-07
novel O 0 4.6151319565979065e-07
mutations O 0 1.2791235803888412e-06
identified O 0 6.456492087636434e-07
in O 0 1.3278150134965472e-08
these O 0 8.012484897790273e-08
23 O 0 5.030522515880875e-06
patients O 0 5.783352321486745e-07
were O 0 6.749595371502437e-08
each O 0 1.8892971631601085e-09
limited O 0 3.981164979904861e-07
to O 0 4.059275582335431e-08
a O 0 9.458533156703197e-08
single O 0 5.787721602246165e-05
family O 0 2.552533260313794e-06
. O 0 1.1737033389636053e-07

These O 0 7.469141394267353e-08
data O 0 5.517293288903602e-08
provide O 0 8.630205439175143e-10
further O 0 2.3198661047718616e-10
evidence O 0 1.8320639449953546e-09
for O 0 9.879035783866286e-11
extensive O 0 1.947312533445711e-08
allelic O 0 1.57176202719711e-06
heterogeneity O 0 0.00011669712694128975
in O 0 1.346128738077823e-05
MPS B-Disease 1 0.9999730587005615
IVA I-Disease 1 0.9999998807907104
in O 0 6.414063682314008e-05
British O 0 0.2969300448894501
- O 1 0.959747314453125
Irish O 0 0.009546829387545586
patients O 0 4.072555384482257e-06
and O 0 3.1282554324718603e-09
provide O 0 4.71379713040676e-10
evidence O 0 5.139081160621117e-09
for O 0 2.5245630586034906e-10
their O 0 2.4185735636450545e-09
transmission O 0 5.195771518629044e-05
to O 0 3.5580967505666194e-08
Australia O 0 8.777731608233807e-08
by O 0 6.095710602949111e-10
British O 0 2.5368462956976146e-06
- O 0 0.00015073790564201772
Irish O 0 8.327326668222668e-07
migrants O 0 9.844510984180488e-09
. O 0 9.237391962457764e-10
. O 0 6.453196643718684e-09

Identification O 0 6.731556823069695e-07
of O 0 1.7098746862842518e-09
constitutional O 0 9.121652766452826e-08
WT1 O 0 0.002503364346921444
mutations O 0 0.00035308345104567707
, O 0 6.05760703820124e-08
in O 0 7.757764564075842e-08
patients O 0 9.494535788689973e-07
with O 0 5.654512733599404e-07
isolated O 1 0.6723225116729736
diffuse B-Disease 1 0.9998517036437988
mesangial I-Disease 1 0.9999998807907104
sclerosis I-Disease 1 1.0
, O 0 1.7050062524504028e-05
and O 0 4.7552333626299514e-08
analysis O 0 4.22813162259672e-09
of O 0 2.3774102686502374e-09
genotype O 0 0.0001845493243308738
/ O 0 0.0008326928946189582
phenotype O 0 1.7060505342669785e-05
correlations O 0 2.095792069667368e-06
by O 0 2.3589497022413752e-09
use O 0 2.00912300130085e-08
of O 0 1.648405523191343e-09
a O 0 1.3175264257370145e-07
computerized O 0 0.0012392475036904216
mutation O 0 7.782329703331925e-06
database O 0 5.772998974862276e-06
. O 0 1.5843477285670815e-07

Constitutional O 0 4.513540716288844e-06
mutations O 0 8.529361366527155e-06
of O 0 2.167412249676204e-09
the O 0 1.5081340620781702e-08
WT1 O 0 3.139729960821569e-05
gene O 0 3.1290809943129716e-07
, O 0 6.952099451673632e-10
encoding O 0 3.3961164991325177e-09
a O 0 6.513097901006404e-07
zinc O 0 0.27084487676620483
- O 0 0.1793416142463684
finger O 0 0.007360716350376606
transcription O 0 2.2683420866087545e-06
factor O 0 1.1639872177227062e-08
involved O 0 1.1394463150793399e-08
in O 0 2.7714483508134435e-07
renal O 0 0.3097546100616455
and O 0 4.990299203200266e-06
gonadal O 0 0.018688589334487915
development O 0 8.821754136079107e-07
, O 0 1.8154757697175228e-08
are O 0 1.0288597751539896e-09
found O 0 1.4409613058319337e-08
in O 0 1.3024607170564195e-08
most O 0 3.4294789230671086e-08
patients O 0 4.5364498646449647e-07
with O 0 1.443532710254658e-06
Denys B-Disease 1 0.9999892711639404
- I-Disease 1 0.9999986886978149
Drash I-Disease 1 0.9999946355819702
syndrome I-Disease 1 0.9999969005584717
( O 0 3.315938954528974e-07
DDS B-Disease 1 0.9999994039535522
) O 0 3.642023500560754e-07
, O 0 1.0149111773216646e-07
or O 0 2.6653062832338037e-06
diffuse B-Disease 1 0.9955859184265137
mesangial I-Disease 1 0.9999997615814209
sclerosis I-Disease 1 0.9999998807907104
( O 0 4.266715404810384e-05
DMS B-Disease 1 0.9991664886474609
) O 0 5.7403500619557235e-08
associated O 0 1.422881723556202e-07
with O 0 2.6504249035497196e-06
pseudohermaphroditism B-Disease 1 0.9999997615814209
and O 0 0.004760447423905134
/ O 0 0.1063767671585083
or O 0 5.235142452875152e-05
Wilms B-Disease 1 0.9991775155067444
tumor I-Disease 1 0.7609214186668396
( O 0 5.366466098166711e-07
WT B-Disease 1 0.9999618530273438
) O 0 5.350227283429376e-08
. O 0 4.262848563030275e-08

Most O 0 7.252260729728732e-07
mutations O 0 7.66635566833429e-05
in O 0 1.2546847756311763e-06
DDS B-Disease 1 0.9999997615814209
patients O 0 0.48605602979660034
lie O 0 0.0008156251278705895
in O 0 2.360907691567604e-09
exon O 0 2.004133875743719e-06
8 O 0 2.666900797976268e-07
or O 0 1.028001062053363e-08
exon O 0 1.6108973568407237e-06
9 O 0 1.2898494787805248e-06
, O 0 1.3505417895132155e-09
encoding O 0 5.908396971676666e-08
zinc O 1 0.6157295107841492
finger O 1 0.9418482184410095
2 O 0 9.279440746468026e-06
or O 0 3.04016930385842e-06
zinc O 0 0.29692932963371277
finger O 1 0.8439749479293823
3 O 0 4.360371349321213e-06
, O 0 2.87402475152021e-08
respectively O 0 1.288762234707974e-07
, O 0 3.237409229583932e-09
with O 0 4.465269043407716e-09
a O 0 3.6300119177212764e-07
hot O 0 0.0049014221876859665
spot O 0 0.00015641159552615136
( O 0 1.2125173087795815e-09
R394W O 0 3.2057780430250205e-08
) O 0 3.986849739234799e-11
in O 0 1.1617193318436136e-10
exon O 0 5.61656349873374e-07
9 O 0 8.280002816718479e-07
. O 0 8.985494304170061e-08

We O 0 2.8560625651152804e-06
analyzed O 0 2.6142549458540998e-08
a O 0 1.4249389446163718e-09
series O 0 4.69720305318333e-07
of O 0 6.405676877818678e-09
24 O 0 3.1583467716700397e-06
patients O 0 1.1048169881178183e-06
, O 0 8.948940255493198e-09
10 O 0 1.7669444574153204e-08
with O 0 1.312557458277297e-07
isolated B-Disease 0 0.19418101012706757
DMS I-Disease 1 0.999381422996521
( O 0 8.370244586330955e-08
IDMS B-Disease 0 0.01458107028156519
) O 0 1.6499821953175342e-08
, O 0 4.955534205208778e-09
10 O 0 4.014247156902684e-09
with O 0 8.315557806781726e-07
DDS B-Disease 1 1.0
, O 0 3.982713315053843e-05
and O 0 9.493014658801258e-07
4 O 0 1.4690643865833408e-06
with O 0 7.041529897833243e-06
urogenital B-Disease 1 0.9997941851615906
abnormalities I-Disease 1 0.99985671043396
and O 0 1.5713238099124283e-05
/ O 0 0.03135455399751663
or O 0 7.017974712653086e-05
WT B-Disease 1 0.999976634979248
. O 0 6.853551894892007e-07

We O 0 2.7933107048738748e-05
report O 0 4.912042328442112e-08
WT1 O 0 5.852205958944978e-06
heterozygous O 0 1.8978438731664937e-07
mutations O 0 1.8192231436842121e-06
in O 0 3.123761160850336e-08
16 O 0 2.4825274067552527e-06
patients O 0 4.064833774464205e-06
, O 0 1.3143294452788723e-08
4 O 0 3.0208701673473115e-07
of O 0 1.7938251772875446e-08
whom O 0 2.754103434199351e-06
presented O 0 7.311190870495921e-07
with O 0 2.8943020424776478e-06
IDMS B-Disease 1 0.9519879817962646
. O 0 6.173149813548662e-07

One O 0 5.364366643334506e-06
male O 0 4.454342615645146e-06
and O 0 1.2048174369283515e-07
two O 0 6.852826572867343e-08
female O 0 4.064299719175324e-05
IDMS B-Disease 1 0.9173808693885803
patients O 0 1.3694958397536539e-05
with O 0 3.075983556755091e-07
WT1 O 1 0.8427414298057556
mutations O 0 0.0228293314576149
underwent O 0 0.00148761214222759
normal O 0 2.991430665133521e-05
puberty O 0 0.002104764571413398
. O 0 2.7201957664146903e-07

Two O 0 8.417491699219681e-06
mutations O 0 0.00015970345702953637
associated O 0 1.2611699276021682e-06
with O 0 3.081074453348265e-07
IDMS B-Disease 1 0.5960538387298584
are O 0 4.3993484410975725e-08
different O 0 1.7795455109492764e-09
from O 0 2.999893222721539e-09
those O 0 1.3804774212644588e-08
described O 0 7.517443464166718e-06
in O 0 7.73917963670101e-06
DDS B-Disease 1 0.9999997615814209
patients O 0 0.009208451956510544
. O 0 1.192457119714163e-07

No O 0 8.607906238466967e-06
WT1 O 0 6.81053934386e-05
mutations O 0 1.276662624150049e-05
were O 0 2.6756154625218187e-07
detected O 0 2.041464767899015e-06
in O 0 1.081956835236042e-08
the O 0 5.444565687184877e-08
six O 0 4.547612491023756e-07
other O 0 2.5112558432738297e-07
IDMS B-Disease 1 0.989365816116333
patients O 0 6.606272108911071e-06
, O 0 1.4966594630294594e-09
suggesting O 0 5.896441024333399e-08
genetic O 0 1.9036531284655211e-06
heterogeneity O 0 4.906825779471546e-06
of O 0 1.197053478563248e-07
this O 0 4.1675793909234926e-05
disease O 1 0.6103318333625793
. O 0 4.7060854058145196e-07

We O 0 4.3724558054236695e-06
analyzed O 0 7.222292310871126e-07
genotype O 0 6.416504220396746e-06
/ O 0 2.8221047614351846e-05
phenotype O 0 3.0612857244705083e-06
correlations O 0 1.2050260920659639e-05
, O 0 3.1586608884026646e-08
on O 0 1.2160712969944143e-07
the O 0 3.802650194728585e-09
basis O 0 1.0681673323631458e-08
of O 0 2.3271531368607157e-09
the O 0 2.0114414667204983e-07
constitution O 0 6.911410110888028e-08
of O 0 2.884439631589686e-10
a O 0 7.354436348805393e-08
WT1 O 0 8.200162119464949e-05
mutation O 0 9.408154255652335e-08
database O 0 5.990289508872593e-08
of O 0 6.52926102073792e-10
84 O 0 6.517198585243023e-07
germ O 0 0.02579987421631813
- O 0 0.24458935856819153
line O 0 0.029943864792585373
mutations O 0 6.49314586098626e-07
, O 0 6.423903631258554e-10
to O 0 2.785416619577319e-10
compare O 0 2.7522123247081254e-08
the O 0 1.1453069603817312e-09
distribution O 0 1.4918171586941753e-07
and O 0 3.072591141517478e-07
type O 0 1.7749586049831123e-06
of O 0 3.9640686289033056e-09
mutations O 0 2.1893738448852673e-06
, O 0 5.035445393986038e-09
according O 0 4.648096074699737e-10
to O 0 1.4932378666898671e-09
the O 0 5.637946998149346e-09
different O 0 1.9454587629752496e-07
symptoms O 0 2.4028913685469888e-05
. O 0 4.950851106855225e-08

This O 0 7.443896521408533e-08
demonstrated O 0 3.2923463066936165e-08
( O 0 2.499952744816625e-10
1 O 0 7.8842736783713e-09
) O 0 3.8498457755054005e-09
the O 0 1.4879050880267641e-08
association O 0 2.584414282580383e-08
between O 0 6.835569621443938e-08
mutations O 0 1.3418570006251684e-06
in O 0 8.941518636618184e-09
exons O 0 8.213865839934442e-06
8 O 0 5.182294444239233e-06
and O 0 1.1835016948680277e-06
9 O 0 7.048167844914133e-06
and O 0 2.8665492664003978e-06
DMS B-Disease 1 0.768678605556488
; O 0 7.641411059466918e-08
( O 0 7.69254326904445e-10
2 O 0 2.863328631974582e-07
) O 0 1.5769666461551424e-08
among O 0 7.0689534226175965e-09
patients O 0 1.8787160627198318e-07
with O 0 6.955314546530644e-08
DMS B-Disease 1 0.7560983896255493
, O 0 1.6451765505465232e-09
a O 0 1.473154515041486e-10
higher O 0 1.7726813072993508e-10
frequency O 0 1.0778744119477324e-08
of O 0 1.008224406739977e-10
exon O 0 1.819894578147796e-06
8 O 0 8.451520443486515e-07
mutations O 0 1.542799623166502e-06
among O 0 1.5607334091782832e-08
46 O 0 4.893470304523362e-06
, O 0 7.097029310898506e-07
XY O 0 0.0043662916868925095
patients O 0 5.416256954049459e-07
with O 0 2.0224874219820776e-08
female O 0 1.831686176956282e-06
phenotype O 0 1.9026695099455537e-06
than O 0 7.460623230315377e-09
among O 0 5.5618465388818095e-09
46 O 0 1.2305919199206983e-06
, O 0 5.701188001694391e-07
XY O 0 0.006914294790476561
patients O 0 4.949624212713388e-07
with O 0 5.193612651055446e-09
sexual O 0 4.619381286374846e-07
ambiguity O 0 1.6455499007861363e-06
or O 0 5.43014948561904e-07
male O 0 4.999454176868312e-06
phenotype O 0 1.7925354768522084e-05
; O 0 5.351359888550178e-08
and O 0 2.5825744387475424e-07
( O 0 1.7639431026950092e-09
3 O 0 6.723884382608958e-08
) O 0 2.282307454137822e-09
statistically O 0 1.976507313372622e-08
significant O 0 1.271163063698566e-09
evidence O 0 1.654789230087772e-07
that O 0 2.2358183571213885e-07
mutations O 0 7.177906695687852e-07
in O 0 1.476985111992235e-08
exons O 0 3.571229535737075e-05
8 O 0 1.310918105446035e-05
and O 0 6.830759389231389e-07
9 O 0 1.23371046356624e-06
preferentially O 0 6.753690513505717e-07
affect O 0 1.4854315111278993e-07
amino O 0 5.2615963141988686e-08
acids O 0 9.939982170692474e-09
with O 0 1.0346310613806864e-10
different O 0 4.938357014983019e-11
functions O 0 7.789892286780287e-09
. O 0 1.40463667364088e-08
. O 0 4.363231198567519e-08

The O 0 7.049472969811177e-07
185delAG O 0 9.368627615913283e-06
BRCA1 O 0 8.681112376507372e-06
mutation O 0 3.929128524760017e-07
originated O 0 3.824349548153805e-08
before O 0 4.601803826886908e-09
the O 0 1.652497028103994e-10
dispersion O 0 1.9196657774500636e-07
of O 0 5.669226754712042e-10
Jews O 0 7.2289350327992e-07
in O 0 2.1204911604399967e-08
the O 0 3.189244424106619e-08
diaspora O 0 2.4037234425122733e-07
and O 0 1.4067083498048305e-07
is O 0 4.006682097212888e-09
not O 0 2.633607110169578e-09
limited O 0 5.134006553220161e-09
to O 0 3.5672753639914845e-09
Ashkenazim O 0 7.256083790707635e-06
. O 0 3.883611299215772e-08

The O 0 2.3549549155177374e-07
185delAG O 0 4.349996288510738e-06
mutation O 0 1.3525141184800304e-06
in O 0 1.0488665935781682e-08
BRCA1 O 0 2.210011189163197e-05
is O 0 4.230126293691683e-08
detected O 0 9.014296438181191e-07
in O 0 6.549995212878912e-09
Ashkenazi O 0 5.376202352636028e-06
Jews O 0 1.7564262577707268e-07
both O 0 2.1599642963110455e-08
in O 0 2.2060623905417742e-07
familial B-Disease 1 0.9904885292053223
breast I-Disease 1 0.9999988079071045
and I-Disease 1 0.9999973773956299
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.955989086534828e-05
in O 0 5.707837047452813e-08
the O 0 3.563231132375222e-08
general O 0 2.5273262593827894e-08
population O 0 2.900607398714783e-08
. O 0 7.084871356255462e-08

All O 0 6.863172643534199e-07
tested O 0 3.004366817549453e-06
Ashkenazi O 0 1.6590603308941354e-06
mutation O 0 2.0736435146773147e-07
carriers O 0 5.44639355837262e-08
share O 0 3.573303786197357e-08
the O 0 3.1669780131693415e-09
same O 0 3.8196530383061145e-09
allelic O 0 8.881926305548404e-07
pattern O 0 0.00017737604503054172
at O 0 1.3189392689128e-07
the O 0 3.95779977679922e-08
BRCA1 O 0 0.0001515519106760621
locus O 0 1.9151935703121126e-05
. O 0 6.011395612404158e-07

Our O 0 2.0899599348922493e-06
previous O 0 5.429797766964839e-08
study O 0 9.706019099553487e-09
showed O 0 2.0942465539519617e-07
that O 0 2.042470415020148e-09
this O 0 5.282597137501455e-10
Ashkenazi O 0 9.60116449277848e-06
mutation O 0 2.5090421331697144e-06
also O 0 4.0603487150292494e-07
occurs O 0 3.782489876869022e-09
in O 0 1.085857403992918e-09
Iraqi O 0 1.309262831483693e-08
Jews O 0 1.4800815684168356e-08
with O 0 5.168332428695521e-10
a O 0 3.0939513173677824e-09
similar O 0 2.4743952664607605e-08
allelic O 0 8.579648238082882e-06
pattern O 0 0.0007898738840594888
. O 0 3.587963988138654e-07

We O 0 1.5431249266839586e-05
extended O 0 2.115001684899198e-08
our O 0 1.0069853839667076e-09
analysis O 0 4.491858829336337e-10
to O 0 1.5481665949224066e-10
other O 0 3.8211794839426716e-11
non O 0 1.5813604870018594e-09
- O 0 1.281038476008689e-05
Ashkenazi O 0 4.277419236586866e-07
subsets O 0 2.1843876041316435e-08
354 O 0 8.209237734035923e-09
of O 0 1.3060913461870882e-10
Moroccan O 0 2.1329130959202303e-06
origin O 0 1.7287840492485884e-08
, O 0 4.5887157962276603e-10
200 O 0 1.7429430121396194e-10
Yemenites O 0 3.601680589326861e-07
and O 0 6.221927972838159e-10
150 O 0 2.5060206687577136e-10
Iranian O 0 8.243442373156995e-09
Jews O 0 6.109287653544015e-08
. O 0 4.0514009924663696e-08

Heteroduplex O 0 0.0003752682532649487
analysis O 0 4.0772124521026853e-07
complemented O 0 1.2774690105743502e-07
by O 0 4.856097746142041e-10
direct O 0 7.903918630702833e-10
DNA O 0 7.216370931928395e-07
sequencing O 0 1.4890385102717119e-07
of O 0 1.5801121522329709e-09
abnormally O 0 9.287694524573453e-07
migrating O 0 1.6287295068195817e-08
bands O 0 4.232515138369308e-08
were O 0 1.1583065173681462e-08
employed O 0 2.459316021941049e-07
. O 0 2.5723702279378813e-08

Four O 0 1.3489827210833027e-07
of O 0 3.1050462201420714e-10
Moroccan O 0 1.3080941698717652e-06
origin O 0 1.0923120186134838e-08
( O 0 3.558066064002219e-10
1 O 0 4.829037170139827e-09
. O 0 1.7813386321563485e-09
1 O 0 2.108130736644398e-08
% O 0 6.33728269860967e-09
) O 0 1.4491692290619085e-08
and O 0 1.683969088617232e-07
none O 0 1.6828044735461845e-08
of O 0 1.428879237153069e-10
the O 0 1.0899166902333945e-08
Yemenites O 0 3.9253859540622216e-06
or O 0 4.249978147186084e-09
Iranians O 0 1.498082546902424e-08
was O 0 2.0867917172040507e-08
a O 0 3.989856778296996e-10
carrier O 0 4.7691305127273154e-08
of O 0 1.6479992370754815e-10
the O 0 9.034520687123404e-09
185delAG O 0 3.4375975701550487e-06
mutation O 0 2.076425857922004e-07
. O 0 1.860110110385449e-08

BRCA1 O 0 0.00028727337485179305
allelic O 0 1.9127859559375793e-05
patterns O 0 0.0022987383417785168
were O 0 9.621619483368704e-07
determined O 0 1.3217641026130877e-06
for O 0 1.1306201308514119e-08
four O 0 1.573496533069374e-08
of O 0 9.50841294589111e-10
these O 0 1.4075491883147606e-08
individuals O 0 5.656729529235349e-10
and O 0 5.836841676654103e-09
for O 0 1.689160339379825e-10
12 O 0 6.249390449575287e-10
additional O 0 1.1890621820498382e-10
non O 0 8.474080459563993e-08
- O 0 0.001110709155909717
Ashkenazi O 0 9.085498277272563e-06
185delAG O 0 9.337449569102318e-08
mutation O 0 1.118748826911542e-08
carriers O 0 3.6790549273746365e-08
who O 0 1.0485790880920831e-05
had O 0 0.07125185430049896
breast B-Disease 1 0.9999707937240601
/ I-Disease 1 0.9999946355819702
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999977350234985
. O 0 5.2618247536884155e-06

Six O 0 8.582373084209394e-06
non O 0 7.578170766464609e-07
- O 0 0.012875777669250965
Ashkenazi O 0 0.00027660373598337173
individuals O 0 6.09139005902648e-09
shared O 0 9.449404814176887e-09
the O 0 7.844717764271536e-09
common O 0 9.129206546276691e-08
Ashkenazi O 0 9.95222944766283e-06
haplotype O 0 7.01025637681596e-05
, O 0 8.91616451781374e-08
four O 0 8.312950683375675e-08
had O 0 2.0013701487187063e-06
a O 0 3.7780480965921015e-09
closely O 0 2.764361113349878e-07
related O 0 1.1851818726427155e-07
pattern O 0 0.12344472855329514
, O 0 1.2322748261794914e-06
and O 0 3.753328883249196e-07
the O 0 4.5316891572610984e-08
rest O 0 2.3484935240958293e-07
( O 0 1.98938843176677e-09
n O 0 4.426553277880885e-05
= O 0 7.426621596096084e-05
6 O 0 1.5501869654599432e-07
) O 0 6.253468298744735e-10
displayed O 0 1.6068186781126315e-08
a O 0 4.341355275272463e-09
distinct O 0 2.1016253981542832e-07
BRCA1 O 0 7.839496538508683e-05
allelic O 0 1.4640735571447294e-05
pattern O 0 0.0035362637136131525
. O 0 8.156711714946141e-07

We O 0 7.30122428649338e-06
conclude O 0 6.063613113838073e-07
that O 0 3.6977523265591117e-09
the O 0 7.336216634179493e-10
185delAG O 0 1.5972216260706773e-06
BRCA1 O 0 2.47016032517422e-05
mutation O 0 1.8106951529262005e-06
occurs O 0 2.2453308545777872e-08
in O 0 8.379628657628757e-10
some O 0 7.624152420504515e-10
non O 0 3.930803700313845e-07
- O 0 0.1860678791999817
Ashkenazi O 0 0.0007824864005669951
populations O 0 1.2785183400865208e-07
at O 0 3.076604926377513e-08
rates O 0 1.8161394166327227e-07
comparable O 0 7.441551375109157e-09
with O 0 9.561388347734123e-10
that O 0 6.865933155353332e-09
of O 0 2.2293100698789203e-09
Ashkenazim O 0 0.0002670040703378618
. O 0 6.269453223239907e-08

The O 0 3.0445690413216653e-07
majority O 0 1.4771484480036179e-08
of O 0 5.12510089922813e-10
Jewish O 0 4.6473562065330043e-07
185delAG O 0 6.075002602301538e-06
mutation O 0 5.301164947013604e-07
carriers O 0 2.4117210273288947e-07
have O 0 8.331188894317165e-08
a O 0 1.7769483662277707e-08
common O 0 1.0508734504810491e-07
allelic O 0 4.6515024223481305e-06
pattern O 0 0.020109888166189194
, O 0 6.979714584076646e-08
supporting O 0 2.560831902087557e-08
the O 0 2.843766822024918e-08
founder O 0 1.4395267271538614e-06
effect O 0 3.0819318652675065e-08
notion O 0 9.684904256346272e-08
, O 0 1.4883932308862313e-08
but O 0 8.41891445446663e-09
dating O 0 1.51801188508216e-07
the O 0 2.8579518751570276e-09
mutations O 0 5.547461867649872e-08
origin O 0 1.6124762636238188e-09
to O 0 3.0045830268221607e-09
an O 0 1.5702689148966442e-10
earlier O 0 2.7940396662984313e-08
date O 0 9.461402328270196e-08
than O 0 8.562358599917275e-10
currently O 0 4.7381374379540375e-09
estimated O 0 3.852977314977579e-08
. O 0 8.993278299840313e-08

However O 0 2.2379770598490722e-05
, O 0 3.4677785087922075e-09
the O 0 1.3171413959511824e-10
different O 0 9.854608101766971e-11
allelic O 0 3.777369954605092e-07
pattern O 0 0.0005218657897785306
at O 0 3.369098919847602e-07
the O 0 6.528831164587245e-08
BRCA1 O 0 7.487235416192561e-05
locus O 0 3.092684210059815e-06
even O 0 2.4874088921933435e-07
in O 0 1.6264284363742831e-09
some O 0 2.000666021739761e-10
Jewish O 0 2.426761227525276e-07
mutation O 0 5.267390292829077e-07
carriers O 0 5.089841010885721e-07
, O 0 2.9704072090908085e-08
might O 0 1.3600401871372014e-07
suggest O 0 9.094274133758518e-08
that O 0 7.662498191507439e-09
the O 0 2.0861579130837526e-09
mutation O 0 1.0284858831255406e-07
arose O 0 4.203414061265676e-09
independently O 0 1.5100162897851988e-08
. O 0 1.5609825654294696e-09
. O 0 1.73015965998502e-08

Crystal O 0 0.003988109063357115
structure O 0 4.712427653430495e-06
of O 0 5.388403501171979e-09
the O 0 9.197717645292869e-07
hemochromatosis B-Disease 1 0.9999996423721313
protein O 0 0.0029563787393271923
HFE O 0 0.3306210935115814
and O 0 1.3593365792985423e-06
characterization O 0 2.523579496482853e-06
of O 0 4.869351588610016e-10
its O 0 1.360729195987176e-09
interaction O 0 2.633973705812309e-09
with O 0 8.22367152153447e-09
transferrin O 0 1.3448223398881964e-05
receptor O 0 1.012508619169239e-06
. O 0 8.133231688134401e-08

HFE O 0 0.0277777798473835
is O 0 5.117087198414083e-07
an O 0 6.797070462027932e-09
MHC O 0 9.037554264068604e-06
- O 0 0.0002022414410021156
related O 0 4.702729654582072e-07
protein O 0 1.208088974635757e-06
that O 0 6.79663259006702e-08
is O 0 5.1309916315744886e-09
mutated O 0 1.1318454653519439e-06
in O 0 1.3611067117835773e-07
the O 0 3.817994183918927e-06
iron B-Disease 1 0.9999831914901733
- I-Disease 1 0.999996542930603
overload I-Disease 1 0.9999833106994629
disease I-Disease 1 0.999943733215332
hereditary B-Disease 1 0.9999996423721313
hemochromatosis I-Disease 1 1.0
. O 0 0.00025886218645609915

HFE O 0 0.0008887358708307147
binds O 0 4.541793259704718e-06
to O 0 4.5508400603466725e-08
transferrin O 0 2.0880731881334214e-06
receptor O 0 1.1135548305674092e-07
( O 0 2.921114905518607e-09
TfR O 0 0.0037110731936991215
) O 0 1.1478378247886667e-08
and O 0 1.4160340455759979e-08
reduces O 0 5.42175691009561e-08
its O 0 6.550291420381882e-10
affinity O 0 8.692690123268676e-09
for O 0 4.665500696887648e-08
iron O 0 0.06401573866605759
- O 0 0.004506479948759079
loaded O 0 3.7960364807076985e-06
transferrin O 0 2.4894218313420424e-06
, O 0 1.5258174723697948e-09
implicating O 0 6.018818794473191e-07
HFE O 0 0.0009494703263044357
in O 0 5.799104201287264e-07
iron O 0 0.03266730532050133
metabolism O 0 0.0001495469332439825
. O 0 1.0948718198733332e-07

The O 0 1.336654804617865e-06
2 O 0 1.2853846556026838e-06
. O 0 2.3940484084050695e-07

6 O 0 0.00011246989743085578
A O 0 4.643272404791787e-06
crystal O 0 0.016618767753243446
structure O 0 5.127720578457229e-05
of O 0 3.090703160069097e-08
HFE O 0 0.23109455406665802
reveals O 0 3.08858543576207e-05
the O 0 1.2833321960670219e-08
locations O 0 2.1839423425262794e-07
of O 0 5.063474759481323e-07
hemochromatosis B-Disease 1 0.9999998807907104
mutations O 1 0.8574564456939697
and O 0 7.627760624018265e-06
a O 0 1.2189316294097807e-06
patch O 1 0.995826780796051
of O 0 1.1101997188234236e-07
histidines O 0 0.009672079235315323
that O 0 1.292838305744226e-06
could O 0 5.19002128385182e-07
be O 0 1.5669188169198378e-09
involved O 0 2.0735193562160248e-09
in O 0 2.3454985864646005e-07
pH O 0 0.0005340922507457435
- O 0 0.0018817289965227246
dependent O 0 9.492489425610984e-07
interactions O 0 1.8450703009875724e-07
. O 0 3.90084942125668e-08

We O 0 7.59504473535344e-05
also O 0 7.847280159012371e-08
demonstrate O 0 6.770522276156044e-08
that O 0 2.516647334971367e-08
soluble O 0 6.591407782252645e-06
TfR O 0 0.3602926731109619
and O 0 9.17662816846132e-07
HFE O 0 0.0017522589769214392
bind O 0 9.501451131654903e-06
tightly O 0 1.8891914805863053e-05
at O 0 1.0911109882272285e-07
the O 0 3.968963380174273e-09
basic O 0 2.558052472068084e-07
pH O 0 1.2871608987552463e-06
of O 0 1.5196768843317443e-10
the O 0 8.149999786155604e-09
cell O 0 9.312665497418493e-05
surface O 0 0.00151916837785393
, O 0 3.0162922826093563e-08
but O 0 1.0219644508424608e-07
not O 0 1.1235838037748636e-08
at O 0 1.440856767231935e-08
the O 0 1.5248582840854397e-08
acidic O 0 5.570890607486945e-06
pH O 0 5.899647135265695e-07
of O 0 2.196946624621887e-09
intracellular O 0 1.4811491382715758e-05
vesicles O 0 0.0001415679871570319
. O 0 5.538802270166343e-07

TfR O 1 0.6142115592956543
HFE O 0 0.005117335356771946
stoichiometry O 0 4.176467700744979e-05
( O 0 4.66569645141135e-08
2 O 0 4.6419167176736664e-08
1 O 0 1.1755647122413393e-08
) O 0 6.174391553592784e-10
differs O 0 2.229311313328708e-08
from O 0 2.928199460683345e-09
TfR O 0 0.006442172918468714
transferrin O 0 1.3954579571873182e-06
stoichiometry O 0 2.6093937322002603e-07
( O 0 1.2130145776723111e-09
2 O 0 3.8322795603562554e-08
2 O 0 6.802363827773661e-07
) O 0 1.0336457911819252e-08
, O 0 1.213956712931008e-09
implying O 0 5.781232825796678e-09
a O 0 3.973187612249518e-10
different O 0 4.531795078088763e-11
mode O 0 3.788137803439895e-08
of O 0 5.00865807162576e-11
binding O 0 9.098764408577154e-09
for O 0 3.4387583891515305e-09
HFE O 0 0.0011513249482959509
and O 0 4.369369435153203e-07
transferrin O 0 1.9523463379300665e-06
to O 0 7.004520341524767e-08
TfR O 0 0.00485739903524518
, O 0 1.2592618503504127e-08
consistent O 0 6.482077452574231e-08
with O 0 2.502869245191164e-09
our O 0 3.500514100807095e-09
demonstration O 0 2.054960290820418e-08
that O 0 8.40781044786354e-09
HFE O 0 6.73791000735946e-05
, O 0 1.1694304191678384e-08
transferrin O 0 1.4262062677516951e-06
, O 0 1.679364025619634e-08
and O 0 1.282016484083215e-07
TfR O 0 0.0025286998134106398
form O 0 7.511643929092315e-08
a O 0 1.092368790978071e-07
ternary O 0 3.165332236676477e-05
complex O 0 0.00014892223407514393
. O 0 2.480406919858069e-06

Identification O 0 1.8098940017807763e-06
of O 0 9.035640680110646e-09
three O 0 4.118672336517193e-08
novel O 0 8.149369932652917e-06
mutations O 0 1.5953559341141954e-05
and O 0 6.033875621369589e-08
a O 0 7.0689267772650055e-09
high O 0 9.662320366032873e-08
frequency O 0 1.9213379687244014e-07
of O 0 7.427367054724243e-10
the O 0 1.523183890128621e-08
Arg778Leu O 0 3.023148929059971e-05
mutation O 0 2.3268819404620444e-07
in O 0 4.4872820126329316e-08
Korean O 0 4.725307007902302e-05
patients O 0 6.677477699668088e-07
with O 0 2.624285002639226e-07
Wilson B-Disease 0 0.2172781229019165
disease I-Disease 0 0.2969217598438263
. O 0 1.9410424556554062e-07

Four O 0 3.4700215110206045e-06
mutations O 0 2.2863465346745215e-05
- O 0 0.0011116322129964828
- O 0 0.00710122799500823
R778L O 0 3.2603998079139274e-06
, O 0 1.2163485774152605e-09
A874V O 0 2.00932994687264e-08
, O 0 2.2134374888516106e-10
L1083F O 0 1.0075045686619433e-08
, O 0 3.593325637041289e-10
and O 0 1.1266133581600002e-09
2304delC O 0 2.0110367415782093e-07
- O 0 4.4513551983982325e-05
- O 0 0.00013679495896212757
in O 0 2.0102845610381337e-08
the O 0 3.4221780964571735e-09
copper O 0 6.04165416007163e-06
- O 0 4.119790446566185e-06
transporting O 0 8.302236231827465e-09
enzyme O 0 2.797991349723361e-08
, O 0 5.453830720369979e-10
P O 0 4.458805051399395e-06
- O 0 1.1962735698034521e-05
type O 0 7.330149855988566e-06
ATPase O 0 4.935011929774191e-06
( O 0 1.4450669549859185e-09
ATP7B O 0 5.695754225598648e-06
) O 0 4.960042931934083e-10
, O 0 2.843194291113349e-10
were O 0 3.883661392478643e-09
identified O 0 1.4344654175602045e-07
in O 0 1.1098843089030197e-07
Korean O 0 0.0003794408112298697
Patients O 0 8.125848580675665e-07
with O 0 4.0373777210334083e-07
Wilson B-Disease 0 0.1382693499326706
disease I-Disease 0 0.1279316544532776
. O 0 1.2893485745735234e-07

Arg778Leu O 0 0.018924426287412643
, O 0 1.8412997349059879e-07
the O 0 2.698906431675141e-09
most O 0 1.1428694657311667e-09
frequently O 0 4.2522103171904746e-08
reported O 0 6.273173625004347e-08
mutation O 0 3.153826710899921e-08
of O 0 2.378960639592975e-10
this O 0 3.721845720505712e-09
enzyme O 0 1.870617154509091e-07
, O 0 1.7713919220341268e-08
was O 0 1.8980672393809073e-05
found O 0 1.6855774731538986e-07
in O 0 2.0614651319306176e-08
six O 0 2.66601514198328e-08
of O 0 8.222098557553181e-10
eight O 0 9.194702954573586e-08
unrelated O 0 3.5633269135360024e-07
patients O 0 2.6224361704407784e-07
studied O 0 2.083097250249466e-08
, O 0 3.309973128917676e-10
an O 0 2.8409866473233514e-11
allele O 0 2.891745509714383e-09
frequency O 0 5.992495033524392e-08
of O 0 1.5945172959774823e-09
37 O 0 7.301964615180623e-07
. O 0 6.456178169855775e-08

5 O 0 4.577558684104588e-06
% O 0 2.199014659254317e-08
, O 0 6.394043516877446e-09
which O 0 6.370318050841206e-09
is O 0 3.9083822289676107e-10
considerably O 0 8.019254593705227e-09
higher O 0 4.665293928951542e-09
than O 0 1.7222633319491365e-09
those O 0 1.3039711532769616e-09
in O 0 2.6430624355811005e-09
other O 0 1.1380926201454145e-09
Asian O 0 9.528354638632663e-08
populations O 0 5.1436540360327854e-08
. O 0 2.746789995455856e-08

The O 0 3.544895150753291e-07
novel O 0 1.4445707563481847e-07
single O 0 2.4150853761284452e-08
nucleotide O 0 5.148856274672653e-08
deletion O 0 2.8002768885926344e-06
, O 0 9.762648467415147e-09
2304delC O 0 1.5421758234879235e-06
, O 0 3.004945980933371e-08
was O 0 1.9518363387760473e-06
found O 0 3.768838041651179e-08
in O 0 9.091322361598486e-09
one O 0 3.1224035978993925e-07
patient O 0 2.417890209471807e-05
. O 0 6.535135099738909e-08

Since O 0 1.264337015527417e-06
a O 0 7.74850406060068e-09
mutation O 0 5.877083708583086e-08
at O 0 2.3227495482558425e-09
cDNA O 0 8.117284266973002e-08
nucleotide O 0 4.5940277004774543e-07
2302 O 0 0.00012209912529215217
( O 0 5.0143311725037165e-09
2302insC O 0 4.0361173887504265e-06
) O 0 1.611425481939932e-08
had O 0 5.379551566875307e-06
been O 0 1.960255247013265e-07
previously O 0 1.5784825109221856e-06
described O 0 3.0114922992652282e-05
, O 0 1.3029476164660991e-08
this O 0 2.460214920674275e-09
region O 0 9.561301972382807e-09
of O 0 2.338141347202338e-10
the O 0 9.498773323457499e-09
ATP7B O 0 7.185636059148237e-05
gene O 0 1.9974402221123455e-06
may O 0 1.834311660786625e-06
be O 0 1.7132020246890534e-08
susceptible O 0 1.3732432080360013e-06
to O 0 1.9418083141431453e-08
gene O 0 6.830212896602461e-06
rearrangements O 0 0.026519332081079483
causing O 0 0.01767159439623356
Wilson B-Disease 1 0.540198802947998
disease I-Disease 1 0.73433518409729
. O 0 6.266440664148831e-07

Disruption O 0 3.609877239796333e-05
of O 0 7.130033785607282e-10
splicing O 0 6.29602027402143e-07
regulated O 0 5.205809543440409e-07
by O 0 2.3828217177168654e-09
a O 0 9.864415062565968e-09
CUG O 0 0.00027233108994551003
- O 0 4.428305692272261e-05
binding O 0 2.014157729490762e-07
protein O 0 8.250050882452342e-07
in O 0 7.4407262218301184e-06
myotonic B-Disease 1 0.9999953508377075
dystrophy I-Disease 1 0.9999980926513672
. O 0 5.746326223743381e-06

Myotonic B-Disease 1 0.9999783039093018
dystrophy I-Disease 1 0.999998927116394
( O 0 0.0075319912284612656
DM B-Disease 1 0.9999991655349731
) O 0 6.531716644531116e-05
is O 0 1.681228241068311e-06
caused O 0 5.406235459304298e-07
by O 0 7.912999144821242e-10
a O 0 1.0132106709193067e-08
CTG O 0 2.025804678851273e-05
expansion O 0 5.30727561454114e-07
in O 0 2.6022060950481318e-08
the O 0 1.7996098833350516e-08
3 O 0 8.918594858187134e-07
untranslated O 0 0.008046151138842106
region O 0 1.3038496717854287e-06
of O 0 4.8033985677875535e-09
the O 0 1.1690577821354964e-06
DM B-Disease 1 0.9999887943267822
gene O 0 3.098051456618123e-05
. O 0 1.5389069574212044e-07

One O 0 1.6859553397807758e-07
model O 0 4.011421879113186e-07
of O 0 2.2136298127861664e-08
DM B-Disease 1 0.9999967813491821
pathogenesis O 0 0.010398397222161293
suggests O 0 1.934498186528799e-06
that O 0 7.055362072350135e-09
RNAs O 0 1.4001115005157772e-06
from O 0 2.953613742473493e-10
the O 0 4.595083202829642e-10
expanded O 0 1.2698381013365179e-08
allele O 0 2.6015163356873927e-08
create O 0 1.1711268399494656e-08
a O 0 1.0622712487418084e-08
gain O 0 1.051546632879763e-06
- O 0 0.0004601971304509789
of O 0 1.4664110814521791e-08
- O 0 0.006337461993098259
function O 0 2.2706505831138202e-07
mutation O 0 1.4553990013155271e-08
by O 0 2.6207724879157013e-10
the O 0 5.495924271237129e-10
inappropriate O 0 1.6553283188613932e-08
binding O 0 3.3972309410046364e-09
of O 0 1.3545835286787877e-10
proteins O 0 2.6280334353145918e-08
to O 0 8.180523813905438e-09
the O 0 1.6134553249003147e-08
CUG O 0 0.00045173417311161757
repeats O 0 2.324495289940387e-05
. O 0 7.48797006622226e-08

Data O 0 7.757994353596587e-06
presented O 0 1.1783308195845166e-07
here O 0 2.0882929163690278e-08
indicate O 0 8.366077963728458e-08
that O 0 4.106809559090152e-09
the O 0 1.2455971809544053e-09
conserved O 0 1.2876651567239605e-07
heterogeneous O 0 2.4012654193938943e-06
nuclear O 0 2.0434968973859213e-05
ribonucleoprotein O 0 2.7357791623217054e-06
, O 0 1.125406967616982e-08
CUG O 0 3.7832246562174987e-06
- O 0 1.5613043160556117e-06
binding O 0 1.913709901657512e-08
protein O 0 8.392753159114363e-08
( O 0 6.125103757526063e-10
CUG O 0 2.3922779291751795e-05
- O 0 0.001146069378592074
BP O 0 0.00010516629117773846
) O 0 2.9443905091852685e-09
, O 0 1.4721918129012579e-09
may O 0 1.2802961180113925e-07
mediate O 0 5.865129423909821e-06
the O 0 5.270927516676238e-08
trans O 0 3.0418279493460432e-05
- O 0 0.015284327790141106
dominant O 0 1.2720177437586244e-05
effect O 0 9.843947879062398e-09
of O 0 4.3883965905600064e-11
the O 0 2.259382014813127e-09
RNA O 0 9.285903615818825e-06
. O 0 9.28546626255411e-08

CUG O 0 0.0040797824040055275
- O 0 0.0699664056301117
BP O 0 0.00037317269016057253
was O 0 1.1898414413735736e-06
found O 0 7.966445281226697e-09
to O 0 3.1171279446517985e-10
bind O 0 1.5226441973936744e-07
to O 0 5.40338795929074e-09
the O 0 1.1275297140400653e-08
human O 0 9.90420517155144e-07
cardiac O 0 0.0012097755679860711
troponin O 0 0.0022677902597934008
T O 0 0.02817174233496189
( O 0 2.558687040021823e-09
cTNT O 0 1.520319869996456e-07
) O 0 4.366582095904903e-10
pre O 0 3.149051508444245e-07
- O 0 0.0001761468593031168
messenger O 0 7.682021418986551e-07
RNA O 0 6.179535034789296e-07
and O 0 3.4387910297084545e-09
regulate O 0 3.650735713733866e-09
its O 0 2.659790165893128e-10
alternative O 0 5.721294549232425e-09
splicing O 0 2.2141800855024485e-06
. O 0 1.3189708170102676e-07

Splicing O 0 1.1306639862596057e-05
of O 0 5.351155962785015e-08
cTNT O 0 8.683269697939977e-05
was O 0 2.2603850084124133e-05
disrupted O 0 0.00020693818805739284
in O 0 1.3795240647596074e-06
DM B-Disease 1 0.9999985694885254
striated O 1 0.9946445226669312
muscle O 1 0.5262649655342102
and O 0 1.8922463596027228e-06
in O 0 1.7327289825175285e-08
normal O 0 4.807122309102851e-07
cells O 0 2.7007183689420344e-07
expressing O 0 6.109072692161988e-10
transcripts O 0 2.069360647283247e-07
that O 0 3.131898651531628e-08
contain O 0 2.853359717391868e-07
CUG O 0 0.000922021979931742
repeats O 0 0.00010094109893543646
. O 0 1.8430390014145814e-07

Altered O 0 0.00022818008437752724
expression O 0 1.346627072962292e-06
of O 0 5.77302339266339e-09
genes O 0 2.6666157282306813e-07
regulated O 0 1.444896270186291e-06
posttranscriptionally O 0 6.057331484043971e-05
by O 0 5.508460532155368e-08
CUG O 0 0.0007675279630348086
- O 0 0.022105969488620758
BP O 0 0.00010417964222142473
therefore O 0 8.113801897025041e-08
may O 0 1.3393527176219777e-08
contribute O 0 4.91843121785962e-10
to O 0 3.517133606578682e-08
DM B-Disease 1 0.9999964237213135
pathogenesis O 0 0.05846631899476051
. O 0 1.1940718991354515e-07
. O 0 6.748771852471691e-08

Identification O 0 1.1771519439207623e-06
of O 0 4.677090270632789e-09
a O 0 3.686381333523059e-08
novel O 0 6.546477834490361e-06
nonsense O 0 0.0003171520947944373
mutation O 0 2.2303418063529534e-06
and O 0 5.539285474753797e-09
a O 0 2.745414728888562e-10
missense O 0 1.9015342900274845e-07
substitution O 0 8.83271233931282e-09
in O 0 1.9043404630991745e-09
the O 0 3.0217441882030016e-09
vasopressin O 0 3.996022357455331e-08
- O 0 0.0006113676354289055
neurophysin O 0 1.974671977222897e-05
II O 0 1.5838393665035255e-05
gene O 0 5.953226533961242e-08
in O 0 4.187058255666898e-09
two O 0 1.9505055348645328e-08
Spanish O 0 4.868766723120643e-07
kindreds O 0 4.613051351043396e-05
with O 0 3.645550634701067e-07
familial B-Disease 1 0.9824113249778748
neurohypophyseal I-Disease 1 0.9997965693473816
diabetes I-Disease 1 0.9999710321426392
insipidus I-Disease 1 0.9987581968307495
. O 0 1.1836612429760862e-05

Familial B-Disease 1 0.9995359182357788
neurohypophyseal I-Disease 1 0.999806821346283
diabetes I-Disease 1 0.9999922513961792
insipidus I-Disease 1 0.9998736381530762
( O 0 0.000955018273089081
FNDI B-Disease 1 0.9999986886978149
) O 0 5.8275281844544224e-06
is O 0 9.173215858027106e-07
an O 0 1.1113625077996403e-06
autosomal B-Disease 1 0.999901533126831
dominant I-Disease 1 0.9999949932098389
disease I-Disease 1 0.9999972581863403
caused O 0 0.1598706692457199
by O 0 9.039082215167582e-05
deficiency O 1 0.7477707266807556
in O 0 5.5280899857734767e-08
the O 0 1.0726818544526395e-07
antidiuretic O 0 5.9812759900523815e-06
hormone O 0 7.515986055750545e-08
arginine O 0 3.208249310659994e-08
vasopressin O 0 8.79515660301422e-09
( O 0 3.1670188693766477e-10
AVP O 0 6.622266823796963e-08
) O 0 1.3265929153793987e-11
encoded O 0 1.1661727139511413e-10
by O 0 4.484710380836532e-10
the O 0 9.80691705620984e-09
AVP O 0 2.6581976271700114e-05
- O 0 0.007286689709872007
neurophysin O 0 0.00031381865846924484
II O 0 0.0005394143518060446
( O 0 2.203018434343562e-09
AVP O 0 4.391059064801084e-06
- O 0 5.547258479055017e-05
NPII O 0 2.255038998555392e-05
) O 0 3.8912442712479844e-10
gene O 0 5.028813365726137e-09
on O 0 7.182686800888405e-08
chromosome O 0 0.00015192186401691288
20p13 O 0 1.250843342859298e-05
. O 0 1.1113014153352196e-07

In O 0 1.50044229485502e-07
this O 0 2.686380229377505e-09
study O 0 1.1574694980254208e-08
, O 0 5.803693969852475e-09
we O 0 1.707678798368306e-08
analyzed O 0 5.5001038390400936e-08
two O 0 7.68849783838732e-09
families O 0 1.035767382973063e-08
with O 0 1.0648093251575119e-07
FNDI B-Disease 1 0.999984860420227
using O 0 1.182276854194697e-08
direct O 0 1.2893794920643131e-09
automated O 0 2.332053838927095e-07
fluorescent O 0 1.5905834516161121e-06
, O 0 7.95041543710795e-09
solid O 0 1.09727182007191e-07
phase O 0 5.579252047027694e-07
, O 0 3.6084100152322662e-09
single O 0 1.067499724172194e-07
- O 0 3.610323119573877e-06
stranded O 0 1.1500160823629813e-08
DNA O 0 1.6515533829419837e-08
sequencing O 0 8.571247600563936e-10
of O 0 5.99931423983513e-11
PCR O 0 3.5227506032242673e-06
- O 0 1.0540754374233074e-05
amplified O 0 4.424751750775613e-06
AVP O 0 5.064322976977564e-06
- O 0 1.4544087207468692e-05
NPII O 0 1.16048631753074e-05
DNA O 0 4.810639893548796e-06
. O 0 3.671897275125957e-08

In O 0 1.677698406865602e-07
one O 0 8.639712945068823e-09
of O 0 5.782277434640548e-10
the O 0 3.200658227342501e-08
families O 0 1.8135963841814373e-08
, O 0 9.554102398112718e-09
affected O 0 3.4998464126800855e-09
individuals O 0 6.975844901724315e-11
presented O 0 3.996111441750827e-09
a O 0 4.662111408038072e-08
novel O 0 5.698835138900904e-06
nonsense O 0 2.7228010367252864e-05
mutation O 0 2.2510940667075374e-08
in O 0 3.945939408556143e-10
exon O 0 1.6793279655757942e-07
3 O 0 8.508447990607237e-08
of O 0 4.760610239351593e-10
the O 0 1.4002818460312483e-08
gene O 0 6.08909317634243e-07
, O 0 3.7191631996336127e-09
consisting O 0 5.26389931643223e-10
in O 0 6.73917277538294e-09
a O 0 3.49505256735938e-07
G O 0 0.08469339460134506
to O 0 2.0872997197329823e-07
T O 0 1.6802547179395333e-05
transition O 0 2.1715058196036807e-08
at O 0 7.71343877659092e-09
nucleotide O 0 4.300438760651559e-08
2101 O 0 1.957674976438284e-05
, O 0 3.4013414307310086e-09
which O 0 7.907115517902241e-10
produces O 0 1.1759827833746073e-10
a O 0 1.0085038359974874e-09
stop O 0 1.3016787647757155e-07
signal O 0 1.4082667121328996e-07
in O 0 2.139250110388957e-09
codon O 0 1.4032382296136348e-06
82 O 0 4.360336447462032e-07
( O 0 1.8781485255914276e-09
Glu O 0 0.00015685248945374042
) O 0 8.080064950455323e-10
of O 0 8.277549756741109e-10
NPII O 0 0.0009433544473722577
. O 0 1.0671007544260647e-07

The O 0 1.6962671907094773e-06
premature O 0 4.463442564883735e-06
termination O 0 4.2185806137240434e-07
eliminates O 0 6.71135239826981e-07
part O 0 4.3071374022929376e-08
of O 0 1.707449848176168e-09
the O 0 1.1825207479887467e-07
C O 0 0.0013778842985630035
- O 0 0.00014575649402104318
terminal O 0 4.277478637959575e-06
domain O 0 9.816782409188818e-08
of O 0 4.346987214631781e-10
NPII O 0 3.804958032560535e-05
, O 0 3.3872779581223256e-10
including O 0 8.63411512425083e-12
a O 0 1.4469858644616806e-10
cysteine O 0 2.2319819326099832e-09
residue O 0 9.09888910882728e-08
in O 0 2.9226419062666764e-09
position O 0 3.3097592222475214e-07
85 O 0 1.8849249272534507e-08
, O 0 5.788658441474581e-09
which O 0 5.8114281387133815e-08
could O 0 5.781224103884597e-07
be O 0 3.830421313466559e-09
involved O 0 8.670860696113891e-10
in O 0 8.787107930174898e-09
the O 0 8.451111455087812e-08
correct O 0 5.568596316152252e-05
folding O 0 2.1434172595036216e-05
of O 0 1.981594888178506e-09
the O 0 6.936926411071909e-08
prohormone O 0 0.0003951666585635394
. O 0 2.937823921911331e-07

In O 0 4.2430798430359573e-07
the O 0 8.188348488147312e-08
second O 0 4.642103704100009e-06
family O 0 7.130081769446406e-08
, O 0 3.7977193612093174e-10
a O 0 2.4565563472300767e-10
G279A O 0 9.734515415971146e-09
substitution O 0 1.951479644546339e-09
at O 0 1.396385140850498e-08
position O 0 1.2710454200259846e-07
- O 0 3.0249718747654697e-06
1 O 0 3.6045024742747955e-09
of O 0 2.7699136387338008e-11
the O 0 3.3894495543584924e-10
signal O 0 2.887525063499652e-08
peptide O 0 1.1157441193176965e-08
was O 0 1.1190373783165342e-07
observed O 0 3.93725052560967e-09
in O 0 1.0745628831188014e-09
all O 0 3.0171483089702633e-09
affected O 0 1.3999907011452706e-08
individuals O 0 1.2413636785169047e-09
. O 0 2.6829200194811165e-08

This O 0 1.8893761932758935e-07
missense O 0 2.3360376872005872e-05
mutation O 0 2.5554838430252858e-05
, O 0 1.1267583488461241e-07
which O 0 9.993251381956725e-08
replaces O 0 5.162926026969217e-05
Ala O 0 0.0007922900258563459
with O 0 1.739461623628813e-07
Thr O 1 0.6964460015296936
, O 0 2.3022791140192567e-07
is O 0 9.700578118554404e-09
frequent O 0 2.52149590096451e-07
among O 0 4.85181601561635e-07
FNDI B-Disease 1 0.9999998807907104
patients O 0 0.02324923314154148
and O 0 1.8142972066925722e-06
is O 0 1.5747461645787553e-07
thought O 0 1.9408328171266476e-06
to O 0 1.038441777012622e-08
reduce O 0 3.3312318237221916e-08
the O 0 1.359281798229972e-09
efficiency O 0 8.583293187314212e-09
of O 0 1.1583340536747144e-10
cleavage O 0 1.4589755892302492e-06
by O 0 1.7863400758599823e-09
signal O 0 3.842867783987458e-07
peptidases O 0 2.578678731879336e-06
. O 0 6.0301919013738825e-09
. O 0 1.8133059498381954e-08

Genetic O 0 0.0004492291191127151
heterogeneity O 0 8.466914732707664e-05
of O 0 4.2073426698152616e-07
Saethre B-Disease 1 0.9946354031562805
- I-Disease 1 0.9999665021896362
Chotzen I-Disease 1 0.9999781847000122
syndrome I-Disease 1 0.9999972581863403
, O 0 8.092195002973313e-08
due O 0 1.4845600304624895e-08
to O 0 7.349035158199513e-09
TWIST O 0 0.00010563688556430861
and O 0 2.2076985715102637e-06
FGFR O 0 0.003574927570298314
mutations O 0 2.133516318281181e-05
. O 0 1.5458466862128262e-07

Thirty O 0 2.2086331227910705e-05
- O 0 0.009528360329568386
two O 0 1.2424237638697377e-07
unrelated O 0 1.7571529724591528e-06
patients O 0 1.406845399287704e-06
with O 0 5.873270758627314e-09
features O 0 1.4965101399866398e-05
of O 0 4.342906265719648e-07
Saethre B-Disease 1 0.9989883303642273
- I-Disease 1 0.9999852180480957
Chotzen I-Disease 1 0.9999556541442871
syndrome I-Disease 1 0.9999856948852539
, O 0 1.4936373915475087e-08
a O 0 7.4491374846275e-08
common O 0 4.933350646751933e-05
autosomal B-Disease 1 0.9397304058074951
dominant I-Disease 1 0.9965327978134155
condition I-Disease 0 0.17941473424434662
of O 0 8.918611911212793e-07
craniosynostosis B-Disease 1 0.9999021291732788
and O 0 0.005910088773816824
limb B-Disease 1 0.998745322227478
anomalies I-Disease 0 0.23764079809188843
, O 0 4.261328001575748e-08
were O 0 5.728865204446265e-08
screened O 0 5.39936991117429e-06
for O 0 5.177125839139762e-09
mutations O 0 9.439138466404984e-07
in O 0 4.811341369759248e-08
TWIST O 0 0.0007661737618036568
, O 0 2.690582050490775e-07
FGFR2 O 0 0.00024082165327854455
, O 0 1.7501335491942882e-08
and O 0 1.2411280181368056e-07
FGFR3 O 0 0.00044331184471957386
. O 0 2.0627560104458098e-07

Nine O 0 3.98049560317304e-05
novel O 0 1.8902708688983694e-05
and O 0 1.305052592215361e-06
three O 0 3.868521858407803e-08
recurrent O 0 0.0012542465701699257
TWIST O 0 0.006699486169964075
mutations O 0 6.350196053972468e-05
were O 0 3.68758406921188e-07
found O 0 3.25494283970329e-07
in O 0 1.2742299304591143e-07
12 O 0 5.966184630779026e-07
families O 0 6.833222698787722e-08
. O 0 1.4650194657406246e-07

Seven O 0 1.6812762169138296e-06
families O 0 2.6974770861443176e-08
were O 0 3.718178831491059e-08
found O 0 4.055591418250515e-08
to O 0 6.461152501913148e-09
have O 0 1.2529511650427594e-08
the O 0 6.8788841289801894e-09
FGFR3 O 0 0.00011281115439487621
P250R O 0 3.4325222486586426e-07
mutation O 0 8.665658697282197e-07
, O 0 1.365990520696414e-08
and O 0 7.498174170450511e-08
one O 0 1.8763124387533026e-08
individual O 0 4.309380585709732e-08
was O 0 5.464792775455862e-05
found O 0 4.527007035903807e-07
to O 0 3.381807189839492e-08
have O 0 2.7629317500554862e-08
an O 0 3.5769842643418315e-09
FGFR2 O 0 5.145364048075862e-05
VV269 O 0 3.4151710792684753e-07
- O 0 1.9583360426622676e-06
270 O 0 2.3049430808441684e-08
deletion O 0 1.9343008261785144e-06
. O 0 8.079548763362254e-08

To O 0 6.000822168061859e-07
date O 0 2.260789102592753e-07
, O 0 9.053559568705793e-10
our O 0 2.1979348896472573e-10
detection O 0 3.5120724106718626e-08
rate O 0 7.264444690235905e-08
for O 0 7.296334092465884e-10
TWIST O 0 1.7298090824624524e-05
or O 0 1.305073453750083e-07
FGFR O 0 0.000205414486117661
mutations O 0 1.5561281543341465e-06
is O 0 4.3039509733944215e-08
68 O 0 6.678317845398851e-07
% O 0 9.295026415223617e-10
in O 0 2.9386413302745495e-08
our O 0 2.6764807898871368e-06
Saethre B-Disease 1 0.8411704301834106
- I-Disease 1 0.9999488592147827
Chotzen I-Disease 1 0.9999486207962036
syndrome I-Disease 1 0.9999880790710449
patients O 0 1.3933852642367128e-05
, O 0 2.2446702274692143e-09
including O 0 3.819798699566945e-09
our O 0 1.8191886397289636e-07
five O 0 2.052625625026394e-08
patients O 0 3.9951913777258596e-08
elsewhere O 0 4.133465569822192e-09
reported O 0 4.4894562734043575e-08
with O 0 1.3863457937191015e-08
TWIST O 0 0.0014965144218876958
mutations O 0 7.928465493023396e-05
. O 0 2.800410641157214e-07

More O 0 7.867538620587311e-09
than O 0 5.583984941104347e-10
35 O 0 2.555497369272075e-09
different O 0 2.2515726783023382e-10
TWIST O 0 1.185890596389072e-05
mutations O 0 2.625536808409379e-06
are O 0 3.4566978168726337e-09
now O 0 7.392690548613245e-08
known O 0 1.7132028062860627e-07
in O 0 1.1201132465998853e-08
the O 0 1.9621550606530036e-08
literature O 0 2.355354666860876e-07
. O 0 7.74162316474758e-08

The O 0 3.9918597849464277e-07
most O 0 1.809252525575289e-09
common O 0 1.569173790905154e-09
phenotypic O 0 7.453272843349623e-08
features O 0 1.2956690625287592e-05
, O 0 1.242827778469291e-07
present O 0 4.731166125537811e-09
in O 0 1.8613797170274893e-09
more O 0 4.958851107517148e-10
than O 0 2.415139199740679e-09
a O 0 8.2755683195046e-08
third O 0 0.00012887483171653003
of O 0 2.534755871863581e-08
our O 0 1.497407652095717e-06
patients O 0 3.124118919117791e-08
with O 0 1.638068902742873e-09
TWIST O 0 0.00010092723096022382
mutations O 0 5.526230779651087e-06
, O 0 2.5327488994975056e-09
are O 0 2.765485895839248e-10
coronal B-Disease 0 2.142332050425466e-05
synostosis I-Disease 0 0.000320313818519935
, O 0 9.910756659792241e-08
brachycephaly B-Disease 0 0.00010355033009545878
, O 0 3.335972564855183e-07
low B-Disease 0 0.0005699390894733369
frontal I-Disease 1 0.9999630451202393
hairline I-Disease 1 0.9999988079071045
, O 0 5.584017708315514e-05
facial B-Disease 1 0.9981606602668762
asymmetry I-Disease 1 0.7110882997512817
, O 0 4.715241630037781e-06
ptosis B-Disease 1 0.9586922526359558
, O 0 1.0296689652022906e-06
hypertelorism B-Disease 0 0.14892233908176422
, O 0 4.648393598927214e-07
broad B-Disease 0 0.0004289869684726
great I-Disease 0 0.002861136570572853
toes I-Disease 1 0.894434928894043
, O 0 3.5593998859440035e-08
and O 0 6.613872471916693e-08
clinodactyly B-Disease 0 5.920554758631624e-05
. O 0 6.638580174467279e-08

Significant O 0 6.77174796237523e-07
intra O 0 2.2229705791687593e-05
- O 0 0.03536573797464371
and O 0 3.017800622728828e-07
interfamilial O 0 3.05632079289353e-06
phenotypic O 0 4.7163027261376556e-07
variability O 0 1.2149960639362689e-05
is O 0 1.4035601125783614e-08
present O 0 8.821293140393038e-10
for O 0 1.2270863214425276e-09
either O 0 2.8077755587219144e-07
TWIST O 0 0.001546412124298513
mutations O 0 7.26828002370894e-05
or O 0 8.047126698329521e-07
FGFR O 0 0.0291501022875309
mutations O 0 0.00012848328333348036
. O 0 3.389912706097675e-07

The O 0 3.961353627346398e-07
overlap O 0 7.618881454618531e-07
in O 0 3.4490334144265944e-08
clinical O 0 6.404874966392526e-06
features O 0 8.565918687963858e-05
and O 0 4.937271569360746e-06
the O 0 3.165880357869355e-08
presence O 0 1.5029772271191177e-07
, O 0 4.743391457395774e-09
in O 0 6.049565848265104e-10
the O 0 2.067500615154927e-09
same O 0 1.0513562465064297e-08
genes O 0 3.608686682810003e-08
, O 0 1.682640027311777e-09
of O 0 5.7636877909272854e-11
mutations O 0 6.362003546200867e-08
for O 0 2.1508970993178167e-10
more O 0 1.0847225201393584e-10
than O 0 2.5505209055864952e-09
one O 0 2.8648798888752935e-07
craniosynostotic B-Disease 0 0.0014977403916418552
condition I-Disease 0 3.6133026242168853e-06
- O 0 3.328791535750497e-06
such O 0 4.6411967602466575e-09
as O 0 6.473811708929134e-08
Saethre B-Disease 0 3.122358248219825e-05
- I-Disease 0 0.0001207548484671861
Chotzen I-Disease 0 1.9710167180164717e-05
, I-Disease 0 2.0440880099670267e-09
Crouzon I-Disease 0 3.549293069227133e-06
, I-Disease 0 1.75574399463585e-08
and I-Disease 0 8.882841484592063e-07
Pfeiffer I-Disease 1 0.5514742136001587
syndromes I-Disease 0 0.036474406719207764
- O 0 0.0007399821770377457
support O 0 3.7289527909933895e-08
the O 0 1.3737846416006505e-08
hypothesis O 0 2.8275464956095675e-06
that O 0 2.896588036094272e-08
TWIST O 0 4.726740371552296e-06
and O 0 8.973488263563922e-08
FGFRs O 0 4.487261321628466e-06
are O 0 4.6418410781789987e-10
components O 0 2.7212898601192137e-08
of O 0 5.075691533740212e-10
the O 0 5.339835684736727e-09
same O 0 2.7739344155008894e-09
molecular O 0 4.7533291080981144e-08
pathway O 0 2.8670603668956574e-08
involved O 0 1.2787623182575203e-09
in O 0 1.6649503997712145e-09
the O 0 2.608028237816029e-09
modulation O 0 1.3782326959699276e-06
of O 0 6.735063493579219e-07
craniofacial O 1 0.9999489784240723
and O 0 0.0011271213879808784
limb O 1 0.9040452837944031
development O 0 3.510405406359496e-07
in O 0 2.6284494580863793e-08
humans O 0 4.93596303385857e-07
. O 0 4.322055158212379e-09
. O 0 1.788857240114794e-08

Mutation O 0 1.5254800928232726e-05
analysis O 0 2.0101852271636744e-07
of O 0 2.9055408745648492e-08
UBE3A O 1 0.5526358485221863
in O 0 0.08576706051826477
Angelman B-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999998807907104
patients O 0 0.3789103329181671
. O 0 1.7930440208147047e-06

Angelman B-Disease 1 0.9999992847442627
syndrome I-Disease 1 1.0
( O 0 0.00531954737380147
AS B-Disease 1 0.9999785423278809
) O 0 8.999573992696241e-07
is O 0 2.2388761067304586e-07
caused O 0 1.0644899930412066e-06
by O 0 3.85284479875736e-08
chromosome O 0 0.001667315373197198
15q11 O 0 2.2224088752409443e-05
- O 0 0.0012034240644425154
q13 O 0 3.1518487730863853e-07
deletions O 0 6.710815370070122e-08
of O 0 6.1660392347562265e-09
maternal O 0 6.712736194458557e-06
origin O 0 2.8129152340738983e-08
, O 0 3.6378000611847483e-09
by O 0 6.354869963587362e-09
paternal O 0 5.493110802490264e-05
uniparental B-Disease 0 0.09749811142683029
disomy I-Disease 0 0.3461315929889679
( O 0 8.964385074250458e-07
UPD B-Disease 1 0.9999946355819702
) O 0 7.924802503112005e-08
15 O 0 2.22153921924928e-08
, O 0 1.351165290763845e-09
by O 0 4.703094802493979e-09
imprinting O 1 0.8437215089797974
defects O 1 0.9998944997787476
, O 0 1.5935077612994064e-07
and O 0 2.1510839331995157e-08
by O 0 2.522124065151843e-09
mutations O 0 6.220925001798605e-07
in O 0 1.9408604501336413e-08
the O 0 8.990980404632865e-08
UBE3A O 0 0.00044896459439769387
gene O 0 4.4756407078239135e-06
. O 0 1.7490731352154398e-07

UBE3A O 0 0.0004053249431308359
encodes O 0 2.385930429227301e-06
a O 0 1.6062050178788922e-07
ubiquitin O 0 5.633103228319669e-06
- O 0 0.00021663324150722474
protein O 0 1.056066139426548e-06
ligase O 0 1.3202007949075778e-06
and O 0 5.554321660383721e-07
shows O 0 7.308148724405328e-06
brain O 0 0.0027996462304145098
- O 0 6.203321390785277e-05
specific O 0 1.9443508136873788e-08
imprinting O 0 0.0003758587990887463
. O 0 3.558118066848692e-07

Here O 0 4.078906840732088e-06
we O 0 1.4372616874425148e-07
describe O 0 1.1774388752883169e-07
UBE3A O 0 1.5912337403278798e-05
coding O 0 0.0007917945040389895
- O 0 0.03501776605844498
region O 0 1.5866959302002215e-06
mutations O 0 6.057977657292213e-07
detected O 0 1.0453878473981604e-07
by O 0 4.875559400652207e-10
SSCP O 0 8.008732038433664e-06
analysis O 0 5.3547193346048516e-08
in O 0 4.6964999000920216e-08
13 O 0 2.1418247797555523e-06
AS B-Disease 1 0.999961256980896
individuals O 0 2.2807592259255216e-08
or O 0 1.454718301374669e-07
families O 0 1.8552776737124077e-07
. O 0 3.5257986041870026e-07

Two O 0 1.0923162108156248e-06
identical O 0 8.06988919066498e-06
de O 0 5.46512353594153e-07
novo O 0 6.4785203903738875e-06
5 O 0 9.292163127838649e-08
- O 0 1.9637556761153974e-05
bp O 0 9.378105687574134e-07
duplications O 0 2.839626631612191e-07
in O 0 1.9376342752508435e-09
exon O 0 3.4293459520995384e-06
16 O 0 5.568270466937975e-07
were O 0 4.0309675597427486e-08
found O 0 1.797612014797778e-07
. O 0 6.996642554213395e-08

Among O 0 1.3098902229558007e-07
the O 0 5.520901069644424e-09
other O 0 4.951280496712229e-10
11 O 0 5.0698982789754155e-09
unique O 0 4.195100267168073e-09
mutations O 0 2.296455704708933e-06
, O 0 2.106587260186643e-08
8 O 0 2.1498458124824538e-07
were O 0 3.557058292358306e-08
small O 0 7.323050610352766e-09
deletions O 0 1.8960778334076167e-06
or O 0 9.940156786569787e-08
insertions O 0 3.865200051222928e-05
predicted O 0 0.0009600386256352067
to O 0 5.476591695696698e-07
cause O 0 2.0096324533369625e-06
frameshifts O 0 0.001653132145293057
, O 0 1.5838220690511662e-07
1 O 0 3.5175870038983703e-07
was O 0 1.5183987670752686e-05
a O 0 5.4869953913794234e-08
mutation O 0 1.434012915524363e-06
to O 0 1.0419495488633856e-08
a O 0 7.946519886559145e-09
stop O 0 8.520999585925892e-07
codon O 0 2.3180179198334372e-07
, O 0 4.897761085587149e-10
1 O 0 2.5832693761884684e-09
was O 0 2.006391355280357e-07
a O 0 3.9321994549368355e-09
missense O 0 2.7321809739078162e-06
mutation O 0 3.3665980936348205e-06
, O 0 3.9831316911431713e-08
and O 0 5.4167021090734124e-08
1 O 0 8.544014207245709e-08
was O 0 0.00034640199737623334
predicted O 0 0.00015402506687678397
to O 0 1.8102342380643677e-07
cause O 0 7.796629830636448e-08
insertion O 0 3.732173183834675e-07
of O 0 1.4799460323899893e-08
an O 0 4.1793012428570364e-07
isoleucine O 1 0.5204898715019226
in O 0 6.500401639186748e-08
the O 0 7.853310890482135e-09
hect O 0 1.938945842994144e-06
domain O 0 4.1279289320073076e-08
of O 0 3.172036522336441e-10
the O 0 4.9862913797937836e-09
UBE3A O 0 2.8991280487389304e-06
protein O 0 7.042726934969323e-08
, O 0 9.039997084236973e-10
which O 0 1.1978237846044237e-10
functions O 0 7.307834892777976e-11
in O 0 6.836436972079696e-10
E2 O 0 1.2544071523734601e-06
binding O 0 1.0736742162009705e-08
and O 0 3.28233129565092e-09
ubiquitin O 0 1.9916370774808456e-08
transfer O 0 1.294797069562037e-08
. O 0 8.172995080713008e-08

Eight O 0 2.3544075702375267e-06
of O 0 1.928854409527503e-09
the O 0 6.126765761393926e-09
cases O 0 4.159495503586186e-08
were O 0 3.5414620924711926e-07
familial O 0 0.005994156002998352
, O 0 1.4887772294969182e-06
and O 0 1.1609787975430663e-07
five O 0 1.3278935284688487e-08
were O 0 4.522596697142944e-08
sporadic O 0 1.757495010679122e-05
. O 0 6.486295092145156e-07

In O 0 5.474983026942937e-07
two O 0 4.577898238267153e-08
familial O 0 0.00013407245569396764
cases O 0 1.0948517228825949e-05
and O 0 3.5301695788803045e-06
one O 0 7.367999899088318e-08
sporadic O 0 1.230503767146729e-05
case O 0 5.640957169816829e-06
, O 0 2.201167426107986e-08
mosaicism O 0 7.178384748840472e-06
for O 0 5.59312285375313e-09
UBE3A O 0 7.48238162486814e-05
mutations O 0 4.133328275202075e-06
was O 0 2.4254084109998075e-06
detected O 0 1.5908171917544678e-06
in O 0 6.651277750790996e-09
the O 0 1.3184099145746586e-07
mother O 0 0.0001277191040571779
of O 0 1.2382877834227202e-08
three O 0 4.172839908278547e-06
AS B-Disease 1 0.9999992847442627
sons O 0 0.0013435914879664779
, O 0 1.0554087381819954e-08
in O 0 2.1496102675655493e-09
the O 0 3.4510733826209616e-08
maternal O 0 6.896161266922718e-06
grandfather O 0 3.1739723453938495e-06
of O 0 3.3751295092088185e-09
two O 0 2.7853246820086497e-07
AS B-Disease 1 0.999982476234436
first O 0 2.6162411813857034e-05
cousins O 0 4.447654646355659e-05
, O 0 6.528432550112484e-08
and O 0 4.19808792173626e-08
in O 0 1.189705489679227e-08
the O 0 8.742510004822179e-08
mother O 0 5.4995443861116655e-06
of O 0 4.505501527418687e-10
an O 0 8.833036702071695e-08
AS B-Disease 1 0.9999550580978394
daughter O 0 0.006332491524517536
. O 0 1.8515515876060817e-07

The O 0 1.4459030417413032e-08
frequencies O 0 2.8223846371133732e-08
with O 0 1.8231444798288976e-08
which O 0 4.0469526396691435e-08
we O 0 2.0824060698032554e-08
detected O 0 5.457624041582676e-08
mutations O 0 2.650060260123155e-08
were O 0 1.533994797853211e-08
5 O 0 2.5481929455395402e-08
( O 0 1.199168542243001e-09
14 O 0 5.624395527092929e-08
% O 0 4.777210294015788e-10
) O 0 1.7457510437246526e-10
of O 0 9.106063819652732e-11
35 O 0 2.242621555126334e-08
in O 0 3.6407850068087555e-09
sporadic O 0 9.695825156086357e-07
cases O 0 6.264928629207134e-07
and O 0 3.09464894598932e-06
8 O 0 8.884400131137227e-07
( O 0 6.140614683403101e-10
80 O 0 3.545291615836277e-09
% O 0 6.097664040360939e-10
) O 0 5.339069186760526e-10
of O 0 3.037958495877291e-10
10 O 0 2.9232900544684526e-08
in O 0 1.850407294057277e-08
familial O 0 0.0001276421535294503
cases O 0 1.6167041394510306e-06
. O 0 1.7589592005151644e-07
. O 0 1.4833604211617057e-07

The O 0 1.94810054381378e-05
hemochromatosis B-Disease 1 0.9999620914459229
845 O 0 0.00032216121326200664
G O 0 0.054618917405605316
- O 0 0.0037268074229359627
- O 0 0.0012025554897263646
> O 0 2.0237868625372357e-07
A O 0 2.4012642541038076e-08
and O 0 6.9854921846967954e-09
187 O 0 3.528885983428154e-08
C O 0 0.0004328772774897516
- O 0 0.004418518859893084
- O 0 0.006640080828219652
> O 0 1.8291409560333705e-06
G O 0 0.0010747950291261077
mutations O 0 2.9394875582511304e-06
: O 0 4.401864206471373e-09
prevalence O 0 1.7092654161388054e-05
in O 0 1.8587305916639707e-08
non O 0 3.0124465411063284e-07
- O 0 0.03628595545887947
Caucasian O 0 0.0007794017437845469
populations O 0 2.458436938468367e-06
. O 0 7.520288392015573e-08

Hemochromatosis B-Disease 1 0.9982724189758301
, O 0 0.0004800907918252051
the O 0 0.0009286219719797373
inherited B-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999997615814209
of I-Disease 0 3.4793563372659264e-06
iron I-Disease 1 0.9986869692802429
metabolism I-Disease 0 0.27405673265457153
, O 0 6.377025556503213e-07
leads O 0 8.5737583503942e-06
, O 0 1.8894968434324255e-07
if O 0 3.068376599912881e-06
untreated O 0 8.659917511977255e-05
, O 0 4.979087808720806e-09
to O 0 5.748676912276096e-08
progressive O 0 0.0016976891783997416
iron B-Disease 1 0.999710738658905
overload I-Disease 1 0.9296056628227234
and O 0 4.855282895732671e-06
premature B-Disease 0 2.1332456526579335e-05
death I-Disease 0 4.3966197154077236e-06
. O 0 1.1403719213376462e-07

The O 0 4.307402195991017e-05
hemochromatosis B-Disease 1 0.9999454021453857
gene O 0 0.0005497154197655618
, O 0 3.1967846325642313e-07
HFE O 0 0.023559650406241417
, O 0 2.0304156578276888e-07
recently O 0 4.916737907478819e-06
has O 0 1.2243092442076886e-06
been O 0 2.4163620082617854e-07
identified O 0 1.483710093452828e-06
, O 0 1.507233982067646e-08
and O 0 1.0010894335721332e-08
characterization O 0 2.9552518299169606e-07
of O 0 8.679331697791781e-10
this O 0 3.928533942598733e-09
gene O 0 2.97418665695659e-07
has O 0 1.5285469316950184e-06
shown O 0 2.645296319769841e-07
that O 0 5.5038185564626474e-08
it O 0 7.751785879861472e-09
contains O 0 3.1155422686168777e-09
two O 0 6.49906226612984e-08
mutations O 0 3.941794602724258e-06
that O 0 6.903241569489182e-07
result O 0 4.5786578084516805e-08
in O 0 2.371473017959147e-09
amino O 0 8.70651195583605e-09
acid O 0 1.1037301739236227e-08
substitutions O 0 1.2033177787529326e-09
- O 0 1.5536532771420752e-07
cDNA O 0 1.0134599826017165e-08
nucleotides O 0 8.435840470610856e-09
845 O 0 3.2043477204979354e-08
G O 0 5.010658423998393e-05
- O 0 5.855814379174262e-05
- O 0 0.00014436790661420673
> O 0 5.103294853370244e-08
A O 0 3.1851104864699664e-08
( O 0 1.750005002021382e-10
C282Y O 0 1.8948629332271594e-08
) O 0 8.566994336156597e-11
and O 0 8.917805938146728e-10
187 O 0 1.538055371952396e-08
C O 0 3.4670301829464734e-05
- O 0 0.0015617090975865722
- O 0 0.0027064387686550617
> O 0 3.6008843835588777e-06
G O 0 0.00023489963496103883
( O 0 2.36545116827358e-09
H63D O 0 1.109953700506594e-05
) O 0 3.3743441374411987e-09
. O 0 6.83057432837586e-09

Although O 0 0.0004938788479194045
hemochromatosis B-Disease 1 0.9999905824661255
is O 0 2.866245722543681e-06
common O 0 1.4402115766642964e-07
in O 0 3.953567073722297e-08
Caucasians O 0 9.08803558559157e-05
, O 0 1.039736030605809e-08
affecting O 0 1.538677452117554e-08
> O 0 5.999860945848923e-07
= O 0 5.6369026424363256e-06
1 O 0 3.437291340446791e-08
/ O 0 1.690163230705366e-06
300 O 0 4.962976141165143e-10
individuals O 0 2.0659937649547544e-10
of O 0 4.0008379942335637e-10
northern O 0 2.6711563805292826e-06
European O 0 1.2478103599278256e-06
origin O 0 2.3915696090170968e-08
, O 0 2.966845791263495e-08
it O 0 8.738008716591139e-08
has O 0 1.1030508062503941e-07
not O 0 1.3969045475903386e-08
been O 0 6.490215476162575e-09
recognized O 0 4.0195469175330345e-10
in O 0 1.0249229243086688e-09
other O 0 1.1093795881933488e-09
populations O 0 8.33455828797014e-08
. O 0 4.148070686937899e-08

The O 0 8.913001892096872e-08
present O 0 1.4837892026164923e-09
study O 0 7.443008986918187e-10
used O 0 2.3697093176622275e-09
PCR O 0 5.704778232029639e-06
and O 0 1.0318258247821177e-08
restriction O 0 3.4986733510322665e-08
- O 0 6.008768832543865e-05
enzyme O 0 4.6750011506446754e-07
digestion O 0 7.822307566129894e-07
to O 0 9.584504301329844e-10
analyze O 0 2.891828110307415e-09
the O 0 9.047513432891563e-11
frequency O 0 4.070942249967402e-09
of O 0 6.820790460215775e-11
the O 0 1.3390251130118713e-09
845 O 0 7.433212800833644e-08
G O 0 0.0001084817195078358
- O 0 3.53094183083158e-05
- O 0 2.8724942239932716e-05
> O 0 2.4061836967348427e-08
A O 0 2.433534973533824e-08
and O 0 2.6970485844657333e-09
187 O 0 3.193010522650752e-09
C O 0 3.3036681088560726e-06
- O 0 7.37270465833717e-06
- O 0 5.509342736331746e-05
> O 0 7.362478982031462e-08
G O 0 6.975361429795157e-06
mutations O 0 2.0685982704549133e-08
in O 0 2.639636731416317e-09
HLA O 0 1.8002874639932998e-05
- O 0 6.574369308509631e-06
typed O 0 1.420362565340838e-07
samples O 0 1.2393793547005316e-08
from O 0 8.486539249119573e-11
non O 0 3.4195681841708847e-09
- O 0 4.6983379434095696e-05
Caucasian O 0 2.1631243726005778e-05
populations O 0 1.8685132374685054e-07
, O 0 1.5827626709263853e-10
comprising O 0 4.458907201798645e-11
Australian O 0 2.4563245659692257e-08
Aboriginal O 0 4.573804801566439e-08
, O 0 3.667015302522003e-10
Chinese O 0 4.103855588688532e-10
, O 0 4.613217585713869e-10
and O 0 6.956228038035306e-09
Pacific O 0 7.154015690957749e-08
Islanders O 0 9.264180675927491e-07
. O 0 9.259357724999973e-09

Results O 0 2.30789137276588e-05
showed O 0 1.9167987375112716e-06
that O 0 3.7590006662924225e-09
the O 0 1.0235885472553719e-09
845 O 0 8.20216484953562e-07
G O 0 0.011431602761149406
- O 0 0.006140108685940504
- O 0 0.0006151367560960352
> O 0 4.5044490804002635e-08
A O 0 2.3102424862031512e-08
mutation O 0 2.922775479419215e-07
was O 0 9.513769327895716e-07
present O 0 4.0132727696651216e-10
in O 0 6.70881350472996e-10
these O 0 3.7091299476266215e-10
populations O 0 9.550326085516758e-10
( O 0 6.0515906522007334e-12
allele O 0 1.0168358516304821e-10
frequency O 0 1.5087611160424785e-08
0 O 0 3.858424690861284e-09
. O 0 1.5886211790494542e-10
32 O 0 2.001125043449292e-09
% O 0 3.316431851363433e-10
) O 0 1.3431408207864592e-09
, O 0 1.559507367687729e-08
and O 0 6.210503897818853e-07
, O 0 3.7889179793637595e-08
furthermore O 0 1.9990170585515443e-07
, O 0 1.939409699502903e-08
it O 0 1.6868318652996095e-07
was O 0 7.040569926175522e-06
always O 0 3.4665376347220445e-07
seen O 0 1.6398201907463772e-08
in O 0 8.870505024960451e-11
conjunction O 0 1.854250197830254e-09
with O 0 2.8595074752502114e-08
HLA O 0 8.308548422064632e-05
haplotypes O 0 1.4343015664053382e-06
common O 0 6.970375210357815e-08
in O 0 4.180515045248967e-09
Caucasians O 0 2.4353284970857203e-06
, O 0 1.794748349936981e-09
suggesting O 0 1.6589030593650023e-08
that O 0 2.012501987280757e-08
845 O 0 7.396258183689497e-07
G O 0 0.13250331580638885
- O 0 0.14878807961940765
- O 0 0.032000601291656494
> O 0 6.933155418664683e-07
A O 0 3.4431029689585557e-06
may O 0 2.2059161892684642e-06
have O 0 1.1797538945756969e-08
been O 0 8.223514313954183e-09
introduced O 0 1.0215255308310134e-08
into O 0 2.636562301816525e-09
these O 0 7.113190592100693e-10
populations O 0 5.1473412199243285e-09
by O 0 1.908358138180688e-09
Caucasian O 0 1.437064383935649e-05
admixture O 0 3.979725534009049e-06
. O 0 1.0636300373789709e-07

187 O 0 2.632597215779242e-06
C O 0 0.00013622532424051315
- O 0 7.922524673631415e-05
- O 0 0.00030215681181289256
> O 0 1.6817814412206644e-06
G O 0 0.0006636903854086995
was O 0 4.323298412600707e-07
present O 0 2.6855334622766236e-10
at O 0 2.3597088172344627e-10
an O 0 1.2242376383475584e-11
allele O 0 4.5193151998468295e-10
frequency O 0 8.202210466379256e-09
of O 0 6.539618291334648e-10
2 O 0 4.990842512597737e-07
. O 0 1.2125484261105157e-07

68 O 0 3.7785732274642214e-05
% O 0 1.0237940273327695e-08
in O 0 1.189736642537298e-09
the O 0 3.5131959563727833e-09
two O 0 8.318513877725309e-09
populations O 0 9.344771711994326e-08
analyzed O 0 1.183722929454234e-06
( O 0 1.2915749580955094e-09
Australian O 0 4.508712834194739e-07
Aboriginal O 0 5.92754588524258e-07
and O 0 2.0335233941182196e-08
Chinese O 0 6.658207762910706e-09
) O 0 2.925927278241147e-09
. O 0 2.0687954460640867e-08

In O 0 1.2829434581362875e-07
the O 0 2.4636617190765264e-09
Australian O 0 7.512615418647783e-09
Aboriginal O 0 8.488085789792876e-09
samples O 0 2.5993425190051767e-09
, O 0 5.614493939209986e-11
187 O 0 1.2122791659407994e-09
C O 0 3.2745408589107683e-06
- O 0 3.678328721434809e-05
- O 0 0.00039234128780663013
> O 0 2.8155997711110103e-07
G O 0 0.0038599849212914705
was O 0 1.5109548030523001e-06
found O 0 7.1669603585178265e-09
to O 0 1.3570305990029397e-09
be O 0 1.7382096872964325e-09
associated O 0 1.8891133102272306e-09
with O 0 2.1677276862419603e-08
HLA O 0 0.0011611328227445483
haplotypes O 0 6.374432359734783e-06
common O 0 1.7145627850823075e-07
in O 0 2.578466506975019e-08
Caucasians O 0 1.4319917681859806e-05
, O 0 5.771437994184225e-09
suggesting O 0 1.4327783048884157e-07
that O 0 5.764312405176497e-08
it O 0 2.713075453186775e-08
was O 0 9.560248059869991e-08
introduced O 0 1.2176420760567908e-08
by O 0 8.331944023609594e-10
recent O 0 2.097062079542411e-08
admixture O 0 3.3010414881573524e-06
. O 0 2.5446578888477234e-07

In O 0 8.952289931585256e-08
the O 0 1.5861452151710864e-09
Chinese O 0 4.660302144188222e-10
samples O 0 1.5172563205823053e-09
analyzed O 0 4.640276607403848e-09
, O 0 6.270162167254512e-11
187 O 0 1.6635696153954882e-09
C O 0 2.5069298317248467e-06
- O 0 5.511515610123752e-06
- O 0 6.209210550878197e-05
> O 0 2.301833461615388e-07
G O 0 0.0013106168480589986
was O 0 1.1125373930553906e-05
present O 0 8.512501814550433e-09
in O 0 8.454896338605522e-09
association O 0 4.4331489590376805e-09
with O 0 4.15802592357295e-09
a O 0 2.5933667657795922e-08
wide O 0 6.277446686908661e-07
variety O 0 1.8865110362753512e-08
of O 0 1.1997662419105382e-08
HLA O 0 0.0005701504996977746
haplotypes O 0 5.185329428059049e-06
, O 0 1.072168043236843e-08
showing O 0 2.102565588302241e-07
this O 0 1.985620334821192e-09
mutation O 0 1.4662046510238724e-07
to O 0 1.5338629921757274e-08
be O 0 2.9580705884768577e-08
widespread O 0 2.1575349506974817e-08
and O 0 8.365102530660806e-07
likely O 0 2.2421559719987272e-07
to O 0 3.241215296156952e-09
predate O 0 2.3333025183092104e-06
the O 0 3.298668005413674e-09
more O 0 1.2179893205122028e-10
genetically O 0 2.8993904166441098e-08
restricted O 0 4.955489885105635e-08
845 O 0 2.92235358756443e-06
G O 0 0.01759759522974491
- O 0 0.004725387319922447
- O 0 0.0006140457699075341
> O 0 9.027289138430206e-08
A O 0 1.0192391641794529e-07
mutation O 0 7.904459380370099e-07
. O 0 2.3792170011915914e-08

Genotype O 0 0.0023774653673171997
- O 0 0.023513562977313995
phenotype O 0 0.00029548234306275845
correlations O 0 0.0004518511123023927
in O 0 1.0164354534936137e-05
attenuated B-Disease 1 0.9966256618499756
adenomatous I-Disease 1 0.9999740123748779
polyposis I-Disease 1 0.9999414682388306
coli I-Disease 1 0.999983549118042
. O 0 0.00025825598277151585

Germ O 1 0.8670433759689331
- O 1 0.5506497025489807
line O 0 0.0011580840218812227
mutations O 0 6.777769954169344e-07
of O 0 6.305797550787418e-10
the O 0 5.3088850648919106e-08
tumor B-Disease 0 0.00024167455558199435
suppressor O 0 2.5184221158269793e-05
APC O 0 1.818572627598769e-06
are O 0 8.963563224995141e-09
implicated O 0 1.0188509804720525e-05
in O 0 2.9303573683137074e-05
attenuated B-Disease 1 0.9998762607574463
adenomatous I-Disease 1 0.9999979734420776
polyposis I-Disease 1 0.9999939203262329
coli I-Disease 1 0.9999997615814209
( O 0 0.03814087063074112
AAPC B-Disease 1 0.999998927116394
) O 0 9.02386091183871e-07
, O 0 8.8786213936487e-09
a O 0 4.05693789673478e-08
variant O 0 0.12708687782287598
of O 0 0.0012041727313771844
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999923706054688
polyposis I-Disease 1 0.9999991655349731
( O 0 0.0001353051484329626
FAP B-Disease 0 0.001743196859024465
) O 0 1.8525990697071393e-07
. O 0 1.4140941573259624e-07

AAPC B-Disease 1 0.9996777772903442
is O 0 1.0488492080185097e-05
recognized O 0 3.349191501911264e-08
by O 0 2.8746207636487497e-09
the O 0 1.2204431909523805e-09
occurrence O 0 3.076259247336566e-07
of O 0 1.4952841187465538e-09
< O 0 2.8783067591575673e-06
100 O 0 1.681816108600742e-08
colonic B-Disease 0 0.001321229268796742
adenomas I-Disease 0 0.015991540625691414
and O 0 4.0977397475217003e-07
a O 0 4.586270563322614e-08
later O 0 1.7627924535190687e-05
onset O 0 0.01048901118338108
of O 0 0.009080690331757069
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.0335206702147843e-07
age O 0 6.233836415958649e-07
> O 0 1.3960421085812413e-07
40 O 0 4.1122671490256835e-08
years O 0 5.422149840228485e-08
) O 0 8.857766964354141e-09
. O 0 2.2478246819446213e-08

The O 0 6.388279985003464e-07
aim O 0 2.2424875112392328e-07
of O 0 2.52835558045561e-10
this O 0 4.414330845303738e-10
study O 0 1.2497570756053733e-09
was O 0 5.036360306576171e-08
to O 0 6.310983402535442e-10
assess O 0 3.211959764826133e-08
genotype O 0 2.134484248017543e-06
- O 0 0.000653125171083957
phenotype O 0 2.4669348931638524e-05
correlations O 0 9.979239621316083e-06
in O 0 4.1802327359619085e-06
AAPC B-Disease 1 0.9999731779098511
families O 0 3.0413643798965495e-06
. O 0 3.3410921673748817e-07

By O 0 1.2006938732156414e-07
protein O 0 3.2779573189145594e-07
- O 0 6.236621993593872e-05
truncation O 0 0.00018549563537817448
test O 0 2.1121646568644792e-05
( O 0 5.160747384991282e-10
PTT O 0 1.0990396503984812e-07
) O 0 4.4819570277354615e-10
assay O 0 4.6289287070067076e-08
, O 0 4.041124934683893e-10
the O 0 1.5462661706600045e-10
entire O 0 1.4726643904339198e-08
coding O 0 1.7494930943939835e-05
region O 0 6.93369841542335e-08
of O 0 2.624554462649087e-10
the O 0 3.1936073785487906e-09
APC B-Disease 0 5.4848921848815735e-08
gene O 0 4.550762255917107e-08
was O 0 6.868096988910111e-07
screened O 0 9.722676850287826e-07
in O 0 3.649802904348576e-09
affected O 0 2.1353784518396424e-08
individuals O 0 4.495269989579498e-10
from O 0 7.1026740044999315e-09
11 O 0 1.987683936022222e-05
AAPC B-Disease 1 0.9999967813491821
kindreds O 0 0.022766824811697006
, O 0 1.2228116474943818e-07
and O 0 2.7031990867953937e-08
their O 0 1.0703429254022012e-09
phenotypic O 0 2.732363668656035e-07
differences O 0 1.7596750012671691e-06
were O 0 8.368805310965399e-07
examined O 0 7.346674829022959e-05
. O 0 3.297349451258924e-07

Five O 0 1.4259533145377645e-06
novel O 0 4.894552603218472e-06
germ O 0 0.019292309880256653
- O 0 0.13752813637256622
line O 0 0.0010299658169969916
APC B-Disease 0 6.775391057090019e-07
mutations O 0 6.399494054676325e-07
were O 0 1.9548929586221675e-08
identified O 0 3.0633307801508636e-07
in O 0 4.170625089727764e-08
seven O 0 8.693321547070809e-07
kindreds O 0 0.0013283226871863008
. O 0 3.172130789153016e-07

Mutations O 0 0.0010292630176991224
were O 0 7.362309588643257e-07
located O 0 5.387460433325941e-08
in O 0 6.4849690062374066e-09
three O 0 4.781825158062247e-09
different O 0 3.224576994309558e-10
regions O 0 9.725458660625463e-09
of O 0 5.603199570991535e-10
the O 0 2.759008310704303e-08
APC B-Disease 0 1.1915670228290764e-07
gene O 0 3.442343299298045e-08
( O 0 1.6737311536729749e-10
1 O 0 3.5258971298191e-09
) O 0 1.194696119810601e-09
at O 0 3.2493487900353557e-09
the O 0 2.1394541693808833e-09
5 O 0 5.7334784031581876e-08
end O 0 2.0845131132318784e-07
spanning O 0 4.857279236603063e-07
exons O 0 8.571371836296748e-06
4 O 0 2.633488747960655e-06
and O 0 6.569352422047814e-07
5 O 0 6.972236832325507e-08
, O 0 4.590206437171673e-09
( O 0 5.5902910772731573e-11
2 O 0 3.072680110349779e-09
) O 0 8.156243042067857e-11
within O 0 4.659197680445537e-11
exon O 0 2.6501419370106305e-07
9 O 0 3.238373437852715e-06
, O 0 3.362723077771079e-08
and O 0 6.76437750257719e-08
( O 0 4.851829493723869e-10
3 O 0 9.029528058590586e-08
) O 0 5.120745605324828e-09
at O 0 2.5813303494715e-08
the O 0 1.2626625967016025e-08
3 O 0 3.1272074352273194e-07
distal O 0 2.3445934402843704e-06
end O 0 1.62067306064273e-06
of O 0 2.647218555473785e-10
the O 0 9.495494168731966e-09
gene O 0 5.856605298504292e-07
. O 0 1.231843071991534e-07

Variability O 0 0.0028409422375261784
in O 0 6.769320748389873e-08
the O 0 7.920492706148252e-09
number O 0 1.334083208348602e-07
of O 0 2.1996826035319827e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.9320549368858337
most O 0 2.3340582799846743e-07
apparent O 0 1.6007212479962618e-06
in O 0 3.07702769930529e-08
individuals O 0 2.7072275532447065e-09
with O 0 3.845943297164922e-08
mutations O 0 3.6204185107635567e-06
in O 0 1.1864405990991145e-07
region O 0 1.3492598327502492e-06
1 O 0 2.282220748384134e-06
, O 0 5.681778247890179e-07
and O 0 4.8513716137676965e-06
upper O 0 0.4721158444881439
- O 1 0.9999611377716064
gastrointestinal O 1 0.9334712028503418
manifestations O 0 0.0001455291494494304
were O 0 1.0629622693159035e-06
more O 0 1.1043387537768012e-08
severe O 0 1.2945302842126694e-05
in O 0 2.9672078127873647e-08
them O 0 6.509359451456476e-08
. O 0 9.777298259905365e-08

In O 0 2.3249143055181776e-07
individuals O 0 2.8587261446944012e-09
with O 0 8.830707720619557e-09
mutations O 0 3.085778189415578e-06
in O 0 3.409098070505934e-08
either O 0 2.813900721321261e-07
region O 0 1.0296926120645367e-06
2 O 0 3.7612726373481564e-06
or O 0 6.526553306684946e-07
region O 0 1.95774214262201e-06
3 O 0 1.7788153172659804e-06
, O 0 4.747846915620357e-08
the O 0 1.0552517082373924e-08
average O 0 1.3492478956322884e-07
number O 0 4.926564489693419e-09
of O 0 1.434830809721177e-09
adenomas B-Disease 0 7.361555617535487e-05
tended O 0 4.092130893695867e-06
to O 0 9.648927878913582e-09
be O 0 4.7832666716374206e-09
lower O 0 5.1680029145018125e-08
than O 0 1.3299281675926977e-09
those O 0 1.6409927861005258e-09
in O 0 3.973690265723917e-09
individuals O 0 1.721507103535913e-10
with O 0 6.296282162310263e-09
mutations O 0 1.9996189166704426e-06
in O 0 2.2358264573085762e-08
region O 0 1.6468011665438098e-07
1 O 0 2.265070691009896e-07
, O 0 4.890148730396504e-08
although O 0 9.467774475524493e-08
age O 0 1.6662083623941726e-07
at O 0 8.550241403781911e-08
diagnosis O 0 0.0008754547452554107
was O 0 3.229437197660445e-07
similar O 0 3.1597092942092786e-08
. O 0 2.1825205465120234e-07

In O 0 2.7367759685148485e-06
all O 0 1.2021528164041229e-06
AAPC B-Disease 1 0.9999363422393799
kindreds O 0 0.024517914280295372
, O 0 2.57787142743382e-08
a O 0 1.5655864382679852e-09
predominance O 0 3.1285217119148e-06
of O 0 7.944007762716865e-08
right O 0 0.3001849949359894
- O 1 0.9999547004699707
sided O 1 0.9999978542327881
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
and O 0 0.10197843611240387
rectal B-Disease 1 0.9998966455459595
polyp I-Disease 1 0.6701971292495728
sparing O 0 4.393572453409433e-06
was O 0 4.8278889153152704e-06
observed O 0 7.488997084692528e-07
. O 0 6.350970238599984e-08

No O 0 0.0007276342366822064
desmoid B-Disease 1 0.9743930101394653
tumors I-Disease 1 0.9999996423721313
were O 0 1.0382029358879663e-05
found O 0 1.319622668916054e-07
in O 0 8.709135634887843e-09
these O 0 3.165536455185247e-08
kindreds O 0 0.0004777712165378034
. O 0 2.960589142730896e-07

Our O 0 6.245273311833444e-07
data O 0 2.0526476873783395e-07
suggest O 0 2.4666562126185454e-07
that O 0 7.027242787671639e-08
, O 0 1.920569836499908e-08
in O 0 1.8244530508582102e-07
AAPC B-Disease 1 0.9999992847442627
families O 0 9.435970014237682e-07
, O 0 3.800873837889185e-09
the O 0 6.218890957754297e-10
location O 0 1.978824002435431e-07
of O 0 1.0761421753713307e-09
the O 0 9.275447609979892e-08
APC B-Disease 0 1.9730268832063302e-05
mutation O 0 1.7255744751309976e-05
may O 0 1.0874332474486437e-06
partially O 0 4.125672603549901e-06
predict O 0 2.2076407901749917e-07
specific O 0 1.0198721867027416e-09
phenotypic O 0 1.275904764952429e-06
expression O 0 1.3277475773065817e-05
. O 0 6.306524937826907e-07

This O 0 5.936540787843114e-07
should O 0 1.2790977166332596e-07
help O 0 2.179558755699418e-09
in O 0 2.7506824595846524e-10
the O 0 5.216892473569601e-10
design O 0 1.0928205256277579e-06
of O 0 1.2758289980041582e-09
tailored O 0 8.36569452076219e-05
clinical O 0 3.889971412718296e-05
- O 0 0.00939407292753458
management O 0 8.027917601793888e-07
protocols O 0 2.032847277178007e-07
in O 0 7.63496488254134e-10
this O 0 1.3850968982875855e-10
subset O 0 3.296921136097808e-08
of O 0 5.277896786282099e-09
FAP B-Disease 0 8.167291525751352e-05
patients O 0 2.323297394468682e-06
. O 0 6.329237134394816e-09
. O 0 5.605877717584917e-08

Wilms B-Disease 1 0.6343306303024292
' I-Disease 0 0.0008903310517780483
tumor I-Disease 0 0.0008580473950132728
1 O 0 1.1503840369186946e-07
and O 0 9.402521072843228e-08
Dax O 0 0.46558812260627747
- O 0 0.0011526176240295172
1 O 0 3.466980302846423e-08
modulate O 0 3.6869198538624914e-06
the O 0 1.9247504923214365e-08
orphan O 0 6.814890184614342e-06
nuclear O 0 3.8859604956087423e-07
receptor O 0 2.0807226164265558e-08
SF O 0 0.01744040846824646
- O 0 8.822747076919768e-06
1 O 0 7.853341088548405e-09
in O 0 7.931373335878789e-10
sex O 0 8.219974034773259e-08
- O 0 2.331892119400436e-06
specific O 0 1.3807136545196386e-09
gene O 0 9.009296775275288e-08
expression O 0 4.647205571473023e-07
. O 0 4.53347865914111e-08

Products O 0 2.5228914637409616e-06
of O 0 2.0313282167450097e-09
steroidogenic O 0 2.293748138981755e-06
factor O 0 7.806971780155436e-08
1 O 0 7.190568851456192e-08
( O 0 9.5930143828582e-09
SF O 1 0.994339644908905
- O 0 0.027584655210375786
1 O 0 4.128087027766014e-07
) O 0 8.059567235818577e-09
and O 0 3.8334752616719925e-07
Wilms B-Disease 0 0.10609598457813263
tumor I-Disease 0 0.00021684117382392287
1 O 0 6.137879893231002e-08
( O 0 3.6820366755563327e-09
WT1 O 0 2.8947742976015434e-05
) O 0 1.892618950449787e-09
genes O 0 1.2510073865712457e-08
are O 0 5.890095633453996e-10
essential O 0 1.2560564810470964e-09
for O 0 6.152479081755757e-10
mammalian O 0 2.7365987875782594e-07
gonadogenesis O 0 3.958807610615622e-06
prior O 0 9.991227400973912e-09
to O 0 7.849218497391064e-10
sexual O 0 1.5585023049879965e-08
differentiation O 0 1.3378230505622923e-06
. O 0 1.3246283003809367e-07

In O 0 5.7657967289515e-08
males O 0 1.1073975514364065e-07
, O 0 2.5304277784243823e-08
SF O 1 0.5827541947364807
- O 0 0.0006209425628185272
1 O 0 9.065525574669664e-08
participates O 0 1.4233750178505034e-08
in O 0 2.0778831100187745e-08
sexual O 0 5.096349298128189e-08
development O 0 1.2599506993282716e-09
by O 0 2.1778125136595605e-10
regulating O 0 1.595028997769532e-08
expression O 0 1.8361228981689237e-08
of O 0 4.973940703756341e-10
the O 0 1.8458528927567386e-08
polypeptide O 0 2.8107459002058022e-05
hormone O 0 1.4290446870290907e-07
Mullerian O 0 3.7662978229491273e-06
inhibiting O 0 1.1269447668382782e-06
substance O 0 1.5776728332639323e-06
( O 0 2.8778371685689308e-08
MIS O 0 0.03776881471276283
) O 0 1.0443391040837469e-08
. O 0 1.7058168211292468e-08

Here O 0 1.6911773172978428e-06
, O 0 1.0742928324702916e-08
we O 0 1.3191892023201035e-08
show O 0 1.926575876609604e-08
that O 0 1.0484785484266013e-08
WT1 O 0 8.578899723943323e-05
- O 0 0.0007117904024198651
KTS O 0 6.509735248982906e-05
isoforms O 0 1.5185078083845838e-08
associate O 0 6.149586795345385e-08
and O 0 1.7356761361497774e-08
synergize O 0 2.320811472600326e-05
with O 0 2.9576726774394047e-06
SF O 1 0.9998373985290527
- O 0 0.03775838762521744
1 O 0 3.839131466065737e-07
to O 0 2.206892979472741e-08
promote O 0 2.2689860657010286e-07
MIS O 0 0.28198859095573425
expression O 0 1.6782710190454964e-06
. O 0 9.293474079186126e-08

In O 0 1.8770610665796994e-07
contrast O 0 1.6357707863789983e-06
, O 0 5.0702684717407465e-08
WT1 O 0 0.00012294687621761113
missense O 0 0.0001335338019998744
mutations O 0 0.0003403981972951442
, O 0 3.0040805398812154e-08
associated O 0 4.843698064860291e-08
with O 0 2.312336988552488e-07
male B-Disease 0 0.0023448318243026733
pseudohermaphroditism I-Disease 1 0.9999969005584717
in O 0 0.0001817430747905746
Denys B-Disease 1 0.9999299049377441
- I-Disease 1 0.9999926090240479
Drash I-Disease 1 0.9999797344207764
syndrome I-Disease 1 0.9999953508377075
, O 0 7.097706316017138e-07
fail O 0 9.963358024833724e-06
to O 0 7.56976081817129e-09
synergize O 0 0.00010186394501943141
with O 0 4.191597781755263e-06
SF O 1 0.9997225403785706
- O 0 0.14615832269191742
1 O 0 1.8756203417069628e-06
. O 0 1.2334253085555247e-07

Additionally O 0 5.655026143358555e-06
, O 0 1.6984632367211816e-08
the O 0 5.712059714113593e-09
X O 0 0.005183186382055283
- O 0 0.01695893704891205
linked O 0 0.00023448077263310552
, O 0 3.913262602850409e-09
candidate O 0 1.2981741237538813e-09
dosage O 0 5.8277006331763914e-08
- O 0 3.046274059670395e-07
sensitive O 0 2.7944668090640334e-07
sex O 0 1.0236090020043775e-07
- O 0 1.0243898032058496e-06
reversal O 0 5.787645562804755e-08
gene O 0 4.5540357263007536e-08
, O 0 3.660650893522188e-09
Dax O 0 0.017382308840751648
- O 0 0.00015489223005715758
1 O 0 1.3799225939692406e-07
, O 0 2.614094274377976e-09
antagonizes O 0 1.085356871044496e-06
synergy O 0 1.981724864208445e-07
between O 0 1.9304737008951633e-07
SF O 1 0.9988372921943665
- O 0 0.05712006986141205
1 O 0 9.435376000510587e-07
and O 0 2.2454578640918044e-07
WT1 O 0 3.6522920709103346e-05
, O 0 3.774346168938791e-09
most O 0 4.792423680122226e-10
likely O 0 4.71964778370193e-09
through O 0 3.062842479639727e-10
a O 0 1.0751143308951328e-09
direct O 0 5.834615457445125e-09
interaction O 0 3.099256673522177e-08
with O 0 2.2696200119298737e-07
SF O 1 0.9993031024932861
- O 0 0.01993383653461933
1 O 0 8.796197903393477e-07
. O 0 6.058925094976075e-08

We O 0 1.416192844772013e-06
propose O 0 4.92799507867403e-08
that O 0 1.2118382741732603e-08
WT1 O 0 2.0532719645416364e-05
and O 0 5.340521056496073e-07
Dax O 1 0.5052509903907776
- O 0 0.0019677586387842894
1 O 0 5.222144139338525e-08
functionally O 0 2.2899311602486705e-07
oppose O 0 2.703864510067433e-08
each O 0 8.054399924795064e-10
other O 0 1.20089660438083e-09
in O 0 2.7750207465260246e-08
testis O 0 2.6475945560378022e-05
development O 0 7.702442239576612e-09
by O 0 1.8521789657555132e-09
modulating O 0 7.320663371501723e-06
SF O 1 0.9728232026100159
- O 0 0.00134979875292629
1 O 0 1.5886901394424058e-07
- O 0 5.443675036076456e-05
mediated O 0 7.2396951509290375e-06
transactivation O 0 9.19310114113614e-05
. O 0 2.6966489485857892e-08
. O 0 1.0820951246159893e-08

A O 0 1.4582326457457384e-06
mouse O 0 4.041812280775048e-05
model O 0 2.3810660422896035e-05
for O 0 5.86071246289066e-06
Prader B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999994039535522
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999983310699463
imprinting O 1 0.9657414555549622
- O 1 0.9772363901138306
centre O 0 0.0009099459275603294
mutations O 0 2.5074128643609583e-05
. O 0 1.2885324451872293e-07

Imprinting O 0 0.00046269199810922146
in O 0 9.449607318856579e-08
the O 0 1.2357042500354964e-08
15q11 O 0 2.7136143216921482e-06
- O 0 0.0001287349296035245
q13 O 0 1.1811158628916019e-06
region O 0 1.1574341485243167e-08
involves O 0 1.2184034892115392e-09
an O 0 1.5134584696596676e-09
imprinting O 0 0.00014450879825744778
centre O 0 1.2164336112618912e-05
( O 0 6.227615090281802e-10
IC O 0 2.564767555668368e-06
) O 0 9.00978736062541e-10
, O 0 1.5744856807220486e-10
mapping O 0 1.5217152338209416e-07
in O 0 4.502410888562736e-09
part O 0 3.4028225570637005e-08
to O 0 6.2024163582918845e-09
the O 0 1.891363066164331e-09
promoter O 0 1.1353036825312302e-05
and O 0 4.9370836308071375e-08
first O 0 6.942111774321802e-09
exon O 0 2.3267109838798206e-07
of O 0 7.680788449704323e-09
SNRPN O 0 0.0014044168638065457
. O 0 1.9290602892851894e-07

Deletion O 0 0.0003023547469638288
of O 0 2.252167696781271e-08
this O 0 1.1667411925486704e-08
IC O 0 8.433713810518384e-05
abolishes O 0 1.3772124475508463e-05
local O 0 1.7922623385402403e-08
paternally O 0 3.3408534250156663e-07
derived O 0 3.678274129725878e-09
gene O 0 1.0357382507208968e-07
expression O 0 4.6287743771245005e-07
and O 0 2.7175300942872127e-07
results O 0 1.103978661376459e-06
in O 0 0.0002150717773474753
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 4.787884608958848e-05
PWS B-Disease 1 0.9999969005584717
) O 0 6.309123250503035e-07
. O 0 2.1720283882586955e-07

We O 0 4.331759555498138e-05
have O 0 1.6357468268779485e-08
created O 0 4.5048249575074806e-09
two O 0 1.8336825391429556e-09
deletion O 0 6.68734446662711e-06
mutations O 0 3.074327469221316e-05
in O 0 4.3845255959240603e-07
mice O 1 0.778460681438446
to O 0 1.127578980231192e-05
understand O 0 0.0004263462615199387
PWS B-Disease 1 0.9999995231628418
and O 0 4.229717433190672e-06
the O 0 1.6375386380218515e-08
mechanism O 0 1.1080778961058968e-07
of O 0 7.95764842909108e-10
this O 0 1.4744463427973642e-08
IC O 0 0.0001765071792760864
. O 0 1.2661456594287301e-07

Mice O 0 0.20592477917671204
harbouring O 0 0.0002472071791999042
an O 0 4.5681463944902134e-08
intragenic O 0 9.252403833670542e-05
deletion O 0 5.904182035010308e-05
in O 0 2.5451674900978105e-07
Snrpn O 0 0.0051223342306911945
are O 0 3.3395401999314345e-08
phenotypically O 0 2.361202859901823e-06
normal O 0 1.6826878663778189e-06
, O 0 8.177029720002338e-09
suggesting O 0 1.1754507767136602e-07
that O 0 8.416895269647284e-08
mutations O 0 4.613706039435783e-07
of O 0 7.491767206602162e-09
SNRPN O 0 0.08405475318431854
are O 0 2.4315443880595922e-08
not O 0 2.042549596126264e-08
sufficient O 0 3.622947275516708e-09
to O 0 1.659004489340532e-08
induce O 0 6.847476470284164e-05
PWS B-Disease 1 0.9999767541885376
. O 0 2.3368386337097036e-06

Mice O 0 0.247176393866539
with O 0 3.283779648199925e-08
a O 0 7.507358290581578e-09
larger O 0 7.926431955240787e-09
deletion O 0 3.339940349178505e-06
involving O 0 1.71734797049794e-07
both O 0 1.6470523860334652e-06
Snrpn O 0 0.049495335668325424
and O 0 1.2681168755079852e-06
the O 0 1.7019436882037553e-07
putative O 0 0.004293035715818405
PWS O 1 0.999997615814209
- O 1 0.9714183211326599
IC O 0 0.021069325506687164
lack O 0 6.376362762239296e-07
expression O 0 5.514915457638381e-08
of O 0 4.027651268057042e-10
the O 0 2.5086821509034962e-08
imprinted O 0 0.00018426340830046684
genes O 0 5.115981821290916e-06
Zfp127 O 0 0.00017155142268165946
( O 0 3.204517096122572e-09
mouse O 0 2.697482614166802e-06
homologue O 0 7.845391678529268e-07
of O 0 4.791594232500529e-09
ZNF127 O 0 0.000828571617603302
) O 0 8.435824483399301e-09
, O 0 7.50063122723077e-09
Ndn O 0 9.830935596255586e-05
and O 0 5.007968439940669e-08
Ipw O 0 1.764040280249901e-05
, O 0 5.8352977561071384e-08
and O 0 4.867462166657788e-08
manifest O 0 1.2335122789863817e-07
several O 0 7.870941676202392e-10
phenotypes O 0 2.1700584511563648e-06
common O 0 8.700238254277792e-07
to O 0 4.9693680921336636e-05
PWS B-Disease 1 0.9999985694885254
infants O 0 0.1091136783361435
. O 0 3.2175157116398623e-07

These O 0 5.796726654239137e-08
data O 0 1.3898146278279455e-07
demonstrate O 0 4.234283679238615e-08
that O 0 2.259408837801402e-08
both O 0 1.4138588078083103e-08
the O 0 5.081712117771531e-08
position O 0 1.152513618762896e-06
of O 0 3.8747138830785843e-10
the O 0 4.2737166694450934e-08
IC O 0 0.00020410599245224148
and O 0 1.979111061700678e-07
its O 0 1.6795009827319518e-09
role O 0 1.1684760714558706e-08
in O 0 3.0768383396662102e-09
the O 0 1.2396530468805622e-09
coordinate O 0 2.6742652536881906e-08
expression O 0 2.1004046502071105e-08
of O 0 1.028535451252921e-10
genes O 0 1.694854923073308e-08
is O 0 1.8602511753229578e-09
conserved O 0 6.912953409710099e-08
between O 0 3.159890411552624e-07
mouse O 0 0.06924735009670258
and O 0 1.9334180251462385e-05
human O 0 2.0357194898679154e-06
, O 0 5.5116554875667134e-08
and O 0 5.52074581605666e-08
indicate O 0 3.8759341691729787e-07
that O 0 4.133751474455494e-08
the O 0 1.678733241305963e-08
mouse O 0 4.190134859527461e-05
is O 0 6.998614576758655e-09
a O 0 1.98538940843207e-09
suitable O 0 3.7162291022241334e-08
model O 0 1.5286314010154456e-06
system O 0 7.12877522346389e-07
in O 0 1.5896290506134392e-08
which O 0 3.7856892731724656e-08
to O 0 1.3675904853016618e-09
investigate O 0 1.3896753747744128e-09
the O 0 2.2580408376438044e-10
molecular O 0 2.919595765149552e-08
mechanisms O 0 2.808058674474978e-08
of O 0 1.6954643244915246e-10
imprinting O 0 2.006336217164062e-05
in O 0 3.454629649013441e-08
this O 0 6.62386812066984e-09
region O 0 8.58024851169148e-09
of O 0 1.7350124115189658e-10
the O 0 2.1596676447188656e-08
genome O 0 9.002046112982498e-07
. O 0 1.1201901628510313e-08
. O 0 1.5765577288107124e-08

Mutations O 0 0.0001014862209558487
of O 0 6.556045040184699e-09
the O 0 7.554673331355843e-09
ATM O 0 1.4495331924990751e-05
gene O 0 5.672661131939094e-07
detected O 0 4.384799012768781e-06
in O 0 2.4786189101178024e-07
Japanese O 1 0.9233251810073853
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.9893501400947571
: O 0 8.732126843824517e-08
possible O 0 1.974928309778079e-08
preponderance O 0 4.997442829335341e-06
of O 0 7.523039968759804e-09
the O 0 1.3386036812335078e-07
two O 0 2.2446420189226046e-07
founder O 0 1.761881503625773e-05
mutations O 0 3.531725269567687e-06
4612del165 O 0 1.8334459355173749e-06
and O 0 5.7650158424848996e-08
7883del5 O 0 3.6505330172076356e-06
. O 0 1.0230468205918442e-07

The O 0 3.998458737441979e-07
ATM O 0 0.00015360661200247705
( O 0 2.3203203625143942e-07
A O 1 0.9999204874038696
- O 1 0.9999959468841553
T O 1 0.9999998807907104
, O 0 2.730818664531398e-07
mutated O 0 1.045247699948959e-06
) O 0 4.580592016800722e-10
gene O 0 2.1484309442598715e-08
on O 0 6.173715405566327e-07
human O 0 9.196383530252206e-07
chromosome O 0 0.0004010894917882979
11q22 O 0 7.593684131279588e-06
. O 0 5.5830000178502814e-08

3 O 0 9.567319466441404e-06
has O 0 5.231705131336639e-07
recently O 0 3.5125989938933344e-07
been O 0 6.642164862569189e-08
identified O 0 9.389152211269902e-08
as O 0 2.6586353119029127e-09
the O 0 1.5387938701039161e-09
gene O 0 2.999563548655715e-07
responsible O 0 2.397829916844785e-07
for O 0 8.024763076264207e-09
the O 0 9.498602366875275e-07
human O 0 0.009268231689929962
recessive B-Disease 1 0.999987006187439
disease I-Disease 1 0.9999992847442627
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.037634141743183136
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999994039535522
T I-Disease 1 0.9999997615814209
) O 0 4.3835265728375816e-07
. O 0 9.586981519760229e-08

In O 0 2.2762336016057816e-07
order O 0 1.6899063481901067e-08
to O 0 2.0777908282809676e-09
define O 0 1.9741570156384114e-07
the O 0 6.993037704461358e-09
types O 0 2.5367883154103765e-06
of O 0 1.2682522765317117e-06
disease O 1 0.9823538064956665
- O 1 0.5260734558105469
causing O 0 5.705388048227178e-06
ATM O 0 0.0002071839990094304
mutations O 0 4.894095582130831e-06
in O 0 5.260241664473142e-08
Japanese O 0 0.0030388864688575268
A B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 0.0018321588868275285
as O 0 2.6780988093833002e-08
well O 0 1.5634924466212397e-08
as O 0 1.0074622025513236e-08
to O 0 5.100304623084639e-09
look O 0 7.066611118489163e-08
for O 0 1.7521424588995416e-10
possible O 0 2.618115946262378e-09
mutational O 0 1.9453061668173177e-06
hotspots O 0 3.1693534765508957e-06
, O 0 1.743716104840587e-08
reverse O 0 5.337021502782591e-05
- O 0 5.801796942250803e-05
transcribed O 0 4.635229288396658e-06
RNA O 0 1.7748569689501892e-06
derived O 0 1.0338129241560523e-09
from O 0 1.9794783867599364e-10
ten O 0 8.550107288840536e-09
patients O 0 1.388968673410318e-08
belonging O 0 1.0064251654284817e-08
to O 0 3.523720337739178e-08
eight O 0 1.264805415956971e-08
unrelated O 0 4.3974782215627783e-07
Japanese O 0 0.12643036246299744
A B-Disease 1 0.9999974966049194
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
families O 0 1.2574816992128035e-06
was O 0 1.7954087070393143e-06
analyzed O 0 1.0042050746505993e-07
for O 0 3.6493971733442265e-10
mutations O 0 3.7964561272474384e-08
by O 0 1.3013541633188908e-10
the O 0 1.76419809316819e-10
restriction O 0 6.106920746873357e-09
endonuclease O 0 4.751045139528287e-07
fingerprinting O 0 1.1547173244252917e-06
method O 0 1.9558652297746448e-07
. O 0 2.0101964537388994e-08

As O 0 2.092490831273608e-06
has O 0 2.718969085435674e-07
been O 0 4.221542226900965e-08
reported O 0 3.8386733791639926e-08
by O 0 2.659629405599162e-09
others O 0 5.534504765591919e-08
, O 0 7.798752754695215e-09
mutations O 0 5.247435410637991e-07
that O 0 7.482287145421651e-08
lead O 0 2.803906227200059e-07
to O 0 1.4251509972140752e-09
exon O 0 3.93302343582036e-07
skipping O 0 7.815693606971763e-06
or O 0 1.0973593589369557e-06
premature O 0 1.0762472584247007e-06
protein O 0 5.111653322842358e-08
truncation O 0 2.6486401111469604e-05
were O 0 3.5703073990589473e-06
also O 0 6.320252623481792e-07
predominant O 0 3.5259404285170604e-06
in O 0 1.717108801813083e-07
our O 0 4.0385680222243536e-07
mutants O 0 4.145424099988304e-06
. O 0 2.2829180323924447e-08

Six O 0 1.3902838702506415e-07
different O 0 1.241550751096554e-09
mutations O 0 2.2180891789957968e-07
were O 0 4.65220750811568e-08
identified O 0 2.2990099068920244e-07
on O 0 7.197332934083533e-07
12 O 0 6.371681848804656e-08
of O 0 4.3770467805792634e-10
the O 0 4.075038617656901e-08
16 O 0 6.784431150208547e-08
alleles O 0 2.082994043917097e-08
examined O 0 3.6877918319078162e-06
. O 0 9.223754915410609e-08

Four O 0 1.5361752048193011e-06
were O 0 4.213337234659775e-08
deletions O 0 2.484639765043539e-07
involving O 0 1.8244477928419656e-07
a O 0 3.6196659038978396e-06
loss O 0 0.0007198628736659884
of O 0 2.202577231713576e-09
a O 0 1.398424558374245e-07
single O 0 8.277966117020696e-07
exon O 0 7.014687071205117e-07
exon O 0 3.0717435492988443e-06
7 O 0 4.633963897049398e-07
, O 0 6.226640869577693e-10
exon O 0 2.1710776820782485e-07
16 O 0 1.094539854307186e-07
, O 0 8.687894847980715e-10
exon O 0 3.390617280274455e-07
33 O 0 4.803318915946875e-07
or O 0 9.17042353165698e-09
exon O 0 5.525077085621888e-06
35 O 0 2.29074453272915e-06
. O 0 1.6213333253745077e-07

The O 0 1.782118488335982e-07
others O 0 4.835876143971518e-09
were O 0 1.3709491319957579e-09
minute O 0 7.756341346976114e-09
deletions O 0 1.7531613138999091e-07
, O 0 1.4712766560620594e-09
4649delA O 0 7.192461737304257e-08
in O 0 1.4290379990455904e-09
exon O 0 8.957642307905189e-07
33 O 0 4.949161507283861e-07
and O 0 1.3083814920378245e-08
7883del5 O 0 5.7052787383327086e-08
in O 0 1.2883911715277918e-09
exon O 0 1.7464841448600055e-06
55 O 0 4.941869633512397e-07
. O 0 6.968009103047734e-08

The O 0 7.11143968601391e-07
mutations O 0 7.2471971179766115e-06
4612del165 O 0 2.5671215553302318e-06
and O 0 4.622946647714343e-08
7883del5 O 0 1.6118073631332663e-07
were O 0 3.127325953755644e-08
found O 0 1.0925370830250358e-08
in O 0 2.8148713915321366e-10
more O 0 2.929643680427141e-11
than O 0 7.651584366108466e-10
two O 0 3.462940156850891e-09
unrelated O 0 9.715042637026272e-08
families O 0 2.1813983508423007e-08
; O 0 3.3337790306120496e-09
44 O 0 4.696596000997033e-09
% O 0 2.3643581537058367e-10
( O 0 2.960686695807624e-10
7 O 0 2.5957970706258493e-07
of O 0 7.943595115023072e-09
16 O 0 7.417081633320777e-07
) O 0 1.1926470921963528e-09
of O 0 6.642345701246555e-11
the O 0 2.489409789419028e-09
mutant O 0 2.2491933293622424e-07
alleles O 0 7.067565199747605e-09
had O 0 1.9527449239831185e-06
one O 0 9.136323364522525e-10
of O 0 8.37154165433951e-11
the O 0 7.551705927255625e-09
two O 0 5.743493147747358e-08
mutations O 0 5.515479642781429e-06
. O 0 1.5257330687745707e-07

The O 0 2.7348639264346275e-07
4612del165 O 0 8.294418876175769e-07
mutations O 0 2.829326831488288e-06
in O 0 7.440472238329221e-09
three O 0 5.80364911684228e-09
different O 0 1.765585899704547e-09
families O 0 1.179951869545448e-08
were O 0 8.228145986777236e-08
all O 0 1.4886735177910282e-09
ascribed O 0 2.3587962516558036e-07
to O 0 1.4402193215801162e-08
the O 0 4.157708399787907e-09
same O 0 1.0268315264738703e-07
T O 0 0.06079121679067612
- O 0 0.0005677324952557683
- O 0 2.0446117559913546e-05
> O 0 3.3799225640507302e-09
A O 0 6.649903960820325e-10
substitution O 0 4.897630634381755e-10
at O 0 1.313141040348853e-09
the O 0 2.2849282188541764e-10
splice O 0 7.345769063249463e-06
donor O 0 2.0034585102024494e-09
site O 0 3.112413793360247e-08
in O 0 3.2927907067659135e-09
intron O 0 0.000484156800666824
33 O 0 2.669048171810573e-06
. O 0 5.801062741284113e-08

Microsatellite O 0 0.0004671975621022284
genotyping O 0 0.0001267961342819035
around O 0 1.0131241623412279e-07
the O 0 6.005296704358898e-09
ATM O 0 2.7066331313108094e-05
locus O 0 7.92393257142976e-06
also O 0 3.34051992467721e-06
indicated O 0 1.2216896720929071e-06
that O 0 1.836981056158038e-08
a O 0 1.5429858279958353e-08
common O 0 2.489917676484765e-07
haplotype O 0 0.01805405505001545
was O 0 0.0031229688320308924
shared O 0 5.739758890399571e-08
by O 0 1.9166643827617236e-09
the O 0 2.047025660090185e-09
mutant O 0 2.490627650786337e-07
alleles O 0 3.516279933890587e-09
in O 0 3.5206553228306348e-09
both O 0 3.122129044186295e-08
mutations O 0 3.0116761990939267e-06
. O 0 2.5252404611819657e-07

This O 0 6.056660026843019e-07
suggests O 0 3.873898322126479e-07
that O 0 2.839750479211034e-08
these O 0 1.7054286871598379e-09
two O 0 7.155582348872258e-09
founder O 0 2.0832358131883666e-05
mutations O 0 5.9310255892341956e-05
may O 0 3.279318661952857e-06
be O 0 3.63721719409682e-09
predominant O 0 6.671876207064997e-08
among O 0 1.7964093546041227e-09
Japanese O 0 1.1532910093592363e-06
ATM O 0 3.0556326237274334e-05
mutant O 0 6.206600119185168e-06
alleles O 0 1.993313532011598e-07
. O 0 6.285449671850074e-08

W474C O 0 2.3179163690656424e-05
amino O 0 4.411877796428598e-07
acid O 0 3.6866342867369895e-08
substitution O 0 3.2470564015341097e-09
affects O 0 6.3423364338177635e-09
early O 0 1.4403037651433692e-09
processing O 0 3.597057762760869e-09
of O 0 6.320689804883983e-11
the O 0 1.576363622968202e-10
alpha O 0 1.6511769729277148e-10
- O 0 1.0782815529353229e-08
subunit O 0 4.601441727647426e-10
of O 0 2.8761040424263307e-11
beta O 0 1.9780903581789744e-09
- O 0 5.579344360739924e-06
hexosaminidase O 0 3.3147198337246664e-06
A O 0 3.522931706356758e-07
and O 0 8.398902906492367e-08
is O 0 6.120108864138274e-09
associated O 0 1.0171024911187487e-08
with O 0 5.793819468635775e-08
subacute O 1 0.9857812523841858
G B-Disease 0 0.4764120578765869
( I-Disease 0 9.988940341543184e-09
M2 I-Disease 0 0.0006515855202451348
) I-Disease 0 7.615977182240385e-08
gangliosidosis I-Disease 0 5.771590076619759e-05
. O 0 2.1508361669475562e-07

Mutations O 0 0.0005669683450832963
in O 0 2.9537350343389335e-08
the O 0 8.626194869520987e-09
HEXA O 0 4.4295808038441464e-05
gene O 0 7.546410785153057e-08
, O 0 9.580058968339245e-11
encoding O 0 1.665324406152635e-10
the O 0 3.59724805498729e-10
alpha O 0 3.9135442109206053e-10
- O 0 3.251030378237374e-08
subunit O 0 6.206247182838354e-10
of O 0 9.665773043066039e-11
beta O 0 8.470085077760814e-09
- O 0 2.6892044843407348e-05
hexosaminidase O 0 5.977192813588772e-06
A O 0 2.1710943087782653e-07
( O 0 5.17863474325253e-10
Hex O 0 3.3626383810769767e-06
A O 0 2.3037043206386443e-07
) O 0 3.733164000152556e-09
, O 0 6.216245851398128e-10
that O 0 6.906397120864938e-10
abolish O 0 1.3554823397043947e-07
Hex O 0 2.7466228402772686e-06
A O 0 2.4338087101227757e-08
enzyme O 0 2.5785482193896314e-07
activity O 0 8.42868939798791e-06
cause O 0 0.009690957143902779
Tay B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
Sachs I-Disease 1 0.9999998807907104
disease I-Disease 1 0.998822033405304
( O 0 1.3485192518203348e-08
TSD B-Disease 0 0.0003088114317506552
) O 0 5.306627315349033e-08
, O 0 9.998456107496168e-08
the O 0 8.083015359261481e-07
fatal O 1 0.7516946792602539
infantile B-Disease 1 0.9790698885917664
form I-Disease 0 1.1668828847177792e-05
of I-Disease 0 1.9291061903459195e-07
G I-Disease 1 0.5168542861938477
( I-Disease 0 4.4766106377380765e-09
M2 I-Disease 0 0.00019786247867159545
) I-Disease 0 1.0632299485280328e-08
gangliosidosis I-Disease 0 3.0807736948190723e-06
, I-Disease 0 5.727310625758264e-09
Type I-Disease 0 2.5578844997653505e-06
1 I-Disease 0 2.6902432637143647e-07
. O 0 2.146987441165038e-07

Less O 0 3.532753908075392e-05
severe O 0 0.008428581058979034
, O 0 4.417283321345167e-07
subacute O 0 0.22583478689193726
( O 0 2.874601250368869e-07
juvenile O 0 0.3115719258785248
- O 1 0.9994481205940247
onset O 1 0.9995324611663818
) O 0 8.334149242728017e-06
and O 0 0.0006787522579543293
chronic O 1 0.7279961109161377
( O 0 1.1783214404204045e-08
adult O 0 3.0457929824478924e-05
- O 1 0.9123836755752563
onset O 0 0.011550803668797016
) O 0 3.283151528421513e-09
variants O 0 6.662732943141236e-08
are O 0 1.4639544687611306e-08
characterized O 0 4.459632805264846e-07
by O 0 3.6491345500877514e-09
a O 0 2.0837092051806394e-08
broad O 0 1.2978377981198719e-06
spectrum O 0 1.6400007325501065e-06
of O 0 1.4044357676823438e-08
clinical O 0 3.3094525861088187e-05
manifestations O 0 0.00010284034215146676
and O 0 1.2865668850281509e-06
are O 0 2.711004976063691e-09
associated O 0 5.480340625751978e-09
with O 0 1.1623699336382742e-08
residual O 0 9.783519089978654e-06
levels O 0 1.2432296614406368e-07
of O 0 2.8352228897965404e-10
Hex O 0 1.852982495620381e-05
A O 0 6.966334353819548e-08
enzyme O 0 1.3963402523131663e-07
activity O 0 8.49328785079706e-08
. O 0 2.3674292748410153e-08

We O 0 6.617583494517021e-06
identified O 0 8.464807876862324e-08
a O 0 1.7257695716921262e-08
1422 O 0 5.082033749204129e-05
G O 0 0.004593745805323124
- O 0 0.011721118353307247
- O 0 0.020188774913549423
> O 0 2.487380925231264e-06
C O 0 7.3112018981191795e-06
( O 0 9.242569209977347e-11
amino O 0 4.031286415795421e-10
acid O 0 2.0945785106363246e-09
W474C O 0 1.0299259223245372e-09
) O 0 4.707530372460855e-12
substitution O 0 5.494087476631826e-11
in O 0 4.443415080324087e-10
the O 0 7.124953516068899e-09
first O 0 5.009449068893446e-07
position O 0 1.3123033681949892e-07
of O 0 8.405684481793685e-11
exon O 0 1.4707843547512311e-06
13 O 0 1.2740574106828717e-07
of O 0 1.1870211480413673e-09
HEXA O 0 0.002228224417194724
of O 0 1.2436814911254146e-09
a O 0 3.062150710775313e-08
non O 0 1.1733653337842043e-07
- O 0 0.0003513424890115857
Jewish O 0 6.366498382703867e-06
proband O 0 0.0001453564764233306
who O 0 1.3825651876686607e-06
manifested O 0 6.778817862596043e-08
a O 0 8.84002737677747e-09
subacute O 0 0.0003034975379705429
variant O 0 0.00017898170335683972
of O 0 8.999438705359353e-08
G B-Disease 0 0.186827152967453
( I-Disease 0 1.1589849080451131e-08
M2 I-Disease 0 0.0004709229397121817
) I-Disease 0 9.960216829085766e-08
gangliosidosis I-Disease 0 0.00011565612658159807
. O 0 2.6453443524587783e-07

On O 0 6.292788839346031e-06
the O 0 5.181762219308439e-08
second O 0 1.0023084087151801e-06
maternally O 0 3.571972911231569e-06
inherited O 0 3.170238414895721e-05
allele O 0 3.482197143966914e-07
, O 0 5.8391833590576425e-08
we O 0 5.7681287302102646e-08
identified O 0 8.351425861974349e-08
the O 0 1.5274407871856965e-07
common O 0 0.0027575669810175896
infantile O 1 0.999994158744812
disease O 1 0.9999752044677734
- O 1 0.9659999012947083
causing O 0 6.538489833474159e-05
4 O 0 3.017644530700636e-06
- O 0 0.0009950200328603387
bp O 0 2.2541762518812902e-06
insertion O 0 8.345423196942647e-08
, O 0 2.515047947682092e-09
+ O 0 4.6036323197995443e-08
TATC O 0 8.391122719331179e-06
1278 O 0 5.344737019186141e-06
, O 0 1.2088064993420744e-09
in O 0 6.149769027352647e-10
exon O 0 2.0622005649784114e-06
11 O 0 9.87977159638831e-07
. O 0 1.0068728784062841e-07

Pulse O 0 0.004677937366068363
- O 0 0.00027594866696745157
chase O 0 1.1251728210481815e-05
analysis O 0 2.3234687063222736e-08
using O 0 1.570617946811126e-08
proband O 0 1.1031850590370595e-05
fibroblasts O 0 1.921828697959427e-06
revealed O 0 7.633240784343798e-06
that O 0 1.725749854131209e-08
the O 0 2.2287318657276955e-09
W474C O 0 1.3749726690548414e-07
- O 0 3.2914681469264906e-07
containing O 0 5.512333367541089e-10
alpha O 0 2.638708973545789e-10
- O 0 7.30876204002584e-09
subunit O 0 3.9543776586548063e-10
precursor O 0 6.587871137497814e-09
was O 0 3.08922153635649e-07
normally O 0 7.326735329549194e-10
synthesized O 0 4.420477495159503e-08
, O 0 8.251823113702983e-10
but O 0 1.9365036241225653e-09
not O 0 1.7039938904339635e-10
phosphorylated O 0 1.7840009469693996e-09
or O 0 2.4121928898779288e-09
secreted O 0 1.8919630306868385e-08
, O 0 3.418161398371922e-08
and O 0 5.701928174062232e-08
the O 0 7.610702290605786e-09
mature O 0 7.914032806866089e-08
lysosomal O 0 4.90385616558342e-07
alpha O 0 7.827973269591837e-10
- O 0 4.735050751492054e-08
subunit O 0 1.1420877576995281e-08
was O 0 4.356508327418851e-07
not O 0 4.485302795842472e-09
detected O 0 1.0048756138303361e-07
. O 0 5.068940822638979e-09

When O 0 2.818753500832827e-06
the O 0 1.9621202440589514e-09
W474C O 0 4.175209511458888e-08
- O 0 2.8294732601352734e-07
containing O 0 5.747684550527765e-10
alpha O 0 7.097550880352799e-10
- O 0 6.550185105425044e-08
subunit O 0 1.3193779402342898e-08
was O 0 7.960477432789048e-07
transiently O 0 1.2339087618329359e-07
co O 0 1.0016663054557284e-06
- O 0 3.7948673252685694e-06
expressed O 0 2.771939067169882e-10
with O 0 1.7296827858892527e-10
the O 0 2.6757884796779763e-10
beta O 0 3.755272204308824e-10
- O 0 1.0830619601165381e-07
subunit O 0 4.219527838245085e-09
to O 0 4.536780728869871e-09
produce O 0 1.151848505465125e-09
Hex O 0 2.471971356499125e-07
A O 0 3.612033694366801e-08
( O 0 6.390029061442704e-10
alphabeta O 0 1.952776528924005e-06
) O 0 7.899125797905526e-10
in O 0 2.236955731760304e-09
COS O 0 0.0010843047639355063
- O 0 0.0032299398444592953
7 O 0 1.504481588199269e-06
cells O 0 1.4504777823276527e-07
, O 0 3.9626676939796823e-10
the O 0 1.0130570687882923e-10
mature O 0 5.594656404817044e-10
alpha O 0 6.932524693192832e-11
- O 0 3.5104648077322054e-08
subunit O 0 1.0267469541247465e-08
was O 0 2.723892066569533e-06
present O 0 1.9881478685590537e-09
, O 0 2.620424099930574e-09
but O 0 2.6449991086252567e-09
its O 0 1.8912359178724358e-10
level O 0 1.9602957479492034e-08
was O 0 1.3634557660680002e-07
much O 0 3.7922692763814325e-10
lower O 0 6.31590211241928e-08
than O 0 7.668986001796441e-10
that O 0 3.5344078774812715e-09
from O 0 3.0745413159838364e-11
normal O 0 2.6724575330483447e-10
alpha O 0 1.1007605243973373e-10
- O 0 1.9433349152109258e-08
subunit O 0 3.3580489500195654e-09
transfections O 0 6.21749677520711e-07
, O 0 1.2143915040230269e-10
although O 0 8.12543643480268e-11
higher O 0 8.895292835653379e-11
than O 0 3.118567071247469e-10
in O 0 4.352788796069262e-09
those O 0 5.50275558452995e-09
cells O 0 6.056267665144333e-08
transfected O 0 5.298344945003919e-07
with O 0 8.117973515631149e-10
an O 0 1.9338709800198473e-10
alpha O 0 1.744127731129197e-09
- O 0 1.0956287042063195e-06
subunit O 0 4.044112955625678e-08
associated O 0 1.2221495637732005e-07
with O 0 4.808553057955578e-07
infantile O 1 0.9592761397361755
TSD B-Disease 0 0.07122073322534561
. O 0 4.956369252795412e-07

Furthermore O 0 2.433792906231247e-05
, O 0 7.46079376057196e-09
the O 0 3.023264416590621e-10
precursor O 0 4.483327042947849e-09
level O 0 1.542779770602465e-08
of O 0 8.529753986463717e-11
the O 0 9.126412403581696e-10
W474C O 0 6.578014133395982e-09
alpha O 0 1.9225911140896557e-10
- O 0 1.62439857120944e-08
subunit O 0 2.4899273753931084e-09
was O 0 2.932122526999592e-07
found O 0 4.92996710121929e-09
to O 0 1.2108579694469768e-09
accumulate O 0 1.628720269764017e-08
in O 0 2.1837065489194174e-10
comparison O 0 5.282700943354257e-09
to O 0 7.294385651057667e-10
the O 0 1.1685016843010487e-10
normal O 0 6.764707127793201e-10
alpha O 0 1.5821650933833808e-10
- O 0 3.4971655793469836e-08
subunit O 0 4.636560912985033e-09
precursor O 0 3.362819356311775e-08
levels O 0 7.424809922440545e-08
. O 0 1.4490504796071946e-08

We O 0 1.9838285879814066e-05
conclude O 0 5.287895419314737e-07
that O 0 8.88534756882109e-09
the O 0 5.995511198619852e-09
1422 O 0 3.692386599141173e-05
G O 0 0.015607650391757488
- O 0 0.00712064653635025
- O 0 0.09893100708723068
> O 0 4.02079604100436e-06
C O 0 3.190416100551374e-05
mutation O 0 1.711657944269973e-07
is O 0 1.6820214554513768e-08
the O 0 3.6101805989119384e-08
cause O 0 3.224217834940646e-07
of O 0 1.582875275296658e-09
Hex B-Disease 0 0.20193839073181152
A I-Disease 0 0.11041887104511261
enzyme I-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9999990463256836
in O 0 3.5856069757755904e-07
the O 0 2.14034741929936e-07
proband O 0 0.0004911344731226563
. O 0 1.9722827460100234e-07

The O 0 2.2778971242587431e-07
resulting O 0 1.0267689276588499e-07
W474C O 0 1.8697949144552695e-07
substitution O 0 1.0476133383008346e-07
clearly O 0 2.403367886927299e-07
interferes O 0 3.3839235413779534e-08
with O 0 1.3675219290298912e-10
alpha O 0 4.3275713568213803e-10
- O 0 3.009368043649374e-08
subunit O 0 1.0287733998026738e-09
processing O 0 1.985175117624749e-07
, O 0 1.8341662411103243e-08
but O 0 5.761077392918423e-09
because O 0 1.4414518190175585e-10
the O 0 1.8842103224891993e-11
base O 0 1.4303387363412412e-09
substitution O 0 6.581239997416333e-09
falls O 0 5.295623850543052e-06
at O 0 1.2170779051245972e-08
the O 0 2.6937636565804723e-09
first O 0 1.0097673452946765e-07
position O 0 2.775428420420667e-08
of O 0 6.655293677271246e-11
exon O 0 9.105710319090576e-07
13 O 0 5.8040949824089694e-08
, O 0 2.2153677503577995e-10
aberrant O 0 9.098785369587858e-08
splicing O 0 6.04984143137699e-06
may O 0 2.9872941013309173e-05
also O 0 1.8719555328061688e-07
contribute O 0 1.922207060189862e-09
to O 0 2.3193640785734715e-08
Hex B-Disease 0 0.003052949672564864
A I-Disease 0 0.0030668119434267282
deficiency I-Disease 0 0.13495604693889618
in O 0 7.651018485432814e-09
this O 0 2.3272518134831444e-08
proband O 0 3.601229764171876e-05
. O 0 3.260462833054589e-08
. O 0 1.6120926815688108e-08

Two O 0 2.567564649780252e-07
frequent O 0 1.3285111890581902e-06
missense O 0 0.0005487590096890926
mutations O 0 0.04512723907828331
in O 0 0.010696381330490112
Pendred B-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
. O 0 6.128379027359188e-05

Pendred B-Disease 1 0.9999972581863403
syndrome I-Disease 1 0.9999998807907104
is O 0 0.006694058421999216
an O 0 0.15510384738445282
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.999896764755249
by O 0 6.416308315237984e-05
early O 0 0.3363172709941864
childhood O 1 0.9999538660049438
deafness B-Disease 1 1.0
and O 1 0.9943056702613831
goiter B-Disease 1 0.9999995231628418
. O 0 5.8784291468327865e-05

A O 0 5.394439085648628e-06
century O 0 6.164069873193512e-06
after O 0 2.7182602835296166e-08
its O 0 3.168329765212974e-10
recognition O 0 3.7850589329480044e-09
as O 0 2.1153812213015044e-07
a O 0 4.2360938095953315e-05
syndrome O 1 0.9989437460899353
by O 0 8.904234505280328e-08
Vaughan O 0 0.00044603340211324394
Pendred O 0 4.126828207517974e-05
, O 0 1.617189404612418e-08
the O 0 4.282823624635057e-07
disease O 0 0.05098418891429901
gene O 0 3.0272951789811486e-06
( O 0 2.225360340446514e-08
PDS O 0 0.00022008593077771366
) O 0 5.686719539710339e-09
was O 0 5.730842644879885e-07
mapped O 0 2.506253258616198e-05
to O 0 1.0271567418840277e-07
chromosome O 0 0.00012811747728846967
7q22 O 0 6.374346867232816e-06
- O 0 0.0009683827520348132
q31 O 0 9.581801350577734e-06
. O 0 7.933604706522601e-08

1 O 0 1.1001456186932046e-05
and O 0 7.712838510087749e-07
, O 0 1.324569609550963e-08
recently O 0 1.1758022537833313e-06
, O 0 6.324048840156138e-09
found O 0 2.9343887320010253e-09
to O 0 1.4826596894668143e-10
encode O 0 6.5861245346354735e-09
a O 0 1.0707828579370471e-07
putative O 0 2.027056871156674e-05
sulfate O 0 8.43430170789361e-05
transporter O 0 0.015551762655377388
. O 0 1.5235114005918149e-06

We O 0 2.5051325792446733e-05
performed O 0 1.9724350863725704e-07
mutation O 0 1.3026743239663574e-08
analysis O 0 2.783076213930258e-09
of O 0 1.1765706464661463e-10
the O 0 1.5663427888057413e-08
PDS B-Disease 0 4.848211392527446e-05
gene O 0 1.0334910029996536e-06
in O 0 6.522234485828449e-08
patients O 0 1.8167908422128676e-07
from O 0 1.2000974658477048e-09
14 O 0 2.778246823709196e-07
Pendred B-Disease 0 0.00014833790191914886
families O 0 4.544826737173935e-09
originating O 0 4.824130428460194e-09
from O 0 2.8144699903975834e-09
seven O 0 1.7548666519928702e-08
countries O 0 7.637367960278141e-10
and O 0 1.840846231004889e-08
identified O 0 8.518532013113145e-08
all O 0 4.018690269447234e-09
mutations O 0 7.042423817438248e-07
. O 0 3.216803179384442e-08

The O 0 1.0575707847237936e-06
mutations O 0 4.3169179662072565e-06
include O 0 1.7223660719878353e-08
three O 0 1.077985842812268e-07
single O 0 3.1882098028290784e-06
base O 0 3.592754183046054e-07
deletions O 0 3.0684964258398395e-06
, O 0 2.481650440699923e-08
one O 0 5.480968123805496e-09
splice O 0 0.00025439541786909103
site O 0 1.997935032704845e-05
mutation O 0 4.937111953040585e-06
and O 0 7.767477683273682e-08
10 O 0 1.5127088914823617e-08
missense O 0 4.483417433220893e-05
mutations O 0 4.480382995097898e-05
. O 0 5.174167654331541e-07

One O 0 7.550354439445073e-07
missense O 0 4.252684811945073e-05
mutation O 0 1.752179923641961e-05
( O 0 2.2804449439917107e-09
L236P O 0 9.103113711717015e-07
) O 0 2.1553058004997183e-08
was O 0 4.115215688216267e-06
found O 0 3.739052090168116e-08
in O 0 1.0483880430456338e-09
a O 0 4.608154302587764e-09
homozygous O 0 8.938811646430622e-08
state O 0 3.324438724305878e-09
in O 0 6.210869152312171e-09
two O 0 1.1462757854019401e-08
consanguineous O 0 6.559432222275063e-06
families O 0 3.916236579470933e-08
and O 0 5.394164404037838e-08
in O 0 1.1203561411932128e-09
a O 0 6.873310365307361e-09
heterozygous O 0 4.330961189680238e-08
state O 0 7.692455006313992e-10
in O 0 2.7966453597372265e-09
five O 0 8.892108160907242e-10
additional O 0 3.157055172842149e-10
non O 0 1.0866001787235291e-07
- O 0 0.0031265870202332735
consanguineous O 0 5.458490704768337e-05
families O 0 1.2779247526850668e-07
. O 0 6.495121596117315e-08

Another O 0 1.3142827128831414e-06
missense O 0 5.622199387289584e-05
mutation O 0 2.0568504623952322e-05
( O 0 4.452851865011098e-09
T416P O 0 9.895679795590695e-07
) O 0 5.98479443780775e-09
was O 0 1.2186677622594289e-06
found O 0 2.765177420371856e-08
in O 0 1.2874799004691795e-09
a O 0 5.337422948059611e-09
homozygous O 0 1.6367711452858202e-07
state O 0 2.513537378234787e-09
in O 0 2.2189349024870353e-08
one O 0 6.295192065408628e-07
family O 0 1.0493606623640517e-06
and O 0 2.1782473424991622e-07
in O 0 1.6043709694102404e-09
a O 0 6.412228970020806e-09
heterozygous O 0 3.2618750367419125e-08
state O 0 1.9822072871988894e-09
in O 0 1.1346879880136385e-08
four O 0 8.67012488470209e-08
families O 0 3.119641078797031e-08
. O 0 1.5038317258131428e-07

Pendred B-Disease 0 0.05220748856663704
patients O 0 0.00028617720818147063
in O 0 5.627292409826623e-08
three O 0 2.5689477212154088e-08
non O 0 2.808873489357211e-07
- O 0 0.021655557677149773
consanguineous O 0 8.925302245188504e-05
families O 0 8.977922050235065e-08
were O 0 3.106613633008237e-08
shown O 0 1.727982912314019e-08
to O 0 1.1662244503440888e-09
be O 0 3.545100324409134e-10
compound O 0 1.2111358138611195e-08
heterozygotes O 0 1.32465856950148e-07
for O 0 2.0218040575059604e-09
L236P O 0 6.488089070444403e-07
and O 0 3.435377493588021e-08
T416P O 0 6.075044325370982e-07
. O 0 2.5263430458721814e-08

In O 0 2.827088962931157e-07
total O 0 6.394168394763255e-08
, O 0 1.7764197224323652e-08
one O 0 1.3779362539878548e-08
or O 0 2.1053098819834304e-08
both O 0 9.658447375215928e-09
of O 0 9.92491644424831e-10
these O 0 1.049803266539584e-08
mutations O 0 2.3800892279268737e-07
were O 0 1.3871886039851233e-07
found O 0 1.222161216674067e-07
in O 0 2.6300593702899278e-08
nine O 0 1.2019792450246314e-07
of O 0 1.1373895159039193e-09
the O 0 1.336519233063882e-07
14 O 0 1.672544840403134e-07
families O 0 3.503706880181312e-09
analyzed O 0 1.1047274028896936e-06
. O 0 7.673573065858363e-08

The O 0 3.289835603936808e-08
identification O 0 1.585033260198543e-08
of O 0 7.691515757635159e-10
two O 0 3.417235916458594e-08
frequent O 0 3.3772805636544945e-06
PDS B-Disease 0 0.003691695397719741
mutations O 0 1.2121594409109093e-05
will O 0 1.9366597214798276e-08
facilitate O 0 5.540226499789469e-09
the O 0 6.702677080028252e-09
molecular O 0 7.243121945066378e-05
diagnosis O 1 0.8602175116539001
of O 0 5.5365828302456066e-05
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
. O 0 1.4954531252442393e-05

Insertional O 0 0.000633233692497015
mutation O 0 6.720833425788442e-06
by O 0 3.09730507908057e-09
transposable O 0 3.7309491744963452e-06
element O 0 1.1740206673493958e-06
, O 0 1.318290543395051e-07
L1 O 0 0.013344715349376202
, O 0 7.437254367914647e-08
in O 0 1.0358128577081516e-08
the O 0 2.578496491878468e-07
DMD B-Disease 1 0.9999991655349731
gene O 0 0.00017470834427513182
results O 0 4.770354735228466e-06
in O 0 7.690759389333834e-07
X B-Disease 1 0.9999338388442993
- I-Disease 1 0.9999884366989136
linked I-Disease 1 0.9999703168869019
dilated I-Disease 1 0.9999436140060425
cardiomyopathy I-Disease 1 0.9999985694885254
. O 0 1.7886541172629222e-05

X B-Disease 1 0.999500036239624
- I-Disease 1 0.9999010562896729
linked I-Disease 1 0.9998832941055298
dilated I-Disease 1 0.999985933303833
cardiomyopathy I-Disease 1 0.9999998807907104
( O 0 8.890639037417714e-06
XLDCM B-Disease 0 0.3532031774520874
) O 0 4.098563977095182e-08
is O 0 1.7675747088219396e-08
a O 0 8.632206061065517e-08
clinical O 0 4.9076224968302995e-05
phenotype O 0 2.0941912225680426e-05
of O 0 1.3333323778397244e-08
dystrophinopathy B-Disease 0 0.09053080528974533
which O 0 2.3005172806733754e-06
is O 0 7.865651951988184e-08
characterized O 0 3.877160452248063e-06
by O 0 1.7373959337874112e-07
preferential O 0 2.2458621970145032e-05
myocardial B-Disease 1 0.999254047870636
involvement I-Disease 0 4.874234946328215e-06
without O 0 1.3053356617831469e-08
any O 0 6.417682496540067e-10
overt O 0 2.994664214384102e-07
clinical O 0 1.590904503245838e-05
signs O 0 1.826981497288216e-05
of O 0 3.4868069178628502e-06
skeletal B-Disease 1 0.9999996423721313
myopathy I-Disease 1 1.0
. O 0 0.0001742933818604797

To O 0 4.1838035258479067e-07
date O 0 3.8070288610470016e-07
, O 0 1.8511969734902323e-09
several O 0 5.193372953904429e-10
mutations O 0 5.101776423543924e-07
in O 0 8.807767670759858e-08
the O 0 1.8558257579570636e-05
Duchenne B-Disease 1 0.9999897480010986
muscular I-Disease 1 0.9996548891067505
dystrophy I-Disease 1 0.9994939565658569
gene O 0 0.0017880065133795142
, O 0 4.57212217952474e-06
DMD O 1 0.9999997615814209
, O 0 2.44863531406736e-06
have O 0 1.0836255341928336e-06
been O 0 1.3632493391924072e-06
identified O 0 7.5357042987889145e-06
in O 0 6.180112563924922e-07
patients O 0 3.955358351959148e-06
with O 0 1.718991313737206e-07
XLDCM B-Disease 1 0.9150636196136475
, O 0 2.0167851744190557e-07
but O 0 2.4184041436114967e-08
a O 0 9.245905707722102e-10
pathogenic O 0 8.055693889730264e-09
correlation O 0 9.790100108375555e-08
of O 0 1.0796166183268951e-09
these O 0 7.017746384008205e-08
cardiospecific O 0 0.00012332588084973395
mutations O 0 9.343903002445586e-06
in O 0 7.727312549832277e-07
DMD O 1 0.9999994039535522
with O 0 3.918414222425781e-06
the O 0 5.056611371401232e-06
XLDCM B-Disease 1 0.6716127395629883
phenotype O 0 0.0019849601667374372
has O 0 1.4340854477268294e-06
remained O 0 2.5090298549912404e-07
to O 0 7.57091633829532e-09
be O 0 2.2573672708858794e-08
elucidated O 0 0.00010706128523452207
. O 0 9.37547923740567e-08

We O 0 0.00012596871238201857
report O 0 4.727317204356041e-08
here O 0 7.13930137230534e-10
the O 0 3.486158237087089e-11
identification O 0 1.127144266810376e-09
of O 0 1.797011567328255e-10
a O 0 1.8915839561373105e-08
unique O 0 7.474157115439084e-08
de O 0 1.125381672295589e-07
novo O 0 6.440730544454709e-07
L1 O 0 1.6402634628320811e-06
insertion O 0 3.2061329591215326e-08
in O 0 3.313992413822575e-09
the O 0 3.999566011714251e-09
muscle O 0 7.805884649769723e-08
exon O 0 2.3418689920617908e-07
1 O 0 1.909049558435072e-07
in O 0 5.123777100379812e-07
DMD O 1 0.9999995231628418
in O 0 2.455459025441087e-06
three O 0 2.095971922244644e-06
XLDCM B-Disease 0 0.14038914442062378
patients O 0 2.9739160254393937e-06
from O 0 5.853830198354615e-10
two O 0 5.506136435684539e-09
unrelated O 0 6.984668061704724e-07
Japanese O 0 0.00014799388009123504
families O 0 1.0289234353422216e-07
. O 0 4.446997792229013e-08

The O 0 1.0474435185869879e-07
insertion O 0 7.763640041957842e-07
was O 0 1.219924683937279e-06
a O 0 5.606644482014644e-09
5 O 0 1.8570266036022076e-07
- O 0 0.00012920286098960787
truncated O 0 5.371287898014998e-06
form O 0 6.554940910064033e-07
of O 0 1.5587898749558349e-09
human O 0 4.545409737488626e-08
L1 O 0 4.079774043930229e-06
inversely O 0 1.4118297642085054e-08
integrated O 0 8.94793458883214e-07
in O 0 3.725973840573715e-08
the O 0 4.114440343983006e-08
5 O 0 5.564448315453774e-07
- O 0 0.004637692589312792
untranslated O 0 0.0033856970258057117
region O 0 1.4850012348688324e-06
in O 0 3.967511830182957e-08
the O 0 1.4072217169314172e-08
muscle O 0 3.071695005019137e-07
exon O 0 1.8949394586798007e-07
1 O 0 2.65666812993004e-07
, O 0 3.028300099572334e-08
which O 0 1.8360141851303524e-08
affected O 0 2.3884365596416046e-09
the O 0 1.2075643818221238e-09
transcription O 0 3.7887627968302695e-06
or O 0 3.2681185757610365e-07
the O 0 1.9199093514998822e-07
stability O 0 6.214390850800555e-07
of O 0 9.541167855786625e-10
the O 0 2.4649466467963066e-07
muscle O 0 1.8102876992998063e-06
form O 0 5.13371301025245e-09
of O 0 2.0751006468699984e-10
dystrophin O 0 1.8732893067863188e-06
transcripts O 0 4.157233433943475e-06
but O 0 1.38576467634266e-07
not O 0 6.02584604436629e-09
that O 0 1.875928745675992e-09
of O 0 4.91361118459821e-10
the O 0 5.491298225024366e-07
brain O 0 0.002426732797175646
or O 0 5.750563758510907e-08
Purkinje O 0 0.0011181277222931385
cell O 0 0.04071443900465965
form O 0 0.00011258621816523373
, O 0 9.569366739015095e-07
probably O 0 6.423943432309898e-06
due O 0 7.457639128460869e-08
to O 0 1.2539744354000959e-08
its O 0 7.656518752341412e-10
unique O 0 1.4866448072581306e-09
site O 0 3.8917201550248137e-07
of O 0 5.832865856980618e-10
integration O 0 6.093891329328471e-07
. O 0 8.199961598620575e-08

We O 0 9.676236004452221e-06
speculate O 0 2.3824894412882713e-07
that O 0 3.938541937031914e-09
this O 0 7.85152082238838e-11
insertion O 0 6.7798757719117475e-09
of O 0 4.359034522227745e-10
an O 0 5.267638325534563e-09
L1 O 0 0.005856763571500778
sequence O 0 5.6042466894723475e-05
in O 0 8.943788998294622e-06
DMD O 1 0.9999998807907104
is O 0 3.809952659139526e-06
responsible O 0 3.587624917145149e-07
for O 0 9.1254026557408e-10
some O 0 2.7407376368415726e-10
of O 0 9.880982698717844e-10
the O 0 2.6103288419676574e-08
population O 0 7.985945238431214e-10
of O 0 3.608738585736404e-10
Japanese O 0 0.00013369023508857936
patients O 0 1.9253641880823125e-07
with O 0 6.013778364177824e-09
XLDCM B-Disease 0 0.0004394124844111502
. O 0 2.8420478415114303e-08
. O 0 3.3512300490201596e-08

Severe O 0 0.09441878646612167
early O 0 8.181214070646092e-05
- O 1 0.9982581734657288
onset O 1 0.9998700618743896
obesity B-Disease 1 0.9999998807907104
, O 0 0.06492629647254944
adrenal B-Disease 1 0.999990701675415
insufficiency I-Disease 1 0.9999980926513672
and O 0 0.005301037337630987
red O 0 0.029544873163104057
hair O 1 0.999849796295166
pigmentation O 1 0.6685178279876709
caused O 0 1.9772593077505007e-05
by O 0 2.1400429872642235e-08
POMC O 0 0.0013889827532693744
mutations O 0 2.0600225980160758e-05
in O 0 1.9147456953305664e-07
humans O 0 6.87937199472799e-06
. O 0 1.603069392785983e-07

Sequential O 0 1.3333852621144615e-05
cleavage O 0 0.0003731762699317187
of O 0 4.34734603871334e-09
the O 0 1.2589538300744607e-09
precursor O 0 7.31424298905381e-09
protein O 0 3.519475555435747e-08
pre O 0 1.147469720308436e-05
- O 0 0.012999610044062138
pro O 0 0.00010447342356201261
- O 0 0.022567836567759514
opiomelanocortin O 0 0.00016885098011698574
( O 0 9.735160455548453e-10
POMC O 0 8.230169328271586e-07
) O 0 9.833991954089072e-11
generates O 0 2.4239293905381487e-10
the O 0 1.1243099784508104e-09
melanocortin O 0 4.2292858779546805e-06
peptides O 0 1.142536461884447e-06
adrenocorticotrophin O 0 3.211016519344412e-05
( O 0 4.607363379705021e-09
ACTH O 0 1.8426435417495668e-06
) O 0 2.9604946272243637e-10
, O 0 4.949147203170412e-10
melanocyte O 0 7.061456017254386e-06
- O 0 0.0013064290396869183
stimulating O 0 3.345289314893307e-06
hormones O 0 7.76093216359186e-08
( O 0 8.442254534335447e-11
MSH O 0 5.500270958691544e-07
) O 0 8.645820170904983e-11
alpha O 0 1.4356431321527197e-10
, O 0 1.8316218333702672e-11
beta O 0 6.767335997137636e-11
and O 0 1.0493417246237868e-10
gamma O 0 4.2156800272863393e-10
as O 0 1.261400650598432e-09
well O 0 3.357573385986967e-10
as O 0 8.776446236424817e-11
the O 0 1.5589438073781992e-10
opioid O 0 2.2120470788422608e-08
- O 0 5.822822686241125e-07
receptor O 0 2.3216422118110813e-09
ligand O 0 3.150506300286793e-09
beta O 0 9.310112680793736e-09
- O 0 1.503458133811364e-05
endorphin O 0 7.409700629068539e-05
. O 0 5.1102883702469626e-08

While O 0 3.94696741068401e-07
a O 0 3.600819642457509e-09
few O 0 1.8313686123150319e-09
cases O 0 6.903818849934851e-09
of O 0 1.745516264861635e-08
isolated O 1 0.8521068692207336
ACTH B-Disease 1 0.9966347813606262
deficiency I-Disease 1 0.5353214144706726
have O 0 9.562069180901744e-07
been O 0 1.6242410083577852e-06
reported O 0 6.719577413605293e-06
( O 0 1.8128666567918117e-08
OMIM O 0 0.046422820538282394
201400 O 0 6.289094017120078e-05
) O 0 1.8689583214381855e-08
, O 0 1.2649381986307162e-08
an O 0 1.692694411303819e-07
inherited O 0 0.4965521991252899
POMC O 1 0.9903370141983032
defect O 1 0.6311177015304565
has O 0 7.649571671208832e-06
not O 0 1.6210380238135258e-07
been O 0 3.744276000361424e-08
described O 0 5.505613671630272e-07
so O 0 4.647418094805289e-08
far O 0 1.7304103039350593e-08
. O 0 3.497819633935251e-08

Recent O 0 5.204730314289918e-06
studies O 0 1.8684008296077081e-07
in O 0 2.315376113060097e-09
animal O 0 8.019517849788826e-08
models O 0 1.9896025094112701e-07
elucidated O 0 1.9230644738854608e-06
a O 0 3.309766682946247e-09
central O 0 7.625799547383849e-09
role O 0 4.007515208570567e-09
of O 0 1.2101415702847618e-10
alpha O 0 1.3497544415486118e-08
- O 0 4.693501614383422e-05
MSH O 0 2.7530542865861207e-05
in O 0 2.722191805304419e-09
the O 0 1.4704182316194192e-09
regulation O 0 7.902809784354758e-08
of O 0 1.3638622176070925e-10
food O 0 6.472426150594401e-09
intake O 0 6.025098642226112e-09
by O 0 2.5050635177326086e-11
activation O 0 2.871818893801503e-10
of O 0 1.2943955629562964e-10
the O 0 9.723103211456419e-09
brain O 0 3.2552484299230855e-06
melanocortin O 0 5.89442208820401e-07
- O 0 2.115125607815571e-05
4 O 0 3.6301013750517086e-08
- O 0 4.73142608825583e-06
receptor O 0 8.591515943123795e-09
( O 0 2.0919464771562701e-10
MC4 O 0 1.6040635273384396e-06
- O 0 4.734193225885974e-06
R O 0 2.088774272124283e-05
; O 0 1.2067493670997465e-09
refs O 0 9.167874281956756e-08
3 O 0 1.899955037742984e-08
- O 0 0.0002199303125962615
5 O 0 2.827603964306036e-07
) O 0 2.1928145965688373e-09
and O 0 8.021533659530178e-09
the O 0 1.9887813618169048e-09
linkage O 0 2.0485074855969287e-05
of O 0 2.8228258841522802e-08
human O 0 9.095959831029177e-05
obesity B-Disease 1 0.9999992847442627
to O 0 7.457466608684626e-07
chromosome O 0 3.501253740978427e-05
2 O 0 1.7031646848408855e-07
in O 0 1.847688047007523e-08
close O 0 2.1031972607943317e-07
proximity O 0 5.665416438205284e-07
to O 0 5.872433916920272e-08
the O 0 1.5823207633047787e-08
POMC O 0 9.371166379423812e-05
locus O 0 6.523143269987486e-07
, O 0 1.450314091044902e-08
led O 0 1.8581951977125755e-08
to O 0 1.4310236329251325e-09
the O 0 7.895179510164496e-10
proposal O 0 7.470362994865809e-09
of O 0 3.5855071689461226e-10
an O 0 1.5710464040807892e-08
association O 0 7.936008294961994e-09
of O 0 6.95826785079845e-10
POMC O 0 0.0028437681030482054
with O 0 6.078069532122754e-07
human O 0 7.207995076896623e-05
obesity B-Disease 1 0.999993085861206
. O 0 1.1086101494584e-06

The O 0 5.7631908134681e-08
dual O 0 2.4031663770074374e-07
role O 0 1.0711297626642136e-08
of O 0 4.82941242552215e-10
alpha O 0 2.3430500206700344e-08
- O 0 0.00016834364214446396
MSH O 0 8.51414879434742e-05
in O 0 3.3646527786146407e-09
regulating O 0 7.277300539954012e-08
food O 0 1.8131743217963958e-08
intake O 0 7.243455257821552e-08
and O 0 1.2139850902315175e-08
influencing O 0 1.6708483485672332e-07
hair O 0 0.08495646715164185
pigmentation O 0 0.00012436177348718047
predicts O 0 3.0445735319517553e-05
that O 0 9.46694385106639e-08
the O 0 2.149451638899791e-08
phenotype O 0 3.51108392351307e-05
associated O 0 1.2148599637384905e-07
with O 0 2.315275615671908e-08
a O 0 1.1423348951211665e-06
defect O 0 0.003235981334000826
in O 0 4.875043657648348e-08
POMC O 0 0.0005772209842689335
function O 0 1.6547497807550826e-06
would O 0 7.103163852661964e-07
include O 0 1.6369475588362548e-06
obesity B-Disease 1 0.9999997615814209
, O 0 1.8372777788044914e-07
alteration O 0 4.1046137084777e-06
in O 0 8.863480616128072e-07
pigmentation O 1 0.9775168895721436
and O 0 0.03750573471188545
ACTH B-Disease 1 0.9844701290130615
deficiency I-Disease 0 0.49964746832847595
. O 0 1.463745746832501e-07

The O 0 6.490366217803967e-07
observation O 0 3.86123565476737e-06
of O 0 3.4793596892512824e-09
these O 0 4.057886826558388e-07
symptoms O 0 1.345494638371747e-05
in O 0 4.662376262842827e-09
two O 0 1.552835016127574e-08
probands O 0 3.449791620369069e-05
prompted O 0 3.7907540217929636e-08
us O 0 3.2636968683164014e-09
to O 0 2.47457693225428e-10
search O 0 1.1203262761938504e-09
for O 0 1.1186714887756466e-09
mutations O 0 1.3117578134824726e-07
within O 0 2.7585387307738074e-09
their O 0 3.531269499035261e-08
POMC O 0 0.0004959612851962447
genes O 0 1.65395454132522e-06
. O 0 2.016663955828335e-07

Patient O 0 0.0014447419671341777
1 O 0 3.0690975449942925e-07
was O 0 1.5647655118300463e-06
found O 0 2.8228258841522802e-08
to O 0 1.5962303701044789e-09
be O 0 1.2753181843905281e-09
a O 0 4.6377615636750136e-10
compound O 0 4.979403911420377e-08
heterozygote O 0 1.1794010390531184e-07
for O 0 1.0859383392514133e-09
two O 0 4.374244966243168e-09
mutations O 0 4.829758282198782e-08
in O 0 1.9631984926604673e-09
exon O 0 3.583731086109765e-06
3 O 0 3.7538122796831885e-06
( O 0 6.513927619522519e-09
G7013T O 0 1.548430418552016e-06
, O 0 9.888622365394895e-09
C7133delta O 0 8.4609519035439e-06
) O 0 8.374914650666199e-10
which O 0 2.3740753807288684e-09
interfere O 0 4.3576235952969e-09
with O 0 1.543125488501218e-10
appropriate O 0 1.4300596817840017e-10
synthesis O 0 5.118216073185522e-09
of O 0 1.1693137569324108e-09
ACTH O 0 3.711714043674874e-06
and O 0 8.167459597530069e-09
alpha O 0 1.6173991923551512e-08
- O 0 0.00011145353346364573
MSH O 0 0.0007227289024740458
. O 0 1.1687195211607104e-07

Patient O 0 0.0015824474394321442
2 O 0 1.0090797104567173e-06
was O 0 1.343813380572101e-07
homozygous O 0 1.8942522217457736e-08
for O 0 3.214867816403455e-10
a O 0 8.175579324642968e-09
mutation O 0 1.9724444655366824e-07
in O 0 8.086791680739225e-09
exon O 0 1.5986503058229573e-05
2 O 0 5.8496170822763816e-06
( O 0 2.3201605969802586e-08
C3804A O 0 4.289292064640904e-06
) O 0 4.562023203646959e-09
which O 0 2.12270858668262e-08
abolishes O 0 2.1088093490106985e-05
POMC O 0 0.0028725387528538704
translation O 0 1.8210845155408606e-05
. O 0 2.167558648125123e-07

These O 0 5.229629778114031e-07
findings O 0 6.717577605286351e-08
represent O 0 2.9731377360064926e-09
the O 0 9.197610673084e-09
first O 0 1.343004925047353e-07
examples O 0 4.9138041191554294e-08
of O 0 4.813872855891077e-09
a O 0 2.2303494915831834e-05
genetic B-Disease 1 0.9999983310699463
defect I-Disease 1 0.9999948740005493
within O 0 2.6623411031323485e-08
the O 0 2.318024172609512e-08
POMC O 0 9.952756226994097e-05
gene O 0 1.2259731647645822e-06
and O 0 1.0742461142854154e-07
define O 0 5.74775583572773e-07
a O 0 1.8629438613970706e-07
new O 0 3.573584035621025e-05
monogenic B-Disease 1 0.9992475509643555
endocrine I-Disease 1 0.998141884803772
disorder I-Disease 0 0.4515363574028015
resulting O 0 6.302784640865866e-07
in O 0 1.409801200225047e-07
early O 0 0.0017677077557891607
- O 1 0.9999840259552002
onset O 1 0.9999798536300659
obesity B-Disease 1 1.0
, O 0 0.4113447964191437
adrenal B-Disease 1 0.9999980926513672
insufficiency I-Disease 1 0.999998927116394
and O 0 0.00033533413079567254
red O 0 0.0036898578982800245
hair O 1 0.998275637626648
pigmentation O 0 0.03180060163140297
. O 0 4.5026279593685103e-08
. O 0 1.9607595547199708e-08

A O 0 5.4289348554448225e-06
European O 0 2.397192702119355e-06
multicenter O 0 0.0007100928341969848
study O 0 3.1387992294185096e-06
of O 0 5.456558938021772e-06
phenylalanine B-Disease 1 0.9999982118606567
hydroxylase I-Disease 1 0.9999891519546509
deficiency I-Disease 1 0.9999998807907104
: O 0 3.784163027376053e-07
classification O 0 1.4718577858729986e-06
of O 0 3.559817440823565e-10
105 O 0 5.310414508130634e-07
mutations O 0 8.567497388867196e-06
and O 0 6.280356501520146e-08
a O 0 3.1868288008496393e-09
general O 0 4.307587175844674e-09
system O 0 1.7464080315221508e-07
for O 0 1.1851841730248225e-09
genotype O 0 1.0105069350174745e-06
- O 0 1.2714888725895435e-05
based O 0 7.968470328023614e-08
prediction O 0 5.674663952959236e-06
of O 0 2.0241499587569933e-09
metabolic O 0 0.000803544360678643
phenotype O 0 0.00017409985593985766
. O 0 1.356626881943157e-07

Phenylketonuria B-Disease 1 0.5397751331329346
( O 0 3.74882489495576e-07
PKU B-Disease 0 0.00039136482519097626
) O 0 2.8031175247633655e-07
and O 0 7.3293463174195495e-06
mild B-Disease 0 0.2489168345928192
hyperphenylalaninemia I-Disease 1 0.9999996423721313
( O 0 0.0004577518266160041
MHP B-Disease 1 0.9999998807907104
) O 0 1.155429004029429e-06
are O 0 1.8388483624676155e-07
allelic B-Disease 0 0.3149658441543579
disorders I-Disease 1 0.9999332427978516
caused O 0 2.8054679205524735e-05
by O 0 2.3121071279774696e-08
mutations O 0 2.531094878577278e-06
in O 0 8.213105751053718e-09
the O 0 1.3204302540259505e-08
gene O 0 7.334348310905625e-07
encoding O 0 5.817910732730525e-06
phenylalanine O 0 0.24218027293682098
hydroxylase O 1 0.5837376713752747
( O 0 7.918937967588136e-07
PAH O 0 0.004646725486963987
) O 0 1.5562269695124087e-08
. O 0 2.4399486875381626e-08

Previous O 0 7.912122782727238e-06
studies O 0 7.989456918267024e-08
have O 0 3.753270760853411e-08
suggested O 0 1.1761370188878573e-07
that O 0 8.106064264268298e-09
the O 0 2.3864057396849603e-09
highly O 0 1.083233414078677e-07
variable O 0 1.623012030904647e-05
metabolic O 0 0.4313274323940277
phenotypes O 0 0.0018760203383862972
of O 0 0.00013302899606060237
PAH B-Disease 1 0.9999892711639404
deficiency I-Disease 1 0.9996519088745117
correlate O 0 0.0007988532306626439
with O 0 7.105409167706966e-05
PAH O 1 0.9984367489814758
genotypes O 0 0.002732937689870596
. O 0 5.385938948165858e-07

We O 0 1.905183307826519e-05
identified O 0 8.926203776127295e-08
both O 0 2.3861645992440117e-09
causative O 0 4.951208666170714e-06
mutations O 0 1.3096921975375153e-05
in O 0 8.885317726026187e-08
686 O 0 0.00014635437401011586
patients O 0 1.3878208847017959e-05
from O 0 9.431543546156718e-09
seven O 0 1.8385695454981033e-07
European O 0 5.755802590101666e-07
centers O 0 5.170433610146574e-07
. O 0 8.425954689528226e-08

On O 0 5.340124289432424e-07
the O 0 6.324660239975799e-10
basis O 0 6.196004265213162e-10
of O 0 6.235218591443825e-11
the O 0 5.717921136572102e-10
phenotypic O 0 1.0428188801370197e-07
characteristics O 0 3.5721700442081783e-07
of O 0 1.5609081804868197e-09
297 O 0 3.6838830510532716e-06
functionally O 0 0.0002330482966499403
hemizygous O 0 0.08682362735271454
patients O 0 0.0001189403046737425
, O 0 2.955869549126078e-09
105 O 0 4.884432414087314e-09
of O 0 3.6896555255516716e-10
the O 0 2.7853188200310797e-08
mutations O 0 1.1640381671895739e-06
were O 0 3.3473330773858834e-08
assigned O 0 7.09042708990637e-08
to O 0 1.1679591516156052e-08
one O 0 1.160931351051886e-09
of O 0 7.169660004580081e-11
four O 0 5.723881812969012e-09
arbitrary O 0 5.427426117421419e-07
phenotype O 0 1.9532142687239684e-05
categories O 0 4.0251254063150554e-07
. O 0 1.7343151625937026e-07

We O 0 6.61406375002116e-06
proposed O 0 2.2328645599145602e-08
and O 0 2.6705018285611004e-07
tested O 0 4.6454772473225603e-07
a O 0 7.373672783472784e-10
simple O 0 1.624392353960502e-08
model O 0 7.387207290321385e-08
for O 0 8.527151207360362e-11
correlation O 0 2.431422387871862e-07
between O 0 3.34100569432394e-08
genotype O 0 1.7736929294187576e-06
and O 0 2.991604119984004e-08
phenotypic O 0 8.738189194446022e-07
outcome O 0 1.0627636584104039e-06
. O 0 1.9700831899172044e-07

The O 0 1.7890317849378334e-07
observed O 0 4.418083960899821e-07
phenotype O 0 2.7628477710095467e-06
matched O 0 5.715718998544617e-06
the O 0 9.854467464265326e-09
predicted O 0 6.350029252644163e-06
phenotype O 0 1.1027495929738507e-05
in O 0 2.142289012851961e-08
79 O 0 1.8025267536359024e-06
% O 0 1.0540723849317146e-09
of O 0 8.46786807340294e-10
the O 0 1.3991277114655531e-07
cases O 0 4.7471502284679445e-07
, O 0 1.885516951460886e-07
and O 0 3.1861898719398596e-07
in O 0 1.66769407172751e-08
only O 0 1.3985574476294005e-08
5 O 0 4.864832536810582e-09
of O 0 2.1523498261455387e-10
184 O 0 2.4989239477690717e-07
patients O 0 1.024985863296024e-06
was O 0 1.3633872413265635e-06
the O 0 5.960916205083322e-09
observed O 0 8.213940105861184e-08
phenotype O 0 9.71269003002817e-08
more O 0 2.927939488084341e-11
than O 0 7.042075811369841e-10
one O 0 1.0513862669370155e-08
category O 0 7.014185712250764e-07
away O 0 2.619281644911098e-07
from O 0 2.693967826594701e-10
that O 0 8.257558192781289e-09
expected O 0 1.1784808684467407e-08
. O 0 1.705907770599424e-08

Among O 0 9.653447250457248e-07
the O 0 3.335854259489679e-08
seven O 0 1.3514623198318532e-08
contributing O 0 3.4927443159915583e-09
centers O 0 3.796615288820249e-08
, O 0 2.567682733101151e-09
the O 0 3.869485010188356e-10
proportion O 0 4.808935472055964e-09
of O 0 8.349554936337711e-10
patients O 0 3.131695436309201e-08
for O 0 4.201343994925111e-10
whom O 0 1.122226045424668e-08
the O 0 2.183482727957653e-09
observed O 0 2.016221714029598e-07
phenotype O 0 1.3030316949880216e-06
did O 0 6.645750545430928e-07
not O 0 1.0032264796677737e-08
match O 0 2.7787820044977707e-07
the O 0 3.361124933931592e-09
predicted O 0 4.412779617268825e-06
phenotype O 0 4.422283836902352e-06
was O 0 1.3869164376956178e-06
4 O 0 7.386883282833878e-08
% O 0 1.2647251024233697e-09
- O 0 0.0005104508018121123
23 O 0 3.2589090892543027e-07
% O 0 2.7786192791090514e-10
( O 0 5.40825217942853e-10
P O 0 0.00011816233018180355
< O 0 5.21930644481472e-07
. O 0 2.7134776647841363e-09
0001 O 0 2.624417732022266e-07
) O 0 5.400768166019532e-10
, O 0 2.390203590607598e-10
suggesting O 0 6.712681965836964e-09
that O 0 6.352845804968865e-09
differences O 0 4.842106271496505e-09
in O 0 2.761985640198361e-10
methods O 0 1.4780391133228932e-08
used O 0 1.1301521496420719e-08
for O 0 8.469370205155258e-10
mutation O 0 1.1357927576227667e-07
detection O 0 7.172732239268953e-06
or O 0 6.899390996295551e-07
phenotype O 0 0.001733460114337504
classification O 0 0.14866308867931366
may O 0 2.0725197828141972e-05
account O 0 6.438040855982763e-08
for O 0 3.2142992711925444e-09
a O 0 9.930052335960227e-09
considerable O 0 1.6636585442597607e-09
proportion O 0 1.7516462946787215e-08
of O 0 9.798049038778345e-10
genotype O 0 3.4600612707436085e-05
- O 0 0.017347590997815132
phenotype O 0 0.00015147014346439391
inconsistencies O 0 4.312185410526581e-05
. O 0 1.9362835246283794e-07

Our O 0 1.7424448515157565e-06
data O 0 2.405982399977802e-07
indicate O 0 2.551038562614849e-07
that O 0 2.4768649353745786e-08
the O 0 2.222738793022927e-08
PAH O 0 0.0021509535145014524
- O 0 0.00047513883328065276
mutation O 0 6.313042035799299e-07
genotype O 0 1.7859738932202163e-07
is O 0 1.3626589856485793e-09
the O 0 4.83043494092783e-10
main O 0 1.3176175706064441e-08
determinant O 0 2.5911595002980903e-07
of O 0 6.840718214107255e-09
metabolic O 0 0.004473577719181776
phenotype O 0 5.964035517536104e-05
in O 0 1.0420116325349227e-07
most O 0 1.2406409268805874e-06
patients O 0 5.374473039410077e-05
with O 0 0.0007009351393207908
PAH B-Disease 1 0.9999802112579346
deficiency I-Disease 1 0.9972299933433533
. O 0 4.1849128251669754e-07

In O 0 3.67087523045484e-07
the O 0 8.587648814284421e-09
present O 0 1.8655526012878454e-09
study O 0 5.410359271706966e-09
, O 0 1.8271992807683546e-09
the O 0 1.4202286013897947e-09
classification O 0 1.540752805340162e-06
of O 0 6.923176254503005e-09
105 O 0 1.1178527529409621e-05
PAH O 0 0.09323809295892715
mutations O 0 2.2287378669716418e-05
may O 0 2.254807327517483e-07
allow O 0 1.684280714897568e-09
the O 0 2.5606108344788936e-09
prediction O 0 3.921718871424673e-06
of O 0 8.806327195243213e-11
the O 0 3.487917954458908e-09
biochemical O 0 3.881527277371788e-07
phenotype O 0 1.6766475141594128e-07
in O 0 1.2612105804166163e-09
> O 0 2.364112638986171e-08
10 O 0 5.677691650163297e-09
, O 0 1.5604021408321955e-09
000 O 0 1.5002492581572824e-09
genotypes O 0 1.040426354848023e-06
, O 0 5.304239536485511e-08
which O 0 1.2486555078794481e-06
may O 0 8.856314934746479e-07
be O 0 3.0324311950380434e-09
useful O 0 6.490722626040224e-09
for O 0 2.24542384685833e-09
the O 0 3.940881398989404e-08
management O 0 6.221019930308103e-07
of O 0 9.37061273020845e-09
hyperphenylalaninemia B-Disease 1 0.9999929666519165
in O 0 5.029578005633084e-06
newborns O 0 6.328486779239029e-05
. O 0 3.4335105425498114e-08

Somatic O 0 0.0002572925586719066
instability O 0 9.659266652306542e-05
of O 0 4.803600184288825e-09
the O 0 2.9617233110457164e-08
CTG O 0 5.0371130782878026e-05
repeat O 0 3.386526077520102e-05
in O 0 1.9521170457892367e-08
mice O 0 1.557401628815569e-05
transgenic O 0 1.931843371494324e-06
for O 0 5.1701913861279536e-08
the O 0 0.00012149797839811072
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
region O 0 0.001580187352374196
is O 0 1.5184504036369617e-06
age O 0 2.7289991066936636e-07
dependent O 0 3.7956741749667344e-08
but O 0 1.0277172179939953e-07
not O 0 3.177778706842105e-09
correlated O 0 1.548764849701456e-08
to O 0 1.5445926759838358e-09
the O 0 5.887422216410698e-10
relative O 0 1.0903574043652497e-08
intertissue O 0 1.6894153986868332e-06
transcription O 0 2.8828258109570015e-06
levels O 0 2.753988326276158e-07
and O 0 1.7037899624483543e-07
proliferative O 0 0.026259444653987885
capacities O 0 1.595123285369482e-05
. O 0 9.617897234193151e-08

A O 0 2.800324864438153e-06
( O 0 1.3591527903145106e-08
CTG O 0 4.272781552572269e-06
) O 0 3.427783168419296e-09
nexpansion O 0 3.3120024909294443e-06
in O 0 1.613593703098104e-08
the O 0 8.165530829273848e-08
3 O 0 7.990338417585008e-06
- O 1 0.7053369283676147
untranslated O 1 0.6019142270088196
region O 0 1.9120328943245113e-05
( O 0 3.823414029824335e-09
UTR O 0 4.717148476629518e-05
) O 0 3.6366812339316823e-10
of O 0 9.858180244348702e-11
the O 0 9.751671115054705e-08
DM O 1 0.9999966621398926
protein O 0 8.682975021656603e-06
kinase O 0 2.7898920961888507e-05
gene O 0 8.414137482759543e-06
( O 0 1.1394354793026196e-08
DMPK O 0 0.0005736214807257056
) O 0 3.4636142842714435e-09
is O 0 4.3253618464689225e-09
responsible O 0 2.738546527325525e-07
for O 0 5.118267836223822e-07
causing O 0 0.17038771510124207
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.00015226282994262874
DM B-Disease 1 0.9999977350234985
) O 0 3.095634838246042e-06
. O 0 2.57336239428696e-07

Major O 0 0.00017815981118474156
instability O 0 0.0031182735692709684
, O 0 3.166714463986864e-07
with O 0 1.3115447394795865e-08
very O 0 7.3245596254878365e-09
large O 0 1.986082409644041e-09
expansions O 0 3.7279189655237133e-06
between O 0 4.999493512514164e-07
generations O 0 2.6776501726999413e-06
and O 0 2.8206795832375064e-07
high O 0 1.769250133065725e-07
levels O 0 1.2689471695637167e-08
of O 0 6.583630862699863e-11
somatic O 0 2.3914151370263426e-07
mosaicism O 0 2.1949281290289946e-05
, O 0 3.970022977028975e-09
is O 0 1.3210189608869882e-09
observed O 0 4.4244590213793344e-08
in O 0 4.713487555818574e-08
patients O 0 7.433269502143958e-07
. O 0 2.9418435687489364e-08

There O 0 1.0885415576922242e-05
is O 0 8.906506643313605e-09
a O 0 4.999996416898966e-09
good O 0 6.16457143109983e-08
correlation O 0 1.5391873375847354e-07
between O 0 1.4549917182193894e-07
repeat O 0 0.0001102294772863388
size O 0 1.4585164080926916e-06
( O 0 4.744848070004082e-09
at O 0 2.3690283512678434e-08
least O 0 1.1497062191168084e-09
in O 0 2.4549942523321988e-08
leucocytes O 0 0.0001267920306418091
) O 0 2.4399520182072365e-09
, O 0 1.360290657892449e-09
clinical O 0 5.864195031790587e-07
severity O 0 6.690855661872774e-05
and O 0 5.453284757095389e-07
age O 0 8.651969096717949e-08
of O 0 2.2307689029332778e-09
onset O 0 0.0006882838788442314
. O 0 4.910604616270575e-07

The O 0 2.0213749394315528e-06
trinucleotide O 0 0.005600579548627138
repeat O 0 0.012084168381989002
instability O 0 2.7973756004939787e-05
mechanisms O 0 1.998103243749938e-06
involved O 0 7.834582760324338e-08
in O 0 5.313460860634223e-06
DM B-Disease 1 1.0
and O 0 0.009002428501844406
other O 0 8.433526090811938e-07
human O 0 0.003088268917053938
genetic B-Disease 1 0.9999996423721313
diseases I-Disease 1 0.9999998807907104
are O 0 3.329850528643874e-07
unknown O 0 4.704408183897613e-06
. O 0 4.1541326822880364e-07

We O 0 8.908461495593656e-06
studied O 0 7.71566419643932e-08
somatic O 0 9.015913065013592e-07
instability O 0 2.8813524295401294e-06
by O 0 3.1140690026632e-09
measuring O 0 8.870981400832534e-05
the O 0 5.034420524907546e-08
CTG O 0 3.259646473452449e-05
repeat O 0 2.2719730623066425e-05
length O 0 2.3043489818519447e-06
at O 0 1.287318429632478e-08
several O 0 6.963352672251233e-10
ages O 0 4.697933491115691e-07
in O 0 4.1084078361564025e-09
various O 0 1.699369645002946e-09
tissues O 0 2.782149692848179e-07
of O 0 3.5359096206555307e-10
transgenic O 0 3.721941538969986e-05
mice O 0 1.631656414247118e-05
carrying O 0 2.911219709744728e-09
a O 0 1.270945393372358e-08
( O 0 3.6967013894440015e-09
CTG O 0 3.6353408177092206e-06
) O 0 1.1286587220382671e-09
55expansion O 0 2.045957927521158e-07
surrounded O 0 8.307387133754673e-08
by O 0 4.583146306913477e-09
45 O 0 1.9217709645857894e-09
kb O 0 1.1764744158426765e-05
of O 0 2.7946456260252717e-09
the O 0 2.1209424971857516e-07
human O 0 8.303621143568307e-06
DM B-Disease 1 0.9999996423721313
region O 0 4.546269792626845e-06
, O 0 1.4318508601007807e-09
using O 0 1.3762334605260662e-09
small O 0 7.11289560584305e-09
- O 0 0.0009105383069254458
pool O 0 2.2965145944908727e-06
PCR O 0 2.3509724087489303e-06
. O 0 1.3450641489498594e-08

These O 0 1.9387978227314306e-06
mice O 0 7.919496420072392e-05
have O 0 8.670538420574303e-08
been O 0 4.825513499895351e-08
shown O 0 6.23116136466706e-08
to O 0 1.3379586327744164e-08
reproduce O 0 1.700281245575752e-05
the O 0 9.045969306953339e-09
intergenerational O 0 6.667044090136187e-06
and O 0 2.4202228132708115e-07
somatic O 0 5.823100650559354e-07
instability O 0 8.307465009238513e-07
of O 0 9.807734624445175e-10
the O 0 3.264252512735766e-08
55 O 0 9.702654324428295e-08
CTG O 0 9.978867637983058e-06
repeat O 0 3.3932064980035648e-06
suggesting O 0 4.265035968842312e-08
that O 0 1.6300061300711377e-09
surrounding O 0 6.505422422975471e-09
sequences O 0 2.8859340091003105e-06
and O 0 4.918792342323286e-07
the O 0 5.7933640107421525e-09
chromatin O 0 2.179532430091058e-06
environment O 0 1.0113891448781942e-06
are O 0 3.5040995105539707e-10
involved O 0 2.3166482066017124e-09
in O 0 3.0088401103967044e-08
instability O 0 5.289496584737208e-06
mechanisms O 0 2.904482926169294e-06
. O 0 1.804188229925785e-07

As O 0 2.1273012862366159e-07
observed O 0 7.29341920191473e-08
in O 0 4.840376988113348e-10
some O 0 8.004072404865781e-11
of O 0 1.020796669415347e-09
the O 0 1.5064556180277577e-07
tissues O 0 3.6575409012584714e-06
of O 0 6.797850460316113e-08
DM B-Disease 1 1.0
patients O 0 0.06708814203739166
, O 0 3.778662716058534e-08
there O 0 4.042439627482963e-08
is O 0 6.550582298814334e-09
a O 0 2.262539666730845e-08
tendency O 0 3.6432188608159777e-06
for O 0 4.231875294635756e-09
repeat O 0 1.0374824341852218e-05
length O 0 4.191777861706214e-06
and O 0 6.562377308227951e-08
somatic O 0 6.532343377330108e-08
mosaicism O 0 2.3077571313478984e-05
to O 0 2.9579576121818718e-08
increase O 0 6.3361222935043315e-09
with O 0 3.732724351834804e-08
the O 0 3.465731310825504e-07
age O 0 2.3763060141845926e-07
of O 0 2.4367047268825104e-10
the O 0 2.7025032878214006e-08
mouse O 0 8.541977149434388e-05
. O 0 7.346221053694535e-08

Furthermore O 0 0.00023600189888384193
, O 0 1.497933226346504e-07
we O 0 4.0762124342563766e-08
observed O 0 6.285567177855e-09
no O 0 8.978171539553159e-10
correlation O 0 2.6124807206429068e-08
between O 0 7.849341621124495e-09
the O 0 2.4820134836289753e-09
somatic O 0 5.498278028426284e-07
mutation O 0 1.0342598216084298e-05
rate O 0 0.00016150496958289295
and O 0 2.8377037324389676e-06
tissue O 0 0.0024434649385511875
proliferation O 0 2.6706427888711914e-05
capacity O 0 1.3034377843723632e-07
. O 0 5.632393396126645e-08

The O 0 5.3853238313195106e-08
somatic O 0 4.5510398649639683e-07
mutation O 0 6.878440217406023e-06
rates O 0 6.168716026877519e-06
in O 0 1.3256734598954267e-09
different O 0 1.325064280521815e-09
tissues O 0 1.4358904536493355e-06
were O 0 1.119799577509184e-07
also O 0 1.3162440382075147e-07
not O 0 1.1942388411512184e-08
correlated O 0 3.2623166390521874e-08
to O 0 5.909261524550402e-09
the O 0 6.627318249741165e-09
relative O 0 3.8236936461544246e-07
inter O 0 6.458875577664003e-05
- O 0 0.2158808559179306
tissue O 0 0.00021602951164823025
difference O 0 2.1460024868247274e-08
in O 0 1.2028444906775348e-10
transcriptional O 0 1.1046168424400093e-08
levels O 0 2.104206053843427e-08
of O 0 1.3279351229744663e-10
the O 0 6.101739558062036e-09
three O 0 2.1736854094456248e-08
genes O 0 6.13354984579928e-08
( O 0 1.0319394228019974e-09
DMAHP O 0 1.3578642210632097e-05
, O 0 8.923578320718661e-09
DMPK O 0 3.8117494113976136e-05
and O 0 3.0340154921759677e-07
59 O 0 1.1121071707975716e-07
) O 0 2.5781882184716665e-10
surrounding O 0 8.293705278106245e-09
the O 0 9.764848840632112e-08
repeat O 0 0.00013254178338684142
. O 0 1.4821099014739048e-08
. O 0 1.518276171452726e-08

A O 0 2.3713757855148287e-06
novel O 0 1.3038248880548053e-06
missense O 0 3.8787216908531263e-05
mutation O 0 8.136058022500947e-05
in O 0 2.4035011847445276e-07
patients O 0 1.2579338317664224e-06
from O 0 2.1476227463068653e-09
a O 0 7.620567430421943e-07
retinoblastoma B-Disease 1 0.7097711563110352
pedigree O 0 0.0227490421384573
showing O 0 6.139422475825995e-05
only O 0 1.5347592352554784e-07
mild O 0 8.87272335603484e-07
expression O 0 3.855998897961399e-08
of O 0 1.6052096318830422e-09
the O 0 4.2846374981309054e-07
tumor B-Disease 0 0.0038509087171405554
phenotype O 0 7.937384361866862e-05
. O 0 9.74733822545204e-08

We O 0 4.5973691157996655e-05
have O 0 1.592858289711785e-08
used O 0 5.8685678538950015e-09
single O 0 2.081421257571492e-08
strand O 0 2.728577101152041e-06
conformation O 0 2.4772948137297135e-08
polymorphism O 0 7.47643866816361e-08
analysis O 0 1.8807554624800105e-08
to O 0 3.1778393250192494e-09
study O 0 1.6619902121206565e-09
the O 0 4.8269006569512385e-09
27 O 0 6.831372445503803e-08
exons O 0 2.0953514479060686e-07
of O 0 2.0615937845747112e-09
the O 0 4.666595287972086e-08
RB1 O 0 3.719103551702574e-05
gene O 0 1.8876075102980394e-07
in O 0 8.688247454813336e-09
individuals O 0 2.660774656160214e-10
from O 0 5.074016762307565e-10
a O 0 2.3858865461079404e-07
family O 0 1.7355324644086068e-06
showing O 0 7.881487545091659e-05
mild O 0 4.629671821021475e-06
expression O 0 5.03772454862883e-08
of O 0 7.898402487604983e-10
the O 0 1.2248472103237873e-07
retinoblastoma B-Disease 0 0.01821725443005562
phenotype O 0 0.00034036312717944384
. O 0 1.456243836628346e-07

In O 0 2.76696169976276e-07
this O 0 1.4495728173358202e-08
family O 0 3.8615336706016024e-08
affected O 0 1.1595798099506283e-08
individuals O 0 8.279696928070734e-10
developed O 0 0.00010182044206885621
unilateral B-Disease 1 0.9859080910682678
tumors I-Disease 1 1.0
and O 0 0.00766369141638279
, O 0 1.0563194052792824e-07
as O 0 2.106430585513408e-08
a O 0 5.076809728166154e-08
result O 0 1.0365683067448117e-07
of O 0 8.461474299004124e-10
linkage O 0 0.0007606057915836573
analysis O 0 8.490596883348189e-07
, O 0 1.2113391179013888e-08
unaffected O 0 3.8923994338802004e-07
mutation O 0 8.735475631738154e-08
carriers O 0 1.4825232597104332e-07
were O 0 5.286972850626626e-07
also O 0 3.4150602346016967e-07
identified O 0 3.792410723235662e-07
within O 0 3.5675205012353217e-09
the O 0 8.405713458614628e-08
pedigree O 0 0.00032674180692993104
. O 0 8.973248810661971e-08

A O 0 1.0665345371307922e-06
single O 0 1.1457822068905443e-07
band O 0 8.437706533470646e-09
shift O 0 1.3304406465408647e-09
using O 0 1.9851129628989383e-09
SSCP O 0 8.593814527557697e-06
was O 0 8.397986448471784e-07
identified O 0 5.358764809670902e-08
in O 0 1.7553076769871723e-09
exon O 0 8.797035116003826e-05
21 O 0 2.0410894649103284e-05
which O 0 3.9941329532666714e-07
resulted O 0 2.938311638445157e-07
in O 0 6.948828179531574e-09
a O 0 6.674142127849336e-08
missense O 0 3.6297886254033074e-05
mutation O 0 4.0568264125795395e-07
converting O 0 4.4608444937921377e-08
a O 0 1.4270018766637804e-07
cys O 0 0.1448330581188202
- O 0 0.049677006900310516
- O 0 0.002752730157226324
> O 0 1.2001191862509586e-07
arg O 0 8.327486966663855e-08
at O 0 5.298622096638894e-10
nucleotide O 0 6.60858567869127e-09
position O 0 7.102229204747346e-08
28 O 0 5.539951608568572e-09
in O 0 3.362033706988399e-10
the O 0 2.293443657208627e-09
exon O 0 1.9353883544681594e-05
. O 0 2.6255315788148437e-07

The O 0 1.110026801143249e-06
mutation O 0 6.877272880956298e-06
destroyed O 0 6.842365564807551e-06
an O 0 5.014503923206348e-09
NdeI O 0 7.138332875911146e-05
restriction O 0 2.3986373776097025e-07
enzyme O 0 3.133554287160223e-07
site O 0 2.2405324671126436e-06
. O 0 9.971888204063362e-08

Analysis O 0 1.6516816003786516e-06
of O 0 3.1798945698824355e-09
all O 0 4.799313835235353e-09
family O 0 7.024814063782969e-09
members O 0 6.827480941717923e-11
demonstrated O 0 3.3922840092515116e-09
that O 0 1.8168674342788904e-09
the O 0 2.711506574826217e-09
missense O 0 8.450774657831062e-06
mutation O 0 8.267021257779561e-06
co O 0 0.0003202283405698836
- O 0 0.005127614829689264
segregated O 0 2.615133416838944e-05
with O 0 1.4943290125302156e-06
patients O 0 1.5818966858205386e-05
with O 0 0.00037434749538078904
tumors B-Disease 1 1.0
or O 0 0.003415621118620038
who O 0 0.017613636329770088
, O 0 6.558711618254165e-08
as O 0 1.6711139139147235e-08
a O 0 4.502456718569192e-08
result O 0 7.076443608866612e-08
of O 0 4.499816352865338e-10
linkage O 0 5.3089861467015e-05
analysis O 0 4.9030188620236e-07
had O 0 1.013481232803315e-05
been O 0 5.919993029124271e-08
predicted O 0 3.1631103070139943e-07
to O 0 8.117710947885826e-10
carry O 0 4.317910473616848e-09
the O 0 3.362753631108717e-09
predisposing O 0 3.6098272175877355e-06
mutation O 0 1.2917118965560803e-06
. O 0 5.247744994107961e-08

These O 0 2.1966508256809902e-07
observations O 0 3.2561570151301567e-07
point O 0 3.206197618510487e-07
to O 0 2.2768376073400987e-09
another O 0 3.3834637314100746e-09
region O 0 2.732117820869462e-08
of O 0 6.748713810011964e-10
the O 0 4.140363785154477e-08
RB1 O 0 4.746859849547036e-05
gene O 0 1.0470620281921583e-07
where O 0 2.135806020930886e-08
mutations O 0 6.72737314744154e-08
only O 0 3.5900873385230625e-09
modify O 0 2.35701307360614e-07
the O 0 1.512172254081179e-08
function O 0 4.05795184121871e-08
of O 0 4.187759028440041e-10
the O 0 1.8433302884091063e-08
gene O 0 1.6026826870074729e-06
and O 0 1.5761254701374128e-07
raise O 0 8.535328888115146e-09
important O 0 3.3946512267846174e-10
questions O 0 5.238838807208879e-10
for O 0 2.1602011845978097e-10
genetic O 0 7.099344543348707e-07
counseling O 0 4.1214072155071335e-08
in O 0 2.445968938502574e-08
families O 0 4.630771766045427e-09
with O 0 7.219205233610637e-09
these O 0 9.254855548590513e-09
distinctive O 0 5.131276793690631e-06
phenotypes O 0 1.2732312825392e-05
. O 0 1.8209272312219582e-08
. O 0 3.130632464376504e-08

Maternal B-Disease 0 0.38445815443992615
disomy I-Disease 0 0.3612254559993744
and O 0 0.03663066029548645
Prader B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999996423721313
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999992847442627
consistent O 0 0.00018758891383185983
with O 0 2.4117937869050365e-08
gamete O 0 1.3786599311060854e-06
complementation O 0 7.592741894768551e-05
in O 0 7.464551643465711e-09
a O 0 1.0619389811949986e-08
case O 0 1.2423905104697042e-07
of O 0 2.07181538591783e-09
familial O 0 0.00020409628632478416
translocation O 0 0.0017200654838234186
( O 0 3.034029560922136e-08
3 O 0 5.87341901336913e-07
; O 0 5.4706102758927955e-08
15 O 0 3.138500659360943e-08
) O 0 1.910200886356961e-09
( O 0 2.1854898446527216e-10
p25 O 0 3.120926450606021e-08
; O 0 1.3527124975709626e-09
q11 O 0 7.531600232368874e-08
. O 0 1.1628371598959575e-09
2 O 0 1.8155864367486174e-08
) O 0 3.833403372510702e-09
. O 0 2.7195360630116738e-08

Maternal B-Disease 0 0.24679186940193176
uniparental I-Disease 0 0.48108920454978943
disomy I-Disease 1 0.8102542757987976
( I-Disease 0 1.0808618753799237e-05
UPD I-Disease 1 0.9999682903289795
) I-Disease 0 1.7078423297789413e-07
for I-Disease 0 8.584258637256426e-09
chromosome I-Disease 0 0.008356659673154354
15 I-Disease 0 4.5416837224365736e-07
is O 0 2.51124809835801e-08
responsible O 0 9.238386411425381e-08
for O 0 1.6466206176346532e-09
an O 0 2.035998480920398e-09
estimated O 0 2.6945768283326288e-08
30 O 0 6.563752208421647e-09
% O 0 6.627778881274082e-11
of O 0 2.0705381853503013e-10
cases O 0 1.6482466946854402e-07
of O 0 3.94344242522493e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
( O 0 1.4918180568201933e-05
PWS B-Disease 1 0.999987006187439
) O 0 4.112918929877196e-07
. O 0 8.998992484521295e-08

We O 0 7.80039990786463e-05
report O 0 1.588216846926116e-08
on O 0 2.341288718454848e-09
an O 0 4.261386729598193e-11
unusual O 0 2.029237000655826e-09
case O 0 1.3360516959437518e-07
of O 0 7.523986766955204e-09
maternal B-Disease 0 0.00010821412433870137
disomy I-Disease 0 0.0011752571444958448
15 I-Disease 0 5.829323299622047e-07
in O 0 1.648886495786428e-06
PWS B-Disease 1 0.9999997615814209
that O 0 5.71060118090827e-05
is O 0 6.494811799484523e-08
most O 0 1.6192689411553829e-09
consistent O 0 3.2604140187686426e-07
with O 0 4.894709526581664e-09
adjacent O 0 3.957916305807885e-06
- O 0 0.0061302464455366135
1 O 0 1.789192083379021e-07
segregation O 0 1.4875610077069723e-06
of O 0 2.1811506767388522e-10
a O 0 6.848514999546751e-08
paternal O 0 6.204214878380299e-05
t O 0 0.00233090715482831
( O 0 1.4375179935299798e-09
3 O 0 5.4774904612031605e-08
; O 0 6.549945030798199e-09
15 O 0 5.095841526525646e-09
) O 0 2.1722491860831639e-10
( O 0 4.341773121585568e-11
p25 O 0 6.1314775479104355e-09
; O 0 7.002082802465281e-10
q11 O 0 3.9066570423074154e-08
. O 0 1.488630996249185e-09
2 O 0 2.930473641526987e-09
) O 0 2.1832774477203998e-10
with O 0 7.041860983214576e-10
simultaneous O 0 1.697963284641446e-06
maternal O 0 0.0001204851214424707
meiotic O 0 8.669634553370997e-05
nondisjunction O 0 7.755088881822303e-05
for O 0 2.293781697915165e-08
chromosome O 0 0.00014448122237809002
15 O 0 4.471117733828578e-07
. O 0 1.8236771381907602e-07

The O 0 1.2735112022710382e-06
patient O 0 8.68624647409888e-06
( O 0 6.264334828642859e-09
J O 0 0.010703003033995628
. O 0 4.5793481007194714e-08
B O 0 5.216821955400519e-05
. O 0 1.989441500427347e-09
) O 0 3.02904201721077e-10
, O 0 4.073247572566885e-10
a O 0 4.984142432107319e-09
17 O 0 3.933042194148584e-07
- O 0 0.0022645031567662954
year O 0 3.232151755128143e-07
- O 0 0.08754168450832367
old O 1 0.5160083770751953
white O 0 7.531249593739631e-06
male O 0 2.408962700428674e-07
with O 0 5.0028603482132894e-08
PWS B-Disease 1 0.9999986886978149
, O 0 4.7607787223569176e-07
was O 0 2.4086325538519304e-06
found O 0 8.74931558314529e-08
to O 0 7.807816615468255e-09
have O 0 3.4624534350768954e-08
47 O 0 1.4616338717132749e-07
chromosomes O 0 2.461096642036864e-07
with O 0 6.975372723871942e-09
a O 0 1.2818208006137866e-07
supernumerary O 0 0.004289564676582813
, O 0 3.700139359352761e-07
paternal O 0 3.7183795939199626e-05
der O 1 0.9653435945510864
( O 0 4.287758148535659e-09
15 O 0 1.3105195151297266e-08
) O 0 1.5709100686933652e-10
consisting O 0 3.6381661572271184e-10
of O 0 3.9842844579141e-09
the O 0 2.5205515612469753e-06
short O 0 0.07828167080879211
arm O 1 0.9507633447647095
and O 0 8.299221576635318e-07
the O 0 2.73749591883643e-08
proximal O 0 6.411036156350747e-05
long O 0 0.0024769101291894913
arm O 0 0.008478129282593727
of O 0 1.3949256194578652e-09
chromosome O 0 9.862974548013881e-05
15 O 0 3.451620500527497e-07
, O 0 1.2682865424551437e-08
and O 0 9.250676669125824e-08
distal O 0 0.0008715764852240682
chromosome O 1 0.9793015718460083
arm O 1 0.8261913061141968
3p O 0 0.0029585608281195164
. O 0 4.678609286656865e-07

The O 0 8.554431474294688e-07
t O 0 3.429908974794671e-05
( O 0 9.129580980093976e-10
3 O 0 2.0190880078985174e-08
; O 0 2.239239460521958e-09
15 O 0 8.18448864237098e-09
) O 0 3.3487810302545995e-09
was O 0 4.005938080808846e-06
present O 0 4.775882356256034e-09
in O 0 3.843037887918399e-09
the O 0 1.2282905359484175e-08
balanced O 0 1.3985766145196976e-07
state O 0 4.831533839677604e-09
in O 0 2.680270583255151e-08
the O 0 1.7556492082348996e-07
patients O 0 3.844510047201766e-06
father O 0 1.4577279898730922e-06
and O 0 4.4942368049305514e-08
a O 0 1.008327714657753e-07
sister O 0 0.00021390018810052425
. O 0 1.4480274046491104e-07

Fluorescent O 0 1.1503063433337957e-05
in O 0 5.107693379358125e-09
situ O 0 6.319529433085336e-08
hybridization O 0 1.2962746431810501e-08
analysis O 0 1.2056939446836168e-08
demonstrated O 0 7.432759474568229e-08
that O 0 7.503152943399982e-08
the O 0 3.0418058827308414e-07
PWS B-Disease 1 0.9999982118606567
critical O 0 3.2886455301195383e-06
region O 0 2.3068042764862184e-07
resided O 0 4.4556577449839097e-07
on O 0 6.322386525425827e-08
the O 0 1.2963233819718312e-09
derivative O 0 8.186145237232267e-07
chromosome O 0 0.0002396198979113251
3 O 0 2.1317375740181888e-06
and O 0 7.61562716888875e-07
that O 0 3.0768433134653606e-07
there O 0 1.0266984418194625e-07
was O 0 3.44506725014071e-06
no O 0 2.7891994491824335e-08
deletion O 0 5.052283995610196e-07
of O 0 8.644674309721267e-09
the O 0 4.901358806819189e-06
PWS B-Disease 1 0.9999995231628418
region O 0 6.617021881538676e-06
on O 0 1.829329448810313e-06
the O 0 7.371050259052936e-08
normal O 0 2.4957370214906405e-07
pair O 0 1.0787020983116236e-06
of O 0 3.7545130893157364e-10
15s O 0 1.8833329562539802e-08
present O 0 2.9879527740916956e-09
in O 0 9.128353184451043e-08
J O 0 0.09516852349042892
. O 0 3.2200696864492784e-07

B O 0 0.005012914538383484
. O 0 1.4341798078021384e-06

Methylation O 0 2.0283216144889593e-05
analysis O 0 1.13420483671689e-07
at O 0 9.791529809177746e-10
exon O 0 2.2220055129196226e-08
alpha O 0 4.570419154248384e-09
of O 0 2.3764978873686005e-10
the O 0 4.765354777447328e-09
small O 0 2.666874543422182e-08
nuclear O 0 1.02500043794862e-05
ribonucleoprotein O 0 4.043522494612262e-06
- O 0 6.909322837600484e-05
associated O 0 6.971718136128402e-08
polypeptide O 0 9.352168603982136e-07
N O 0 2.288340328959748e-05
( O 0 1.174692121352905e-09
SNRPN O 0 4.923537289869273e-06
) O 0 4.742367054610952e-10
gene O 0 1.3744450910735395e-08
showed O 0 9.014347597258165e-07
a O 0 3.961999084367562e-08
pattern O 0 0.0014826074475422502
characteristic O 0 5.079990387457656e-06
of O 0 9.840643855341114e-09
only O 0 1.1201649385839119e-07
the O 0 1.0670905226106697e-07
maternal O 0 2.2103336959844455e-05
chromosome O 0 0.00025488462415523827
15 O 0 8.530856376864904e-08
in O 0 2.638083458350593e-07
J O 1 0.9021317362785339
. O 0 5.73503086798155e-07

B O 0 0.004593382123857737
. O 0 1.6932674498093547e-06

Maternal B-Disease 0 0.030547484755516052
disomy I-Disease 0 0.0010917744366452098
was O 0 3.7275667637004517e-06
confirmed O 0 2.3922313019397734e-08
by O 0 5.444268924570395e-10
polymerase O 0 4.659374098991975e-06
chain O 0 7.592040219606133e-06
reaction O 0 4.792471752779193e-09
analysis O 0 9.571680115172398e-10
of O 0 1.0092190971811021e-10
microsatellite O 0 7.997642387636006e-05
repeats O 0 2.2941043425817043e-05
at O 0 1.2778486713216353e-08
the O 0 6.40583253108673e-10
gamma O 0 1.0118727544750072e-07
- O 0 0.0003762034757528454
aminobutyric O 0 2.045785731752403e-05
acid O 0 1.0655467974629573e-07
receptor O 0 5.046646656126086e-09
beta3 O 0 4.1914154280675575e-07
subunit O 0 9.620942620358619e-08
( O 0 7.999379825207598e-09
GABRB3 O 0 1.2780147699231748e-05
) O 0 2.0140638046228787e-09
locus O 0 3.813300679667009e-07
. O 0 1.1014508771722831e-07

A O 0 2.0177802070975304e-05
niece O 0 0.00077043630881235
( O 0 2.4713200375003908e-08
B O 0 0.00014042173279449344
. O 0 2.7366084509594657e-08
B O 0 2.2461084881797433e-05
. O 0 2.256517861454199e-09
) O 0 9.548080381893698e-11
with O 0 1.2363802204262697e-09
45 O 0 2.2373919605911397e-08
chromosomes O 0 6.142963684396818e-07
and O 0 8.029053333302727e-08
the O 0 6.521398976389037e-09
derivative O 0 1.2211271496198606e-06
3 O 0 5.948436410108116e-07
but O 0 3.252941382925201e-07
without O 0 6.8262639985050555e-09
the O 0 4.0309828364115674e-08
der O 0 0.4730599820613861
( O 0 9.707162851313456e-10
15 O 0 3.9103973392684566e-09
) O 0 1.6885322307036432e-10
demonstrated O 0 3.5859468727750254e-09
a O 0 1.4687230986965005e-08
phenotype O 0 1.205074386234628e-05
consistent O 0 1.1599423714869772e-06
with O 0 8.191110012489844e-09
that O 0 1.3569749057751324e-07
reported O 0 3.476947370018024e-07
for O 0 5.467415409299292e-09
haploinsufficiency O 0 2.2224299755180255e-05
of O 0 3.343439081149313e-09
distal O 0 4.1833394789136946e-05
3 O 0 1.837134186644107e-05
p O 0 0.0074369353242218494
. O 0 4.2795980448318005e-07

Uniparental B-Disease 1 0.999722421169281
disomy I-Disease 1 0.9999080896377563
associated O 0 8.338360930792987e-05
with O 0 1.309210801991867e-07
unbalanced O 0 0.0004490698338486254
segregation O 0 3.594062218326144e-05
of O 0 2.9864599682127846e-09
non O 0 5.19020488809474e-07
- O 0 0.1249004676938057
Robertsonian O 0 0.0015252366429194808
translocations O 0 0.0001268914493266493
has O 0 5.831909220432863e-06
been O 0 2.6379979090052075e-07
reported O 0 2.0702054825960658e-07
previously O 0 3.442856950641726e-06
but O 0 2.282645027662511e-06
has O 0 3.070531192861381e-06
not O 0 4.268967188636452e-07
, O 0 5.812733405718973e-09
to O 0 7.0289956077829174e-09
our O 0 3.5046829882645625e-09
knowledge O 0 7.61827989581576e-10
, O 0 4.6307785384058775e-10
been O 0 2.865222059611483e-09
observed O 0 2.982350144620227e-09
in O 0 2.1336742095368066e-10
a O 0 5.5482840544129886e-09
case O 0 5.631683848150715e-07
of O 0 1.7510426175704197e-07
PWS B-Disease 1 0.9999971389770508
. O 0 1.9371345842955634e-06

Furthermore O 0 0.00047653220826759934
, O 0 1.40468401355065e-07
our O 0 1.3397819742522188e-08
findings O 0 1.2829846518513932e-08
are O 0 1.0156229190982913e-09
best O 0 2.853682801173818e-08
interpreted O 0 7.522350742306116e-09
as O 0 4.400134923088217e-09
true O 0 3.2604443589434595e-08
gamete O 0 3.031152289167949e-07
complementation O 0 4.4107557187089697e-05
resulting O 0 3.246219364427816e-07
in O 0 1.2496574299802887e-06
maternal B-Disease 0 0.23238396644592285
UPD I-Disease 1 0.9999874830245972
15 I-Disease 0 7.197362720035017e-05
and O 0 5.850572415511124e-05
PWS B-Disease 1 0.9999164342880249

Schwartz B-Disease 1 0.911611020565033
- I-Disease 1 0.9992283582687378
Jampel I-Disease 1 0.9992462396621704
syndrome I-Disease 1 0.9999481439590454
type I-Disease 0 0.0013591793831437826
2 I-Disease 0 3.267864713052404e-06
and O 0 2.2319623894873075e-05
Stuve B-Disease 1 0.9978703260421753
- I-Disease 1 0.9999964237213135
Wiedemann I-Disease 1 0.9999977350234985
syndrome I-Disease 1 0.9999912977218628
: O 0 4.165646494413977e-09
a O 0 2.70204836283483e-09
case O 0 1.216325387076722e-07
for O 0 7.792820611030038e-09
" O 0 2.557625293775345e-07
lumping O 0 4.718669515568763e-06
" O 0 2.1789308846109634e-07
. O 0 9.578314141833744e-09

Recent O 0 2.284931952090119e-06
studies O 0 1.2845167418618075e-07
demonstrated O 0 1.2159506468378822e-07
the O 0 6.971037080916176e-09
existence O 0 6.002768060398012e-08
of O 0 7.345541952474832e-10
a O 0 8.860912714681035e-08
genetically O 0 9.184140026263776e-07
distinct O 0 3.6691385929543685e-08
, O 0 2.1774367198190703e-08
usually O 0 3.4013676319943897e-09
lethal O 0 5.607542874486171e-09
form O 0 6.260667984037127e-09
of O 0 1.6720089757171763e-09
the O 0 3.2115699468704406e-06
Schwartz B-Disease 1 0.9893194437026978
- I-Disease 1 0.9999237060546875
Jampel I-Disease 1 0.9999380111694336
syndrome I-Disease 1 0.9999418258666992
( O 0 4.295878319737767e-09
SJS B-Disease 0 0.009711732156574726
) O 0 8.093731240776947e-10
of O 0 2.062341186714889e-09
myotonia B-Disease 1 0.9603770971298218
and O 0 0.0010410620598122478
skeletal B-Disease 1 0.9981399774551392
dysplasia I-Disease 1 0.9999860525131226
, O 0 5.181574351809104e-07
which O 0 2.0326959315752902e-07
we O 0 2.4166638468159363e-07
called O 0 1.8363596154813422e-06
SJS B-Disease 1 0.5314322710037231
type I-Disease 0 4.056717807543464e-05
2 I-Disease 0 1.5785547020641388e-06
. O 0 1.2426215789673734e-07

This O 0 0.0003284502017777413
disorder O 0 0.3927333950996399
is O 0 7.59026548280417e-08
reminiscent O 0 1.3725239114137366e-05
of O 0 1.253304926507326e-08
another O 0 1.0848870033441926e-06
rare O 0 7.00687087373808e-06
condition O 0 5.307265018927865e-05
, O 0 1.7241047700622403e-08
the O 0 9.640855580528296e-08
Stuve B-Disease 1 0.9389019012451172
- I-Disease 1 0.9999858140945435
Wiedemann I-Disease 1 0.9999964237213135
syndrome I-Disease 1 0.9999877214431763
( O 0 3.9914208826985487e-08
SWS B-Disease 0 0.27811843156814575
) O 0 9.310432425024828e-09
, O 0 7.418022862637486e-10
which O 0 3.3387996811740095e-09
comprises O 0 3.6792142665831307e-09
campomelia B-Disease 0 3.710848977789283e-05
at O 0 5.546730790229049e-07
birth O 0 7.336233466048725e-06
with O 0 5.747229465669079e-07
skeletal B-Disease 1 0.97296541929245
dysplasia I-Disease 1 0.9999502897262573
, O 0 9.536678930999187e-07
contractures B-Disease 0 0.1807541400194168
, O 0 2.07421507525396e-07
and O 0 1.5818218912500015e-07
early B-Disease 0 1.7248569292860338e-06
death I-Disease 0 8.178660209523514e-06
. O 0 1.2615268474291952e-07

To O 0 5.888000487175304e-07
test O 0 1.42302951644524e-07
for O 0 6.518096479224411e-11
possible O 0 2.406811194788361e-09
nosologic O 0 1.7490161553723738e-05
identity O 0 2.3378706828225404e-06
between O 0 6.500756626337534e-06
these O 0 6.54452815069817e-05
disorders O 1 0.8189061880111694
, O 0 3.579162921596435e-08
we O 0 1.470390174063141e-07
reviewed O 0 2.2841506464033046e-08
the O 0 4.1195264977034185e-09
literature O 0 7.92897214552113e-09
and O 0 8.017924102432517e-09
obtained O 0 2.7937396840371775e-09
a O 0 5.32708943623561e-09
follow O 0 8.145558894057103e-08
- O 0 0.0001468305999878794
up O 0 2.2282128497863596e-07
of O 0 4.711343537522339e-10
the O 0 1.3942693222190883e-08
only O 0 2.8616572222972536e-08
two O 0 1.1032417646106296e-08
surviving O 0 2.9703856853302568e-05
patients O 0 1.177703978783029e-07
, O 0 2.13181527985995e-10
one O 0 8.421447983408825e-10
with O 0 9.838655223859405e-09
SJS B-Disease 0 0.002536924323067069
type I-Disease 0 7.598197043989785e-06
2 I-Disease 0 4.3992312726004457e-07
at O 0 2.9677295287910965e-07
age O 0 2.0731532401896402e-07
10 O 0 3.3588689607455535e-09
years O 0 1.075734257227623e-08
and O 0 7.724525019625617e-09
another O 0 8.335413248516943e-09
with O 0 1.8298688075901737e-07
SWS B-Disease 1 0.6363751292228699
at O 0 2.740469255968492e-07
age O 0 9.224775965321896e-08
7 O 0 3.5346857885087957e-08
years O 0 1.2977540819747446e-08
. O 0 3.405978432624579e-08

Patients O 0 0.0009216346661560237
reported O 0 2.9347932013479294e-06
as O 0 3.459383890458412e-08
having O 0 3.8228952803365246e-07
either O 0 5.399990072874061e-07
neonatal O 1 0.9998962879180908
SJS B-Disease 1 0.9998137354850769
or O 0 1.711375625745859e-05
SWS B-Disease 0 0.35739657282829285
presented O 0 3.861997655008054e-08
a O 0 1.365211677040179e-08
combination O 0 1.4628432154495385e-06
of O 0 8.482599511694389e-09
a O 0 4.231859747960698e-06
severe O 0 0.0007510142168030143
, O 0 8.157280717568938e-08
prenatal O 0 0.012829026207327843
- O 1 0.9981131553649902
onset O 1 0.9945703148841858
neuromuscular B-Disease 1 0.9999877214431763
disorder I-Disease 1 0.9997943043708801
( O 0 1.1363074037262777e-07
with O 0 1.9151586457155645e-05
congenital B-Disease 1 0.9999983310699463
joint I-Disease 1 0.6583542823791504
contractures I-Disease 1 0.9999926090240479
, O 0 0.18923169374465942
respiratory O 1 0.9999483823776245
and O 0 0.002547413343563676
feeding O 0 0.007815364748239517
difficulties O 0 8.165676263161004e-06
, O 0 1.1040354408464736e-08
tendency O 0 8.723617952455243e-07
to O 0 1.9212439639204604e-08
hyperthermia B-Disease 0 0.006814633496105671
, O 0 8.7651002900202e-08
and O 0 3.1050322490955296e-07
frequent O 0 2.0227787445037393e-06
death O 0 0.00022561587684322149
in O 0 2.0247898646630347e-06
infancy O 0 0.003471007104963064
) O 0 1.6136821878731666e-09
with O 0 1.636985103026234e-09
a O 0 9.62369597345969e-08
distinct O 0 2.20322090171976e-06
campomelic B-Disease 0 0.4762480854988098
- I-Disease 1 0.9928596019744873
metaphyseal I-Disease 1 0.647711455821991
skeletal I-Disease 1 0.9571157097816467
dysplasia I-Disease 1 0.9988048076629639
. O 0 1.2859155731348437e-06

The O 0 6.245654304848358e-08
similarity O 0 7.518423217334202e-08
of O 0 7.778945265712878e-10
the O 0 3.411843252365543e-08
clinical O 0 9.089935701922514e-06
and O 0 3.7670164942937845e-07
radiographic O 0 0.0025761679280549288
findings O 0 6.7770088207907975e-06
is O 0 7.511815880434369e-08
so O 0 4.110102835852558e-08
extensive O 0 1.5004566478182824e-07
that O 0 3.903576725861058e-06
these O 0 9.524671895633219e-07
disorders O 0 0.020616119727492332
appear O 0 4.5209665699985635e-07
to O 0 7.775363286555148e-08
be O 0 3.236534240613764e-08
a O 0 4.005071829737972e-08
single O 0 2.450012107146904e-05
entity O 0 3.901652235072106e-05
. O 0 8.740356634007185e-07

The O 0 7.221892701636534e-07
follow O 0 2.466818500579393e-07
- O 0 0.0001504845859017223
up O 0 6.601873678846459e-07
observation O 0 1.8395988945485442e-06
of O 0 2.4501733975057505e-10
an O 0 8.332393441889963e-09
identical O 0 2.2499349142890424e-05
and O 0 4.2160183966188924e-07
unique O 0 1.944951755206148e-08
pattern O 0 0.0007794099510647357
of O 0 3.833142727671657e-07
progressive O 0 0.4860169291496277
bone B-Disease 1 0.999832272529602
dysplasia I-Disease 1 0.9999630451202393
in O 0 4.444640353540308e-07
the O 0 3.919936375496036e-07
two O 0 4.407741016621003e-06
patients O 0 4.9577811296330765e-06
( O 0 7.924810252468717e-10
one O 0 1.1561236412660492e-08
with O 0 8.041145349579892e-08
SJS B-Disease 1 0.7822114825248718
type I-Disease 0 0.005817890167236328
2 I-Disease 0 1.7916029264597455e-06
, O 0 4.158519573138619e-08
one O 0 5.2335213496235156e-08
with O 0 6.487618975370424e-07
SWS B-Disease 1 0.9890804886817932
) O 0 3.8755452180794236e-08
surviving O 0 7.349850079663156e-07
beyond O 0 3.064198779156868e-07
infancy O 0 5.826516826346051e-06
adds O 0 1.2436161966888903e-07
to O 0 4.01639121960784e-09
the O 0 5.654777202046546e-10
evidence O 0 5.48166845248943e-09
in O 0 6.351582593211447e-10
favor O 0 7.562065973409915e-10
of O 0 5.002349645621962e-10
identity O 0 1.7634147297940217e-06
. O 0 1.0716696152712757e-07

The O 0 4.420102754920663e-07
hypothesis O 0 4.3100812945340294e-06
that O 0 8.301241649633084e-08
SWS B-Disease 0 0.009834307245910168
and O 0 9.07002259964429e-08
SJS B-Disease 0 0.012193077243864536
type I-Disease 0 0.0008489737519994378
2 I-Disease 0 7.914740649539453e-07
are O 0 9.952350943365218e-09
the O 0 1.6661194024436554e-07
same O 0 9.184653754346073e-05
disorder O 0 0.4770699441432953
should O 0 4.5717638386122417e-07
be O 0 1.5762592342483117e-09
testable O 0 8.36527647152252e-09
by O 0 9.241317433517082e-11
molecular O 0 3.298581674471279e-08
methods O 0 7.041859930723149e-07
. O 0 1.023173279435241e-08
. O 0 2.8228258841522802e-08

A O 0 3.3363937745889416e-06
mouse O 0 4.580184759106487e-05
model O 0 5.540489382838132e-06
of O 0 7.887598485467606e-07
severe O 1 0.9992859959602356
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999998807907104
disease I-Disease 1 1.0
: O 1 0.8903281688690186
defects O 1 0.9999719858169556
in O 0 6.77605567034334e-05
hemostasis O 1 0.9995506405830383
and O 0 0.003985126968473196
thrombosis B-Disease 1 0.9780234694480896
. O 0 1.0324281447537942e-06

von B-Disease 1 0.9902734160423279
Willebrand I-Disease 1 0.9579171538352966
factor I-Disease 0 0.0001224771694978699
( I-Disease 0 9.502534226157877e-07
vWf I-Disease 0 0.00345022976398468
) I-Disease 0 0.0008685244829393923
deficiency I-Disease 1 0.9998175501823425
causes O 1 0.5301263928413391
severe O 1 0.9999457597732544
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999997615814209
disease I-Disease 1 1.0
in O 0 0.005547514650970697
humans O 0 0.0006303056143224239
. O 0 8.872275429894216e-07

We O 0 1.0391906926088268e-06
generated O 0 1.6626592325152956e-09
a O 0 2.04914307744275e-09
mouse O 0 8.832799721858464e-06
model O 0 2.3766533558955416e-06
for O 0 2.6823009591225855e-08
this O 0 2.3040954033604066e-07
disease O 0 2.8475329600041732e-05
by O 0 1.199424171094421e-10
using O 0 6.63930022071213e-09
gene O 0 3.4652487101993756e-07
targeting O 0 2.286065182488528e-06
. O 0 1.6287131643366592e-07

vWf B-Disease 0 0.003177521051838994
- I-Disease 1 0.9945541620254517
deficient I-Disease 1 0.7714024186134338
mice O 0 0.021394498646259308
appeared O 0 8.987773071567062e-06
normal O 0 2.3279717709101533e-07
at O 0 6.957384357519913e-08
birth O 0 3.29067529492022e-06
; O 0 8.730540734802616e-09
they O 0 2.5987837659613433e-08
were O 0 2.0056617699992785e-08
viable O 0 6.576649411726976e-07
and O 0 4.008194025573175e-07
fertile O 0 8.00183079263661e-06
. O 0 4.1529324334987905e-07

Neither O 0 0.00011578953854041174
vWf O 0 0.00037814516690559685
nor O 0 6.169512198539451e-05
vWf O 0 9.136278094956651e-05
propolypeptide O 0 0.004048650152981281
( O 0 1.3376470633374993e-06
von B-Disease 1 0.8513727188110352
Willebrand I-Disease 1 0.9552513957023621
antigen O 0 0.04608166962862015
II O 0 0.2239791452884674
) O 0 1.6999216256863292e-08
were O 0 2.6958106857932762e-08
detectable O 0 1.4690249372506514e-07
in O 0 1.721659037556833e-09
plasma O 0 7.331435881496873e-06
, O 0 6.212862047050294e-08
platelets O 0 6.786035555705894e-07
, O 0 2.6385256646221933e-08
or O 0 4.8635175886602156e-08
endothelial O 0 4.406999778439058e-07
cells O 0 2.7030393923155316e-08
of O 0 1.5369922001795544e-10
the O 0 5.362555732801866e-09
homozygous O 0 4.527007035903807e-07
mutant O 0 1.097499807656277e-05
mice O 0 0.00010712489165598527
. O 0 3.2572184949231087e-08

The O 0 8.352635063602065e-07
mutant O 0 4.102422099094838e-05
mice O 0 0.024773908779025078
exhibited O 0 0.0005293798167258501
defects O 1 0.8890748620033264
in O 0 2.5641315914981533e-07
hemostasis O 0 0.19589513540267944
with O 0 6.464076136580843e-07
a O 0 4.691165031545097e-06
highly O 0 0.001418687985278666
prolonged O 1 0.9228779673576355
bleeding O 1 0.9999198913574219
time O 0 9.213847806677222e-05
and O 0 6.795284207328223e-06
spontaneous O 0 1.7988595573115163e-05
bleeding O 0 0.274358332157135
events O 0 3.2154659379557415e-08
in O 0 3.675854731710615e-09
approximately O 0 5.066959296584628e-09
10 O 0 1.1493955121011368e-08
% O 0 5.162500427147165e-10
of O 0 8.736320999958025e-09
neonates O 0 0.001319209928624332
. O 0 2.6502354444346565e-07

As O 0 1.9039001699638902e-06
in O 0 2.167177903800166e-08
the O 0 3.745783061503971e-08
human O 0 4.192029336991254e-06
disease O 0 0.010774102061986923
, O 0 1.387847725631275e-09
the O 0 1.3209309202011355e-09
factor O 0 2.3154568040695267e-08
VIII O 0 0.0001404556242050603
level O 0 2.5824044769251486e-07
in O 0 1.1497111707114982e-08
these O 0 2.0838164971337392e-08
mice O 0 5.292315108818002e-05
was O 0 2.5856302272586618e-06
reduced O 0 7.146024216808655e-08
strongly O 0 2.4798948672355436e-08
as O 0 3.0794229388675376e-08
a O 0 3.053329749036493e-07
result O 0 9.46262616707827e-07
of O 0 6.120645767992983e-09
the O 0 3.2872080168999673e-07
lack O 0 6.867717416980668e-08
of O 0 3.225991973554443e-10
protection O 0 4.445581325285275e-08
provided O 0 2.8634519200210207e-09
by O 0 3.3924649756045255e-09
vWf O 0 1.3176725133234868e-06
. O 0 8.98911096669508e-08

Defective O 1 0.9799490571022034
thrombosis B-Disease 1 0.947208821773529
in O 0 2.1121840632076783e-07
mutant O 0 8.2275306340307e-05
mice O 0 0.190155491232872
was O 0 0.00016529066488146782
also O 0 4.341639225913241e-07
evident O 0 1.953846151536709e-07
in O 0 4.012027599031853e-09
an O 0 2.2410766575831076e-09
in O 0 1.1698586099839758e-08
vivo O 0 5.4868878578417934e-06
model O 0 1.4555650977854384e-06
of O 0 4.4471164528658846e-08
vascular B-Disease 1 0.9997608065605164
injury I-Disease 1 0.6048610210418701
. O 0 1.9870047651693312e-07

In O 0 9.28553660628495e-08
this O 0 4.15216083737846e-09
model O 0 2.250686748084263e-07
, O 0 8.357171066286639e-10
the O 0 2.3334689736032033e-09
exteriorized O 0 3.568162355804816e-05
mesentery O 0 8.983228326542303e-05
was O 0 3.7546608382399427e-06
superfused O 0 4.674159299611347e-06
with O 0 3.611881993492716e-08
ferric O 0 0.00011114469089079648
chloride O 0 3.549103348632343e-05
and O 0 3.0450846679741517e-06
the O 0 1.862879450698074e-08
accumulation O 0 1.7258197715364076e-07
of O 0 1.5916973294949344e-09
fluorescently O 0 0.00023691338719800115
labeled O 0 6.566177034983411e-05
platelets O 0 5.45355214853771e-06
was O 0 3.860304502723011e-07
observed O 0 1.1233610486272028e-08
by O 0 7.754650810376518e-10
intravital O 0 1.9300498479424277e-06
microscopy O 0 8.526934038854961e-07
. O 0 6.368863125771895e-08

We O 0 9.733549813972786e-05
conclude O 0 2.119708142345189e-06
that O 0 1.9717818489084493e-08
these O 0 5.85468207248141e-09
mice O 0 4.0409257053397596e-05
very O 0 2.6153523791094813e-08
closely O 0 4.57720079793944e-06
mimic O 1 0.6164906620979309
severe O 0 0.18963952362537384
human O 1 0.5124068260192871
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999996423721313
disease I-Disease 1 1.0
and O 1 0.7633836269378662
will O 0 4.318680294090882e-05
be O 0 5.46626068853584e-08
very O 0 2.1692443397114403e-09
useful O 0 9.096851050216515e-10
for O 0 9.395695332869991e-11
investigating O 0 2.3247395120051806e-09
the O 0 1.5761149052551104e-09
role O 0 3.803310555383632e-09
of O 0 1.3308866508854322e-10
vWf O 0 4.051331714549633e-08
in O 0 1.6737711661107824e-08
normal O 0 5.787622967545758e-07
physiology O 0 3.0716732908331323e-06
and O 0 5.383037660067203e-07
in O 0 7.783403361827368e-07
disease O 0 0.0009504903573542833
models O 0 6.341492735373322e-07
. O 0 7.534254109486938e-09
. O 0 4.362632211041273e-08

Oral O 0 0.009781081229448318
contraceptives O 0 0.15701180696487427
and O 0 1.8670966710487846e-06
the O 0 3.780111867968117e-08
risk O 0 2.883249180740677e-06
of O 0 1.0246261581414728e-06
hereditary B-Disease 1 0.9999974966049194
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 1.2405047527863644e-05

Hereditary B-Disease 1 0.9999125003814697
Ovarian I-Disease 1 0.9999833106994629
Cancer I-Disease 1 0.996953010559082
Clinical O 0 0.0005764852976426482
Study O 0 5.0762905630108435e-06
Group O 0 1.9578990759328008e-05
. O 0 3.2411307415713964e-07

BACKGROUND O 0 0.0010360819287598133
Women O 0 1.0042938811238855e-05
with O 0 2.8262848061899604e-08
mutations O 0 2.2054762212064816e-06
in O 0 7.719811456752268e-09
either O 0 8.728214595521422e-08
the O 0 1.131907580997904e-07
BRCA1 O 0 0.00029891845770180225
or O 0 4.0302762727151276e-07
the O 0 7.864226603260249e-08
BRCA2 O 0 5.508825324795907e-06
gene O 0 4.1660385363684327e-07
have O 0 1.8154503322875826e-07
a O 0 2.3996527431791037e-08
high O 0 6.622874025197234e-06
lifetime O 0 6.2682493080501445e-06
risk O 0 1.3235174264991656e-05
of O 0 5.509852053364739e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
. O 0 4.815703050553566e-06

Oral O 0 0.005613649729639292
contraceptives O 1 0.6695241332054138
protect O 0 0.03396661952137947
against O 1 0.9971075654029846
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
in O 0 6.117987254583568e-07
general O 0 3.4370623325230554e-07
, O 0 3.835870643342787e-07
but O 0 7.194594786597008e-07
it O 0 1.7845759714418818e-07
is O 0 2.3878820698541858e-08
not O 0 1.4988085439426868e-08
known O 0 1.6473627795221546e-08
whether O 0 1.8581527427841138e-08
they O 0 5.13582108396804e-07
also O 0 1.2390623851388227e-06
protect O 0 9.002458227769239e-07
against O 0 3.885896603605943e-06
hereditary B-Disease 0 0.008561952970921993
forms I-Disease 0 8.285394869744778e-06
of I-Disease 0 0.005988969933241606
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
. O 0 4.089937647222541e-06

METHODS O 0 2.7949839932261966e-05
We O 0 3.2524354764973396e-07
enrolled O 0 7.80480924333915e-09
207 O 0 1.965055844266317e-06
women O 0 1.2424996384652331e-05
with O 0 0.0006085979985073209
hereditary B-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.0007172467303462327
161 O 0 9.522269465378486e-06
of O 0 8.464419920528599e-08
their O 0 6.989145276747877e-06
sisters O 0 0.00014254081179387867
as O 0 2.0409139267485443e-08
controls O 0 2.3481895823351806e-06
in O 0 4.40468639339997e-09
a O 0 5.189853169440539e-08
case O 0 3.8512475839524996e-06
- O 0 0.00917255599051714
control O 0 1.7645686966716312e-05
study O 0 4.909738038350042e-08
. O 0 1.289252349323533e-08

All O 0 5.818520776301739e-07
the O 0 3.150928407080755e-08
patients O 0 3.212982946365628e-08
carried O 0 1.9561126052280997e-08
a O 0 9.58978896292706e-10
pathogenic O 0 5.004921987961097e-08
mutation O 0 1.9572496512409998e-07
in O 0 2.918146835284574e-09
either O 0 9.781103926798096e-08
BRCA1 O 0 5.491068441187963e-05
( O 0 4.851591572929692e-09
179 O 0 2.3720582476016716e-07
women O 0 6.966280921005819e-07
) O 0 6.660977103223331e-09
or O 0 4.051231883295259e-07
BRCA2 O 0 0.0002376252959948033
( O 0 8.706432907956696e-08
28 O 0 7.984823241713457e-06
women O 0 1.827592541303602e-06
) O 0 3.948683513499418e-08
. O 0 1.0876203759835334e-07

The O 0 6.928482321200136e-07
control O 0 1.4040028872841503e-05
women O 0 1.1648393893892717e-07
were O 0 2.5031461348135053e-09
enrolled O 0 1.0173348830022633e-09
regardless O 0 4.805873032864838e-09
of O 0 2.0081364349167075e-10
whether O 0 1.9188422584193177e-07
or O 0 3.883689316808159e-07
not O 0 4.109139410957141e-07
they O 0 9.322483407459004e-08
had O 0 1.1594114539548173e-06
either O 0 3.605955356533741e-08
mutation O 0 1.3054722103333916e-06
. O 0 7.82171198920878e-08

Lifetime O 0 5.058497208665358e-06
histories O 0 4.461901880858932e-06
of O 0 3.60189811310363e-09
oral O 0 1.3001323168282397e-05
- O 0 0.0004659435944631696
contraceptive O 0 0.00043358164839446545
use O 0 1.971507401776762e-08
were O 0 5.718185924763475e-09
obtained O 0 1.050577957961707e-09
by O 0 1.5011079046445275e-09
interview O 0 3.679339670270565e-06
or O 0 4.775882356256034e-09
by O 0 5.133181657512864e-10
written O 0 1.5111572437831455e-08
questionnaire O 0 4.142188458899909e-08
and O 0 1.8684165326021684e-08
were O 0 9.248962484775802e-09
compared O 0 1.223718903986537e-08
between O 0 2.5596776254133147e-07
patients O 0 2.6356594844401116e-06
and O 0 8.921231824388087e-07
control O 0 0.004466789774596691
women O 0 1.2390529491312918e-06
, O 0 3.527558467553149e-09
after O 0 9.128645395151125e-09
adjustment O 0 2.008417965271292e-08
for O 0 2.392288034336332e-10
year O 0 1.246876046856471e-09
of O 0 6.164483923321029e-10
birth O 0 8.099751539702993e-06
and O 0 5.4378197944515705e-08
parity O 0 3.723484496731544e-06
. O 0 6.113997130796633e-08

RESULTS O 0 2.9866616387153044e-05
The O 0 2.3331008236482376e-08
adjusted O 0 3.707523865159601e-05
odds O 0 0.00018654191808309406
ratio O 0 0.00017157872207462788
for O 0 0.08195680379867554
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.024222729029134e-05
with O 0 7.892656839203482e-08
any O 0 1.6538640679186756e-08
past O 0 8.890623348634108e-08
use O 0 2.0588206695038025e-08
of O 0 4.808018427837624e-09
oral O 0 0.0020905788987874985
contraceptives O 0 0.138021320104599
was O 0 1.2085236448911019e-05
0 O 0 1.214969415741507e-06
. O 0 6.997723289714486e-08

5 O 0 5.086492933514819e-07
( O 0 3.215488764141128e-09
95 O 0 7.88173579735485e-08
percent O 0 3.9312462263296766e-07
confidence O 0 4.8692913878767285e-06
interval O 0 7.225279205158586e-06
, O 0 2.505496254912032e-09
0 O 0 2.3336436782983583e-08
. O 0 2.9233598874967015e-10
3 O 0 9.895527952608063e-09
to O 0 1.5197711533687652e-08
0 O 0 3.2999730592564447e-07
. O 0 3.5165814704640752e-09
8 O 0 8.606772183838984e-08
) O 0 1.2242044711285871e-08
. O 0 5.4432366169976376e-08

The O 0 8.882910151442047e-06
risk O 0 5.339998551789904e-06
decreased O 0 5.089117962597811e-07
with O 0 1.5302592526467151e-09
increasing O 0 1.3002260379479935e-09
duration O 0 1.0878734713060112e-07
of O 0 1.661548815201641e-10
use O 0 1.4304094975159387e-07
( O 0 3.5958507282884966e-09
P O 0 8.495317160850391e-05
for O 0 2.0335766404144806e-09
trend O 0 5.824178401780955e-07
, O 0 7.148471814488744e-10
< O 0 8.181038957388864e-09
0 O 0 7.391178780125074e-09
. O 0 1.7843437838394038e-10
001 O 0 3.2017819506791056e-08
) O 0 8.473535068054261e-11
; O 0 7.564874421328582e-11
use O 0 5.161970850764419e-09
for O 0 8.572739851331335e-09
six O 0 5.210652531673077e-08
or O 0 9.940702483390851e-09
more O 0 2.221580475136875e-09
years O 0 2.1598000898848113e-07
was O 0 1.9861699911416508e-05
associated O 0 1.7808433838695237e-08
with O 0 1.3976233503854019e-09
a O 0 7.164309145935022e-09
60 O 0 6.022134790839573e-09
percent O 0 1.8303813575926142e-08
reduction O 0 7.271791702123664e-08
in O 0 3.0041323384466523e-07
risk O 0 6.490189662144985e-06
. O 0 5.374938893965009e-08

Oral O 0 0.00019824053742922843
- O 0 0.00017595347890164703
contraceptive O 0 0.00032591677154414356
use O 0 1.3526765769711346e-06
protected O 0 0.015552228316664696
against O 1 0.9883952140808105
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
both O 0 1.5518290297222848e-07
for O 0 5.545671033502231e-09
carriers O 0 9.16748987833671e-08
of O 0 7.787377964696418e-10
the O 0 3.5695441624739033e-07
BRCA1 O 0 0.00010217935050604865
mutation O 0 7.255927130245254e-07
( O 0 1.0459931809592149e-09
odds O 0 1.844063831413223e-06
ratio O 0 2.450597094139084e-07
, O 0 1.2187381104311612e-09
0 O 0 2.0022179469947332e-08
. O 0 4.440941225869466e-10
5 O 0 1.5624899152300031e-09
; O 0 8.42581782123375e-10
95 O 0 8.999713685398092e-08
percent O 0 5.186182079341961e-07
confidence O 0 4.122569407627452e-06
interval O 0 2.1422783902380615e-06
, O 0 7.819303537992539e-10
0 O 0 9.2195309164822e-09
. O 0 3.469675657896687e-10
3 O 0 3.347331523073649e-09
to O 0 3.0029960740307615e-09
0 O 0 1.1313366599097208e-07
. O 0 3.128816317143901e-09
9 O 0 1.037580972251817e-07
) O 0 1.131877369608958e-09
and O 0 1.1379998277050163e-08
for O 0 5.200628261370355e-10
carriers O 0 1.1819430767445738e-08
of O 0 3.914223667411676e-10
the O 0 1.2674938432155614e-07
BRCA2 O 0 2.752828731900081e-05
mutation O 0 9.857494660536759e-07
( O 0 6.289173626328193e-10
odds O 0 1.3487323258232209e-06
ratio O 0 2.0343735229744198e-07
, O 0 1.6735978158877174e-09
0 O 0 2.5128963798692894e-08
. O 0 6.398004903651611e-10
4 O 0 6.5421916772834265e-09
; O 0 1.1038496783299934e-09
95 O 0 1.573387606867982e-07
percent O 0 3.042267167074897e-07
confidence O 0 2.279186446685344e-06
interval O 0 3.7683241771446774e-06
, O 0 1.4218548560762656e-09
0 O 0 8.854641464495216e-09
. O 0 2.1920693038524064e-10
2 O 0 4.045453749768058e-09
to O 0 2.9300935011633555e-09
1 O 0 1.1946877265245348e-08
. O 0 2.3653969893899784e-09
1 O 0 2.82777303795001e-08
) O 0 2.3761421275025896e-08
. O 0 7.689455117088073e-08

CONCLUSIONS O 0 4.9720463721314445e-05
Oral O 0 0.00011424933472881094
- O 0 0.0007235351949930191
contraceptive O 0 0.0026733463164418936
use O 0 1.2296146678636433e-06
may O 0 8.437097562818963e-07
reduce O 0 9.412928392293907e-08
the O 0 9.097917796907495e-08
risk O 0 2.3834492822061293e-05
of O 0 0.0003149585099890828
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.5166549676214345e-05
women O 0 4.4264193093113136e-06
with O 0 2.29152092856566e-08
pathogenic O 0 6.033208705957804e-07
mutations O 0 1.3147076742825448e-06
in O 0 1.3597907688733812e-08
the O 0 2.2076619643485174e-07
BRCA1 O 0 0.0003206334076821804
or O 0 1.2949398069395102e-06
BRCA2 O 0 0.0001910822611534968
gene O 0 7.49615064705722e-05

A O 0 1.0746446605480742e-05
Japanese O 0 4.344091212260537e-05
family O 0 9.190773084810644e-07
with O 0 9.05624176539277e-07
adrenoleukodystrophy B-Disease 1 0.9999982118606567
with O 0 3.5265517794869083e-07
a O 0 5.742748143688914e-08
codon O 0 3.242675347792101e-06
291 O 0 8.092733878584113e-07
deletion O 0 1.1480148714326788e-05
: O 0 1.8775189403186232e-08
a O 0 6.706362398745114e-08
clinical O 0 1.7252388715860434e-05
, O 0 2.6016206078338655e-08
biochemical O 0 7.213382559712045e-06
, O 0 7.918441013998745e-08
pathological O 0 6.911899981787428e-05
, O 0 7.834881188273357e-08
and O 0 2.3335486787345872e-07
genetic O 0 5.40421251571388e-06
report O 0 2.0793150667941518e-07
. O 0 5.118941359683049e-08

We O 0 3.506298889988102e-05
report O 0 1.4104731604902554e-08
a O 0 9.558854818791929e-10
Japanese O 0 4.3991153688693885e-06
family O 0 6.370661367327557e-07
with O 0 3.198089689249173e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.000659397104755044
ALD B-Disease 1 1.0
) O 0 4.3294087959111494e-07
with O 0 4.331861447326446e-08
a O 0 1.865674903456238e-07
three O 0 1.5515418283484905e-07
base O 0 1.3744892157774302e-06
pair O 0 3.4627155400812626e-05
deletion O 0 3.1936019695422146e-06
( O 0 1.4802276071534948e-09
delGAG O 0 3.412885121178988e-07
291 O 0 1.6400682056882943e-07
) O 0 6.824281140183075e-10
in O 0 4.532810571333812e-09
the O 0 7.068827585499093e-07
ALD B-Disease 1 0.9999961853027344
gene O 0 6.90297456458211e-05
. O 0 4.2474363226574496e-07

A O 0 5.663482056661451e-07
variety O 0 2.3726865805429043e-08
of O 0 2.3706361318431846e-09
phenotypes O 0 7.592141628265381e-06
were O 0 1.6803356572836492e-07
observed O 0 4.598121350340989e-08
within O 0 2.0656085730763607e-09
this O 0 1.1177335501599828e-08
family O 0 6.983069624766358e-07
. O 0 2.0748146312143945e-07

While O 0 1.8921309674624354e-06
the O 0 4.73125894018267e-08
proband O 0 7.423519855365157e-05
( O 0 1.8933166145984615e-08
patient O 0 3.3486792290204903e-06
1 O 0 7.589063955038e-08
) O 0 3.14000949686033e-08
was O 0 3.8367888919310644e-06
classified O 0 1.379953005198331e-06
as O 0 1.1259178336331388e-06
having O 0 7.324422313104151e-07
a O 0 6.052179202242769e-08
rare O 0 1.2098594481813052e-07
intermediate O 0 9.675669616626692e-07
type O 0 1.4171293514664285e-05
of O 0 1.3655293784609057e-08
adult O 0 0.0006210129940882325
cerebral O 0 0.049947455525398254
and O 0 6.212522293935763e-06
cerebello O 0 0.07926992326974869
- O 1 0.9984232187271118
brain O 1 0.7053537368774414
stem O 0 4.4147118387627415e-06
forms O 0 2.8837496302003274e-06
, O 0 2.6398600994070875e-07
his O 0 2.4076907720882446e-06
younger O 0 1.8493718698664452e-06
brother O 0 2.583596824479173e-06
( O 0 1.2136928129180546e-09
patient O 0 8.025958209145756e-07
2 O 0 2.036003934335895e-07
) O 0 3.0848607224243096e-08
and O 0 1.5993541637726594e-06
nephew O 0 0.0043923817574977875
( O 0 4.6594532676635936e-08
patient O 0 1.1232559700147249e-05
3 O 0 5.034507353229856e-07
) O 0 8.090189140830262e-08
had O 0 1.1457769687694963e-05
a O 0 6.892479632369941e-06
childhood O 1 0.9834659099578857
ALD B-Disease 1 0.9999988079071045
type O 0 0.3896912634372711
. O 0 1.3280576922625187e-06

Another O 0 5.437883373815566e-06
nephew O 0 0.00026184358284808695
( O 0 2.5331752695478826e-08
patient O 0 9.272505849367008e-06
4 O 0 7.318585062421334e-07
) O 0 1.1280481437836443e-08
of O 0 5.387478019258651e-09
patient O 0 0.0008153290837071836
1 O 0 8.76206399880175e-07
was O 0 1.7161644791485742e-05
classified O 0 1.0008613571699243e-05
as O 0 2.6970812996296445e-06
having O 0 1.100801455322653e-06
an O 0 2.4309834145697096e-08
adolescent O 0 0.001479918835684657
form O 0 2.503367795725353e-06
. O 0 2.412033666132629e-07

The O 0 1.0605791089801642e-07
tau O 0 4.4233956941752695e-08
level O 0 1.1534622501585545e-07
in O 0 3.1145499512774677e-09
the O 0 1.2315939557083766e-07
cerebrospinal O 0 0.006875466089695692
fluid O 0 3.5959204979008064e-05
( O 0 6.905481342300845e-08
CSF O 0 0.033739011734724045
) O 0 5.786384260630939e-09
in O 0 1.8006501179002044e-08
patient O 0 4.3443583308544476e-06
1 O 0 3.9266711837626644e-07
was O 0 7.100396032910794e-05
as O 0 1.1411127331939497e-07
high O 0 3.1685630119682173e-07
as O 0 4.292309796483096e-08
that O 0 4.0941493750779046e-08
of O 0 6.227927062951721e-09
patients O 0 5.3661315178032964e-06
with O 0 4.839388930122368e-05
Alzheimers B-Disease 1 0.9999991655349731
disease I-Disease 1 0.9989606142044067
( O 0 5.347949638689897e-09
AD B-Disease 0 7.421549526043236e-06
) O 0 2.226633988300364e-08
. O 0 2.6902323924105076e-08

His O 0 1.2133703421568498e-05
brain O 0 8.434816663793754e-06
magnetic O 0 1.4306552031939646e-07
resonance O 0 3.073262462294224e-07
image O 0 1.0053076948679518e-05
( O 0 2.8795650308666154e-09
MRI O 0 3.0588624213123694e-05
) O 0 1.955761952388002e-08
showed O 0 6.623633089475334e-05
abnormalities B-Disease 0 0.08159090578556061
in I-Disease 0 1.2087949130545894e-07
the I-Disease 0 1.009538891594275e-06
bilateral I-Disease 0 9.817932732403278e-05
cerebellar I-Disease 1 0.9543710947036743
hemispheres I-Disease 1 0.544293999671936
and O 0 0.00178958335891366
brain O 0 0.157932311296463
stem O 0 3.664191535790451e-05
, O 0 2.7408194114286744e-07
but O 0 7.11912093720457e-07
not O 0 1.423512827614104e-07
in O 0 3.705612172666406e-08
the O 0 7.428138246723393e-07
cerebral O 0 0.003181372070685029
white O 0 6.991238478804007e-06
matter O 0 2.8347825420382833e-08
, O 0 9.690698243858265e-10
where O 0 2.1351980183936803e-09
marked O 0 1.652278136532459e-08
reductions O 0 8.51604582408072e-08
of O 0 1.9718673360813455e-09
the O 0 2.128398136846954e-06
cerebral O 0 0.40609467029571533
blood O 0 2.9888753488194197e-05
flow O 0 3.728665660673869e-06
and O 0 4.4958576950193674e-07
oxygen O 0 2.640111240737042e-08
metabolism O 0 2.63555875790189e-07
were O 0 4.990306390340038e-09
clearly O 0 9.561083480491561e-09
demonstrated O 0 7.686075109702983e-10
by O 0 5.46334436024587e-11
positron O 0 2.71088282488563e-07
emission O 0 9.690521807215191e-08
tomography O 0 3.8195950764929876e-05
( O 0 1.746568578653296e-08
PET O 0 7.082619504217291e-06
) O 0 2.67173145829247e-08
. O 0 3.8321843476296635e-08

In O 0 1.4241335293263546e-06
patients O 0 1.532746523480455e-06
2 O 0 3.0198737022146815e-07
and O 0 3.760813740427693e-07
3 O 0 2.84672267980568e-07
, O 0 2.332646786840087e-08
the O 0 1.3416435962199103e-08
autopsy O 0 0.0004947513225488365
findings O 0 2.2307112601538392e-07
showed O 0 8.624553629488219e-06
massive O 0 1.7682510588201694e-05
demyelination B-Disease 1 0.9999991655349731
of I-Disease 0 1.5313482890633168e-06
the I-Disease 0 1.8428525436320342e-05
cerebral I-Disease 0 0.05124920606613159
white I-Disease 0 4.563305992633104e-06
matter I-Disease 0 5.274324088588855e-09
with O 0 7.218732833713659e-10
sparing O 0 1.2365813262249503e-08
of O 0 1.514425918003326e-09
the O 0 2.1497267255199404e-07
U O 0 0.32828447222709656
- O 0 0.21639595925807953
fibers O 0 0.0015594868455082178
, O 0 4.534306707881797e-09
compatible O 0 3.4914403812535966e-08
with O 0 1.3927881070685544e-09
the O 0 2.5890209975898415e-09
findings O 0 1.6029922278448794e-08
of O 0 2.716425662185884e-08
childhood O 1 0.7941319346427917
ALD B-Disease 1 0.9999978542327881
. O 0 4.313239060138585e-06

Oleic O 0 0.22927525639533997
and O 0 2.536770080041606e-05
erucic O 0 0.001700249733403325
acids O 0 1.9287231225462165e-06
( O 0 1.8043280203272616e-09
Lorenzos O 0 2.3293093818210764e-06
Oil O 0 1.4302486306405626e-07
) O 0 2.9587729488689263e-10
were O 0 7.917316802164009e-10
administered O 0 1.396392446118e-09
to O 0 6.844268263250797e-09
patients O 0 1.686116846144614e-08
1 O 0 1.0395892147130326e-08
and O 0 5.898111226088076e-07
4 O 0 5.139464974490693e-06
, O 0 9.152045521432228e-08
but O 0 1.8096296017233726e-08
sufficient O 0 5.825060989117503e-10
effectiveness O 0 9.079711205117746e-09
was O 0 1.9125667449770845e-07
not O 0 6.285782561121778e-09
obtained O 0 1.4344867516058457e-08
. O 0 2.5649379509218306e-08

The O 0 5.547207138079102e-07
findings O 0 2.109514838366522e-07
in O 0 2.0322972194009026e-09
this O 0 3.5858578328884505e-09
family O 0 2.1515845105568587e-08
suggest O 0 2.8366142146296625e-07
that O 0 3.410580973195465e-08
delGAG291 O 0 1.729120754134783e-06
is O 0 1.2259499193589818e-08
part O 0 8.768273218606737e-09
of O 0 1.6134360514286072e-09
the O 0 1.124725059753473e-07
cause O 0 1.6592898077760765e-07
of O 0 1.998333054586965e-09
Japanese O 0 0.005962753668427467
ALD B-Disease 1 0.9999984502792358
with O 0 2.6943919095856472e-08
phenotypic O 0 2.2923879896552535e-06
variations O 0 7.752994861220941e-06
. O 0 4.048822006552655e-07

Moreover O 0 4.011197597719729e-05
, O 0 3.656235847415701e-08
although O 0 5.99208149765218e-09
the O 0 3.115885327531487e-10
scale O 0 3.460348807493574e-06
of O 0 6.821799125589223e-09
the O 0 6.937482055491273e-08
study O 0 9.38918773840669e-08
is O 0 3.5060686798260576e-08
limited O 0 2.935398697445635e-07
, O 0 2.358811279634665e-08
there O 0 9.726404570642444e-09
is O 0 6.484989767407967e-10
a O 0 2.434248580485132e-09
possibility O 0 4.286026822342137e-08
that O 0 5.876096906831663e-07
PET O 0 4.595751306624152e-05
can O 0 3.6458914109971374e-07
detect O 0 4.361386345408391e-06
an O 0 1.281871675473667e-08
insidious B-Disease 0 0.0067697931081056595
lesion I-Disease 1 0.9928862452507019
which O 0 7.98743621999165e-06
is O 0 4.408790132970353e-08
undetectable O 0 1.540312155157153e-06
by O 0 2.1509299896749212e-10
computed O 0 1.6971233662843588e-07
tomogram O 0 9.73345959209837e-06
( O 0 1.1607586003492543e-09
CT O 0 0.00021574813581537455
) O 0 8.539818296959822e-10
or O 0 1.4444827556303608e-09
MRI O 0 3.35581466970325e-06
analysis O 0 5.7158878519203427e-08
, O 0 1.0259032734438733e-08
and O 0 7.079035668766664e-08
that O 0 4.585343660323815e-08
the O 0 5.92389826081785e-09
higher O 0 3.1462864313880345e-08
level O 0 4.032344236293284e-08
of O 0 1.117231585023859e-10
tau O 0 1.6042974726460102e-09
reflects O 0 1.2717935593542506e-09
the O 0 9.858631966341846e-11
process O 0 1.1038511077421376e-10
of O 0 1.7754897552180182e-10
neuronal B-Disease 0 0.0003698622458614409
degeneration I-Disease 1 0.9990494847297668
in O 0 6.175805174279958e-05
ALD B-Disease 1 0.9999971389770508
. O 0 2.4056801066763e-06

Lorenzos O 0 0.0002663074410520494
Oil O 0 2.312986453034682e-06
should O 0 5.266506164502971e-08
be O 0 4.547061616122505e-10
given O 0 2.700819429213297e-11
in O 0 1.2707382368581932e-10
the O 0 1.5191182756169042e-09
early O 0 1.556671520575037e-07
stage O 0 1.4863165233691689e-05
. O 0 1.5483957227502287e-08
. O 0 2.1348366630036253e-08

Nonsense O 0 0.0010385815985500813
mutation O 0 8.813783097139094e-06
in O 0 3.811800208808336e-09
exon O 0 1.7312213458353654e-06
4 O 0 1.4581909226762946e-06
of O 0 1.2024397477716775e-08
human O 0 6.224687467693002e-07
complement O 0 7.584200716337364e-07
C9 O 0 2.8545040549943224e-05
gene O 0 4.346239620645065e-06
is O 0 5.5287863176545216e-08
the O 0 1.277239558561405e-08
major O 0 2.5103292955463985e-07
cause O 0 3.2056840382210794e-07
of O 0 4.583714297012875e-09
Japanese O 0 0.00013208971358835697
complement B-Disease 0 5.012331166653894e-05
C9 I-Disease 1 0.6504945755004883
deficiency I-Disease 0 0.4397745132446289
. O 0 1.657679717936844e-07

Deficiency B-Disease 1 0.9993788003921509
of I-Disease 0 4.838240741378286e-08
the I-Disease 0 1.5792986118867702e-07
ninth I-Disease 0 9.632117325963918e-06
component I-Disease 0 1.895094783321838e-07
of I-Disease 0 2.427483769551486e-09
human I-Disease 0 2.8490040904216585e-07
complement I-Disease 0 9.039520136866486e-07
( O 0 5.36944355644664e-09
C9 O 0 6.608301191590726e-06
) O 0 5.039182848776136e-09
is O 0 3.237545120882146e-09
the O 0 3.8873744223622e-09
most O 0 4.00322370808226e-08
common O 0 8.043831621762365e-05
complement B-Disease 1 0.9999988079071045
deficiency I-Disease 1 0.9999996423721313
in O 0 3.3427878065594996e-07
Japan O 0 0.00017799800843931735
but O 0 3.1735015681988443e-07
is O 0 5.334776176368905e-09
rare O 0 9.325397343218356e-09
in O 0 5.2826703011987775e-09
other O 0 1.669695159911555e-09
countries O 0 1.7127632645497215e-09
. O 0 2.2180337566624075e-08

We O 0 2.1004702830396127e-06
studied O 0 1.4055424379932902e-08
the O 0 1.6473014619045045e-10
molecular O 0 1.1152611278930635e-08
basis O 0 9.237695941521906e-09
of O 0 3.300721473920021e-08
C9 B-Disease 1 0.9752919673919678
deficiency I-Disease 1 0.978745698928833
in O 0 8.076944624235693e-08
four O 0 3.7042278222543246e-07
Japanese O 0 0.00020085320284124464
C9 B-Disease 0 0.024302907288074493
- I-Disease 1 0.9960747957229614
deficient I-Disease 1 0.8699076175689697
patients O 0 8.231767424149439e-05
who O 0 0.00011718901805579662
had O 0 0.010710054077208042
suffered O 0 0.07647320628166199
from O 0 1.6341522268703557e-06
meningococcal B-Disease 1 0.9999994039535522
meningitis I-Disease 1 0.9999994039535522
. O 0 6.43641033093445e-06

Direct O 0 1.0003014239146069e-07
sequencing O 0 1.9271055862191133e-07
of O 0 2.3647745983623736e-09
amplified O 0 1.245058570020774e-06
C9 O 0 2.157293920390657e-06
cDNA O 0 1.9021946684461e-07
and O 0 8.440817822474855e-08
DNA O 0 7.685871423745994e-06
revealed O 0 2.517147095204564e-07
a O 0 7.31369520501346e-10
nonsense O 0 8.574638172831328e-07
substitution O 0 3.176439555829802e-09
( O 0 9.995982513943957e-11
CGA O 0 2.1895063184729224e-07
- O 0 0.0003874964313581586
- O 0 0.0004331667150836438
> O 0 1.2599110732480767e-07
TGA O 0 1.2838042948715156e-06
) O 0 1.3031302426025348e-10
at O 0 7.683242236877774e-11
codon O 0 3.0907487680309487e-09
95 O 0 1.2808787364093632e-09
in O 0 1.342722599773083e-10
exon O 0 7.874791094764078e-07
4 O 0 8.04546914423554e-07
in O 0 3.007864535220506e-08
the O 0 5.9096368687505674e-08
four O 0 7.837584803382924e-07
C9 B-Disease 0 0.016562912613153458
- I-Disease 1 0.5816447138786316
deficient I-Disease 0 0.01260785199701786
individuals O 0 8.961512421024054e-09
. O 0 1.9783479743296084e-08

An O 0 3.767874900972856e-08
allele O 0 1.0839256958661281e-07
- O 0 7.5639136412064545e-06
specific O 0 1.032808238932148e-08
polymerase O 0 7.635395377292298e-06
chain O 0 2.9739461751887575e-05
reaction O 0 2.369668408164216e-07
system O 0 3.8283455978671554e-06
designed O 0 4.27456725446973e-05
to O 0 3.3560400680698876e-08
detect O 0 1.6077129885161412e-06
exclusively O 0 5.157916316278488e-09
only O 0 1.5464330260783754e-08
one O 0 9.506965881200813e-09
of O 0 3.7126407503862424e-10
the O 0 1.9236788162402263e-08
normal O 0 1.1417625955800759e-07
and O 0 6.699814036892349e-09
mutant O 0 5.0883265600987215e-08
alleles O 0 8.478970858760704e-10
indicated O 0 6.272575348020837e-08
that O 0 1.4693424255085574e-08
all O 0 1.5673433662044545e-09
the O 0 5.31779020818135e-09
four O 0 3.187511055102732e-08
patients O 0 1.076838795910362e-08
were O 0 6.346108638588532e-10
homozygous O 0 3.71914188335154e-09
for O 0 3.589530617187364e-10
the O 0 1.267686067230045e-09
mutation O 0 1.5509849404793385e-08
in O 0 3.3143845445948728e-09
exon O 0 3.5072102946287487e-06
4 O 0 2.0628614947781898e-05
and O 0 2.6093414362549083e-06
that O 0 4.4684625777335896e-07
the O 0 4.6690438182395155e-08
parents O 0 1.3808198140452532e-08
of O 0 5.658467028268888e-10
patient O 0 1.0361092108723824e-06
2 O 0 5.2453835053256626e-08
were O 0 4.3400905980206517e-08
heterozygous O 0 3.9370652871184575e-07
. O 0 4.917629325973394e-08

The O 0 3.334859286496794e-07
common O 0 2.9479153340616904e-08
mutation O 0 9.260668321076082e-08
at O 0 1.6608843189658273e-09
codon O 0 3.8358042075969934e-08
95 O 0 1.8278102587032663e-08
in O 0 8.714565180589773e-10
exon O 0 2.8731642487400677e-06
4 O 0 3.3306555451417807e-06
might O 0 2.2275019091466675e-06
be O 0 2.4488677752287913e-08
responsible O 0 1.2895227996523317e-08
for O 0 1.4953526195071731e-09
most O 0 5.568526262322848e-08
Japanese O 0 0.0038259155116975307
C9 B-Disease 1 0.9453158378601074
deficiency I-Disease 1 0.644210934638977
. O 0 1.0690111906797028e-08
. O 0 2.159008793967132e-08

BRCA1 O 0 0.0008377657504752278
required O 0 1.6008419834179222e-07
for O 0 3.0623066304968916e-09
transcription O 0 8.424551197094843e-05
- O 1 0.684019923210144
coupled O 0 0.002151363529264927
repair O 0 0.0022489672992378473
of O 0 2.705792478963076e-09
oxidative O 0 2.355009928578511e-05
DNA O 0 0.028831586241722107
damage O 0 0.0004092965682502836
. O 0 6.528071594402718e-07

The O 0 8.265323413070291e-05
breast B-Disease 1 0.999347984790802
and I-Disease 1 0.9876202940940857
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999961853027344
susceptibility O 0 0.013487117365002632
gene O 0 7.38285671104677e-05
BRCA1 O 0 0.0012991416733711958
encodes O 0 9.493644029134884e-06
a O 0 0.00017801155627239496
zinc O 1 0.9991833567619324
finger O 1 0.9835523962974548
protein O 0 3.0256844638643088e-06
of O 0 3.6235969780307187e-09
unknown O 0 1.7548082951179822e-06
function O 0 2.6488783078093547e-06
. O 0 2.3033528862015373e-07

Association O 0 4.4797906184612657e-07
of O 0 1.451932463147898e-09
the O 0 6.397129936885904e-09
BRCA1 O 0 2.7433272862253943e-06
protein O 0 5.140868353237238e-08
with O 0 4.601681258264989e-09
the O 0 7.001207791290653e-08
DNA O 0 0.0018844545120373368
repair O 0 0.00035769245005212724
protein O 0 5.700753149540105e-07
Rad51 O 0 0.00011269126844126731
and O 0 1.0905534253424776e-07
changes O 0 4.397987307669382e-09
in O 0 6.399225593867186e-10
the O 0 1.2280555461430254e-09
phosphorylation O 0 2.531595910681972e-08
and O 0 2.998104520202105e-08
cellular O 0 3.778555424105434e-07
localization O 0 5.966606408946973e-07
of O 0 7.188971640204045e-10
the O 0 4.802574338214072e-09
protein O 0 1.6156994320226659e-07
after O 0 1.260635684730005e-07
exposure O 0 7.149070597733953e-07
to O 0 6.985291900463153e-09
DNA O 0 5.484191933646798e-05
- O 0 0.002307812450453639
damaging O 0 2.0210741240589414e-06
agents O 0 1.1511028930044631e-07
are O 0 2.738272497637695e-09
consistent O 0 4.874560133316663e-08
with O 0 5.831953253654376e-10
a O 0 7.635231114022645e-09
role O 0 3.5452391244916726e-08
for O 0 1.4921188729033474e-09
BRCA1 O 0 1.3081966017125524e-06
in O 0 5.8773526490085715e-08
DNA O 0 0.000434486340964213
repair O 0 0.008515601046383381
. O 0 4.1479844981040515e-07

Here O 0 2.265899456688203e-05
, O 0 3.0293861641439435e-08
it O 0 2.3573258900455585e-09
is O 0 3.0130981043541283e-10
shown O 0 7.469822094208212e-09
that O 0 5.060768248910108e-09
mouse O 0 1.5765714124427177e-05
embryonic O 0 2.4217426926043117e-06
stem O 0 3.7320169212762266e-06
cells O 0 4.6983645916043315e-06
deficient B-Disease 0 5.414382758317515e-05
in I-Disease 0 1.1571648528274636e-08
BRCA1 I-Disease 0 2.5645189452916384e-05
are O 0 3.463364706135508e-08
defective O 0 0.0005341920186765492
in O 0 5.843628514412558e-07
the O 0 2.0567058811593597e-07
ability O 0 9.335363415630127e-07
to O 0 5.161399752040552e-09
carry O 0 1.1946215572322672e-08
out O 0 8.282859731423287e-09
transcription O 0 1.7770385056792293e-06
- O 0 0.00502022122964263
coupled O 0 2.1721352823078632e-05
repair O 0 4.696837277151644e-05
of O 0 7.23269388824832e-10
oxidative O 0 2.99348721455317e-06
DNA O 0 0.0597684271633625
damage O 0 0.0061853909865021706
, O 0 1.2822940220758028e-07
and O 0 1.2921626080242277e-07
are O 0 2.1187354093399335e-09
hypersensitive O 0 8.110063390631694e-06
to O 0 6.6074012927686e-09
ionizing O 0 2.723043053265428e-07
radiation O 0 1.0392977856099606e-06
and O 0 5.221743037964188e-09
hydrogen O 0 2.433845835980719e-08
peroxide O 0 1.0486471182957757e-05
. O 0 9.245931664736418e-08

These O 0 2.4617359031253727e-06
results O 0 4.344455817317794e-07
suggest O 0 1.7471360536092106e-07
that O 0 4.6160209876688896e-08
BRCA1 O 0 6.964726708247326e-06
participates O 0 8.369254089757305e-08
, O 0 1.908020585972281e-08
directly O 0 1.2030429985543378e-08
or O 0 3.773628520775674e-08
indirectly O 0 2.259818927541346e-07
, O 0 5.277172032691624e-09
in O 0 4.144518062076941e-09
transcription O 0 4.079031350556761e-05
- O 0 0.39322352409362793
coupled O 0 0.0004105286789126694
repair O 0 0.0005300599150359631
of O 0 2.0151744717367137e-09
oxidative O 0 1.0375852980359923e-05
DNA O 0 0.04947777837514877
damage O 0 0.00019753882952500135
. O 0 7.338476848417486e-08
. O 0 4.561442423778317e-08

Truncation O 0 0.004800565540790558
mutations O 0 0.0008746051462367177
in O 0 4.25866311104528e-08
the O 0 1.394053850134469e-08
transactivation O 0 6.579402543138713e-05
region O 0 6.238344099074311e-07
of O 0 3.5282110566470237e-09
PAX6 O 0 0.0007888065883889794
result O 0 1.1150791578984354e-06
in O 0 1.3414158672730991e-08
dominant O 0 1.33231742438511e-05
- O 0 0.036081910133361816
negative O 0 1.3963579021947226e-06
mutants O 0 6.388039764715359e-06
. O 0 1.673991434358868e-08

PAX6 O 0 0.0006252618040889502
is O 0 7.119984246628519e-08
a O 0 2.06765449206614e-09
transcription O 0 8.63322384248022e-07
factor O 0 1.572326446819261e-08
with O 0 1.544504413253378e-09
two O 0 4.642772832852415e-09
DNA O 0 0.00013767642667517066
- O 0 8.092016651062295e-05
binding O 0 2.372080984969216e-07
domains O 0 5.903800115447666e-07
( O 0 1.8769739096313742e-09
paired O 0 8.938459359342232e-06
box O 0 0.001497289864346385
and O 0 6.939731065358501e-07
homeobox O 0 4.17826367993257e-06
) O 0 1.0888258294983189e-08
and O 0 6.583122935666097e-09
a O 0 1.3052428027293672e-09
proline O 0 3.486038849587203e-06
- O 0 2.7979918741039e-05
serine O 0 9.174256661026448e-07
- O 0 7.765166628814768e-06
threonine O 0 4.04122874897439e-06
( O 0 5.286265869486328e-10
PST O 0 3.112276772299083e-06
) O 0 2.2671478028257752e-09
- O 0 3.782557314480073e-06
rich O 0 1.9666098083348516e-08
transactivation O 0 5.9354874792916235e-06
domain O 0 9.963567890736158e-07
. O 0 6.483313796934453e-08

PAX6 O 0 0.0035480677615851164
regulates O 0 0.00029089348390698433
eye O 0 0.11813367903232574
development O 0 3.784260513839399e-07
in O 0 1.25408687878803e-08
animals O 0 1.7888027059598244e-08
ranging O 0 4.358679195348714e-09
from O 0 1.8090661191294544e-09
jellyfish O 0 1.343471325299106e-07
to O 0 2.4318400626555103e-09
Drosophila O 0 6.245127526227634e-09
to O 0 2.8070181734562993e-09
humans O 0 4.0847343285577153e-08
. O 0 5.8480749132172605e-09

Heterozygous O 0 4.172832632320933e-05
mutations O 0 8.982817234937102e-05
in O 0 2.0892091612267905e-08
the O 0 1.5267060504697838e-08
human O 0 1.3539603571643966e-07
PAX6 O 0 0.00015913722745608538
gene O 0 1.1040417120966595e-05
result O 0 2.7558613169276214e-07
in O 0 1.9655026495257744e-09
various O 0 2.6179962642203236e-09
phenotypes O 0 3.0833998607704416e-05
, O 0 2.811708199601526e-08
including O 0 6.72846340421529e-07
aniridia B-Disease 1 0.9999997615814209
, O 0 0.0015066383639350533
Peters B-Disease 1 0.9999991655349731
anomaly I-Disease 1 0.9999977350234985
, O 0 7.486421509383945e-06
autosomal B-Disease 0 0.07532334327697754
dominant I-Disease 0 0.06540617346763611
keratitis I-Disease 1 0.9997994303703308
, O 0 4.1764997149584815e-05
and O 0 2.8196618586662225e-05
familial B-Disease 1 0.9929666519165039
foveal I-Disease 1 0.9995939135551453
dysplasia I-Disease 1 0.9999698400497437
. O 0 1.1962188182224054e-05

It O 0 2.285999926243676e-06
is O 0 1.0981319853442528e-08
believed O 0 4.580841661550039e-08
that O 0 1.813536765205015e-09
the O 0 5.920777201851024e-10
mutated O 0 3.4674965831982263e-07
allele O 0 2.215872818567277e-08
of O 0 1.1536976929349407e-09
PAX6 O 0 2.449696694384329e-05
produces O 0 1.2353436495970982e-08
an O 0 2.1159285434890762e-09
inactive O 0 3.7642047345798346e-07
protein O 0 2.549190639911103e-06
and O 0 2.2437236111727543e-05
aniridia B-Disease 1 0.9999995231628418
is O 0 4.5209679228719324e-05
caused O 0 4.579506367008435e-06
due O 0 4.9184361472498495e-08
to O 0 4.4783554642435774e-08
genetic O 0 1.531822999822907e-05
haploinsufficiency O 0 0.0008475196664221585
. O 0 3.321673887057841e-07

However O 0 1.1401014489820227e-05
, O 0 1.4919510071820241e-09
several O 0 2.6293645039032754e-10
truncation O 0 1.1816288861155044e-05
mutations O 0 9.042340388987213e-05
have O 0 3.446881237323396e-06
been O 0 6.676713724118599e-07
found O 0 2.5230883693438955e-07
to O 0 1.5178562406958918e-08
occur O 0 5.274535030963534e-09
in O 0 2.9821682900887936e-09
the O 0 1.439882026943451e-07
C O 0 0.09117124229669571
- O 0 0.008612404577434063
terminal O 0 1.9698514734045602e-05
half O 0 1.468182553310271e-08
of O 0 3.3798175369526007e-10
PAX6 O 0 2.7872752980329096e-05
in O 0 1.636409052707677e-07
patients O 0 3.830986372577172e-07
with O 0 1.0770855851660599e-07
Aniridia B-Disease 1 0.9999991655349731
resulting O 0 1.1354563866916578e-06
in O 0 8.348125746238111e-09
mutant O 0 1.160792294285784e-06
proteins O 0 5.7269861741815475e-08
that O 0 2.6547906983864777e-08
retain O 0 6.339170965929952e-08
the O 0 3.853636521000681e-09
DNA O 0 2.30700898100622e-05
- O 0 1.9470326151349582e-05
binding O 0 5.301154359926841e-08
domains O 0 1.5112690334717627e-06
but O 0 1.5292408761524712e-06
have O 0 1.0641489325280418e-06
lost O 0 3.080713941017166e-05
most O 0 1.0038097020270698e-09
of O 0 2.0461035643570824e-10
the O 0 1.0661074689721772e-08
transactivation O 0 2.2368203644873574e-05
domain O 0 2.3054897155816434e-06
. O 0 7.859952688704652e-08

It O 0 1.4800167264183983e-05
is O 0 4.367261041693382e-08
not O 0 1.8975139681742803e-08
clear O 0 5.069163311333114e-09
whether O 0 2.774901419755338e-10
such O 0 6.925497397780589e-10
mutants O 0 3.066848512389697e-05
really O 0 1.4105146874499042e-05
behave O 0 7.660966616640508e-08
as O 0 1.1379216680040827e-08
loss O 0 3.2020252547226846e-06
- O 0 0.0015801836270838976
of O 0 2.9395327061365606e-08
- O 0 0.0029822473879903555
function O 0 1.6571202365867066e-07
mutants O 0 2.8343183089418744e-07
as O 0 1.2484847600191529e-09
predicted O 0 6.723922751916689e-08
by O 0 3.342444321319249e-09
haploinsufficiency O 0 4.686483953264542e-05
. O 0 1.3760353567704442e-07

Contrary O 0 3.9283873775275424e-05
to O 0 5.105455969101058e-08
this O 0 7.885984087963038e-10
theory O 0 9.15108486765348e-08
, O 0 5.001818070837771e-09
our O 0 1.4619335741983264e-09
data O 0 4.245864815288769e-08
showed O 0 1.90319212833856e-06
that O 0 4.230882755251741e-09
these O 0 3.598208675459347e-10
mutants O 0 9.204106987681371e-08
are O 0 1.7004971042400285e-10
dominant O 0 1.6511998524038063e-07
- O 0 9.744193812366575e-05
negative O 0 3.521812175222294e-08
in O 0 5.524301016635036e-10
transient O 0 2.1694358309787276e-08
transfection O 0 2.315908886885154e-06
assays O 0 5.366547952689871e-07
when O 0 2.701496555346239e-07
they O 0 1.0060797528410603e-08
are O 0 2.791309683392029e-10
coexpressed O 0 3.1566064535581972e-06
with O 0 2.9864043682437114e-08
wild O 0 4.731042281491682e-05
- O 0 0.11931080371141434
type O 0 0.0004986451822333038
PAX6 O 0 0.0003475006378721446
. O 0 1.0289587493161889e-07

We O 0 8.156536205206066e-05
found O 0 2.266094156766485e-08
that O 0 1.5092008753825326e-09
the O 0 1.1610952199703206e-09
dominant O 0 3.886215381498914e-06
- O 0 0.014529192820191383
negative O 0 7.990216204234457e-07
effects O 0 1.827812297960918e-06
result O 0 1.7924161710425324e-08
from O 0 3.9923897521276785e-11
the O 0 1.1190357668278139e-10
enhanced O 0 3.33582228506657e-08
DNA O 0 5.477696504385676e-06
binding O 0 5.1406132683951e-08
ability O 0 1.2545965155652539e-08
of O 0 1.0207260037198296e-10
these O 0 4.788816898582127e-09
mutants O 0 2.9964578516228357e-06
. O 0 1.9915761484412542e-08

Kinetic O 0 1.9893343505827943e-06
studies O 0 8.326931322244491e-08
of O 0 5.150461723779642e-10
binding O 0 1.21371283512417e-06
and O 0 8.69840562245372e-07
dissociation O 0 3.173775667164591e-06
revealed O 0 2.4736837076488882e-06
that O 0 1.4685795912683375e-09
various O 0 3.3789523262717225e-11
truncation O 0 2.213677589679719e-06
mutants O 0 1.018000239128014e-05
have O 0 1.2542835747808567e-07
3 O 0 5.254295132317566e-08
- O 0 0.0015579120954498649
5 O 0 8.684372119205364e-07
- O 0 0.00017143924196716398
fold O 0 1.6642630384922086e-07
higher O 0 4.4751746752780264e-10
affinity O 0 3.622620814436317e-10
to O 0 8.169445675498821e-11
various O 0 6.107435304020248e-12
DNA O 0 5.733182320000196e-07
- O 0 2.0071597646165174e-06
binding O 0 7.64836372013633e-09
sites O 0 3.532798587002617e-08
when O 0 3.926205849325015e-08
compared O 0 3.3059996962236937e-09
with O 0 9.596706762593499e-10
the O 0 4.155887012302628e-08
wild O 0 1.252253059647046e-05
- O 0 0.05280498415231705
type O 0 0.0001464941306039691
PAX6 O 0 0.00025186233688145876
. O 0 9.829804525907093e-08

These O 0 8.142061460603145e-07
results O 0 1.0352088253284819e-07
provide O 0 1.487978074088403e-09
a O 0 3.832453021601623e-09
new O 0 2.3280065875042055e-08
insight O 0 2.7912751221492726e-08
into O 0 1.3895509187733524e-09
the O 0 4.433247935420326e-10
role O 0 9.602968420452385e-10
of O 0 2.127773374160924e-10
mutant O 0 1.8160144463763572e-06
PAX6 O 0 3.966936856159009e-05
in O 0 1.716378648097816e-07
causing O 0 5.270221663522534e-06
aniridia B-Disease 1 0.9999697208404541
. O 0 2.460397467984876e-07
. O 0 4.426130217893842e-08

Reversal O 0 0.002042504260316491
of O 0 1.6593688997090794e-05
severe O 1 0.974019467830658
hypertrophic B-Disease 1 0.9999771118164062
cardiomyopathy I-Disease 1 1.0
and O 0 0.04659433662891388
excellent O 0 2.650717033247929e-05
neuropsychologic O 0 0.0006393311778083444
outcome O 0 2.284334868818405e-06
in O 0 2.1638554414948885e-07
very B-Disease 0 1.090723458219145e-06
- I-Disease 0 0.13642792403697968
long I-Disease 0 0.0005316335591487586
- I-Disease 0 0.003676135092973709
chain I-Disease 0 0.0001129339580074884
acyl I-Disease 0 4.095196572961868e-07
- I-Disease 0 1.0340704648115207e-05
coenzyme I-Disease 0 7.0767136151062e-08
A I-Disease 0 2.0862798919552006e-06
dehydrogenase I-Disease 0 0.003022628603503108
deficiency I-Disease 1 0.6602115035057068
. O 0 1.4977288742556993e-07

Very B-Disease 0 5.588305430137552e-05
- I-Disease 0 0.0078436229377985
long I-Disease 0 9.512338874628767e-05
- I-Disease 0 0.003594375913962722
chain I-Disease 0 5.3656913223676383e-05
acyl I-Disease 0 4.029642184377735e-07
- I-Disease 0 4.225222255627159e-06
coenzyme I-Disease 0 1.1383297859879349e-08
A I-Disease 0 2.374683383266074e-08
dehydrogenase I-Disease 0 9.672421583672985e-07
( I-Disease 0 2.5017202531785188e-08
VLCAD I-Disease 0 0.06533821672201157
) I-Disease 0 1.9476340185065055e-06
deficiency I-Disease 0 0.01700173318386078
is O 0 2.3729181464204885e-07
a O 0 2.0918283553328365e-05
disorder O 1 0.7669296264648438
of O 0 3.375176049758011e-08
fatty O 0 0.00011248373630223796
acid O 0 4.594036511207378e-07
beta O 0 1.986423470157206e-09
oxidation O 0 1.7469577073825349e-07
that O 0 3.020792291863472e-07
reportedly O 0 1.0103353815793525e-06
has O 0 2.368281144526918e-07
high O 0 3.083073067955411e-07
rates O 0 2.451289446980809e-06
of O 0 1.0821529450311118e-08
morbidity O 1 0.5199462175369263
and O 0 1.0463374565006234e-05
mortality O 0 0.0005111331702210009
. O 0 7.22645410178302e-08

We O 0 9.437676453671884e-06
describe O 0 5.362261745744945e-08
the O 0 1.4015796301336536e-09
outcome O 0 1.6657064616509842e-09
of O 0 2.9460614503484805e-11
a O 0 1.1917676623340867e-08
5 O 0 2.3698694917584362e-07
- O 0 0.008102857507765293
year O 0 5.020315256842878e-07
- O 0 0.1521766185760498
old O 0 0.3862629234790802
girl O 0 0.007951166480779648
with O 0 2.1624251530738547e-05
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999996423721313
who O 0 1.3004151696804911e-05
was O 0 7.645725759175548e-07
first O 0 3.562428929626549e-08
seen O 0 2.1830615537510312e-07
at O 0 1.8470785789759248e-08
5 O 0 8.91913742862016e-09
months O 0 6.583072753585384e-09
of O 0 1.929671311629022e-09
age O 0 9.304803825216368e-06
with O 0 1.4968783943913877e-05
severe O 1 0.7753273248672485
hypertrophic B-Disease 1 0.9999899864196777
cardiomyopathy I-Disease 1 1.0
, O 0 0.12436409294605255
hepatomegaly B-Disease 1 0.9999997615814209
, O 0 0.005333755165338516
encephalopathy B-Disease 1 0.9780296087265015
, O 0 8.888705451681744e-07
and O 0 2.184193590437644e-06
hypotonia B-Disease 0 0.10871940106153488
. O 0 7.150168812586344e-07

Biochemical O 0 0.0020370413549244404
studies O 0 0.00017062039114534855
indicated O 1 0.9734846949577332
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
caused O 0 0.017951106652617455
by O 0 1.1719919967845271e-07
a O 0 6.721216436744726e-07
stable O 0 4.4647462345892563e-05
yet O 0 2.6619252935233817e-07
inactive O 0 6.534773433486407e-07
enzyme O 0 4.089056801603874e-06
. O 0 9.69862128386012e-08

Molecular O 0 2.038257480307948e-05
genetic O 0 3.8415459130192176e-05
analysis O 0 2.60077285929583e-07
of O 0 1.2767864987495159e-08
her O 0 2.297624814673327e-05
VLCAD O 0 0.024969421327114105
gene O 0 1.2722918654617388e-05
revealed O 0 1.1888640074175783e-05
a O 0 9.414705459676043e-08
T1372C O 0 7.305159670067951e-06
( O 0 1.914534086822073e-09
F458L O 0 4.0461509343003854e-07
) O 0 1.4743948284490216e-09
missense O 0 2.332530357307405e-06
mutation O 0 1.0522154298087116e-05
and O 0 1.6501513755429187e-06
a O 0 1.1382187039998826e-05
1668 O 1 0.9971902966499329
ACAG O 1 0.9304680824279785
1669 O 0 0.0006769502651877701
splice O 0 0.001031191204674542
site O 0 3.827233740594238e-05
mutation O 0 2.3757473172736354e-05
. O 0 1.5047325518935395e-07

After O 0 3.7539552977250423e-07
initial O 0 5.8025008797812916e-08
treatment O 0 1.4939344339381933e-07
with O 0 7.494396214724475e-09
intravenous O 0 1.3422777556115761e-05
glucose O 0 0.0007967834826558828
and O 0 1.0902098210863187e-06
carnitine O 0 2.6625535610946827e-05
, O 0 7.17971460062472e-08
the O 0 4.6604846204445494e-08
patient O 0 2.8531869247672148e-05
has O 0 2.846573181614076e-07
thrived O 0 2.6534951302892296e-06
on O 0 1.0255280358251184e-07
a O 0 3.345501298213094e-08
low O 0 5.8421042922418565e-05
- O 0 0.007594730239361525
fat O 0 1.514288942416897e-05
diet O 0 2.855403380408461e-08
supplemented O 0 2.566678869442285e-09
with O 0 1.0451496335051047e-09
medium O 0 4.205636287224479e-06
- O 0 2.2161864762892947e-05
chain O 0 8.374765457119793e-06
triglyceride O 0 6.687202471766795e-07
oil O 0 5.414151260652034e-08
and O 0 1.6041024508695045e-08
carnitine O 0 3.267990962285694e-07
and O 0 7.603158103108854e-09
avoidance O 0 3.057942876694142e-07
of O 0 2.1254138449222637e-09
fasting O 0 3.1067818326846464e-06
. O 0 4.6826624355844615e-08

Her O 0 0.046709150075912476
ventricular O 0 0.01894000545144081
hypertrophy O 0 0.00017698966257739812
resolved O 0 1.0823737284226809e-06
significantly O 0 2.6833711785911873e-07
over O 0 1.6792429846645973e-07
1 O 0 9.225661870004842e-07
year O 0 5.534124056794099e-07
, O 0 2.292924961011522e-07
and O 0 9.72464363258041e-07
cognitively O 0 0.0005998538690619171
, O 0 1.6545084235985996e-07
she O 0 3.115424533461919e-06
is O 0 1.01419050935192e-09
in O 0 1.852164754900798e-09
the O 0 2.5974244977078342e-09
superior O 0 9.185868066197145e-08
range O 0 4.6572235845587784e-08
for O 0 6.250096884485856e-09
age O 0 2.5913399781529733e-07
. O 0 2.532185128245601e-08

Clinical O 0 0.00019779644208028913
recognition O 0 2.239626610389678e-06
of O 0 0.00011720074689947069
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
is O 0 5.060460807726486e-06
important O 0 2.3617089084382314e-07
because O 0 3.0294033876998583e-06
it O 0 3.938552310955856e-07
is O 0 2.0463669869741352e-08
one O 0 2.398046561324918e-08
of O 0 1.3531381570786039e-09
the O 0 1.2128063531235966e-07
few O 0 8.598410090598918e-07
directly O 0 2.2714682927471586e-05
treatable O 1 0.9489448666572571
causes O 0 6.16706586242799e-07
of O 0 1.8426715087116463e-06
cardiomyopathy B-Disease 1 1.0
in O 0 3.062733230763115e-05
children O 0 4.249699031788623e-06
. O 0 2.7351108045081673e-08
. O 0 3.466642795046937e-08

Cloning O 0 4.195789006189443e-05
of O 0 1.7314967237780365e-08
a O 0 6.41228012909778e-08
novel O 0 2.4388752990489593e-06
member O 0 8.125414119319885e-09
of O 0 4.3014269923702386e-10
the O 0 2.0382920240535896e-08
low O 0 1.3783345821138937e-05
- O 0 0.00021397220552898943
density O 0 6.662135660917556e-07
lipoprotein O 0 9.948533988790587e-05
receptor O 0 7.912113915153896e-07
family O 0 4.2615397433110047e-07
. O 0 7.100834409357049e-08

A O 0 1.2257154935468861e-07
gene O 0 1.8521627964673826e-07
encoding O 0 8.937379902818066e-08
a O 0 1.0038451137006632e-07
novel O 0 9.505910384177696e-06
transmembrane O 0 8.505951700499281e-05
protein O 0 6.424549610528629e-06
was O 0 2.6762611469166586e-06
identified O 0 9.89681137042453e-09
by O 0 7.705520249645659e-11
DNA O 0 2.7219681442147703e-07
sequence O 0 3.0652241633788435e-08
analysis O 0 3.503052070641388e-09
within O 0 5.592596941106365e-10
the O 0 1.4093939171289094e-07
insulin B-Disease 0 0.06422789394855499
- I-Disease 1 0.9998965263366699
dependent I-Disease 1 0.9983882904052734
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 6.591256806132151e-06
IDDM B-Disease 0 0.02429659478366375
) O 0 6.825157328194109e-09
locus O 0 1.0688163456507027e-06
IDDM4 O 0 0.0001591261534485966
on O 0 2.3716290797892725e-06
chromosome O 0 0.0013615022180601954
11q13 O 0 3.2452615414513275e-05
. O 0 1.5048503598791285e-07

Based O 0 8.57953807553713e-07
on O 0 8.470299661667013e-08
its O 0 2.9772577736508765e-09
chromosomal O 0 0.0019386534113436937
position O 0 2.46854451688705e-05
, O 0 4.6513353169075344e-09
this O 0 3.174057683352771e-10
gene O 0 5.239873956952579e-08
is O 0 3.0911437853831103e-09
a O 0 1.3250793795549498e-09
candidate O 0 1.5342396242346013e-09
for O 0 6.63530549949165e-11
conferring O 0 1.2071693333837175e-07
susceptibility O 0 0.009249327704310417
to O 0 1.7337017197860405e-05
diabetes B-Disease 1 0.991348922252655
. O 0 1.4108492223385838e-06

The O 0 1.5025115374101006e-07
gene O 0 7.760094149489305e-07
, O 0 9.990693605743672e-09
termed O 0 8.979023959909682e-07
low O 0 1.800213794922456e-05
- O 0 0.00015712373715359718
density O 0 1.0705679187594797e-06
lipoprotein O 0 3.851544897770509e-05
receptor O 0 1.1705923697036269e-07
related O 0 7.934951185006867e-08
protein O 0 1.1501693961690762e-06
5 O 0 1.2051287967551616e-07
( O 0 2.904270601788994e-09
LRP5 O 0 0.0003407020412851125
) O 0 1.789197678903065e-09
, O 0 1.2899617485295778e-10
encodes O 0 8.614483015811913e-10
a O 0 1.3946762855709949e-08
protein O 0 3.2016785667110526e-07
of O 0 1.9270867568366157e-08
1615 O 0 7.125724368961528e-05
amino O 0 2.704997541513876e-07
acids O 0 3.30245946145169e-08
that O 0 1.1798613197555596e-09
contains O 0 3.5284650201639067e-10
conserved O 0 1.1473152028429467e-07
modules O 0 1.6514941307832487e-05
which O 0 2.5808901682466967e-07
are O 0 6.302658950296802e-10
characteristic O 0 8.683281293997425e-08
of O 0 8.203223100800017e-10
the O 0 1.657189727666264e-07
low O 0 0.0003220002690795809
- O 0 0.0282736886292696
density O 0 1.6992406017379835e-05
lipoprotein O 0 0.02019764855504036
( O 0 1.4987913132813446e-08
LDL O 0 5.1119797717547044e-05
) O 0 5.95493876431874e-09
receptor O 0 1.2771766932928585e-07
family O 0 3.7433090938066016e-07
. O 0 8.575246113196044e-08

These O 0 1.998319305585028e-07
modules O 0 2.1875173672469828e-07
include O 0 1.7139299979263e-09
a O 0 2.1184565213161477e-09
putative O 0 5.5714899360737036e-08
signal O 0 1.0054393584368881e-07
peptide O 0 5.583188578128784e-09
for O 0 2.675762666992654e-10
protein O 0 1.2089847345464477e-08
export O 0 7.967725679236537e-08
, O 0 6.711145861260093e-09
four O 0 3.3866272008964415e-09
epidermal O 0 2.6655818146537058e-05
growth O 0 2.207302713941317e-06
factor O 0 9.143108492537522e-09
( O 0 8.659257755283534e-10
EGF O 0 1.5097564300958766e-06
) O 0 9.498913877692416e-10
repeats O 0 2.9529698508667934e-07
with O 0 4.0895113961880725e-09
associated O 0 3.1801754118987446e-08
spacer O 0 8.844357216730714e-05
domains O 0 9.240478902938776e-06
, O 0 8.113059379866172e-08
three O 0 3.557479288929244e-08
LDL O 0 0.0017092205816879869
- O 0 0.006822351831942797
receptor O 0 5.233032425167039e-07
( O 0 3.962685291014623e-09
LDLR O 0 4.3971147533738986e-05
) O 0 4.981538292980758e-09
repeats O 0 2.1560681489063427e-06
, O 0 2.578647073647744e-09
a O 0 5.727299967617228e-09
single O 0 5.162986326467944e-06
transmembrane O 0 1.2365679140202701e-05
spanning O 0 2.756100457190769e-06
domain O 0 1.612250525795389e-05
, O 0 2.67679673982002e-08
and O 0 3.2570677266363646e-09
a O 0 4.820984944586826e-09
cytoplasmic O 0 1.598996459506452e-05
domain O 0 7.147862561396323e-06
. O 0 1.4506770185107598e-07

The O 0 2.802114273947609e-08
encoded O 0 1.8031075299518307e-08
protein O 0 1.751237505231984e-06
has O 0 2.875124778256577e-07
a O 0 4.31713642612408e-09
unique O 0 1.329092125246234e-08
organization O 0 1.1404551969462773e-08
of O 0 2.232011908631648e-09
EGF O 0 0.00016578423674218357
and O 0 5.2053060244361404e-06
LDLR O 0 0.0009230442810803652
repeats O 0 3.7625177355948836e-05
; O 0 2.215517902470765e-08
therefore O 0 1.9106025206383492e-08
, O 0 2.0228996255866605e-09
LRP5 O 0 2.0101511836401187e-05
likely O 0 1.781825353930344e-08
represents O 0 5.457577167966576e-10
a O 0 9.346194929094054e-09
new O 0 9.836875847213378e-08
category O 0 5.419553303909197e-07
of O 0 1.6874157626745045e-09
the O 0 5.43964461030555e-07
LDLR O 0 0.017005354166030884
family O 0 1.0504361398488982e-06
. O 0 5.3855497839094824e-08

Both O 0 5.9713470363931265e-06
human O 0 5.373492513172096e-07
and O 0 8.023203008633573e-07
mouse O 0 0.0002679879544302821
LRP5 O 0 0.0005630874074995518
cDNAs O 0 8.645906746096443e-06
have O 0 5.630061536976427e-07
been O 0 1.332204107029611e-07
isolated O 0 5.41740155313164e-06
and O 0 3.797013548023642e-08
the O 0 6.325794332795454e-10
encoded O 0 1.87742230650656e-08
mature O 0 1.1661810361829339e-07
proteins O 0 2.085712269561668e-09
are O 0 5.063488517365045e-10
95 O 0 3.522698932556523e-08
% O 0 8.216110014558353e-10
identical O 0 1.39419944389374e-06
, O 0 3.224709388405245e-08
indicating O 0 1.6383233969463618e-07
a O 0 4.57840485523775e-08
high O 0 8.862406843945791e-07
degree O 0 1.4028721295744617e-08
of O 0 1.9758004954351094e-10
evolutionary O 0 2.7460208684715326e-07
conservation O 0 9.566486625089965e-08
. O 0 6.114531547751767e-09
. O 0 1.1173050928903194e-08

The O 0 7.507983355026226e-07
APC B-Disease 0 1.1644344795058714e-06
variants O 0 6.306350428531005e-07
I1307K O 0 4.449366315384395e-06
and O 0 2.3169813800905104e-07
E1317Q O 0 9.695972948975395e-07
are O 0 2.0822790602892383e-08
associated O 0 4.3621262193482835e-06
with O 1 0.98334139585495
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.20129211246967316
but O 0 0.0001495725882705301
not O 0 2.871958940886543e-06
always O 0 9.8309169516142e-07
with O 0 6.4053344850378835e-09
a O 0 2.7337085839462816e-07
family O 0 6.437758202082478e-07
history O 0 3.1716849662188906e-06
. O 0 1.578649602151927e-07

Classical O 1 0.8771250247955322
familial B-Disease 1 0.9999815225601196
adenomatous I-Disease 1 0.9998468160629272
polyposis I-Disease 1 0.999995231628418
( O 0 0.0005382738308981061
FAP B-Disease 0 0.0027234265580773354
) O 0 5.196122856432339e-07
is O 0 2.7678739300540656e-08
a O 0 2.078908636349297e-07
high O 0 0.004135444760322571
- O 1 0.9999096393585205
penetrance O 1 0.9993220567703247
autosomal B-Disease 1 0.9999319314956665
dominant I-Disease 1 0.999757707118988
disease I-Disease 1 0.9987233281135559
that O 0 7.394579597530537e-07
predisposes O 0 1.0914353879343253e-05
to O 0 2.0295940927894662e-08
hundreds O 0 1.5937480224437195e-09
or O 0 1.194689946970584e-08
thousands O 0 2.924165798390277e-08
of O 0 0.00016742604202590883
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9998944997787476
carcinoma I-Disease 1 1.0
and O 0 0.033947527408599854
that O 0 1.9364806576049887e-06
results O 0 2.9426891501316277e-07
from O 0 1.1795350252086223e-09
truncating O 0 1.0099161954713054e-05
mutations O 0 2.6830819024326047e-06
in O 0 6.522966167210598e-09
the O 0 1.4946119009096037e-08
APC B-Disease 0 1.521757326372608e-06
gene O 0 1.003622628559242e-06
. O 0 1.6434437100087962e-07

A O 0 2.082457740471e-06
variant O 0 7.537726196460426e-05
of O 0 5.3519418230507654e-08
FAP B-Disease 0 0.00038568320451304317
is O 0 1.2195770068501588e-05
attenuated B-Disease 1 0.9845629334449768
adenomatous I-Disease 1 0.9999932050704956
polyposis I-Disease 1 0.9999812841415405
coli I-Disease 1 0.9999994039535522
, O 0 2.5080731575144455e-05
which O 0 1.0853900676011108e-06
results O 0 4.158806063969678e-07
from O 0 3.7969178912078405e-09
germ O 0 0.13280066847801208
- O 0 0.3270128071308136
line O 0 0.11183219403028488
mutations O 0 1.7481938812125009e-06
in O 0 9.403628986603962e-09
the O 0 1.8004545410121864e-08
5 O 0 5.651374976878287e-07
and O 0 3.2400737381976796e-07
3 O 0 6.435732302634278e-08
regions O 0 5.016053350459515e-09
of O 0 3.3418307010535386e-10
the O 0 1.6075329511977543e-08
APC B-Disease 0 1.0522659295020276e-06
gene O 0 3.8829301729492727e-07
. O 0 7.086100595188327e-08

Attenuated B-Disease 1 0.9963982105255127
adenomatous I-Disease 1 0.9999312162399292
polyposis I-Disease 1 0.9999645948410034
coli I-Disease 1 0.9999979734420776
patients O 1 0.9968001842498779
have O 0 3.558355456334539e-05
" O 0 1.1626176274148747e-05
multiple O 0 0.00042111618677154183
" O 1 0.9879655241966248
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
( O 0 2.027614982580417e-06
typically O 0 1.8983833172114828e-07
fewer O 0 4.937890984990645e-09
than O 0 4.448776902421514e-09
100 O 0 1.4213024535081331e-08
) O 0 4.244380846785134e-09
without O 0 6.298981891639244e-10
the O 0 2.1530368599087524e-09
florid O 0 0.001576236798427999
phenotype O 0 4.552009613689734e-06
of O 0 1.0730595301211565e-09
classical O 0 4.374165655463003e-06
FAP B-Disease 0 3.687707067001611e-05
. O 0 5.8234117972233435e-08

Another O 0 6.2880912992113736e-06
group O 0 2.1116334210091736e-06
of O 0 7.013421399193476e-09
patients O 0 1.1227911045352812e-06
with O 0 9.797590649895938e-08
multiple O 0 0.0002249956742161885
adenomas B-Disease 1 0.9757347106933594
has O 0 0.004099841695278883
no O 0 1.958145503522246e-06
mutations O 0 8.664765687171894e-07
in O 0 1.0045456910745543e-08
the O 0 1.9672965478889637e-08
APC B-Disease 0 1.4912809547240613e-06
gene O 0 5.114245595905231e-06
, O 0 1.3269408327687415e-07
and O 0 7.158151760222609e-08
their O 0 4.3588809006678275e-08
phenotype O 0 3.5223274608142674e-06
probably O 0 1.2935425957039115e-06
results O 0 1.499334700838517e-08
from O 0 1.675791450050923e-10
variation O 0 1.0662436125130625e-06
at O 0 6.951733553250961e-07
a O 0 2.8571312782332825e-07
locus O 0 2.120760655088816e-05
, O 0 2.3741812071875756e-07
or O 0 1.4842796325353902e-08
loci O 0 8.099696913177468e-09
, O 0 1.611246358557139e-09
elsewhere O 0 2.4269561915701843e-09
in O 0 9.335553441403022e-10
the O 0 5.315498707858524e-09
genome O 0 1.770137373569014e-06
. O 0 1.1788085174657681e-07

Recently O 0 0.0003591171116568148
, O 0 1.8585308225738117e-07
however O 0 3.467641462862048e-08
, O 0 2.8344010472025616e-10
a O 0 1.6582633044492923e-09
missense O 0 1.3743786439590622e-05
variant O 0 0.00042919168481603265
of O 0 2.1721857024203928e-07
APC B-Disease 0 6.0591453802771866e-05
( O 0 2.5021448024631354e-08
I1307K O 0 3.806182576227002e-06
) O 0 4.793733410224377e-09
was O 0 5.284245503389684e-07
described O 0 1.5099796257800335e-07
that O 0 6.644278460754549e-09
confers O 0 8.838779486097792e-09
an O 0 2.9657183375775276e-09
increased O 0 8.853688768795109e-07
risk O 0 0.0002839772787410766
of O 0 0.0822737067937851
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.64485878587584e-06
including O 0 2.661533748948841e-08
multiple O 0 2.103757651639171e-05
adenomas B-Disease 0 0.36990365386009216
, O 0 3.386413425232604e-07
in O 0 4.441962460077775e-07
Ashkenazim O 0 0.022741619497537613
. O 0 3.42135820119438e-07

We O 0 8.903030538931489e-05
have O 0 6.386791540080594e-09
studied O 0 1.995666742971025e-09
a O 0 1.9366770409590117e-09
set O 0 2.257957731899296e-07
of O 0 6.711117217506057e-10
164 O 0 1.3369148291531019e-05
patients O 0 9.5837970093271e-07
with O 0 6.282704703153286e-07
multiple O 1 0.9989249110221863
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9186046719551086
/ I-Disease 1 0.9989244341850281
or I-Disease 0 0.08340445905923843
carcinoma I-Disease 1 1.0
and O 0 0.00020294108253438026
analyzed O 0 1.9555774997570552e-05
codons O 0 1.8938129869638942e-05
1263 O 0 5.52738165424671e-05
- O 0 0.00540879275649786
1377 O 0 4.883095243712887e-05
( O 0 1.4000433035121773e-09
exon O 0 2.872365030270885e-07
15G O 0 6.090956048865337e-06
) O 0 4.099208472663207e-10
of O 0 2.5126673311448577e-11
the O 0 1.2409281380243442e-09
APC B-Disease 0 4.2537923405916445e-08
gene O 0 5.963806870568078e-08
for O 0 3.16630166530274e-09
germ O 0 0.013890467584133148
- O 0 0.007921447977423668
line O 0 0.00022236227232497185
variants O 0 1.4419531453313539e-06
. O 0 1.3426476641598128e-07

Three O 0 1.315701229032129e-05
patients O 0 1.652198420742934e-06
with O 0 2.2314117220645358e-09
the O 0 2.1516326498272065e-09
I1307K O 0 1.3982125324218941e-07
allele O 0 1.0535020855684252e-08
were O 0 3.400552017751579e-08
detected O 0 2.9577643090306083e-07
, O 0 3.827980155080013e-10
each O 0 2.2879580174883785e-11
of O 0 8.545162910600368e-10
Ashkenazi O 0 0.0002020101819653064
descent O 0 3.212290903320536e-05
. O 0 9.582338122982037e-08

Four O 0 3.6846555303782225e-05
patients O 0 2.087416396534536e-05
had O 0 3.270271690780646e-06
a O 0 3.4431181461513916e-08
germ O 1 0.520983874797821
- O 1 0.7850754261016846
line O 0 0.00670854514464736
E1317Q O 0 2.2091445828209544e-07
missense O 0 6.285138169914717e-07
variant O 0 1.0495736205484718e-05
of O 0 1.1619775364124507e-08
APC O 0 7.292928785318509e-06
that O 0 3.802137825914542e-06
was O 0 4.8873716878006235e-05
not O 0 6.697440113612174e-08
present O 0 2.127035880761241e-09
in O 0 1.4791643465628113e-08
controls O 0 0.0003913267282769084
; O 0 4.661836072727965e-08
one O 0 1.1013138845328285e-08
of O 0 1.6035052174956377e-09
these O 0 3.363043887816275e-08
individuals O 0 2.862277970194782e-09
had O 0 2.8663389457506128e-06
an O 0 1.5009589127146228e-09
unusually O 0 2.7640806976592103e-08
large O 0 3.500988388083215e-09
number O 0 4.8994948542713246e-08
of O 0 5.4076356725829555e-09
metaplastic B-Disease 0 0.005372453946620226
polyps I-Disease 0 3.6182038456900045e-05
of I-Disease 0 6.653012585289275e-10
the I-Disease 0 6.036545840970575e-08
colorectum I-Disease 0 0.000161910051247105
. O 0 1.5999597735572024e-07

There O 0 2.665766487552901e-06
is O 0 1.6455971030282512e-09
increasing O 0 2.9587107763795473e-10
evidence O 0 2.498873108436328e-08
that O 0 2.5054733399088036e-08
there O 0 8.526216177529022e-09
exist O 0 6.270624908211175e-08
germ O 0 0.00036695320159196854
- O 0 0.0022970594000071287
line O 0 0.0001961399830179289
variants O 0 1.2966950180270942e-08
of O 0 2.763324014054547e-10
the O 0 4.369192119213494e-09
APC B-Disease 0 8.158821884762801e-08
gene O 0 6.237296901190348e-08
that O 0 2.9570438542236843e-08
predispose O 0 1.9541573692549719e-07
to O 0 2.4923791919206906e-09
the O 0 4.488064919705437e-10
development O 0 4.4537689092294386e-09
of O 0 3.671210890843213e-08
multiple O 1 0.9955049157142639
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.999981164932251
carcinoma I-Disease 1 1.0
, O 0 0.00329100014641881
but O 0 2.0571701497829054e-06
without O 0 4.1525094474081925e-09
the O 0 3.6035541217671607e-09
florid O 0 0.0022064056247472763
phenotype O 0 6.736097930115648e-06
of O 0 6.718686162976439e-10
classical O 0 2.3529778445663396e-06
FAP B-Disease 0 9.04031276149908e-06
, O 0 6.021919318754954e-08
and O 0 1.2049813591374914e-08
possibly O 0 2.3495423384645164e-09
with O 0 9.937797251780012e-10
importance O 0 1.4145176407964755e-07
for O 0 0.03636951372027397
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0039012122433632612
in O 0 2.7896199128463195e-08
the O 0 2.4501854767322584e-08
general O 0 1.7337834279373965e-08
population O 0 1.226529988684888e-08
. O 0 6.546335917789747e-09
. O 0 2.701658097237214e-08

Genomic O 0 9.650463471189141e-05
structure O 0 1.2633965525310487e-05
of O 0 1.9893629854550454e-08
the O 0 2.410925844742451e-06
human O 0 0.030210020020604134
congenital B-Disease 1 0.999998927116394
chloride I-Disease 1 0.9999781847000122
diarrhea I-Disease 1 1.0
( O 0 1.8958493456011638e-05
CLD B-Disease 1 0.578752338886261
) O 0 3.330170628146334e-08
gene O 0 1.7774995058061904e-06
. O 0 3.084820150434098e-07

Congenital B-Disease 1 0.999995231628418
chloride I-Disease 1 0.9999454021453857
diarrhea I-Disease 1 1.0
( O 0 0.0003434086393099278
CLD B-Disease 1 0.997225821018219
) O 0 1.3096033626425196e-06
is O 0 2.504960434634995e-07
caused O 0 1.735580553940963e-06
by O 0 3.107449231265491e-08
mutations O 0 1.6436897567473352e-06
in O 0 1.1733223281851224e-08
a O 0 1.0364416880292993e-07
gene O 0 4.5877418415329885e-06
which O 0 2.1915056436228042e-07
encodes O 0 1.6213115259233746e-06
an O 0 5.288931788527407e-06
intestinal O 0 0.17912159860134125
anion O 0 4.128560613025911e-05
transporter O 0 0.026520170271396637
. O 0 1.0263797776133288e-06

We O 0 0.0001933224411914125
report O 0 2.1465126565090031e-07
here O 0 5.494658950055964e-09
the O 0 5.750074860699783e-10
complete O 0 4.2133695643542524e-08
genomic O 0 4.6131606268318137e-07
organization O 0 2.0584320026273417e-08
of O 0 5.459930285667269e-10
the O 0 9.223579411354876e-08
human O 0 7.589380857098149e-07
CLD B-Disease 0 4.2396903154440224e-05
gene O 0 4.581103780765261e-07
which O 0 4.570107492440911e-08
spans O 0 1.075100385605765e-06
approximately O 0 1.1343828987264715e-08
39kb O 0 6.379555270541459e-05
, O 0 1.2527050508026605e-08
and O 0 9.690887203817056e-09
comprises O 0 5.618227216785954e-09
21 O 0 8.152055386290158e-08
exons O 0 2.5714396542753093e-05
. O 0 4.793462267116411e-07

All O 0 7.020731374041134e-08
exon O 0 1.9418807823967654e-06
/ O 0 7.89096302469261e-05
intron O 0 0.0033469698391854763
boundaries O 0 1.6816495190141723e-05
conform O 0 1.037726974573161e-06
to O 0 2.2072412786400264e-09
the O 0 2.943233878838214e-09
GT O 0 7.937567715998739e-06
/ O 0 9.492965909885243e-05
AG O 0 0.1614605039358139
rule O 0 5.924233391851885e-06
. O 0 1.2130158211220987e-07

An O 0 3.367890144545527e-08
analysis O 0 2.1786828341419096e-08
of O 0 2.4039978341328094e-10
the O 0 1.2927134918072625e-09
putative O 0 5.44651754808001e-07
promoter O 0 1.305623027292313e-05
region O 0 5.1680029145018125e-08
sequence O 0 5.477761533256853e-07
shows O 0 4.6898401251382893e-07
a O 0 9.481472318384476e-08
putative O 0 9.366322046844289e-06
TATA O 0 0.0021990991663187742
box O 0 0.000604652042966336
and O 0 7.424781642839662e-07
predicts O 0 4.086600711161736e-06
multiple O 0 9.788475807681607e-08
transcription O 0 7.318938969547162e-06
factor O 0 4.529952235543533e-08
binding O 0 4.0742694551454406e-08
sites O 0 3.90548422046777e-07
. O 0 1.5962774568833993e-07

The O 0 2.1365848112964159e-07
genomic O 0 1.3412312682703487e-06
structure O 0 4.368587724457029e-06
was O 0 9.366917907982497e-08
determined O 0 2.2722346226800028e-09
using O 0 1.0595753163755717e-09
DNA O 0 6.4215605561912525e-06
from O 0 1.2662935977569845e-10
several O 0 2.0542918754973272e-10
sources O 0 2.1599540211969526e-10
including O 0 5.92491222750624e-10
multiple O 0 2.3017982186956942e-07
large O 0 1.4009984852236812e-06
- O 1 0.7228348851203918
insert O 0 0.004446002654731274
libaries O 0 3.6269928386900574e-05
and O 0 2.1195528887574255e-08
genomic O 0 1.4869013398310926e-07
DNA O 0 1.111116671381751e-05
from O 0 3.468102693915398e-09
Finnish O 0 0.009737741202116013
CLD B-Disease 1 0.7448206543922424
patients O 0 1.4814274436503183e-05
and O 0 1.0565108254922961e-07
controls O 0 4.87885954498779e-05
. O 0 5.189343141864811e-07

Exon O 0 8.672679541632533e-06
- O 0 7.350724627031013e-05
specific O 0 1.9026494157969864e-08
primers O 0 4.2020594264613464e-05
developed O 0 6.61774720356334e-06
in O 0 4.700494216081097e-09
this O 0 1.2804829419010844e-09
study O 0 2.9643383303579185e-09
will O 0 1.2891753220500846e-09
facilitate O 0 1.430486062936609e-09
mutation O 0 9.815374291122225e-09
screening O 0 4.3363918678096525e-08
studies O 0 1.6861193552486498e-09
of O 0 1.1736619454083552e-09
patients O 0 6.309604714260786e-07
with O 0 2.05954606258274e-07
the O 0 0.00034283261629752815
disease O 1 0.9568064212799072
. O 0 8.857809916662518e-07

Genomic O 0 3.276415100117447e-06
sequencing O 0 1.6926762782532023e-06
of O 0 2.829152467853646e-09
a O 0 1.0680516027150588e-07
BAC O 0 0.0009446987533010542
clone O 1 0.8776715397834778
H O 1 0.9999995231628418
_ O 0 2.0719685380754527e-06
RG364P16 O 0 1.91179105968331e-06
revealed O 0 4.534449089987902e-06
the O 0 2.87570101065171e-09
presence O 0 4.1728274169372526e-09
of O 0 2.599618853516006e-10
another O 0 5.095659005860398e-08
, O 0 2.5588580143676154e-09
highly O 0 7.229756793236675e-10
homologous O 0 1.2266469617827624e-08
gene O 0 1.3157959699583444e-07
3 O 0 6.06156049798301e-08
of O 0 5.598437713416615e-09
the O 0 2.910703358338651e-07
CLD B-Disease 0 0.004983045626431704
gene O 0 9.288985893363133e-06
, O 0 1.506920632721176e-08
with O 0 1.1775995734097933e-09
a O 0 1.1852119286004381e-08
similar O 0 3.786173152775518e-08
genomic O 0 1.168664857686963e-05
structure O 0 0.00035263370955362916
, O 0 1.7924195461205272e-08
recently O 0 2.1673187688975304e-07
identified O 0 3.2233296565209457e-07
as O 0 2.950087605313456e-07
the O 0 0.00026343969511799514
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 7.913448644103482e-05
( O 0 1.6399829050328663e-08
PDS B-Disease 0 2.037876402027905e-05
) O 0 3.812578253103993e-09
. O 0 5.0551052233061e-09
. O 0 3.433739692582094e-08

The O 0 4.07546679070947e-07
APCI1307K O 0 0.00011722814087988809
allele O 0 1.3179476809455082e-05
and O 0 6.052561730029993e-05
cancer B-Disease 0 0.01684466004371643
risk O 0 3.6335109143692534e-06
in O 0 7.578833560728526e-09
a O 0 4.7860158502999184e-08
community O 0 1.5552922505435163e-08
- O 0 8.452458132524043e-05
based O 0 3.5481480864518744e-08
study O 0 2.2512560704512907e-09
of O 0 3.922062952188554e-10
Ashkenazi O 0 1.1054513379349373e-05
Jews O 0 2.7992840045953926e-07
. O 0 2.7011171965796166e-08

Mutations O 0 0.0007080828072503209
in O 0 6.754540748943327e-08
APC O 0 2.7839273570862133e-06
are O 0 3.448974439379526e-08
classically O 0 0.0976126566529274
associated O 0 5.301574128679931e-05
with O 0 0.0019121405202895403
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999973773956299
polyposis I-Disease 1 0.9999997615814209
( O 0 0.0005043214769102633
FAP B-Disease 0 0.010634901002049446
) O 0 1.5687309939949046e-07
, O 0 1.832718510286213e-08
a O 0 4.4641220142693783e-07
highly O 0 0.012857384979724884
penetrant O 1 0.9999339580535889
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999996423721313
disorder I-Disease 1 1.0
characterized O 1 0.6911526322364807
by O 0 1.1014799383701757e-05
multiple O 1 0.5691006183624268
intestinal O 1 0.9999402761459351
polyps B-Disease 1 0.9884633421897888
and O 0 4.214676664560102e-05
, O 0 5.20694669603472e-08
without O 0 3.5201586090494175e-09
surgical O 0 3.2559528335696086e-05
intervention O 0 1.341535380561254e-07
, O 0 9.186507665681631e-10
the O 0 1.3889758232465965e-09
development O 0 3.7245709449962305e-07
of O 0 0.0005022763507440686
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.6214506786127458e-06
CRC B-Disease 0 0.0302886925637722
) O 0 5.391716584313144e-08
. O 0 7.51532667209176e-08

APC B-Disease 0 3.538296732585877e-05
is O 0 1.8747962826637377e-07
a O 0 2.093822104143328e-06
tumour O 1 0.9999970197677612
- O 0 0.017176274210214615
suppressor O 0 0.00013518831110559404
gene O 0 8.572237675252836e-06
, O 0 2.858356928925332e-08
and O 0 1.1539997402110203e-08
somatic O 0 1.2223528074173373e-06
loss O 0 0.00019568888819776475
occurs O 0 7.656743719053338e-07
in O 0 5.197220616537379e-06
tumours B-Disease 1 0.9999982118606567
. O 0 4.477194579521893e-06

The O 0 2.472056053193228e-07
germline O 0 4.1378782043466344e-05
T O 0 0.2668880820274353
- O 0 0.003486736211925745
to O 0 3.8528455093000957e-07
- O 0 6.066013520467095e-05
A O 0 3.4462067333151936e-07
transversion O 0 5.5975183386181016e-06
responsible O 0 2.8773817106753086e-08
for O 0 1.7338082358708817e-10
the O 0 5.430765837033391e-10
APC O 0 2.0836376180000116e-08
I1307K O 0 4.324042013337248e-09
allele O 0 2.272575877482197e-10
converts O 0 1.6254392276593421e-09
the O 0 9.55843515448862e-10
wild O 0 2.1360266089232027e-07
- O 0 3.0129083825158887e-05
type O 0 4.009324584330898e-06
sequence O 0 8.039455678954255e-07
to O 0 3.048333496735722e-08
a O 0 4.0603291040497425e-07
homopolymer O 1 0.8757452368736267
tract O 1 0.9992493987083435
( O 0 5.72669591747399e-07
A8 O 1 0.8684175610542297
) O 0 7.01296940519569e-08
that O 0 2.0492110763825622e-07
is O 0 9.659741095902064e-08
genetically O 0 3.765274232137017e-05
unstable O 1 0.682374119758606
and O 0 3.186767207807861e-05
prone O 0 0.0005338424234651029
to O 0 1.1369366781366352e-08
somatic O 0 1.3090113952785032e-06
mutation O 0 7.55844803279615e-06
. O 0 1.800702307264146e-07

The O 0 9.505156839395568e-08
I1307K O 0 4.654288545680174e-07
allele O 0 1.843309718196906e-07
was O 0 9.657600230639218e-07
found O 0 1.879059396969751e-08
in O 0 7.453198946905104e-09
6 O 0 1.470219217480917e-06
. O 0 2.2532468335612066e-07

1 O 0 3.693067469612288e-07
% O 0 1.946260930196786e-09
of O 0 4.574053080741436e-10
unselected O 0 0.00010640501568559557
Ashkenazi O 0 0.0009996097069233656
Jews O 0 8.901242836145684e-06
and O 0 1.270225027383276e-07
higher O 0 1.3553267841359684e-08
proportions O 0 8.484024647259503e-07
of O 0 8.11390687971425e-09
Ashkenazim O 0 0.0021972458343952894
with O 0 5.853266316080408e-07
family O 0 1.5103612440725556e-06
or O 0 1.623950112161765e-07
personal O 0 2.059603048110148e-07
histories O 0 1.1841671039292123e-05
of O 0 5.689793169949553e-08
CRC B-Disease 0 0.07324667274951935
( O 0 3.082013932953487e-08
ref O 0 0.006827813573181629
. O 0 1.932147242200699e-08
2 O 0 1.8369705756526855e-08
) O 0 6.3559486562780876e-09
. O 0 2.9611245011551546e-08

To O 0 9.676411139025731e-08
evaluate O 0 2.69697810750813e-08
the O 0 5.898572186247009e-10
role O 0 1.1197580640498472e-09
of O 0 2.2487357809186648e-10
I1307K O 0 1.8608110394779942e-06
in O 0 1.0718367775552906e-06
cancer B-Disease 0 0.0084144975990057
, O 0 2.6346180348468806e-08
we O 0 7.809384072743342e-08
genotyped O 0 1.0869085826925584e-06
5 O 0 9.243088960886325e-09
, O 0 1.901095725287405e-09
081 O 0 7.541225386376027e-06
Ashkenazi O 0 4.30875797974295e-06
volunteers O 0 5.502713840144224e-09
in O 0 2.901838491720099e-10
a O 0 4.568248890279847e-09
community O 0 1.0554207285906614e-08
survey O 0 7.152623879846942e-07
. O 0 1.3644750218588797e-08

Risk O 0 0.00019721283752005547
of O 0 4.219658578108465e-08
developing O 0 2.3262473405338824e-05
colorectal B-Disease 1 0.9999997615814209
, I-Disease 0 0.0005389395519159734
breast I-Disease 1 0.9733773469924927
and I-Disease 0 3.0117653295747004e-05
other I-Disease 0 1.6984655815122096e-07
cancers I-Disease 0 0.4943842887878418
were O 0 2.3382200708965684e-07
compared O 0 1.313144650794129e-07
between O 0 9.054724614543375e-08
genotyped O 0 0.00030210864497348666
I1307K O 0 1.7505294636066537e-06
carriers O 0 2.1520509108086117e-07
and O 0 3.266781334332336e-08
non O 0 3.230907541507122e-09
- O 0 5.628562212223187e-05
carriers O 0 3.5468295322971244e-07
and O 0 7.698891124618967e-08
their O 0 2.653113728712242e-09
first O 0 4.355947069711874e-08
- O 0 5.2124391913821455e-06
degree O 0 3.4063681653151434e-08
relatives O 0 4.314191670573564e-08
. O 0 2.585725766834912e-08

Sperm O 0 7.502961125283036e-06
DNA O 0 3.3144162898679497e-06
analysis O 0 2.037739932347904e-08
in O 0 2.972446067062151e-09
a O 0 6.492682018688356e-07
Friedreich B-Disease 1 0.9996864795684814
ataxia I-Disease 1 0.9999420642852783
premutation O 1 0.8547890186309814
carrier O 0 0.00015054902178235352
suggests O 0 1.1448879604358808e-06
both O 0 7.888049324833446e-09
meiotic O 0 7.812630428816192e-06
and O 0 7.490526598985525e-08
mitotic O 0 9.633628224037238e-07
expansion O 0 8.991440836325637e-07
in O 0 1.7418345876762942e-08
the O 0 3.463721753860227e-08
FRDA B-Disease 0 0.0001742918830132112
gene O 0 2.072367806249531e-06
. O 0 1.0524941984613179e-07

Friedreich B-Disease 1 0.9991716146469116
ataxia I-Disease 1 0.9999644756317139
is O 0 0.047313131392002106
usually O 0 0.00028695171931758523
caused O 0 9.18180012376979e-06
by O 0 3.0699149888846478e-09
an O 0 8.491967684598478e-10
expansion O 0 5.538432219509559e-07
of O 0 7.0281247488424015e-09
a O 0 2.8597694381460315e-06
GAA O 0 0.00037615219480358064
trinucleotide O 0 0.00035960410605184734
repeat O 0 1.6447937014163472e-05
in O 0 2.0995343241736464e-09
intron O 0 7.271552021848038e-05
1 O 0 1.6512668565837885e-08
of O 0 3.971202533481488e-10
the O 0 2.7607086394709768e-08
FRDA B-Disease 0 0.0003624345699790865
gene O 0 1.3773484397461289e-06
. O 0 1.4814590088008117e-07

Occasionally O 0 0.0002500761183910072
, O 0 3.291756200951568e-08
a O 0 5.35697397552326e-09
fully O 0 8.1343145552637e-09
expanded O 0 4.969732625426104e-09
allele O 0 2.798477680698852e-07
has O 0 4.5292264871932275e-07
been O 0 6.318553147366401e-08
found O 0 4.155245036940869e-08
to O 0 8.813056950884857e-09
arise O 0 4.522318519661894e-09
from O 0 5.675369202373659e-11
a O 0 7.382767286401304e-09
premutation O 0 1.6078194676083513e-05
of O 0 9.720427796011677e-10
100 O 0 2.6739019887145332e-09
or O 0 5.417267967544603e-09
less O 0 8.56801563031695e-09
triplet O 0 0.024350518360733986
repeats O 0 0.000362599064828828
. O 0 2.3429119266893395e-07

We O 0 6.069057417334989e-05
have O 0 1.7842706867554625e-08
examined O 0 5.081372833615205e-08
the O 0 4.0289649394509297e-10
sperm O 0 7.022844972226494e-09
DNA O 0 1.002658649440491e-07
of O 0 6.908409261319193e-11
a O 0 6.943968600126027e-08
premutation O 0 0.0011499718530103564
carrier O 0 2.8049384127371013e-05
. O 0 9.676964651816888e-08

This O 0 1.9108290416625096e-07
mans O 0 1.6518391703357338e-06
leucocyte O 0 6.193332410475705e-06
DNA O 0 3.909443330485374e-05
showed O 0 1.3565547760663321e-06
one O 0 1.2062016940816989e-09
normal O 0 7.125143586250715e-09
allele O 0 3.8159413406901876e-08
and O 0 4.562625832704725e-08
one O 0 5.902353605868882e-10
allele O 0 3.6129946257013046e-10
of O 0 6.220630954789641e-11
approximately O 0 1.458555165534392e-09
100 O 0 9.534823597334707e-09
repeats O 0 2.064701766357757e-05
. O 0 1.2731186416203855e-07

His O 0 5.7582637964515015e-06
sperm O 0 1.1092712384197512e-06
showed O 0 3.1069961892171705e-07
an O 0 9.95609983345247e-11
expanded O 0 9.449657945026502e-09
allele O 0 1.1611116690346535e-07
in O 0 1.1833528823501638e-08
a O 0 9.491261465655043e-08
tight O 0 7.053560693748295e-05
range O 0 2.1552158102622343e-07
centering O 0 4.95264544042584e-07
on O 0 1.8822596814516146e-07
a O 0 3.322771391367496e-09
size O 0 1.4019172489554421e-08
of O 0 1.7983521616304898e-10
approximately O 0 3.019134275916713e-09
320 O 0 5.199523300802866e-08
trinucleotide O 0 0.00012787240848410875
repeats O 0 5.168896677787416e-05
. O 0 1.1115367470893034e-07

His O 0 0.00015949088265188038
affected O 0 9.078778020921163e-06
son O 0 1.3240943189885002e-05
has O 0 8.066860601729786e-08
repeat O 0 1.7243930869881297e-06
sizes O 0 6.403285368605793e-08
of O 0 1.0883062229183338e-09
1040 O 0 2.9513375920942053e-05
and O 0 1.4356712085827894e-07
540 O 0 4.259573245235515e-07
. O 0 7.00024642696917e-08

These O 0 6.772162208790178e-08
data O 0 1.2581254793531116e-07
suggest O 0 4.543451126437503e-08
that O 0 1.9327324185525185e-09
expansion O 0 3.382594115919346e-08
occurs O 0 6.846370137481017e-09
in O 0 1.2259773196632295e-09
two O 0 2.1331556965265008e-08
stages O 0 1.9616441932157613e-05
, O 0 2.1668885352710276e-08
the O 0 5.600990338194833e-09
first O 0 7.186400807768223e-08
during O 0 1.355052781093491e-08
meiosis O 0 9.95770577105759e-09
followed O 0 1.0350544421555696e-08
by O 0 4.841974599045784e-10
a O 0 6.30446539418017e-09
second O 0 3.673648905078153e-07
mitotic O 0 2.4557214146625483e-06
expansion O 0 2.6744753540697275e-06
. O 0 3.2228743407358706e-07

We O 0 5.7099041441688314e-05
also O 0 1.6150970338912884e-07
show O 0 2.432704775401362e-07
that O 0 1.4157127026237504e-08
in O 0 1.1042055048093857e-09
all O 0 6.156670173673717e-10
informative O 0 5.467266532832582e-07
carrier O 0 1.3927860891271848e-05
father O 0 3.1252088774635922e-06
to O 0 1.9979452758889238e-08
affected O 0 1.5143109877158167e-08
child O 0 5.889971816941397e-07
transmissions O 0 1.9749488274101168e-05
, O 0 1.0478688139414771e-08
with O 0 4.938776498875086e-09
the O 0 7.992364103870386e-09
notable O 0 1.2838879293042282e-08
exception O 0 7.958107062222552e-09
of O 0 5.023518823144002e-10
the O 0 2.612121896561348e-08
premutation O 0 1.2889647223346401e-05
carrier O 0 3.551947429514257e-07
, O 0 4.3328160503897095e-10
the O 0 4.998474897877081e-11
expansion O 0 6.484647485649475e-09
size O 0 3.5228332251335814e-08
decreases O 0 1.3893706807266426e-07
. O 0 3.4983180796643865e-09
. O 0 1.0207815925866726e-08

The O 0 4.623660743163782e-07
R496H O 0 3.7527920540014748e-06
mutation O 0 5.580135393756791e-07
of O 0 4.1535788142255115e-09
arylsulfatase O 0 0.00018335766799282283
A O 0 5.972440703772008e-06
does O 0 1.1945931873924565e-05
not O 0 3.82178677682532e-06
cause O 0 5.378051719162613e-05
metachromatic B-Disease 1 0.9999814033508301
leukodystrophy I-Disease 1 0.9999814033508301
. O 0 2.352125920879189e-05

Deficiency B-Disease 1 0.9989922642707825
of I-Disease 0 8.140495566522077e-08
arylsulfatase I-Disease 0 0.000605241337325424
A I-Disease 0 9.657199370849412e-06
( O 0 8.141581986365054e-08
ARSA O 0 0.03674650564789772
) O 0 7.90672682882132e-09
enzyme O 0 8.745693094169837e-07
activity O 0 1.1079147043346893e-05
causes O 0 0.0011786146787926555
metachromatic B-Disease 1 0.9999978542327881
leukodystrophy I-Disease 1 0.9999990463256836
( O 0 0.000119353411719203
MLD B-Disease 1 0.9999808073043823
) O 0 2.559235952048766e-07
. O 0 8.750484425945615e-08

A O 0 4.931765715809888e-07
number O 0 2.8421183628779545e-08
of O 0 9.171228221305228e-09
ARSA O 0 0.035015180706977844
gene O 0 1.844069265644066e-05
mutations O 0 1.8729138901107945e-05
responsible O 0 1.7845892443801858e-06
for O 0 5.785117878076562e-07
MLD B-Disease 1 0.9999979734420776
have O 0 9.409386620973237e-06
been O 0 6.936938348189869e-07
identified O 0 2.8921112971147522e-06
. O 0 9.92394078025427e-08

Recently O 0 0.00010845875658560544
, O 0 9.632728392716672e-09
the O 0 8.162285292101501e-10
R496H O 0 1.2678457039783098e-07
mutation O 0 6.816534181552925e-08
of O 0 7.934505275031256e-10
ARSA O 0 0.035576287657022476
was O 0 1.6541185914320522e-06
proposed O 0 4.491603977641034e-09
to O 0 4.479790760569813e-08
be O 0 3.3840652946537375e-08
a O 0 4.940814335441246e-08
cause O 0 1.0724604635470314e-06
of O 0 8.964489950358256e-08
MLD B-Disease 1 0.9999984502792358
( O 0 3.438209006390025e-08
Draghia O 0 0.00013905118976254016
et O 0 3.7479312595678493e-06
al O 0 1.4665763956145383e-05
. O 0 1.9050460764447052e-08
, O 0 1.3187054781482743e-09
1997 O 0 2.479724692250329e-08
) O 0 2.5606350373408304e-09
. O 0 1.4799968361955962e-08

We O 0 1.6679552572895773e-05
have O 0 5.185081253245016e-09
investigated O 0 1.882962941124333e-08
the O 0 2.9173841120666566e-09
R496H O 0 7.81038011155033e-07
mutation O 0 1.7342485989502165e-06
and O 0 3.815778200078057e-07
found O 0 5.306354111667133e-08
this O 0 1.3057731562682307e-09
mutation O 0 5.229450295018978e-08
at O 0 1.656952086648289e-08
a O 0 2.032277679475669e-09
relatively O 0 5.067055663943165e-09
high O 0 4.41232330672392e-08
frequency O 0 1.3533123421893833e-07
in O 0 3.117087699067156e-09
an O 0 3.313101570867616e-09
African O 0 1.319503062369165e-09
American O 0 4.219213423084511e-09
population O 0 5.248040335636972e-10
( O 0 1.2007975169758822e-10
f O 0 8.392171366722323e-06
= O 0 7.483652098017046e-06
0 O 0 5.2583654763793675e-08
. O 0 1.5762802174634771e-09
09 O 0 9.353741603490562e-08
, O 0 7.955690550787153e-10
n O 0 6.400796792149777e-06
= O 0 9.894264621834736e-06
61 O 0 1.0570369113338529e-07
subjects O 0 1.7067515045710024e-07
) O 0 8.825169039994307e-09
. O 0 2.439897528461188e-08

The O 0 1.2725678288916242e-06
ARSA O 0 0.00018100047600455582
enzyme O 0 3.6220410493115196e-07
activity O 0 2.3272924920547666e-07
in O 0 6.53027365515868e-09
subjects O 0 3.527705985106877e-06
with O 0 8.145447623064683e-07
and O 0 1.479361230849463e-06
without O 0 6.776539773767354e-09
the O 0 1.8798758105731395e-09
R496H O 0 4.910759230369877e-07
mutation O 0 3.196830391516414e-07
was O 0 1.977387682927656e-06
determined O 0 1.2161356153228553e-06
and O 0 5.6277002613569493e-08
found O 0 6.36036574519494e-08
to O 0 7.080450448171405e-09
be O 0 2.2498406693216566e-08
normal O 0 1.3184917690978182e-07
. O 0 3.6276162518333877e-08

It O 0 1.360534497507615e-05
is O 0 2.6667626329412997e-08
therefore O 0 1.2742563448853161e-08
concluded O 0 3.857609698343367e-08
that O 0 5.3569233493533375e-09
the O 0 2.4942241605430127e-09
R496H O 0 9.994296306103934e-07
mutation O 0 2.266961587338301e-07
of O 0 4.318750690401885e-09
ARSA O 0 0.42869383096694946
does O 0 6.406119155144552e-07
not O 0 2.683635313971422e-09
negatively O 0 4.647865703422127e-10
influence O 0 3.2515540260291687e-10
the O 0 7.291909853712752e-10
activity O 0 1.8569835447124206e-08
of O 0 2.8581592648180276e-09
ARSA O 0 0.40108251571655273
and O 0 7.260302368194971e-07
is O 0 2.0220825902583783e-08
not O 0 7.958228742666051e-09
a O 0 2.87241341823119e-08
cause O 0 3.843310878437478e-06
of O 0 1.2445647143977112e-06
MLD B-Disease 1 0.9999711513519287

Down O 0 0.002844249363988638
- O 0 0.00010444712097523734
regulation O 0 3.5614618809631793e-07
of O 0 1.2104792723732771e-09
transmembrane O 0 2.906635927502066e-05
carbonic O 0 9.895341463561635e-06
anhydrases O 0 0.0002578040584921837
in O 0 3.913879936590092e-06
renal B-Disease 1 0.9925795197486877
cell I-Disease 1 0.9999443292617798
carcinoma I-Disease 1 1.0
cell O 1 0.9998083710670471
lines O 0 0.18760131299495697
by O 0 9.135831646744919e-07
wild O 0 0.0003613854933064431
- O 1 0.9883413910865784
type O 1 0.6671795845031738
von B-Disease 1 0.9983822107315063
Hippel I-Disease 1 0.9927034378051758
- I-Disease 1 0.9436345100402832
Lindau I-Disease 1 0.8947609663009644
transgenes O 0 0.0006842548027634621
. O 0 1.016125224850839e-06

To O 0 9.907748790283222e-07
discover O 0 2.50120535838505e-07
genes O 0 2.8409640862037122e-08
involved O 0 1.0200847277985758e-08
in O 0 4.899970917904284e-07
von B-Disease 1 0.9999260902404785
Hippel I-Disease 1 0.999963641166687
- I-Disease 1 0.9999518394470215
Lindau I-Disease 1 0.9998130202293396
( O 0 2.517574557714397e-07
VHL B-Disease 0 0.0002597573911771178
) O 0 1.5430504873847894e-08
- O 0 5.9255595260765404e-05
mediated O 0 0.00011757675383705646
carcinogenesis O 0 0.01468617282807827
, O 0 1.2710768260149052e-07
we O 0 3.1347857998298423e-07
used O 0 3.3482961043773685e-06
renal B-Disease 0 0.3730526268482208
cell I-Disease 1 0.9991785883903503
carcinoma I-Disease 1 1.0
cell O 1 0.9998214840888977
lines O 1 0.9789116382598877
stably O 0 0.28446894884109497
transfected O 0 0.0028080588672310114
with O 0 1.526990786260285e-06
wild O 0 0.001041788375005126
- O 1 0.9680595993995667
type O 0 0.19603055715560913
VHL O 0 0.025069862604141235
- O 0 0.011222892440855503
expressing O 0 1.4455838481808314e-07
transgenes O 0 2.8794165700674057e-05
. O 0 1.8114016597792215e-07

Large O 0 2.3869878873483685e-07
- O 0 1.5991337932064198e-05
scale O 0 1.6961054143393994e-06
RNA O 0 2.6747661650006194e-06
differential O 0 5.073226930107921e-06
display O 0 8.413049386035709e-07
technology O 0 9.80264417194121e-07
applied O 0 8.70188401336236e-08
to O 0 1.979865338341824e-08
these O 0 2.452372305228323e-09
cell O 0 3.208579801139422e-05
lines O 0 0.0002048374735750258
identified O 0 3.5231565220783523e-07
several O 0 9.80986736287548e-10
differentially O 0 3.6058389696336235e-07
expressed O 0 5.1603761264118475e-09
genes O 0 1.3369310636335285e-07
, O 0 1.0728036237139804e-09
including O 0 1.8618333263997755e-10
an O 0 2.592351444619112e-09
alpha O 0 2.5075435061694407e-08
carbonic O 0 1.2520128223059146e-07
anhydrase O 0 1.773943694161062e-07
gene O 0 1.5578029888274614e-07
, O 0 1.0942659223189821e-08
termed O 0 5.350030278350459e-06
CA12 O 0 0.001138962572440505
. O 0 2.436700867747277e-07

The O 0 8.516078509046565e-08
deduced O 0 5.507882860911195e-08
protein O 0 5.389760193708071e-09
sequence O 0 3.6494884625426494e-07
was O 0 2.664660598838964e-07
classified O 0 1.3568404710895265e-07
as O 0 3.353826016905259e-08
a O 0 7.993023132257804e-08
one O 0 4.894245194009272e-06
- O 1 0.9827994704246521
pass O 0 0.004948148038238287
transmembrane O 0 0.00745925959199667
CA O 0 0.00024109573860187083
possessing O 0 1.708568220237794e-08
an O 0 4.553295074316566e-09
apparently O 0 2.8378642014104116e-07
intact O 0 1.3220910588529478e-08
catalytic O 0 1.7409412578217598e-08
domain O 0 2.674995869256236e-07
in O 0 4.800302821905689e-09
the O 0 8.64602700545447e-09
extracellular O 0 1.3662058336194605e-05
CA O 0 0.002787031466141343
module O 0 0.00023427001724485308
. O 0 1.1102039820798382e-07

Reintroduced O 0 0.0003009590436704457
wild O 0 0.00033105287002399564
- O 1 0.7519242167472839
type O 0 0.004889301955699921
VHL B-Disease 0 0.000827123352792114
strongly O 0 2.839867647708161e-07
inhibited O 0 1.0708814670579159e-06
the O 0 7.347815245140055e-09
overexpression O 0 4.3909028590860544e-07
of O 0 1.5248923235233747e-09
the O 0 3.9421216513346735e-08
CA12 O 0 6.092879266361706e-05
gene O 0 1.2114712433231034e-07
in O 0 3.467361953113368e-09
the O 0 2.326603798508131e-08
parental O 0 0.00025256717344745994
renal B-Disease 1 0.9406167268753052
cell I-Disease 1 0.9995402097702026
carcinoma I-Disease 1 1.0
cell O 1 0.9997473359107971
lines O 1 0.9349474906921387
. O 0 6.648446742474334e-06

Similar O 0 1.360541432404716e-06
results O 0 4.947537490807008e-07
were O 0 1.2371073943029387e-08
obtained O 0 8.530820494456748e-09
with O 0 9.8877164234068e-09
CA9 O 0 0.00140434131026268
, O 0 7.92067478272429e-09
encoding O 0 3.133326842430506e-08
another O 0 7.560906396975042e-06
transmembrane O 1 0.5911031365394592
CA O 0 0.2549060881137848
with O 0 7.328947226881155e-09
an O 0 3.911770019016103e-09
intact O 0 1.8900857412518235e-06
catalytic O 0 1.3435831078822957e-06
domain O 0 9.100708666665014e-06
. O 0 2.8213628411322134e-07

Although O 0 4.137382802582579e-06
both O 0 2.1240451175685848e-08
domains O 0 1.3243983687516447e-07
of O 0 7.152376024777141e-09
the O 0 1.419248292222619e-07
VHL B-Disease 0 0.0005155189428478479
protein O 0 4.654288545680174e-07
contribute O 0 4.325559910256516e-09
to O 0 2.483296901445442e-09
regulation O 0 9.576893233997907e-08
of O 0 1.4260320702064178e-09
CA12 O 0 0.0015695616602897644
expression O 0 1.051816525432514e-06
, O 0 1.962277673683843e-09
the O 0 4.851486989920772e-10
elongin O 0 4.969261340193043e-07
binding O 0 4.202548087306468e-09
domain O 0 2.781366958970466e-07
alone O 0 2.55490959943927e-07
could O 0 6.087536519316927e-08
effectively O 0 7.207320606994472e-08
regulate O 0 1.0815823543453007e-06
CA9 O 0 0.0006435095565393567
expression O 0 5.155016424396308e-06
. O 0 2.1981449549457466e-07

We O 0 3.845324317808263e-05
mapped O 0 5.987885015201755e-05
CA12 O 0 0.0008505770820192993
and O 0 2.9589068617497105e-07
CA9 O 0 0.0001273115340154618
loci O 0 3.568574413748138e-07
to O 0 3.022385186568499e-08
chromosome O 0 5.504930959432386e-05
bands O 0 3.390505298739299e-06
15q22 O 0 1.74027281900635e-05
and O 0 3.5108408269479696e-07
17q21 O 0 3.2848806768015493e-06
. O 0 1.0689177543099504e-07

2 O 0 2.5799774903134676e-06
respectively O 0 5.956804329798615e-07
, O 0 1.2068053223401876e-08
regions O 0 6.953882092375352e-08
prone O 0 0.0005054191569797695
to O 0 1.4110650425891436e-08
amplification O 0 2.1727212242694804e-06
in O 0 5.137434921920203e-09
some O 0 5.305299310975897e-09
human O 0 6.640861556661548e-06
cancers B-Disease 1 0.5057041049003601
. O 0 1.7169533350624988e-07

Additional O 0 4.4146048594484455e-08
experiments O 0 3.5024174849240808e-06
are O 0 4.6187489388671565e-09
needed O 0 2.0716225179739922e-08
to O 0 5.187571483489251e-10
define O 0 8.095776848904279e-08
the O 0 1.298348273337524e-08
role O 0 9.213135143681939e-08
of O 0 3.4618459210378205e-08
CA O 0 0.1818840205669403
IX O 0 0.004932026378810406
and O 0 2.7451920686871745e-05
CA O 0 0.0016343320021405816
XII O 0 1.5089781300048344e-05
enzymes O 0 7.101240839801903e-08
in O 0 2.61015808966647e-09
the O 0 3.4686056249455532e-09
regulation O 0 1.7014080810895393e-07
of O 0 2.8754267855646276e-09
pH O 0 3.2433244996354915e-06
in O 0 2.347553484938203e-09
the O 0 3.1850544424116833e-09
extracellular O 0 5.776208809038508e-07
microenvironment O 0 1.1793794328696094e-05
and O 0 5.892708543342451e-08
its O 0 3.126953418419731e-10
potential O 0 1.6143871794938036e-09
impact O 0 2.6720934798163398e-08
on O 0 2.995717750309268e-06
cancer B-Disease 0 0.0002471746411174536
cell O 0 4.772677493747324e-05
growth O 0 3.974707396992017e-06
. O 0 3.807028292612813e-08

A O 0 1.3650613084337238e-07
gene O 0 6.563716681284859e-08
encoding O 0 1.9952718588456264e-08
a O 0 7.246522670811828e-08
transmembrane O 0 1.4257887414714787e-05
protein O 0 2.6288563503840123e-07
is O 0 9.415295210146724e-09
mutated O 0 4.895598976872861e-06
in O 0 3.4893084830400767e-06
patients O 0 0.0014586311299353838
with O 1 0.7405677437782288
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9998419284820557
optic B-Disease 1 0.9999995231628418
atrophy I-Disease 1 0.9999936819076538
( O 0 0.22056090831756592
Wolfram B-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
) O 0 1.1984211596427485e-06
. O 0 2.1599525723559054e-07

Wolfram B-Disease 1 0.9999732971191406
syndrome I-Disease 1 0.9999997615814209
( O 0 5.967772449366748e-05
WFS B-Disease 1 0.723926305770874
; O 0 6.979899808357004e-06
OMIM O 0 0.24541661143302917
222300 O 0 0.0009416756802238524
) O 0 5.0007333385337915e-08
is O 0 6.09341483936987e-08
an O 0 5.546748980123084e-06
autosomal B-Disease 1 0.999988317489624
recessive I-Disease 1 0.9999990463256836
neurodegenerative I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999817609786987
defined O 0 0.002485334174707532
by O 0 2.9257332698762184e-06
young O 0 0.00010593383922241628
- O 0 0.40200719237327576
onset O 0 0.0047600725665688515
non O 0 9.3880271379021e-06
- O 1 0.9433468580245972
immune O 0 0.009169782511889935
insulin B-Disease 0 0.01520142238587141
- I-Disease 1 0.9977253079414368
dependent I-Disease 1 0.9111014008522034
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.08970800042152405
progressive O 0 0.33881983160972595
optic B-Disease 1 0.9999854564666748
atrophy I-Disease 1 0.9991980195045471
. O 0 3.4228437471028883e-06

Linkage O 0 0.000609761627856642
to O 0 1.0347607570793116e-07
markers O 0 2.4154636776074767e-05
on O 0 6.981158549024258e-07
chromosome O 0 0.001146667287684977
4p O 0 0.007296533789485693
was O 0 6.255789048736915e-05
confirmed O 0 1.4123179425951093e-06
in O 0 1.9462357059296664e-08
five O 0 1.7553998077346478e-07
families O 0 1.5006598630407098e-07
. O 0 1.9584764743285632e-07

On O 0 2.0950915313733276e-07
the O 0 4.890376992250367e-10
basis O 0 4.960941657472517e-10
of O 0 4.747633952639774e-10
meiotic O 0 0.0009322335827164352
recombinants O 1 0.8994070887565613
and O 0 0.11999544501304626
disease O 1 0.9358859658241272
- O 0 0.1314689666032791
associated O 0 1.6112522871480905e-06
haplotypes O 0 3.710873716045171e-05
, O 0 1.2505923407957198e-08
the O 0 4.569965295075917e-09
WFS B-Disease 0 4.197477755951695e-05
gene O 0 9.78315256361384e-07
was O 0 6.285263793870399e-07
localized O 0 3.7678753983527713e-07
to O 0 3.0493165326106464e-08
a O 0 8.885097457778102e-08
BAC O 0 8.752002031542361e-05
/ O 0 1.0698559890442993e-05
P1 O 0 7.25080753909424e-05
contig O 0 2.6498739771341207e-06
of O 0 2.511446606234813e-10
less O 0 1.841599511775982e-10
than O 0 1.837568014417812e-10
250 O 0 1.7723575940209457e-09
kb O 0 0.0006346064037643373
. O 0 4.2732929728117597e-07

Mutations O 0 0.0011244703782722354
in O 0 1.6384509748945675e-08
a O 0 2.2135074217999318e-08
novel O 0 5.324701760400785e-06
gene O 0 4.301326953282114e-06
( O 0 6.4702043722775215e-09
WFS1 O 0 1.4582949006580748e-05
) O 0 1.269626070943275e-10
encoding O 0 5.148114157194073e-10
a O 0 1.1446481096299976e-08
putative O 0 8.837938594297157e-07
transmembrane O 0 3.5071502679784317e-06
protein O 0 1.0319438388251e-06
were O 0 4.270494287084148e-07
found O 0 4.4685646116704447e-07
in O 0 1.846162867025214e-08
all O 0 1.295721041572051e-08
affected O 0 3.0315479904174936e-08
individuals O 0 3.765026068691668e-10
in O 0 4.470640391218694e-08
six O 0 9.612869007469271e-07
WFS B-Disease 0 0.011970343999564648
families O 0 1.720851514619426e-07
, O 0 3.6121644342301806e-08
and O 0 8.065245538091403e-08
these O 0 5.041259409921395e-09
mutations O 0 8.416010359724169e-07
were O 0 1.6392439761148125e-07
associated O 0 3.4481324462376506e-08
with O 0 1.5818189069705113e-07
the O 0 4.0051389078143984e-05
disease O 1 0.5604486465454102
phenotype O 0 0.0001987613650271669
. O 0 1.213358160612188e-07

WFS1 O 0 0.0029595147352665663
appears O 0 9.346229489892721e-06
to O 0 9.446631032972164e-09
function O 0 1.6243086875533663e-08
in O 0 6.321226653227541e-09
survival O 0 9.662569937063381e-06
of O 0 1.5140706466354459e-09
islet O 0 0.000948876200709492
beta O 0 4.4606323967855133e-07
- O 0 0.004182037431746721
cells O 0 4.383030500321183e-06
and O 0 2.1059284094349096e-08
neurons O 0 1.1774097430361508e-07
. O 0 2.9322848593693607e-09
. O 0 1.0788348880907961e-08

Stable O 0 2.0974974177079275e-05
interaction O 0 5.991055473941742e-08
between O 0 2.1346412637512913e-08
the O 0 6.165357113729897e-09
products O 0 1.5818852716620313e-07
of O 0 1.1342417005621996e-09
the O 0 7.071356833421305e-08
BRCA1 O 0 0.0001389727258356288
and O 0 3.2915916108322563e-06
BRCA2 O 0 3.207698682672344e-05
tumor B-Disease 0 9.30141413846286e-06
suppressor O 0 1.9297774542792467e-06
genes O 0 1.7585061584668438e-07
in O 0 3.4476261845384215e-08
mitotic O 0 5.791984949610196e-05
and O 0 4.272309070074698e-06
meiotic O 0 0.0009577298769727349
cells O 0 0.00028061840566806495
. O 0 4.978677452527336e-07

BRCA1 O 0 0.07873494923114777
and O 0 1.3604359082819428e-05
BRCA2 O 0 3.9856047806097195e-05
account O 0 2.1831303342878527e-07
for O 0 3.6892351396033973e-09
most O 0 6.121883444620835e-09
cases O 0 3.1253463816938165e-08
of O 0 8.677051965833016e-09
familial O 0 0.059445276856422424
, O 0 6.435388968384359e-07
early O 0 6.092617695685476e-06
onset O 0 0.038903601467609406
breast B-Disease 1 0.9956130981445312
and I-Disease 0 0.040011487901210785
/ I-Disease 1 0.9998689889907837
or I-Disease 1 0.9996812343597412
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 1.09947632154217e-06
encode O 0 2.1724675036693952e-07
products O 0 1.9240704205003567e-05
that O 0 1.036161023648674e-07
each O 0 8.155967012868359e-10
interact O 0 8.23575785346975e-09
with O 0 1.3045341695772095e-08
hRAD51 O 0 3.3857089874800295e-05
. O 0 1.4311777363218425e-07

Results O 0 4.516908575169509e-06
presented O 0 2.8431049514665574e-08
here O 0 4.020591859443812e-09
show O 0 1.0201201661175219e-07
that O 0 3.0284674323866057e-08
BRCA1 O 0 1.9767616322496906e-05
and O 0 3.1875285912974505e-06
BRCA2 O 0 3.122280759271234e-05
coexist O 0 1.1626540981524158e-05
in O 0 5.113288459313026e-09
a O 0 5.649047452038758e-08
biochemical O 0 7.812674994056579e-06
complex O 0 4.297841314837569e-06
and O 0 4.0833438106346875e-06
colocalize O 0 0.0001710460492176935
in O 0 6.560813403666543e-08
subnuclear O 0 1.6694844816811383e-05
foci O 0 3.175789061060641e-06
in O 0 1.906109936555822e-09
somatic O 0 1.5922181262340018e-07
cells O 0 4.046346020913916e-06
and O 0 6.623921677828548e-08
on O 0 4.9944894442432997e-08
the O 0 1.3718489677572165e-09
axial O 0 1.5543255571515147e-08
elements O 0 7.123814782517002e-08
of O 0 3.0070712586649506e-09
developing O 0 2.923254953657306e-07
synaptonemal O 0 3.454607940511778e-05
complexes O 0 1.0934868441836443e-05
. O 0 1.5582919843382115e-07

Like O 0 1.4945207112759817e-05
BRCA1 O 0 0.0005893241614103317
and O 0 1.5135651665332261e-06
RAD51 O 0 0.000407898478442803
, O 0 2.8800059226341546e-08
BRCA2 O 0 9.013660360324138e-07
relocates O 0 1.286577600012606e-07
to O 0 1.1104344110890452e-08
PCNA O 0 2.0851601220783778e-05
+ O 0 4.251107199593207e-08
replication O 0 1.0118337741005234e-06
sites O 0 2.8730930523579445e-08
following O 0 3.1928459875985027e-09
exposure O 0 3.1616568207937235e-07
of O 0 7.835890269980439e-10
S O 0 2.7228037652093917e-05
phase O 0 1.642024471948389e-07
cells O 0 9.991821769972375e-08
to O 0 8.826342434709034e-10
hydroxyurea O 0 5.048815978625498e-07
or O 0 3.39004770921747e-08
UV O 0 2.6296806026948616e-05
irradiation O 0 1.1613182095970842e-06
. O 0 7.335075480341402e-08

Thus O 0 2.5882577574520838e-06
, O 0 1.5929858321328538e-08
BRCA1 O 0 4.9779118853621185e-06
and O 0 4.062072207489109e-07
BRCA2 O 0 5.957218036201084e-06
participate O 0 1.4578744433890733e-08
, O 0 2.2103472829826387e-08
together O 0 5.750738907295272e-08
, O 0 5.57224177910598e-09
in O 0 1.661901505300989e-09
a O 0 3.610807652876247e-08
pathway O 0 1.9829908524116036e-06
( O 0 2.2827524759350126e-08
s O 0 0.0005363328382372856
) O 0 1.2079105715656624e-08
associated O 0 8.98074503652424e-09
with O 0 2.014152178375639e-09
the O 0 2.6766882044171325e-09
activation O 0 4.0707481829826975e-09
of O 0 1.3095743378599423e-09
double O 0 0.009219356812536716
- O 0 0.4255501329898834
strand O 1 0.811770498752594
break O 0 0.01067962683737278
repair O 0 0.0050093624740839005
and O 0 1.714917630124546e-07
/ O 0 9.465803714192589e-07
or O 0 4.174443013482687e-09
homologous O 0 8.647449334375779e-08
recombination O 0 1.3499132478500542e-07
. O 0 1.486779268589089e-07

Dysfunction O 1 0.5566961765289307
of O 0 6.401501906339035e-08
this O 0 2.1345639922287774e-08
pathway O 0 1.656571839703247e-06
may O 0 3.379490863153478e-06
be O 0 6.38310160283595e-09
a O 0 4.866623992683117e-09
general O 0 1.3745132143583305e-08
phenomenon O 0 3.944156105717411e-06
in O 0 5.181989592983882e-08
the O 0 1.265338767098001e-08
majority O 0 1.0347149803635602e-08
of O 0 3.5428832090289575e-10
cases O 0 1.3420428324195655e-08
of O 0 4.3015543127467026e-08
hereditary B-Disease 1 0.9987949132919312
breast I-Disease 1 0.9993689656257629
and I-Disease 0 0.009566020220518112
/ I-Disease 1 0.9934525489807129
or I-Disease 1 0.9945783615112305
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 4.243589728503139e-07
. O 0 1.0699947949888156e-07

A O 0 4.157523108005989e-06
novel O 0 4.493158030527411e-06
Arg362Ser O 0 0.00010430061229271814
mutation O 0 1.3654405393026536e-06
in O 0 2.049643343937646e-09
the O 0 1.9409482909793496e-09
sterol O 0 1.8135144273401238e-05
27 O 0 5.723541107727215e-06
- O 0 0.00026417989283800125
hydroxylase O 0 0.0002502910210750997
gene O 0 4.467982307687635e-06
( O 0 7.771445709181535e-09
CYP27 O 0 6.723796104779467e-05
) O 0 1.3107688268121365e-09
: O 0 2.6324153967749453e-10
its O 0 4.834868616576671e-10
effects O 0 1.9891167823971045e-07
on O 0 1.1879101435852135e-07
pre O 0 6.489143288490595e-06
- O 0 8.197760507755447e-06
mRNA O 0 1.923899084488312e-08
splicing O 0 1.0436047404027704e-07
and O 0 1.7578045685695542e-08
enzyme O 0 2.1407695172115382e-08
activity O 0 4.4742140659082e-08
. O 0 1.5313402101924112e-08

A O 0 3.230661604902707e-06
novel O 0 1.164661534858169e-05
C O 0 0.0002495214284863323
to O 0 4.768473171878895e-09
A O 0 1.2765259072011759e-08
mutation O 0 3.0064566658438707e-07
in O 0 7.285268832646352e-09
the O 0 1.1518139331201382e-08
sterol O 0 8.719928882783279e-05
27 O 0 1.5762318071210757e-05
- O 0 0.0004822051269002259
hydroxylase O 0 9.7640797321219e-05
gene O 0 4.2043243411171716e-06
( O 0 4.615543502950459e-09
CYP27 O 0 8.663271000841632e-05
) O 0 3.4190332787176203e-09
was O 0 5.445469142273396e-08
identified O 0 4.057384650479889e-09
by O 0 1.9404587658922168e-10
sequencing O 0 2.3701633722339466e-07
amplified O 0 2.3664283617108595e-06
CYP27 O 0 7.070020728860982e-06
gene O 0 2.21180286530398e-07
products O 0 1.8432746173857595e-07
from O 0 6.744068636876932e-10
a O 0 1.0116893633949076e-07
patient O 0 7.189961615949869e-05
with O 0 8.168058229784947e-06
cerebrotendinous B-Disease 1 0.9999991655349731
xanthomatosis I-Disease 1 0.9999953508377075
( O 0 8.365038866031682e-07
CTX B-Disease 0 0.03958073630928993
) O 0 7.075755803498396e-08
. O 0 6.013448228259222e-08

The O 0 2.72158644065712e-07
mutation O 0 7.505284997932904e-07
changed O 0 6.71619346803709e-08
the O 0 1.4717959073706766e-09
adrenodoxin O 0 7.747265726720798e-07
cofactor O 0 1.2549890016089194e-08
binding O 0 1.8132677581661483e-08
residue O 0 1.9162069975209306e-07
362Arg O 0 4.864677976001985e-07
to O 0 4.500393391282387e-09
362Ser O 0 8.563630444768933e-07
( O 0 1.3816857658000004e-09
CGT O 0 2.731779659370659e-06
362Arg O 0 9.7892370831687e-07
to O 0 1.0671267425266251e-08
AGT O 0 8.101544153760187e-06
362Ser O 0 1.0607996046019252e-05
) O 0 5.937336844397123e-09
, O 0 3.2895328683224534e-09
and O 0 7.279201952314907e-08
was O 0 3.972430022258777e-06
responsible O 0 1.2249422525201226e-06
for O 0 6.172066946419363e-07
deficiency O 0 0.003756944788619876
in O 0 4.217708848841539e-09
the O 0 9.835540382141517e-09
sterol O 0 2.3917531507322565e-05
27 O 0 3.0675571451865835e-06
- O 0 2.1463403754751198e-05
hydroxylase O 0 1.972129439309356e-06
activity O 0 2.242436210053711e-07
, O 0 6.831040177956993e-10
as O 0 6.07668471097611e-10
confirmed O 0 6.2789529131634936e-09
by O 0 8.31666610578985e-11
expression O 0 1.0951507478651479e-09
of O 0 1.7728358711610603e-11
mutant O 0 2.931620812773872e-08
cDNA O 0 6.850759071141965e-09
into O 0 8.150963459740979e-09
COS O 0 0.00013509372365660965
- O 0 4.0965183870866895e-05
1 O 0 5.744249165218207e-08
cells O 0 4.4241258478905365e-07
. O 0 2.198670578934525e-08

Quantitative O 0 1.5413789924423327e-06
analysis O 0 3.287393042228359e-07
showed O 0 2.7030732780986e-06
that O 0 6.120272288967499e-09
the O 0 4.057289781922435e-10
expression O 0 9.002886436348945e-09
of O 0 2.4103749551862563e-10
CYP27 O 0 3.8824887269584e-06
gene O 0 1.934060911423785e-08
mRNA O 0 1.0591333143850079e-08
in O 0 5.03816410812874e-09
the O 0 1.1956770684662388e-08
patient O 0 6.191367560859362e-07
represented O 0 1.2614782107789324e-08
52 O 0 7.529293384322955e-07
. O 0 9.099861131289799e-08

5 O 0 9.920087222781149e-07
% O 0 1.6681832581966205e-09
of O 0 1.8055285044837888e-10
the O 0 6.388277906665962e-09
normal O 0 2.3212190569665836e-07
level O 0 3.3973435620282544e-07
. O 0 8.064383649752926e-08

As O 0 3.134146027150564e-07
the O 0 1.7750233505253732e-09
mutation O 0 4.8422663212477346e-08
occurred O 0 5.612232456542188e-08
at O 0 1.4822222338395363e-09
the O 0 5.141667647201587e-10
penultimate O 0 1.4013389204592386e-07
nucleotide O 0 7.151448322417764e-09
of O 0 1.7289504550266344e-10
exon O 0 8.675812637193303e-07
6 O 0 1.0392581089035957e-06
( O 0 1.2179365294073818e-09
- O 0 2.499944093869999e-05
2 O 0 1.1121920096002214e-07
position O 0 3.28730145326972e-08
of O 0 8.41807179519094e-11
exon O 0 1.8856316046367283e-06
6 O 0 2.2583894860872533e-06
- O 0 0.0007602524710819125
intron O 0 0.008954561315476894
6 O 0 8.115409286801878e-07
splice O 0 5.489607428899035e-05
site O 0 1.2087805771443527e-05
) O 0 7.693262138452894e-10
of O 0 7.47200842865503e-11
the O 0 4.837103162458334e-09
gene O 0 5.371596785153088e-07
, O 0 7.975540938787162e-08
we O 0 6.690022757993574e-08
hypothesized O 0 7.617938280191083e-08
that O 0 1.592010967499391e-08
the O 0 3.0456021704594605e-08
mutation O 0 1.7410662621841766e-05
may O 0 3.6622282095777337e-06
partially O 0 1.8702082797972253e-06
affect O 0 7.156278680753303e-09
the O 0 4.436411515928995e-10
normal O 0 1.1388482379359743e-09
splicing O 0 9.431903258416696e-09
efficiency O 0 2.0132620903723364e-08
in O 0 3.6317390761375634e-10
exon O 0 2.392182295807288e-06
6 O 0 8.467070074402727e-06
and O 0 1.2742583521685447e-06
cause O 0 7.755738096193454e-08
alternative O 0 4.961057342711683e-09
splicing O 0 1.2839659575547557e-06
elsewhere O 0 5.956645168225805e-07
, O 0 4.233425165978133e-09
which O 0 4.203509984535003e-09
resulted O 0 1.5652647178399093e-08
in O 0 3.6544003378935486e-09
decreased O 0 6.054350478734705e-07
transcript O 0 1.889813029265497e-05
in O 0 8.349180546929347e-08
the O 0 2.51267891826501e-07
patient O 0 4.976690615876578e-05
. O 0 5.410207748468565e-08

Transfection O 0 0.0006753989146091044
of O 0 9.686345947557129e-08
constructed O 0 3.912501779268496e-05
minigenes O 0 0.000720132899004966
, O 0 9.357774644058736e-08
with O 0 1.2677085159396029e-08
or O 0 4.274352605193599e-08
without O 0 3.9515373195797565e-09
the O 0 2.6481590253979448e-09
mutation O 0 2.530418612423091e-07
, O 0 3.6271510239771487e-09
into O 0 1.0659814364544218e-08
COS O 0 0.01593955233693123
- O 0 0.0005900891846977174
1 O 0 1.5292802402200323e-07
cells O 0 4.1532055661264167e-07
confirmed O 0 3.5215034444036064e-08
that O 0 2.5118025437365077e-09
the O 0 5.448070883318223e-10
mutant O 0 1.1825044339275337e-06
minigene O 0 2.5830158847384155e-05
was O 0 1.6749517044445383e-06
responsible O 0 5.48341505535177e-09
for O 0 4.690736341017576e-11
a O 0 5.262865698796304e-10
mRNA O 0 8.410247609447197e-09
species O 0 1.0387657400912076e-10
alternatively O 0 1.9635290726682797e-08
spliced O 0 0.00027253423468209803
at O 0 5.180487505640485e-07
an O 0 6.71743327629315e-09
activated O 0 3.4429453990014736e-06
cryptic O 0 2.4778487386356574e-06
5 O 0 4.0544314572343865e-08
splice O 0 4.180268297204748e-05
site O 0 2.135135673597688e-06
88 O 0 7.686185199418105e-08
bp O 0 1.9121415562040056e-07
upstream O 0 2.6697449584389688e-08
from O 0 1.291244194900898e-10
the O 0 9.901527375788532e-10
3 O 0 1.90642364117366e-08
end O 0 1.023138107569821e-08
of O 0 2.3246632396833888e-10
exon O 0 1.0333597856515553e-05
6 O 0 2.3075531316862907e-06
. O 0 9.113478682820642e-08

Our O 0 2.1752228462901257e-07
data O 0 4.1124476268805665e-08
suggest O 0 3.270066528671123e-08
that O 0 1.583787212489085e-09
the O 0 4.6540331588573736e-09
C O 0 1.5403342331410386e-05
to O 0 1.7297132615112787e-09
A O 0 2.3876225441199495e-08
mutation O 0 1.41339171477739e-07
at O 0 5.352041476669456e-09
the O 0 5.380102474639159e-10
penultimate O 0 5.086550913802057e-08
nucleotide O 0 1.4948222659683097e-09
of O 0 7.066398854949085e-11
exon O 0 4.720316439943417e-07
6 O 0 3.109518900146213e-07
of O 0 4.15071810255796e-10
the O 0 3.486575650413215e-08
CYP27 O 0 6.70976223773323e-05
gene O 0 1.1075154588979785e-06
not O 0 2.702150823097327e-07
only O 0 2.084305528171626e-08
causes O 0 1.5463170655038994e-07
the O 0 2.4997082164190942e-06
deficiency B-Disease 0 0.014265256002545357
in I-Disease 0 6.089601267689204e-09
the I-Disease 0 9.830925407072755e-09
sterol I-Disease 0 1.650925878493581e-05
27 I-Disease 0 2.030602672675741e-06
- I-Disease 0 3.485588968032971e-05
hydroxylase I-Disease 0 1.4836882655799855e-05
activity I-Disease 0 1.991935050682514e-06
, O 0 3.626883327001451e-08
but O 0 1.97156438730417e-07
also O 0 3.2244670933323505e-07
partially O 0 4.855420411331579e-05
leads O 0 2.411219384157448e-07
to O 0 2.6969804167720213e-10
alternative O 0 4.727131464044021e-10
pre O 0 7.256370793129463e-08
- O 0 3.242853097162879e-07
mRNA O 0 9.200448181090337e-10
splicing O 0 3.714887952810386e-09
of O 0 8.433145848307788e-11
the O 0 1.9107910809168516e-09
gene O 0 1.3663455433743366e-07
. O 0 2.291512224417147e-08

To O 0 5.337391939974623e-06
our O 0 5.952443160595067e-08
knowledge O 0 3.655947988789876e-09
, O 0 9.350112906147956e-10
this O 0 3.9219658076738995e-10
is O 0 2.9688933533833506e-09
the O 0 3.567486528410768e-09
first O 0 2.2207009919839038e-07
report O 0 5.653000290095633e-09
regarding O 0 6.251870132700788e-10
effects O 0 1.5380648221707816e-07
on O 0 6.917780837056853e-08
pre O 0 1.678006924521469e-06
- O 0 9.072788316188962e-07
mRNA O 0 1.1874401462108608e-09
splicing O 0 2.776210594745976e-09
of O 0 4.8993281653864074e-11
a O 0 1.685919959193427e-09
mutation O 0 3.932299108555526e-08
at O 0 5.332019714643366e-09
the O 0 4.5463264264355985e-09
- O 0 0.010960900224745274
2 O 0 1.3349656455829972e-06
position O 0 3.3556310086169105e-07
of O 0 2.0249829590923696e-10
a O 0 1.932796145354132e-08
5 O 0 1.656008095096695e-07
splice O 0 0.00048477438394911587
site O 0 4.22228840761818e-05
. O 0 1.1967510715749086e-07

ATM O 0 0.001372318947687745
germline O 0 0.0018420183332636952
mutations O 0 0.0014545489102602005
in O 0 8.935570576795726e-07
classical O 0 0.4456593692302704
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.9985804557800293
in O 0 1.176122964352544e-06
the O 0 3.294269390607951e-07
Dutch O 0 0.0008233017870225012
population O 0 8.763829839608661e-08
. O 0 5.305220796003596e-08

Germline O 0 0.003595209214836359
mutations O 0 0.000641042715869844
in O 0 1.3738475246327653e-08
the O 0 5.680248271744404e-09
ATM O 0 3.0291228540590964e-05
gene O 0 9.600419161870377e-07
are O 0 5.273106840064656e-09
responsible O 0 1.7426563658773375e-07
for O 0 5.632295483337657e-07
the O 1 0.7555856108665466
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.6935499310493469
A B-Disease 1 0.9999980926513672
- I-Disease 1 0.999998927116394
T I-Disease 1 0.9999995231628418
) O 0 1.287435907215695e-06
. O 0 1.5214945392472146e-07

In O 0 1.0378259958088165e-06
our O 0 6.281302944444178e-08
study O 0 7.626280051908907e-09
, O 0 2.546534982883486e-09
we O 0 1.1647111719526038e-08
have O 0 7.289267522914145e-10
determined O 0 3.663926939623252e-09
the O 0 2.679577948416778e-10
ATM O 0 1.2967973361810436e-06
mutation O 0 2.4630427475358374e-08
spectrum O 0 6.972555866013863e-08
in O 0 3.321834896041764e-08
19 O 0 2.911164074248518e-07
classical O 0 8.422028622590005e-05
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.0428856797516346
, O 0 1.2449963282534782e-09
including O 0 7.975543836469257e-11
some O 0 1.9728256528406263e-10
immigrant O 0 1.2991578159926576e-06
populations O 0 3.7028434007879696e-07
, O 0 6.241341221624452e-09
as O 0 5.200839758856546e-09
well O 0 9.067597339651456e-09
as O 0 1.0895425894830169e-08
12 O 0 3.4157545680812973e-09
of O 0 2.14056716796307e-10
Dutch O 0 6.005080649629235e-06
ethnic O 0 2.7391202195303777e-08
origin O 0 1.2788648007244774e-07
. O 0 8.191691591719064e-08

Both O 0 1.183209974442434e-07
the O 0 2.769794837931272e-09
protein O 0 2.8600965151781566e-08
truncation O 0 1.6371350284316577e-05
test O 0 3.2208365155383945e-05
( O 0 7.459865503101071e-10
PTT O 0 3.254809541886061e-07
) O 0 1.675265037803797e-09
and O 0 1.81491388584476e-09
the O 0 2.3649582292506466e-10
restriction O 0 8.437819332129948e-09
endonuclease O 0 1.7641311842453433e-06
fingerprinting O 0 8.442397302133031e-06
( O 0 9.542768797388135e-10
REF O 0 4.083857129444368e-05
) O 0 3.794872055484788e-11
method O 0 2.309378022147257e-09
were O 0 5.845420592009987e-09
used O 0 3.4277695704076905e-07
and O 0 1.9701133169292007e-07
compared O 0 1.2668310844787811e-08
for O 0 7.460192463781823e-10
their O 0 1.737334609508423e-09
detection O 0 8.510233584502203e-08
efficiency O 0 1.7213380942848744e-08
, O 0 2.357720407797359e-10
identifying O 0 1.1832732571548377e-09
76 O 0 2.0467034289595176e-07
% O 0 8.536431006511691e-10
and O 0 1.2470717791757124e-08
60 O 0 3.9476724111864314e-09
% O 0 1.9907651915840319e-10
of O 0 1.4524469127419337e-10
the O 0 6.05282579613231e-08
mutations O 0 5.855963536305353e-06
, O 0 1.590393239325749e-08
respectively O 0 9.25586576272508e-08
. O 0 4.152179045036064e-08

Most O 0 2.074224312309525e-06
patients O 0 5.104509909870103e-06
were O 0 4.095562999850699e-08
found O 0 2.887761851866344e-08
to O 0 3.1397862088056172e-09
be O 0 2.2090775875227564e-09
compound O 0 1.0560474095200334e-07
heterozygote O 0 7.425867806887254e-06
. O 0 6.085041093228938e-08

Seventeen O 0 1.121389232139336e-05
mutations O 0 4.520148650044575e-05
were O 0 2.0201557049404073e-07
distinct O 0 3.6956738114213294e-08
, O 0 1.79082366713601e-08
of O 0 3.39276273741973e-09
which O 0 1.1271619086983264e-06
10 O 0 4.45169057172734e-08
were O 0 2.518881103696913e-07
not O 0 2.193678056983117e-07
reported O 0 1.8225679809802386e-07
previously O 0 1.8699514612308121e-06
. O 0 1.5139795550567214e-07

Mutations O 0 0.002755370456725359
are O 0 2.080159333672782e-08
small O 0 6.492530513213524e-09
deletions O 0 6.919930910953553e-06
or O 0 3.3083845210057916e-06
point O 0 0.00010655599908204749
mutations O 0 0.0002597658021841198
frequently O 0 1.118068212235812e-06
affecting O 0 9.671503420349836e-08
splice O 0 0.00509961973875761
sites O 0 2.8233429475221783e-05
. O 0 5.618251179839717e-07

Moreover O 0 3.2824435038492084e-05
, O 0 2.4999886605314714e-08
a O 0 1.1349715833830487e-08
16 O 0 3.1328610816672153e-07
. O 0 8.346027868810779e-08

7 O 0 6.521764134959085e-06
- O 0 2.997902083734516e-05
kb O 0 4.163697212788975e-06
genomic O 0 9.365056712340447e-07
deletion O 0 2.0818260964006186e-06
of O 0 3.2661815474455125e-09
the O 0 7.76516699829699e-08
3 O 0 2.9625141451106174e-06
end O 0 1.444565555175359e-06
of O 0 1.0236275160835362e-09
the O 0 1.1357381701770919e-08
gene O 0 7.817728260306467e-07
, O 0 1.4064863940177474e-08
most O 0 1.4484334842634894e-09
likely O 0 1.4369760492627393e-08
a O 0 4.519541629832702e-09
result O 0 1.4602734133006834e-08
of O 0 1.2253711934029354e-10
recombination O 0 3.367697232192768e-08
between O 0 2.774974063868285e-07
two O 0 4.45258251602354e-07
LINE O 0 0.01485284510999918
elements O 0 3.2417551665275823e-07
, O 0 1.8432563919645872e-08
was O 0 1.2498242085712263e-06
identified O 0 7.685259788559051e-07
. O 0 3.7159740173819955e-08

The O 0 4.2889217866104445e-07
most O 0 4.537265674287028e-09
frequently O 0 6.105350536245169e-08
found O 0 2.2726561965669134e-08
mutation O 0 1.1289009194115351e-07
, O 0 3.468757725499927e-09
identified O 0 2.2678719346913567e-07
in O 0 1.1730224791506316e-08
three O 0 9.928237432177411e-08
unrelated O 0 5.5902842177602e-06
Turkish O 0 0.003648012410849333
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
individuals O 0 4.928164685225056e-07
, O 0 4.3425082196790754e-08
was O 0 2.0056290850334335e-06
previously O 0 6.271690153880627e-07
described O 0 2.3601919565408025e-06
to O 0 3.8042628602852346e-08
be O 0 5.359968469065279e-09
a O 0 1.050440179284351e-08
Turkish O 0 1.2343482012511231e-05
A B-Disease 1 0.9999886751174927
- I-Disease 1 0.9999850988388062
T I-Disease 1 0.9999978542327881
founder O 0 0.00015605884254910052
mutation O 0 3.391986638234812e-06
. O 0 3.781849855499786e-08

The O 0 3.014254161826102e-07
presence O 0 9.681502710634504e-09
of O 0 1.0179462828219243e-09
a O 0 3.4212007449241355e-08
founder O 0 2.355941660425742e-06
mutation O 0 5.864513923370396e-07
among O 0 1.3353295136298016e-09
relatively O 0 1.3876201299112267e-09
small O 0 2.543282695555149e-09
ethnic O 0 5.901593880253131e-08
population O 0 5.6678888249450665e-09
groups O 0 1.5787776641573714e-09
in O 0 3.949314653084457e-09
Western O 0 9.158976013168285e-07
Europe O 0 1.822360786718491e-06
could O 0 7.777736499292587e-08
indicate O 0 2.6600961433587145e-09
a O 0 4.476028159228207e-10
high O 0 4.2491215879181254e-08
carrier O 0 2.2169549751538398e-08
frequency O 0 4.355564797720035e-08
in O 0 2.8963877962695506e-09
such O 0 1.0476124412406307e-09
communities O 0 4.908539352754815e-08
. O 0 7.459914996843509e-08

In O 0 1.4956092400097987e-06
patients O 0 1.021577077153779e-06
of O 0 9.053455762852991e-10
Dutch O 0 1.8899607312050648e-05
ethnic O 0 1.252500112514099e-07
origin O 0 1.836766045926197e-06
, O 0 3.0942484841034457e-07
however O 0 2.644067933488259e-07
, O 0 3.979583329538627e-09
no O 0 1.1359477802841411e-09
significant O 0 4.2145867351628397e-10
founder O 0 5.166357368580066e-07
effect O 0 2.9589179462163884e-07
could O 0 6.178120770528039e-07
be O 0 6.636717397867642e-09
identified O 0 1.7166732391160622e-07
. O 0 3.713919127790177e-08

The O 0 3.115645483831031e-07
observed O 0 2.4409362708865956e-07
genetic O 0 8.179418387044279e-07
heterogeneity O 0 1.442277721253049e-06
including O 0 4.663507624513841e-08
the O 0 8.128455419864622e-08
relative O 0 4.053589464092511e-07
high O 0 2.874721303669503e-06
percentage O 0 8.883874897946953e-07
of O 0 2.8789006734086797e-09
splice O 0 0.1541944146156311
- O 1 0.6080185174942017
site O 0 0.0001965314440894872
mutations O 0 2.1156340153538622e-05
had O 0 4.747304046759382e-06
no O 0 4.870171377291399e-09
reflection O 0 2.2896946560990727e-08
on O 0 1.1457068183062802e-07
the O 0 4.928418206873175e-08
phenotype O 0 5.480495383380912e-05
. O 0 7.490812237165301e-08

All O 0 2.4472906261507887e-06
patients O 0 1.4862082480249228e-06
manifested O 0 4.239447832787846e-07
classical O 0 5.558759585255757e-05
A B-Disease 1 0.999985933303833
- I-Disease 1 0.9999977350234985
T I-Disease 1 0.9999997615814209
and O 0 3.5461430343275424e-06
increased O 0 2.1213365286598673e-08
cellular O 0 5.686446456820704e-06
radioresistant O 0 6.876518455101177e-06
DNA O 0 4.253753559169127e-06
synthesis O 0 1.3769201814284315e-06
. O 0 1.307249561932622e-07

Determination O 0 2.968267654068768e-05
of O 0 3.2071585387427604e-09
the O 0 1.49191115017544e-09
genomic O 0 2.965961130030337e-07
structure O 0 2.0890613541268976e-06
of O 0 1.4737200348946544e-09
the O 0 4.020486343847551e-08
COL4A4 O 0 0.00011652510147541761
gene O 0 1.6517888070666231e-06
and O 0 7.277369462599381e-08
of O 0 1.9938861672841313e-09
novel O 0 0.0011475317878648639
mutations O 0 0.008076517842710018
causing O 0 0.006434930954128504
autosomal B-Disease 1 0.9999465942382812
recessive I-Disease 1 0.9999946355819702
Alport I-Disease 1 0.999998927116394
syndrome I-Disease 1 0.9999980926513672
. O 0 6.0055834183003753e-05

Autosomal B-Disease 1 0.9999053478240967
recessive I-Disease 1 0.9999767541885376
Alport I-Disease 1 0.9999974966049194
syndrome I-Disease 1 0.9999990463256836
is O 0 2.860695713025052e-05
a O 0 1.3718067748413887e-05
progressive O 0 0.4305139183998108
hematuric B-Disease 1 0.9996850490570068
glomerulonephritis I-Disease 1 0.999998927116394
characterized O 1 0.757243275642395
by O 0 8.640706255391706e-06
glomerular B-Disease 1 0.999017596244812
basement I-Disease 1 0.9999198913574219
membrane I-Disease 1 0.985405683517456
abnormalities I-Disease 1 0.999946117401123
and O 0 5.682434675691184e-06
associated O 0 1.1907865626881176e-07
with O 0 1.0775809045071583e-07
mutations O 0 1.3479348126566038e-05
in O 0 9.152395108458222e-08
either O 0 2.625188812999113e-07
the O 0 1.955052084667841e-07
COL4A3 O 0 0.009247132577002048
or O 0 5.3200658101104636e-08
the O 0 1.0057228827520248e-08
COL4A4 O 0 1.792110015230719e-05
gene O 0 2.3558736472750752e-07
, O 0 1.9195764977553154e-09
which O 0 2.756380956814297e-10
encode O 0 4.120595420431528e-09
the O 0 1.9051260125024783e-08
alpha3 O 0 8.818443166092038e-05
and O 0 5.747464797423163e-07
alpha4 O 0 0.00011535642261151224
type O 0 0.0007703504525125027
IV O 0 0.025708818808197975
collagen O 0 0.0027148821391165257
chains O 0 0.004072647541761398
, O 0 7.844870708595408e-08
respectively O 0 1.5541408515673538e-07
. O 0 3.8021664039433745e-08

To O 0 2.3041856422878482e-07
date O 0 1.3847329682903364e-07
, O 0 8.631687031801505e-10
mutation O 0 6.6068217563497456e-09
screening O 0 1.1171798064424365e-07
in O 0 5.410349057655139e-09
the O 0 3.1685566170835955e-08
two O 0 1.7347336722650653e-07
genes O 0 7.907649887783919e-06
has O 0 7.84315270720981e-05
been O 0 2.5830158847384155e-05
hampered O 0 0.0004520574293565005
by O 0 3.058158171143077e-08
the O 0 8.914157945127954e-08
lack O 0 2.9365850195972598e-08
of O 0 2.813523858335998e-10
genomic O 0 1.0845953966054367e-06
structure O 0 2.5471031221968587e-06
information O 0 4.6968494871180155e-08
. O 0 5.2903260439052247e-08

We O 0 0.0001872218999778852
report O 0 6.683122677486608e-08
here O 0 1.3693105538337136e-09
the O 0 1.9825689701047366e-10
complete O 0 1.4080432819696398e-08
characterization O 0 9.685326176622766e-07
of O 0 9.88850445970968e-10
the O 0 1.009258632223009e-08
48 O 0 2.032150803188415e-08
exons O 0 2.241119148038706e-07
of O 0 1.3508663077033134e-09
the O 0 2.8562530118847462e-08
COL4A4 O 0 3.7415466067614034e-05
gene O 0 1.3715532531932695e-07
, O 0 6.016862008628721e-10
a O 0 3.175293084023423e-10
comprehensive O 0 5.272788072829826e-08
gene O 0 7.820703444849642e-07
screen O 0 0.009187189862132072
, O 0 3.2543005090701627e-07
and O 0 4.0110730736842015e-08
the O 0 8.718837873900043e-10
subsequent O 0 1.1585120418544648e-08
detection O 0 3.958880370191764e-07
of O 0 6.500978089185594e-10
10 O 0 1.1423645140951066e-08
novel O 0 1.1683154070851742e-06
mutations O 0 1.2523224768301588e-06
in O 0 9.036005366169775e-08
eight O 0 7.517715857829899e-06
patients O 0 6.416063115466386e-05
diagnosed O 0 0.04748965799808502
with O 0 5.6372806284343824e-05
autosomal B-Disease 1 0.9999916553497314
recessive I-Disease 1 0.9999979734420776
Alport I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999983310699463
. O 0 5.464271816890687e-05

Furthermore O 0 3.212921365047805e-05
, O 0 2.980623037274199e-08
we O 0 1.0000989369984836e-08
identified O 0 8.687613406443973e-10
a O 0 2.617021321871249e-10
glycine O 0 4.466412804049469e-07
to O 0 2.9613207441769873e-09
alanine O 0 9.249283294820998e-08
substitution O 0 8.338418844289208e-09
in O 0 4.730173586153796e-09
the O 0 3.5862752767457096e-09
collagenous O 0 6.260789814405143e-05
domain O 0 2.346038399991812e-06
that O 0 1.1016504686267581e-07
is O 0 1.4750707322264134e-08
apparently O 0 4.5560207695416466e-07
silent O 0 1.8071242493533646e-06
in O 0 1.6375940603552408e-09
the O 0 1.1219128959183422e-09
heterozygous O 0 4.000254705260886e-08
carriers O 0 2.9395215150884724e-08
, O 0 1.2131164961459717e-09
in O 0 3.54757800913319e-09
11 O 0 2.943865240467858e-07
. O 0 1.073920401495343e-07

5 O 0 9.108923677558778e-07
% O 0 1.9832622211168882e-09
of O 0 1.511271108256551e-10
all O 0 3.545785220993025e-09
control O 0 2.9548957627412165e-06
individuals O 0 5.351061371783317e-09
, O 0 2.2448769954053205e-08
and O 0 2.2110351949322649e-07
in O 0 9.103295006696044e-09
one O 0 1.0728639665558148e-07
control O 0 2.0782058527402114e-06
individual O 0 2.801267273699892e-10
homozygous O 0 1.7389060191774774e-09
for O 0 5.522159118864778e-11
this O 0 2.2422601275717824e-10
glycine O 0 1.340879265399053e-07
substitution O 0 5.584778861589257e-08
. O 0 4.43158718610448e-08

There O 0 1.539572076580953e-05
has O 0 1.2812895420211134e-06
been O 0 9.74495861782998e-08
no O 0 1.4472329112891202e-08
previous O 0 1.4829922179160349e-08
finding O 0 1.2695057227674056e-09
of O 0 3.393387307260021e-11
a O 0 1.160966656144069e-09
glycine O 0 1.8337330232043314e-07
substitution O 0 3.70307589037111e-08
that O 0 2.78061378367056e-07
is O 0 6.086143855554838e-08
not O 0 6.944895858396194e-08
associated O 0 6.8666929919913855e-09
with O 0 3.090241840197905e-09
any O 0 1.491963175226374e-08
obvious O 0 2.424968386094406e-07
phenotype O 0 1.5691648513893597e-06
in O 0 5.241170164538289e-09
homozygous O 0 4.880225787928794e-07
individuals O 0 6.1984901655876e-09
. O 0 4.7518064150153805e-08

Founder O 0 0.00016022099589463323
BRCA1 O 0 0.001081350608728826
and O 0 3.000209517267649e-06
BRCA2 O 0 6.278577347984537e-05
mutations O 0 1.4185883628670126e-05
in O 0 1.079998526165582e-07
French O 0 0.00044072867603972554
Canadian O 0 0.20879746973514557
breast B-Disease 1 0.9999921321868896
and I-Disease 1 0.9999762773513794
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
families O 0 8.95863377081696e-06
. O 0 3.6619729826270486e-07

We O 0 1.6020550901885144e-05
have O 0 7.04584168786937e-09
identified O 0 9.832351821614793e-09
four O 0 3.101922274595381e-09
mutations O 0 1.5080944137935148e-07
in O 0 1.564899654304952e-09
each O 0 9.953218249592055e-10
of O 0 1.1688840118040389e-08
the O 0 0.00023658652207814157
breast B-Disease 1 0.9998724460601807
cancer I-Disease 1 0.5233012437820435
- O 0 0.0039004022255539894
susceptibility O 0 8.41801447677426e-05
genes O 0 2.3264722130988957e-06
, O 0 7.217913378099183e-08
BRCA1 O 0 4.160685421084054e-05
and O 0 1.153497805717052e-06
BRCA2 O 0 6.038474111846881e-06
, O 0 1.6954627923837506e-08
in O 0 1.8317363625897087e-08
French O 0 4.497257395996712e-05
Canadian O 0 0.004867597948759794
breast B-Disease 1 0.9997112154960632
cancer I-Disease 1 0.9885668754577637
and O 0 0.1941300332546234
breast B-Disease 1 0.9999969005584717
/ I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.775554551386449e-06
from O 0 3.9749654234810805e-08
Quebec O 0 0.0001403606729581952
. O 0 4.986299018128193e-07

To O 0 1.6157870277311304e-06
identify O 0 6.457619292632444e-07
founder O 0 2.332523990844493e-06
effects O 0 2.3742501070955768e-05
, O 0 6.227526228030911e-08
we O 0 6.07751289294356e-08
examined O 0 1.1246134334896851e-07
independently O 0 6.596649626544604e-08
ascertained O 0 2.8393308184604393e-06
French O 0 2.1727008061134256e-05
Canadian O 0 0.00020583521109074354
cancer B-Disease 0 0.0018204916268587112
families O 0 2.9293503178706715e-09
for O 0 1.4579293328154108e-09
the O 0 3.379529323055408e-09
distribution O 0 9.13444893058113e-08
of O 0 7.7019096655917e-10
these O 0 2.240427177113702e-09
eight O 0 1.2847943153815322e-08
mutations O 0 1.4278718936111545e-06
. O 0 8.631004533299347e-08

Mutations O 0 0.0027718248311430216
were O 0 5.441200983113959e-07
found O 0 1.971018548374559e-08
in O 0 6.242909522669038e-10
41 O 0 3.797339687139356e-08
of O 0 9.179449977914089e-10
97 O 0 7.058096798573388e-06
families O 0 1.4587929797471588e-07
. O 0 1.0375413950214352e-07

Six O 0 1.0793309002110618e-06
of O 0 1.4601388986790198e-09
eight O 0 1.6331780372524918e-08
mutations O 0 5.491381784850091e-07
were O 0 2.1718786769042708e-08
observed O 0 5.60733184329365e-08
at O 0 3.371309276190004e-08
least O 0 7.833667936552047e-09
twice O 0 3.291023631390999e-06
. O 0 1.8797302914208558e-07

The O 0 5.402905571827432e-07
BRCA1 O 0 2.1428673790069297e-05
C4446T O 0 3.5943687635153765e-06
mutation O 0 8.145236279233359e-06
was O 0 1.4180849348122138e-06
the O 0 2.5546493809258664e-09
most O 0 2.474743077129915e-09
common O 0 1.3826269196215435e-07
mutation O 0 8.297177373606246e-06
found O 0 1.021071511786431e-06
, O 0 6.238460859009365e-09
followed O 0 1.545386218992917e-08
by O 0 3.900757938879451e-09
the O 0 9.305375670010108e-08
BRCA2 O 0 7.52924825064838e-05
8765delAG O 0 1.4505772924167104e-05
mutation O 0 2.3064224023983115e-06
. O 0 6.712581779311222e-08

Together O 0 1.2676387996179983e-05
, O 0 3.1421901525163776e-08
these O 0 1.1607674821334513e-09
mutations O 0 6.080434644673005e-08
were O 0 3.543522097970708e-08
found O 0 2.874205762282145e-08
in O 0 1.1151888301697e-08
28 O 0 1.4272468717990705e-07
of O 0 7.456892325841125e-10
41 O 0 1.942558810696937e-06
families O 0 7.248635025547401e-09
identified O 0 8.760852097111638e-07
to O 0 2.601293225268364e-08
have O 0 1.3122578579327637e-08
a O 0 2.9759874564661004e-08
mutation O 0 4.396091753733344e-06
. O 0 1.607309769724452e-07

The O 0 7.384290938716731e-07
odds O 0 5.2953209888073616e-06
of O 0 1.2550793737631238e-09
detection O 0 4.621580956154503e-06
of O 0 5.743432396343451e-10
any O 0 3.0461526634439906e-09
of O 0 8.974849752263481e-10
the O 0 4.1294960340110265e-08
four O 0 2.6790320362124476e-07
BRCA1 O 0 4.368743611848913e-05
mutations O 0 4.400587840791559e-06
was O 0 6.2446456468023825e-06
18 O 0 1.4169465600843978e-07
. O 0 1.474607245199877e-07

7x O 0 0.00010775548435049132
greater O 0 5.124783228893648e-07
if O 0 4.7418470217053255e-07
one O 0 2.179987079742318e-09
or O 0 8.682279339922161e-10
more O 0 1.0008305989517297e-10
cases O 0 1.6688562709532562e-07
of O 0 0.0029499593656510115
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.0006371723720803857
also O 0 1.8032980733551085e-05
present O 0 3.2554858364619577e-08
in O 0 6.221292636610087e-08
the O 0 2.2438266000790463e-07
family O 0 2.3273153146874392e-06
. O 0 2.427078413802519e-07

The O 0 2.9445305926856236e-07
odds O 0 9.115475450016675e-07
of O 0 3.004719251187282e-10
detection O 0 1.4007218851475045e-06
of O 0 3.1671698597079967e-10
any O 0 1.209860656103956e-09
of O 0 7.60767948637664e-10
the O 0 5.2375256132108916e-08
four O 0 3.4663460724004835e-07
BRCA2 O 0 1.0914936865447089e-05
mutations O 0 1.2755738225678215e-06
was O 0 1.9264125512563623e-06
5 O 0 3.6587684348887706e-07
. O 0 1.35833573722266e-07

3x O 0 8.22701258584857e-05
greater O 0 3.305825373445259e-07
if O 0 2.630210644838371e-07
there O 0 3.6031899686150837e-09
were O 0 4.731797620394218e-09
at O 0 1.8446343341693705e-09
least O 0 1.3940897047870493e-10
five O 0 2.937502241451284e-09
cases O 0 4.489790228490165e-08
of O 0 1.4584885548174498e-06
breast B-Disease 1 0.9999853372573853
cancer I-Disease 1 0.8032880425453186
in O 0 1.4151085281355336e-07
the O 0 2.446473388317827e-07
family O 0 2.184578761443845e-06
. O 0 2.2122586074146966e-07

Interestingly O 0 8.551985956728458e-05
, O 0 1.2209608435398422e-08
the O 0 4.135703446372929e-10
presence O 0 7.767411158710047e-10
of O 0 2.3716209551771783e-10
a O 0 3.2934190130617935e-06
breast B-Disease 1 0.9271219968795776
cancer I-Disease 0 0.0015890061622485518
case O 0 5.760652044273229e-08
< O 0 2.4616858240733563e-07
36 O 0 8.790665617652849e-08
years O 0 1.9543561435853007e-08
of O 0 5.3671502797669746e-09
age O 0 2.2192473352333764e-06
was O 0 1.0405176453787135e-06
strongly O 0 2.6695297083989544e-09
predictive O 0 8.088321834520684e-08
of O 0 1.5097507688466294e-09
the O 0 2.3389823411434918e-08
presence O 0 7.058081230582047e-09
of O 0 3.0019795677072025e-11
any O 0 2.484953909309695e-10
of O 0 1.107400213196108e-10
the O 0 2.3529327375371167e-09
eight O 0 1.4378314538987524e-08
mutations O 0 1.902675279552568e-07
screened O 0 6.919304269104032e-06
. O 0 3.557784467034253e-08

Carriers O 0 5.741527729696827e-06
of O 0 2.797173603852343e-09
the O 0 2.4291142430854507e-09
same O 0 3.4472888987835404e-09
mutation O 0 1.414577042169185e-07
, O 0 7.49785178388862e-10
from O 0 3.945515442138614e-11
different O 0 7.330523965620728e-10
families O 0 1.3054450853644539e-08
, O 0 8.857816702345644e-09
shared O 0 1.8818283820110082e-08
similar O 0 1.3763496120589025e-08
haplotypes O 0 1.0853303137992043e-05
, O 0 8.11497447017473e-09
indicating O 0 7.372076282763373e-08
that O 0 1.2662127346629859e-08
the O 0 7.825360914814894e-10
mutant O 0 1.3824606526213756e-07
alleles O 0 4.29655067080148e-09
were O 0 1.8123952827409084e-07
likely O 0 1.0342832013066072e-07
to O 0 1.0543664608064773e-08
be O 0 1.0139066475289837e-08
identical O 0 4.4404802679309796e-07
by O 0 3.53672291453222e-08
descent O 0 7.861233825678937e-06
for O 0 6.633692262170143e-09
a O 0 1.1347165695951844e-07
mutation O 0 2.1090775135235162e-06
in O 0 3.878562537806829e-08
the O 0 5.599936159228491e-08
founder O 0 1.1415994777053129e-05
population O 0 1.5672963371571313e-08
. O 0 2.1842209818601077e-08

The O 0 3.943791071492342e-08
identification O 0 1.2316569986126069e-08
of O 0 5.517087897644046e-10
common O 0 2.838202703969728e-07
BRCA1 O 0 0.0008745355298742652
and O 0 7.633771929249633e-06
BRCA2 O 0 6.263328396016732e-05
mutations O 0 1.0460611520102248e-05
will O 0 1.4603179998573523e-08
facilitate O 0 5.13243980648781e-09
carrier O 0 1.6468641206301982e-07
detection O 0 2.751152806013124e-06
in O 0 2.3971823637225498e-08
French O 0 5.377990601118654e-05
Canadian O 0 0.003686998039484024
breast B-Disease 1 0.9993274211883545
cancer I-Disease 1 0.9562419652938843
and O 0 0.06660116463899612
breast B-Disease 1 0.9999951124191284
/ I-Disease 1 0.9999991655349731
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 1.4479790479526855e-05
. O 0 7.931982963782502e-07

Are O 0 2.0084542029508157e-06
Dp71 O 0 0.0005390763399191201
and O 0 2.835723762473208e-06
Dp140 O 0 4.741946031572297e-05
brain O 0 0.00020745123038068414
dystrophin O 0 2.2553804228664376e-06
isoforms O 0 6.645243644243237e-08
related O 0 4.913147790830408e-07
to O 0 2.0629546781947283e-07
cognitive B-Disease 0 0.000665274215862155
impairment I-Disease 0 0.012718552723526955
in O 0 0.0001088101344066672
Duchenne B-Disease 1 0.9999872446060181
muscular I-Disease 1 0.9999686479568481
dystrophy I-Disease 1 0.9999382495880127
? O 0 0.000714954046998173

Molecular O 0 2.6018544303951785e-05
study O 0 1.2291902748984285e-06
and O 0 5.750695208917023e-08
neuropsychological O 0 1.989785687328549e-06
analysis O 0 7.3450552307008365e-09
were O 0 6.806787578028661e-09
performed O 0 1.3073668014840223e-07
concurrently O 0 2.1903161950831418e-08
on O 0 1.6323672298312886e-06
49 O 0 5.558197517530061e-05
patients O 0 6.664958618785022e-06
with O 0 1.3551476513384841e-05
Duchenne B-Disease 1 0.9999964237213135
muscular I-Disease 1 0.9999872446060181
dystrophy I-Disease 1 0.9999805688858032
( O 0 9.16125463845674e-06
DMD B-Disease 1 0.9999997615814209
) O 0 3.309163957965211e-06
in O 0 1.7355147008402128e-07
order O 0 6.480519800788898e-07
to O 0 2.655894704162165e-08
find O 0 1.1679256672891825e-08
a O 0 6.08154304693187e-10
molecular O 0 1.6878536257536325e-07
explanation O 0 7.373675892097253e-09
for O 0 8.013852914601216e-10
the O 0 6.463324098149315e-08
cognitive B-Disease 0 4.435058872331865e-05
impairment I-Disease 0 1.568248808325734e-05
observed O 0 2.3016313832613378e-07
in O 0 7.226302756180303e-08
most O 0 8.82968379301019e-06
DMD B-Disease 1 0.9999997615814209
patients O 0 0.005629055667668581
. O 0 1.8961397074690467e-07

Complete O 0 4.5404030970530584e-06
analysis O 0 1.0257177507355664e-07
of O 0 2.9885038888011195e-10
the O 0 4.4320414005483144e-09
dystrophin O 0 5.316440820024582e-06
gene O 0 3.5970506360172294e-06
was O 0 9.14022257347824e-06
performed O 0 7.498144327655609e-07
to O 0 2.2787491893438983e-09
define O 0 1.8832507464594528e-07
the O 0 3.0328362043974266e-09
localization O 0 5.212034466239857e-07
of O 0 8.523805550275654e-10
deletions O 0 4.888343937636819e-06
and O 0 8.329550951202691e-07
duplications O 0 6.216107522050152e-06
in O 0 3.435541273688614e-08
relation O 0 6.530599989673647e-07
to O 0 3.434165307680814e-08
the O 0 1.3258258491077868e-08
different O 0 2.044988463012487e-07
DMD B-Disease 1 0.9999951124191284
promoters O 0 0.0007274327799677849
. O 0 4.218640867748036e-07

Qualitative O 0 8.521113272763614e-07
analysis O 0 6.342194325270611e-08
of O 0 2.332044279906853e-10
the O 0 2.13577644458951e-09
Dp71 O 0 1.1445100426499266e-05
transcript O 0 1.2748715562338475e-05
and O 0 8.343386781461959e-08
testing O 0 4.3567364826913035e-08
for O 0 7.837665239041058e-11
the O 0 1.1804705823958983e-10
specific O 0 1.7198170665366774e-10
first O 0 8.462317957480536e-09
exon O 0 9.525555810796504e-08
of O 0 2.0545203316402194e-09
Dp140 O 0 8.388989840568684e-07
were O 0 5.666335312071169e-08
also O 0 5.394987567797216e-08
carried O 0 2.0501337871792202e-07
out O 0 1.8703458692925778e-07
. O 0 5.9474501767908805e-08

Neuropsychological O 0 0.0009542351472191513
analysis O 0 8.160352535924176e-07
assessed O 0 8.986348234429897e-07
verbal O 0 1.1679873750836123e-05
and O 0 3.9123773376559257e-07
visuospatial O 0 4.949792491970584e-05
intelligence O 0 1.9959511519118678e-06
, O 0 2.1106290049033305e-08
verbal O 0 2.1040309547970537e-06
memory O 0 0.007967918179929256
, O 0 2.496248896477482e-07
and O 0 1.3569594159434928e-07
reading O 0 2.4468097308272263e-06
skills O 0 6.72532132739434e-06
. O 0 4.877126613678229e-08

Comparison O 0 1.1831880328827538e-06
of O 0 2.264006315755296e-09
molecular O 0 6.809925139350526e-07
and O 0 1.0883466217137538e-07
psychometric O 0 1.948384851857554e-05
findings O 0 2.06798929980323e-07
demonstrated O 0 3.056059227901642e-08
that O 0 3.448886953805186e-09
deletions O 0 1.889188894210747e-07
and O 0 1.7562436482876365e-07
duplications O 0 7.737113264738582e-06
that O 0 1.8179431435783044e-06
were O 0 2.624362593905971e-07
localized O 0 2.330581446585711e-05
in O 0 1.855912614701083e-06
the O 0 1.203144535111278e-07
distal O 0 7.0924274950812105e-06
part O 0 5.583414122156682e-07
of O 0 1.9076376034377063e-09
the O 0 6.638514626899905e-09
gene O 0 1.6994685836380086e-07
seemed O 0 2.1104486336298578e-07
to O 0 3.6985614570994585e-10
be O 0 4.771873451936415e-10
preferentially O 0 8.220597536023888e-09
associated O 0 7.885386565931185e-09
with O 0 2.3712344088266946e-08
cognitive B-Disease 0 0.00015057501150295138
impairment I-Disease 0 0.00033492487273178995
. O 0 2.752360330759984e-07

Two O 0 7.788482321302581e-07
altered O 0 1.4377045772562269e-05
Dp71 O 0 5.6972963648149744e-05
transcripts O 0 1.2054789294779766e-05
and O 0 6.208940561691634e-08
two O 0 4.854088242467469e-10
deleted O 0 1.0337724631881429e-07
Dp140 O 0 1.8575148530430852e-08
DNA O 0 3.44524039519456e-07
sequences O 0 1.1701804680797068e-07
were O 0 1.544061092317861e-07
found O 0 1.026843321483284e-07
in O 0 3.566835005130997e-08
four O 0 1.4115166777628474e-06
patients O 0 1.387360316584818e-05
with O 0 4.926754627376795e-05
severe O 1 0.9688246846199036
cerebral B-Disease 1 0.999344527721405
dysfunction I-Disease 1 0.8718658089637756
. O 0 1.7417669369024225e-06

These O 0 2.4147749400071916e-07
findings O 0 2.761804118733835e-08
suggest O 0 1.549669015332711e-08
that O 0 3.892246802639221e-10
some O 0 8.313775015644786e-12
sequences O 0 2.2370299745944067e-07
located O 0 1.5213247479550773e-06
in O 0 8.25642842983143e-08
the O 0 1.3069623605588276e-08
distal O 0 1.3896650443712133e-06
part O 0 9.902630893066089e-08
of O 0 1.5144576703818302e-09
the O 0 1.553436312917711e-08
gene O 0 1.1768926242439193e-06
and O 0 9.153334872280539e-07
, O 0 3.0518518823186014e-09
in O 0 1.149517703247227e-09
particular O 0 5.711078721049034e-09
, O 0 4.189343094651576e-09
some O 0 6.590305523523909e-10
DMD B-Disease 1 0.9999943971633911
isoforms O 0 3.4504984114391846e-07
expressed O 0 7.161631287999626e-09
in O 0 6.057191370700821e-08
the O 0 1.9064110574618098e-06
brain O 0 0.38233107328414917
may O 0 6.907384431542596e-06
be O 0 4.092546745937398e-09
related O 0 1.544363570360474e-08
to O 0 7.547346569936053e-08
the O 0 2.601504718313663e-07
cognitive B-Disease 0 0.004816058557480574
impairment I-Disease 0 0.0003636171168182045
associated O 0 8.175737775673042e-07
with O 0 9.571042937750462e-06
DMD B-Disease 1 0.9999998807907104
. O 0 3.6915921555191744e-06
. O 0 2.0489063956574682e-07

I1307K O 0 0.00011040663957828656
APC O 0 3.324207864352502e-05
and O 0 7.811378850419715e-07
hMLH1 O 0 6.3203583522408735e-06
mutations O 0 6.789947292418219e-06
in O 0 1.2298213114547707e-08
a O 0 9.881009788159645e-08
non O 0 6.793546845074161e-07
- O 0 0.26043665409088135
Jewish O 0 2.6226956833852455e-05
family O 0 7.963241159814061e-07
with O 0 1.7275554853313224e-07
hereditary B-Disease 0 0.410885751247406
non I-Disease 0 0.00020573513756971806
- I-Disease 1 0.9999411106109619
polyposis I-Disease 1 0.9999439716339111
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 2.3373613657895476e-05

We O 0 1.2435890312190168e-05
describe O 0 2.1249553583402303e-07
a O 0 4.153779187276996e-08
French O 0 1.5894698663032614e-05
Canadian O 0 5.399398651206866e-05
hereditary B-Disease 1 0.9624714851379395
non I-Disease 0 0.007774979341775179
- I-Disease 1 0.9999972581863403
polyposis I-Disease 1 0.9999963045120239
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0001346200006082654
HNPCC B-Disease 1 0.9422411322593689
) O 0 1.592661504901116e-07
kindred O 0 1.0697365723899566e-05
which O 0 1.6518882262062107e-07
carries O 0 2.838737600541208e-08
a O 0 3.4955515815227045e-08
novel O 0 5.913384484301787e-06
truncating O 0 1.913298365252558e-05
mutation O 0 5.038824383518659e-06
in O 0 1.7682449993117189e-07
hMLH1 O 0 7.083245873218402e-05
. O 0 2.077475613759816e-07

Interestingly O 0 7.626964361406863e-05
, O 0 2.9114101351979116e-08
the O 0 1.1466884108912723e-09
I1307K O 0 1.345321294365931e-07
APC O 0 1.4528494318710727e-07
polymorphism O 0 7.018239557510242e-06
, O 0 7.238548871413286e-09
associated O 0 3.547198978992583e-09
with O 0 1.4919083746178785e-09
an O 0 6.7860335128955285e-09
increased O 0 3.619762537709903e-06
risk O 0 0.00019959091150667518
of O 0 0.0038046478293836117
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.6677102394169196e-05
is O 0 2.861578707324952e-07
also O 0 1.4773845578019973e-06
present O 0 1.861466003560963e-08
in O 0 3.7512528194838524e-08
this O 0 7.663845735805808e-08
family O 0 4.726212807781849e-07
. O 0 1.354141261344921e-07

The O 0 1.2280145256227115e-07
I1307K O 0 2.63094818819809e-07
polymorphism O 0 9.85634142125491e-06
has O 0 5.215345595388499e-07
previously O 0 1.5762036298383464e-07
only O 0 9.253637855977104e-09
been O 0 1.345554920817449e-07
identified O 0 6.114872803664184e-07
in O 0 1.6457109452971963e-08
individuals O 0 6.36074803939124e-10
of O 0 2.914720242941371e-09
self O 0 0.013154271058738232
- O 0 0.3992884159088135
reported O 0 3.4157123991462868e-06
Ashkenazi O 0 2.6055147372971987e-06
Jewish O 0 3.8478439989830804e-08
origins O 0 2.2097978558122122e-07
. O 0 5.385754775488749e-08

In O 0 1.377287759396495e-07
addition O 0 1.3552801547689342e-08
, O 0 1.0338469635939873e-08
in O 0 3.646476676166799e-09
this O 0 1.563713070140693e-08
family O 0 1.6154159254710976e-07
, O 0 9.26801568823521e-09
there O 0 1.0010436035656767e-08
appears O 0 5.347758360585431e-07
to O 0 4.702209466245222e-08
be O 0 7.745034480421964e-08
no O 0 2.25288090405229e-08
relationship O 0 5.6596491049276665e-08
between O 0 1.9289439379122086e-08
the O 0 5.759407617489387e-09
I1307K O 0 1.5421318266817252e-07
polymorphism O 0 9.786502914721495e-07
and O 0 3.497105538485812e-08
the O 0 2.3489059586268013e-09
presence O 0 1.707193497679782e-08
or O 0 1.61981343893558e-08
absence O 0 2.1439650055299353e-08
of O 0 1.0355046597965156e-08
cancer B-Disease 0 0.0024121718015521765
. O 0 1.4370090006821101e-08
. O 0 6.206040126244261e-08

Identification O 0 1.1193357067895704e-06
of O 0 2.196946624621887e-09
a O 0 3.521382296867159e-08
novel O 0 2.548714064687374e-06
mutation O 0 5.082022767055605e-07
of O 0 8.223008385321862e-10
the O 0 2.2803765986623148e-08
CPO O 0 7.364377961494029e-05
gene O 0 1.221466732204135e-07
in O 0 1.0248041526494944e-08
a O 0 1.2120548831262568e-07
Japanese O 0 0.000581754429731518
hereditary B-Disease 0 0.40183934569358826
coproporphyria I-Disease 0 0.002900008112192154
family O 0 5.82611119170906e-06
. O 0 2.873962614557968e-07

Hereditary B-Disease 1 0.9987186193466187
coproporphyria I-Disease 1 0.8118526339530945
( O 0 4.302393335819943e-06
HCP B-Disease 0 0.376367449760437
) O 0 2.3262541049007268e-07
is O 0 1.2419533845786646e-07
an O 0 1.0044595910585485e-06
autosomal B-Disease 1 0.9999243021011353
dominant I-Disease 1 0.9999979734420776
disease I-Disease 1 0.9999933242797852
characterized O 0 0.007613067515194416
by O 0 2.586804157544975e-06
a O 0 0.0015794646460562944
deficiency B-Disease 1 0.849842369556427
of I-Disease 0 1.959118378636049e-08
coproporphyrinogen I-Disease 0 0.02799297124147415
oxidase I-Disease 0 6.463768659159541e-05
( O 0 1.0592949628573933e-08
CPO O 0 0.0005250020767562091
) O 0 5.787024637271543e-09
caused O 0 2.650287811434282e-08
by O 0 4.5972134432581413e-10
a O 0 1.3089556105683187e-08
mutation O 0 7.232465577544644e-07
in O 0 1.3575362167728144e-08
the O 0 4.860874724954556e-08
CPO O 0 0.00016722502186894417
gene O 0 1.4685740552522475e-06
. O 0 9.374406317874673e-08

Only O 0 5.343359248399793e-07
11 O 0 6.41078869989542e-08
mutations O 0 8.897782777239627e-08
of O 0 3.283074923032814e-10
the O 0 1.9360761882580846e-08
gene O 0 1.3402902823145268e-06
have O 0 6.219287911335414e-07
been O 0 4.718381205748301e-07
reported O 0 1.041284008351795e-06
in O 0 8.061952030402608e-07
HCP B-Disease 1 0.995628833770752
patients O 0 7.04468839103356e-05
. O 0 1.5112100015812757e-07

We O 0 3.567505700630136e-05
report O 0 1.1416173784084549e-08
another O 0 5.463701158170409e-10
mutation O 0 2.8115314520960055e-08
in O 0 1.1091342289049066e-09
a O 0 6.913652583762087e-08
Japanese O 0 0.00017987545288633555
family O 0 3.7043303109385306e-06
. O 0 3.51151044242215e-07

Polymerase O 0 0.0008184848120436072
chain O 0 7.752731471555308e-05
reaction O 0 1.0724543244577944e-06
- O 0 0.00010902689245995134
single O 0 4.4805767629441107e-07
strand O 0 3.2426535199192585e-06
conformational O 0 4.1769681047298945e-09
polymorphism O 0 2.6591189339342236e-07
and O 0 2.5206621234730164e-09
direct O 0 6.048562206650843e-10
sequence O 0 1.4323521213555068e-07
analyses O 0 1.5076629722443613e-07
demonstrated O 0 8.94081964020188e-09
a O 0 9.037863790695155e-09
C O 0 1.7777636458049528e-05
to O 0 2.4120134778371494e-09
T O 0 1.3508562233255361e-06
substitution O 0 6.181933298599063e-10
in O 0 3.3188363168790147e-10
exon O 0 1.2528799686606362e-07
1 O 0 2.1590912169244802e-08
of O 0 4.737122916154135e-10
the O 0 4.812587661717771e-09
CPO O 0 3.967916654801229e-06
gene O 0 8.715500321443415e-09
at O 0 9.753708951620865e-10
nucleotide O 0 9.785018129093714e-09
position O 0 2.406875125871011e-07
85 O 0 3.1021489377280886e-08
, O 0 7.753530262277764e-09
which O 0 5.474701580965302e-08
lies O 0 1.1093007969975588e-06
in O 0 2.8928983653031537e-09
the O 0 5.057699592470044e-09
putative O 0 2.0690113444743474e-07
presequence O 0 1.6363823078791029e-06
for O 0 3.097835321597131e-10
targeting O 0 2.9273243384864145e-08
to O 0 6.624209181183005e-09
mitochondria O 0 5.42937755199091e-07
. O 0 1.995074150329401e-08

This O 0 3.4605253773634104e-08
mutation O 0 9.466889849818472e-08
changes O 0 3.545697291329475e-09
the O 0 1.75676043157047e-10
codon O 0 1.4524927038905844e-08
for O 0 7.961622333629848e-11
glutamine O 0 7.366506959982644e-09
to O 0 1.0344420875441074e-09
a O 0 1.1660576948457901e-09
termination O 0 9.717859938973561e-08
codon O 0 2.891869144150405e-07
at O 0 2.0443346571141774e-08
amino O 0 2.1639891656377586e-08
acid O 0 2.511222589873796e-07
position O 0 1.0781030823636684e-07
29 O 0 2.3702288842741837e-07
. O 0 2.636649121257051e-08

MaeI O 0 9.340733959106728e-05
restriction O 0 5.841666848027671e-07
analysis O 0 7.558626435866245e-08
showed O 0 8.094115173662431e-07
two O 0 1.4389005542625455e-09
other O 0 8.010506147293484e-10
carriers O 0 7.755753017590905e-08
in O 0 2.282386901697464e-08
the O 0 8.43737311129189e-08
family O 0 1.5669307913412922e-06
. O 0 2.421065516955423e-07

The O 0 7.422243015753338e-06
C O 0 0.03919026628136635
- O 1 0.6012620329856873
T O 1 0.7610575556755066
mutation O 0 4.780050403496716e-06
is O 0 5.3322839477232264e-09
located O 0 1.6419141601886622e-08
within O 0 3.5812697252168846e-10
a O 0 3.869280007506859e-09
recently O 0 2.335735018732521e-07
proposed O 0 4.506406359183757e-09
putative O 0 6.187318035699718e-08
alternative O 0 2.6632589467112666e-09
translation O 0 2.07505923555118e-08
initiation O 0 2.531705511898963e-09
codon O 0 1.276723651244538e-07
( O 0 2.579481905851111e-10
TIC O 0 4.96056827614666e-07
- O 0 3.6695771541417344e-06
1 O 0 1.5180560808403243e-08
) O 0 2.2032023427875913e-10
, O 0 9.969478020899203e-11
supporting O 0 1.5741440373417959e-09
that O 0 3.35840937282228e-08
TIC O 0 2.1852038116776384e-05
- O 0 4.729129796032794e-05
1 O 0 5.11305735528822e-08
is O 0 1.293434515048375e-08
the O 0 6.66059607468128e-09
real O 0 4.941483098264143e-07
TIC O 0 5.313754172675544e-06
rather O 0 3.8563480186937227e-10
than O 0 2.371444707272019e-10
TIC O 0 6.20641640125541e-06
- O 0 9.855025382421445e-06
2 O 0 4.716518375857959e-08
. O 0 3.1863427452094584e-09
. O 0 1.2787507941425247e-08

Human B-Disease 0 3.3240808079426643e-06
complement I-Disease 0 3.916239620593842e-06
factor I-Disease 0 0.00020541876438073814
H I-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9998123049736023
associated O 0 0.0002904021821450442
with O 0 0.051460109651088715
hemolytic B-Disease 1 0.999998927116394
uremic I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999990463256836
. O 0 7.81690760049969e-05

This O 0 7.441270355457164e-08
study O 0 6.8016481336030665e-09
reports O 0 1.0069359568376512e-08
on O 0 6.323930534790634e-08
six O 0 6.29620089398486e-08
cases O 0 1.266657676524119e-07
of O 0 7.064777491905261e-07
deficiency B-Disease 1 0.6261338591575623
in I-Disease 0 3.65684940106803e-08
the I-Disease 0 2.944077515110166e-08
human I-Disease 0 1.8856548322787603e-08
complement I-Disease 0 3.083964861261279e-09
regulatory I-Disease 0 3.587499630697266e-09
protein I-Disease 0 4.7200732211649665e-08
Factor I-Disease 0 8.247281471085444e-07
H I-Disease 1 0.9999983310699463
( O 0 1.1649911257904932e-08
FH O 0 0.0009892620146274567
) O 0 9.66024815696187e-10
in O 0 2.004218041529171e-10
the O 0 2.348080618830295e-10
context O 0 2.439468183013105e-09
of O 0 1.0736619593387786e-08
an O 0 0.0001084560644812882
acute B-Disease 1 0.9999669790267944
renal I-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
. O 0 2.45982882915996e-05

Five O 0 3.08126828940658e-07
of O 0 6.954565812122837e-10
the O 0 2.6041462319881248e-09
cases O 0 6.610426872555308e-09
were O 0 2.538994436918074e-08
observed O 0 1.1184270931607898e-07
in O 0 2.3714061825330646e-08
children O 0 5.4105171898299886e-08
presenting O 0 8.85103816017363e-07
with O 0 0.0009910502703860402
idiopathic O 1 0.9999994039535522
hemolytic B-Disease 1 0.9999997615814209
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 0.00010668319009710103
HUS B-Disease 1 0.9999878406524658
) O 0 5.716024588764412e-06
. O 0 1.2582122508320026e-06

Two O 0 1.0217676305046552e-07
of O 0 1.1266263477693883e-09
the O 0 4.396932595795988e-08
children O 0 7.670089985367667e-08
exhibited O 0 1.6526427089047502e-06
a O 0 7.23870357433043e-07
homozygous O 0 0.25218701362609863
deficiency O 1 0.8482123613357544
characterized O 0 9.666054211265873e-06
by O 0 4.397083586127337e-08
the O 0 1.8718554883889738e-07
absence O 0 3.827209837936607e-08
of O 0 2.2109183928087361e-10
the O 0 4.779153961464999e-09
150 O 0 6.560707532798915e-10
- O 0 5.821534614369739e-06
kD O 0 5.057171961198037e-07
form O 0 5.84775117218328e-09
of O 0 4.200078063121282e-10
Factor O 0 9.263094398193061e-07
H O 1 0.9999995231628418
and O 0 1.9414589758071088e-07
the O 0 8.094472314645884e-10
presence O 0 2.0768755604194666e-09
, O 0 9.127765904226592e-11
upon O 0 2.4111187005293466e-11
immunoblotting O 0 1.1907820862688823e-07
, O 0 5.617804138546845e-11
of O 0 8.515185084823074e-12
the O 0 8.631456660523895e-10
42 O 0 6.732928881092448e-09
- O 0 8.48881597903528e-07
kD O 0 5.770185111941828e-07
Factor O 0 8.165780940316836e-08
H O 1 0.9999755620956421
- O 0 5.320052423485322e-06
like O 0 3.369239465200735e-08
protein O 0 8.098105297449365e-09
1 O 0 1.5130947605968004e-09
( O 0 1.0755177998200693e-10
FHL O 0 7.711013836342318e-07
- O 0 2.2999181965133175e-05
1 O 0 4.285961452410447e-08
) O 0 6.637536631437513e-10
and O 0 5.335508923565158e-09
other O 0 4.0075665008743044e-10
FH O 0 0.006942341569811106
- O 0 2.2001231627655216e-05
related O 0 1.1841051872352182e-07
protein O 0 8.483232250000583e-07
( O 0 3.3350320283176416e-09
FHR O 0 3.005949292855803e-05
) O 0 1.6568596494792587e-09
bands O 0 1.3405851007064484e-07
. O 0 6.903926674795002e-08

Southern O 0 3.4622303246578667e-06
blot O 0 0.0005669186939485371
and O 0 1.127951332335897e-08
PCR O 0 1.1098885721594343e-07
analysis O 0 6.290516996187989e-10
of O 0 2.7089707213545644e-11
DNA O 0 5.501244231709279e-06
of O 0 1.888608824884841e-09
one O 0 3.651942961369059e-07
patient O 0 1.4008464859216474e-05
with O 0 2.647050223458791e-07
homozygous O 0 0.0475725494325161
deficiency O 1 0.6073998212814331
ruled O 0 0.00011462580732768402
out O 0 2.4338983166671824e-06
the O 0 1.2181136987976515e-08
presence O 0 1.7205373126216728e-08
of O 0 1.0438282876945593e-10
a O 0 3.1960813995368653e-09
large O 0 1.0907318603869953e-08
deletion O 0 7.22904530903179e-07
of O 0 1.0537849481906392e-09
the O 0 4.120330387991089e-08
FH O 0 0.0039376504719257355
gene O 0 8.29587634143536e-08
as O 0 5.857418106103296e-09
the O 0 6.306149380463921e-09
underlying O 0 1.1174093742738478e-05
defect O 0 2.7548403522814624e-05
for O 0 4.201425873873177e-09
the O 0 2.1713212845497765e-06
deficiency O 0 0.13691304624080658
. O 0 1.1608260308548779e-07

The O 0 7.121674343579798e-07
other O 0 2.734045212449132e-09
four O 0 2.047854685827133e-08
children O 0 1.9195811162830978e-08
presented O 0 2.708799407002971e-08
with O 0 8.037255838644342e-07
heterozygous O 0 0.05344714596867561
deficiency O 1 0.8393682241439819
and O 0 1.1895259603988961e-06
exhibited O 0 3.8220127862587105e-06
a O 0 3.5747530091612134e-07
normal O 0 2.3542704639112344e-06
immunoblotting O 0 6.456307892221957e-05
pattern O 0 3.169301271555014e-05
of O 0 8.968210618576222e-10
proteins O 0 2.022815337454631e-08
of O 0 1.024920814884922e-09
the O 0 6.328581889647467e-07
FH O 1 0.6441260576248169
family O 0 5.560236218116188e-07
. O 0 3.7306886468968514e-08

Factor B-Disease 1 0.51655113697052
H I-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9998487234115601
is O 0 5.257022053228866e-07
the O 0 1.8782698418817745e-07
only O 0 1.4145166460366454e-05
complement B-Disease 1 0.9999972581863403
deficiency I-Disease 1 0.9999996423721313
associated O 0 7.153699698392302e-06
with O 0 4.924157110508531e-06
HUS B-Disease 1 0.9999760389328003
. O 0 1.3533109267882537e-05

These O 0 1.0757223378732306e-07
observations O 0 1.4996525976584962e-07
suggest O 0 2.035121937637996e-08
a O 0 5.701520366940827e-10
role O 0 5.826208404613453e-09
for O 0 6.62481580704366e-09
FH O 0 0.14770185947418213
and O 0 6.291159024840454e-07
/ O 0 9.571033842803445e-06
or O 0 7.878578855979868e-08
FH O 0 0.0028754808008670807
receptors O 0 2.2039995428713155e-07
in O 0 7.580164052001237e-09
the O 0 2.4981488877529046e-08
pathogenesis O 0 0.0001259793934877962
of O 0 3.419472704990767e-07
idiopathic O 1 0.9999115467071533
HUS B-Disease 1 0.9999853372573853
. O 0 4.838000677409582e-06
. O 0 2.7257036094852083e-07

Further O 0 2.6485247417440405e-07
evidence O 0 5.672726288707963e-08
for O 0 5.775642186733876e-10
a O 0 4.59667193197788e-09
major O 0 1.1594647020274351e-08
ancient O 0 1.3395899713941617e-06
mutation O 0 0.00849292054772377
underlying O 1 0.7848899364471436
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999996423721313
from O 0 2.734047370722692e-07
linkage O 0 0.016940027475357056
disequilibrium O 0 0.025719434022903442
studies O 0 5.039748316448822e-07
in O 0 7.655193812183825e-09
the O 0 2.4133079534749413e-08
Japanese O 0 2.3234902073454577e-06
population O 0 8.129909190301987e-09
. O 0 2.626329731469923e-08

The O 0 0.001410393393598497
myotonic B-Disease 1 0.9999916553497314
dystrophy I-Disease 1 0.9999992847442627
( O 0 0.0005833037430420518
DM B-Disease 1 0.9999992847442627
) O 0 7.661604286113288e-06
mutation O 0 5.337606489774771e-05
is O 0 1.2503805635333265e-07
an O 0 9.256995525674938e-08
unstable O 0 0.01445814874023199
( O 0 1.8766096232525342e-08
CTG O 0 5.161514309293125e-06
) O 0 1.3307173141186013e-09
n O 0 1.657836151025549e-06
repeat O 0 2.768408739939332e-05
, O 0 1.326331755535648e-08
present O 0 1.1947896005892744e-09
at O 0 1.8622108299837237e-09
a O 0 3.4419456174106244e-10
copy O 0 3.592665223095537e-07
number O 0 4.305057199616158e-09
of O 0 3.888039334931648e-10
5 O 0 1.5107762862953678e-07
- O 0 0.0003777120728045702
37 O 0 1.5567353273127083e-07
repeats O 0 8.031776701500348e-07
on O 0 7.75888935322655e-08
normal O 0 3.629422806739058e-08
chromosomes O 0 5.784191614566225e-08
but O 0 2.8426536680115078e-09
amplified O 0 1.6415164338923205e-08
to O 0 2.3003819682454463e-10
50 O 0 1.0017626311809025e-10
- O 0 2.068555602363631e-07
3000 O 0 5.393482549465034e-09
copies O 0 5.314345941087595e-08
on O 0 1.0220681360806338e-05
DM B-Disease 1 0.9999947547912598
chromosomes O 0 0.00021326157730072737
. O 0 1.0517858584080386e-07

Previous O 0 1.2053730642946903e-05
findings O 0 5.443463919618807e-07
in O 0 8.593006306512052e-09
Caucasian O 0 7.071530126268044e-05
populations O 0 4.6480565174533695e-07
of O 0 2.197202420006761e-09
a O 0 4.61248419014737e-05
DM B-Disease 1 0.9999998807907104
founder O 0 0.06802878528833389
chromosome O 0 0.017621053382754326
raise O 0 1.5189633018053428e-07
a O 0 1.307094432689837e-08
question O 0 1.5078375881216743e-08
about O 0 1.0724252597071882e-09
the O 0 1.336889154934795e-09
molecular O 0 7.362998388771302e-08
events O 0 1.351480438671615e-08
involved O 0 3.566649420250201e-09
in O 0 2.206546945160426e-09
the O 0 1.932393356440798e-09
expansion O 0 5.42808322734345e-07
mutation O 0 9.029507737068343e-07
. O 0 3.67518318000748e-08

To O 0 1.234277249295701e-07
investigate O 0 3.146160310052437e-08
whether O 0 3.65399599466798e-09
a O 0 5.185931684081879e-09
founder O 0 2.2218205231183674e-06
chromosome O 0 8.248001540778205e-05
for O 0 1.584434805579349e-08
the O 0 2.50701350523741e-06
DM B-Disease 1 0.9999998807907104
mutation O 0 0.000407292100135237
exists O 0 3.8000570157237235e-07
in O 0 2.5904582923175212e-09
the O 0 1.2716583341898513e-08
Japanese O 0 1.0765926163003314e-05
population O 0 8.010188956575348e-09
, O 0 5.95698335104089e-09
we O 0 6.198161628390153e-08
genotyped O 0 1.7588936884749273e-07
families O 0 8.625560682373745e-11
using O 0 7.490176812119387e-10
polymorphic O 0 1.7753043835000426e-07
markers O 0 0.0003163991787005216
near O 0 7.381329851341434e-06
the O 0 6.254034445873913e-08
( O 0 1.865011700630248e-09
CTG O 0 1.3812538099955418e-06
) O 0 9.841839565538635e-10
n O 0 9.709168580229743e-07
repeat O 0 1.5959190932335332e-05
region O 0 8.458721367787803e-07
and O 0 2.6244777018291643e-07
constructed O 0 0.00011428638390498236
haplotypes O 0 0.00015696992340963334
. O 0 2.362585291848518e-07

Six O 0 3.009158717759419e-07
different O 0 2.36968689115713e-09
haplotypes O 0 2.550868657635874e-06
were O 0 4.730501075300708e-07
found O 0 7.056696631480008e-07
and O 0 2.770940909613273e-06
DM B-Disease 1 0.9999984502792358
alleles O 0 9.324115126219112e-06
were O 0 1.1210578350073774e-06
always O 0 5.56293059617019e-07
haplotype O 0 5.285815859679133e-06
A O 0 2.2818528577772668e-06
. O 0 3.151163241454924e-07

To O 0 6.46736907583545e-07
find O 0 3.28544622618665e-08
an O 0 9.560927743956782e-11
origin O 0 9.449419025031602e-10
of O 0 5.159045413094532e-10
the O 0 3.6261152303040944e-08
( O 0 1.624751000406377e-09
CTG O 0 7.626456977050111e-07
) O 0 7.403492263691192e-10
n O 0 6.727090635649802e-07
repeat O 0 7.326047580136219e-06
mutation O 0 1.6226200614255504e-06
and O 0 2.3159674356065807e-07
to O 0 1.0241612891093155e-08
investigate O 0 1.1040185654564993e-08
the O 0 2.146492539267797e-09
mechanism O 0 1.8009696844956125e-08
of O 0 6.194867535613824e-11
the O 0 7.187409001296885e-10
expansion O 0 8.005412155398517e-08
mutation O 0 5.344148235053581e-08
in O 0 9.735550143830096e-10
the O 0 9.370023867916188e-09
Japanese O 0 2.8013880637445254e-06
population O 0 1.8754207076199236e-09
we O 0 1.306748043106154e-08
have O 0 1.6302539873613853e-10
studied O 0 9.360338060204754e-10
90 O 0 1.1829325297085802e-09
Japanese O 0 7.563783583464101e-06
DM B-Disease 1 0.999998927116394
families O 0 1.707457286670433e-08
comprising O 0 5.949168380148251e-10
190 O 0 1.3325212933068542e-08
affected O 0 3.249753177669845e-08
and O 0 1.180458397698203e-08
130 O 0 1.4502863798782073e-08
unaffected O 0 1.7778351093511446e-06
members O 0 2.029144186010967e-09
. O 0 3.04612512991298e-08

The O 0 2.010393473028671e-06
results O 0 8.824749784253072e-07
suggest O 0 4.2074910311384883e-07
that O 0 1.1258062926344792e-08
a O 0 8.602124346168694e-09
few O 0 2.0504499431694967e-08
common O 0 3.7500793581557446e-08
ancestral O 0 1.8981892253577826e-06
mutations O 0 3.899915554939071e-06
in O 0 3.571225803966627e-08
both O 0 1.0754967405546267e-07
Caucasian O 0 0.006437742151319981
and O 0 1.3322743370736134e-06
Japanese O 0 4.346405603428138e-06
populations O 0 5.608957920344437e-08
have O 0 4.353876814633395e-09
originated O 0 1.948964989395563e-09
by O 0 1.0625943874797983e-10
expansion O 0 6.120786100183295e-09
of O 0 8.086397523809907e-11
an O 0 8.875739587743681e-10
ancestral O 0 1.6781381191321998e-06
n O 0 8.167564374161884e-05
= O 0 5.263892944640247e-06
5 O 0 3.4811253879496462e-09
repeat O 0 1.1119084319943795e-06
to O 0 2.057148584810875e-08
n O 0 1.3094373571220785e-05
= O 0 1.3301161743584089e-05
19 O 0 9.316528348790598e-08
- O 0 4.4570961108547635e-06
37 O 0 1.2505469548784731e-08
copies O 0 4.5573202100968047e-08
. O 0 5.797633662041335e-08

These O 0 7.560615955526373e-08
data O 0 1.7362390636321834e-08
support O 0 5.162243965628477e-10
multistep O 0 2.0387544097388854e-08
models O 0 3.1081430051926873e-07
of O 0 1.3053697012210819e-09
triplet O 0 0.011354105547070503
repeat O 0 0.00017412261513527483
expansion O 0 9.448792752664303e-07
that O 0 3.0935404993215343e-07
have O 0 1.7267936414100404e-08
been O 0 1.7783037264962331e-09
proposed O 0 7.479013519606781e-10
for O 0 9.664288924682296e-09
both O 0 5.872573183296481e-06
DM B-Disease 1 0.9999997615814209
and O 0 0.0025470934342592955
Friedreichs B-Disease 0 0.10602662712335587
ataxia I-Disease 1 0.9903732538223267
. O 0 5.079260745333158e-07
. O 0 1.0149363305345105e-07

The O 0 3.647424762220908e-08
molecular O 0 9.351762031428734e-08
basis O 0 1.2765701740136137e-07
of O 0 2.469034370733425e-05
C6 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
in O 0 7.832227879589482e-07
the O 0 1.3657918884746323e-07
western O 0 3.7169991173868766e-06
Cape O 0 2.971659569084295e-06
, O 0 2.792924336247893e-09
South O 0 8.104799320562961e-08
Africa O 0 2.5307317130796037e-08
. O 0 2.067914728343112e-09

Deficiency B-Disease 1 0.9993337988853455
of I-Disease 0 5.465447117103395e-08
the I-Disease 0 1.2537478255580936e-07
sixth I-Disease 0 1.140785388997756e-05
component I-Disease 0 1.09594154196202e-07
of I-Disease 0 2.325715398043826e-09
human I-Disease 0 2.1233894642591622e-07
complement I-Disease 0 3.8254518130997894e-07
( O 0 4.207985959681082e-09
C6 O 0 0.004593383986502886
) O 0 1.5219670856936318e-08
has O 0 3.5248569929535734e-07
been O 0 3.4815627714124275e-07
reported O 0 3.5131719755554514e-07
in O 0 3.992058683621735e-09
a O 0 6.396593477120405e-09
number O 0 4.590051005948226e-08
of O 0 3.1607143569090113e-09
families O 0 6.592320467291302e-09
from O 0 2.1160041774326288e-10
the O 0 3.109593693650936e-09
western O 0 5.670443101735145e-07
Cape O 0 4.864130005444167e-07
, O 0 8.472618162613799e-10
South O 0 8.548692420617954e-08
Africa O 0 6.876273772604691e-09
. O 0 3.004434256936861e-09

Meningococcal B-Disease 1 0.999492883682251
disease I-Disease 1 0.9998893737792969
is O 0 9.734349077916704e-07
endemic O 0 6.316691383290163e-07
in O 0 5.6215746724319615e-08
the O 0 2.448188922699046e-07
Cape O 0 7.922179065644741e-06
and O 0 5.930888136163048e-08
almost O 0 1.3356530326191773e-09
all O 0 4.662586983172901e-10
pedigrees O 0 2.0624294450044545e-07
of O 0 9.769110853596885e-09
total O 0 0.011887636035680771
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
( O 0 3.243994513013604e-07
C6Q0 O 0 0.023175647482275963
) O 0 3.331962616925921e-08
have O 0 1.4697745598368783e-07
been O 0 2.2591035531149828e-07
ascertained O 0 8.091089512163308e-06
because O 0 1.2135885185671214e-07
of O 0 8.679141672018886e-08
recurrent O 1 0.9998490810394287
disease O 1 0.9986977577209473
. O 0 7.400068398055737e-07

We O 0 3.9411490433849394e-05
have O 0 1.4252170110751194e-08
sequenced O 0 5.249377110772002e-08
the O 0 8.913469407012542e-10
expressed O 0 4.034632627991641e-10
exons O 0 7.614523269694473e-07
of O 0 2.6585034174075872e-09
the O 0 2.2658435128164456e-08
C6 O 0 7.691369683016092e-05
gene O 0 3.4556975947452884e-08
from O 0 3.4479971655621e-10
selected O 0 1.1787866682766435e-08
cases O 0 1.0490430213394575e-07
and O 0 8.294202416436747e-06
have O 0 1.7994987047131872e-06
found O 0 5.331630745786242e-07
three O 0 2.043183400246562e-07
molecular O 0 0.007002711296081543
defects O 1 0.9989823698997498
leading O 0 0.00012125052307965234
to O 0 2.114607923431322e-06
total O 0 1.3009435861022212e-05
deficiency O 0 0.4317677915096283
879delG O 0 3.9915954403113574e-05
, O 0 1.564264096032275e-07
which O 0 2.741195999078627e-07
is O 0 4.979716905495479e-08
the O 0 6.147170950043801e-08
common O 0 9.044451871886849e-07
defect O 0 3.834236486000009e-05
in O 0 1.2287169504077156e-08
the O 0 7.26955846630517e-08
Cape O 0 6.679498710582266e-06
and O 0 2.357336192915227e-08
hitherto O 0 1.3202280513269216e-07
unreported O 0 1.2618777134321135e-08
, O 0 6.776126770802193e-09
and O 0 1.1258062926344792e-08
1195delC O 0 4.4075966343370965e-07
and O 0 1.1203743355281404e-07
1936delG O 0 1.4164440926833777e-06
, O 0 1.2567784146710892e-08
which O 0 2.8107377758601615e-08
have O 0 1.979329233847693e-08
been O 0 3.125936842707233e-08
previously O 0 2.107546208662825e-07
reported O 0 2.256534799016663e-07
in O 0 2.0548897694538937e-08
African O 0 1.9593688449504043e-08
- O 0 7.429016113746911e-05
Americans O 0 1.5486105553463858e-07
. O 0 1.1042629033397589e-08

We O 0 0.0001048465637722984
also O 0 8.84625492858504e-08
show O 0 3.0198844314099915e-08
that O 0 2.7409061686967107e-09
the O 0 2.7209199338074086e-09
879delG O 0 2.7429075998952612e-05
and O 0 9.295661129726795e-07
1195delC O 0 0.00020929655875079334
defects O 1 0.7049303650856018
are O 0 9.774572262699621e-09
associated O 0 4.4539497423556895e-08
with O 0 2.265980185711669e-07
characteristic O 0 0.0175494197756052
C6 O 1 0.9981845021247864
/ O 0 0.0466485321521759
C7 O 0 0.05350281298160553
region O 0 1.971247684195987e-06
DNA O 0 0.0014905473217368126
marker O 0 0.0002899888495448977
haplotypes O 0 6.761726399417967e-05
, O 0 5.626702659355942e-08
although O 0 4.853183188657795e-09
small O 0 3.047093910524268e-09
variations O 0 2.3150189463194693e-06
were O 0 5.557909048548026e-07
observed O 0 1.2848282722188742e-06
. O 0 2.10549714552144e-07

The O 0 6.732013275723148e-07
1936delG O 0 2.6331714252592064e-05
defect O 0 0.00016440462786704302
was O 0 5.975923045298259e-07
observed O 0 2.02252223857613e-08
only O 0 9.003623624437296e-09
once O 0 3.280518399151333e-07
in O 0 9.084111241008941e-09
the O 0 7.188168638094794e-08
Cape O 0 3.538170858519152e-06
, O 0 3.139325244205793e-09
but O 0 3.1807925182647523e-09
its O 0 1.8579736360546661e-10
associated O 0 4.092453043114119e-09
haplotype O 0 3.4788022276188713e-06
could O 0 8.501113484271627e-07
be O 0 1.5943721010103218e-08
deduced O 0 4.4564399104274344e-07
. O 0 1.9933548145445457e-08

The O 0 6.729374746328176e-08
data O 0 1.3838391055287502e-07
from O 0 2.7233848509666814e-10
the O 0 1.28219868056334e-09
haplotypes O 0 4.202063792035915e-06
indicate O 0 2.7296182452118956e-06
that O 0 1.1742697836325533e-07
these O 0 4.243506435130939e-09
three O 0 2.145159427868748e-08
molecular O 0 0.00148212187923491
defects O 1 0.9972010850906372
account O 0 5.190447041059087e-07
for O 0 6.682345343733687e-08
the O 0 2.287419374624733e-05
defects O 1 0.9886581301689148
in O 0 7.341107988168005e-08
all O 0 1.535818583420223e-08
the O 0 4.558415511723979e-08
38 O 0 2.4153712274710415e-07
unrelated O 0 1.3111349517203053e-07
C6Q0 O 0 0.0018012758810073137
individuals O 0 8.346359159361327e-09
we O 0 8.2759001429622e-08
have O 0 3.0784406135353493e-09
studied O 0 1.2065014765028081e-08
from O 0 2.9231256304385056e-10
the O 0 1.3817735400323272e-08
Cape O 0 3.717800154845463e-06
. O 0 3.712184337700819e-08

We O 0 2.7555026463232934e-05
have O 0 6.850605416275357e-08
also O 0 9.182693716525137e-09
observed O 0 5.529130930881365e-09
the O 0 1.9118848726407123e-09
879delG O 0 7.938589988043532e-06
defect O 0 2.071900962619111e-05
in O 0 2.223896444775164e-08
two O 0 1.9130804957967484e-06
Dutch O 1 0.9998152852058411
C6 B-Disease 1 1.0
- I-Disease 1 0.9999979734420776
deficient I-Disease 1 0.9999997615814209
kindreds O 0 0.2351151406764984
, O 0 9.081204410676946e-08
but O 0 1.2885516653682316e-08
the O 0 2.6338782266321914e-09
879delG O 0 6.132490852905903e-06
defect O 0 5.501653504325077e-06
in O 0 2.7921203127334593e-09
the O 0 1.5832958055739255e-08
Cape O 0 1.4494838751488714e-06
probably O 0 6.429499990190379e-07
did O 0 1.12885352621106e-07
not O 0 1.3604748438922343e-09
come O 0 1.2720209607852695e-10
from O 0 1.5451128224097666e-11
The O 0 2.0841772752078214e-09
Netherlands O 0 1.4166953405947424e-06
. O 0 3.964484296403725e-09
. O 0 1.3256868491851037e-08

Complement B-Disease 1 0.9988196492195129
C7 I-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9999997615814209
: O 0 6.135667263151845e-06
seven O 0 6.645802130833545e-08
further O 0 4.6734541570003785e-08
molecular O 0 0.012476478703320026
defects O 1 0.9999749660491943
and O 0 4.330699084675871e-06
their O 0 1.3739450821503851e-07
associated O 0 8.771687021180696e-07
marker O 0 0.001714213052764535
haplotypes O 0 0.0010760389268398285
. O 0 9.533741831546649e-07

Seven O 0 5.344403462004266e-07
further O 0 6.525106677202075e-09
molecular O 0 6.161198484733177e-07
bases O 0 4.240541329636471e-06
of O 0 7.639725663466379e-05
C7 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
are O 0 2.5108156478381716e-06
described O 0 4.873284342465922e-05
. O 0 8.153530188792502e-07

All O 0 1.2670744808929157e-07
these O 0 2.310320601495164e-09
new O 0 4.850777113318827e-09
molecular O 0 1.746218003972899e-05
defects O 0 0.14374850690364838
involve O 0 4.857566082705489e-08
single O 0 7.893582733231597e-06
- O 0 0.00011938914394704625
nucleotide O 0 1.009823904496443e-06
events O 0 5.261776436782384e-08
, O 0 1.8934638301715268e-09
deletions O 0 4.0748055596395716e-08
and O 0 2.263802940660753e-07
substitutions O 0 8.339869594919946e-08
, O 0 1.6807891745074244e-09
some O 0 2.3444322871934986e-11
of O 0 3.07895597906338e-10
which O 0 3.2103770308822277e-07
alter O 0 1.348217574559385e-05
splice O 0 7.194570207502693e-05
sites O 0 1.466886033085757e-06
, O 0 9.97319649087558e-09
and O 0 1.6005513359118595e-08
others O 0 9.03491681469859e-09
codons O 0 9.116397450270597e-07
. O 0 5.3280576395309254e-08

They O 0 6.465324531745864e-06
are O 0 1.1166313429455954e-09
distributed O 0 1.1225550489157854e-09
along O 0 4.035313949657393e-08
the O 0 4.1537475681252545e-08
C7 O 0 0.0007635592482984066
gene O 0 8.000777597771958e-06
, O 0 2.0474718809282422e-08
but O 0 1.0174862064005197e-09
predominantly O 0 1.716667502593694e-10
towards O 0 1.0172475084502253e-09
the O 0 2.4666801934358773e-09
3 O 0 1.9693131037001876e-07
end O 0 1.262224031961523e-06
. O 0 1.0530243343964685e-07

All O 0 8.659710033498413e-07
were O 0 3.1913803155703135e-08
found O 0 2.7918594103226724e-09
in O 0 7.175012806115433e-10
compound O 0 1.049921749540772e-07
heterozygous O 0 8.081797204795294e-07
individuals O 0 1.1523149545666911e-08
. O 0 5.418169735094125e-08

The O 0 2.321672764082905e-05
C6 O 0 0.3670864403247833
/ O 0 0.06482300162315369
C7 O 0 0.09757398813962936
marker O 0 0.006244965363293886
haplotypes O 0 0.001890053041279316
associated O 0 9.214194506057538e-06
with O 0 1.931762426465866e-06
most O 0 1.3480582310876343e-05
C7 B-Disease 1 0.9999622106552124
defects I-Disease 1 0.9999648332595825
are O 0 7.677026587771252e-07
tabulated O 0 0.0012157317250967026
. O 0 8.909501048037782e-08
. O 0 1.036030639056662e-07

A O 0 8.152464033628348e-06
genome O 0 8.046918082982302e-06
- O 0 0.00020799490448553115
wide O 0 9.18989655929181e-07
search O 0 4.425522703854767e-08
for O 0 1.7914446592826039e-09
chromosomal O 0 0.0011355014285072684
loci O 0 1.1270070672253496e-06
linked O 0 0.01166418008506298
to O 0 3.148317409795709e-05
mental O 1 0.6027610301971436
health O 0 1.1235451893298887e-05
wellness O 0 3.778251993935555e-05
in O 0 4.625716343298336e-08
relatives O 0 1.0501501179760453e-07
at O 0 1.2340642285835202e-07
high O 0 7.535502845712472e-06
risk O 0 8.35440823721001e-06
for O 0 7.668062949051091e-07
bipolar B-Disease 1 0.9999972581863403
affective I-Disease 1 0.99968421459198
disorder I-Disease 1 0.9918837547302246
among O 0 4.743167991705377e-08
the O 0 6.203129032655852e-08
Old O 0 0.002766964491456747
Order O 0 1.0497475955162372e-07
Amish O 0 0.0001431801065336913
. O 0 6.071672942198347e-08

Bipolar B-Disease 1 0.9999269247055054
affective I-Disease 1 0.999828577041626
disorder I-Disease 1 0.9999666213989258
( O 0 0.0003645764954853803
BPAD B-Disease 1 0.9999982118606567
; O 0 0.0013040308840572834
manic B-Disease 1 0.9999911785125732
- I-Disease 1 0.999998927116394
depressive I-Disease 1 0.9999997615814209
illness I-Disease 1 0.9999662637710571
) O 0 9.386197064031876e-08
is O 0 1.537415883490212e-08
characterized O 0 1.1736735814338317e-06
by O 0 9.481359697360858e-09
episodes O 0 8.587293450545985e-06
of O 0 1.4366409573085548e-07
mania B-Disease 1 0.9968628883361816
and O 0 8.226557838497683e-05
/ O 0 0.0017435778863728046
or O 0 1.1014473102477496e-06
hypomania B-Disease 0 0.29675161838531494
interspersed O 0 0.0007418461609631777
with O 0 5.771958058176097e-07
periods O 0 7.683877811359707e-06
of O 0 5.523473944890611e-08
depression B-Disease 0 0.0029815244488418102
. O 0 1.9333700151946687e-07

Compelling O 0 2.2494646145787556e-06
evidence O 0 3.236231975733972e-07
supports O 0 3.913742219197047e-08
a O 0 3.373700874220731e-09
significant O 0 1.545677252856592e-09
genetic O 0 1.0718081284721848e-06
component O 0 6.327332471300906e-07
in O 0 3.739636866839646e-08
the O 0 1.5120690477488097e-07
susceptibility O 0 0.0006243666866794229
to O 0 6.975495239203156e-07
develop O 0 6.271163874771446e-05
BPAD B-Disease 1 0.9999836683273315
. O 0 1.4813547295489116e-06

To O 0 4.630367982372263e-07
date O 0 1.2303489711484872e-06
, O 0 8.729341693936021e-09
however O 0 2.8696153009377667e-08
, O 0 7.412153113506292e-10
linkage O 0 7.810209353920072e-06
studies O 0 1.0917063519855219e-07
have O 0 6.626878246152046e-08
attempted O 0 6.658103757217759e-06
only O 0 1.7035569399581618e-08
to O 0 1.3716690894227668e-08
identify O 0 3.8409368130487564e-07
chromosomal O 0 0.0014312206767499447
loci O 0 6.606571787415305e-07
that O 0 5.685144969902467e-06
cause O 0 6.626841695833718e-06
or O 0 1.304047003714004e-07
increase O 0 2.799465619318653e-07
the O 0 1.0977339570672484e-06
risk O 0 6.266706805035938e-06
of O 0 1.5052716406671607e-08
developing O 0 5.558027987717651e-05
BPAD B-Disease 1 0.9999866485595703
. O 0 1.49208187849581e-06

To O 0 3.550968585841474e-07
determine O 0 5.1101228137895305e-08
whether O 0 9.065902695226669e-09
there O 0 5.28353965023598e-08
could O 0 1.2553334727272158e-06
be O 0 6.413990227827071e-09
protective O 0 2.014372739722603e-07
alleles O 0 1.454208575779603e-08
that O 0 4.544573357634363e-07
prevent O 0 1.3073596392132458e-06
or O 0 9.936005085364741e-08
reduce O 0 4.059906132169999e-06
the O 0 6.689243718938087e-07
risk O 0 2.431963139315485e-06
of O 0 2.58932209007412e-09
developing O 0 7.0323767431546e-06
BPAD B-Disease 1 0.9999988079071045
, O 0 2.5836158101810724e-08
similar O 0 2.2510113772966633e-09
to O 0 5.9555862463867015e-09
what O 0 1.601613064394769e-09
is O 0 1.0420961871204781e-09
observed O 0 9.92115456455167e-09
in O 0 1.135127458695706e-08
other O 0 1.2051430076098768e-06
genetic B-Disease 1 0.9999998807907104
disorders I-Disease 1 1.0
, O 0 1.9864487512677442e-06
we O 0 4.575376351567684e-06
used O 0 8.114580123219639e-05
mental O 0 0.38663139939308167
health O 0 1.4448671208810993e-05
wellness O 0 0.0008672418771311641
( O 0 8.724498457013397e-09
absence O 0 3.303933837628392e-08
of O 0 2.5341888587604444e-09
any O 0 3.924599695892539e-06
psychiatric B-Disease 1 0.8805435299873352
disorder I-Disease 0 0.2597188353538513
) O 0 3.832540951265173e-09
as O 0 2.654289410486399e-08
the O 0 2.0428890934454103e-07
phenotype O 0 5.8686608099378645e-05
in O 0 1.038210584169974e-07
our O 0 2.4830384859342303e-07
genome O 0 5.047853051109996e-07
- O 0 0.00018338666995987296
wide O 0 2.4810835839161882e-06
linkage O 0 4.052583972224966e-05
scan O 0 0.00025939877377822995
of O 0 3.471588572168116e-10
several O 0 5.148202975036043e-10
large O 0 2.657369257974551e-08
multigeneration O 0 0.00022838056611362845
Old O 0 0.0009684786782599986
Order O 0 2.6557072985156083e-08
Amish O 0 5.344191777112428e-06
pedigrees O 0 3.737440863460506e-07
exhibiting O 0 7.659593137532283e-08
an O 0 4.4488110972906725e-09
extremely O 0 3.7140367226129456e-07
high O 0 4.970127974956995e-06
incidence O 0 0.1023377776145935
of O 0 7.021299666121195e-07
BPAD B-Disease 1 0.999996542930603
. O 0 3.4590320865390822e-06

We O 0 0.00024796489742584527
have O 0 7.530938717081881e-08
found O 0 5.593581597906905e-09
strong O 0 2.4894477590464703e-09
evidence O 0 5.672863956363017e-09
for O 0 1.345214356573976e-10
a O 0 1.2286935024974355e-08
locus O 0 3.4145530207752017e-06
on O 0 7.695697604503948e-06
chromosome O 0 0.0003736878279596567
4p O 0 6.199903873493895e-05
at O 0 4.1929503424853465e-08
D4S2949 O 0 9.302908665631549e-08
( O 0 1.1910075703447376e-10
maximum O 0 2.156637091133007e-09
GENEHUNTER O 0 4.792562685906887e-05
- O 0 1.2416185199981555e-05
PLUS O 0 4.3687524708957426e-08
nonparametric O 0 5.890757961424242e-07
linkage O 0 1.499134123150725e-05
score O 0 8.674358468852006e-06
= O 0 7.777348969284503e-07
4 O 0 1.4853360319477815e-08
. O 0 2.8984048494606895e-09
05 O 0 8.708658242539968e-06
, O 0 7.3726211802238595e-09
P O 0 0.0008181916200555861
= O 0 5.325631263985997e-06
5 O 0 1.2241250679778659e-08
. O 0 7.947182356637938e-10
22 O 0 5.26047960747178e-09
x O 0 1.3250847587187309e-05
10 O 0 3.166804418697211e-08
( O 0 2.268315757447681e-09
- O 0 0.0004167313745710999
4 O 0 6.327223900370882e-07
) O 0 1.795436577189946e-09
; O 0 3.0166577569268327e-10
SIBPAL O 0 3.9203587220981717e-07
Pempirical O 0 8.428236952795487e-08
value O 0 1.7685340691908635e-10
< O 0 8.350593994066458e-09
3 O 0 9.767788355929952e-09
x O 0 2.385120387771167e-05
10 O 0 4.3659948545382576e-08
( O 0 1.8300069237753291e-09
- O 0 0.0006561270565725863
5 O 0 1.9953982643983181e-07
) O 0 1.8505369459020926e-09
) O 0 9.103915954433717e-10
and O 0 9.845900983407319e-09
suggestive O 0 1.5380456943603349e-06
evidence O 0 3.796267833422462e-08
for O 0 6.863691281999706e-10
a O 0 3.086861966039578e-08
locus O 0 8.784731107880361e-06
on O 0 3.7090194382471964e-05
chromosome O 0 0.06990495324134827
4q O 0 0.04430573433637619
at O 0 1.0891814383739984e-07
D4S397 O 0 1.3823631661580293e-07
( O 0 3.080724009230096e-10
maximum O 0 4.27957935755785e-09
GENEHUNTER O 0 4.989801163901575e-05
- O 0 1.9557715859264135e-05
PLUS O 0 4.024452948669932e-08
nonparametric O 0 3.082326429648674e-07
linkage O 0 1.2492017049225979e-05
score O 0 4.601000000548083e-06
= O 0 3.3085282780120906e-07
3 O 0 5.630328203665158e-09
. O 0 1.3507219787101121e-09
29 O 0 9.803628842064427e-08
, O 0 3.7852037060304156e-09
P O 0 5.5745040299370885e-05
= O 0 9.698358098830795e-07
2 O 0 1.0439248576687987e-08
. O 0 5.874321029608609e-10
57 O 0 1.0484185963832715e-08
x O 0 0.00015809260366950184
10 O 0 1.2808347094050987e-07
( O 0 7.419045822132375e-09
- O 0 0.0014024884440004826
3 O 0 4.349977871243027e-07
) O 0 1.1314543746365757e-09
; O 0 4.1519374049947544e-10
SIBPAL O 0 3.3527715004311176e-07
Pempirical O 0 5.402164404699761e-08
value O 0 2.7410301806085613e-10
< O 0 8.906914317208248e-09
1 O 0 8.803178630500952e-09
x O 0 0.00013031608250457793
10 O 0 8.271970131090711e-08
( O 0 6.129314389369256e-09
- O 0 0.01067912857979536
3 O 0 2.3024533675197745e-06
) O 0 5.682610826340806e-09
) O 0 6.334137103713999e-10
that O 0 1.0271289596630595e-08
are O 0 1.965480223020677e-09
linked O 0 0.00011389083374524489
to O 0 4.5687402234761976e-06
mental O 0 0.018094483762979507
health O 0 4.153765985392965e-06
wellness O 0 0.0003224650863558054
. O 0 1.16084713397413e-07

These O 0 2.1319369807315525e-06
findings O 0 3.0022189889677975e-07
are O 0 2.421758571458099e-09
consistent O 0 7.218023512223226e-08
with O 0 3.69441055525499e-09
the O 0 1.3469872328641941e-08
hypothesis O 0 1.3047725815340527e-06
that O 0 5.025744709286073e-09
certain O 0 2.7055280238386104e-10
alleles O 0 2.0980502668521694e-08
could O 0 7.210000148916151e-06
prevent O 0 3.7657702023352613e-07
or O 0 1.63785731643884e-08
modify O 0 2.704623057070421e-06
the O 0 1.3080875760351773e-07
clinical O 0 1.026292648020899e-05
manifestations O 0 6.556617790920427e-06
of O 0 2.8251079697838577e-07
BPAD B-Disease 1 0.9999998807907104
and O 0 1.330108534602914e-05
perhaps O 0 1.2782289893209509e-08
other O 0 1.623700840447384e-09
related O 0 4.626731879397994e-06
affective B-Disease 1 0.9989976286888123
disorders I-Disease 1 0.9989418387413025
. O 0 8.099103752101655e-07

Segregation O 0 0.004414786584675312
distortion O 0 0.09956157207489014
in O 0 3.155037484248169e-05
myotonic B-Disease 1 0.999985933303833
dystrophy I-Disease 1 0.9999979734420776
. O 0 4.8395322664873675e-05

Myotonic B-Disease 1 0.9999885559082031
dystrophy I-Disease 1 0.9999991655349731
( O 0 0.030151929706335068
DM B-Disease 1 0.9999994039535522
) O 0 1.2557175068650395e-05
is O 0 5.765603532381647e-07
an O 0 9.996737162509817e-07
autosomal B-Disease 1 0.999683141708374
dominant I-Disease 1 0.9999886751174927
disease I-Disease 1 0.9999973773956299
which O 0 0.0013999856309965253
, O 0 8.483978319873131e-08
in O 0 1.2738432531023136e-08
the O 0 5.0081879976460186e-08
typical O 0 4.702461410488468e-06
pedigree O 0 0.00011150254431413487
, O 0 1.0009265638544207e-09
shows O 0 4.170551459736771e-09
a O 0 1.1469268867969618e-09
three O 0 3.91382259934403e-09
generation O 0 2.4979919999168487e-07
anticipation O 0 3.4595355913324966e-08
cascade O 0 2.8673433916992508e-05
. O 0 8.969399090119623e-08

This O 0 7.659124889869418e-07
results O 0 1.7799592342271353e-06
in O 0 1.3522212611860596e-06
infertility B-Disease 1 0.9998984336853027
and O 1 0.9855816960334778
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00039349906728602946
CDM B-Disease 0 0.47902414202690125
) O 0 3.65132244439792e-08
with O 0 1.1819251355404958e-08
the O 0 3.485724775487142e-08
disappearance O 0 3.595390353439143e-06
of O 0 2.8394964601829997e-07
DM B-Disease 1 0.9999997615814209
in O 0 1.0610804110910976e-06
that O 0 4.532251125510811e-07
pedigree O 0 3.447174094617367e-05
. O 0 4.4619167027803996e-08

The O 0 3.316839780609371e-08
concept O 0 1.3013581323662038e-08
of O 0 9.122758104496143e-10
segregation O 0 8.826526936900336e-06
distortion O 0 0.00043439812725409865
, O 0 4.864536329307612e-09
where O 0 5.525536028727629e-09
there O 0 7.689198722182766e-10
is O 0 1.0266362759914216e-10
preferential O 0 2.617986272213102e-09
transmission O 0 1.307702677877387e-05
of O 0 2.0637842823578723e-10
the O 0 5.833366567564724e-10
larger O 0 1.5176963019669643e-09
allele O 0 3.7555910381570357e-08
at O 0 6.971092858520933e-08
the O 0 8.232306214495111e-08
DM B-Disease 1 0.9999979734420776
locus O 0 3.358846515766345e-05
, O 0 1.6807538827379176e-07
has O 0 1.5438298817116447e-07
been O 0 6.864561186148421e-08
put O 0 1.0896879985011765e-06
forward O 0 1.4216757904250699e-07
to O 0 1.2174632857409051e-08
explain O 0 1.749623805835654e-07
partially O 0 4.674061074183555e-06
the O 0 9.342131512823926e-09
maintenance O 0 3.729277295860811e-06
of O 0 5.0517535044036777e-08
DM B-Disease 1 0.9999996423721313
in O 0 9.808796903598704e-07
the O 0 3.8034720262203336e-08
population O 0 1.6615947728837455e-08
. O 0 3.1369445707696286e-08

In O 0 7.976589699865144e-08
a O 0 1.2464916210319643e-08
survey O 0 6.897055868648749e-07
of O 0 4.977378509352093e-09
DM B-Disease 1 0.9999992847442627
in O 0 1.4484197663477971e-06
Northern O 0 4.8987790250976104e-06
Ireland O 0 3.8316698010021355e-06
, O 0 4.1343328760490294e-09
59 O 0 9.456765326376626e-08
pedigrees O 0 1.3394111419984256e-06
were O 0 6.714311240330062e-08
ascertained O 0 7.3979053922812454e-06
. O 0 8.261374517815057e-08

Sibships O 0 0.0008249501115642488
where O 0 1.1348804491717601e-06
the O 0 3.6962217730973634e-09
status O 0 3.399305059659241e-09
of O 0 6.338572444697377e-10
all O 0 4.1931160765784625e-09
the O 0 4.089768523840576e-09
members O 0 1.32171898425959e-10
had O 0 3.322843156183808e-07
been O 0 1.2657055847853371e-08
identified O 0 6.663724150257622e-08
were O 0 5.508636657935995e-09
examined O 0 4.268641617954927e-08
to O 0 1.1537460986588144e-09
determine O 0 7.2599943834461556e-09
the O 0 1.9461976474843823e-09
transmission O 0 2.757774018391501e-05
of O 0 1.1038601144264248e-09
the O 0 2.2339536087656597e-07
DM B-Disease 1 0.9999990463256836
expansion O 0 5.674193289451068e-06
from O 0 1.571337193695399e-08
affected O 0 1.257974417967489e-07
parents O 0 3.0463574773875735e-08
to O 0 3.2868043842171346e-09
their O 0 1.4121233071762163e-08
offspring O 0 4.17771929051014e-07
. O 0 2.1773328029439654e-08

Where O 0 8.616519266979594e-07
the O 0 5.3647348785546e-09
transmitting O 0 2.4801731342449784e-05
parent O 0 5.626354777632514e-06
was O 0 3.620991719799349e-06
male O 0 2.568968113791925e-07
, O 0 2.327077641695041e-09
58 O 0 1.3159328204892518e-07
. O 0 4.3388737935856625e-08

3 O 0 9.49962554841477e-07
% O 0 3.1246354392777675e-09
of O 0 3.503050072239944e-10
the O 0 2.957314748641693e-08
offspring O 0 9.909883829095634e-07
were O 0 1.8202922547061462e-07
affected O 0 1.2752536804327974e-07
, O 0 4.025674016361336e-08
and O 0 8.845361065823454e-08
in O 0 1.2459685727606029e-08
the O 0 1.4585587848614523e-08
case O 0 1.2725347176001378e-07
of O 0 3.2271366134928314e-10
a O 0 1.4732830777575145e-07
female O 0 9.361592105960881e-07
transmitting O 0 1.948050339706242e-05
parent O 0 4.899709438177524e-07
, O 0 3.6677025860853973e-09
68 O 0 2.763802058325382e-07
. O 0 2.3764005874227223e-08

7 O 0 8.157986485457513e-06
% O 0 2.879269977995591e-08
were O 0 5.037417238895614e-08
affected O 0 1.9538758522230637e-07
. O 0 1.1737100180653215e-07

Studies O 0 2.6266661734553054e-06
on O 0 1.4460249531111913e-07
meiotic O 0 3.23302301694639e-05
drive O 0 0.00010174123599426821
in O 0 1.200044863480798e-07
DM B-Disease 1 0.9999985694885254
have O 0 4.773963610205101e-06
shown O 0 4.8333063773498e-08
increased O 0 1.4542751003432386e-08
transmission O 0 2.96931521006627e-05
of O 0 2.1517793102887595e-10
the O 0 6.987247447298728e-10
larger O 0 1.6015886394882273e-09
allele O 0 3.9174018695575796e-08
at O 0 4.0984385663023204e-08
the O 0 6.878178737679264e-08
DM B-Disease 1 0.999996542930603
locus O 0 2.7877586035174318e-06
in O 0 4.236351713871045e-08
non O 0 3.806001700468187e-07
- O 1 0.7487205266952515
DM O 1 0.9999954700469971
heterozygotes O 0 3.676049891510047e-05
for O 0 2.811177424177913e-08
CTGn O 0 0.00015836914826650172
. O 0 1.8369256338246487e-07

This O 0 2.291659200182039e-07
study O 0 2.9010152058361882e-09
provides O 0 8.970332254776281e-10
further O 0 4.025025035492291e-10
evidence O 0 1.593764054064195e-08
that O 0 2.4040184953832977e-08
the O 0 8.761306702353977e-08
DM B-Disease 1 0.9999984502792358
expansion O 0 2.4848653993103653e-05
tends O 0 1.1505907195896725e-06
to O 0 3.1958620194671994e-09
be O 0 3.5218978844397952e-09
transmitted O 0 7.439438718392921e-07
preferentially O 0 1.2256580816938367e-07
. O 0 2.3509018731715514e-08

Diagnosis O 1 0.9707226157188416
of O 0 9.974766726372764e-06
hemochromatosis B-Disease 1 0.9999707937240601
. O 0 4.789734157384373e-05

If O 0 0.0019535841420292854
untreated O 0 0.16283808648586273
, O 0 7.128012384782778e-06
hemochromatosis B-Disease 1 0.9999997615814209
can O 1 0.7929227948188782
cause O 0 0.004795651417225599
serious O 0 0.025190945714712143
illness O 1 0.8827999830245972
and O 0 3.916493824362988e-06
early B-Disease 0 0.00015119971067178994
death I-Disease 0 0.002731112064793706
, O 0 6.753696766281791e-07
but O 0 3.7106381114426767e-06
the O 0 8.751885616220534e-06
disease O 0 0.1218286007642746
is O 0 7.645070354556083e-08
still O 0 2.2805750177212758e-07
substantially O 0 4.940352482663002e-07
under O 0 4.788782916875789e-07
- O 1 0.9980448484420776
diagnosed O 1 0.8886677026748657
. O 0 2.9337476803448226e-07

The O 0 9.724367799890388e-08
cornerstone O 0 7.844077032359564e-08
of O 0 2.2179805214683768e-10
screening O 0 1.1240816633062423e-07
and O 0 9.810583456726363e-09
case O 0 5.80592995902407e-09
detection O 0 8.09481775831955e-07
is O 0 1.4760888067399947e-09
the O 0 5.146789106014182e-10
measurement O 0 3.567427597772621e-07
of O 0 5.822517468168087e-10
serum O 0 1.168390213024395e-06
transferrin O 0 2.6281938403371896e-08
saturation O 0 2.8367512783233906e-08
and O 0 4.777039652736903e-09
the O 0 1.6551476855752867e-09
serum O 0 1.6755187743910938e-06
ferritin O 0 7.424465820804471e-06
level O 0 2.404826204838173e-07
. O 0 4.4178477764944546e-08

Once O 0 0.00010369290976086631
the O 0 8.43907912440045e-08
diagnosis O 0 0.0005367519916035235
is O 0 6.3768830216304195e-09
suspected O 0 3.6559367799782194e-06
, O 0 4.649543861034999e-09
physicians O 0 1.469160171296835e-08
must O 0 7.589552986075887e-09
use O 0 3.9314439703730386e-08
serum O 0 4.865668233833276e-05
ferritin O 0 0.00028106343233957887
levels O 0 6.9568272920150775e-06
and O 0 7.917693437775597e-06
hepatic O 0 0.23464436829090118
iron O 1 0.7001801133155823
stores O 0 0.0002775955363176763
on O 0 0.00041126785799860954
liver O 0 0.0010148981818929315
biopsy O 0 0.0010253905784338713
specimens O 0 5.91994790966055e-08
to O 0 7.643551569458396e-09
assess O 0 3.833617938653333e-07
patients O 0 1.1247700371086466e-07
for O 0 5.52515422302946e-10
the O 0 6.3916418824305765e-09
presence O 0 6.195466539793415e-08
of O 0 6.303698540932601e-08
iron B-Disease 1 0.9766097664833069
overload I-Disease 0 0.05035153403878212
. O 0 1.1985270020886674e-07

Liver O 1 0.9901076555252075
biopsy O 1 0.9577033519744873
is O 0 5.676675982613233e-07
also O 0 1.0333427269415552e-07
used O 0 1.9352701485786383e-07
to O 0 8.4702467262332e-09
establish O 0 2.8591747636141918e-08
the O 0 9.909995490886558e-09
presence O 0 5.865951635541933e-08
or O 0 1.0284466611665266e-07
absence O 0 2.774021368168178e-07
of O 0 1.435697072338371e-07
cirrhosis B-Disease 1 0.8429521322250366
, O 0 4.4090177198086167e-07
which O 0 9.37104232434649e-07
can O 0 2.3060022158460924e-06
affect O 0 2.0609011244232533e-06
prognosis O 0 0.012611867859959602
and O 0 3.406973405617464e-07
management O 0 1.4678082607133547e-06
. O 0 3.8711053917950267e-08

A O 0 4.022155337679578e-07
DNA O 0 1.3677818969881628e-05
- O 0 7.681049282837193e-06
based O 0 4.8114515038832906e-08
test O 0 1.0923312032673493e-07
for O 0 5.6645330787086223e-11
the O 0 7.356351638954095e-10
HFE O 0 3.169295086991042e-05
gene O 0 8.762041403542753e-08
is O 0 1.2768904822380023e-09
commercially O 0 2.6889447113376264e-08
available O 0 2.232051166117799e-08
, O 0 1.5136036424223676e-08
but O 0 1.2483854838762909e-08
its O 0 7.956889591653749e-10
place O 0 2.971232788695488e-07
in O 0 1.1880683103981937e-08
the O 0 1.8610369068028376e-07
diagnosis O 0 0.04026782140135765
of O 0 1.5060103919495305e-07
hemochromatosis B-Disease 1 1.0
is O 0 8.579484529036563e-06
still O 0 4.0299227066498133e-07
being O 0 4.538842901524731e-08
evaluated O 0 2.999440198436787e-07
. O 0 2.365718643204673e-08

Currently O 0 4.735547463496914e-06
, O 0 2.4445698798558624e-08
the O 0 8.759626912713259e-10
most O 0 1.1254702031449071e-10
useful O 0 4.5785919500218597e-10
role O 0 1.0638137037943807e-09
for O 0 4.369356543243441e-10
this O 0 2.409787702717381e-09
test O 0 2.9857329764126916e-07
is O 0 1.846678643335764e-10
in O 0 1.3473712423550666e-10
the O 0 7.978256388874172e-10
detection O 0 1.2502844128903234e-06
of O 0 3.352598199057866e-08
hemochromatosis B-Disease 1 0.9999998807907104
in O 0 5.401481303124456e-06
the O 0 5.596689334197436e-07
family O 0 9.127604982950288e-08
members O 0 1.1648966513622128e-10
of O 0 1.0849837694948405e-09
patients O 0 9.935265410376815e-08
with O 0 2.960140355057206e-09
a O 0 1.0533417338365325e-07
proven O 0 1.1812750926765148e-05
case O 0 9.711911275189777e-08
of O 0 3.7087146687042605e-09
the O 0 1.476630313845817e-05
disease O 0 0.0731520801782608
. O 0 1.5508081219195446e-07

It O 0 1.4930000133972499e-06
is O 0 1.0015382301276077e-08
crucial O 0 7.937116208722728e-08
to O 0 1.363199999104836e-06
diagnose O 1 0.9996102452278137
hemochromatosis B-Disease 1 0.9999997615814209
before O 1 0.6515442132949829
hepatic B-Disease 1 0.9999245405197144
cirrhosis I-Disease 1 0.9998303651809692
develops O 0 0.03517664596438408
because O 0 9.615706403565127e-06
phlebotomy O 1 0.8378275036811829
therapy O 1 0.6382157206535339
can O 0 0.008974464610219002
avert O 1 0.7805630564689636
serious O 1 0.9939020872116089
chronic O 1 0.999998927116394
disease O 1 0.9999978542327881
and O 0 0.052187513560056686
can O 0 0.0007021319470368326
even O 0 2.8371456210152246e-05
lead O 0 8.037153747864068e-05
to O 0 6.869512247931198e-08
normal O 0 5.786232577520423e-07
life O 0 4.2271182110198424e-07
expectancy O 0 6.94196205586195e-05
. O 0 4.530692709892037e-09
. O 0 1.442743258195378e-08

Prevalence O 0 0.034047096967697144
of O 0 1.5316148349597825e-08
the O 0 1.7960436693442716e-08
I1307K O 0 8.290575124192401e-07
APC B-Disease 0 1.5079102411164058e-07
gene O 0 9.739309803080687e-08
variant O 0 2.5787776394281536e-05
in O 0 3.775089751911764e-08
Israeli O 0 2.7148721528647e-06
Jews O 0 2.147780122641052e-07
of O 0 1.3031400958318784e-10
differing O 0 1.4533094727653406e-09
ethnic O 0 3.16213899509421e-08
origin O 0 3.3958986023208126e-07
and O 0 4.849784545513103e-06
risk O 0 6.689742804155685e-06
for O 0 2.5407649445696734e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 1.3530516298487782e-05

BACKGROUND O 0 0.0006293560145422816
& O 0 0.00023402244551107287
AIMS O 0 1.778883301994938e-06
Israeli O 0 1.3314742091097287e-06
Jews O 0 2.3301350893234485e-07
of O 0 1.3470121684733272e-09
European O 0 1.204303316626465e-06
birth O 0 9.109105121751782e-06
, O 0 9.387289168216739e-08
i O 0 9.765175491338596e-06
. O 0 2.945945154486651e-10
e O 0 3.294116091012711e-09
. O 0 6.08516292910366e-10
, O 0 1.8399949619496425e-10
Ashkenazim O 0 1.5186692792212853e-07
, O 0 6.038107236427948e-10
have O 0 1.2384342440441287e-08
the O 0 2.3952497940626927e-07
highest O 1 0.9655953049659729
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9965534210205078
of O 0 7.891092224099339e-08
any O 0 2.2006013011832692e-07
Israeli O 0 3.7351121136453e-05
ethnic O 0 1.3413670103545883e-06
group O 0 1.8697142877499573e-05
. O 0 1.6856417062172113e-07

The O 0 3.5366559814065113e-07
I1307K O 0 1.7522531834401889e-06
APC B-Disease 0 5.844653969688807e-07
gene O 0 3.088228766046086e-07
variant O 0 0.0005334635498002172
was O 0 9.668665006756783e-05
found O 0 2.484355547949235e-07
in O 0 5.031981586967049e-08
6 O 0 6.280671186686959e-06
. O 0 4.536134099453193e-07

1 O 0 1.938940812351575e-07
% O 0 1.3258150133310664e-09
of O 0 9.823567653777232e-11
American O 0 5.2324136134984656e-08
Jews O 0 5.330649628376705e-07
, O 0 2.4998646708240813e-08
28 O 0 3.4156261818907296e-08
% O 0 7.936847012945947e-11
of O 0 8.658861405663743e-10
their O 0 6.158796168165281e-05
familial O 1 0.9999958276748657
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.006781942211091518
, O 0 3.7866677757847356e-06
but O 0 5.838487140863435e-06
not O 0 1.9507368165250227e-07
in O 0 4.455417368376402e-09
non O 0 5.362670663089375e-08
- O 0 0.004417130257934332
Jews O 0 6.282120921241585e-06
. O 0 1.245832379481726e-07

We O 0 5.526620952878147e-06
assessed O 0 2.75687792594681e-08
the O 0 3.117777591654658e-09
I1307K O 0 7.112016078281158e-07
prevalence O 0 8.283217903226614e-05
in O 0 1.0021516061442526e-08
Israeli O 0 1.6293747648887802e-06
Jews O 0 4.863118974185454e-08
of O 0 1.284312795002407e-10
differing O 0 6.942743602245116e-10
ethnic O 0 9.633794206820312e-09
origin O 0 6.458604673298396e-08
and O 0 2.0577174382196972e-06
risk O 0 5.44926842849236e-06
for O 0 1.0862995623028837e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 7.268314675457077e-06

METHODS O 0 1.3677278047907748e-06
DNA O 0 2.1040348201495362e-06
samples O 0 1.631639889865255e-08
from O 0 4.4055890879857174e-11
500 O 0 2.307989493965934e-10
unrelated O 0 8.182240662790718e-09
Jews O 0 3.8668852653245267e-07
of O 0 7.738136353907521e-09
European O 0 3.989689048466971e-06
or O 0 7.755338060633221e-08
non O 0 8.394433592684436e-08
- O 0 0.0039997100830078125
European O 0 8.814404282020405e-07
origin O 0 2.6789264140347768e-08
, O 0 4.833119238156769e-09
with O 0 8.842759413596468e-09
or O 0 4.184098756354615e-08
without O 0 3.5936291720162217e-09
a O 0 1.0495550206712778e-08
personal O 0 1.0781724313346785e-06
and O 0 1.2344316928647459e-05
/ O 0 0.00019363698083907366
or O 0 3.185709545050486e-07
family O 0 1.1407831124188306e-07
history O 0 1.0909570136163893e-07
of O 0 2.4350332861189372e-09
neoplasia B-Disease 0 0.0029738303273916245
, O 0 1.7187200995749663e-08
were O 0 1.830056639562372e-08
examined O 0 2.140535286798695e-07
for O 0 1.0329613830961648e-09
the O 0 5.767289312785806e-09
I1307K O 0 1.5264272690274083e-07
variant O 0 4.583402528623992e-07
by O 0 1.2040755059672392e-09
the O 0 6.063959889779369e-10
allele O 0 8.612484059256076e-09
- O 0 3.850791927106911e-06
specific O 0 2.8220601411277357e-09
oligonucleotide O 0 1.1286095286777709e-05
( O 0 1.1909269126419986e-08
ASO O 0 0.00015193925355561078
) O 0 5.891646059907885e-10
method O 0 2.7940396662984313e-08
. O 0 1.7348916969694983e-08

RESULTS O 0 1.0860260772460606e-05
In O 0 4.414013154985241e-09
persons O 0 1.177105524163835e-09
at O 0 1.915342195957237e-08
average O 0 4.063632331963163e-06
risk O 0 3.73023867723532e-05
for O 0 0.0026859675999730825
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.008191813729354e-06
I1307K O 0 6.439841854444239e-06
was O 0 9.718944966152776e-06
found O 0 7.751744846018482e-08
in O 0 1.0218373702741701e-08
5 O 0 2.539237584642251e-07
. O 0 1.1481449035954938e-07

0 O 0 1.4957734038034687e-06
% O 0 7.521701594903618e-10
of O 0 3.7905605737575954e-11
120 O 0 2.8266715634828188e-09
European O 0 8.086006459961936e-07
and O 0 1.7490931725205883e-07
1 O 0 2.9791800670864177e-07
. O 0 2.3145035754623677e-07

6 O 0 8.13008864497533e-06
% O 0 2.8815376751367694e-09
of O 0 8.583873889467242e-11
188 O 0 1.4263074277209853e-08
non O 0 7.736752394293944e-08
- O 0 0.009132935665547848
European O 0 2.447568249408505e-06
Jews O 0 3.403660571166256e-07
( O 0 3.279484017681966e-09
P O 0 0.0005410293233580887
= O 0 4.322281711210962e-06
0 O 0 4.450595625371534e-08
. O 0 1.948760486314427e-09
08 O 0 9.583068560914398e-08
) O 0 2.7065254482039336e-09
. O 0 1.555784834295082e-08

It O 0 6.176906595101173e-07
occurred O 0 1.4139052950667974e-07
in O 0 2.405508015002056e-09
15 O 0 2.2665611609795633e-08
. O 0 2.4659147612737797e-08

4 O 0 8.515718832313723e-07
% O 0 1.4321486219159851e-09
of O 0 2.2840829227988024e-10
52 O 0 4.220648861519294e-07
Ashkenazi O 0 0.0001209870824823156
Israelis O 0 0.0001353214174741879
with O 0 2.700563754842733e-06
familial O 1 0.9844881296157837
cancer B-Disease 1 0.9983341097831726
( O 0 5.447265607472218e-07
P O 1 0.7916523814201355
= O 0 0.003744034795090556
0 O 0 5.2130958465568256e-06
. O 0 1.0093899760477143e-07
02 O 0 5.275118019198999e-05
) O 0 2.8035722632324678e-09
and O 0 1.6205046904360643e-07
was O 0 7.037690465949709e-06
not O 0 9.574682735546958e-08
detected O 0 5.021095716983837e-07
in O 0 4.822640065071937e-09
51 O 0 6.303055783973832e-07
non O 0 9.006032541947206e-08
- O 0 0.0020891749300062656
European O 0 1.3858254988008412e-07
Jews O 0 5.117203727422748e-08
at O 0 6.328503587837986e-08
increased O 0 1.643191239963926e-06
cancer B-Disease 0 0.00037462200270965695
risk O 0 9.822567790251924e-07
. O 0 2.8693799336565462e-08

Colorectal B-Disease 1 0.9975417852401733
neoplasia I-Disease 1 0.9085599780082703
occurred O 0 0.0008420912199653685
personally O 0 9.395952656632289e-05
or O 0 7.814671789674321e-07
in O 0 4.296110134305309e-08
the O 0 9.754293728292396e-08
families O 0 4.512659579347655e-09
of O 0 9.161014169478676e-10
13 O 0 3.2623105994389334e-08
of O 0 2.1305146535866015e-10
20 O 0 6.250108874894522e-09
Ashkenazi O 0 6.250409114727518e-07
I1307K O 0 2.53240735048621e-08
carriers O 0 9.385638044534517e-09
, O 0 3.078041599380299e-09
8 O 0 1.0661034721692886e-08
of O 0 1.2778382796341248e-09
whom O 0 8.79235813044943e-06
also O 0 0.00023110043548513204
had O 0 0.0002736554015427828
a O 0 4.224087319926184e-07
personal O 0 1.557617179059889e-05
or O 0 1.3008639143663459e-06
family O 0 1.1771727770337748e-07
history O 0 1.5598904212765774e-07
of O 0 1.137153660124568e-08
noncolonic O 0 0.006361119449138641
neoplasia B-Disease 0 0.018015453591942787
. O 0 3.6515424994831847e-07

CONCLUSIONS O 0 4.051386349601671e-05
The O 0 7.072961949461387e-08
I1307K O 0 1.8005698620982002e-06
APC O 0 8.221163625421468e-07
variant O 0 7.709389319643378e-05
may O 0 4.409307621244807e-07
represent O 0 4.126625985367838e-10
a O 0 1.225099133250751e-08
susceptibility O 0 1.7023512555169873e-05
gene O 0 1.0625532922858838e-05
for O 0 1.2710548617178574e-05
colorectal B-Disease 1 1.0
, I-Disease 0 9.905055776471272e-06
or I-Disease 0 6.053726906429802e-07
other I-Disease 0 2.2023877477295173e-07
, I-Disease 0 9.89548243524041e-06
cancers I-Disease 0 0.31431737542152405
in O 0 1.4064869446883677e-07
Ashkenazi O 0 0.0018468210473656654
Jews O 0 1.6532116205780767e-05
, O 0 2.751706631443085e-07
and O 0 1.4148361060506431e-06
partially O 0 0.00011872003233293071
explains O 0 1.9814651750493795e-06
the O 0 4.3745784772397656e-09
higher O 0 4.3349942302484124e-08
incidence O 0 0.4573199152946472
of O 0 0.007619035895913839
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.2756090604380006e-06
European O 0 9.445132491237018e-06
Israelis O 0 9.337893425254151e-05
. O 0 3.4567199236335e-07

Systematic O 0 7.915292371762916e-06
analysis O 0 2.409298076599953e-07
of O 0 4.6842409950897945e-09
coproporphyrinogen O 0 0.00028446316719055176
oxidase O 0 7.434373401338235e-05
gene O 0 0.00048360307118855417
defects O 1 0.9605557322502136
in O 0 6.448505018852302e-07
hereditary B-Disease 1 0.9661608934402466
coproporphyria I-Disease 0 0.3327524960041046
and O 0 8.413302566623315e-06
mutation O 0 2.753894659690559e-05
update O 0 0.00023259897716343403
. O 0 7.890096753726539e-07

Hereditary B-Disease 1 0.9985729455947876
coproporphyria I-Disease 1 0.7738698124885559
( O 0 1.5084553979249904e-06
HC B-Disease 1 0.9678034782409668
) O 0 2.7342273369868053e-06
is O 0 2.1759187802672386e-06
an O 0 4.7932713641785085e-05
acute O 1 0.9998444318771362
hepatic B-Disease 1 0.9999955892562866
porphyria I-Disease 1 0.9999977350234985
with O 0 0.14459078013896942
autosomal O 1 0.9999570846557617
dominant O 1 0.9986817240715027
inheritance O 1 0.941519558429718
caused O 0 0.14003559947013855
by O 0 5.922635182287195e-07
deficient B-Disease 0 0.0023791964631527662
activity I-Disease 0 1.0412843920448722e-07
of I-Disease 0 4.6794546015860305e-09
coproporphyrinogen I-Disease 0 0.011110288091003895
III I-Disease 0 0.013179754838347435
oxidase I-Disease 0 3.0154526029946283e-05
( O 0 1.3322519087921592e-08
CPO O 0 3.776876110350713e-05
) O 0 9.548837276440736e-09
. O 0 2.3905526447265402e-08

Clinical O 0 0.0013683353317901492
manifestations O 0 0.00013190606841817498
of O 0 1.0384937354501744e-07
the O 0 2.9361171982600354e-05
disease O 1 0.8421642184257507
are O 0 6.293054610750914e-08
characterized O 0 0.00014041583926882595
by O 0 5.434871127363294e-06
acute O 0 0.3626934289932251
attacks O 1 0.7159817218780518
of O 0 0.00022187558352015913
neurological B-Disease 1 0.9999949932098389
dysfunction I-Disease 1 0.8620383143424988
often O 0 6.972834853513632e-06
precipitated O 0 1.1679734370773076e-06
by O 0 1.0863593580268116e-08
drugs O 0 4.4743936200575263e-07
, O 0 6.130401519754969e-09
fasting O 0 2.1338743749765854e-07
, O 0 3.179045915402412e-09
cyclical O 0 5.652881372952834e-05
hormonal O 0 8.16106785350712e-06
changes O 0 2.957403069103748e-07
, O 0 1.2027591367314017e-07
or O 0 7.418449968099594e-06
infectious B-Disease 1 0.9800779819488525
diseases I-Disease 1 0.5497972369194031
. O 0 5.463257934934518e-07

Skin O 1 0.999925971031189
photosensitivity O 1 0.9989601373672485
may O 0 0.0022996333427727222
also O 0 6.625222113143536e-07
be O 0 2.7757405263173496e-08
present O 0 2.2980685798756895e-08
. O 0 2.2912549013653916e-07

The O 0 3.2196919619309483e-07
seven O 0 1.0002209727133504e-08
exons O 0 3.2502993008165504e-07
, O 0 1.9785131311067516e-09
the O 0 5.759294707807783e-10
exon O 0 9.378749723509827e-07
/ O 0 3.3816009818110615e-05
intron O 0 0.0015952703543007374
boundaries O 0 5.6653530918993056e-05
and O 0 5.4994114151440954e-08
part O 0 8.731003142692373e-10
of O 0 1.3974735257882287e-10
3 O 0 9.460044303466475e-09
noncoding O 0 6.673899406450801e-07
sequence O 0 1.682500396782416e-07
of O 0 4.4461703763154503e-10
the O 0 4.421554677946915e-09
CPO O 0 3.1626234431314515e-06
gene O 0 2.9272907653421498e-08
were O 0 1.0533835137493952e-08
systematically O 0 3.4429936590640864e-07
analyzed O 0 1.21661365426462e-08
by O 0 1.0091959906644021e-10
an O 0 1.0303890379814717e-10
exon O 0 4.0216070829046657e-07
- O 0 2.605002373456955e-05
by O 0 9.951648394235235e-09
- O 0 3.658276909845881e-06
exon O 0 9.240797567144909e-07
denaturing O 0 2.8686672521871515e-05
gradient O 0 3.1744900752528338e-06
gel O 0 0.00010215752990916371
electrophoresis O 0 1.053818232321646e-05
( O 0 2.068131665922124e-09
DGGE O 0 3.4756983495753957e-06
) O 0 2.8137492336099967e-10
strategy O 0 3.781602586627741e-09
followed O 0 3.9632952475443517e-10
by O 0 1.627646281643358e-11
direct O 0 1.2785640601808979e-10
sequencing O 0 6.412231101649013e-08
in O 0 4.327259883751822e-09
seven O 0 6.823217546525484e-09
unrelated O 0 1.3113026398059446e-07
heterozygous O 0 9.75336092778889e-07
HC B-Disease 0 0.08776182681322098
patients O 0 1.4217724128684495e-05
from O 0 2.9400933243550753e-08
France O 0 0.00014266319340094924
, O 0 1.8261276579778496e-07
Holland O 0 0.0005063430871814489
, O 0 1.9731324130134453e-08
and O 0 6.543816510884426e-08
Czech O 0 3.340007606311701e-05
Republic O 0 1.2218295069033047e-06
. O 0 2.8880160130029253e-07

Seven O 0 4.593283392750891e-06
novel O 0 6.683876108581899e-06
mutations O 0 4.9310317990602925e-05
and O 0 1.221806940066017e-07
two O 0 1.9131543016470687e-09
new O 0 3.203333420742638e-08
polymorphisms O 0 5.0877260946435854e-05
were O 0 1.5268656170519534e-06
detected O 0 1.3181626854930073e-05
. O 0 1.6255678758625436e-07

Among O 0 3.709958491526777e-07
these O 0 1.2787069181285915e-08
mutations O 0 3.3567033597137197e-07
two O 0 8.508849624888626e-09
are O 0 5.9061857626829806e-09
missense O 0 4.773533146362752e-05
( O 0 1.1856482906580368e-08
G197W O 0 4.668225301429629e-06
, O 0 2.362999396154919e-08
W427R O 0 5.608411584034911e-07
) O 0 2.5317443697048247e-09
, O 0 1.8675605506501824e-09
two O 0 2.9147868563228485e-09
are O 0 9.9272874365397e-09
nonsense O 0 0.00026101607363671064
( O 0 1.472006516678448e-09
Q306X O 0 5.4225633761006975e-08
, O 0 1.826913509361816e-09
Q385X O 0 1.0931398719549179e-07
) O 0 1.5394221453135515e-09
, O 0 7.806085777772864e-10
two O 0 7.832364756765742e-10
are O 0 1.764100393542023e-10
small O 0 5.073864439708586e-09
deletions O 0 2.125862465618411e-06
( O 0 7.406518509611715e-09
662de14bp O 0 4.939447535434738e-07
; O 0 3.3768356999530624e-09
1168del3bp O 0 3.2250113690679427e-07
removing O 0 1.404524052617262e-08
a O 0 4.8981743105969144e-09
glycine O 0 1.3069320630165748e-06
at O 0 2.0263688327304408e-07
position O 0 9.14183928557577e-08
390 O 0 2.944875099331057e-08
) O 0 2.8420734654588387e-09
, O 0 4.263049468988811e-09
and O 0 1.1942502986528325e-08
one O 0 1.994544085448524e-09
is O 0 4.682881304951536e-10
a O 0 5.176442052778896e-10
splicing O 0 8.361338359463844e-07
mutation O 0 4.352276619101758e-07
( O 0 6.069560409827091e-10
IVS1 O 0 1.193388470710488e-05
- O 0 0.00011807942064478993
15c O 0 3.5925384622714773e-07
- O 0 2.1061845473013818e-05
- O 0 0.0007009579567238688
> O 0 7.515254765166901e-07
g O 0 3.3034772059181705e-05
) O 0 5.188105500764095e-10
which O 0 9.757392671616572e-10
creates O 0 7.677532498640005e-10
a O 0 6.333110147416221e-10
new O 0 8.45354186651548e-09
acceptor O 0 3.72432573669812e-08
splice O 0 3.941340764868073e-05
site O 0 7.528363312303554e-06
. O 0 1.3538777920985012e-07

The O 0 7.952130545163527e-07
pathological O 0 7.412947979901219e-06
significance O 0 3.33128902241242e-08
of O 0 1.8579676686059088e-09
the O 0 2.744234350871011e-08
point O 0 4.922358584735775e-06
mutations O 0 1.5183389905359945e-06
G197W O 0 7.556909054073913e-07
, O 0 5.03745312130377e-09
W427R O 0 3.693898804613127e-07
, O 0 1.6957796944438996e-08
and O 0 1.6555524950945255e-08
the O 0 2.5104087697513933e-09
in O 0 1.2549506323011883e-08
- O 0 0.002183787524700165
frame O 0 0.017736872658133507
deletion O 0 7.787257345626131e-07
390delGly O 0 2.1196929367306439e-07
were O 0 6.2982641324538235e-09
assessed O 0 4.534963959912375e-09
by O 0 2.0931927302569875e-09
their O 0 1.1483086481689497e-08
respective O 0 5.3594879645402216e-09
expression O 0 7.192571160885564e-08
in O 0 1.6104291233887125e-09
a O 0 1.6263075330869015e-09
prokaryotic O 0 5.524640300791361e-09
system O 0 1.2563685203303976e-08
using O 0 1.9214629887187584e-09
site O 0 6.847978966106893e-07
- O 0 3.090341488132253e-05
directed O 0 5.218261094341869e-07
mutagenesis O 0 1.1183988135599066e-06
. O 0 2.6321067991830205e-08

These O 0 2.3495356344938045e-06
mutations O 0 7.062944860081188e-06
resulted O 0 4.0639514509166474e-07
in O 0 4.252169816254536e-08
the O 0 2.260741638338004e-07
absence O 0 5.013832264921803e-07
or O 0 1.8945810253967466e-08
a O 0 3.0373239923164874e-08
dramatic O 0 4.7766689021955244e-06
decrease O 0 1.8295858126293751e-06
of O 0 5.26163335123897e-09
CPO O 0 0.0023994322400540113
activity O 0 9.532423632663267e-07
. O 0 3.1821958401678785e-08

The O 0 2.8542007157739135e-07
two O 0 9.39326838533816e-09
polymorphisms O 0 4.6408199523284566e-06
were O 0 6.556534515311796e-08
localized O 0 8.995189091365319e-07
in O 0 1.1094098084640791e-08
noncoding O 0 2.0181956642773002e-05
part O 0 1.1261685983754433e-07
of O 0 4.4094078388567937e-10
the O 0 3.612438348454816e-09
gene O 0 4.4388116293703206e-08
1 O 0 1.1429115431838e-08
) O 0 3.151556238201181e-10
a O 0 8.926846817303158e-09
C O 0 0.00013058101467322558
/ O 0 4.699717464973219e-06
G O 0 7.0371061156038195e-06
polymorphism O 0 3.6201797115609224e-07
in O 0 7.153877046306434e-09
the O 0 1.7745977132221924e-08
promotor O 0 1.57968643179629e-05
region O 0 2.2809122413036675e-07
, O 0 1.1059527738055408e-09
142 O 0 2.3502684243226213e-09
bp O 0 4.673079700978633e-08
upstream O 0 3.7088208060254146e-09
from O 0 9.742784704003249e-12
the O 0 1.6019291795843493e-11
transcriptional O 0 3.2023785845325392e-09
initiation O 0 1.1317737858007604e-09
site O 0 2.0194835315123782e-07
( O 0 3.2248476111718105e-10
- O 0 3.0035132567718392e-06
142C O 0 2.0169812842141255e-07
/ O 0 7.997771263035247e-07
G O 0 4.946292392560281e-06
) O 0 2.9866750739238057e-10
, O 0 3.2114480519318533e-10
and O 0 3.2243450132085627e-09
2 O 0 9.817509472043184e-09
) O 0 2.10776271436508e-10
a O 0 8.634898351900233e-10
6 O 0 3.293571282370067e-08
bp O 0 1.1348929973564736e-07
deletion O 0 1.737650201505403e-08
polymorphism O 0 5.288147804094478e-07
in O 0 8.511869431515606e-09
the O 0 5.844183359471344e-09
3 O 0 2.566053680652658e-08
noncoding O 0 1.9111403162241913e-06
part O 0 3.5514116092372205e-08
of O 0 8.954195163113354e-10
the O 0 2.3202579413350577e-08
CPO O 0 3.460879815975204e-05
gene O 0 1.2089044787444436e-07
, O 0 8.352740721306873e-10
574 O 0 1.3539108500992825e-08
bp O 0 1.1857414961014001e-07
downstream O 0 2.2895985551940612e-08
of O 0 1.7190462942018314e-10
the O 0 1.0511496562060074e-08
last O 0 5.716203688166388e-08
base O 0 2.4196256109831893e-09
of O 0 2.250304977080564e-11
the O 0 7.791002842871819e-10
normal O 0 3.146670124465345e-08
termination O 0 1.044698123564558e-07
codon O 0 3.7059805890748976e-07
( O 0 8.201376799910065e-10
+ O 0 6.293318932648617e-08
574 O 0 9.055602845364774e-07
delATTCTT O 0 2.4180412765417714e-06
) O 0 8.905995940722278e-09
. O 0 1.6613729059145044e-08

Five O 0 6.824314368714113e-06
intragenic O 0 0.0001068726705852896
dimorphisms O 0 0.0002977681579068303
are O 0 2.0612083062587772e-07
now O 0 2.2785727082919038e-07
well O 0 6.728951262857663e-08
characterized O 0 4.3906570681429e-06
and O 0 2.276270549828041e-07
the O 0 4.07026723436843e-09
high O 0 3.847065954687423e-08
degree O 0 7.323298634176467e-10
of O 0 5.7117050672461644e-11
allelic O 0 5.414955239757546e-07
heterogeneity O 0 1.495975175203057e-05
in O 0 2.6247303708260006e-07
HC B-Disease 1 0.9061132669448853
is O 0 1.8817189584297012e-06
demonstrated O 0 2.8899418680339295e-07
with O 0 1.1840460167888978e-08
seven O 0 9.727981975515831e-09
new O 0 5.240530676076105e-09
different O 0 5.181746698390555e-10
mutations O 0 6.367332616719068e-08
making O 0 3.656854596911785e-09
a O 0 7.253932121642492e-09
total O 0 4.377900708618654e-09
of O 0 1.3662582176721116e-09
nineteen O 0 2.3688080545980483e-06
CPO O 0 0.01001973170787096
gene B-Disease 0 0.00018918217392638326
defects I-Disease 1 0.8674724698066711
reported O 0 1.4897302662575385e-06
so O 0 5.332256236556532e-08
far O 0 1.7272647312438494e-08
. O 0 9.91298332309043e-09
. O 0 4.710934931040356e-08

Coincidence O 0 6.9355232881207485e-06
of O 0 1.1337188965399037e-08
two O 0 2.2997655335643685e-08
novel O 0 1.6360734207410133e-06
arylsulfatase O 0 1.5783780327183194e-05
A O 0 1.671250089430032e-07
alleles O 0 1.1180133441257567e-07
and O 0 2.0708846193429054e-07
mutation O 0 5.346718126020278e-07
459 O 0 4.660155923374987e-07
+ O 0 1.7796775182432611e-06
1G O 0 0.0008246388752013445
> O 0 3.2878833735594526e-06
A O 0 5.848071964464907e-07
within O 0 8.52397263884086e-09
a O 0 2.6308177325518045e-07
family O 0 9.332548870588653e-06
with O 0 0.0002259144384879619
metachromatic B-Disease 1 0.9999994039535522
leukodystrophy I-Disease 1 0.9999959468841553
: O 0 2.4398788767143742e-08
molecular O 0 2.19387015221173e-08
basis O 0 2.8524842488053537e-09
of O 0 1.762318957432285e-09
phenotypic O 0 5.845116902492009e-06
heterogeneity O 0 0.0004844003124162555
. O 0 1.411540893059282e-06

In O 0 1.227536131409579e-06
a O 0 2.2071860428241052e-07
family O 0 3.0404254403038067e-07
with O 0 1.719363496022197e-07
three O 0 1.2900759429612663e-06
siblings O 0 1.1130457096442115e-05
, O 0 3.3631128992794856e-09
one O 0 2.914714691826248e-09
developed O 0 6.98596011261543e-07
classical O 0 7.814709533704445e-06
late O 0 0.00019418854208197445
infantile O 1 0.9999649524688721
metachromatic B-Disease 1 0.9999983310699463
leukodystrophy I-Disease 1 0.9999978542327881
( O 0 2.5508063117740676e-05
MLD B-Disease 1 0.9999916553497314
) O 0 1.579970501097705e-07
, O 0 3.055924935324583e-08
fatal O 0 3.762776032090187e-05
at O 0 7.16248734988767e-07
age O 0 5.937678793088708e-07
5 O 0 9.333763983931931e-08
years O 0 1.3069303861357184e-07
, O 0 2.3338039056852722e-08
with O 0 3.4152293437728076e-07
deficient O 0 0.10489746928215027
arylsulfatase O 0 0.00042174450936727226
A O 0 5.464693458634429e-06
( O 0 1.3361505679654329e-08
ARSA O 0 0.0013261473504826427
) O 0 9.336604822607342e-10
activity O 0 2.1194558996739943e-08
and O 0 2.870277704403179e-08
increased O 0 9.674934631220822e-08
galactosylsulfatide O 0 0.0009693197207525373
( O 0 5.077972105027584e-07
GS O 1 0.9999921321868896
) O 0 2.153941558447059e-08
excretion O 0 1.0380164638945644e-07
. O 0 1.9826694952485013e-08

The O 0 2.658490245721623e-07
two O 0 1.054796872068664e-08
other O 0 4.154236510345299e-09
siblings O 0 3.0511923796439078e-06
, O 0 3.5443740387108846e-08
apparently O 0 1.7600040109755355e-06
healthy O 0 3.847762997111204e-08
at O 0 3.984504726162186e-09
12 O 0 3.321909414211177e-09
( O 0 6.681469266744955e-11
1 O 0 8.209800839154013e-09
/ O 0 1.038761456584325e-05
2 O 0 2.817050415160338e-07
) O 0 5.264504387980651e-09
and O 0 3.4641445267880044e-08
15 O 0 1.0373866210500182e-08
years O 0 1.9847277599183144e-08
, O 0 4.0748266982859604e-09
respectively O 0 1.0280446360866335e-07
, O 0 9.210675244730737e-08
and O 0 2.387930635450175e-07
their O 0 4.046320611905685e-07
father O 0 9.303390834247693e-05
, O 0 7.930231049613212e-08
apparently O 0 4.697606357240147e-07
healthy O 0 9.212499207933433e-09
as O 0 1.4583464436057625e-09
well O 0 4.4290584533257515e-09
, O 0 8.611953372650305e-10
presented O 0 2.0193537508816917e-08
ARSA O 0 0.04920968413352966
and O 0 5.158424301043851e-06
GS O 1 0.9999949932098389
values O 0 5.0429932230144914e-08
within O 0 3.3420349820900697e-10
the O 0 6.406772889988588e-10
range O 0 5.28347925410344e-08
of O 0 8.955159103152255e-08
MLD B-Disease 1 0.9999850988388062
patients O 0 5.203209366300143e-05
. O 0 3.568760931216275e-08

Mutation O 0 1.0776095223263837e-05
screening O 0 1.8387114550932893e-06
and O 0 1.608164801325529e-08
sequence O 0 1.944921912411246e-08
analysis O 0 1.2927685588692839e-08
disclosed O 0 3.5987278579341364e-07
the O 0 1.249273928749517e-08
involvement O 0 1.5811869502613263e-07
of O 0 1.2631076184987933e-09
three O 0 2.8766024229298637e-08
different O 0 8.537998752444764e-09
ARSA O 0 0.14658361673355103
mutations O 0 1.2563994005176937e-06
being O 0 1.2011285299706742e-08
the O 0 7.935908874490138e-11
molecular O 0 5.647881273773692e-09
basis O 0 2.5530517699934308e-09
of O 0 3.2122524640243455e-09
intrafamilial O 0 5.928182144998573e-05
phenotypic O 0 3.648277697720914e-06
heterogeneity O 0 0.0001178904203698039
. O 0 9.283762096856663e-07

The O 0 3.4945701372635085e-06
late O 0 1.4945064322091639e-05
infantile O 1 0.988593578338623
patient O 1 0.5119953751564026
inherited O 0 0.28603339195251465
from O 0 4.636160895188368e-07
his O 0 4.131072273594327e-05
mother O 0 0.00011437435750849545
the O 0 9.035950654379121e-09
frequent O 0 1.8982511562626314e-07
0 O 0 9.115389048020006e-07
- O 0 0.00492449663579464
type O 0 0.00014655139239039272
mutation O 0 4.902701107312168e-07
459 O 0 6.736155455655535e-08
+ O 0 1.0096248814761566e-07
1G O 0 4.762111711897887e-05
> O 0 1.3466066093315021e-06
A O 0 5.567756488744635e-06
, O 0 2.0925597254972672e-07
and O 0 8.257342187789618e-08
from O 0 7.1936940848615905e-09
his O 0 6.420991212507943e-06
father O 0 3.328064622110105e-06
a O 0 3.761598676987887e-08
novel O 0 4.640342012862675e-06
, O 0 1.1035848679341598e-08
single O 0 2.9643240395671455e-07
basepair O 0 1.0860909469556645e-06
microdeletion O 0 8.625441694221081e-08
of O 0 4.051487617617866e-11
guanine O 0 5.550888193539549e-09
at O 0 6.246697048517547e-10
nucleotide O 0 6.281516196082748e-09
7 O 0 5.848041162437312e-09
in O 0 4.542216047731529e-10
exon O 0 1.4323045434139203e-06
1 O 0 1.8280007907378604e-07
( O 0 7.1403127854807735e-09
7delG O 0 9.065324775292538e-06
) O 0 1.9093130632086286e-08
. O 0 6.308810895916395e-08

The O 0 2.2048350274417317e-06
two O 0 2.3149625860696688e-07
clinically O 0 0.00027102281455881894
unaffected O 0 5.9930829593213275e-05
siblings O 0 6.65489778839401e-06
carried O 0 1.4153071106193238e-06
the O 0 3.52030795625069e-08
maternal O 0 1.0885457413678523e-05
mutation O 0 7.754981652396964e-07
459 O 0 3.6273021919441817e-07
+ O 0 4.3270972582831746e-07
1G O 0 0.00011075271322624758
> O 0 1.7109117607105873e-06
A O 0 4.485793851927156e-06
and O 0 9.846680768532678e-07
, O 0 5.896404253746823e-09
on O 0 9.555436264463424e-08
their O 0 3.0928731575841084e-08
paternal O 0 5.895872732253338e-07
allele O 0 2.8843874844142192e-08
, O 0 7.062629370224727e-10
a O 0 7.47053030547562e-10
novel O 0 4.778737050514792e-08
cytosine O 0 3.7876173308859507e-08
to O 0 1.8847144678257877e-10
thymidine O 0 5.724408680407578e-08
transition O 0 1.5512600981537616e-08
at O 0 1.4575761708712776e-09
nucleotide O 0 1.7356132531176627e-08
2435 O 0 4.716775094948389e-07
in O 0 6.293925935985101e-10
exon O 0 5.731908458983526e-07
8 O 0 7.84026155997708e-07
, O 0 3.011818350273643e-09
resulting O 0 1.1964133017627887e-09
in O 0 4.56928328507189e-10
substitution O 0 4.569904454854168e-09
of O 0 1.4221803734670857e-09
alanine O 0 8.635130507173017e-05
464 O 0 2.203180883952882e-06
by O 0 1.907240800846921e-07
valine O 0 0.002697243355214596
( O 0 1.2986008712800867e-08
A464V O 0 6.046906833034882e-07
) O 0 4.911758999526228e-09
. O 0 1.8001934165567945e-08

The O 0 8.513706006851862e-07
fathers O 0 9.831113629843458e-07
genotype O 0 1.511251753072429e-06
thus O 0 5.7221818394737056e-08
was O 0 2.813632420384238e-07
7delG O 0 7.757121238682885e-06
/ O 0 3.983381611760706e-05
A464V O 0 8.82700624060817e-06
. O 0 5.918322187881131e-08

Mutation O 0 0.00017295604629907757
A464V O 0 2.2573196474695578e-05
was O 0 3.678315351862693e-06
not O 0 2.2777856045763656e-08
found O 0 4.416320642519622e-09
in O 0 5.627579735545396e-09
18 O 0 4.2680474621192843e-07
unrelated O 0 9.609747212380171e-05
MLD B-Disease 1 0.9999990463256836
patients O 0 0.005964599084109068
and O 0 2.2039070302071195e-07
50 O 0 1.1463019866653212e-08
controls O 0 2.2357031411956996e-05
. O 0 2.9425206093947054e-07

A464V O 0 0.00022853499103803188
, O 0 1.444659005755966e-07
although O 0 3.2247278625163744e-08
clearly O 0 1.5684513243741094e-07
modifying O 0 1.978917453016038e-06
ARSA O 1 0.9663156270980835
and O 0 0.002727402839809656
GS O 1 0.999998927116394
levels O 0 0.0009256308549083769
, O 0 2.0416115376065136e-07
apparently O 0 1.2882686633020057e-06
bears O 0 6.221969215403078e-07
little O 0 9.293382063901845e-09
significance O 0 4.797355845909124e-09
for O 0 2.0164663272481675e-09
clinical O 0 6.94206732987368e-07
manifestation O 0 7.945687343635655e-07
of O 0 8.930273764917729e-08
MLD B-Disease 1 0.9999977350234985
, O 0 1.5278793341622077e-07
mimicking O 0 3.289278993179323e-06
the O 0 1.883253908374627e-08
frequent O 0 1.17765603135922e-06
ARSA O 0 0.007997971959412098
pseudodeficiency O 0 4.680682104662992e-05
allele O 0 9.54090864979662e-07
. O 0 1.4069082965306734e-07

Our O 0 7.620177711942233e-06
results O 0 2.748391807472217e-07
demonstrate O 0 1.2729760356933184e-08
that O 0 2.3165951379411354e-09
in O 0 3.570309603517785e-10
certain O 0 2.8643150074003643e-09
genetic O 0 0.0001479896454839036
conditions O 0 0.008365962654352188
MLD B-Disease 1 0.9999942779541016
- O 1 0.8434745073318481
like O 0 0.00018424197332933545
ARSA O 1 0.8093370795249939
and O 0 3.467533315415494e-05
GS O 1 0.9999951124191284
values O 0 7.485062951673171e-07
need O 0 3.287759398062917e-08
not O 0 6.0754015152042484e-09
be O 0 3.9037931220953226e-10
paralleled O 0 2.9726157890763716e-07
by O 0 1.506570725950951e-07
clinical O 0 0.048169005662202835
disease O 1 0.9726685881614685
, O 0 1.6398109536908123e-08
a O 0 2.2188546111578944e-08
finding O 0 1.6045041206780297e-07
with O 0 2.1579985798325652e-07
serious O 0 2.5518077109154547e-06
diagnostic O 0 8.173383685061708e-05
and O 0 2.6071427328133723e-06
prognostic O 0 0.004293336067348719
implications O 0 1.3524596397473942e-05
. O 0 3.915945683274913e-07

Moreover O 0 1.8438688130117953e-05
, O 0 3.527862801888659e-08
further O 0 2.1314232157010338e-08
ARSA O 0 0.0016693247016519308
alleles O 0 1.8105087917774654e-07
functionally O 0 3.052545707760146e-06
similar O 0 2.2428210399993986e-07
to O 0 8.830678410731707e-08
A464V O 0 8.50678679853445e-06
might O 0 3.5015154935535975e-06
exist O 0 4.52075965995391e-07
which O 0 2.7209455311094644e-07
, O 0 5.03606001345247e-09
together O 0 3.730003861335263e-09
with O 0 2.3214752786770987e-08
0 O 0 4.797486326424405e-06
- O 0 0.07618961483240128
type O 0 0.04024240002036095
mutations O 0 0.000476650835480541
, O 0 1.0462500767971505e-06
may O 0 2.008859701163601e-05
cause O 0 3.423385805945145e-06
pathological O 0 0.0022659311071038246
ARSA O 1 0.9981814622879028
and O 0 0.01699817180633545
GS O 1 0.9999996423721313
levels O 0 0.004526521544903517
, O 0 1.4334453624087473e-07
but O 0 1.1783757258854166e-07
not O 0 1.9799031747425033e-08
clinical O 0 4.113271927508322e-07
outbreak O 0 7.815104368091852e-07
of O 0 3.488305466703423e-08
the O 0 0.0001726693008095026
disease O 1 0.7736608386039734
. O 0 2.323251457880815e-08
. O 0 9.982125703800193e-08

Human O 0 0.016708871349692345
MLH1 O 1 0.9968421459197998
deficiency O 1 0.9982329607009888
predisposes O 0 0.009764723479747772
to O 0 1.304061424889369e-05
hematological B-Disease 1 0.9903539419174194
malignancy I-Disease 1 0.9992685914039612
and O 0 6.915658013895154e-05
neurofibromatosis B-Disease 1 0.9990407824516296
type I-Disease 0 0.15447883307933807
1 I-Disease 0 1.5801777408341877e-05
. O 0 1.6258218238363042e-06

Heterozygous O 0 6.628510891459882e-05
germ O 0 0.050399940460920334
- O 0 0.29848504066467285
line O 0 0.0049352096393704414
mutations O 0 9.533005709272402e-07
in O 0 8.18045853279159e-10
the O 0 5.9424918319450626e-09
DNA O 0 0.0009555612341500819
mismatch O 0 0.3956383466720581
repair O 0 0.19737333059310913
genes O 0 1.751575109665282e-05
lead O 0 0.00025184120750054717
to O 0 9.426262295164634e-06
hereditary B-Disease 1 0.999903678894043
nonpolyposis I-Disease 1 0.9999897480010986
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 0.00011799411004176363

The O 0 0.0003054412081837654
disease O 0 0.28160303831100464
susceptibility O 0 7.63570424169302e-05
of O 0 5.133735214712942e-08
individuals O 0 4.024603583729913e-07
who O 0 0.0001355962740490213
constitutionally O 0 0.0003875141846947372
lack O 0 9.361502861793269e-07
both O 0 1.4434236561555736e-07
wild O 0 3.102389018749818e-05
- O 0 0.17353571951389313
type O 0 8.05752060841769e-05
alleles O 0 3.422401917418938e-08
is O 0 2.499373685793671e-08
unknown O 0 2.1263642224766954e-07
. O 0 4.666711106438015e-08

We O 0 6.718276563333347e-05
have O 0 1.0715121590010313e-07
identified O 0 8.627909409142376e-08
three O 0 7.990169414995307e-09
offspring O 0 2.4638583795422164e-07
in O 0 1.4876326837054421e-08
a O 0 1.1517804523464292e-05
hereditary B-Disease 1 0.9999740123748779
nonpolyposis I-Disease 1 0.9999977350234985
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.09351420402526855
who O 0 0.009700370021164417
developed O 0 0.014174376614391804
hematological B-Disease 1 0.9101086854934692
malignancy I-Disease 1 0.8968790769577026
at O 0 2.2504937646772305e-07
a O 0 2.7078797870672133e-08
very O 0 6.485292658453545e-08
early O 0 1.2800974218407646e-06
age O 0 2.2209094368008664e-06
, O 0 2.043352154146305e-08
and O 0 9.98250655470656e-08
at O 0 3.808074211519852e-08
least O 0 1.3459052761177759e-09
two O 0 2.22166951502345e-09
of O 0 8.844812104946698e-10
them O 0 1.670795235497735e-08
displayed O 0 3.800194861014461e-07
signs O 0 6.78156538924668e-07
of O 0 1.6826600557351412e-08
neurofibromatosis B-Disease 1 0.996752917766571
type I-Disease 0 0.013437663204967976
1 I-Disease 0 2.5760093649296323e-06
( O 0 3.3519587105956816e-08
NF1 B-Disease 0 0.0004132863541599363
) O 0 2.7762860455027294e-08
. O 0 5.7081198434616454e-08

DNA O 0 7.4719714575621765e-06
sequence O 0 1.6968385807558661e-07
analysis O 0 2.664383202954923e-08
and O 0 3.600112208346218e-09
allele O 0 7.676717039828418e-09
- O 0 2.4403154839092167e-06
specific O 0 1.99676342127475e-09
amplification O 0 2.0907054931740277e-06
in O 0 4.623140270609838e-08
two O 0 9.11709534534566e-08
siblings O 0 4.841342160943896e-06
revealed O 0 1.351478658762062e-06
a O 0 3.25339399864788e-08
homozygous O 0 1.3158832189219538e-05
MLH1 O 0 0.0019978864584118128
mutation O 0 1.970978928511613e-06
( O 0 3.936845072161077e-09
C676T O 0 1.272691633857903e-06
- O 0 0.00797999557107687
- O 0 0.017754409462213516
> O 0 1.707729779809597e-06
Arg226Stop O 0 1.7898484657052904e-05
) O 0 2.419644040685398e-09
. O 0 1.0626036051064602e-08

Thus O 0 3.3061262456612894e-06
, O 0 8.49056291940542e-09
a O 0 2.7929938362092344e-09
homozygous O 0 1.8645094996827538e-06
germ O 0 0.26905983686447144
- O 1 0.8858281970024109
line O 0 0.31316515803337097
MLH1 O 0 0.04382270574569702
mutation O 0 6.737319199601188e-05
and O 0 4.405862455314491e-06
consequent O 0 0.0012907928321510553
mismatch O 1 0.9999076128005981
repair O 1 0.999977707862854
deficiency O 1 0.9995561242103577
results O 0 5.45276179764187e-06
in O 0 6.424730258913769e-08
a O 0 1.7068180113710696e-06
mutator O 1 0.9214204549789429
phenotype O 0 0.03718806430697441
characterized O 0 0.0002788411220535636
by O 0 4.215482022118522e-06
leukemia B-Disease 1 0.9997652173042297
and O 0 0.0044167195446789265
/ O 1 0.9979867935180664
or O 1 0.881293773651123
lymphoma B-Disease 1 1.0
associated O 0 0.0020256591960787773
with O 0 1.7187556295539252e-05
neurofibromatosis B-Disease 1 0.9999340772628784
type I-Disease 0 0.4026261866092682
1 I-Disease 0 1.0444224244565703e-05
. O 0 2.0440585046799242e-07
. O 0 1.314461570700587e-07

Missense O 0 0.0026455700863152742
mutations O 0 0.002040598075836897
in O 0 1.0891004365021217e-07
the O 0 3.213326493778368e-08
most O 0 1.440443875289077e-09
ancient O 0 1.5914796591687264e-08
residues O 0 3.856197849927412e-07
of O 0 8.710676624446023e-10
the O 0 3.890045974230816e-08
PAX6 O 0 0.00016525221872143447
paired O 0 6.369146376528079e-06
domain O 0 3.1997370797398617e-07
underlie O 0 1.2953881878274842e-06
a O 0 1.249714820517056e-08
spectrum O 0 1.2127836725994712e-06
of O 0 2.870497439744213e-07
human O 0 0.05179609730839729
congenital B-Disease 1 0.9999974966049194
eye I-Disease 1 0.9999672174453735
malformations I-Disease 1 0.9997192025184631
. O 0 6.793871762056369e-06

Mutations O 0 0.000576936115976423
of O 0 1.5426207866653385e-08
the O 0 5.091948196422891e-08
human O 0 4.6328770508807793e-07
PAX6 O 0 0.0019933567382395267
gene O 0 0.00025907426606863737
underlie O 1 0.9920571446418762
aniridia B-Disease 1 0.9999996423721313
( O 0 0.007844903506338596
congenital B-Disease 1 0.9999977350234985
absence I-Disease 0 2.363079875067342e-05
of I-Disease 0 2.5982435758464817e-08
the I-Disease 0 3.830105924862437e-06
iris I-Disease 1 0.9322402477264404
) O 0 4.5350614641392895e-07
, O 0 8.976463128362866e-09
a O 0 1.0488950152875987e-07
rare O 0 1.1823694876511581e-05
dominant O 1 0.8446044325828552
malformation B-Disease 1 0.9979504942893982
of I-Disease 0 1.3863409265013615e-07
the I-Disease 0 4.961143986292882e-06
eye I-Disease 1 0.9149926900863647
. O 0 3.907719587914471e-07

The O 0 1.32026954702269e-07
spectrum O 0 1.6089201437807787e-07
of O 0 3.4340128518550728e-09
PAX6 O 0 0.0010093969758599997
mutations O 0 0.00022832394461147487
in O 0 6.398098776116967e-06
aniridia B-Disease 1 0.9999994039535522
patients O 0 0.0035634299274533987
is O 0 1.3803036047477235e-08
highly O 0 1.3557507116956913e-08
biased O 0 6.216159817995504e-05
, O 0 2.0898866637253377e-08
with O 0 1.1553873413561178e-08
92 O 0 1.3559028957388364e-06
% O 0 4.175508272474815e-10
of O 0 2.645254848498979e-10
all O 0 2.2395481025228037e-08
reported O 0 1.2202388006699039e-06
mutations O 0 3.362959205333027e-06
leading O 0 3.005031658176449e-06
to O 0 7.33591534185507e-08
premature O 0 3.4789340475072095e-07
truncation O 0 1.5119567251531407e-06
of O 0 8.241839211109436e-09
the O 0 1.2965521989372064e-07
protein O 0 1.5853951254030108e-06
( O 0 2.0740689166132142e-09
nonsense O 0 5.378017704060767e-06
, O 0 1.5217681281765039e-10
splicing O 0 2.3864661358175e-08
, O 0 6.495289306407415e-10
insertions O 0 2.7562311544215845e-08
and O 0 2.486848416083376e-08
deletions O 0 1.5567680122785532e-07
) O 0 7.503321519664041e-09
and O 0 6.501393556845869e-08
just O 0 2.1277274697695248e-07
2 O 0 4.674532760873262e-08
% O 0 1.0116865123421803e-09
leading O 0 5.229948740748114e-08
to O 0 2.748611060976458e-10
substitution O 0 5.805285141491368e-10
of O 0 7.339576169052009e-10
one O 0 1.249984649120961e-07
amino O 0 5.881423348341741e-08
acid O 0 4.9766597953748715e-08
by O 0 9.100981634979632e-10
another O 0 2.9154001879305724e-08
( O 0 2.0032215886089944e-09
missense O 0 4.6214663598220795e-06
) O 0 1.1781168929303476e-08
. O 0 2.7459831741794005e-08

The O 0 1.1076003403331924e-07
extraordinary O 0 9.774852038901827e-09
conservation O 0 4.753335947071946e-09
of O 0 1.065644933406773e-10
the O 0 1.1459013737891155e-09
PAX6 O 0 3.4249403597641503e-06
protein O 0 1.0055735799596732e-07
at O 0 8.7387048708365e-09
the O 0 2.361506545867087e-09
amino O 0 4.0292380987239085e-08
acid O 0 2.0967546277006477e-07
level O 0 4.270058084898665e-08
amongst O 0 9.116588373103696e-09
vertebrates O 0 3.869666613809386e-07
predicts O 0 1.6941532521741465e-05
that O 0 8.136862561514135e-08
pathological O 0 7.593568170705112e-06
missense O 0 0.00017045294225681573
mutations O 0 0.00030131390667520463
should O 0 3.1311874408856966e-06
in O 0 2.5408061432585782e-08
fact O 0 6.111001766839763e-07
be O 0 1.2984295381102129e-06
common O 0 5.860885039510322e-07
even O 0 1.081018240256526e-06
though O 0 2.999883577103901e-07
they O 0 2.4318674718415423e-07
are O 0 2.992972092386026e-09
hardly O 0 1.467547576794459e-07
ever O 0 1.5315906409796298e-07
seen O 0 3.0063966960369726e-07
in O 0 3.8149082115523925e-07
aniridia B-Disease 1 0.9999948740005493
patients O 0 3.6510486097540706e-05
. O 0 3.934249903636555e-08

This O 0 1.0174526323680766e-06
indicates O 0 2.0607103579095565e-06
that O 0 7.021159831310797e-08
there O 0 5.710556028049041e-09
is O 0 3.331145914664546e-10
a O 0 1.6711672046199055e-09
heavy O 0 1.8309036704522441e-06
ascertainment O 0 2.5578267013770528e-05
bias O 0 2.3060323655954562e-05
in O 0 2.572001056577733e-09
the O 0 1.7489214521049234e-09
selection O 0 1.6054055862468886e-09
of O 0 7.753230835128022e-10
patients O 0 9.383136756468957e-08
for O 0 4.808355380525597e-10
PAX6 O 0 3.3994299883488566e-05
mutation O 0 1.5950875820180954e-07
analysis O 0 3.6279278248230185e-08
and O 0 8.491975478364111e-08
that O 0 4.886941695758651e-08
the O 0 1.0466088440352905e-07
missing O 0 6.418094926630147e-06
PAX6 O 0 0.0037703108973801136
missense O 0 0.0004171093460172415
mutations O 0 0.0007391335675492883
frequently O 0 2.7235048037255183e-05
may O 0 9.769823009264655e-06
underlie O 0 0.00017529420438222587
phenotypes O 0 1.774430347722955e-05
distinct O 0 1.365963697708139e-07
from O 0 1.8569627968645364e-07
textbook O 1 0.9447653293609619
aniridia B-Disease 1 0.999994158744812
. O 0 6.3593984123144764e-06

Here O 0 5.960878297628369e-06
we O 0 1.5787443885528774e-07
present O 0 6.010966169256449e-10
four O 0 3.782836266452705e-09
novel O 0 1.0055532584374305e-06
PAX6 O 0 0.00012753266491927207
missense O 0 0.00014990098134148866
mutations O 0 0.0003362544812262058
, O 0 1.2560288098484307e-07
two O 0 2.9974753346095895e-08
in O 0 1.0838823527592467e-07
association O 0 2.5909298528858926e-07
with O 0 2.1245440962047724e-07
atypical O 0 0.0010896556777879596
phenotypes O 0 6.138842582004145e-05
ectopia B-Disease 0 0.000770038808695972
pupillae I-Disease 0 0.000406660110456869
( O 0 1.4338658260726334e-08
displaced B-Disease 0 3.064376983274997e-07
pupils I-Disease 0 8.385811270272825e-06
) O 0 1.140908580055111e-06
and O 0 0.0046350606717169285
congenital B-Disease 1 0.9999933242797852
nystagmus I-Disease 0 0.33687451481819153
( O 0 2.8783805561261033e-08
searching B-Disease 0 8.478968993586022e-07
gaze I-Disease 0 0.00048331779544241726
) O 0 1.5275713138862557e-08
, O 0 1.0573752540210535e-08
and O 0 8.106067639346293e-08
two O 0 3.391340896996553e-08
in O 0 1.9615568191966304e-07
association O 0 4.8629612336981154e-08
with O 0 3.735642906121939e-09
more O 0 2.9534350520776798e-09
recognizable O 0 0.0008265561191365123
aniridia B-Disease 1 0.9999871253967285
phenotypes O 0 0.0004452570283319801
. O 0 2.7070413466390164e-07

Strikingly O 0 0.00019701193377841264
, O 0 4.556277417577803e-07
all O 0 3.263416648024986e-09
four O 0 1.0825327301233756e-08
mutations O 0 6.211623713170411e-07
are O 0 1.7714855138351027e-09
located O 0 1.1113671405382775e-07
within O 0 1.5318486035198475e-08
the O 0 5.042127426690968e-08
PAX6 O 0 0.00023419028730131686
paired O 0 2.253254751849454e-05
domain O 0 7.947885023895651e-06
and O 0 9.078084417524224e-07
affect O 0 1.7321812606496678e-07
amino O 0 1.0549744189347621e-07
acids O 0 8.319612732066162e-08
which O 0 5.550912263174723e-08
are O 0 2.8313212885322514e-10
highly O 0 9.14914033423031e-10
conserved O 0 9.84019692396032e-08
in O 0 1.887032752279083e-08
all O 0 2.4808823884114872e-09
known O 0 1.6050060480665707e-07
paired O 0 2.34946401178604e-06
domain O 0 3.3996835213656595e-07
proteins O 0 1.811146006502895e-07
. O 0 8.854983235551117e-08

Our O 0 5.018256160838064e-06
results O 0 9.250923227455132e-08
support O 0 9.135625589351548e-10
the O 0 1.512881264709165e-09
hypothesis O 0 9.015551540869637e-07
that O 0 7.702442239576612e-09
the O 0 9.333595007987583e-10
under O 0 1.7254527806542796e-09
- O 0 4.496286294397578e-07
representation O 0 7.87432430371382e-09
of O 0 1.1661021037667751e-09
missense O 0 9.719100489746779e-05
mutations O 0 3.245917469030246e-05
is O 0 1.292032010269395e-07
caused O 0 2.389490987297904e-07
by O 0 5.58020785135227e-09
ascertainment O 0 0.00013553565077017993
bias O 0 0.006974008399993181
and O 0 9.217105230163725e-07
suggest O 0 3.8345100961123535e-07
that O 0 1.3764232420498956e-08
a O 0 3.858483754726194e-09
substantial O 0 4.1264097916382525e-08
burden O 0 1.2772999298249488e-06
of O 0 8.326641598443985e-09
PAX6 B-Disease 1 0.6772310733795166
- I-Disease 1 0.9944374561309814
related I-Disease 0 0.023644451051950455
disease I-Disease 1 0.9784572124481201
remains O 0 3.1964111713023158e-06
to O 0 2.3168263751927043e-08
be O 0 1.2210865207862298e-08
uncovered O 0 3.2715754514356377e-06
. O 0 1.4141770421360889e-08
. O 0 2.20640465897759e-08

The O 0 4.429314230947057e-07
chromosomal O 0 0.00039437931263819337
order O 0 6.266775187668827e-08
of O 0 1.3576700874651237e-09
genes O 0 4.342152806202648e-07
controlling O 0 7.383462798316032e-05
the O 0 3.7704202782151697e-07
major O 0 1.3396164888490603e-07
histocompatibility O 0 5.266333118925104e-06
complex O 0 7.95135747466702e-07
, O 0 8.485980806938187e-09
properdin O 0 1.8897504787673824e-06
factor O 0 1.200523342959059e-07
B O 0 0.0016986059490591288
, O 0 1.1666282517808213e-07
and O 0 1.453780714655295e-05
deficiency B-Disease 0 5.6142387620639056e-05
of I-Disease 0 5.332362884580277e-10
the I-Disease 0 5.0380322136334144e-08
second I-Disease 0 4.36061100117513e-07
component I-Disease 0 2.3641712587618713e-08
of I-Disease 0 5.328936181214772e-10
complement I-Disease 0 3.428452544085303e-07
. O 0 3.035493989500537e-08

The O 0 3.227956142382027e-07
relationship O 0 3.949602600528124e-08
of O 0 2.0539589473678177e-10
the O 0 5.534742109070123e-10
genes O 0 1.01179695732867e-08
coding O 0 1.7435585277780774e-06
for O 0 3.4165954510001484e-09
HLA O 0 1.4740386177436449e-05
to O 0 1.4145568050238921e-09
those O 0 1.0553915380517864e-10
coding O 0 1.962413733735957e-07
for O 0 8.106338378333078e-10
properdin O 0 3.4383319871267304e-06
Factor O 0 1.1717907710817599e-07
B O 0 3.831729554804042e-05
allotypes O 0 9.622237485018559e-06
and O 0 5.208884203966591e-07
for O 0 8.074988500084146e-08
deficiency B-Disease 0 0.003251979360356927
of I-Disease 0 1.0265368555195664e-09
the I-Disease 0 6.296080101719781e-08
second I-Disease 0 7.914408115539118e-07
component I-Disease 0 3.110218216306748e-08
of I-Disease 0 2.2869786064916298e-09
complement I-Disease 0 9.366870017402107e-07
( O 0 8.460091294182348e-09
C2 O 0 0.0004916004836559296
) O 0 1.3684384736478705e-09
was O 0 1.9712804544269602e-07
studied O 0 4.2554148649287526e-08
in O 0 6.782746808653428e-09
families O 0 1.2193404064220204e-09
of O 0 4.599829406259914e-09
patients O 0 4.804143827641383e-06
with O 0 3.6649150843004463e-06
connective O 1 0.9999529123306274
tissue O 1 0.9999417066574097
disorders O 1 0.9948423504829407
. O 0 5.82457232667366e-07

Patients O 0 0.0007651858031749725
were O 0 6.902768490135713e-08
selected O 0 5.094811239558794e-09
because O 0 4.2175480885475736e-09
they O 0 5.813554082578776e-09
were O 0 1.528759674407354e-09
heterozygous O 0 1.314700437404781e-08
or O 0 7.680143632171621e-09
homozygous O 0 4.006969447800657e-06
for O 0 0.0003150428819935769
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.999998927116394
. O 0 3.939524503948633e-06

12 O 0 3.2616999305901118e-06
families O 0 1.9342895285490158e-08
with O 0 5.052309681730094e-09
15 O 0 2.0059793826021632e-08
matings O 0 4.281829751562327e-05
informative O 0 0.0009333516354672611
for O 0 0.059105806052684784
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
were O 0 2.9566856483143056e-06
found O 0 1.1213710422453005e-06
. O 0 1.1690126200392115e-07

Of O 0 9.07465960153786e-08
57 O 0 4.806544779967226e-07
informative O 0 8.054420277403551e-07
meioses O 0 0.0002028565650107339
, O 0 6.321853707191849e-09
two O 0 1.9924518979141936e-10
crossovers O 0 1.729774226078007e-07
were O 0 1.8777772936573456e-07
noted O 0 1.0903954006380445e-07
between O 0 1.2449374935386004e-06
the O 0 0.04864989221096039
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999984502792358
gene O 0 3.0659780350106303e-06
and O 0 1.8375422428107413e-07
the O 0 2.6327143132220954e-08
HLA O 0 0.024546140804886818
- O 0 0.14318260550498962
B O 0 0.0005298155010677874
gene O 0 9.74999778691199e-08
, O 0 2.758742401187675e-10
with O 0 2.5856724747419513e-11
a O 0 7.542859392639656e-11
recombinant O 0 3.615140409252149e-09
fraction O 0 1.620801604040878e-09
of O 0 1.7836232490964221e-09
0 O 0 1.0617505949994666e-06
. O 0 6.217722159362893e-08

035 O 0 0.06559261679649353
. O 0 3.5967335861641914e-05

A O 0 3.545270828908542e-06
lod O 0 0.0030724680982530117
score O 0 5.106462140247459e-06
of O 0 4.972593448115958e-10
13 O 0 3.874835741157767e-08
was O 0 6.72435831461371e-08
calculated O 0 4.1986403687133134e-08
for O 0 3.0686682084279937e-09
linkage O 0 0.15807266533374786
between O 0 0.44663944840431213
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
and O 0 9.778091225598473e-06
HLA O 0 0.04524052515625954
- O 0 0.4260161519050598
B O 0 0.0026370936539024115
at O 0 1.3355664352232566e-09
a O 0 9.362564890036396e-11
maximum O 0 2.6965177313265087e-10
likelihood O 0 5.218574461451908e-10
value O 0 8.583627558733653e-11
of O 0 1.5417479792834143e-11
the O 0 5.492442611831905e-11
recombinant O 0 3.9340652957520206e-10
fraction O 0 3.105674051262497e-10
of O 0 4.274666176584674e-10
0 O 0 4.5409515792016464e-07
. O 0 3.923600644384351e-08

04 O 0 0.010469609871506691
. O 0 7.108949830580968e-06

18 O 0 1.936073022079654e-05
families O 0 4.857371393995891e-08
with O 0 5.856591656083765e-09
21 O 0 2.2219079909291395e-08
informative O 0 5.980471939892595e-08
matings O 0 6.009187927702442e-06
for O 0 4.305245937530344e-09
both O 0 2.3537777948945404e-08
properdin O 0 4.0042719774646685e-05
Factor O 0 2.192337547057832e-07
B O 0 1.3457474778988399e-05
allotype O 0 5.217571924731601e-06
and O 0 3.682323210796312e-07
HLA O 0 0.0004700192657765001
- O 0 0.042518991976976395
B O 0 0.000410092732636258
were O 0 1.5106328632441546e-08
found O 0 2.2706629465574224e-08
. O 0 1.9055656608202298e-08

Of O 0 9.542795709194252e-08
72 O 0 1.257319809155888e-06
informative O 0 7.491346991628234e-07
meioses O 0 7.346702477661893e-05
, O 0 2.5577762130524206e-08
three O 0 4.42639791486954e-09
recombinants O 0 1.8528446162235923e-05
were O 0 3.9060839185367513e-07
found O 0 1.9574140708300547e-07
, O 0 3.3586877723479347e-10
giving O 0 3.364726205989932e-11
a O 0 1.9569979317624053e-11
recombinant O 0 5.141118086804397e-10
fraction O 0 1.34723321387753e-09
of O 0 1.5695870159149194e-09
0 O 0 1.196895254906849e-06
. O 0 7.056334538901865e-08

042 O 0 0.005365725606679916
. O 0 1.629019243409857e-05

A O 0 6.008741365803871e-06
lod O 0 0.0015532196266576648
score O 0 9.499203770246822e-06
of O 0 9.3399887823864e-10
16 O 0 1.5467042757677518e-08
between O 0 2.7347248021669657e-08
HLA O 0 0.010968014597892761
- O 0 0.23711952567100525
B O 0 0.0010143202962353826
and O 0 1.1778023001340898e-08
Factor O 0 6.7164598327451586e-09
B O 0 2.070208665827522e-06
allotypes O 0 3.057814694784611e-07
was O 0 4.775748507768185e-08
calculated O 0 6.415679099092131e-09
at O 0 5.850447903910094e-10
a O 0 1.6751268427928068e-10
maximum O 0 2.82601247958425e-10
likelihood O 0 7.475376984089621e-10
value O 0 2.1497692515026756e-10
of O 0 2.62896700936599e-11
the O 0 1.309713587582806e-10
recombinant O 0 6.274675778961125e-10
fraction O 0 4.263884800792539e-10
of O 0 6.166106514271519e-10
0 O 0 1.2491391316871159e-06
. O 0 4.2988805404320374e-08

04 O 0 0.012486276216804981
. O 0 6.209749699337408e-06

A O 0 1.5500776839871833e-07
crossover O 0 4.5081495159138285e-07
was O 0 2.4473699795635184e-06
shown O 0 2.2755536122076592e-08
to O 0 1.9615180590903947e-09
have O 0 4.856090640714683e-09
occurred O 0 1.0306259845549448e-08
between O 0 6.366501215104847e-10
genes O 0 8.546536811593342e-09
for O 0 4.823630939121415e-10
Factor O 0 2.5027080852169092e-08
B O 0 8.367596819880418e-06
and O 0 1.1887482997963161e-08
HLA O 0 7.0097580646688584e-06
- O 0 0.001701862784102559
D O 0 0.0003145183145534247
, O 0 1.2142993277564074e-09
in O 0 3.5062724945689183e-10
which O 0 2.1452699172641587e-08
HLA O 0 1.8363703929935582e-05
- O 0 0.00443720119073987
D O 0 9.056959243025631e-05
segregared O 0 1.1291738246654859e-06
with O 0 6.067769842132975e-09
HLA O 0 2.8493501304183155e-05
- O 0 0.00010654208017513156
A O 0 1.2240757314430084e-06
and O 0 1.6756018794694683e-06
B O 0 2.807657074299641e-05
. O 0 2.090644279917342e-08

These O 0 8.903487014322309e-08
studies O 0 8.062088774352105e-09
suggest O 0 2.6855875745468438e-08
that O 0 8.462459621938478e-10
the O 0 2.1886685519501015e-10
genes O 0 6.960713783144001e-09
for O 0 3.303327389403421e-09
Factor O 0 3.6172916679788614e-06
B O 1 0.9916918277740479
and O 1 0.7491795420646667
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
are O 0 4.589934654575245e-09
located O 0 5.3442708036754993e-08
outside O 0 8.549670837965095e-08
those O 0 3.3748657202181676e-09
for O 0 2.5034039285998233e-09
HLA O 0 0.0005409128498286009
, O 0 5.114673573558548e-09
that O 0 2.106582019933967e-09
the O 0 6.302202093522169e-10
order O 0 7.906707510940691e-10
of O 0 7.285872599682719e-11
genese O 0 4.195021119812736e-06
is O 0 1.5722903867754212e-08
HLA O 0 3.0320711630338337e-06
- O 0 2.8950748856004793e-06
A O 0 2.4030404688346607e-07
, O 0 5.056465024466661e-09
- O 0 3.3601668292249087e-06
B O 0 3.359567699590116e-06
, O 0 4.390592611702715e-10
- O 0 1.1415496601330233e-06
D O 0 3.862930043396773e-06
, O 0 2.720420277935176e-10
Factor O 0 3.242625057353621e-09
B O 0 6.873306119814515e-06
allotype O 0 0.00010248809849144891
, O 0 0.00017212654347531497
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999995231628418
, O 0 2.3267181514796675e-09
that O 0 5.196186259048829e-10
the O 0 1.6038194383671822e-10
genes O 0 1.610703392884716e-08
coding O 0 0.00199862546287477
for O 0 0.02218814007937908
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
and O 0 9.965820026991423e-07
Factor O 0 1.2438688656857266e-07
B O 0 2.0721876353491098e-05
allotypes O 0 4.3269614025120973e-07
are O 0 2.3439103435940467e-10
approximately O 0 2.9927824107822687e-10
3 O 0 9.840929493520889e-08
- O 0 0.0004273394588381052
- O 0 0.0006696180207654834
5 O 0 1.911805647125675e-08
centimorgans O 0 1.5040325251902686e-07
from O 0 7.460288636851331e-11
the O 0 1.5182723966944423e-09
HLA O 0 1.724534922686871e-05
- O 0 2.206763565482106e-05
A O 0 3.8290872339530324e-07
and O 0 4.3698278773263155e-07
HLA O 0 2.5074297809624113e-05
- O 0 0.0012813658686354756
B O 0 6.085748282202985e-06
loci O 0 9.942593415246392e-10
, O 0 6.420216580593774e-10
and O 0 4.880455595213107e-09
that O 0 1.530680471262258e-08
the O 0 1.2785556613437166e-08
apparent O 0 2.473409779213398e-07
lack O 0 2.6516719930924637e-09
of O 0 6.289638254663998e-11
recombinants O 0 2.1804971765959635e-06
between O 0 5.443337336430432e-09
the O 0 1.6085197618309621e-09
Factor O 0 6.590236267811633e-08
B O 0 0.00018231704598292708
gene O 0 4.792434992850758e-05
and O 1 0.7599084377288818
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
gene O 0 1.7645821571932174e-05
suggests O 0 2.514839252398815e-06
that O 0 2.0173737880213594e-07
these O 0 7.181232497543988e-09
two O 0 1.806791161129695e-08
genes O 0 2.493789224899956e-06
lie O 0 0.0028195062186568975
in O 0 1.168525098904638e-08
close O 0 1.5487935911551176e-07
proximity O 0 4.909813355880033e-07
to O 0 3.167149031924055e-08
one O 0 8.171884502417015e-09
another O 0 1.5739743730591726e-07
. O 0 1.5654266860565258e-07

Distribution O 0 5.860829332959838e-07
of O 0 6.9765708765601175e-09
emerin O 0 0.00011112953507108614
and O 0 5.554941822083492e-07
lamins O 0 6.938003934919834e-05
in O 0 3.775507551040391e-08
the O 0 1.0238730965284049e-06
heart O 0 0.0015316848875954747
and O 0 7.940099067127449e-08
implications O 0 5.816396253521816e-08
for O 0 9.855726901264461e-09
Emery B-Disease 0 0.4517868459224701
- I-Disease 1 0.999606192111969
Dreifuss I-Disease 1 0.9999485015869141
muscular I-Disease 1 0.9993914365768433
dystrophy I-Disease 1 0.998613715171814
. O 0 4.5727929887107166e-07

Emerin O 0 0.004114126320928335
is O 0 4.957843913189208e-08
a O 0 4.148749344068392e-09
nuclear O 0 1.142025553235726e-06
membrane O 0 7.393718988168985e-07
protein O 0 7.180645411608566e-07
which O 0 2.0959429036793154e-07
is O 0 4.5360042832953695e-08
missing O 0 6.511619403681834e-07
or O 0 7.558021053455377e-08
defective O 0 6.544559437315911e-05
in O 0 2.896174009947572e-06
Emery B-Disease 1 0.9950697422027588
- I-Disease 1 0.9999773502349854
Dreifuss I-Disease 1 0.9999891519546509
muscular I-Disease 1 0.9999300241470337
dystrophy I-Disease 1 0.9999425411224365
( O 0 1.659568260947708e-05
EDMD B-Disease 1 0.9999867677688599
) O 0 5.191952254790522e-07
. O 0 1.077075353350665e-07

It O 0 1.3088031664665323e-05
is O 0 4.9423316994534616e-08
one O 0 6.854994349936305e-09
member O 0 2.92543461677397e-10
of O 0 1.7758522430355583e-10
a O 0 8.338358270520985e-08
family O 0 3.821911320756044e-07
of O 0 1.0895425894830169e-08
lamina O 0 0.006808485835790634
- O 0 0.021860476583242416
associated O 0 9.469761153013678e-08
proteins O 0 1.7989165712606336e-08
which O 0 2.1521826543136058e-09
includes O 0 2.6972903910404966e-09
LAP1 O 0 8.304121001856402e-05
, O 0 6.903528859680819e-09
LAP2 O 0 6.205191766639473e-06
and O 0 6.195111978968271e-08
lamin O 0 8.274454739876091e-05
B O 0 0.0003145797527395189
receptor O 0 5.551409572035482e-07
( O 0 1.473001454144196e-08
LBR O 0 0.0003404728486202657
) O 0 3.817164184738431e-08
. O 0 5.217036758153881e-08

A O 0 4.1679024320728786e-07
panel O 0 1.9645334248252766e-07
of O 0 1.4297714123756577e-09
16 O 0 6.256694717876599e-08
monoclonal O 0 5.541916380025214e-06
antibodies O 0 2.9706450277444674e-06
( O 0 1.0068893496750775e-09
mAbs O 0 2.959346829811693e-07
) O 0 2.245355235075408e-09
has O 0 4.3007666761241126e-08
been O 0 4.7645485778957664e-08
mapped O 0 1.7570073396200314e-05
to O 0 2.1374809477947565e-08
six O 0 6.683308351185246e-10
specific O 0 2.3074733096484223e-11
sites O 0 3.738279907850028e-09
throughout O 0 1.4093106681656309e-09
the O 0 8.790674299596901e-10
emerin O 0 7.763181741893277e-08
molecule O 0 2.87570101065171e-09
using O 0 1.9542618634460496e-09
phage O 0 3.9320365630146625e-08
- O 0 1.193624939332949e-06
displayed O 0 1.3651752617249713e-08
peptide O 0 2.6786288742641773e-09
libraries O 0 3.176015450634395e-09
and O 0 1.0757486457180221e-08
has O 0 8.343080004635794e-09
been O 0 9.72455005410211e-09
used O 0 5.3970151014937073e-08
to O 0 5.749331677407099e-09
localize O 0 1.121224613598315e-05
emerin O 0 5.414754195953719e-05
in O 0 7.543143709654032e-08
human O 0 9.132120908361685e-07
and O 0 3.552936959749786e-06
rabbit O 1 0.7344610691070557
heart O 0 0.013824027962982655
. O 0 2.0098441666505096e-07

Several O 0 1.35120131972144e-07
mAbs O 0 2.090944690280594e-06
against O 0 9.843087411809393e-08
different O 0 2.5644475432073932e-09
emerin O 0 4.458789771888405e-05
epitopes O 0 0.0001552999601699412
did O 0 3.122822818113491e-05
not O 0 5.416495341137306e-08
recognize O 0 1.4462258057790223e-08
intercalated O 0 1.326423671343946e-06
discs O 0 0.06397148221731186
in O 0 5.0942780944751576e-06
the O 0 1.600009090907406e-05
heart O 0 0.16905418038368225
, O 0 3.1967232416718616e-08
though O 0 3.388043623431258e-08
they O 0 1.2379287817054774e-08
recognized O 0 1.5398597952298587e-09
cardiomyocyte O 0 1.1336873058098718e-06
nuclei O 0 2.106107501731458e-07
strongly O 0 1.302172876194163e-07
, O 0 4.076933457497489e-09
both O 0 9.533259515137615e-09
at O 0 8.085175551286738e-08
the O 0 1.0157536678434553e-07
rim O 0 0.0005960606504231691
and O 0 1.5926768526242085e-07
in O 0 6.0004876623054315e-09
intranuclear O 0 1.8028442354989238e-05
spots O 0 1.7714446585159749e-06
or O 0 2.5123307878516243e-08
channels O 0 5.199503334551991e-07
. O 0 8.669545792372446e-08

A O 0 3.3504106795589905e-06
polyclonal O 0 0.00011686595826176926
rabbit O 0 0.0004206014855299145
antiserum O 0 3.920722519978881e-05
against O 0 2.7310659334034426e-06
emerin O 0 0.0001880649506347254
did O 0 6.883802143420326e-06
recognize O 0 4.903458616922762e-08
both O 0 1.566396790053659e-08
nuclear O 0 4.172704393567983e-06
membrane O 0 4.913456905342173e-06
and O 0 1.7691810683118092e-07
intercalated O 0 4.184286126474035e-07
discs O 0 0.0005687691154889762
but O 0 5.293031790642999e-07
, O 0 4.066393055612849e-10
after O 0 6.179867728661748e-11
affinity O 0 1.6188234086556008e-10
purification O 0 1.2593146969663849e-08
against O 0 7.43068966357896e-08
a O 0 4.228889682877934e-09
pure O 0 6.676879138467484e-08
- O 0 0.0009306050487793982
emerin O 0 4.263305982021848e-06
band O 0 1.0117530990783052e-07
on O 0 4.0256717959152866e-09
a O 0 1.6044504613788035e-09
western O 0 4.280871621631377e-07
blot O 0 0.04585709422826767
, O 0 7.624974784903316e-08
it O 0 6.979900746273415e-08
stained O 0 0.000410524575272575
only O 0 3.947657756242506e-09
the O 0 8.176589405550772e-10
nuclear O 0 4.280439043213846e-07
membrane O 0 9.666446203482337e-07
. O 0 3.719973662441589e-08

These O 0 5.197688892621954e-07
results O 0 1.1613708750246587e-07
would O 0 2.20918821014493e-08
not O 0 5.12222042559074e-09
be O 0 1.8528715228782744e-09
expected O 0 9.498229758264642e-09
if O 0 8.18033996097256e-08
immunostaining O 0 1.8547536456026137e-05
at O 0 1.2012344541290076e-07
intercalated O 0 6.575921815965557e-07
discs O 0 0.002785254968330264
were O 0 1.8394848666503094e-06
due O 0 5.050134888051616e-08
to O 0 2.0215573659498887e-09
a O 0 4.393677421887787e-09
product O 0 1.9011952190339798e-07
of O 0 1.3285642586069457e-09
the O 0 2.02772909574378e-08
emerin O 0 1.8776889191940427e-05
gene O 0 1.5778864508320112e-06
and O 0 1.3639802318721195e-06
, O 0 1.3627636796798015e-08
therefore O 0 1.5561617772164027e-08
, O 0 3.1962871238633284e-10
cast O 0 2.1454364951267735e-09
some O 0 1.4327818098625045e-10
doubt O 0 1.5013950971365375e-08
upon O 0 1.503508428868372e-10
the O 0 2.970009349567704e-09
hypothesis O 0 8.253337909991387e-06
that O 0 2.9296172670001397e-06
cardiac B-Disease 0 0.4455225467681885
defects I-Disease 1 0.9811680316925049
in O 0 6.589987151528476e-06
EDMD B-Disease 1 1.0
are O 0 3.83815131499432e-05
caused O 0 3.662137532955967e-05
by O 0 3.860193231730591e-08
absence O 0 7.096407728113263e-08
of O 0 2.092418460719614e-09
emerin O 0 0.0003529108362272382
from O 0 1.9385518967851567e-08
intercalated O 0 2.2935839297133498e-05
discs O 0 0.0009762959089130163
. O 0 4.6314013957271527e-07

Although O 0 1.0955044672300573e-05
emerin O 0 0.00016365777992177755
was O 0 2.4634430246806005e-06
abundant O 0 1.4448526819421659e-08
in O 0 4.611961923473018e-09
the O 0 1.060687981890851e-08
membranes O 0 2.645142330948147e-06
of O 0 4.839797895783704e-09
cardiomyocyte O 0 8.337534382008016e-05
nuclei O 0 8.819046342978254e-06
, O 0 8.908752846537027e-08
it O 0 9.810044332425605e-08
was O 0 1.3166651342544355e-06
absent O 0 1.5547376719382555e-08
from O 0 1.8442322669010025e-10
many O 0 2.385489861200796e-10
non O 0 1.4502005818428643e-08
- O 0 8.352613804163411e-05
myocyte O 0 2.7731093723559752e-05
cells O 0 3.300703497188806e-07
in O 0 4.4814121302749754e-09
the O 0 5.112384471317455e-08
heart O 0 9.731527825351804e-05
. O 0 8.323168287915905e-08

This O 0 2.1369960023776002e-08
distribution O 0 1.2460612985876196e-08
of O 0 6.846967437468265e-10
emerin O 0 0.00013405711797531694
was O 0 3.2169218684430234e-06
similar O 0 6.10886630170171e-09
to O 0 1.0282187545840316e-08
that O 0 1.4846676776869572e-08
of O 0 8.185108701930233e-10
lamin O 0 0.0001650684280321002
A O 0 4.404925675771665e-06
, O 0 3.232590417567849e-09
a O 0 1.2617423772454117e-09
candidate O 0 5.9355702575203395e-09
gene O 0 7.276800317868037e-08
for O 0 3.955149097123467e-09
an O 0 1.316490170211182e-07
autosomal O 0 0.07447373121976852
form O 0 3.131760604446754e-05
of O 0 7.828083653294016e-06
EDMD B-Disease 1 0.9999983310699463
. O 0 9.363929166283924e-06

In O 0 1.0708706099649135e-07
contrast O 0 7.859545689825609e-07
, O 0 6.490799364655686e-08
lamin O 0 0.003306527389213443
B1 O 1 0.9905263185501099
was O 0 2.094019509968348e-05
absent O 0 1.1313301939708253e-07
from O 0 1.0991141330407572e-09
cardiomyocyte O 0 1.199679263663711e-05
nuclei O 0 1.9065129208684084e-06
, O 0 1.1251644060905619e-08
showing O 0 4.502130082073563e-07
that O 0 1.6632634469715413e-07
lamin O 0 0.00607970030978322
B1 O 1 0.9741399884223938
is O 0 1.1901848750994759e-07
not O 0 8.645499427473169e-09
essential O 0 1.6335627295305244e-10
for O 0 4.1872779549256833e-11
localization O 0 1.8326176132177352e-07
of O 0 3.533981440817513e-10
emerin O 0 4.5915810915175825e-05
to O 0 1.2677423555373935e-08
the O 0 5.328390173531261e-09
nuclear O 0 2.5278575321863173e-06
lamina O 0 3.680963709484786e-05
. O 0 1.1326504534281412e-07

Lamin O 1 0.9401929974555969
B1 O 1 0.9996122717857361
is O 0 1.5068902939674444e-05
also O 0 1.3897392818762455e-06
almost O 0 4.673659148579645e-08
completely O 0 2.047929046966601e-05
absent O 0 3.154567025376309e-07
from O 0 2.5274660586660502e-08
skeletal O 1 0.5338354706764221
muscle O 0 0.00011826174886664376
nuclei O 0 2.0065122953383252e-05
. O 0 2.2277772870893386e-07

In O 0 1.066816821548855e-05
EDMD B-Disease 1 0.9999638795852661
, O 0 2.6144794773586e-08
the O 0 1.9680038154668011e-10
additional O 0 1.2716012964819612e-10
absence O 0 1.102402524821855e-08
of O 0 4.046279311609169e-09
lamin O 1 0.8254671096801758
B1 O 1 0.9997871518135071
from O 0 2.65200264948362e-06
heart O 1 0.5245904922485352
and O 0 2.9215036192908883e-05
skeletal O 1 0.8718358874320984
muscle O 0 0.00025963332154788077
nuclei O 0 1.4343097973323893e-05
which O 0 2.536030933697475e-06
already O 0 2.451146883686306e-06
lack O 0 2.6645921025192365e-07
emerin O 0 0.0007694667438045144
may O 0 1.4716780469825608e-06
offer O 0 7.551702041475039e-10
an O 0 2.0455573346289668e-10
alternative O 0 4.553555754682748e-09
explanation O 0 1.4082473853704869e-08
of O 0 2.202749538326998e-09
why O 0 3.9477158679801505e-06
these O 0 4.507921858021291e-08
tissues O 0 7.086127311595192e-07
are O 0 1.056858600634314e-09
particularly O 0 1.4830543015875719e-08
affected O 0 3.483425103922855e-08
. O 0 3.358651134988122e-09
. O 0 1.6804822422500365e-08

Genetic O 0 7.076574547681957e-05
mapping O 0 1.1290573638689239e-05
of O 0 2.3968256712691982e-08
the O 0 3.9103628068914986e-07
copper B-Disease 0 0.0016609667800366879
toxicosis I-Disease 0 0.004470378626137972
locus O 0 8.942338354245294e-07
in O 0 4.920012486309133e-08
Bedlington O 0 0.0013049514964222908
terriers O 0 0.003318750998005271
to O 0 1.9309506171794055e-07
dog O 0 0.0001204592699650675
chromosome O 0 0.0008159853750839829
10 O 0 1.111189078528696e-07
, O 0 5.5811870680599895e-09
in O 0 3.0344851076336e-09
a O 0 1.3615573379865964e-07
region O 0 4.763875949720386e-06
syntenic O 0 0.001236512209288776
to O 0 3.196083468992583e-07
human O 0 1.5123792707072425e-07
chromosome O 0 4.173930938122794e-05
region O 0 4.6885296001164534e-07
2p13 O 0 2.4717453470657347e-06
- O 0 3.125707007711753e-05
p16 O 0 6.181668368299142e-07
. O 0 2.6708502076644436e-08

Abnormal O 1 0.9978035092353821
hepatic B-Disease 1 0.9989379048347473
copper I-Disease 0 0.37910833954811096
accumulation I-Disease 0 0.00023395106836687773
is O 0 8.959361963434276e-08
recognized O 0 6.979355049452352e-08
as O 0 2.323306262042024e-06
an O 0 0.0030011467169970274
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 3.066992212552577e-05
man O 1 0.512414813041687
, O 0 5.655990094055596e-07
mouse O 0 0.007859361357986927
, O 0 1.9498811809626204e-07
rat O 0 0.0010317281121388078
and O 0 2.983774720632937e-07
dog O 0 6.519910675706342e-05
. O 0 1.0390228055712214e-07

The O 0 7.069414095894899e-06
major O 0 1.0842281881195959e-06
cause O 0 6.41876840745681e-06
of O 0 1.246213798822282e-07
hepatic B-Disease 1 0.9960854053497314
copper I-Disease 1 0.9199990034103394
accumulation I-Disease 0 0.00400379067286849
in O 0 3.0413439162657596e-06
man O 0 0.03763100132346153
is O 0 1.303074839142937e-07
a O 0 9.599204275900775e-08
dysfunctional O 0 0.00011923964484594762
ATP7B O 0 0.0006867500487715006
gene O 0 8.043796697165817e-06
, O 0 4.0063903838927217e-07
causing O 0 1.4027863471710589e-05
Wilson B-Disease 0 0.24936819076538086
disease I-Disease 1 0.9223496913909912
( O 0 1.3251514019430033e-07
WD B-Disease 1 0.9992769360542297
) O 0 1.5238920525462163e-07
. O 0 1.0098809610781245e-07

Mutations O 0 0.0013956970069557428
in O 0 7.086533315714405e-08
the O 0 1.403158567114815e-08
ATP7B O 0 8.063577843131498e-05
genes O 0 2.9734228519373573e-06
have O 0 3.2066579933598405e-06
also O 0 5.332551040737599e-07
been O 0 2.439181798763457e-07
demonstrated O 0 8.424380126825781e-08
in O 0 3.5442859314116504e-08
mouse O 0 0.0048826574347913265
and O 0 3.8454963942058384e-06
rat O 0 0.003053842345252633
. O 0 1.4060042019536922e-07

The O 0 5.903811484131438e-07
ATP7B O 0 4.59479633718729e-05
gene O 0 1.3621105608763173e-05
has O 0 2.1962832761346363e-06
been O 0 8.67353193712006e-08
excluded O 0 1.5325784374908835e-07
in O 0 2.6081576898207004e-09
the O 0 2.5114719193197743e-09
much O 0 2.3505968727022264e-08
rarer O 0 1.212158258567797e-05
human O 0 0.00024935088003985584
copper B-Disease 1 0.9902682900428772
overload I-Disease 1 0.9992133378982544
disease O 1 0.6036782264709473
non B-Disease 0 9.88402234725072e-07
- I-Disease 1 0.6488154530525208
Indian I-Disease 0 0.0074295224621891975
childhood I-Disease 0 0.0718696340918541
cirrhosis I-Disease 0 0.017418213188648224
, O 0 4.301133671447133e-09
indicating O 0 1.0019550700235413e-07
genetic O 0 4.08494042858365e-06
heterogeneity O 0 5.531442002393305e-05
. O 0 3.4550126315480156e-07

By O 0 6.029389254536e-08
investigating O 0 5.8209689512978e-08
the O 0 4.359462835168415e-08
common O 0 3.0382509521587053e-06
autosomal O 1 0.6309894919395447
recessive O 1 0.9858798384666443
copper B-Disease 1 0.9874574542045593
toxicosis I-Disease 1 0.9813296794891357
( O 0 1.0051248722220407e-07
CT B-Disease 1 0.6807004809379578
) O 0 4.89783147372691e-08
in O 0 3.497632405924378e-08
Bedlington O 0 0.022904008626937866
terriers O 0 0.12769430875778198
, O 0 3.1511936526840145e-07
we O 0 1.6274726988285693e-07
have O 0 2.7987638873128162e-09
identified O 0 6.940178653991325e-09
a O 0 5.962698113037845e-10
new O 0 1.5915828655010955e-08
locus O 0 4.5967536266289244e-07
involved O 0 1.221584398081177e-07
in O 0 4.306087794248015e-05
progressive O 1 0.9999470710754395
liver B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999997615814209
. O 0 9.25566564546898e-06

We O 0 2.5883859962050337e-06
examined O 0 6.99939164405805e-08
whether O 0 1.761495616037223e-09
the O 0 3.2244618086707533e-09
WD B-Disease 0 0.3318772614002228
gene O 0 8.636858183308505e-06
ATP7B O 0 0.007990685291588306
was O 0 1.1770243872888386e-05
also O 0 3.563190276167916e-08
causative O 0 2.565129477716255e-07
for O 0 4.0540584222981124e-09
CT B-Disease 0 0.012382100336253643
by O 0 4.332099123871558e-09
investigating O 0 2.347330863017305e-08
the O 0 6.997162671495971e-08
chromosomal O 0 0.16044481098651886
co O 0 0.0037045874632894993
- O 0 0.0011871983297169209
localization O 0 1.390539273415925e-05
of O 0 4.1701619934997325e-09
ATP7B O 0 0.0012875316897407174
and O 0 3.24302220633399e-08
C04107 O 0 1.3487507999343507e-08
, O 0 1.2936051535517024e-11
using O 0 4.640953593648689e-11
fluorescence O 0 2.8407944885344705e-09
in O 0 1.0070256850625015e-09
situ O 0 1.0200209032973362e-07
hybridization O 0 5.345320985838953e-08
( O 0 2.890587325055094e-09
FISH O 0 3.3170300639540073e-07
) O 0 5.157207993988777e-09
. O 0 2.0676120371376783e-08

C04107 O 0 0.00015731441089883447
is O 0 2.4753582295033993e-08
an O 0 3.82364556683612e-10
anonymous O 0 2.49534259921802e-09
microsatellite O 0 1.9490369595587254e-05
marker O 0 7.597478543175384e-05
closely O 0 1.5458615507668583e-06
linked O 0 3.557019226718694e-05
to O 0 4.1847053466881334e-07
CT B-Disease 1 0.9050698280334473
. O 0 6.040428388587316e-07

However O 0 1.7662085156189278e-05
, O 0 5.09037469953455e-08
BAC O 0 6.221854619070655e-06
clones O 0 1.713492201815825e-05
containing O 0 4.169397413988918e-07
ATP7B O 0 0.0068655721843242645
and O 0 5.637513709189079e-07
C04107 O 0 7.151314207476389e-07
mapped O 0 2.561195105954539e-05
to O 0 3.013911609173192e-08
the O 0 6.942760588657393e-09
canine O 0 0.0002702716155909002
chromosome O 0 0.0021103082690387964
regions O 0 1.9312096810608637e-06
CFA22q11 O 0 0.004281523171812296
and O 0 1.177105900751485e-06
CFA10q26 O 0 0.00013698461407329887
, O 0 2.4574022816636898e-08
respectively O 0 2.1332777322413676e-08
, O 0 5.541037073619748e-10
demonstrating O 0 9.518796417751219e-09
that O 0 9.872268691424324e-08
WD B-Disease 1 0.9847177863121033
cannot O 0 1.8635744254424935e-06
be O 0 8.228970282964099e-10
homologous O 0 1.0931811900150024e-08
to O 0 1.707359587044266e-08
CT B-Disease 0 0.17985615134239197
. O 0 6.836077091065818e-07

The O 0 1.5280454590538284e-06
copper O 0 4.003008143627085e-05
transport O 0 9.638214351070928e-07
genes O 0 7.600144158459443e-07
CTR1 O 0 0.00026141107082366943
and O 0 4.7439820605177374e-07
CTR2 O 0 0.00023864294053055346
were O 0 1.5003550402070687e-07
also O 0 5.657523161062272e-08
excluded O 0 1.7366033944199444e-08
as O 0 2.651464381386859e-09
candidate O 0 2.7402788926877975e-09
genes O 0 2.835159662595288e-09
for O 0 2.295815759723041e-09
CT B-Disease 1 0.8420705199241638
since O 0 3.613909257182968e-06
they O 0 9.52473868665038e-08
both O 0 7.882273500570136e-09
mapped O 0 7.171656761784106e-05
to O 0 1.3261501408123877e-07
canine O 0 0.004655649419873953
chromosome O 0 0.009839797392487526
region O 0 1.0158103577850852e-05
CFA11q22 O 0 0.002788604935631156
. O 0 3.388400102721789e-07

2 O 0 3.154213118250482e-05
- O 0 0.003696352941915393
22 O 0 2.330491724933381e-06
. O 0 1.356154797349518e-07

5 O 0 1.3163751646061428e-05
. O 0 1.960030658665346e-06

A O 0 2.064074351437739e-07
transcribed O 0 9.69700863606704e-07
sequence O 0 1.1902977803401882e-06
identified O 0 7.636980967618001e-07
from O 0 7.16508408160621e-10
the O 0 3.5851261959152225e-09
C04107 O 0 1.343748408544343e-06
- O 0 4.3629814172163606e-05
containing O 0 9.850675297684575e-08
BAC O 0 1.2815197806048673e-05
was O 0 7.734914788670721e-07
found O 0 3.8330818519227705e-09
to O 0 5.13089071230155e-10
be O 0 2.950230060250192e-10
homologous O 0 2.1112158687941474e-09
to O 0 2.190640779886621e-09
a O 0 3.239348789207952e-09
gene O 0 2.2809186361882894e-07
expressed O 0 1.4036288797925067e-09
from O 0 1.6718878503851897e-09
human O 0 7.939750901186926e-08
chromosome O 0 1.1740849913621787e-05
2p13 O 0 8.485108651257178e-07
- O 0 6.609870615648106e-05
p16 O 0 9.935417466522267e-08
, O 0 2.676698196424354e-09
a O 0 5.357127186300659e-09
region O 0 5.1539164047653685e-08
devoid O 0 1.0012788465019185e-07
of O 0 1.3267681397977071e-10
any O 0 7.588115691348207e-10
positional O 0 3.543148068274604e-06
candidate O 0 9.795815003599273e-08
genes O 0 4.2696350988080667e-07
. O 0 1.2596129295161518e-07

Molecular O 0 2.299039124409319e-06
analysis O 0 1.1693092005771177e-07
of O 0 7.527312662070074e-10
the O 0 3.78987063953673e-09
APC B-Disease 0 9.423922620044323e-08
gene O 0 7.835315329884907e-08
in O 0 2.6153808008189117e-09
205 O 0 3.58270817457651e-08
families O 0 6.494202953177819e-09
: O 0 1.1087872842097113e-09
extended O 0 2.3801366921816225e-07
genotype O 0 1.0088765520777088e-05
- O 0 0.0026926116552203894
phenotype O 0 1.0900811503233854e-05
correlations O 0 2.289691565238172e-06
in O 0 2.6002663133795068e-08
FAP B-Disease 0 1.828279437177116e-06
and O 0 4.708482848059248e-08
evidence O 0 1.5440544842704185e-08
for O 0 2.81087431108773e-10
the O 0 1.9241108706324894e-09
role O 0 6.947463493389705e-09
of O 0 2.640022922495433e-10
APC B-Disease 0 1.1764409890702154e-07
amino O 0 6.844137701023101e-09
acid O 0 1.576419350612923e-08
changes O 0 1.9877546719726524e-08
in O 0 0.00044973238254897296
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
predisposition O 1 0.9307042956352234
. O 0 1.8159937553718919e-06

BACKGROUND O 0 0.0005299872136674821
/ O 0 0.0012055017286911607
AIMS O 0 6.835406566096935e-06
The O 0 1.1530251420310833e-08
development O 0 6.973473887228465e-08
of O 0 3.819154517259449e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.8963509066670667e-06
a O 0 1.1948448452869798e-08
variable O 0 3.4738317822302633e-07
range O 0 6.057907739887014e-07
of O 0 1.332284949029372e-08
extracolonic O 0 0.09137600660324097
manifestations O 0 0.007193739991635084
in O 0 0.0006149049149826169
familial B-Disease 1 0.9999994039535522
adenomatous I-Disease 1 0.9999853372573853
polyposis I-Disease 1 0.9999996423721313
( O 0 5.7570068747736514e-05
FAP B-Disease 0 0.00275123817846179
) O 0 3.2767476909612014e-07
is O 0 7.251832556676163e-08
the O 0 2.696818590663952e-08
result O 0 8.730528122669057e-08
of O 0 9.041997151015835e-10
the O 0 1.4214981547411298e-07
dominant O 0 6.001124347676523e-05
inheritance O 0 0.0001005228768917732
of O 0 2.765382123470772e-05
adenomatous B-Disease 1 0.9999970197677612
polyposis I-Disease 1 0.9999834299087524
coli I-Disease 1 0.9999970197677612
( O 0 2.2114072635304183e-06
APC B-Disease 0 1.0025035408034455e-05
) O 0 1.109253222608686e-08
gene O 0 1.2344072501946357e-06
mutations O 0 3.77870601369068e-05
. O 0 3.089613187512441e-07

In O 0 2.5910830458997225e-07
this O 0 1.3709047230747728e-09
study O 0 1.0596036270626996e-09
, O 0 3.9572730509140897e-11
direct O 0 1.6442378014680514e-10
mutation O 0 2.6800201169407956e-08
analysis O 0 3.815291638176177e-09
of O 0 4.174751655483533e-10
the O 0 2.1066876243480692e-08
APC B-Disease 0 2.3768454582295817e-07
gene O 0 5.475813509292493e-07
was O 0 1.5894038369879127e-06
performed O 0 1.2981220720575948e-07
to O 0 8.98726926212845e-10
determine O 0 9.423793301266414e-09
genotype O 0 4.191391553831636e-07
- O 0 0.00015938248543534428
phenotype O 0 1.4287642216004315e-06
correlations O 0 4.992889444110915e-07
for O 0 8.815696617148205e-09
nine O 0 5.43732085134252e-07
extracolonic O 0 0.0005843440303578973
manifestations O 0 5.6281114666489884e-05
and O 0 6.002001100569032e-07
to O 0 7.308789573556851e-09
investigate O 0 1.6582546891186212e-08
the O 0 6.104812655394198e-09
incidence O 0 0.0003208896378055215
of O 0 5.6631557221464845e-09
APC B-Disease 0 2.3646011868549976e-06
mutations O 0 8.652808674014523e-07
in O 0 3.2416931361467505e-08
non O 0 5.959866030025296e-06
- O 1 0.9996641874313354
FAP O 1 0.9986017346382141
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
. O 0 6.021487024554517e-06

METHODS O 0 6.055809990357375e-06
The O 0 1.1375874464647495e-08
APC B-Disease 0 1.0417095097636775e-07
gene O 0 1.7640475391544896e-07
was O 0 2.7436124128144e-07
analysed O 0 1.3643064278312522e-07
in O 0 1.202645538711522e-09
190 O 0 7.418762493216491e-09
unrelated O 0 1.8736737672497839e-07
FAP B-Disease 0 1.0320518413209356e-05
and O 0 1.322252046520589e-06
15 O 0 6.963903587120512e-08
non O 0 7.618314725732489e-07
- O 1 0.9994882345199585
FAP O 1 0.9981050491333008
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
patients O 0 2.809998477459885e-06
using O 0 3.470036702424295e-08
denaturing O 0 5.135771061759442e-05
gradient O 0 1.5040159269119613e-05
gel O 0 0.002547917189076543
electrophoresis O 0 2.446321195748169e-05
, O 0 1.9120891536772433e-09
the O 0 2.2735080484892478e-10
protein O 0 1.2822873429740866e-08
truncation O 0 1.7314676370006055e-05
test O 0 3.68261753465049e-05
, O 0 4.875894132894132e-10
and O 0 2.4989754709991985e-10
direct O 0 8.243564164622796e-10
sequencing O 0 9.80413119577861e-07
. O 0 1.2227721413182735e-07

RESULTS O 0 7.250309135997668e-05
Chain O 0 8.733401045901701e-06
terminating O 0 6.11643031334097e-07
signals O 0 1.4921757838237681e-06
were O 0 5.954044368650102e-08
only O 0 3.5423106670151583e-09
identified O 0 2.493660247182561e-07
in O 0 3.048444341402501e-08
patients O 0 1.7051765155429166e-07
belonging O 0 1.1159574597741084e-07
to O 0 9.280189772198355e-08
the O 0 4.4195335391350454e-08
FAP B-Disease 0 1.5537451645286637e-06
group O 0 3.2909784408730047e-07
( O 0 2.1526536109206518e-10
105 O 0 2.8004686569715886e-08
patients O 0 1.5936080899336957e-07
) O 0 5.1111239685042165e-09
. O 0 4.982880952297819e-08

Amino O 0 1.09608554339502e-05
acid O 0 1.9476785837468924e-06
changes O 0 1.1993567028412144e-08
were O 0 4.8483999037785e-09
identified O 0 6.724550871695101e-08
in O 0 1.769095980819202e-08
four O 0 1.9018785906155244e-06
patients O 0 3.940603164664935e-06
, O 0 1.635955904077946e-08
three O 0 1.027740381687181e-08
of O 0 1.2390485082391933e-08
whom O 0 1.2102465234420379e-06
belonged O 0 8.199871444958262e-06
to O 0 5.076345033216967e-08
the O 0 6.644582661863296e-09
non O 0 5.994941432163614e-08
- O 0 0.000470724975457415
FAP O 0 2.0548916381812887e-06
group O 0 6.99183260621794e-07
of O 0 3.1950153243087698e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
patients O 0 0.0015505836345255375
. O 0 2.5854404839265044e-07

Genotype O 0 0.004418603144586086
- O 0 0.056889552623033524
phenotype O 0 9.746794967213646e-05
correlations O 0 1.3644299542647786e-05
identified O 0 5.1436036301311105e-06
significant O 0 2.8534000051649855e-08
differences O 0 7.620104952366091e-06
in O 0 5.926172548242903e-07
the O 0 2.4632217332509754e-07
nature O 0 9.710714721222757e-07
of O 0 1.362258750248202e-09
certain O 0 1.9598322964498038e-08
extracolonic O 0 0.00016540686192456633
manifestations O 0 9.121647963183932e-06
in O 0 7.487598452371458e-08
FAP B-Disease 0 9.394708285981324e-06
patients O 0 4.3813531647174386e-07
belonging O 0 2.3302012763792845e-08
to O 0 1.2299057772224842e-08
three O 0 1.7114121675376737e-08
mutation O 0 2.9514258130802773e-06
subgroups O 0 1.99535716092214e-05
. O 0 5.14902808390616e-07

CONCLUSIONS O 0 8.427989996562246e-06
Extended O 0 1.0882693004532484e-06
genotype O 0 1.1112629181297962e-05
- O 0 0.0005129722412675619
phenotype O 0 1.0055118764284998e-05
correlations O 0 4.283606540411711e-05
made O 0 1.548411205476441e-06
in O 0 2.4485036220767142e-08
this O 0 1.5251782059522156e-08
study O 0 9.877975060135213e-08
may O 0 1.1426149058024748e-06
have O 0 3.5730653991095096e-08
the O 0 4.526564456597271e-09
potential O 0 8.324895439670854e-09
to O 0 4.235412021103002e-09
determine O 0 9.144085488799192e-09
the O 0 2.2181285974642861e-10
most O 0 5.342784895057129e-11
appropriate O 0 1.4536191694780598e-10
surveillance O 0 6.714573146382463e-07
and O 0 1.0746576073472625e-08
prophylactic O 0 7.849313305996475e-07
treatment O 0 1.8137146184926678e-07
regimens O 0 1.794065269677958e-07
for O 0 1.0503855563115394e-09
those O 0 2.509213281598477e-08
patients O 0 9.999790506753925e-08
with O 0 3.8588979123233e-08
mutations O 0 0.00016397048602811992
associated O 0 1.8732641819951823e-06
with O 0 8.174115464498755e-07
life O 0 0.0007932176231406629
threatening O 0 0.004939522594213486
conditions O 0 6.593899161089212e-05
. O 0 9.330238981419825e-08

This O 0 1.8927305234228697e-07
study O 0 2.2768388063809653e-08
also O 0 1.284975681414835e-08
provided O 0 4.315421631151395e-10
evidence O 0 4.114446117142734e-09
for O 0 1.4985790386390363e-09
the O 0 1.9691771768748367e-08
pathological O 0 2.7507974664331414e-05
nature O 0 4.4330923287816404e-07
of O 0 1.1703178426358818e-09
amino O 0 9.347232321488264e-08
acid O 0 8.120489525254015e-08
changes O 0 5.327597474291679e-09
in O 0 7.680876379367874e-09
APC O 0 2.2864985282922135e-07
associated O 0 1.0022376706331215e-08
with O 0 2.3513937463803813e-09
both O 0 5.2995471122585514e-08
FAP B-Disease 0 1.4601419024984352e-06
and O 0 3.3679037869660533e-07
non O 0 1.1511812090247986e-06
- O 1 0.9995601773262024
FAP O 1 0.9982884526252747
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 0.008454776369035244
. O 0 4.2928583354751026e-08
. O 0 1.3050274105808057e-07

Inherited B-Disease 1 0.9995805621147156
colorectal I-Disease 1 0.999998927116394
polyposis I-Disease 1 0.9999583959579468
and O 1 0.997671902179718
cancer B-Disease 1 0.9985699653625488
risk O 0 1.048623107635649e-05
of O 0 9.863602157267337e-10
the O 0 6.740242497471627e-08
APC O 0 7.54203756514471e-06
I1307K O 0 1.6920226926231408e-06
polymorphism O 0 1.930878897837829e-05
. O 0 1.4050966967715794e-07

Germ O 1 0.7332025766372681
- O 1 0.6709016561508179
line O 0 0.001731561729684472
and O 0 1.9858864774846552e-08
somatic O 0 7.079427177814068e-08
truncating O 0 5.050972049502889e-06
mutations O 0 4.409599569044076e-06
of O 0 1.4877936660440128e-09
the O 0 1.9552100383180004e-08
APC B-Disease 0 5.042348902861704e-07
gene O 0 3.1827187285671243e-07
are O 0 2.5558872795983234e-09
thought O 0 1.3531563070046104e-07
to O 0 1.092222490228778e-08
initiate O 0 2.0442219465621747e-05
colorectal B-Disease 1 0.9999997615814209
tumor I-Disease 1 0.9589306116104126
formation O 0 3.8533784390892833e-05
in O 0 0.001651678467169404
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999984502792358
polyposis I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 0.015318332239985466
sporadic O 1 0.9755158424377441
colorectal O 1 0.9999998807907104
carcinogenesis O 1 0.999832034111023
, O 0 7.877038115111645e-06
respectively O 0 6.487621249107178e-06
. O 0 5.163333298696671e-07

Recently O 0 0.00044346225331537426
, O 0 1.0919771398221201e-07
an O 0 4.260724661975246e-09
isoleucine O 0 0.0023428204003721476
- O 0 0.0004982893005944788
- O 0 0.0003023178142029792
> O 0 1.4657126712336321e-07
lysine O 0 9.16862404665153e-07
polymorphism O 0 2.130151699475391e-07
at O 0 9.552516111455134e-09
codon O 0 3.2851991704774264e-07
1307 O 0 3.5790997117146617e-06
( O 0 7.282124903085219e-10
I1307K O 0 6.469627322758242e-08
) O 0 1.6347471987199214e-10
of O 0 4.043204659964772e-11
the O 0 2.970796719736768e-09
APC B-Disease 0 7.778685784387562e-08
gene O 0 7.567771831418213e-08
has O 0 1.1675742683792123e-07
been O 0 8.912232729585412e-09
identified O 0 8.865185918693896e-09
in O 0 6.733991697593922e-10
6 O 0 5.901278754549821e-08
% O 0 1.1331670046743625e-09
- O 0 0.000488467572722584
7 O 0 3.956498630941496e-07
% O 0 1.914712138839647e-10
of O 0 1.187937942459527e-10
the O 0 2.0385057197813694e-08
Ashkenazi O 0 1.35572008730378e-05
Jewish O 0 1.4262398906339513e-07
population O 0 4.102127970639913e-09
. O 0 1.3223709238729953e-08

To O 0 5.912511369388085e-07
assess O 0 6.356611379487731e-07
the O 0 1.676742655831731e-08
risk O 0 6.541133501514196e-08
of O 0 8.5963909601805e-11
this O 0 2.5946120807418538e-09
common O 0 1.5282093812629682e-08
APC B-Disease 0 1.9178085608473339e-07
allelic O 0 1.954242634383263e-06
variant O 0 0.06122084707021713
in O 0 0.002096648095175624
colorectal O 1 0.9999998807907104
carcinogenesis O 1 0.9998040795326233
, O 0 4.495422399486415e-05
we O 0 3.512747070999467e-06
have O 0 1.2880184030450437e-08
analyzed O 0 2.499898066332662e-08
a O 0 1.0666012517646095e-09
large O 0 5.03286257114155e-09
cohort O 0 1.4481807397714874e-07
of O 0 2.451454317320412e-10
unselected O 0 1.342042196483817e-05
Ashkenazi O 0 7.80209757067496e-06
Jewish O 0 1.1152105372502774e-07
subjects O 0 2.4415277266598423e-07
with O 0 7.592205264472796e-08
adenomatous B-Disease 0 0.002193074207752943
polyps I-Disease 1 0.6987538933753967
and O 0 9.38296943786554e-06
. O 0 2.913182242991752e-06
or O 0 0.15394483506679535
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 4.561111950351915e-07
for O 0 3.798482417494142e-09
the O 0 4.256503061128569e-08
APC O 0 1.6979406609607395e-06
I1307K O 0 6.808412535974639e-07
polymorphism O 0 9.84702001005644e-06
. O 0 1.5337555225869437e-07

The O 0 1.7114098227466457e-07
APC O 0 3.6761900901183253e-07
I1307K O 0 2.1202124855790316e-07
allele O 0 8.177688215482704e-08
was O 0 2.9287548386491835e-07
identified O 0 3.9957097186515966e-08
in O 0 7.923722233904584e-10
48 O 0 4.276905229971817e-08
( O 0 4.436741807278821e-10
10 O 0 2.758901551658255e-09
. O 0 8.238046911301922e-10
1 O 0 7.376165900296883e-09
% O 0 6.360468818300546e-10
) O 0 2.9987934357933455e-10
of O 0 6.575213706838667e-10
476 O 0 2.841183049895335e-05
patients O 0 5.489289833349176e-06
. O 0 1.0242202108656784e-07

Compared O 0 2.0641248283936875e-06
with O 0 3.085165234395504e-09
the O 0 4.558158850365146e-10
frequency O 0 7.285633074616271e-08
in O 0 1.8105297261428177e-09
two O 0 1.0650460513517146e-09
separate O 0 4.941961062598921e-09
population O 0 4.648497142767383e-09
control O 0 8.723668543098029e-07
groups O 0 3.9692285014325535e-09
, O 0 8.492324066189383e-10
the O 0 9.224310204558606e-10
APC O 0 1.512882619181255e-07
I1307K O 0 5.392333690679152e-08
allele O 0 1.1845926906062232e-08
is O 0 9.650823251661222e-09
associated O 0 5.586437978877257e-09
with O 0 1.8431677295538407e-09
an O 0 3.3621891937229975e-09
estimated O 0 4.754544136176264e-08
relative O 0 2.1099192792917165e-07
risk O 0 1.8803488899266085e-07
of O 0 3.4516098312842303e-10
1 O 0 9.684033557277871e-07
. O 0 2.15069476894314e-07

5 O 0 4.3821405597554985e-06
- O 0 0.00026626026374287903
1 O 0 7.293383532669395e-07
. O 0 1.260963955473926e-07

7 O 0 3.324991121189669e-05
for O 0 2.1630416995321866e-06
colorectal B-Disease 1 0.9999980926513672
neoplasia I-Disease 1 0.9996720552444458
( O 0 1.5743047470095917e-06
both O 0 1.0784454389067832e-05
P O 1 0.9975414276123047
= O 0 0.18346014618873596
. O 0 6.27063116098725e-07
01 O 0 0.00014852544700261205
) O 0 1.3940672616286065e-08
. O 0 2.998619308414163e-08

Furthermore O 0 1.6377582142013125e-05
, O 0 1.075781508319551e-08
compared O 0 4.5758352662517154e-09
with O 0 1.2419776318495224e-08
noncarriers O 0 0.0004975118790753186
, O 0 1.679251937503068e-08
APC O 0 1.542300935852836e-07
I1307K O 0 2.805484200507635e-07
carriers O 0 1.4601988596041338e-07
had O 0 7.331775009333796e-07
increased O 0 3.626812183910033e-09
numbers O 0 1.595783771790593e-08
of O 0 6.560548104772579e-09
adenomas B-Disease 1 0.9011755585670471
and O 1 0.8558341264724731
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.999990701675415
per O 0 3.337647740409011e-06
patient O 0 0.003705875715240836
( O 0 4.2576075998113083e-07
P O 1 0.986348032951355
= O 0 0.11170867085456848
. O 0 1.3261693538879626e-06
03 O 0 8.596711268182844e-05
) O 0 3.5669827092021933e-09
, O 0 1.4004359893959872e-09
as O 0 3.859182751142498e-09
well O 0 1.1241412245510674e-08
as O 0 9.672494805101906e-09
a O 0 4.576230594466324e-08
younger O 0 1.1260896144449362e-06
age O 0 5.416226755983189e-08
at O 0 4.307827339289361e-08
diagnosis O 0 0.00024582023615948856
. O 0 4.555808175155107e-08

We O 0 1.762106694513932e-05
conclude O 0 3.2079134371088003e-07
that O 0 4.369574924112385e-09
the O 0 1.5471992576010507e-09
APC O 0 4.087092975169071e-07
I1307K O 0 6.711378546242486e-07
variant O 0 0.00014404734247364104
leads O 0 1.6450007024104707e-05
to O 0 4.578544476885327e-08
increased O 0 1.2390329402478528e-06
adenoma B-Disease 1 0.9999979734420776
formation O 0 2.0618897906388156e-05
and O 0 3.611909846767958e-07
directly O 0 3.234687406816761e-09
contributes O 0 6.9163923477333356e-09
to O 0 4.679785003958159e-09
3 O 0 1.3031017154219171e-08
% O 0 3.735199372023601e-10
- O 0 1.0203639249084517e-05
4 O 0 5.411105519215198e-08
% O 0 6.313147227210436e-11
of O 0 6.855000594940819e-11
all O 0 6.857596268616817e-09
Ashkenazi O 0 0.0005118669359944761
Jewish O 0 0.13335280120372772
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
. O 0 3.892520908266306e-06

The O 0 1.0535165273495295e-07
estimated O 0 1.3066807191819407e-08
relative O 0 8.761507075405461e-08
risk O 0 1.3333925608094432e-07
for O 0 1.161440721375584e-09
carriers O 0 4.2175506109742855e-07
may O 0 1.995929181930478e-07
justify O 0 1.871637245187685e-08
specific O 0 1.9805658502125567e-10
clinical O 0 2.4085990091293752e-08
screening O 0 2.0362868724532746e-08
for O 0 6.624433779300887e-10
the O 0 1.1478789030405778e-09
360 O 0 3.55971216947637e-08
, O 0 6.919344541778116e-10
000 O 0 1.9186346955635258e-10
Americans O 0 4.09585743099683e-09
expected O 0 3.850741947530878e-09
to O 0 2.0214811158325574e-08
harbor O 0 6.478147156485647e-07
this O 0 1.1341545758103422e-10
allele O 0 6.307063316057793e-09
, O 0 1.935296145560983e-09
and O 0 3.2233979929685574e-09
genetic O 0 1.0740556177779581e-07
testing O 0 1.273863148298915e-07
in O 0 1.3318930403016793e-09
the O 0 2.7590332241089754e-09
setting O 0 1.3764683615136164e-07
of O 0 4.21711376930034e-09
long O 0 3.3001854262693087e-06
- O 0 0.00031351775396615267
term O 0 4.78707534057321e-07
- O 0 3.3775929750845535e-06
outcome O 0 8.553483255013816e-09
studies O 0 9.51389078629461e-10
may O 0 1.2940358784518935e-09
impact O 0 1.1251723996963392e-09
significantly O 0 6.488992312370101e-07
on O 1 0.7016693353652954
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.012660686857998371
in O 0 3.6813499804111416e-08
this O 0 2.775057872383968e-08
population O 0 3.156095118583835e-08
. O 0 1.2214329103699129e-07

Localization O 0 0.00012655854516196996
of O 0 2.2591029491536574e-08
human O 0 4.4479014604803524e-07
BRCA1 O 0 0.00031091892742551863
and O 0 1.7329193724435754e-06
its O 0 9.933882694213025e-08
loss O 0 0.00010572475002845749
in O 0 1.7992690004575707e-07
high O 0 1.791624708857853e-05
- O 0 0.2211005687713623
grade O 0 0.0008052614284679294
, O 0 3.4520478919830566e-08
non B-Disease 0 4.01635958269253e-07
- I-Disease 1 0.9769624471664429
inherited I-Disease 1 0.9860559701919556
breast I-Disease 1 0.9996569156646729
carcinomas I-Disease 1 0.9999991655349731
. O 0 3.952459155698307e-05

Although O 0 1.229313397743681e-06
the O 0 2.76189227044199e-09
link O 0 1.2932933941556257e-06
between O 0 3.968738226944879e-08
the O 0 7.632306164850888e-07
BRCA1 O 1 0.6727764010429382
tumour B-Disease 1 0.9999992847442627
- O 0 0.0037923979107290506
suppressor O 0 6.36069307802245e-05
gene O 0 3.418245614739135e-05
and O 0 0.0005820771912112832
hereditary B-Disease 1 0.9999219179153442
breast I-Disease 1 0.9999985694885254
and I-Disease 1 0.9999979734420776
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 5.902133580093505e-06
established O 0 1.2731140941468766e-06
, O 0 2.0835820180309383e-08
the O 0 2.7051629825081136e-09
role O 0 1.634475097489485e-07
, O 0 3.8335809193768e-08
if O 0 1.1356775075910264e-08
any O 0 2.8639202120928076e-10
, O 0 2.6869681479801955e-10
of O 0 1.8128337719858223e-10
BRCA1 O 0 2.0246960048098117e-05
in O 0 2.404422616564261e-07
non B-Disease 0 8.210827218135819e-06
- I-Disease 1 0.9988088607788086
familial I-Disease 1 0.9988804459571838
cancers I-Disease 1 0.9998503923416138
is O 0 2.1941572470041137e-07
unclear O 0 1.856938069977332e-07
. O 0 9.879049400751683e-08

BRCA1 O 0 0.005235455930233002
mutations O 0 0.0004138958756811917
are O 0 5.3002246147570986e-08
rare O 0 2.853370801858546e-07
in O 0 3.232213146020513e-07
sporadic B-Disease 1 0.8925135135650635
cancers I-Disease 1 0.9999959468841553
, O 0 2.0613098968169652e-05
but O 0 1.8406397430226207e-05
loss O 0 2.3346034140558913e-05
of O 0 5.8305584360596185e-08
BRCA1 O 0 0.011432928033173084
resulting O 0 1.5495102161366958e-06
from O 0 1.0531283400894154e-08
reduced O 0 8.29669716040371e-07
expression O 0 2.7679643608280458e-06
or O 0 1.6783496903371997e-07
incorrect O 0 5.356605925044278e-06
subcellular O 0 3.0016408345545642e-05
localization O 0 1.546316889289301e-05
is O 0 2.2464016424805777e-08
postulated O 0 1.2084012723789783e-06
to O 0 9.918414178855528e-08
be O 0 1.0539602968151485e-08
important O 0 4.960052368829793e-10
in O 0 5.829943194868292e-09
non B-Disease 0 4.879913717559248e-07
- I-Disease 1 0.9553055763244629
familial I-Disease 1 0.9987004995346069
breast I-Disease 1 0.999996542930603
and I-Disease 1 0.99988853931427
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999996423721313
. O 0 1.015839461615542e-05

Epigenetic O 0 0.07448183745145798
loss O 0 0.16803374886512756
, O 0 2.908818999003415e-07
however O 0 2.013205175899202e-07
, O 0 1.3182660296706672e-08
has O 0 1.6924846590882225e-07
not O 0 1.4301102524427733e-08
received O 0 8.04157851419518e-11
general O 0 8.264518513989572e-10
acceptance O 0 4.0746190421714346e-08
due O 0 7.887631170433451e-08
to O 0 2.4602992976241467e-09
controversy O 0 3.367027767708919e-09
regarding O 0 4.468180270222888e-10
the O 0 4.4184417236081686e-10
subcellular O 0 4.274809555226966e-07
localization O 0 9.261424906981119e-07
of O 0 1.5517890306071536e-09
BRCA1 O 0 1.7562953871674836e-05
proteins O 0 4.493757046475366e-07
, O 0 9.180102011896452e-09
reports O 0 1.3433694157072296e-08
of O 0 5.336768804653502e-10
which O 0 2.830390712915687e-07
have O 0 7.971312498966654e-08
ranged O 0 5.900131228031569e-08
from O 0 2.391015163638599e-10
exclusively O 0 8.125909722878077e-09
nuclear O 0 1.4538087498294772e-06
, O 0 2.3890414646565716e-10
to O 0 8.684527402769149e-11
conditionally O 0 3.6209733877967665e-08
nuclear O 0 1.2227714023538283e-06
, O 0 2.569700008336895e-10
to O 0 4.971531519792904e-10
the O 0 8.925246319790858e-09
ER O 0 0.006689973175525665
/ O 0 1.7068739907699637e-05
golgi O 0 4.214445198158501e-06
, O 0 1.5727875668503088e-09
to O 0 2.921821118384571e-10
cytoplasmic O 0 2.2481876271740475e-07
invaginations O 0 1.8915029613708612e-06
into O 0 2.9361129083582682e-09
the O 0 2.132141796451492e-09
nucleus O 0 9.127325739655134e-08
. O 0 3.7029064259286315e-08

In O 0 3.2145561590368743e-07
an O 0 5.533298264026598e-09
attempt O 0 1.5863932958382065e-06
to O 0 2.2884938388756382e-08
resolve O 0 7.854632855242016e-08
this O 0 1.5536458786158391e-09
issue O 0 8.44569711944132e-08
, O 0 7.20120567621052e-08
we O 0 3.569986972706829e-07
have O 0 1.5905873951282956e-08
comprehensively O 0 1.36667240440147e-05
characterized O 0 4.996176130589447e-07
19 O 0 6.130193241915549e-08
anti O 0 4.161046035733307e-06
- O 0 0.03577436879277229
BRCA1 O 0 0.0006247798446565866
antibodies O 0 2.0308855255279923e-06
. O 0 6.846347133659947e-08

These O 0 1.8207853713647637e-07
reagents O 0 2.474311031619436e-07
detect O 0 2.6556469947536243e-06
a O 0 2.366037810119792e-09
220 O 0 1.156269124891196e-08
- O 0 1.7672262401902117e-05
kD O 0 4.17842284150538e-06
protein O 0 2.3905345258867783e-08
localized O 0 6.893479564951122e-08
in O 0 4.820301935382076e-10
discrete O 0 1.0790967053253553e-07
nuclear O 0 3.26434092130512e-05
foci O 0 5.184281235415256e-06
in O 0 2.989077074744273e-08
all O 0 2.2685419764911785e-08
epithelial O 0 1.7016860510921106e-05
cell O 0 0.0074241794645786285
lines O 0 0.006915496662259102
, O 0 1.659612003379607e-08
including O 0 7.179982164373655e-10
those O 0 4.3077078015762993e-10
derived O 0 3.352845778792357e-09
from O 0 6.61885692920805e-08
breast B-Disease 0 0.4243282973766327
malignancies I-Disease 0 0.08081357181072235
. O 0 6.247763053579547e-07

Immunohistochemical O 0 0.001786352600902319
staining O 0 0.00023804324155207723
of O 0 1.1195369609140471e-07
human O 0 3.450772283031256e-06
breast O 0 0.07644487917423248
specimens O 0 3.18274737765023e-06
also O 0 6.502472160718753e-07
revealed O 0 1.2084325135219842e-05
BRCA1 O 0 1.8727549104369245e-05
nuclear O 0 9.806602065509651e-06
foci O 0 1.08912936411798e-05
in O 0 6.419892315534526e-07
benign O 1 0.7854000329971313
breast O 1 0.9652859568595886
, O 0 3.821108748525148e-06
invasive B-Disease 0 0.07504831999540329
lobular I-Disease 1 0.9999761581420898
cancers I-Disease 1 0.9999961853027344
and O 0 0.0007278727716766298
low B-Disease 0 0.033122435212135315
- I-Disease 1 0.9854680895805359
grade I-Disease 0 0.14219434559345245
ductal I-Disease 1 0.9981762170791626
carcinomas I-Disease 1 0.9999971389770508
. O 0 0.00013432788546197116

Conversely O 0 0.000124311976833269
, O 0 8.278441043785278e-08
BRCA1 O 0 8.16897772892844e-06
expression O 0 8.91699585281458e-07
was O 0 1.7923464383784449e-06
reduced O 0 1.5601179370605678e-07
or O 0 2.667183025550912e-07
undetectable O 0 4.696653559221886e-05
in O 0 6.482408387853411e-09
the O 0 8.475580237643499e-09
majority O 0 1.2972146024026188e-08
of O 0 1.407913674533745e-09
high O 0 2.9038926641078433e-06
- O 0 0.01373535580933094
grade O 0 0.00017048789595719427
, O 0 4.280716581206434e-08
ductal B-Disease 0 0.011628109961748123
carcinomas I-Disease 1 0.9999998807907104
, O 0 2.3791433250153204e-06
suggesting O 0 8.211086992560013e-07
that O 0 9.017634283736697e-08
absence O 0 1.6152535309288396e-08
of O 0 1.141586269959305e-09
BRCA1 O 0 0.0035872310400009155
may O 0 5.0004459808405954e-06
contribute O 0 3.0352955704415763e-09
to O 0 1.2280398919983782e-08
the O 0 1.0615157641780115e-08
pathogenesis O 0 6.940393177501392e-06
of O 0 3.207707710561891e-10
a O 0 5.7888351889801015e-09
significant O 0 1.5019842036778641e-09
percentage O 0 1.0079950385488701e-07
of O 0 1.009478012292675e-08
sporadic B-Disease 1 0.6692280173301697
breast I-Disease 1 0.9999878406524658
cancers I-Disease 1 0.999936580657959
. O 0 3.939269959118974e-07
. O 0 1.1903346575081741e-07

